<SEC-DOCUMENT>0000950170-24-023513.txt : 20240301
<SEC-HEADER>0000950170-24-023513.hdr.sgml : 20240301
<ACCEPTANCE-DATETIME>20240301061125
ACCESSION NUMBER:		0000950170-24-023513
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240301
DATE AS OF CHANGE:		20240301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39659
		FILM NUMBER:		24706753

	BUSINESS ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bdsx-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:bdsx="http://biodesix.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_d5282462-cbef-460a-bbd7-6dfd5e11ed79" name="dei:EntityCentralIndexKey" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386">0001439725</ix:nonNumeric><ix:nonNumeric id="F_11f7e262-b3b3-43f8-aa23-9b8633f293d4" name="dei:DocumentFiscalPeriodFocus" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386">FY</ix:nonNumeric><ix:nonNumeric id="F_a5db4e91-6ac6-4602-956c-2ece0366f9fb" name="dei:AmendmentFlag" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386">false</ix:nonNumeric><ix:nonFraction id="F_f09beae6-63bc-4fe9-8088-f12fc07a80bf" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_edf6892d-6c5b-4273-a943-cdd4ba7438d9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e86b8b3b-a85c-44b9-8d6d-7549b1a94605" name="us-gaap:PreferredStockValue" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_73a3f454-52cd-4af4-83d5-15d25b949308" name="us-gaap:PreferredStockValue" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_19d8db26-ae6e-4ab2-b567-298bf67cb775" name="us-gaap:NumberOfOperatingSegments" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_5b4950ae-8a2a-400a-848c-b12899bcf89d" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric id="F_9df9a806-ab12-4618-8e6a-94161b6cb0d5" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric id="F_693c0deb-e916-4d0f-82f1-e7179ddec20e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_9bb1d43b-581c-4729-85e9-b735fa97e35b">P3Y</ix:nonNumeric><ix:nonNumeric id="F_9b208ef9-2e89-4c6b-beef-d077b508f0ac" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_d3bdd13a-c3cc-4e09-816e-ad5c1a5a1b08" format="ixt-sec:durwordsen">five years</ix:nonNumeric><ix:nonNumeric id="F_4a3ac985-50cc-430f-afc9-a367fa948051" name="us-gaap:InvestmentTypeExtensibleEnumeration" contextRef="C_1c0d6b7f-113f-45cf-8621-8ade2e3145cb">http://biodesix.com/20231231#RepurchaseMember</ix:nonNumeric><ix:nonNumeric id="F_6810bc43-8b88-4896-94db-50fb78cff4b9" name="bdsx:LeaseExpirationMonthYear" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386">2023-01</ix:nonNumeric><ix:nonNumeric id="F_d0f0a6d5-c980-4547-82e0-7fbd7882d4e9" name="bdsx:LeaseExpirationMonthYear" contextRef="C_f4b0b71b-6cf2-47ef-afea-3440028e862e">2024-01</ix:nonNumeric><ix:nonNumeric id="F_f032350b-436c-49d5-a43e-3d8d73323d62" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_9bb1d43b-581c-4729-85e9-b735fa97e35b">P1Y</ix:nonNumeric><ix:nonNumeric id="F_d4ab91cf-5309-48b9-bf44-1a128879ae56" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_d3bdd13a-c3cc-4e09-816e-ad5c1a5a1b08" format="ixt-sec:durwordsen">four years</ix:nonNumeric><ix:nonNumeric id="F_d101e6ae-d1d1-4191-8ad1-1ab4d344cdcb" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" contextRef="C_1e68ff14-2525-4276-b2c4-9d9450d9086c">P7Y</ix:nonNumeric><ix:nonNumeric id="F_afd70d36-dcbf-4fdb-b7a0-f4dc56cc9f89" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_2753e6cc-4205-46f0-b9c5-73fa3a85b6e5">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_969e4251-ea3d-4fbe-a713-b5983a44c323" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_ff19ba49-adcc-49c8-a36f-54b474d1fd4d">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bdsx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_240c8f68-bf9d-46de-aa49-fa8df526c0a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5347cdc-ebae-4937-a95c-7a2fb92191f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20959b72-6f50-4526-8ce1-58ad102071d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d858a437-a837-4dd7-a056-993b112468b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_495df2dc-9e4b-4eba-91de-cd835b8ec284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:BiopharmaServicesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b4b468c-46c8-4f63-a0d6-3132df34cab5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f68a71f-ae27-4a7e-8505-b345faef0785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b77a60af-bc6d-4b65-8356-5aad89c73994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6780030-af98-4868-9310-acae4f9730f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c930115-3fec-4523-bf83-0ba7a2e9ab92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2f00f89-3407-44e8-b573-6c7ef85347d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e46eb83a-79be-44c5-a843-5a8c6569843c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-03</xbrli:startDate><xbrli:endDate>2023-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c326e24-3804-4962-872f-a522021fc168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:AstrazenecaUkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_590d203a-30d9-4b19-b794-c99db48ab3b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f022e96-f9de-4099-becb-8ed34b6193c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3384de12-4804-4762-b479-c95f25937875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc3d622b-07f0-4622-b168-11fadcf7c53f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_762beb25-d2a5-4129-9298-0e23686a893a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_355e90bf-4c9e-415d-b1b6-9150cd16a047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3fb17ed-8bf4-45c6-95cf-234368989352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cc23b54-53b8-41be-ba0d-255e20378a4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5662ec44-a16f-45a0-917c-97f0fd92ca72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c13b6e2-c1b8-4e30-b455-351cad2472f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8740db4-2867-4e82-a5dd-07d9793a7524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f98ad46-d032-45e8-8dc6-864069fa3ada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_854423ce-c02a-4357-a5be-bd8070c81d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c75f007c-cad7-4f11-be83-4e80d54a65e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b9a9bf1-c88b-455d-836c-503d4aebec7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea1e80b7-5077-4687-98eb-b1b280706184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6516a5f0-169d-455b-a52b-b1f028e503fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf25d082-7144-45c9-82a7-485c56547da3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_829c0cf6-e0e1-4b9b-b982-f1e2c2517ed1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-02</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb7558dc-7e0e-47e9-be24-11751dfeab98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_527ecbd0-9d14-456c-8b14-6369be5c77b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_941cb925-fd9e-40a4-a574-1909da8d340f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9449bbf-0db7-4011-804f-4ab3c76ffe06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09d39f03-6b12-424b-8512-f460834da55b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7afe2c5e-ef01-4ae6-9496-8f640f10072d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c470b55e-4817-47fd-b1a2-60ddf9f1e696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32ca7091-08cb-42b8-a3c3-0e36d7da15be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbf7a7b5-3d35-4435-8e39-b2016e8d14e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba93e9bf-54a2-4a63-a29e-47cf3846d702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0845ddd1-8e8f-416b-a225-6a579305755e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ExistingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_185c0faf-f292-4fd9-ace9-12ff64d5d8f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c99d259-788c-49d8-9e0a-022979f1851a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62ca78ec-9f39-4920-83f6-28d44aeb971e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f01b403a-323f-485f-af41-68ca5c0839f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7bda97d-3509-499d-a965-e2fdeb9c2460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30e47baf-60a9-4e0a-aa84-25a0a6d4d64d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_757ef04f-cd64-48a3-98e8-6c7d33aefba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7447f4c3-b576-4564-b8e9-f58111485a6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_820acf83-d376-4b0f-8f41-f85aedc1f651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32deb686-8097-4424-ac3a-cb9f560483da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdff4690-cd03-400e-9532-0ec16ccf2ac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31b2a0f0-6bf1-4d74-ad13-990f695890b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbece915-caf9-4b49-8367-e61f916c83c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce211496-7721-4eba-82cd-0d0e044cc26e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c93f4cec-77cf-4fd9-a863-07647a7dfbe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef3c2187-563e-494f-893c-b00f9a7afdcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8c71793-b3d7-4472-9294-cc317e43c263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39f4972b-0662-4c51-a7b3-8e295b8cc3f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2c8094a-10da-431f-951a-d7eb2e067421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78dba0fb-71f8-42e4-a64b-0fd12fbe76a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c62ec6f1-4811-4fd5-bb74-172abde325bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e530c247-1fb1-40c9-a68a-591017a52ecf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f80b84d-e3ac-46dc-8317-ba012a0d08c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25e96d73-e3b0-4a75-a22b-6a05aced6c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_103305fa-0498-4e12-8c27-50a1a8d26ffb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b25b640-1c47-4745-9cca-376992b9713c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8dffbb6-3dd7-4318-8445-46c6c30532bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75eae973-2f26-420e-8dcd-287d48f37677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bb1d43b-581c-4729-85e9-b735fa97e35b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ecadbe3-1544-4bda-a218-b85b4bdae48a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecb41f0c-f59d-45ea-a050-526c1d52cf1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_458ca6db-5494-45ba-a80b-51438237e3b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04f15e86-b867-4b21-85db-2828b6000f59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c37573b7-4513-43c3-9695-25908f198e7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d94f7ed2-8768-4f75-92ef-17e38595fb19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6dcab58-44c5-4023-bb77-3783ed60c728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_677ab76d-419b-473f-b103-ff9ac04bad1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e430ec9b-f398-4f86-972f-96b4e020ff48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eca8f48e-2cf8-4fe3-bd45-8790ffacd616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_704abf95-1ce3-4ffb-aa7b-013f8330fca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa2e75a9-b401-42d8-9753-7018d23b85ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f39b903-335d-4dc6-a073-8be5fe3da6ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1c1115e-2162-4e21-818c-b98821ff9dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72b4a1e8-4024-43cf-af5a-fe28f78fef95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baaedbd4-6935-478d-9fd7-ed5496a4e509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d7940c5-ed73-407d-b4e5-5389b5b92763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75b2228d-4f1c-40ab-9389-611290f07a73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d5a6062-37b8-4fa8-a4da-c6e14c894954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b7739ff-0980-4012-9fc1-66675c283f56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ce221be-74ad-4978-8b6b-94c91f43b705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c0d6b7f-113f-45cf-8621-8ade2e3145cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccfbd687-78ce-4465-b1b8-3bfc531b0880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_732dfeaf-3c70-43c0-9cb2-16621b310dc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20fb35f1-6660-4090-b128-abf211be9258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff19ba49-adcc-49c8-a36f-54b474d1fd4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1cccb8e-8913-45ca-a2a9-4d5492eb8d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c183917b-8a29-4963-b916-51ff5dc6f28a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d48cbf14-8cb6-4e55-8fec-7e43385ec4b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e23c71c0-bc98-4ec5-ae85-cdfd84f091ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39626716-1586-4d2d-8868-a094e33c5618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de229b36-03e8-4ba3-9d97-4bb97a183372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6b84852-36d5-4f3d-bb6a-b0b710f9dd00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6645f92e-5a21-48d7-be04-51e4d7d14345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce2a287f-cb92-4030-b3b1-332c05321abe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82a5e47a-b63c-44b3-bca7-2b170af6b51a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5009b344-d4d5-4e3f-897a-d9f8b21265c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4270ff6e-22b1-452e-a4a6-a180a3e2a6f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_642aa182-ab63-4cc2-a2bb-672f223f0786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b343d002-35a7-4d20-972f-2d42c271e7a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1ab286d-70e8-4911-8d81-5934ba62030b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba1bede0-706e-4693-ba5f-95a79f81fcbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-24</xbrli:startDate><xbrli:endDate>2023-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9312e759-444e-4716-9451-2b8b8320f87e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0a3cf0a-87dc-4d4e-85f5-ae4fff2592a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26baecb2-9cae-47d3-9fff-e9ca8610e979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67ce5508-c2c7-4b2b-ac66-a6d8f43f57a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_101bd2f5-f908-4988-9b9f-58f2c06e0547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f300fdd-ce4b-4d8a-b6e0-51a7c1714a99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_286d0721-729c-4546-81b4-7c2234ec5f19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5636267d-0318-4aa5-a493-1e9d911a7cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea26ef97-074e-45f4-81e8-41983d384792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9caae3bf-4fbb-41ab-a4e1-b00953245f32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e68ff14-2525-4276-b2c4-9d9450d9086c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47a08558-9395-40a3-8dcc-94e5904208d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96996321-13b7-427c-bd23-e8321fa8a247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a255c06-b8fd-42be-a476-41c0489c1cce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d34c69b7-5581-4027-8f30-edb22143832c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42326201-3aba-4a78-8961-e432c28f468d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e31ab29-a697-425a-af3d-43c74dbcb485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6192e64b-6b5d-4c2e-807b-fa9c59db0323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">bdsx:CashCollateralizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d33768d0-8007-4c23-a3e3-f26f30749f9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb308a59-4d7b-4ffa-b075-a3e642ac4c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_921ada3a-dad1-481f-91bb-6926ac721bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0f57e5e-3320-4697-9d41-f219f5580721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef8c27b1-4741-4250-99d6-cf03e3702f8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c69ea8bf-9f71-4ba2-a888-5910c8e5e8a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e88dd606-cce8-4094-846e-9bb4b5f5df2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a9c086d-ca5a-4f0b-a935-2933e71c3b61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ec35fb1-0374-47a3-b8d9-e1479123e997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4b0b71b-6cf2-47ef-afea-3440028e862e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76c1c45c-0a3f-4fbd-beae-7e98904be82f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_693c76f1-5bcb-4f13-8dd7-aab03824f0b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94dfe6a6-75a6-4855-8b8a-25382e1bcc1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_937cac9a-b5f5-41ce-8603-758663d5645c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d399ad7-37d8-4601-9860-f4ed0a5dd125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8071c03-dc27-49ba-8d1a-dda3eae00a0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbe102ae-9f7e-4e28-816c-b752eedef674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e89c5ad9-ee99-495b-8bf2-d125fc70e5e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5c7a2fb-eba1-497c-b9c5-a66efa1ceb59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c78507c9-28f4-4078-b9c2-60788d6de761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77f1704b-d027-4f10-90c1-a41d7fa1aa89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab1111f8-759d-41b6-837c-e3d03f7a0ae9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:BiopharmaServicesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7feedfcd-2f75-4050-b434-093d5964efa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4348c38b-37a4-4aad-80bf-51c279e91cbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c641c015-2bd6-4a8d-8ea4-9455265a0578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50b4b982-898d-46bc-b9ea-b684abcdac48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fff8f12c-e13d-40af-8269-13c52984316c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:LPCFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bced1c1d-85b9-42ae-8100-73aca910ab35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b34059f4-8b80-437f-b778-005b358d00cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac9d67d1-000b-4fd0-b45a-e660f6627d18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efd69ce4-92d9-4a44-8134-87ed7ac60445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c3c29e1-2f9b-4ce8-a3c1-35be4a21e942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05eb759d-55fd-4a20-ad8a-062b720cf18a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62d6cec9-2f4c-4985-b1ad-fb315c4d7129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40f12cf5-75b2-497c-a527-a856346a9ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da96c3b7-099a-40dd-9b01-f364329a97fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b1fa878-d68c-49bb-adba-1cf66b1bc52e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4dff87f-d0d5-422b-9f9a-13850ed49e16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da03390b-83f8-418c-9f18-c9c25626feb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85c18ff1-b0e9-4dde-b440-56dc6c7fe909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dc723fd-79de-4621-8b96-50bc34902a0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8c554b0-2f2a-45d2-827d-c5c7753bf0df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4a9239d-0ac1-4ebc-99ad-6594a4338815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9e2f35d-f819-4cf0-98d0-27d991f1b000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheStateOfColoradoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fd25448-a781-4c46-af90-bee7da9ce5c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_234399c4-abaf-4cff-b6b4-cf1365245c8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55007458-a47c-4577-8a1f-a5b74438afae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e27675e3-4b86-41b3-82b6-66aeb3068eb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdcc9d4c-66e6-411d-9680-d5105860c125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-03</xbrli:startDate><xbrli:endDate>2023-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35044628-f95d-4526-999c-ceb308c83552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21cb25e9-02bb-4719-b5c1-a096cb7c970b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_118e49be-c761-4dd8-a46b-5ab677d5c06f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aae49741-9ea1-4f75-bfc7-d624530d36a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6b06b8a-9d90-4601-bafe-371bd4da5153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fa0d7e8-75b7-4df5-8285-781f19947e03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a229531-ccdd-4632-a059-50b71306f89f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed3993d6-58b6-4ff5-b5d7-5c4851329b29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd518e59-60e3-4745-ae35-197791782cc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3bdd13a-c3cc-4e09-816e-ad5c1a5a1b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2753e6cc-4205-46f0-b9c5-73fa3a85b6e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db52ea64-8d04-4f5f-808f-473c14c90cd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18694c42-145b-4b80-97fa-d13aaaf257c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e811ab96-e279-4509-9656-8567a594d9e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ff65011-fa8e-4a77-8fc2-78505357e43f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f95c0d4d-7ab7-4ea8-bed2-8c4d7965b3da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47cf66b1-0604-4cd3-8aee-7a4e96842346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_980bcbe0-d568-4e08-a672-b071c73a3261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff6853d0-09e3-4b96-93ec-2bc31e1bfcc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7c3261f-f9bd-43a8-901f-c9c1d238ad41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87753004-7a65-4879-90a7-b55ed68ef8d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bb7dca5-b8b4-43e7-8305-8b91be0a1148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b5d3398-91f7-41ab-97d0-7393bc19f7ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3ab2048-daf6-40f1-a535-fe1a3ed66ded"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc5a7859-ac48-440b-b875-07120eb3a782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_944a3fdd-0063-430b-812d-8df10d978153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbc0f234-0a0a-4688-a7d0-ab581da9ada6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6410b666-1ca1-4444-9f01-8f35821f9a25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4c92134-cf3d-4b48-a86a-aff01ba5002e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_722b4124-2675-4c60-83df-552c2446203f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_886c7268-fb43-44e3-b7bd-e66c3277e3a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d3ecb2f-0211-4617-a06a-2d4546f0e40f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6598444-e68b-421f-8188-c98635eea90e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-23</xbrli:startDate><xbrli:endDate>2023-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8e10b10-ed99-44ce-9379-a3351b13b1d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63b83fa5-85b9-4152-a156-9afea82f699b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:SecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35232c44-4da5-4420-b843-8dbdf84d2418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f11691d-c0c2-4bb0-ab80-31641907e9da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d56ae6a-1cf7-4302-8a0a-2f707300fff3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9c98e4a-80fa-483a-9bc2-c5a38ceacbe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccdfd811-c49b-4466-bf12-ded5e7a5e155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_532807c3-5af3-4d5a-94dc-2349407eba05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-27</xbrli:startDate><xbrli:endDate>2023-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01111575-2dc6-44fe-bdc7-2295733d2ca3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3ff8863-2403-499a-a2df-4ae38da7415d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b293fb96-2665-4a34-bf96-3204f1af238a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51c21cd5-9bbf-406e-95cd-7db5c3f7f76f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acdf8992-5bd5-4c91-833c-0190220805bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56c9ae72-9e34-4992-b029-01bdfc7ad040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4f1f778-0ed2-4f8c-a95b-459652dcae55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81062d5c-36cb-4b6f-acd2-1864d8d3f30d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_SubscriptionAgreement"><xbrli:measure>bdsx:SubscriptionAgreement</xbrli:measure></xbrli:unit><xbrli:unit id="U_Facility"><xbrli:measure>bdsx:Facility</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Officer"><xbrli:measure>bdsx:Officer</xbrli:measure></xbrli:unit><xbrli:unit id="U_Test"><xbrli:measure>bdsx:Test</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>bdsx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>bdsx:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U_RenewalOption"><xbrli:measure>bdsx:RenewalOption</xbrli:measure></xbrli:unit><xbrli:unit id="U_ShareHolder"><xbrli:measure>bdsx:ShareHolder</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> 	 	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b686a659-eddf-48d9-ac79-0fc138acfabc" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_5a7ece8e-7dad-45ee-a26b-81dbb662f18d" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c2cf3b4-1b7d-4693-b155-5abdd162b9cd" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93d2670d-2e98-49aa-87db-51d29a52572a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f482c86-652b-432b-bb16-4c2a6281d4e3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ce0a3684-a55d-4669-a10d-fae36047cbb9" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0364b057-9f45-4722-96db-b0e10f7a7208" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-39659</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b311f35c-98de-4bc9-867e-e5cc29c9d301" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dc0b4ded-df24-459b-84fd-15a0857d5710" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_179dc34d-6721-488a-bf89-95ce1eccee6c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20-3986492</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_4cc11474-8401-4fd2-969d-6ce736865177" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">919 West Dillon Rd</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">.,</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_31e89ec4-47a6-4a1c-9dbb-8b0ada20d26b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Louisville</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_10808f2d-6e33-4e83-a472-c77495d69e01" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CO</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_96f59277-e87d-4245-9cac-9914865f277f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80027</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd63bf97-c83d-47d8-8ad4-4424e4123e71" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">303</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fac7cd8-4cd0-449b-817b-2f0f734b7d4a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">417-0500</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:39%;"/>
   </tr>
   <tr style="height:4.3pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4df7b38d-9fc6-4fce-9cb1-9d25211e6110" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0f053ecb-40ff-4d0c-a3f7-55816743e433" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">BDSX</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_66c83f99-4163-4ad2-9eda-f8aabde93fb0" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The NASDAQ Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744; </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d379cb83-ef63-4c64-b026-51ba840fddda" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2f54cb2-6788-400c-b600-8462aa6201b8" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_454c3a86-54b3-454a-a229-e63193062f6a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db0cd6f9-abb4-4c08-ac50-ba967a9734e3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;"/>
    <td style="width:1%;"/>
    <td style="width:55.84%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2bcd8156-7c20-4a76-af5b-59b6adcd1ac2" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e1ef7f33-94e2-4845-aef8-d5be6941d0ce" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_7f631311-715e-41ec-aa7d-b1e7204bb036" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d09b8693-d7a9-41fc-a669-df15749543d3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60ae698e-b039-47ec-bc3a-928ae40657d1" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0cdc5e66-36fb-455e-a58a-3e099ae96b98" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78ba50f8-a1c4-4025-a582-f1b16e777ce4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the aggregate market value of common stock held by non-affiliates of the Registrant wa</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2786e90-9340-47ba-8fb6-845d723215d5" contextRef="C_6516a5f0-169d-455b-a52b-b1f028e503fa" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> based on the closing price of the common stock as reported on the NASDAQ Global Market for that date.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 23</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, 2024 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff4f7e28-712d-4597-a2ee-1abf52293f2a" contextRef="C_e23c71c0-bc98-4ec5-ae85-cdfd84f091ab" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,942,061</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_546db015-1ffd-4db1-b685-2ddf0b78a29a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Company&#8217;s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:83%;"/>
    <td style="width:6.9%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factor"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#n1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#n1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors, and assumptions described under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, regarding, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to achieve or sustain profitability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our audited financial statements include a statement that there is a substantial doubt about our ability to continue as a going concern and a continuation of negative financial trends could result in our inability to continue as a going concern;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attain significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties managing our growth, which could disrupt our operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to retain sales and marketing personnel, and failure to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests to generate revenue growth;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to maintain our current relationships, or enter into new relationships, with biopharmaceutical companies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant fluctuation in our operating results, causing our operating results to fall below expectations or any guidance we provide;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product performance and reliability to maintain and grow our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party suppliers, including courier services and single source suppliers; making us vulnerable to supply problems and price fluctuations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of a pandemic, epidemic, or outbreak of an infectious disease in the United States (U.S.) or worldwide, including the COVID-19 pandemic on our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">natural or man-made disasters and other similar events negatively impacting our business, financial condition, and results of operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to offer high-quality support for our diagnostic tests, which may adversely affect our relationships with providers and negatively impact our reputation among patients and providers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to continue to innovate and improve our diagnostic tests and services we offer;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">security or data privacy breaches or other unauthorized or improper access;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant disruptions in our information technology systems;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the incurrence of substantial liabilities and limiting or halting the marketing and sale of our diagnostic tests due to product liability lawsuits;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to compete successfully with competition from many sources, including larger companies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance issues, service interruptions or price increases by our shipping carriers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-containment efforts of our customers, purchasing groups and integrated delivery networks having a material adverse effect on our sales and profitability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential effects of litigation and other proceedings;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic and financial market conditions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract and retain key personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">current and future debt financing placing restrictions on our operating and financial flexibility;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests, or expand our operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the acquisition of other businesses, which could require significant management attention;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the uncertainty of the insurance coverage and reimbursement status of newly approved diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future healthcare reform measures that could hinder or prevent the commercial success of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with anti-corruption, anti-bribery, anti-money laundering and similar laws;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with healthcare fraud and abuse laws;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or unanticipated problems with our diagnostic tests, causing them to be subject to restrictions or withdrawal from the market;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future product recalls;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">legal proceedings initiated by third parties alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the volatility of the trading price of our common stock;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inaccurate estimates or judgments relating to our critical accounting policies, which could cause our operating results to fall below the expectations of securities analysts and investors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other risks, uncertainties and factors, including those set forth under Item 1A. "Risk Factors".</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These risks are not exhaustive. Other sections of this Annual Report on Form 10-K may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K or to conform these statements to actual results or to changes in our expectations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference and have filed as exhibits with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mission</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vision</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is a world where all critical diseases are diagnosed early and treated quickly with the guidance of personalized diagnostic solutions, so humanity can thrive without the burden of disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Business Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc. (&#8220;Biodesix&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;) is a leading diagnostic solutions company with a focus in lung disease. By combining a multi-omic approach with a holistic view of the patient&#8217;s disease state, we believe our testing solutions provide physicians with greater insights to help personalize their patients&#8217; care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, radiomics, and artificial intelligence (AI) enabled informatics, to discover innovative diagnostic tests for potential clinical use. Our multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in a single segment and derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) prior to May 11, 2023, Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other). During fiscal years 2023 and 2022, we derived 92% and 90%, respectively, of our total revenues from our diagnostic testing business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. Since our inception, we have performed over 600,000 tests and continue to generate a large and growing body of clinical evidence. We have participated in 27 clinical studies, three of which are ongoing, and have published over 300 clinical and scientific peer-reviewed publications, presentations, and abstracts. We have curated a biobank encompassing thousands of biological specimens with associated clinical data, including tumor genomic profiles and immune profiles, which are used for both internal and external research and development initiatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have commercialized five diagnostic tests which are currently on market and we perform more than 30 assays for clinical and research use as part of our laboratory services that have been used by over 65 biopharmaceutical customers and academic partners.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Blood-Based Lung Tests</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have five diagnostic blood-based tests across the lung cancer continuum of care, which generated $45.1 million and $29.3 million in revenue for fiscal year 2023 and 2022, respectively, an annual growth rate of 54%.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnosis</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify CDT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#174; and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">XL2&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tests, together marketed as our Nodify Lung</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nodule Risk Assessment testing, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. The Nodify CDT and XL2 tests have an established average turnaround time of one and five business days, respectively, from receipt of the blood sample, providing physicians with timely results to guide diagnostic planning. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment &amp; Monitoring</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GeneStrat&#174; ddPCR, GeneStrat NGS&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VeriStrat&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tests, marketed as part of our IQLung&#153; testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient&#8217;s immune system to help guide treatment decisions. The GeneStrat ddPCR tumor genomic profiling test and the VeriStrat immune profiling test have an established average turnaround time of two business days from receipt of the blood sample, and the GeneStrat NGS test has an established average turnaround time of three business days from receipt of the blood sample, providing physicians with timely results to facilitate rapid treatment decisions. The GeneStrat ddPCR test evaluates the </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">presence of actionable mutations in lung cancer. The test is covered independent of stage and can be used multiple times per patient to monitor changes in mutation status. The GeneStrat NGS test is a broad 52 gene panel, including guideline recommended mutations that help identify advanced stage patients eligible for targeted therapy or clinical trial enrollment. The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#8217;s immune response to their lung cancer.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 Pandemic</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program. We generated $0.1 million and $5.2 million in revenue from COVID-19 testing during fiscal year 2023 and 2022, respectively. These tests under the Biodesix WorkSafe testing program were utilized by healthcare providers, including hospitals and nursing homes, and were also offered to businesses and educational systems. We announced multiple partnerships for COVID-19 testing and maintained an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State, which expired on August 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two United States Food and Drug Administration (FDA) Emergency Use Authorization (EUA)-authorized tests, a part of our customizable WorkSafe program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad granted us permission to utilize both tests for commercial diagnostic services. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Beginning in second quarter 2021, we began partnering with GenScript Biotech Corporation to commercialize the blood-based cPass SARS-CoV-2 Neutralizing Antibody testing as a service. The test was the first surrogate neutralizing antibody test with FDA EUA and uses ELISA (as defined below) technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic disrupted, and in the future may continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#8217; public health orders and the guidance from the Centers for Disease Control and Prevention (CDC). Employees who can perform their duties remotely have the option to work from home. Our sales, marketing and business development efforts may be constrained by our operational response to future COVID-19 variant outbreaks. We will continue to adjust our operational norms, as needed, including complying with government directives and guidelines as they are modified and supplemented.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See &#8220;Risk Factors&#8221; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Full Year Results for 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, compared to the prior year:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Total Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $49.1 million, an increase of 28% primarily driven by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lung Diagnostic Revenue of $45.1 million, an increase of 54%;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biopharma Services and other revenue of $3.9 million, an increase of 6%;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">COVID-19 Revenue of $0.1 million, a decrease of 99%;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gross Margin </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $36.1 million, resulting in a 73% overall gross margin percentage as compared to 63% in the prior year;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses, excluding Direct costs and expenses, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were $77.4 million, an increase of 4% and including non-cash share-based compensation expense of $5.4 million as compared to $6.0 million in the prior year;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $52.1 million and decreased 20%, due primarily to an overall decrease in total operating expenses and other expenses of $9.2 million and $4.1 million, respectively;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basic and Diluted Net Loss Per Common Share </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $0.64;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used by Operating Activities </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $22.9 million, compared to $45.0 million used in the prior year; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $26.3 million as of December 31, 2023.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Market Opportunity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnostic Testing Market Size and Opportunity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite significant advances over the last decade, lung cancer is still the deadliest type of cancer in both men and women in the United States. While diagnostic testing has become routinely used at certain points in the lung cancer continuum of care (diagnosis, treatment and monitoring), we believe there is substantial need for novel, advanced testing to improve on the current standard of care. We estimate that in the United States, the lung cancer continuum of care represents over 10 million annual testing opportunities and is over a $27 billion market annually for testing alone.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img35377828_0.jpg" alt="img35377828_0.jpg" style="width:614px;height:180px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 15% of oncology trials involving the use of biomarker testing in 2000, compared to 55% in 2018. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their research and development pipelines and increase chances of drug development success. We estimate that biopharmaceutical partnering and research opportunities represent over a $2 billion market annually.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lung Cancer Continuum of Care &#8211; Clinical Unmet Needs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Standards of care in lung cancer have evolved rapidly over the past decade, along with our understanding of the disease. With the introduction of numerous treatment options, physicians need an ever-increasing amount of information in order to select the best treatment plan for each individual patient. We believe that the lung cancer continuum of care has a variety of clinical unmet needs ranging from initial diagnosis of lung cancer after discovery of a lung nodule to treatment guidance for early and advanced stage disease, and monitoring for disease progression.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnosis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We estimate approximately 1.6 million new incidental lung nodules and potentially 4 million lung nodules from the adoption of screening could be identified annually in the United States. Following initial discovery of a nodule, patients are typically evaluated by a pulmonologist for risk of lung cancer before an invasive procedure is carried out to obtain a tissue sample to confirm diagnosis. This risk assessment is based on clinical factors such as the patient&#8217;s smoking history and age, and radiological features such as the size and location of the nodule, obtained from a computed tomography (CT) scan. On initial assessment, we estimate that approximately 80% of patients are identified as low to moderate risk (5-65%) where guideline recommendations for their care plan are unclear, often</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">resulting in either </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">overtreatment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of patients with benign nodules or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">undertreatment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in patients with cancer. An estimated 17% of patients initially scheduled for watchful waiting, or follow-up CT scans in intervals up to a year, are later diagnosed with malignant nodules, potentially delaying their diagnosis. Conversely, we estimate that 62% of biopsies and 35% of surgeries performed on lung nodules find benign disease, representing a significant overtreatment that incurs both risk and cost to the patient and their providers. We therefore believe that there is a clear clinical need for blood-based diagnostic testing to help improve the initial risk assessment of pulmonary nodules, helping direct patients to the relevant treatment pathway, and ultimately improving patient outcomes and saving costs to the system.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment Guidance &#8211; Early Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We estimate that there are over 700 thousand testing opportunities annually in the United States in early-stage lung cancer to assess a patient&#8217;s risk of recurrence following curative-intent surgery, and to detect potential target mutations for therapeutics. Depending on a patient&#8217;s risk of recurrence, they may also receive chemotherapy, radiotherapy or chemoradiation post-surgery. The assessment of risk of recurrence is primarily based on the stage of cancer at diagnosis, with stage I patients typically receiving no additional treatment beyond surgery. However, 20 to 40% of patients with stage I disease do still recur within five years following surgery, representing a sub-group of patients who may have </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">benefited from more intensive treatment protocol. We believe there is a clear clinical need for blood-based diagnostic testing prior to surgery to identify stage I patients who may benefit from a more intensive treatment protocol and we also believe there is the need for identifying stage II and IIIA patients who may benefit from a less intensive treatment protocol. There have also been recent advances in the use of targeted therapies in early-stage lung disease. These therapies typically target specific genomic mutations or alterations found in some tumors. We believe there is therefore an emerging need for testing designed specifically for mutation detection in early-stage disease.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment Guidance &#8211; Advanced Stage: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate that there are over 3 million diagnostic testing opportunities annually in the United States to guide advanced stage lung cancer treatment decisions. With nearly 60 FDA-approved systemic treatment regimens listed in national treatment guidelines for non-small cell lung cancer (NSCLC), there is an elevated need for personalized biomarkers to help physicians identify the right patient for the right treatment. Multiple tissue-based diagnostic tests have been approved to identify patients eligible for targeted therapies and immunotherapy; however, about 50% of patients do not have sufficient tissue collected following diagnosis to facilitate testing. To compound the issue, different molecular tests take varying amounts of time (days versus weeks) to report results back to the ordering physician. Physicians are often left with a dilemma to either make treatment decisions prior to receiving critical diagnostic test results, or delay treatment initiation while waiting for the test results. Therefore, we believe there is an imminent need for a blood-based testing solution that measures tumor mutations and the patient&#8217;s immune profile, to provide physicians with more comprehensive and timely information to initiate personalized treatment as quickly as possible.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Monitoring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We estimate that there are over 800 thousand testing opportunities in the United States for blood-based tumor genomic and immune profiling to monitor for disease recurrence and progression in NSCLC patients. Unfortunately, advanced stage lung cancer is often terminal, so repeat tissue biopsy to assess the evolution of resistance mutations or to detect disease progression is not feasible from either a cost or risk perspective to the patient, which we believe demonstrates an important need for blood-based testing to help routinely monitor these patients. As a patient progresses through therapies, changes in their immune system occur and blood-based immune profiling could help physicians identify these changes prior to subsequent therapy selection.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Limitations in Biomarker Discovery and Companion Diagnostics</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate that the biopharmaceutical biomarker testing and companion diagnostic market opportunity represents a $2 billion market annually</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 15% of oncology trials involving the use of biomarker testing in 2000 compared to 55% in 2018. From 2005 to 2015, a study identified that incorporating biomarkers into clinical development programs increased their probability of therapeutic success rate from phase 1 to FDA-approval by 570%, representing an increase from 1.6% without biomarkers to 10.7% with biomarkers. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their product development efforts and increase chances of drug development success. However, we believe as the market continues to advance, inherent limitations of both biomarker discovery and companion diagnostic development have become more apparent.</span></p>
  <p style="margin-left:4.16%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biomarker Discovery</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are many limitations with biomarker discovery in biopharmaceutical drug development, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biomarkers with clinical utility are difficult to discover and validate in independent datasets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Classical statistical approaches to biomarker discovery are limited. Single-omic tests fail to see the whole biological picture;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tissue biopsies are limited by the amount of a sample that can be collected: longitudinal testing is difficult and the information gathered is only from the tumor being sampled, this does not account for tumor heterogeneity or the host's immune response;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials are expensive and take years to complete. It is often difficult to meet clinical trial enrollment goals with long diagnostic testing turnaround times.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companion Diagnostics (CDx): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While developing CDx is critical to precision medicine, the promise of CDx has not been fully realized and there are multiple limitations that still need resolution. The path to co-develop a successful CDx with a corresponding drug has several challenges, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Traditional CDx agreements may fail to realize the full value of a testing opportunity, leading to difficulty in funding appropriate commercialization;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug development is a lengthy, complex and costly process. There can be a financial impact to a pharmaceutical company to have a drug selected by a test;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current diagnostic reimbursement policies may not always support the coverage and payment of new CDx;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory agencies continue to work on defining the co-development process, but the environment is continually changing.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic Test Discovery and Development at Biodesix</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics to discover innovative diagnostic tests for potential clinical use. We focus on the use of technologies that are capable of single and multi-omic tests in our research and development. We continuously evolve and improve our test discovery and development process. All of the technologies that we employ have been chosen and developed to provide high-quality data to enable our clinical test discovery and development. We feel that this level of data integrity is crucial for the development of diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and learn about biological discoveries that are clinically meaningful. Additionally, we incorporate clinical and molecular profiling data aggregated through our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or other collaborative partnerships, into our platform. Our curated biobank encompasses thousands of biological specimens with associated clinical data, including tumor genomic profiles and immune profiles, which are used for both internal and external research and development initiatives. With our multi-omic approach we are able to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To achieve our discovery and development objectives, we utilize different technologies, including ddPCR, NGS, LC-MS, ELISA, single cell analyses, and our proprietary DeepMALDI&#174; mass spectrometry platform for the blood-based molecular analysis of the tumor, immune system, and host-status of each patient and/or clinical dataset. We continuously revisit our technology strategy and roadmap to integrate new technologies into our evolving platform, which ultimately support the addition of new service and product revenue offerings. Most diagnostic companies focus their strategy on using a single technology to discover biomarkers for a broad range of clinical questions. We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a multi-omic approach to solving diagnostic challenges. Because of this approach, we believe we are unique in the diagnostics market, allowing for a broader and more holistic understanding of each patient&#8217;s disease state.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are experts in many technologies, but we are a true market leader with over 15 years of experience in the field of clinical proteomics. For over 15 years, we have been discovering and developing proteomic-based diagnostic tests and have a deep understanding of how to incorporate technologies that can be applied to blood samples in order to extract important protein-based biological information in the form of diagnostic tests, which can aid clinicians and scientists in understanding the dynamic biology of their system of interest, such as a patient with cancer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our suite of technologies that assist us in discovery, development and commercialization of novel diagnostic tests includes:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DeepMALDI Mass Spectrometry</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed DeepMALDI, a proprietary high-density matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry (MS) technology, to discover potential tests for disease diagnosis, and monitoring for disease progression or recurrence in lung and other disease states. DeepMALDI technology overcomes the limitations of conventional MALDI and other mass spectrometry methods to produce highly sensitive, stable, and reproducible data. This method yields substantially higher quality data content and is thereby well suited for the discovery of biomarkers with clinical utility. We intend to maintain our leadership role in the discovery of proteomics-based diagnostic tests. We utilize our DeepMALDI and MALDI-ToF technologies in our discovery and development efforts and as part of our collaborations with our biopharmaceutical customers and other collaborative partners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquid Chromatography (LC) Mass Spectrometry (MS)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use Multiple Reaction Monitoring (MRM) MS with triple quadrupole mass spectrometers and up-front liquid chromatography (LC) sample injection in the Nodify XL2 test and as part of our collaborations with our biopharmaceutical customers and other collaborative partners. This mass spectrometry method offers highly sensitive, specific, and cost-effective analysis for simultaneous quantitation of hundreds to several thousands of targeted peptides in a single experiment. We have since included the MRM technologies as part of our services for discovery and development with our biopharmaceutical customers and academic partners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enzyme-Linked Immunosorbent Assay (ELISA)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELISA is the most widely used ligand binding assay platform within and outside the pharmaceutical industry. Formats include direct, indirect and sandwich assays and are typically run in manually or semi-automated modes. We use a semi-automated implementation of ELISA in clinical testing for the Nodify CDT test, and as part of our collaborations with our biopharmaceutical customers and other collaborative partners. The acquisition of Oncimmune USA in 2019 expanded our ability to conduct very high throughput and cost-effective ELISAs in our clinical testing laboratory. We have now included the ELISA technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Droplet Digital Polymerase Chain Reaction Technology (ddPCR)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use the ddPCR technology for multiplexed, semi-automated nucleic acid detection. This allows high sensitivity, fast turn-around times, flexibility in our laboratory workflows, rapid scaling from low to moderate anolyte complexity, and high-volume scalability. ddPCR is an absolute quantitation method based on the partitioning of circulating nucleic acids into up to 20,000 droplets per reaction and is used for the GeneStrat ddPCR test. Our strategy with ddPCR relies on a menu of off-the-shelf and custom research use assays, including early access and beta evaluation, which we develop and make available as a part of our commercial pipeline, biopharmaceutical and collaborative test services. We have included the ddPCR technologies for research and development both internally and externally with our biopharmaceutical customers and other collaborative partners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Generation Sequencing Technology (NGS)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use NGS technology for broad genomic sequencing of clinical specimens. Our strategy with NGS relies on a menu of off-the-shelf and custom research use assays, including early access and beta evaluation, which we develop and make available as a part of our commercial pipeline, biopharmaceutical and collaborative test services. The NGS technology integrates automated systems to yield high sensitivity results with a rapid turnaround time. Since adoption of this technology, we have included the NGS technologies for research and product development both internally and externally with our biopharmaceutical customers and other collaborative partners.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Solutions and Products</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To help address the current limitations with standard of care in lung cancer diagnosis, treatment, and monitoring, we use combinations of tumor, immune and host profiling, radiological imaging, patient clinical profiling, and our proprietary AI platform to provide a holistic view of each patient&#8217;s dynamic disease state.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have five blood-based diagnostic tests across the lung cancer continuum of care to help address clinical unmet needs by physicians.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnosis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We believe there is a clinical need to help physicians reclassify risk of malignancy in patients presenting with suspicious lung nodules. We offer blood-based Nodify Lung Nodule Risk Assessment testing to aid physicians in stratifying patients into distinct nodule management treatment pathways: diagnostic procedure or imaging surveillance. Nodify Lung consists of two blood-based proteomic tests: the Nodify CDT test helps identify patients with lung nodules that are likely malignant and the Nodify XL2 test conversely helps identify those that are likely benign. The Nodify CDT and XL2 tests have established average turnaround times of one business day and five business days from receipt of the blood sample, respectively, providing physicians with timely results to guide diagnostic planning</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment Guidance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We believe there is an ongoing need for a blood-based testing solution that measures tumor-specific mutations and the patient&#8217;s immune profile to provide physicians with more comprehensive information to personalize treatment plans. We offer the blood-based IQLung testing strategy, which consists of the GeneStrat ddPCR and GeneStrat NGS tumor profiling tests and the VeriStrat immune profiling test for patients diagnosed with NSCLC. With an established average turnaround time of three business days, we are able to quickly provide critical diagnostic information to physicians to facilitate personalized treatment decisions for their patients.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Monitoring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We believe longitudinally monitoring advanced NSCLC patients for the dynamic evolution of their tumor and immune profile while on treatment can provide an earlier indication of treatment resistance and/or disease progression. We offer the IQLung testing strategy as a blood-based monitoring tool for physicians to track their patients&#8217; disease evolution.</span></div></div>
  <p style="font-size:10pt;margin-top:15pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><img src="img35377828_1.jpg" alt="img35377828_1.jpg" style="width:548px;height:189px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnosis &#8211; Nodule Management</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our blood-based nodule management offering, Nodify Lung Nodule Risk Assessment, assists</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">physicians in reclassifying a patient&#8217;s risk of lung cancer by incorporating their protein biomarker results with radiographic imaging and clinical characteristics. Nodify Lung testing consists of the Nodify CDT and Nodify XL2 proteomic tests, which can be ordered separately or together from a single blood draw to help reclassify risk of cancer to aid physicians in stratifying patients into distinct nodule management pathways: intervention or surveillance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nodify CDT test is used to help identify lung nodules that are likely malignant and the Nodify XL2 test helps identify lung nodules that are likely benign. Nodify Lung testing is available for patients 40 years or older, with nodules between 8 and 30mm, and less than 65% pre-test risk of lung cancer. The testing strategy starts with the Nodify CDT test to determine if a nodule is likely malignant or at a higher risk of lung cancer. The Nodify CDT test helps physicians identify cancer more quickly by prioritizing patients with a higher risk of malignancy for a diagnostic procedure, such as biopsy or surgery. If the nodule is not identified as having a high risk of malignancy by the Nodify CDT test, then the Nodify XL2 test is performed to help determine if the patient&#8217;s nodule is likely benign or has a reduced risk of lung cancer and may be a candidate for CT imaging surveillance. Nodify Lung Risk Assessment testing is represented graphically in the image below starting with the patient&#8217;s pre-test risk of malignancy and ending with the guideline-recommended diagnostic procedure for each risk category.</span></p>
  <p style="font-size:10pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><img src="img35377828_2.jpg" alt="img35377828_2.jpg" style="width:580px;height:234px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We launched the Nodify Lung combined offering of the Nodify CDT and Nodify XL2 tests in March 2020. However, the Nodify XL2 test has been available to all physicians since September 2019 and has been available to a select group of physicians since October 2018. We acquired the Nodify XL2 test from Integrated Diagnostics (Indi) in July 2018 and acquired the Nodify CDT test from Oncimmune USA in October 2019.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify CDT Test</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nodify CDT test is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely malignant or at a higher risk of being cancerous. Results allow physicians to identify patients who may be better candidates for timely invasive diagnostic procedures such as bronchoscopy, transthoracic needle biopsy, or surgical resection, with the goal of diagnosing cancer earlier. The Nodify CDT test enhances lung nodule risk assessment to facilitate compliance with clinical treatment guidelines such as those of the American College of Chest Physicians (ACCP). The Nodify CDT test is validated for use in patients who are 40 years or older, have no history of cancer except non-melanomatous skin cancer, have nodules between 8 and 30mm, and pre-test risk of lung cancer of less than 65%.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The test measures the levels of seven circulating autoantibodies (P53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) associated with lung cancer, combined with an algorithm to report out three potential results: High Level, Moderate Level, or No Significant Levels of Antibodies Detected (NSLAD). The seven autoantibodies have shown to be elevated for all types of lung cancer, and from the earliest stage of the disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike the tumor antigens themselves, the autoantibody levels can be measured accurately through a blood sample, based upon the signal amplification generated by the immune response to cancer. This mechanism of action likely reflects very early events in a tumor&#8217;s evolution; as the immune system initiates a response to the cancer, it can also trigger an expansion of self-reactive antibodies that can be measured in circulation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the test result of High Level, Moderate Level, or NSLAD, each test report includes the patient&#8217;s pre-test risk of malignancy as calculated by the Solitary Pulmonary Nodule (SPN) Risk Assessment calculator, and their post-test risk of cancer incorporating the result of the test. The SPN Risk Assessment calculator was developed by Stephen Swensen, M.D., of the Mayo Clinic and is designed to provide a risk of malignancy for a patient with a newly discovered incidental nodule. The model incorporates six clinical and radiologic factors into the equation: age, nodule size, smoking status, nodule location, spiculation (nodule edge characteristic), and previous history of lung cancer. Incorporating the autoantibody levels with the risk model provides physicians with a more accurate assessment of risk. The Nodify CDT test has an established average turnaround time of one business day from receipt of the blood</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sample, providing physicians with timely results to guide diagnostic planning. The Nodify CDT test has been studied in 17 peer-reviewed published studies and presentations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify XL2 Test</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nodify XL2 test is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely benign or at a reduced risk of being cancerous. Results allow physicians to identify patients who may be better candidates for routine CT surveillance to monitor for growth or shrinkage of the nodule over time instead of an invasive diagnostic procedure. The Nodify XL2 test is used for patients who are 40 years or older, have no history of lung cancer or other recent cancer diagnoses, have nodules between 8 and 30mm, and have a pre-test risk of lung cancer of less than or equal to 50%.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nodify XL2 test integrates peptides measured by LC-MS with clinical and radiological characteristics that are combined by an algorithm to report out three potential results: Likely Benign, Reduced Risk, or Indeterminate. Specifically, the Nodify XL2 test measures the relative abundance of two peptides (LG3BP and C163A) in circulation in the patient&#8217;s blood. The native proteins from which the peptides are derived have been associated with an inflammatory response to lung cancer. The clinical factors are patient age and smoking status, and radiological factors are nodule size, location, and edge characteristics.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the test result of Likely Benign, Reduced Risk, or Indeterminate, each test report includes the patient&#8217;s pre-test risk of lung cancer as calculated by the SPN Risk Assessment calculator, and their post-Nodify XL2 risk of malignancy incorporating the result of the test. Incorporating the peptide levels with the risk model provides physicians with a revised assessment of risk incorporating the patient&#8217;s biology. The Nodify XL2 test has an established average turnaround time of five business days from receipt of the blood sample, providing physicians with timely results to guide diagnostic planning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify Lung Risk Assessment Testing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In summary, the inclusion of Nodify Lung Risk Assessment testing into clinical practice helps physicians reclassify risk of malignancy of low to moderate risk lung nodules by incorporating the patient&#8217;s own biology into the assessment. The Nodify CDT test helps physicians identify patients with a high-risk lung nodule who may benefit from timely intervention, which can ultimately help identify lung cancer earlier. The Nodify XL2 test helps physicians identify patients with a very low risk lung nodule who may benefit from CT surveillance and could avoid unnecessary invasive procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Blood samples for the Nodify XL2 and Nodify CDT tests can be collected in the physician&#8217;s office, laboratory, or at home through use of mobile phlebotomy. Mobile phlebotomy options facilitate testing for patients even if they are not seen in person by the physician and instead are seen through telehealth visits. This benefits the patient as scheduling can be conveniently fit to their needs and can keep them away from a physician&#8217;s office or hospital for safety concerns. Additionally, mobile phlebotomy benefits the physician as the logistics around a blood draw or tissue sampling are out of their hands. We have a national network of contracted nurses and phlebotomists to support at-home or mobile blood collection.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on November 14, 2023, the Company announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+&#153; device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient&#8217;s upper arm. Capillary blood draws using the Tasso+ device enable blood specimen collection for healthcare providers who do not have convenient access to phlebotomy services or a licensed phlebotomist on staff in the clinic or office. The Tasso+ device was validated by Biodesix to be administered in minutes by any healthcare provider at the time of lung nodule evaluation, creating efficiencies in the Nodify Lung workflow. Biodesix received approval from the New York State Clinical Laboratory Evaluation Program (NYS-CLEP) to use the Tasso+ device as a specimen collection method in support of Nodify Lung testing after entering into a supply agreement with Tasso, Inc. The device is now available for clinical use to collect specimens for Nodify Lung testing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both tests require a single blood sample shipped at ambient temperature to our certified, high-complexity clinical laboratory in De Soto, Kansas. Nodify CDT testing requires whole blood and Nodify XL2 testing requires a whole blood K2EDTA tube. Results for the Nodify CDT test alone are typically available within one day. If both tests are ordered for the patient and Nodify CDT returns a result of NSLAD, then both test results are typically available within four to five business days. All results are available through secure communication methods, including a portal, fax, hard copy, or mobile device.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment Guidance and Monitoring</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Profiling the tumor through blood-based genomic testing can help identify mutations in genes that may be driving growth of the tumor and may be targets for therapeutics. However, tumors also have intrinsic mechanisms that prevent the patient&#8217;s immune system from identifying and eliminating the cancer cells. Profiling the immune system can show if the patient&#8217;s immune system may have been subverted and therefore, is less likely to be responsive to immunotherapies. Our blood-based IQLung testing strategy consists of the GeneStrat ddPCR and GeneStrat NGS tumor profiling tests and the VeriStrat immune profiling test, which can be ordered together or separately for patients with NSCLC. Together, the tests have an established average turnaround time of three business days, providing physicians with timely results to facilitate treatment decisions.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img35377828_3.jpg" alt="img35377828_3.jpg" style="width:581px;height:258px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GeneStrat ddPCR Test</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GeneStrat test is a blood-based tumor profiling test that detects the guideline recommended, actionable mutations in lung cancer: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR, KRAS, BRAF, EML4-ALK, ROS-1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RET. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Physicians can order one or any combination of the gene tests, whichever they deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated guideline-recommended targeted therapy. The GeneStrat test performance and potential clinical utility have been published in multiple peer reviewed studies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GeneStrat test results have an established average turnaround time of two business days from the start of processing the sample in our Louisville, Colorado clinical laboratory. In a study at Eastern Carolina University, it was observed that blood-based testing was up to three weeks faster than tissue-based testing, with tissue-based testing taking a median of 26 days from sample collection. With GeneStrat testing, results are typically available in time for the patients first oncology visit, allowing the patient to start front-line treatment as quickly as possible. In the same study, it was observed that only 4% of patients had tissue-based molecular test results prior to start of front-line treatment. Meanwhile, after integrating Biodesix testing at the institution, 72% of patients had molecular test results available. Testing with the GeneStrat test can help physicians identify driver mutations quickly to help speed up time to treatment.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GeneStrat NGS Test</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GeneStrat NGS test is a blood-based 52-gene tumor profiling test panel that detects the guideline recommended, actionable mutations in lung cancer including five gene classes (SNV, INDELS, CNA, fusions, and exon-skipping). Specific variants of relevance to NSCLC include EGFR, KRAS, BRAF, EML4-ALK, ROS-1, RET, MET, NTRK. The GeneStrat NGS test is used for late-stage, metastatic NSCLC and physicians can order one or any combination of the IQLung tests, whichever they deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated guideline-recommended targeted therapy. The GeneStrat NGS test performance and potential clinical utility have been published in multiple published studies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GeneStrat NGS test results have an established average turnaround time of three business days from the start of processing the sample in our Louisville, Colorado clinical laboratory.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img35377828_4.jpg" alt="img35377828_4.jpg" style="width:616px;height:186px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that rapid, blood-based tumor profiling with the GeneStrat ddPCR and GeneStrat NGS tests can be complementary to both targeted tissue-based testing (including PD-L1) and tissue-based broad genomic sequencing. Testing with GeneStrat ddPCR and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GeneStrat NGS tests at diagnosis can help quickly identify patients who are eligible for targeted therapies. Additionally, blood-based testing upfront can help save valuable tissue for diagnostic evaluation, PD-L1 testing and broad genomic profiling for rare mutations to enroll in clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VeriStrat Test</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#8217;s immune response to their lung cancer. Results help inform physicians whether their patient has a more aggressive cancer and can help with treatment planning. The VeriStrat test profiles the patient&#8217;s immune system by measuring eight protein features measured by mass spectrometry and interpreted by a proprietary machine learning-based algorithm to produce either a VeriStrat Good or VeriStrat Poor test result.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The presence of a VeriStrat Poor result indicates the presence of chronic inflammation and a chronic acute phase immune response. A chronic acute phase immune response can trigger the immune system to provide growth factors to the tumor to increase blood flow and tumor growth. The test has been studied in over 85 peer-reviewed and published clinical studies across many different types of therapies such as chemotherapy, targeted therapies, immune therapies, and combinations. The results consistently show the test to be predictive of outcomes, independent of other prognostic factors including PD-L1 expression and performance status. Patients who test as VeriStrat Poor, on average, have an overall survival that is less than half of those who test as VeriStrat Good, independent of treatment type, demonstrating that the test is strongly prognostic. Conversely, patients with a VeriStrat Good test result typically respond better to standard of care treatments than those patients that test as VeriStrat Poor. By using the VeriStrat test for immune profiling, physicians can help identify the patient's immune response to lung cancer to help guide treatment decisions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GeneStrat ddPCR testing is performed using digital PCR technology, GeneStrat NGS testing is performed using NGS technology, and the protein features in VeriStrat are measured using MALDI-ToF mass spectrometry. Results have an established average turnaround time of three business days through secure communication methods, including a portal, fax, hard copy, or mobile device.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GeneStrat ddPCR and GeneStrat NGS tests require cell-free (cf) whole blood specimen collection tubes, and VeriStrat requires a whole blood sample spotted onto our proprietary BCD. Both sample types are shipped at ambient temperature and testing is performed in our certified, high-complexity clinical laboratory in Louisville, Colorado.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharmaceutical Diagnostic Discovery, Development and Testing Services Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our leadership in clinical proteomics and our multi-omic approach to probe the cancer disease state provides our customers with a clear and distinct advantage over other diagnostic service providers who solely focus on either genomics or proteomics. We recognize each clinical development program is complex, which is why we offer end-to-end diagnostic solutions, including: initial biomarker discovery, assay design and validation, testing of clinical trial samples, and commercialization of Companion Diagnostics.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At our core, we hold the belief that no single technology can address all diagnostic research questions. We have embraced a multi-omic approach, harnessing the combined power of genomics and proteomics and with our broad technology and service offerings, we are able to provide the depth and breadth of biomarker tools and diagnostic services required by our biopharmaceutical partners. Our capabilities and expertise allow us to unlock the potential detection of critical disease drivers and resistance mutations, early disease detection, monitoring of treatment responses and resistance, deeper insights into the underlying biology of disease, and the tracking of protein changes and degradation for a comprehensive view of treatment response. We specialize in developing state-of-the-art diagnostics solutions that play a crucial role in personalizing treatment decisions.&#8239;Our team of scientists are dedicated to creating innovative and reliable diagnostic tools that can contribute to the success of drug development and patient care. Key aspects of our expertise include:</span><span style="color:#881798;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Customized CDx Development:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8239;We have a proven track record of developing custom-made diagnostic assays to support the specific needs of any given drug development program. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cutting-Edge Technology:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8239;We have expertise in genomics (ddPCR and NGS) and proteomics (LC-MS/MS and ELISA). Our diagnostics are based on the latest advancements in technology, ensuring accuracy, sensitivity, and reproducibility. We have expertise in liquid biopsy and tissue-based assays. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory Compliance:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have a deep understanding of the regulatory landscape and work closely with regulatory authorities to ensure that our diagnostics meet all necessary compliance standards. Additionally, we have a phase gated product development process pursuant to the FDA and IVDR design control elements. Our quality management system (QMS) infrastructure is highly certified in local, US governmental and international standards and regulations and scalable to support global expansion as evidenced by multiple CE marked products under the IVDR and international registrations and commercial markets.&#8239;The Biodesix QMS is currently under the purview of CLIA, CAP, NYS-CLEP, and ISO13485. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborative Approach:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We believe in fostering a collaborative and transparent relationship with our partners, working hand-in-hand to achieve shared objectives and milestones. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img35377828_5.jpg" alt="img35377828_5.jpg" style="width:586px;height:252px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we provide benefit to our biopharmaceutical customers as they integrate strategies for increasing the probability of success for pivotal clinical trials. Specifically, our diagnostic testing services may help enable quicker enrollment rates for patients in prospective clinical trials, ranging from phase 1 to phase 3, and could help identify patient populations who may experience the greatest benefit from new therapeutics. Ultimately, our goal is to help biopharmaceutical customers realize greater efficiency in their clinical development programs. We have the ability to access and leverage our sample and data biobank for our partners&#8217; data mining needs, including new test discovery. Additionally, we can leverage our FDA approved, GMP manufacturing facility to design, build and supply clinical trial sites with sample collection kits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our biopharmaceutical discovery, diagnostic development and testing revenue continues to grow, it is important to note that we benefit greatly from these partnerships in many ways that expand beyond revenue. We are continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment landscape, while our Diagnostic Cortex&#174; platform continues to be powered through these biomarker analyses. Additionally, our anonymized sample and data biobank continue to grow and can be further leveraged for internal test development and external partnering. Importantly, we look to supplement our product development efforts with companion diagnostics as they are developed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have over 65 biopharmaceutical customers and academic partners who have utilized our diagnostic tests and services. The following are a few case studies of early-stage biomarker discovery and development with our biopharmaceutical customers.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AstraZeneca: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We provided services to AstraZeneca to retrospectively analyze samples from the FLAURA clinical trial (NCT02296125). The goal of this analysis was to interpret and establish the clinical utility of blood-based longitudinal monitoring of EGFR sensitizing and resistance mutations by ddPCR in advanced NSCLC patients treated with osimertinib. The data demonstrated that these circulating DNA mutations could be tracked in blood to interpret the patient&#8217;s prognosis, and could help AstraZeneca to identify disease progression three months (median) in advance of standard imaging. We have used our ddPCR assay to monitor EGFR sensitizing and resistance mutations in clinical trial samples from seven different clinical trials for Tagrisso.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Genentech: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We partnered with Genentech to discover a novel proteomic classifier for advanced NSCLC patients treated with atezolizumab. The test was discovered on a small clinical cohort (n=77) and was independently validated on blinded samples (n=270) from the POPLAR clinical trial (NCT01903993). The validation revealed that the proteomic test was predictive of progression free survival and overall survival for atezolizumab versus the control arm docetaxel. Additionally, an analysis compared the correlation between our proteomic classifier with standard of care biomarkers (PD-L1 expression status and tumor mutation burden), which revealed there was no significant correlation. We published additional work on the Genentech classifier with three posters presented at the society of immunotherapy conference (SITC). This data reinforces that our classifier provides unique and valuable information in the treatment of patients with advanced NSCLC. It is our belief that Genentech could use this strategy to identify patients that could derive a longer progression free survival from atezolizumab.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HiberCell:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In January 2021, we announced a broad collaboration with HiberCell for CDx discovery, development and commercialization. The agreement initially focuses on the further development of an ELISA as a CDx in future registrational trials for Imprime PGG programs.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Competitive Advantages</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the following are our key competitive advantages:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our proprietary extensively validated deep learning platform, which is tailored to discover diagnostic tests that address clinical unmet needs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our platform is an extensively validated deep learning platform optimized for discovery of diagnostic tests. By combining our multi-omic approach with deep learning techniques, we believe we have overcome many standard machine learning challenges. This has enabled us to develop commercial tests for clinical unmet needs and collaborate with our biopharmaceutical customers and academic partners.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our driven approach to precision medicine combined with our diverse technology platforms, partnership and biobank enable us to accelerate development of new tests. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives. Our biobank, clinical trials, commercial testing and other partnerships provide an ongoing source of new data that can further enhance our test discovery platform. We are continuously identifying and incorporating new market insights and input from our customers, key opinion leaders, and scientific experts to leverage this data in developing our diagnostic tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our leadership in clinical proteomics, demonstrated research, development, and scientific expertise, combined with our intellectual property portfolio. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our leadership in clinical proteomics and our multi-omic approach, we believe provides us with a distinct advantage over our competitors, who focus on any single technology, such as genomics or proteomics. Our certified, high-complexity laboratories offer significant advantages in development of commercial tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our proprietary technologies and processes are protected by a portfolio of approximately 116 issued patents in the United States and internationally, and 18 uniquely registered United States trademarks. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We take efforts to protect our proprietary position using a variety of methods, such as a pursuit of United States and foreign patent applications related to our proprietary technology, use of trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our demonstrated success commercializing diagnostic tests in lung disease as well as unprecedented turnaround times. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With five diagnostic tests launched and multiple improvements and several tests currently in development, our commercial portfolio of blood-based solutions currently addresses clinical unmet needs within diagnosis, treatment and monitoring of lung cancer. Our diagnostic tests provide rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a patient&#8217;s care plan. For example, the blood-based IQLung strategy for lung cancer patients integrates the GeneStrat ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer with results in an unprecedented two to three business days, expediting time to treatment.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our depth and breadth of point of care access to physicians allows us to drive adoption of our diagnostic tests while incorporating real-life feedback to inform new product development. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial team&#8217;s primary focus is to articulate the scientific and clinical evidence behind our tests, how they impact clinical care and can ultimately help to improve patient outcomes. Our demonstrated scientific expertise, leadership in clinical proteomics and breadth of data, including peer-reviewed publications, presentations and clinical studies, forms the basis of our relationships with major hospitals and physician networks across the United States.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial infrastructure, which includes our extensive knowledge and experience in sales, marketing, reimbursement and operations, provides us with the ability to launch, scale and drive revenue. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our commitment to commercial excellence helps us to leverage insights, operational excellence and proven approaches to deliver revenue growth and enhance the brand of our company and products. We are able to deploy rapid clinical testing turnaround times and develop commercial tests at scale. Scaling of our test capacity to meet volumes is then achieved by adding instrumentation and qualified personnel to our quality systems.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to provide swift, comprehensive and actionable insights to improve patient outcomes across lung disease and to help answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. To achieve this, we intend to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drive increased awareness, adoption, and reimbursement coverage of our diagnostic tests by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continuously educating physicians, key opinion leaders, hospital systems, advocacy groups, patients, payers, academic research organizations, and technology assessment and guideline organizations on the clinical data and benefits of our tests;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilizing our pulmonology focused sales force and commercial reach with targeted awareness campaigns to employ highly targeted sales and marketing tactics in pulmonology clinics specializing in the management of lung nodules and the diagnosis of lung cancer;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continuing to invest in the expansion of our sales force and commercial support team;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incorporating our testing services into diagnostic pathways and protocols via a top-down strategy that introduces our diagnostic tests to the largest United States health systems; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">leveraging our clinical data to gain broad coverage from public and private payers for our tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deepen our relationships with current biopharmaceutical customers and establish new customer opportunities by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">leveraging existing projects and relationships to expand sales with our current biopharmaceutical customers; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">targeting companies developing novel CDx strategies and drug development projects best suited to our platform for new test discovery, development and commercialization.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further demonstrate the clinical utility and health economic benefits of our diagnostic tests by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investing in commercial clinical testing, research studies and clinical trials to further demonstrate the clinical utility of our tests;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">providing rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a patient&#8217;s care plan; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">providing timely and actionable clinical information to help improve overall patient outcomes and lower the overall healthcare cost.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Introduce new diagnostic tests in lung disease by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">engaging with our customers, key opinion leaders, leading academic centers, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and to identify additional clinical unmet needs;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entering strategic partnerships with biopharmaceutical companies, academic research organizations, technology providers, and other diagnostic companies; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing CDx tests to support the therapeutics&#8217; regulatory approval and adoption process for our biopharmaceutical customers.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enhance our proprietary AI platform and expand our technology portfolio by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continuing to invest in research and development capabilities to foster innovation in test discovery and development;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, acquiring technologies, and integrating new data types into our proprietary AI platform;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entering strategic partnerships across our commercial product portfolio and product development efforts in order to further our development capabilities, accelerate launch of commercial products, or expand our service offering; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving &#8220;Explainable AI&#8221; by developing and incorporating computational tools that determine how the Diagnostic Cortex platform makes decisions for patient classification and outcome prediction.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue to expand and leverage our biobank by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanding and enhancing the robustness of our samples and the data set, including through our collaborations and partnerships;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursuing commercial opportunities with companies and researchers who are interested in utilizing our biobank for their own discovery and development efforts; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.2857295918914%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">monetizing these commercial opportunities.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Diagnostic Tests in Development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the goal of finding solutions for clinical unmet needs related to diagnosis, treatment and monitoring in lung disease, our diagnostic tests in development include the following:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Early-Stage NSCLC&#8212;Risk of Recurrence (ROR)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, surgical resection of the tumor without systemic or radiation therapy is the standard of care for stage I NSCLC patients. However, 20 to 40% of surgically treated patients will suffer a recurrence within five years after surgery. From market research with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pulmonologists, thoracic surgeons, and medical oncologists, we identified a significant clinical unmet need for a blood-based test to help identify stage I NSCLC patients who are at a higher risk of recurrence and may benefit from a more aggressive surgical procedure, or from neoadjuvant or adjuvant systemic treatment. Based on this unmet diagnostic need, we discovered the Risk of Recurrence (ROR) test, which is a pre-surgery blood-based proteomic test, designed with the Diagnostic Cortex platform to predict whether a stage I NSCLC patient has a higher risk of recurrence post-surgical resection. Knowing this information early and before surgery may change the surgical plan and/or support treatment decisions such as neoadjuvant or adjuvant therapy, which have the potential to reduce tumor volume and address micro-metastatic disease as early as possible. Our ROR test validated in an independent sample set, and we are currently working with major academic institutions across the United States to further validate the test.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Late-Stage NSCLC&#8212;Immunotherapy Treatment Guidance (PIR)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2015, the first immunotherapy-based treatment regimen was approved by the FDA for use in lung cancer. Currently, there are 9 immune checkpoint inhibitor (ICI) regimens (single agent or combinations) recommended by the NCCN guidelines for treatment of advanced NSCLC patients. For a portion of patients treated, these drugs can result in significant improvement in overall survival compared with platinum-based chemotherapy options.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The combination ICI regimens see some improvement in performance over single agent ICI, but side effect profiles are worse, and costs are higher than for single agent ICI. In addition, recent data have shown that a subset of patients experience more rapid disease progression on ICI compared with chemotherapy. We utilized the Diagnostic Cortex platform to discover our Primary Immune Response (PIR) test. PIR is a blood-based proteomic test designed to profile a patient's potential to mount an immune response to their cancer and predict those patients likely to respond to ICI monotherapy treatment, ICI + chemotherapy combination treatment, or who would be highly resistant to ICI therapy. Our PIR test has been validated in multiple independent sample sets for advanced stage NSCLC patients treated with single agent ICI, and we are currently working with major academic institutions across the United States to further validate the test.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Monitoring &#8211; Progression &amp; Resistance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Blood-based monitoring with our ddPCR technology may offer a feasible method to non-invasively evaluate therapeutic mechanism of action, disease progression, and the emergence of resistance mutations in patients treated with targeted therapies. Our internal validation studies have shown the utility of the GeneStrat </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ddPCR test as an example in all three of these indications. The test can identify disease progression up to three months (median) in advance of standard imaging. Using ddPCR for longitudinal blood-based monitoring of EGFR cell-free DNA mutations is a cost-effective testing method while patients are being treated with targeted therapies. Additional utility for ddPCR may exist in early stage MRD (minimal residual disease) given the sensitivity of this technology.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Trials</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. We have participated in 27 clinical studies, three of which are ongoing, and have published over 300 peer-reviewed publications and presentations. The following are our ongoing clinical studies for our diagnostic testing solutions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ORACLE Registry Study (NCT03766958)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ORACLE registry study was designed to develop real-world clinical utility data for the Nodify XL2 test and is titled &#8220;An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test&#8221;. The study objectives are to show a reduction in invasive procedures on patients with benign nodules compared to a historical control obtained from chart review. The first patient enrolled on October 16, 2018. Study enrollment was closed on May 12, 2022, with 494 prospective registry patients enrolled and 348 retrospective chart review patients accrued. As of February 1, 2024 all ORACLE participants have completed the study, site closeout visits are being conducted on the last three open sites and the study will be officially closed by the March 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 12, 2023, we announced the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by the Nodify XL2 test experiencing invasive procedures. The ORACLE study showed patients with benign nodules managed with the Nodify XL2 test were 74% less likely to undergo an unnecessary invasive procedure compared to the control group. Additionally, the proportion of patients sent to CT surveillance with malignant nodules did not differ between the Nodify XL2 group and the control group.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ALTITUDE Clinical Utility Study (NCT04171492)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ALTITUDE clinical utility study is designed to evaluate the performance of Nodify Lung testing (Nodify XL2 and Nodify CDT tests) in a randomized controlled study (RCT). The study is titled &#8220;A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules&#8221;. We received central institutional review board (IRB) approval in December 2019 and have an enrollment goal of 2,000 patients. The study objectives are to evaluate how the addition of the Nodify Lung test result impacts the clinical decision making for patients with new, incidentally identified solid lung nodules assessed as low to moderate risk of lung cancer. The trial has an adaptive study design with a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">blinded standard of care arm and 2:1 randomization for open-label results for the Nodify XL2 test. The study launched in December of 2020. Phase 1 of the study with only the Nodify XL2 test is expected to enroll 500 patients. Phase 2 of the adaptive study design will include an open-label arm for the Nodify CDT test, which is aligned with our commercial testing algorithm.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">INSIGHT Observational Study (NCT03289780)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The INSIGHT observational study is designed to evaluate the real-world clinical utility and performance of the IQLung (GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests) testing strategy. The title is &#8220;Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)&#8221; and the first patient enrolled on May 11, 2016. On June 27, 2023, we completed enrollment of 5,000 patients with non-small cell lung cancer. Final analysis with 3-year follow-up is estimated to be completed by 2026. Results of an interim analysis were presented most recently at the World Conference on Lung Cancer 2023. Additionally, data on the first 2,000 patients with 1-year follow-up data was published in the Journal for ImmunoTherapy of Cancer in September 2021. The study rationale is to guide the adoption of the VeriStrat test and inform medical decision making, including treatment choice, and enable the validation of additional mass spectrometry-based proteomic tests. The primary study objective is to describe the impact of the VeriStrat test results on treatment decisions, including but not limited to the percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat Good and those classified as VeriStrat Poor, and the percentage of patients receiving systemic therapy or supportive therapies only.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our lung cancer and nodule management tests, commercial efforts are focused on the promotion of our testing strategies to healthcare professionals actively involved in the diagnosis and treatment of lung cancer. Primarily focusing on pulmonology, the commercial team, consisting of specialty sales representatives, medical affairs, marketing and customer care representatives, works to educate and inform the entire patient care group consisting of physicians, nurses, office staff, laboratory personnel, and administration as to the appropriate use and value provided by our testing. The team&#8217;s goal is to drive test adoption through articulating the scientific and clinical evidence behind our tests, how they impact the clinical care of a patient, and how the tests can ultimately help to improve patient outcomes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients with pulmonary nodules are concentrated in the pulmonology sub-specialty, where additional resources such as lung cancer screening and nodule management clinics may exist to provide an increased level of care. We are also engaging large hospital systems in a &#8220;top-down&#8221; approach, with a goal of incorporating our tests into system-wide pathways and protocols.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After a physician orders our tests, blood is collected either in the physician office or laboratory, third-party &#8220;store front&#8221; patient service centers, or it can be collected in the patient&#8217;s home or workplace. We have contracted with a network of patient service centers and mobile phlebotomy services to be enable collection of blood samples outside of the physician office, at home or work for patients across the United States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on November 14, 2023, the Company announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+&#153; device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient&#8217;s upper arm. Capillary blood draws using the Tasso+ device enable blood specimen collection for healthcare providers who do not have convenient access to phlebotomy services or a licensed phlebotomist on staff in the clinic or office. The Tasso+ device was validated by Biodesix to be administered in minutes by any healthcare provider at the time of lung nodule evaluation, creating efficiencies in the Nodify Lung workflow. Biodesix received approval from the New York State Clinical Laboratory Evaluation Program (NYS-CLEP) to use the Tasso+ device as a specimen collection method in support of Nodify Lung testing after entering into a supply agreement with Tasso, Inc. The device is now available for clinical use to collect specimens for Nodify Lung testing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business development team is focused on selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally. Our team consists of customer facing business development associates that work with our biopharmaceutical customers to identify projects, draw up statements of work and negotiate service agreements. Alliance managers help to manage the contractual obligations and scope of the project, whereas our operations team assures the project is managed with adequate resources and delivers on time. We take a two-pronged approach generating business in this segment. Primarily, we leverage existing projects and relationships to expand sales in current accounts. We also actively map ongoing drug development projects in biopharmaceutical companies and target programs best suited to our platform for new test development.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary source of reimbursement for our tests in the United States is from third-party payers, including government payers, such as Medicare, and commercial payers, such as insurance companies. Reimbursement for laboratory tests in the United States is determined by various payers, including private third-party payers, managed care organizations, and state and federal health care programs, such as Medicare and Medicaid. In Medicare, coverage of an item or service depends on whether it is &#8220;reasonable and necessary&#8221; under Section 1862(a)(1)(A) of the Social Security Act (SSA). For single-source laboratory tests, this determination is typically made by the Medicare Administrative Contractor (MAC) with jurisdiction over the laboratory where the test is performed. Our Louisville, Colorado laboratory is currently under the jurisdiction of Novitas Solutions, Inc. Our De Soto, Kansas laboratory is under the jurisdiction of Wisconsin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Physicians Service Insurance Corporation (WPS), which participates in the MolDX program (administered by another MAC, Palmetto GBA) to set coverage policy for molecular diagnostic tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicare pays for clinical diagnostic laboratory tests (CDLTs), on the Clinical Laboratory Fee Schedule (CLFS). Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) added Section 1834A to the SSA, which established the current CLFS rate setting processes and coding provisions for CDLTs, and created a new subcategory of CDLTs called Advanced Diagnostic Laboratory Tests (ADLTs), with separate reporting and payment requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Section 1834A and its implementing regulations, clinical laboratories that receive the majority of their Medicare revenues from payments made under the CLFS and the Physician Fee Schedule report on a triennial basis (or annually for ADLTs), private payer rates and volumes for their tests with specific billing codes based on final payments made during a set data collection period. The payment rate for a test for the ensuing three-year period (or one year for ADLTs) is set at the weighted median of the rates reported under the specific billing code for that test. Newly established codes for CDLTs are priced until the next private payer rate reporting cycle either based on the payment rate of a comparable code on the CLFS, as determined by CMS ("crosswalking") or at the median of rates submitted by the individual MACs based on statutory and regulatory factors ("gapfilling"). New ADLTs are initially priced at &#8220;actual list charge&#8221; for a nine-month period, after which they are priced based on private payer rates, with a recoupment provision if actual list charge is more than 130% of the weighted median of private payer rates reported.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The various payers in the United States also determine their own billing rules. In December 2020, Medicare revised its billing rules for clinical laboratory tests to require cancer-related protein-based Multianalyte Assays with Algorithmic Analyses to be billed directly to Medicare by the performing laboratory in most cases when performed on a specimen collected from a hospital outpatient. Molecular pathology tests and most ADLTs are also generally required to be billed directly to Medicare by the laboratory under these circumstances.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 6, 2023, the Company announced that the Centers for Medicare &amp; Medicaid Services (CMS) has designated the Nodify CDT Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023. Obtaining ADLT status is a recognition that the Nodify CDT test meets the stringent criteria established under the Protecting Access to Medicare Act of 2014. ADLT status is reserved for innovative tests with Medicare coverage that are offered and furnished by a single laboratory and provide new clinical diagnostic information that cannot be obtained from any other test or combination of tests. The Nodify XL2 test was previously awarded ADLT status on May 17, 2019. We believe that our lung cancer tests can both improve patient outcomes and help guide cost-effective treatment choices for patients with and at-risk of lung cancer. Achieving broad coverage and adequate reimbursement for each of our tests is a key component of our financial success and will continue to be important over time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with applicable laws and regulations, as well as internal compliance policies and procedures adds complexity to the billing process. The Centers for Medicare &amp; Medicaid Services (CMS) is responsible for overseeing the establishment of new Healthcare Common Procedure Coding System (HCPCS) codes for billing the Medicare program and other payers. CMS continuously evaluates and implements changes to the Medicare billing, coding, and reimbursement processes. To receive reimbursement from third-party payers, we bill our tests using a variety of HCPCS codes or Current Procedural Terminology (CPT) codes, as defined by the American Medical Association. For some of the tests we conduct, there may not be a specific CPT or HCPCS code, in which case the test may be billed under a miscellaneous code for an unlisted molecular pathology procedure or unlisted multiple anolyte test with algorithmic analysis (MAAA) procedure. Because these miscellaneous codes do not describe a specific service, the third-party payer claim may be examined to determine the service provided, whether the service was appropriate and medically necessary and whether payment should be rendered. This process can result in a delay in processing the claim, a lower reimbursement amount, and/or denial of the claim.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We primarily face competition from lung cancer diagnostic solutions companies in the United States, Europe and Asia seeking to answer clinical questions in the space, all of whom provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories, and other medical facilities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnosis&#8212;Nodule Management</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not aware of any other company that offers two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. We are aware of efforts by Veracyte, Inc. to develop and validate a test that may be competitive to the Nodify XL2 and/or Nodify CDT tests in the future. Additionally, Veracyte currently markets a test that is used post-bronchoscopy that is not competitive with our pre-bronchoscopy nodule risk assessment tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment Guidance and Monitoring&#8212;NSCLC</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are unaware of any other diagnostic test available, commercially or in development, that will compete with our VeriStrat immune profiling test. There is substantial interest and activity in tumor profiling through liquid biopsy. Our genomic test offerings, the GeneStrat ddPCR and GeneStrat NGS tests, face competition from academic hospital laboratories, and companies such as Guardant Health and Foundation Medicine. We believe that there are several companies and academic research institutions in the process of developing tests for monitoring patients or following treatment for recurrence or progression of lung cancer.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biopharmaceutical Diagnostic Discovery, Development &amp; Testing Services</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are aware of a number of companies who compete with our diagnostic tests and services, including diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. From the perspective of tumor profiling, we believe Guardant Health and Foundation Medicine are our most significant competitors. Conversely, in the immune profiling market, we believe Adaptive Biotechnologies and Personalis are our most significant competitors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Laboratory Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout 2023, we performed the VeriStrat, GeneStrat ddPCR, and GeneStrat NGS tests in our Boulder, Colorado high-complexity CLIA certified clinical laboratory. The laboratory was College of American Pathology (CAP) accredited, New York State Department of Health (NYSDOH)&#8212;permitted and licensed, ISO 13485:2016 Quality Management Systems&#8212;Requirements for Regulatory Purposes for Medical Devices certified, along with all other states that require licensing: California, Maryland, Pennsylvania, and Rhode Island. All aspects of the testing process from receipt of the test requisition form through to delivery of test results were performed in the Boulder, Colorado facility. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within three days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we relocated our Boulder, Colorado clinical laboratory to Louisville, Colorado. Throughout this transition, we have ensured the maintenance and updating of all relevant certifications and licenses to accurately reflect our new location, guaranteeing our commitment to upholding the highest standards of quality and compliance. As a result, our laboratory operations continued seamlessly without delaying testing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Nodify XL2 and Nodify CDT tests are performed in our De Soto, Kansas high-complexity CLIA certified clinical laboratory. This clinical laboratory is also CAP-accredited, NYSDOH&#8212;permitted and licensed, ISO 13485:2016 Quality Management Systems&#8212;Requirements for Regulatory Purposes for Medical Devices certified and licensed by California, Maryland, Pennsylvania, and Rhode Island. Receipt of requisitions and testing is performed in our De Soto, Kansas clinical laboratory. Delivery of the test results is performed by personnel from our Louisville, Colorado headquarters. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within five days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Personnel in both facilities are responsible for quality assurance oversight, licensing, and regulation compliance and maintenance to ensure data integrity and consistent, validated processes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supply Chain</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party suppliers to provide certain components of our diagnostic tests, including a select few (located in the United States, Europe and China), as critical single source providers of components. Bio-Rad, as described below, is the sole source supplier for our GeneStrat test. Oncimmune is also the sole source supplier for our Nodify CDT tests but there are known secondary suppliers for these materials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test, but these supplies are able to be supplied by known suppliers. A disruption to this supply would negatively impact our ability to perform the GeneStrat tests until alternatives could be validated.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All materials for our VeriStrat test and Nodify XL2 test have alternative suppliers readily available, and a disruption in any single supplier would not materially impact our ability to deliver the test.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have initiated the second source qualification process for the majority of these critical components, however, we may not be successful in securing second sourcing for all of them at all or on a timely basis. A disruption to this supply would negatively impact our ability to perform these tests until an alternative supplier could be validated.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends, in part, on our ability to obtain and maintain intellectual property and proprietary protection for our products and other know-how, to operate our business without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of others, and to defend and enforce our intellectual property and proprietary rights. We take efforts to protect our proprietary position using a variety of methods, which include pursuit of United States and foreign patent applications related to our proprietary technology, inventions and improvements that we determine are important to our business. We also may rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities to develop and maintain our proprietary position. For more information regarding risks relating to intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have invested heavily in the protection of our key assets, namely the VeriStrat&#174; and GeneStrat&#174; tests, and we acquired a patent portfolio relating to the Nodify XL2&#174; and Nodify CDT&#174; tests in our acquisitions of Indi in June 2018, and of Oncimmune USA in October 2019 from Oncimmune Limited (Oncimmune). We own patents and patent applications as well as trade secrets relating to our products currently in development, a collection device for whole blood, our business strategy, client lists and business methods. Further, we have expanded our access to key intellectual property through license and co-development agreements, including our Non-Exclusive License Agreement with Bio-Rad (the Bio-Rad License), which allows us to use the Droplet Digital PCR&#153; technology developed by Bio-Rad and which we employ in our GeneStrat test.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patent strategy has focused on creating and acquiring protection for our VeriStrat and Nodify XL2 proteomic tests, while utilizing trade secret and some methods patent protection for our genomic test (the GeneStrat ddPCR and GeneStrat NGS&#174; tests) and ELISA test (the Nodify CDT test). We have entered into a non-exclusive license agreement with Bio-Rad, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. Bio-Rad owns patents relating to ddPCR and to which we have a non-exclusive license to utilize for the performance of ddPCR in cancer detection testing for third parties as set forth in the Bio-Rad License Agreement. We have patent protection in the United States and other countries around the world for the primary use of the VeriStrat test for profiling of patients with NSCLC, and various other uses of the VeriStrat test, such as breast cancer, prostate cancer, head and neck cancer have received patent protection. We have also received patent protection relating to our core classifier development program, our Diagnostic Cortex platform and our approaches to using MALDI-ToF technology (DeepMALDI&#174; techniques). Additionally, our first device patent was issued in 2019 for our internally designed blood collection device.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our patent portfolio includes 52 issued United States patents, 64 issued foreign patents, and 33 pending applications (including 19 foreign patent applications). With regard to our product development efforts, new applications have been filed around developments relating to COVID/micro-organisms diagnostics, new analytic methodologies using Shapley values and semi-quantitative spectra analysis in MALDI, and national stage applications are now in active prosecution to protect our pipeline ROR and PIR tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent portfolio can be broken down into five major categories:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued patents and patent applications relating to the VeriStrat and Nodify tests and uses of these tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued patents and patent applications relating to methods for developing classifiers, including using the Diagnostic Cortex and DeepMALDI technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued patents and patent applications relating to tests currently in development;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued patents and patent applications relating to our novel blood collection device; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued patents and patent applications relating to tests developed for our third-party partners.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patents relating to the VeriStrat test are scheduled to expire between 2026 and 2032. The patents relating to the Nodify XL2 test are scheduled to expire beginning in 2031 (excluding any patent term extension granted by the United States Patent and Trademark Office (USPTO)), and the patents relating to the Nodify CDT test are scheduled to expire in 2027. The patent related to the blood collection device is scheduled to expire in 2039. Should our current patent applications in prosecution in the United States issue, the resulting patents would be scheduled to have expiration dates between 2036 and 2040 (excluding any patent term extension(s) granted by the USPTO).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have three pending Patent Cooperation Treaty (PCT) applications. PCT patent applications are not eligible to become issued patents until, among other things, we file such PCT applications as national stage patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to any such PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. Provisional patent applications are not eligible to become issued patents but can become the basis of PCT foreign stage and United States non-provisional patent applications, if such applications are filed within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent applications, we will lose our priority date and any patent protection on the inventions disclosed in any such provisional patent application.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed, including the United States, the patent term is generally 20 years from the earliest filing date of a non-provisional patent application, assuming the patent has not been terminally disclaimed over a commonly-owned patent or a patent naming a common inventor, or over a patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research agreement. The life of a patent, and the protection it affords, is therefore limited and once the patent lives of our issued patents have expired, we may face competition, including from other competing technologies. In the United States, the term of a patent may also be eligible for patent term adjustment for delays within the USPTO. The term of a patent that covers a biological product may also be eligible for patent term extension when FDA approval is granted for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements are met. Any such patent term extension can be for no more than five years, only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering the approved biological product, a method for using it or a method for manufacturing it may be extended. We may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. There can be no assurance that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to maintain and solidify our proprietary and intellectual property position will depend on our success in obtaining effective patent claims and maintaining and enforcing claims that are granted. However, our owned and licensed patents could be invalidated or narrowed or otherwise fail to adequately protect our proprietary and intellectual property position and our pending owned and licensed patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because branding is as much a part of any intellectual property strategy as patent or trade secret protection we have a number of registered and pending trademarks relating to our company and products. We have received or filed for trademark protection in the United States for our trade name (Biodesix), the names of five of our commercial tests (namely the VeriStrat, GeneStrat ddPCR, GeneStrat NGS, Nodify XL2 and Nodify CDT tests), and a suite of research tests (ImmunoStrat&#174; test), as well as having trademark protection for our core development and methodological platforms, such as our Diagnostic Cortex and DeepMALDI technologies. In all, as of December 31, 2023, we have 18 uniquely registered United States trademarks, 8 of which (including Biodesix, VeriStrat, and GeneStrat) have received foreign issuances as well, with four trademarks pending approval from the USPTO. We will continue to pursue protection in the United States and abroad for our branded assets and will continue to use branding to protect products currently in development, key Biodesix developments and non-trade secret methodologies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on trade secrets, including know-how, confidential information, unpatented technologies and other proprietary information, to strengthen or enhance our competitive position, protect and maintain aspects of our business that are not amenable to, or that we do not presently consider appropriate for, patent protection, and prevent competitors from reverse engineering or copying our technologies. We have decided that some technologies, such as our laboratory methodologies (including sample preparation and assay development), and some information (such as client and billing information) are best kept as trade secrets. However, trade secrets and confidential know-how are difficult to protect. To avoid inadvertent and improper disclosure of trade secrets, and to avoid the risks of former employees using these trade secrets to future employment, it is our policy to require employees, consultants and independent contractors to assign all rights to intellectual property they develop in connection with their employment with or services for the Company to the Company. We also protect our existing and developing intellectual property expressly through confidentiality provisions in agreements with third parties. There can be no assurance, however, that these agreements will be self-executing or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information, or adequate remedies in the event of unauthorized use or disclosure of such trade secrets or other intellectual property or proprietary information.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our trade secrets and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to pursue additional intellectual property protection to the extent we believe it would advance our business objectives, which may include objectives within and outside the United States. Despite our efforts to protect our intellectual property rights, and despite the breadth of protection that has issued around our key assets, these rights may not be respected in the future or may be circumvented or challenged (and potentially invalidated) in a legal proceeding in any jurisdiction where we have intellectual property rights. In addition, the laws of various foreign countries where we have received intellectual property protection and where we may eventually distribute our products may not afford the same protections or assurances to the same extent as the laws in the United States. See &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical laboratory tests like our diagnostic tests are regulated under CLIA and state law. The FDA regulates medical devices pursuant to the FDCA, including many diagnostic test kits, such as in vitro diagnostic tests (IVDs). However, most Laboratory Developed Tests (LDTs) are not currently subject to the FDA&#8217;s regulation (although reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to such regulation) because the FDA has historically exercised enforcement discretion over LDTs. LDTs are a subset of IVDs that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently market our GeneStrat, VeriStrat, Nodify XL2 and Nodify CDT tests as LDTs in the United States. As a result, we believe our diagnostic services are not currently subject to the FDA&#8217;s enforcement of its medical device regulations and the applicable FDCA provisions. If the FDA disagrees with the LDT status of any of our tests, the FDA may consider the test to be an unapproved medical device and may subject us to FDA enforcement action, including, without limitation, requiring us to seek clearance, authorization or approval for the laboratory test. If the FDA were to begin enforcement with respect to our LDTs, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA&#8217;s authority to regulate LDTs has been contested for many years, and there have been several legislative and administrative proposals regarding LDT regulation seeking to end or limit enforcement discretion and to bring LDTs under new or existing FDA regulatory frameworks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood that Congress will pass legislation or the extent to which such legislation may affect the FDA&#8217;s plans to regulate certain LDTs as medical devices or pursuant to a new framework. It is also unclear at this time whether the FDA will finalize its plans to end enforcement discretion in the absence of legislation, via notice and comment rulemaking or otherwise. Until legislation is passed reforming the federal government&#8217;s regulation of LDTs or until the FDA finalizes its proposed rulemaking to end enforcement discretion, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval. Even if a new framework is not established via legislative or administrative action, the FDA may attempt to regulate and enforce against certain LDTs on a case-by-case basis at any time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 29, 2023, FDA announced a proposed rule to amend its regulations to explicitly regulate LDTs as IVD tests in accordance with the agency&#8217;s regulatory authority over medical devices and to phase out its enforcement discretion policy for LDTs. If this rule is finalized, our tests that are currently offered as LDTs would become subject to statutory and regulatory provisions that are applicable to medical devices, including but not limited to, medical device reporting and correction and removal reporting requirements, quality systems regulations, registration and listing requirements, and premarket review requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA finalizes its proposed rule and pre-market review is required, our business could be negatively impacted as a result of commercial delay that may be caused by the new requirements. The cost of conducting clinical trials and otherwise developing data and information to support pre-market applications may be significant. If we are required to submit applications for our currently marketed tests, we may be required to conduct additional studies, which may be time-consuming, costly and could result in our currently-marketed tests being withdrawn from the market. Continued compliance with the FDA&#8217;s regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA including penalties for failure to comply with these requirements. Failure to comply with applicable regulatory requirements could result in an enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. There are other regulatory and legislative proposals that would increase general FDA oversight of clinical laboratories and LDTs. Until the FDA finalizes its regulatory position regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government&#8217;s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval. The outcome and ultimate impact of such proposals on the business is difficult to predict at this time and we are monitoring developments and anticipate that our products will be able to comply with requirements that may be imposed by the FDA. In the meantime, we maintain our CLIA accreditation, which permits the use of LDTs for diagnostics purposes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal and State Laboratory Licensing Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biodesix Boulder, Colorado clinical laboratory was a CAP-accredited clinical laboratory regulated by CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. In addition to holding a CLIA Certificate and CAP laboratory accreditation, Biodesix&#8217;s Quality Management System (QMS) holds an ISO 13485:2016 certificate (successfully passed surveillance audit in March 2023). The Biodesix Boulder, Colorado clinical laboratory received approval from the NYSDOH, NYS CLEP in Soluble Tumor Markers, and Molecular and Cellular Tumor Markers and Virology as well as held state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CLIA regulations establish standards for proficiency testing; facility administration; general laboratory systems; pre-analytic, analytic systems, post- analytic systems; personnel qualifications and responsibilities; quality control, quality assessment; and specific provisions for laboratories performing moderate to high complexity tests. Our Boulder, Colorado clinical laboratory was inspected biennially as part of its ongoing certification under CLIA certificate of accreditation by CAP. The Boulder, Colorado clinical laboratory most recently passed its CAP inspection in February April 2023. In January 2024, we relocated our Boulder, Colorado clinical laboratory to Louisville, Colorado. All certifications and licenses have been successfully updated to accurately reflect our new location. All laboratory operations continued seamlessly without delaying testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate applicable to the type of laboratory examinations it performs and that it complies with, among other things,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">standards covering operations, personnel, facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services are accurate, reliable and timely.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biodesix De Soto, Kansas clinical laboratory is a CAP-accredited clinical laboratory regulated by CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. In addition to holding a CLIA Certificate and CAP laboratory accreditation, the De Soto, Kansas clinical laboratory passed its CAP inspection in May 2023. Biodesix&#8217;s QMS holds an ISO 13485:2016 certificate (recently passed surveillance audit in January 2024). The De Soto, Kansas clinical laboratory has received approval from the NYSDOH, NYS CLEP in Soluble Tumor Markers and Diagnostic Immunology as well as holding state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The International Organization for Standardization (ISO) is an independent, non-governmental international organization that defines world-class specifications for products, services and systems, to ensure quality, safety and efficiency. ISO 13485:2016 is a harmonized, international regulatory benchmark for quality management systems that addresses most or all of the QMS requirements in markets including the United States, European Union, Australia, Japan and Canada. The ISO 13485:2016 certificate confirms that an organization operates a QMS that conforms to the standards established by ISO. On January 31, 2024, the FDA issued a final rule to harmonize and modernize its Quality System Regulation (QSR), which would supplant the existing requirements with ISO 13485:2016. The rule amends the current good manufacturing practice requirements of the QSR in 21 CFR 820. The QMSR rule emphasizes risk management activities and risk-based decision making and aims to reduce regulatory burdens on device manufacturers and importers by harmonizing domestic and international requirements. Device manufacturers and importers will have two years to modify their quality systems to meet the requirements of the QMSR rule by February 2, 2026.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. Laboratories such as ours, which are performing high complexity testing, are required to meet more stringent CLIA requirements than laboratories performing less complex tests, and therefore our laboratories are also subject to random, unannounced survey and inspection at any time. In addition, a laboratory that is certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and use proprietary LDTs. CLIA requires analytical validation including accuracy, precision, specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance standards applicable to the testing we perform may change over time and any such changes could have a material effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. State laws may require that out-of-state laboratories maintain an in-state laboratory license to perform tests on samples from patients who reside in that state. As a condition of licensure, certain states may require that laboratory personnel meet qualifications, quality control procedures, facility requirements, record maintenance requirements or other state-specific requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our Louisville, Colorado clinical laboratory is located in the State of Colorado, we do not need a specific State of Colorado laboratory license, however, we maintain licenses to conduct testing in other states where nonresident laboratories are required to obtain state laboratory licenses. We maintain licenses for our Louisville, Colorado and De Soto, Kansas laboratories with the NYSDOH. We also hold licenses in other states in which we operate, including California, Maryland, Pennsylvania and Rhode Island, that require licensing of out-of-state laboratories under certain circumstances. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states until such requirements are met.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with CLIA certification and state clinical laboratory licensure requirements may result in a range of enforcement actions, including certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and revocation of the laboratory&#8217;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CLIA and state laws and regulations, operating together, sometimes limit the ability of laboratories to offer consumer-initiated testing, also known as direct access testing. We do not offer direct access testing and instead require that our tests be ordered by licensed healthcare providers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Louisville, Colorado and De Soto, Kansas laboratories are certified and adhere to the NYS CLEP, based on New York State Public Health Law, Article 5 Title 5. NYS CLEP is exempt from CLIA and establishes their own method of laboratory certification and test validation approval. To process New York State patient specimens a laboratory must submit a robust analytical and clinical validation package to demonstrate clinical utility of the test and receive approval prior to offering the test in the state of New York. All of our tests have obtained NYS CLEP approval including GeneStrat ddPCR, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT tests. NYS CLEP requires semi-annual inspections to ensure the laboratory meets all general and specialty standards. Due to the pandemic, NYSDOH CLEP routine re-inspections were delayed by multiple years. Most recently the Boulder, Colorado laboratory successfully passed the NYS CLEP audit in October 2023. The De Soto, Kansas laboratory passed NYS CLEP inspection in May 2019 and still pending new audit assignment.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory framework for medical devices in the United States and Internationally</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, which are defined to include, among other things, IVDs. The FDA regulates the research, design, development, pre-clinical and clinical testing, manufacturing, safety, effectiveness, packaging, labeling, storage, recordkeeping, pre-market clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical devices. It is possible that one of our current, or future, tests will be subject to FDA authority and oversight as either an IVD or a CDx pursuant to the FDA&#8217;s authority to regulate medical devices under the FDCA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical devices are subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product design, development, manufacture, and release;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory and clinical testing, labeling, packaging, storage and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product safety and efficacy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">service operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">record keeping;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product marketing, promotion and advertising, sales and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">post-market approval studies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product import and export</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries in which we may offer any of our diagnostic tests in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, violation of the local anti-kickback law may also constitute a violation of the Foreign Corrupt Practices Act of 1997 (FCPA).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FCPA prohibits any United States individual, business entity or employee of a United States business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the Securities and Exchange Commission (SEC) to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The standard of intent and knowledge in anti-bribery cases is minimal. Intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA&#8217;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2 million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-Bribery Act.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When marketing our diagnostic tests outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our diagnostic tests or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the European Economic Area (EEA), a medical device must meet the Medical Devices Directive&#8217;s (MDD)/In Vitro Medical Devices Directive&#8217;s (IVDD) Essential Requirements or, applicable on May 26, 2021, the Medical Devices Regulation&#8217;s (MDR) / applicable on May 26, 2022, In Vitro Medical Devices Regulation&#8217;s (IVDR) General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation. Before placing a medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high-risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits and examines the device&#8217;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers of medical devices must document in a clinical evaluation report (CER) the evaluation of the clinical data related to the device. The CER is part of the device&#8217;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the benefit-risk ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter alia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#8220;substantially equivalent&#8221; devices is very restrictive and requires, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter alia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#8220;equivalent device&#8221; is not its own, that the manufacture has in place a contract with the manufacturer of the &#8220;equivalent device.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. Initially, the government stated the CE mark will be accepted in the UK until July 1, 2023. However, on July 1, 2023, the government updated their guidance for regulating medical devices stating their intention to extend recognition and acceptance of the CE marking for placing most goods on the market in Great Britain, indefinitely, if the device was placed on the EU market before January 1, 2021.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Device classification</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the FDCA, medical devices are classified into one of three classes: Class I, Class II or Class III, depending on the degree of risk to patients that is associated with each medical device and the amount of oversight needed to provide reasonable assurances with respect to safety and effectiveness of the medical device.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the FDA&#8217;s Center for Devices and Radiological Health (CDRH) announced that the Center intends to initiate the reclassification process for most IVD tests that are currently Class III (high risk) into Class II (moderate risk). The majority of these tests are infectious disease and companion diagnostic IVDs. Reclassification would allow manufacturers of certain types of tests to seek marketing clearance through the less burdensome premarket notification (510(k)) pathway rather than the premarket approval pathway, the most stringent type of FDA medical device review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#8217;s QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class II devices are subject to the General Controls as well as any special controls deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process, although some Class II devices are exempt from the 510(k) requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class III devices include devices deemed by the FDA to pose the greatest risk: such as life-supporting or life-sustaining devices, implantable devices, or those deemed novel and not substantially equivalent to a predicate device following the 510(k) process. CDx tests are regularly considered Class III devices.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Premarket submission process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless a statutory or regulatory exemption or enforcement discretion policy applies, before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, the manufacturer must obtain the FDA&#8217;s: (1) permission for commercial distribution under section 510(k) of the FDCA (510(k) clearance); or (2) approval of a Premarket Approval (PMA); or (3) de novo classification and authorization. These processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 510(k)-clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and therefore a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different questions of safety or effectiveness than the predicate device. Premarket notifications typically include bench, analytical, and preclinical data. Clinical data is sometimes required to support substantial equivalence. If a manufacturer obtains a 510(k) clearance for its device and then makes a modification that could significantly affect the device&#8217;s safety or effectiveness or constitutes a major change or modification in the intended use of the device, a new clearance, authorization or approval may be required.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous, costly, and time-consuming PMA approval process or seek reclassification of the device through the De Novo process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a predicate device is not available, the FDA allows the submission of a direct De Novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. A De Novo request includes a description of the device, a discussion of the general controls and any specific controls recommended to provide reasonable assurance of the safety and effectiveness of the device, a description of the probable benefits of the device when compared to the probable risks when the device is used as intended, non-clinical data including bench performance and animal testing, technical information about the device, and clinical data (if applicable). FDA&#8217;s goal is to review a De Novo request within 150 review days after receiving the petition. As with a 510(k) submission or PMA, the length of the review can be prolonged if the FDA requests additional information from the applicant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain a PMA, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling, and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once filed as a PMA, the FDA has 180 days to review the filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to approval of a PMA, the FDA may conduct inspections of any clinical trial data and clinical trial sites, as well as inspections of any manufacturing facility and processes. The FDA can delay, limit or deny approval of a PMA application for many reasons, including (1) the device may not be shown safe or effective to the FDA&#8217;s satisfaction; (2) the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval; (3) the manufacturing process or facilities may not meet applicable requirements; and (4) changes in FDA approval policies or adoption of new regulations may require additional data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when data is available. The PMA process can be expensive, uncertain and lengthy. A number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. New PMA applications or PMA supplements are required for any modifications to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a condition of PMA application approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer-term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 510(k), De Novo or PMA processes can be expensive, lengthy and unpredictable. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k)-clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device, which may limit the market for the device.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companion Diagnostics and the Premarket Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that one of our future product candidates may include a companion diagnostic or complementary diagnostic (collectively CDx). CDx&#8217;s can identify patients who are most likely to benefit from a particular therapeutic product, identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product, or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. The use of the CDx will be stipulated in the labeling of both the CDx and the therapeutic product. The FDA may require an application for the CDx to be separate from the drug approval process, and this could potentially delay the approval of any new drug application or the CDx, or complicate the review process. CDx&#8217;s are generally regulated as Class III medical devices by the FDA and are therefore most often subject to the PMA approval process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA issued guidance in July 2016 for the co-development of CDx tests with a therapeutic product and issued another draft guidance in December 2018 specific to oncology CDx tests. The FDA finalized this draft guidance in April 2020 in &#8220;Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products.&#8221; The guidance is meant to guide the development of CDx products, which are defined as IVDs that provide information that is essential for the safe and effective use of the therapeutic product. A CDx is often developed and approved or cleared contemporaneously with the therapeutic, and the use of the CDx is stipulated in the labeling of both the CDx and the corresponding therapeutic product. While it supports contemporaneous marketing authorizations, if there are any deficiencies in the submissions, the FDA may place a PMA review of a CDx on hold or request additional testing, which could potentially delay the approval of the corresponding new drug application or the marketing authorization of the CDx, or otherwise complicate the review process. Some oncology CDx tests can be developed in a way that results in labeling for a specific group of oncology therapeutic products, rather than a single therapeutic product.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-Market FDA Regulation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if regulatory clearance, authorization or approval of a device is granted, the FDA may impose limitations on the uses and indications for which the device may be labeled and promoted, and the device remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared, authorized or approved. After a device, including a device exempt from FDA premarket review, is placed on the market, numerous post-market regulatory requirements apply, and the FDA has broad authority to enforce these requirements. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties; unanticipated expenditures, including requirements to repair, replace, and/or refund the cost of the devices, recall or seizure of our products; operating restrictions, partial suspension or total shutdown of production; the FDA&#8217;s refusal of our requests for 510(k) clearance, De Novo classification, or PMA of new products, new intended uses or modifications to existing products; the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; and withdrawing 510(k) clearance or PMAs that have already been granted and criminal prosecution. In the event that a supplier fails to maintain compliance with the FDA&#8217;s or our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal and State Fraud and Abuse Laws</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute (AKS), the federal prohibition against physician self-referral (Stark Law), the Eliminating Kickbacks in Recovery Act (EKRA), and the federal False Claims Act (FCA). We are also subject to similar state and foreign fraud and abuse laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The AKS (Social Security Act &#167; 1128B(b)) prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any item or service that may be reimbursable, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. There are a number of statutory exceptions and regulatory safe harbors to the AKS that provide protection from AKS liability to arrangements that fully satisfy the applicable requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EKRA (18 USC &#167; 220) prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program. The term &#8220;health care benefit program&#8221; is broadly defined such that EKRA extends to referrals reimbursed by both governmental and commercial third-party payers. EKRA includes a number of statutory exceptions that provide protection from EKRA liability if the applicable requirements are met.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Stark Law (Social Security Act &#167; 1877) generally prohibits, among other things, clinical laboratories and other so-called &#8220;designated health services&#8221; entities from billing Medicare for any designated health services when the physician ordering the service, or any member of such physician&#8217;s immediate family, has a financial relationship, such as a direct or indirect investment interest in or compensation arrangement with the billing entity, unless the arrangement meets an exception to the prohibition. The Stark Law also prohibits physicians from making such referrals to a designated health services entity. There are also similar state laws that apply where Medicaid and/or commercial payers are billed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FCA (31 USC &#167; 3729) imposes penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the government that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#8220;qui tam&#8221; whistleblower to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $13,508 to $27,018 per false claim or statement for penalties assessed after January 30, 2023, with respect to violations occurring after November 2, 2015.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payer knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular provider, practitioner, or supplier, and contracting with an individual or entity that the person knows or should know is excluded from participation in a federal health care program. In addition, federal criminal statutes created by the Health Insurance Portability and Accountability Act (HIPAA) prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to these federal laws, there are often similar state anti-kickback and false claims laws that typically apply to arrangements involving reimbursement by a state-funded Medicaid or other health care program. Often, these laws closely follow the language of their federal law counterparts, although they do not always have the same exceptions or safe harbors. In some states, these anti-kickback laws apply with respect to all payers, including commercial payers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A number of states have enacted laws that require pharmaceutical and medical device companies to monitor and report payments, gifts and other remuneration made to physicians and other healthcare providers, and, in some states, marketing expenditures. In addition, some state statutes impose outright bans on certain manufacturer gifts to physicians or other health care professionals. Some of these laws, referred to as &#8220;aggregate spend&#8221; or &#8220;gift&#8221; laws, carry substantial fines if they are violated.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs and extensive annual trainings for all of our employees and contractors. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-Corruption</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FCPA and similar international bribery laws make it unlawful for persons or entities to make payments to foreign government officials to assist in obtaining and maintaining business. Specifically, the anti-bribery provisions of the FCPA prohibit any offer, payment, promise to pay, or authorizing the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to do or omit to do an act in violation of his or her duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business, to any person. In addition to the anti-bribery provisions of the FCPA, the statute also contains accounting requirements designed to operate in tandem with the anti-bribery provisions. Covered companies are required to make and keep books and records that accurately and fairly reflect the transactions of the company and devise and maintain an adequate system of internal accounting controls. With our international operations through our third-party partnerships, we could incur significant fines and penalties, as well as criminal liability, if we fail to comply with either the anti-bribery or accounting requirements of the FCPA, or similar international bribery laws. Even an unsuccessful challenge of our compliance with these laws could cause us to incur adverse publicity and significant legal and related costs. We successfully passed our latest FCPA compliance review in 2023 with no findings.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Privacy and Data Protection Laws</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous federal and state laws and regulations, including HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (HITECH) Act, govern the collection, dissemination, security, use and confidentiality of protected health information (PHI) and personal information. In the course of performing our business we obtain personal information, including PHI. Laws and regulations relating to privacy, data protection, and consumer protection are evolving and, in some cases, particularly with regard to newer laws, may be subject to potentially differing interpretations. Under HIPAA and HITECH, the HHS issues regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of PHI, used or disclosed by CEs and their authorized business associates (BAs). Because we are a health care provider that electronically transmits health care information, and we also provide certain services to CEs and receive PHI from them, we are at times either a CE or a BA, as defined by HIPAA. Our subcontractors that create, receive, maintain, transmit or otherwise process PHI on our behalf are HIPAA BAs and must also comply with HIPAA, as applicable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA and HITECH include the privacy and security rules, breach notification requirements and electronic transaction standards. The privacy rule governs the use and disclosure of PHI, generally prohibits the use or disclosure of PHI except as permitted under the rule, and mandates certain safeguards to protect the privacy of PHI. The privacy rule also sets forth individual rights, such as the right to access or amend certain records containing such individual&#8217;s PHI, or to request restrictions on the use or disclosure of such individual&#8217;s PHI. The security rule requires CEs and BAs to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI (also referred to as ePHI) by implementing administrative, physical and technical safeguards. Under HIPAA&#8217;s breach notification rule, a CE must notify individuals, the Secretary of HHS, and in some circumstances, the media of certain breaches of unsecured PHI or ePHI, and similar breach notification provisions apply to certain BAs under the HITECH Act.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Penalties for failure to comply with a requirement of HIPAA and HITECH vary depending on the number and nature of the violations and any history of prior violations, but can be significant and include civil monetary or criminal penalties. HIPAA is enforced by the Department of Health and Human Services, Office for Civil Rights, and HIPAA also authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in improper use, access to or disclosure of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA CEs, such as us, and their BAs for compliance with the HIPAA privacy and security standards and breach notification rules. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be subject to state privacy, cybersecurity, and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. California, for example, has enacted the Confidentiality of Medical Information Act, which, in addition to HIPAA and HITECH, sets forth standards with which all California health care providers must abide. Colorado has enacted the Colorado Privacy Act, and Virginia has enacted the Consumer Data Protection Act, both of which also have standards that must be complied with that supplement Federal data protection requirements. State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA, and state laws may differ from each other in regards to personal information treatment, which may complicate compliance efforts. For instance, the California Consumer Privacy Act (CCPA) became effective on January 1, 2020 and was amended by the passage of the California Privacy Rights Act (CPRA) in November of 2020, which amendments came into force on January 1, 2023. The CCPA, among other things, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. Although there are certain exemptions for PHI and clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future and the CCPA may increase our compliance costs and potential liability. Additionally, the CPRA imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency &#8211; the California Privacy Protection Agency &#8211; specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that could continue to make compliance challenging and costly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Federal Trade Commission (FTC) and state attorneys general enforce consumer protection laws that prohibit unfair and deceptive acts and practices, including Section 5 of the FTC Act, which creates standards for the collection, use, dissemination and security of health-related and other personal information. Claims of unfair or deceptive trade practices regarding privacy and security can lead to significant liabilities and consequences, including regulatory investigations, penalties, fines and orders as well as civil claims, which could impact our data practices and operations or cause reputational damage.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may add additional compliance burden and complexity. For example, in the EEA, the collection and use of personal data is governed by the European Union's General Data Protection Regulation (GDPR). In the United Kingdom, the GDPR has been adopted in substantially the same form, however the UK may potentially make revisions in the coming years. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data. European and United Kingdom data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to ensure a legal bases to process personal information, provide robust disclosures to individuals, facilitate data subject rights, provide data security breach notifications within 72 hours after discovering a breach in certain circumstances, limit retention of personal information and apply enhanced protections to health data and other categories of sensitive personal information. The GDPR also has requirements around international transfers of personal data. Requirements around transfers to the United States and other jurisdictions have increased since a July 2020 decision by the Court of Justice of the European Union invalidated the Privacy Shield as a basis to transfer personal data from Europe to the United States, and added requirements for reliance on Standard Contractual Clauses. Regulatory guidance on requirements for international transfers, and other GDPR compliance matters, continues to evolve; for example, in July 2023, the European Commission completed adoption of a new adequacy decision for data flows to the United States. However, it is widely expected that the new adequacy decision will itself face scrutiny from the Court of Justice, underscoring that GDPR compliance is an ongoing endeavor. Failure to comply with the requirements of the GDPR may result in fines of up to &#8364;20 million or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. To comply with the GDPR and other applicable international data protection laws and regulations, we may be required to put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business relies on secure and continuous processing of information and the availability of our IT networks and IT resources, as well as critical IT vendors that support our technology, research and other data processing operations. While we take steps to protect our systems and data, security incidents, data breaches, computer malware and computer hacking attacks have become more prevalent across industries, including the life sciences sector, and may occur on our systems or those of our third-party service providers. Unauthorized persons may in the future be able to exploit weaknesses in the security systems of our (or our third-party service providers) IT networks and gain access to PHI and other personal information, sensitive trade secrets, or other proprietary information. Any wrongful use or disclosure of PHI, other personal information, trade secrets or other proprietary information by us or our third-party service providers could subject us to regulatory fines or penalties, third-party claims or otherwise could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, failures to adequately protect PHI or our IT systems could be viewed as violations of the HIPAA security rule or violations of other applicable information security laws, regulations, contractual obligations or industry standards, and could further result in costly data breach notification obligations that negatively impact our reputation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, data security incidents or data breaches, as well as attacks on our IT systems, could result in operational disruptions or data loss or corruption that could adversely impact our business and operations, resulting in substantial investment of resources to investigate, recover and remediate and subject us to heightened regulatory scrutiny. See Item 1C. "Cybersecurity" for additional information on our cybersecurity practices.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act (ACA) was enacted in the United States. The ACA made a number of substantial changes to the way healthcare is financed both by governmental and private insurers. For example, the ACA requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices. The medical device tax was permanently repealed at the end of 2019. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in 2017, the Trump administration sought to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. The Trump administration issued three executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. For example, on December 20, 2019, President Trump signed appropriations legislation for fiscal year 2020 that repealed certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high-cost employer-sponsored insurance plans, for tax years beginning after December 31, 2019; the annual fee imposed on certain health insurance providers based on market share, for calendar years beginning December 31, 2020; and the medical device excise tax on non-exempt medical devices, for sales after December 31, 2019. While Congress did not pass comprehensive legislation that would repeal all or part of the ACA, two bills affecting the implementation of certain taxes under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACA have been signed into law. Specifically, the Tax Cuts and Jobs Act of 2017 (TCJA), among other things, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment, or penalty, imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Beginning in 2021, the Biden administration has signaled its intent to pursue policies strengthening the ACA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that started in 2013 and, due to subsequent statutory amendments, will remain in effect through 2030 unless additional Congressional action is taken. In 2020, the CARES Act temporarily suspended the 2% cut in Medicare payments from May 1, 2020 through December 31, 2020, and it extended the sequestration reductions through fiscal year 2030 to offset the cost of such temporary suspension. The Consolidated Appropriations Act of 2021 further extended the temporary suspension through March 31, 2021. On April 14, 2021, Congress enacted legislation that further extended the suspension through December 31, 2021. On December 10, 2021, further legislation was enacted to extend the suspension through March 31, 2022, after which a 1.0% sequestration applied for Medicare payments made between April 1, 2022 and June 30, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The American Taxpayer Relief Act of 2012 made other changes, including reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve R&amp;D, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. Additionally, the Biden administration has already indicated a shift in direction from Trump administration policies by issuing orders and other documents rolling back regulations and Executive Orders from the Trump administration, and as noted, indicating that it will pursue policies strengthening the ACA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, in its enactment of the Consolidated Appropriations Act, Congress enacted the No Surprises Act. This law, which took effect January 1, 2022, bars out-of-network providers from billing patients in excess of the in-network cost sharing for services furnished with respect to a visit at certain in-network health care facilities. The law establishes an independent dispute resolution process between the provider and the payer to determine the appropriate payment rate to the provider. As written, the No Surprises Act may apply to laboratory tests furnished by an independent laboratory with respect to a hospital visit. The law establishes a notice and consent exception that generally does not apply to laboratory tests, although it allows HHS to apply this exception to certain advanced tests. Regulations and subregulatory guidance were issued by HHS, the Department of Labor, and the Department of the Treasury in 2021 and 2022, with the first set of regulations was issued as an Interim Final Rule on July 1, 2021, a second set issued as an Interim Final Rule on September 30, 2021, and a third set issued as a Final Rule on August 19, 2022. These regulations and subregulatory guidance have provided additional information on the applicability of the No Surprises Act, the rules governing the independent dispute resolution process, and specific provider requirements (including the obligation to furnish a &#8220;good faith estimates&#8221; of &#8220;expected charges&#8221; to uninsured or self-pay patients), as well as areas of temporary enforcement discretion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Environmental, Health and Safety Regulations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to various federal, state, local, and foreign environmental, health and safety laws and regulations and permitting and licensing requirements. Such laws include those governing laboratory practices, the generation, storage, use, manufacture, handling, transportation, treatment, remediation, release and disposal of, and exposure to potential bloodborne pathogens, hazardous materials and associated wastes. Our operations involve the generation, use, storage and disposal of hazardous materials as well as regulated medical waste, and the risk of injury, contamination or non-compliance with environmental, health and safety laws and regulations or permitting or licensing requirements cannot be eliminated. Compliance with environmental laws and regulations has not had a material effect on our capital expenditures, earning or competitive position. The Boulder, Colorado clinical laboratory passed an on-site inspection from the CDC in June 2021 due to COVID testing, which the Company no longer provides commercially. To date, there has not been a for cause OSHA or EPA inspection.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in Delaware in 2005 as Elston Technologies, Inc. Throughout 2023, our principal executive offices were located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301. Effective December 11, 2023, we relocated our principal executive offices to 919 West Dillon Rd, Louisville, CO 80027, and our telephone number is (303) 417-0500. On June 20, 2006, we changed our name to Biodesix, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to Section 404 of the Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) until December 31, 2025 (the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering (IPO)).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we are a &#8220;smaller reporting company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For certain risks related to our status as an emerging growth company, see &#8220;Risk Factors&#8212;General Risk Factors&#8212;We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our culture is underpinned by our cultural beliefs including an unwavering commitment to inclusion and diversity. We are committed to fostering a diverse and inclusive workplace that attracts and retains exceptional talent offering opportunities for our team members to grow and develop in their careers, supported by a competitive suite of benefits and health and wellness programs. We regularly engage our team members in monthly all-hands meetings to align and focus on the current state of affairs of our business, our partnerships, new products, clinical trials, and other pertinent information about our business. We engage our team members in programs such as peer recognition and recruitment that focuses on recognizing outstanding individual contributions to company performance, cultural fit of new team members and acknowledging the diversity of our team to ensure our team members feel valued and can do their best work. We have a national annual community service initiative, &#8220;Biodesix Gives Back&#8221; that allows each team member to invest ten hours of paid community service to organizations of their choosing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had approximately 217 full-time and part-time employees, all of whom are located in the United States. The majority of our team member base is located in proximity to our corporate office and testing facilities located in Louisville, Colorado and our laboratory in De Soto, Kansas.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diversity, Equity and Inclusion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that a diverse employee population, including cultural background, gender, ethnicity, sexual orientation and lived experiences, is critical to our success. Our employees are encouraged to leverage their personal strengths and experiences to continually innovate and contribute to the development of new ideas and process improvements that drive better experiences for our partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Engagement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our company culture emphasizes the satisfaction and well-being of our team members and a diverse, engaged workforce. We solicit the opinion and views of our team members through surveys and peer focus groups. We have an established and valued Peer Recognition Culture. Teammates recognize other teammates publicly for their support and contributions fostering collaboration, engagement and retention. We regularly review feedback we receive on our current cultural beliefs to determine if any modifications are needed. During 2021, we updated our cultural beliefs to align with our core values that reflect our current focus on Teamwork, Innovation, Making an Impact and Excel. Additionally, the Company annually celebrates our top sales performers through our President&#8217;s Club and other top company performers as nominated by fellow team members through our four (4) Performance Excellence Awards that recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">creativity and innovation, an entrepreneurial spirit, a strategic impact on the success of the Company and lastly, embodying the Biodesix cultural beliefs and goes &#8220;above and beyond&#8221; daily.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Training and Development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We invest in our team members' career growth and provide team members with a wide range of development opportunities, including face-to-face, virtual, and self-directed learning, mentoring, coaching, and external development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Health, Safety and Wellness</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The physical health, financial stability, life balance and mental health of each of our team members is vital to our success. We sponsor several cancer awareness activities in our local communities to bring engagement and awareness of health, safety and wellness to positively impact lives. We provide an Employee Assistance Program to enhance physical, financial, and mental well-being for all our team members.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pay Equity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The main objective of our compensation program is to provide a compensation package that will attract, retain, motivate, and reward superior team members who operate in a highly competitive and technologically challenging environment. We emphasize overall Company performance and provide equity incentives for all team members to align their financial interests with the interests of shareholders. In addition, we offer an employee stock purchase plan to all employees in which participants are eligible to purchase shares at a discount to market. We think like customers and act like owners.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biodesix seeks fairness in total compensation. We benchmark with external comparisons, internal comparisons and look at the relationship between team member roles within the organization. We also review our compensation practices, both in terms of our overall workforce and individual team members, to ensure our pay is fair and equitable. We currently have no pay disparities based on gender, race, or ethnicity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file with, or furnish to, the SEC reports including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. These reports are available free of charge on our corporate website (</span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.biodesix.com</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Copies of any materials we file with the SEC can be obtained at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.sec.gov</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The information provided on our website (or any other website referred to in this report) is not part of this report and is not incorporated by reference as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk</span><span id="item_1a_risk_factor"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Factors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Factors Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of the principal risks that could adversely affect our business, operations and financial results. This summary does not address all of the risk that we face and should be read in conjunction with the entire Risk Factors section below beginning at &#8220;Risks Related to Our Business and Industry&#8221; within this Item 1A. "Risk Factors."</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audited financial statements include a statement that there is a substantial doubt about our ability to continue as a going concern and a continuation of negative financial trends could result in our inability to continue as a going concern;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may encounter difficulties in managing our growth, which could disrupt our operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success and revenue growth are highly dependent on the demand for, and increased adoption of, our diagnostic tests, which are subject to a number of risks and uncertainty;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We need to ensure strong product performance and reliability to maintain and grow our business;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend upon third-party suppliers, including single source suppliers, making us vulnerable to supply problems and price fluctuations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Natural or man-made disasters or other similar events may significantly disrupt our business, and negatively impact our business, financial condition and results of operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services we offer, we could lose customers or market share;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are any security or data privacy breaches or other unauthorized or improper access.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations and cash flows. All of the risks described below should be carefully considered together with the other information contained and incorporated by reference in this report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Business and Industry</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses since our inception and expect to continue to incur losses for the foreseeable future. We reported net losses of $52.1 million and $65.4 million the years ended December 31, 2023 and 2022, respectively. As a result of these losses, as of December 31, 2023, we had an accumulated deficit of approximately $419.6 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our sales and marketing, research and development, regulatory and other expenses will continue to increase as we expand our marketing efforts for our diagnostic tests and services, expand existing relationships with our customers, obtain regulatory clearances or approvals or certifications for future enhancements to our existing diagnostic tests and services and conduct further clinical trials. In addition, we expect our general and administrative expenses to increase due to the additional costs associated with scaling our business operations and testing capacity as well as being a public company, including due to legal, accounting, insurance, exchange listing and compliance, investor relations and other expenses. As a result, we expect to continue to incur operating losses and may never achieve profitability. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an emerging growth company and, as such, we have incurred significant losses since inception and have yet to generate positive cash flows from operations. Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our Perceptive Term Loan Facility and may result in our inability to continue as a going concern. Any such impacts could have a material and adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial statements as of and for the period ended December 31, 2023 were prepared on the assumption that we would continue as a going concern. These financial statements did not include any adjustments that might result from the outcome of this uncertainty. As of December 31, 2023, we maintained cash and cash equivalents of $26.3 million and we have $40.0 million in principal balance outstanding on our Perceptive Term Loan (as defined below). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in both underwritten public offerings and private placements, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technology. Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in the Perceptive Term Loan Facility or to obtain waivers or amendments that impact the related covenants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default (as defined in the Perceptive Term Loan Facility), causing an acceleration and repayment of the outstanding balances. As a result, our management has determined that there is a substantial doubt about our ability to continue as a going concern over the next twelve months from the date these financial statements were issued. Although we have taken steps to improve our liquidity, including through raising debt and equity capital, and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses, we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, if we are not able to improve our operating results, we may need to limit our operations substantially. We will need to raise additional capital in the form of debt or equity to increase our liquidity but there is no assurance that we will be able to secure any such funding in a sufficient amount or on terms that are acceptable to us. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. Furthermore, the reaction of investors to the inclusion of a going concern statement in this report, and our potential inability to continue as a going concern, could materially adversely affect the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends, in part, on the acceptance of our diagnostic tests and services as being safe and relatively simple for medical personnel to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict how quickly, if at all, payers, providers, clinics and patients will accept future diagnostic tests and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over other available alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of market acceptance of our current and future diagnostic tests and services depends on a number of factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether there is adequate utilization of our tests by clinicians, biopharmaceutical companies and other target groups based on the potential and perceived advantages of our diagnostic tests over those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of use of our diagnostic tests relative to those currently on the market;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to provide incremental data that show the clinical benefits and cost effectiveness, and operational benefits, of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the coverage and reimbursement acceptance of our products and services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing pressure, including from group purchasing organizations (GPOs), seeking to obtain discounts on our diagnostic tests based on the collective bargaining power of the GPO members;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative publicity regarding our or our competitors&#8217; diagnostic tests resulting from defects or errors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accuracy of our tests relative to those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements by the FDA or other regulatory authorities or conformity assessment bodies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings contained in the labeling cleared or approved by the FDA or other regulatory authorities or conformity assessment bodies.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, even if our diagnostic tests achieve widespread market acceptance, they may not maintain that market acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had approximately 217 full and part-time employees. Over the next several years, we expect to continue to significantly increase the number of our employees and the scope of our operations, particularly in the areas of sales, marketing and reimbursement, product development, regulatory affairs and other functional areas, including finance, accounting, quality and legal. Additionally, we expect to expand our testing capacity as we commercialize additional diagnostic tests. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. Any inability to manage growth could delay the execution of our business plans or disrupt our operations and have a material and adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have experienced multiple cycles of growth and anticipate further growth in our business operations. This future growth could put strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to maintain the quality or expected turnaround times of our diagnostic tests and services, or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could materially adversely affect our operations. Additionally, if we are required to reduce expenses substantially to sustain our operations, we may not have the human resources to maintain growth in our business operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely on our direct sales force to sell our diagnostic tests in the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of our diagnostic tests. The members of our United States sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure. Identifying and recruiting qualified sales and marketing personnel and training them on how to promote our diagnostic tests, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or diagnostic tests that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our diagnostic tests. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time, or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of our diagnostic tests will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our diagnostic tests in a cost-effective manner is critical to achieving broad acceptance of our diagnostic tests. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad use of our diagnostic tests, which in turn could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We collaborate with biopharmaceutical companies to analyze patient samples for multiple applications primarily to support clinical trials, including patient identification, companion or complementary diagnostics and retrospective testing. The revenue attributable to our biopharmaceutical customers may also fluctuate in the future, which could have a material adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or permanent loss of revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success depends in part on our ability to maintain these relationships and to establish new relationships. Many factors have the potential to impact such collaborations, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers&#8217; satisfaction with our tests or services and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our tests due to changes in research and product development plans, failures in their clinical trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting relationship will be successful or that clinical or research studies conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our existing or potential relationships with biopharmaceutical companies can also be a catalyst for adverse speculation about us, our tests and our technology, which can adversely affect our reputation and our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our quarterly and annual revenue and operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of demand for our diagnostic tests, which may vary significantly;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost of manufacturing our diagnostic tests, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenditures that we may incur to acquire, develop, or commercialize additional tests and technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated pricing pressures;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coverage and reimbursement policies with respect to lung cancer treatment equipment, and potential future diagnostic tests that compete with our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and success or failure of clinical trials for our diagnostic tests or any enhancements to such tests we develop or competing diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positive or negative coverage, or public perception, of our diagnostic tests or those of our competitors or broader industry trends;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, conformity certification, commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our diagnostic tests, which may change from time to time;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost of obtaining regulatory approvals, conformity certifications or clearances for planned or future improvements or enhancements to our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements or in the status of regulatory approvals or applications or conformity certifications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing, discounts, and incentives for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general market conditions.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cumulative effects of these factors has resulted in large fluctuations and unpredictability in our quarterly and annual financial results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any publicly stated guidance we may provide, and could in turn negatively impact our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We need to ensure strong product performance and reliability to maintain and grow our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We need to maintain and continuously improve the performance and reliability of our diagnostic tests, including the Nodify XL2 and Nodify CDT tests, and the GeneStrat and VeriStrat tests to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. Our diagnostic tests may contain errors or defects, and while we have made efforts to test them extensively, we cannot assure that our current diagnostic tests, or those developed in the future, will not have performance problems. Performance issues with our diagnostic tests will increase our costs in the near-term and accordingly adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend upon third-party suppliers, including single source suppliers, making us vulnerable to supply problems and price fluctuations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party suppliers to provide certain components of our diagnostic tests, including a select few (located in the United States, Europe and China), as critical single source providers of components. Bio-Rad, as described below, is the sole source supplier</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for our GeneStrat test. Oncimmune is also the sole source supplier for our Nodify CDT tests but there are known secondary suppliers for these materials. While we have initiated the second source qualification process for the majority of these critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our suppliers are not obligated to perform services or supply diagnostic testing materials for any specific period, in any specific quantity or at any specific price, except as may be provided in a particular purchase order. We depend on our suppliers and to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements. These suppliers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. These suppliers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers. If we inaccurately forecast demand for finished goods, we may be unable to meet customer demand which could harm our competitive position and reputation. In addition, if we fail to effectively manage our relationships, we may be required to change suppliers. While we believe replacement suppliers exist for all materials, components and services necessary to manufacture our diagnostic tests, establishing additional or replacement suppliers for any of these materials, components or services, if required, could be time-consuming and expensive, may result in interruptions in our operations and product delivery, may affect the performance of our diagnostic tests or could require that we modify their processes. Even if we are able to find replacement suppliers, we will be required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any of these events could require that we obtain a new regulatory authority approval before we implement the change, which we may not obtain on a timely basis or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our diagnostic tests, the supply of our diagnostic tests to customers and the development of any future diagnostic tests will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test. Under the terms of this arrangement, we were granted non-exclusive rights to utilize the intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. We agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad. For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with respect to such tests, please see &#8220;Business&#8212;Material Agreements&#8212;Agreements with Bio-Rad&#8221; previously filed with our Form S-1 on October 23, 2020 and &#8220;First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021&#8221; previously filed with our Form 10-Q on August 10, 2021.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This relationship may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with Bio-Rad, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to sufficiently reduce costs in the performance, manufacturing and production of our diagnostic tests to achieve sustainable gross margins.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We partner with suppliers in the development and production of supplies for our diagnostic tests. While we are undertaking a number of initiatives designed to reduce the cost of performing our diagnostic tests, including reducing the costs of supplies, there is no guarantee that we will be able to achieve planned cost reductions from our various cost savings initiatives. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our diagnostic tests, changes to labor costs or less favorable terms with third-party suppliers. If we are unable to reduce our costs, or if cost reductions are less significant or less timely than projected, we will not be able to achieve sustainable gross margins, which would adversely affect our ability to invest in and grow our business and adversely impact our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including a future outbreak of the novel strain of coronavirus disease, COVID-19, and its variants could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. For much of 2020 and 2021, COVID-19 spread throughout the United States and to most countries globally, creating significant uncertainty and economic disruption. Numerous U.S. state and local jurisdictions chose to impose &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. In March 2020, the Governor of Colorado, where our headquarters are located, issued &#8220;stay at home&#8221; orders limiting non-essential activities, travel and business operations. Disruptions or potential disruptions due to the orders and restrictions have included, and in the future may continue to include, the inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to assemble diagnostic tests; inventory shortages or obsolescence; delays in actions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of regulatory bodies; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business; delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives; business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we conduct business; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#8217; capacity to manufacture our diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic also negatively affected our non-COVID-19 testing-related revenue and our clinical studies. For example, cancer patients had more limited access to hospitals, healthcare providers and medical resources as they took steps to control the spread of COVID-19. Our biopharmaceutical customers have faced challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The extent to which the a future pandemic or epidemic, including a future outbreak of the COVID-19 virus, impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the resurgence of COVID-19 or any other virus and the actions to contain or treat its impact, among others.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the potential economic impact brought by, and the duration of, any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets and a reduction in our ability to access capital, which could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including COVID-19, could materially affect our business. Such economic recession could have a material adverse effect on our long-term business. To the extent a pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Natural or man-made disasters and other similar events may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A significant portion of our employee base, operating facilities and infrastructure are centralized in Louisville, Colorado and we operate a laboratory facility in De Soto, Kansas. Any of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of terrorism or other criminal activities, infectious disease outbreaks or pandemic events power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business, financial condition and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business, financial condition and results of operations. In addition, the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In implementing and using our diagnostic tests and services, providers depend on our support to resolve issues in a timely manner. We may be unable to respond quickly enough to accommodate short-term increases in demand for customer support. Increased customer demand for support could increase costs and adversely affect our business, financial condition and results of operations. Our sales are highly dependent on our reputation and on positive recommendations from our existing patients, care partners, providers and clinics. Any failure to maintain high-quality customer support, or a market perception that we do not maintain high-quality customer support, could adversely affect our reputation, our ability to sell our diagnostic tests and services, and in turn our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our estimates of the annual total addressable market for our diagnostic tests and services are based on a number of internal and third-party estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, our estimates of the annual total addressable market for our diagnostic tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the annual total addressable market for them is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services we offer, we could lose customers or market share.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep pace with evolving standards of care. If we do not leverage or scale our sample and data biobank to discover new diagnostic tests or applications or update our diagnostic tests to reflect new scientific knowledge, including about lung cancer biology, information about new cancer therapies or relevant clinical trials, our diagnostic tests could become obsolete and sales of our current diagnostic tests and any new tests we develop could decline or fail to grow as expected. This failure to make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are any security or data privacy breaches or other unauthorized or improper access.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with various facets of our business, we collect and use a variety of personal data, such as names, mailing addresses, email addresses, mobile phone numbers, location information, prescription information and other medical information. Any failure to prevent or mitigate security breaches or improper access to, use, disclosure or other misappropriation of our data or consumers&#8217; personal data could result in significant liability under state, (e.g., state breach notification and privacy laws such as the CCPA) federal (e.g., HIPAA), and the HITECH Act and laws in other jurisdictions (e.g., the GDPR). Such an incident may also cause a material loss of revenue from the potential adverse impact to our reputation and brand, affect our ability to retain or attract new users of our diagnostic tests and services and potentially disrupt our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates would likely result in delays in our marketing approval efforts and significantly increased costs in an effort to recover or reproduce the data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These threats pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. Because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we and our partners may be unable to anticipate these techniques or to implement adequate preventative measures. We have in the past experienced, and may in the future, experience security incidents. While no security incidents in the past have had a material adverse effect on our business, financial condition and results of operations, we cannot predict the impact of any such future events. Further, we do not have any control over the operations of the facilities or technology of our cloud and service providers, including any third-party vendors that collect, process and store personal data on our behalf. Our systems, servers and platforms and those of our service providers may be vulnerable to computer viruses or physical or electronic break-ins that our or their security measures may not detect. Individuals able to circumvent such security measures may misappropriate our confidential or proprietary information, disrupt our operations, damage our computers or otherwise impair our reputation and business. We may need to expend significant resources and make significant capital investments to protect against security breaches or to mitigate the impact of any such breaches. In addition, to the extent that our cloud and other service providers, experience security breaches that result in the unauthorized or improper use of confidential data, employee data or personal data, we may not be indemnified for any losses resulting from such breaches. There can be no assurance that we or our third-party providers will be successful in preventing cyber-attacks or successfully mitigating their effects. Recent cyber-attacks purportedly originated by Russian controlled entities have exacerbated in the wake of Russia&#8217;s invasion of Ukraine and our systems may be infiltrated by foreign actors. If we are unable to prevent or mitigate the impact of such security breaches, our ability to attract and retain new customers, patients and other partners could be harmed as they may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reluctant to entrust their data to us, and we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business or other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have significant payer concentration, with a limited number of customers accounting for a substantial portion of our revenues.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, Medicare reimbursed 43% of our diagnostic test revenue to us and one</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customer accounted for 10% of our total revenue. For the year ended December 31, 2022, Medicare reimbursed 37% of our diagnostic test revenue to us and one customer accounted for 10% of our total revenue. There are risks whenever a large percentage of total revenues are concentrated with a limited number of payers and customers. It is not possible for us to predict the level of demand for our diagnostic tests and services that will be generated by any of these customers in the future. In addition, revenues from these larger customers may fluctuate from time to time based on these customers&#8217; business needs, the timing of which may be affected by market conditions or other factors outside of our control. These payers and customers could also potentially pressure us to reduce the prices we charge for our diagnostic tests and services, which could have an adverse effect on our margins and financial position and could negatively affect our revenues and results of operations. If any of our largest payers terminates its relationship with us or our tests are no longer reimbursable by such payer, such termination could negatively affect our revenues and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic tests and manage our inventory.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To ensure adequate inventory supply, we must forecast inventory needs and manufacture our diagnostic tests based on our estimates of future demand for our diagnostic tests. Our ability to accurately forecast demand for them could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our diagnostic tests or for those of our competitors, our failure to accurately forecast customer acceptance of new diagnostic tests, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our diagnostic tests, our supply chain partners and/or internal manufacturing team may not be able to deliver components and diagnostic tests to meet our requirements, and this could result in damage to our reputation, sales growth and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience significant disruptions in our information technology systems, our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on our information technology systems for the efficient functioning of our business, including the performance, distribution and maintenance of our diagnostic tests and services, as well as for accounting, data storage, compliance, purchasing and inventory management. We do not have redundant information technology in all aspects of our systems at this time. Our information technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to an unintentional event that involves a third party gaining unauthorized access to our systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions would disrupt our operations, including our ability to timely ship and track diagnostic test orders and results, project inventory requirements, manage our supply chain and otherwise adequately service our customers or disrupt our customers&#8217; ability to use our diagnostic tests. In the event we experience significant disruptions, we may be unable to repair our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition and results of operations. We are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our diagnostic tests and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and negatively impact sales.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of the marketing and sale of our diagnostic tests and services. For example, we may be sued if our diagnostic tests or services cause or are perceived to cause injury or are found to be otherwise unsuitable during</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, medical personnel, care partners and patients collect samples for our diagnostic tests. If these medical personnel, care partners or patients are not properly trained, are negligent or use our diagnostic tests incorrectly, the capabilities of such tests may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies for our diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic tests and services. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our diagnostic tests and services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">harm to our reputation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals, or labeling, marketing, or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse impact on the market price of our common stock; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exhaustion of any available insurance and our capital resources.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive and costs may continue to rise. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of our diagnostic tests and services. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face competition from many sources, including larger companies, and we may be unable to compete successfully.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are a number of lung cancer diagnostic solutions companies in the United States, Europe and Asia. Notable competitors in the United States include Veracyte, Inc., Guardant Health, Inc. and Foundation Medicine, Inc. These competitors all provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical facilities. Many of these organizations are significantly larger with greater financial and personnel resources than us, and enjoy significantly greater market share and have greater resources than we do. As a consequence, they may be able to spend more on product development, marketing, sales and other product initiatives than we can. Some of our competitors have:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantially greater name recognition;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">broader, deeper, or longer-term relations with healthcare professionals, customers, and third-party payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">more established distribution networks;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional lines of diagnostic tests and the ability to offer rebates or bundle them to offer greater discounts or other incentives to gain a competitive advantage;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval or certification for diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater financial and human resources for product development, sales and marketing and patent litigation.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our continued success depends on our ability to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">further penetrate the lung disease diagnostic solutions market and increase utilization of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain and widen our technology lead over competitors by continuing to innovate and deliver new product enhancements on a continuous basis; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effectively manufacture our diagnostic tests and their component parts as well as drive down the cost of service.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or diagnostic tests that could effectively compete with our existing diagnostic tests, which may cause our revenue to decline and would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, development of our diagnostic tests. Because of the complex and technical nature of diagnostic testing and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our diagnostic tests, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we attain greater commercial success, our competitors are likely to develop diagnostic tests that offer features and functionality similar to our diagnostic tests that are currently on the market. Improvements in existing competitive diagnostic tests or the introduction of new competitive diagnostic tests may make it more difficult for us to compete for sales, particularly if those competitive diagnostic tests demonstrate better reliability, convenience or effectiveness or are offered at lower prices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expedited, reliable shipping and delivery services and secure warehousing are essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our diagnostic tests to our customers and for tracking of these shipments, and from time to time require warehousing for our diagnostic tests, sample collection kits and supplies. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our diagnostic tests and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, civil unrest and disturbances or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability to process orders for our diagnostic tests on a timely basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed. Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are typically received within days from the United States and outside the United States for analysis at our Louisville, Colorado and De Soto, Kansas facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural disaster, civil unrest or disturbances, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our sales and profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In an effort to reduce costs, many hospitals in the United States have become members of GPOs and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors on behalf of their members, which may include hospitals and other providers. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our diagnostic tests, thereby reducing our revenue and margins.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#8217; notice. Accordingly, the members of such groups may choose to purchase alternative diagnostic tests due to the price or quality offered by other companies, which could result in a decline in our revenue.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pricing and reimbursement of medical devices is not harmonized at the European level, but is the exclusive competence of the EU Member States. In Europe, pricing and reimbursement decisions are generally made by regional or centralized bodies based on an assessment of the efficacy and clinical effectiveness of the devices or broad device types or procedures. There is a general trend for EU Member States to adopt cost containment measures to control public spend on medical devices. Due to the competitive nature of product offers and prices, we may not be able to obtain new, or maintain existing, contract positions with the EU Member States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation and other legal proceedings may adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our diagnostic tests and services, even if the regulatory or legal action is unfounded or not material to our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General economic and financial market conditions may exacerbate our business risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global macroeconomic conditions and the world&#8217;s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result of uncertainties with respect to financial institutions and the global credit markets and other macroeconomic challenges such as inflationary pressures currently or potentially affecting the economy of the United States and other parts of the world, customers and distributors may experience serious cash flow problems and other financial difficulties, decreasing demand for our products. Our customers and distributors may respond to such economic pressures by reducing or deferring their capital spending or reducing staff.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, events in the United States or foreign markets, such as the United Kingdom&#8217;s exit from the European Union, the worldwide effects from the spread of COVID-19, Russia's invasion of Ukraine and political and social unrest in various countries around the world, can impact the global economy and capital markets. Additionally, if our customers and distributors are not successful in generating sufficient revenue or are precluded from securing financing, their businesses will suffer, which may materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the benefits or costs of our Co-Development and Collaboration Agreement with AVEO Oncology.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2014, we entered into a Co-Development and Collaboration Agreement with AVEO Oncology (formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) whereby the two parties agreed to various terms and conditions necessary for the co-development of AVEO&#8217;s compound ficlatuzumab (the Collaboration Agreement).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were granted a limited legal interest in ficlatuzumab and may not have the right to control the development and exploitation of ficlatuzumab. As consideration for the grant, we agreed to cover the first $15.0 million of ficlatuzumab&#8217;s clinical development costs, with both parties then sharing all costs equally after the cap was reached.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October of 2016, the Collaboration Agreement was amended to eliminate the requirement that we cover all of the initial costs. Under the amended terms, we agreed to allow AVEO to recapture its cost that it otherwise would not have been responsible for said recapture to occur out of any royalties or revenues eventually derived from the Collaboration Agreement. As part of the Collaboration Agreement, unless we or AVEO exercised our right to opt-out of co-development, we would equally share in any income received from licensing rights to ficlatuzumab to any third parties. In September 2020, we exercised our opt-out right for the payment of half of the development and regulatory costs for ficlatuzumab. This opt-out was effective as of December 2, 2020 with remaining obligations estimated to be $0.1 million. Following the effective date, we will be entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab. Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (SCCHN), metastatic pancreatic ductal cancer (PDAC), and acute myeloid leukemia (AML).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our relationship with AVEO may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with AVEO, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are exposed to significant future payments and other obligations associated with our acquisitions of Integrated Diagnostics and Oncimmune, U.S.A., and may not realize the advantages we expect from these acquisitions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, we purchased select assets and liabilities from Integrated Diagnostics, Inc. and IND Funding, LLC (collectively, the Seller or Indi) which included the CLIA lab in Seattle, Washington, and all rights to the Nodify XL2 test and intellectual property rights related to that test. The purchase was made for total consideration of $27.6 million, consisting of $8.0 million (10,649,604 shares) of our Series G Preferred Stock and contingent consideration with an initial fair market value of $19.6 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The acquisition of Indi included a contingent consideration arrangement that requires additional consideration to be paid by us to the Seller based on the milestone of the attainment of a three consecutive month gross margin target of $2 million within a seven-year period. Under the terms of the original agreement, when the gross margin target was achieved, the Company was required to issue 2,520,108 shares of common stock. For the six months following the achievement of the milestone, Indi had the option to require the Company to redeem the common shares for $37.0 million in cash over eight equal installments. If Indi elected not to exercise this option, we had 12 months to repurchase the common stock in two equal quarterly cash installments totaling $37 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, the Company entered into an amendment to the original agreement in which all parties agreed to forgo the issuance of common stock and agreed that the Company would instead make six quarterly installments of approximately $4.6 million each, which began in January 2022, and final payment of approximately $9.3 million in July 2023 for a total of $37.0 million (together, the Milestone Payments). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA, in which the parties agreed to restructure the Milestone Payments. The Company made five quarterly installments of $2.0 million each beginning in April 2022, three quarterly installments of $3.0 million which began in July 2023, will make one installment of $5.0 million in April 2024, and will make one installment of approximately $8.4 million in July 2024. In addition, the Company agreed to an exit fee of approximately $6.1 million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to 10%, with such interest to be payable quarterly on the following installment payment date. Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan, and, commencing January 1, 2024, consent from Perceptive.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on October 31, 2019 we completed an acquisition of Freenome's United States operations (formerly "Oncimmune USA" or "Oncimmune") including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule (IPN) malignancy test, then marketed in the United States as the EarlyCDT Lung&#174; test. We renamed and relaunched the test on February 28, 2020 as the Nodify CDT test and the De Soto, Kansas lab is the sole United States provider of the Nodify CDT test.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the acquisition, we and Oncimmune entered into several agreements to govern the relationship between the parties and to allow us to provide the Nodify CDT test. The overarching umbrella Purchase and Commercialization Agreement (PCA) defines the general relationship between the parties. Included under the PCA was (a) an APA whereby we acquired all of the United States assets associated with the De Soto, Kansas clinical laboratory, as well as the trademarks and patent application associated with the test; (b) an intellectual property license granting us the rights necessary under Oncimmune&#8217;s background intellectual property rights to perform the Nodify CDT test; (c) a supply agreement for supplying us with the necessary materials and reagents needed to run the Nodify CDT test; and (d) a development agreement where Oncimmune agrees to assist us in further developing the Nodify CDT test.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We agreed to a revenue share payment of 8% of recognized revenue for non-screening tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. Royalty expenses were $1.0 million and $0.9 million for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our acquisitions may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of these acquisitions, we will achieve the revenue or specific net income that justifies our entry into them. This could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on our senior management and other key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Louisville, Colorado and our laboratory facility in De Soto, Kansas. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting, or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued and may continue to issue equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Moreover, liquidity available to our employee securityholders could lead to disparities of wealth among our employees, which could adversely impact relations among employees and our culture in general. Our anticipated headcount growth may result in a change to our corporate culture, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership by certain shareholders over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and its research and development credit carryforwards to offset future taxable income. The applicable rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company, as well as changes in ownership arising from new issuances of stock by the company. We believe that our NOLs are currently not subject to limitation under these rules. However, if we undergo an ownership change now or in the future, our ability to utilize NOLs and research and development credit carryforwards could be limited by Sections 382 and 383 of the Code. Future changes in stock ownership may be beyond our control. In addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules similar to those applicable to NOLs and other attributes. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed interest expense carryovers, even if we attain profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The terms of the Perceptive Term Loan Facility require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 16, 2022 (Closing Date), we entered into a credit agreement and guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender) that provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $50.0 million (the Perceptive Term Loan Facility) to refinance long-term debt. The Perceptive Term Loan Facility provides for an &#8220;interest-only&#8221; period during the term of the loan with principal due at the maturity date, which will be November 21, 2027.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to 2% to 10% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment. The Perceptive Term Loan Facility contains customary affirmative and negative covenants for a loan, requires us to comply with a minimum cash requirement covenant, and has a trailing twelve month net revenue requirement. Failure to comply with the covenants and loan requirements may result in an event of default.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2023, the Company entered into the First Amendment with the Lender, whereby, subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold of each fiscal quarter commencing on the fiscal quarter ending June 30, 2023 through and including the fiscal quarter ending</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024. As consideration for the First Amendment, the Company agreed to issue to Perceptive a warrant to purchase up to 500,000 shares of the Company&#8217;s common stock which are equity classified at a per share exercise price equal to $1.6254.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 4, 2023, the Company entered into the Second Amendment to the Credit Agreement and Guaranty (the Second Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby, subject to the terms and conditions of the Second Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing with the fiscal quarter ending June 30, 2024 through and including the fiscal quarter ending December 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility contains certain covenants limiting our ability to, among other things, engage in certain corporate changes, make certain restricted payments, repay other certain indebtedness or enter into, amend or terminate any other agreements that have the impact of restricting our ability to make loan repayments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement also contains certain customary events of default, the occurrence of which could result in the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility is immediately due and payable in whole or in part, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to raise additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase our sales and marketing efforts to drive market adoption of and address competitive developments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fund development and marketing efforts of our diagnostic tests or any other future diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our technologies into other types of cancer management and lung disease detection diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire, license, or invest in technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or invest in complementary businesses or assets; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">finance capital expenditures and general and administrative expenses.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our present and future funding requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve revenue growth;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and international commercial third-party payers and government payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of and reimbursement for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our rate of progress in, and cost of research and development activities associated with, diagnostic tests in research and early development;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to international expansion; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our diagnostic tests.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, our stockholders could experience dilution. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or diagnostic tests, pay a portion of our royalties, or grant licenses on terms that are not favorable to us.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Governmental Regulation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future diagnostic tests could limit our ability, and that of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford the clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or in the future plan to develop and sell. In addition, because our clinical diagnostics and diagnostic tests represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our diagnostic tests, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our diagnostic tests will depend substantially, both domestically and internationally, on the extent to which the costs of our diagnostic tests are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our diagnostic tests or services. Even if coverage is provided, the available reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our diagnostic tests or services. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly launched, cleared, authorized or approved diagnostic tests. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by the CMS, an agency within HHS. CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare, although it frequently delegates this authority to local Medicare Administrative Contractors (MACs). Private payers tend to follow Medicare to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel diagnostic tests such as ours. Additionally, reimbursement authorities or bodies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, the reimbursement process and timelines vary significantly. In Europe, pricing and reimbursement of medical devices is the exclusive competence of the European Union (EU) Member States. However, the European Commission is facilitating a voluntary corporation between the EU Member States on health technology assessments (HTA) which consists of a network of the EU Member States&#8217; national authorities and bodies responsible for HTA and a joint action to support cooperation at scientific and technical level between the HTA bodies. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products in those countries would be negatively affected. An increasing number of countries are taking initiatives to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. These price control efforts have impacted all regions of the world, but have been most prominent in the EU. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized, certified or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics to be sold by us or our collaborators. For example, in May 2018 the United States government released a &#8220;blueprint,&#8221; or plan, to reduce the cost of drugs. This blueprint contains certain measures that HHS has been working to implement, although it is possible that HHS&#8217;s regulatory priorities may change under the Biden administration. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience pricing pressures on our clinical diagnostics sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new diagnostic tests.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Measures to reduce healthcare costs may hurt our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The majority of our customers are healthcare providers who depend upon reimbursement by government and commercial insurance payers for lung cancer diagnostic solutions services. With a majority of United States patients with lung cancer covered by Medicare, the Medicare reimbursement rate is an important factor in a customer&#8217;s decision to use our diagnostic tests and limits the prices we may charge for them. Commercial insurance payers may also exert downward pressure on payment rates for lung cancer treatment services. A reduction in reimbursement rates for lung cancer treatments may adversely affect our customers&#8217; businesses and cause them to enact cost reduction measures that may include reducing the scope of their programs, thereby potentially reducing demand for our diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our diagnostic tests. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our diagnostic tests. The effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our diagnostic tests. For example, the ACA, contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been judicial challenges to certain aspects of the ACA, as well as efforts by the Trump administration and Congress to repeal, replace or alter the implementation of certain aspects of the ACA. For example, as part of the TCJA, Congress eliminated the tax penalty, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance. The Further Consolidated Appropriations Act of 2020, Pub. L. No. 116-94, signed into law December 20, 2019, fully repealed the ACA&#8217;s &#8220;Cadillac Tax&#8221; on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share (repeal effective in 2021), and the medical device excise tax on non-exempt medical devices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken, with the exception of a temporary suspension of the 2% cut in Medicare payments from May 1, 2020 through March 31, 2022, and a reduction of the cut to 1% from April 1, 2022 through June 30, 2022. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biden administration and Congress may continue to pursue significant changes to the current healthcare laws, and the Biden administration has indicated its intent to strengthen the ACA and focus on reducing the cost of healthcare. We face uncertainties that might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the ACA are likely to have an impact on our results of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may harm:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. Future changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Future changes in healthcare policy could also decrease our revenue and impact sales of and reimbursement for our current and future diagnostic tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We must comply with anti-corruption, anti-bribery, anti-money laundering and similar laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the FCPA, which generally prohibits companies in the United States from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. We are also subject to requirements under the United States Treasury Department&#8217;s Office of Foreign</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets Control, United States domestic bribery laws and other anti-corruption, anti-bribery and anti-money laundering laws. While we have policies and procedures in place designed to promote compliance with such laws, our employees or other agents may nonetheless engage in prohibited conduct under these laws for which we or our executives might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, international customers may currently order our diagnostic tests, either directly from us or through a potential joint venture, and we are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-United States government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent distributors to sell our diagnostic tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents and we could be held responsible for their actions. Other United States companies in the medical device and biopharmaceutical field have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including laws promulgated by OECD countries in which we operate, such as Israel. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We must comply with healthcare fraud and abuse laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various federal and state laws, as well as the laws of foreign countries, prohibit payments to induce the referral, purchase, order or use of healthcare products or services and require medical device companies to limit prevent, and/or monitor, and report certain payments to third-party payers, health care professionals, and other individuals. These healthcare fraud and abuse, anti-kickback, public reporting and aggregate spend laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with lung cancer treatment providers, hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. These laws prohibit certain marketing initiatives that are commonplace in other industries. If we were to offer or pay inappropriate inducements for the purchase, order or use of our diagnostic tests or our services, or our arrangements are perceived as inappropriate inducements, we could be subject to claims under various healthcare fraud and abuse laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions under applicable United States federal and state healthcare laws and regulations include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, a criminal law, prohibits, among other things, persons and entities from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, leasing, ordering, or arranging for, referring, or recommending the purchase, lease, order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Eliminating Kickbacks in Recovery Act, which prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Beneficiary Inducement Statute, which prohibits any person, organization, or entity from giving anything of value to a federal health care program beneficiary that is likely to induce or influence the beneficiary&#8217;s choice of provider, practitioner, or supplier for covered services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal civil False Claims Act, which may be enforced through civil whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">qui tam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actions and is often used to enforce the federal Anti-Kickback Statute and other healthcare laws and regulations, imposes civil penalties and potential exclusion from federal healthcare programs, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal criminal statutes created by HIPAA impose criminal liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private insurance plans, or, in any matter involving a healthcare benefit program, for knowingly and willfully making materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for health care benefits; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other federal and state laws, as well as the laws of foreign countries, generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payments to government or commercial payers that are false or fraudulent, or for items or services that were not provided as claimed. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates and medical devices from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If any physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers can also be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers, by providing improper financial inducements, or through certain other activities. We attempt to ensure that any billing and coding information we provide for our diagnostic tests emphasizes the need for physicians and other providers to make independent judgments, use accurate and appropriate billing and coding that complies with all applicable payer policies, and document the medical need for their patients as appropriate. Nevertheless, the government may not regard any billing errors that may be made by our customers as inadvertent and may examine our role in providing information to our customers, physicians and patients concerning the benefits and potential coverage of more frequent therapy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA regulation of our industry generally or our tests specifically could be disruptive to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations are subject to extensive federal, state, local and foreign laws and regulations, including FDA laws and regulations, all of which are subject to change. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. We believe that we are in material compliance with all statutory and regulatory requirements applicable to us, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has recently increased its attention to marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding genetic laboratory tests with claims to predict a patient&#8217;s response to specific medications that have not been reviewed by the FDA and may not be supported by clinical evidence. Among other tests, the FDA notice cited genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications. As explained by the FDA in its update to this safety communication, the FDA sent notices to several firms marketing such pharmacogenetic tests where the FDA believes the relationship between genetic variations and the medication&#8217;s effects has not been established, including a warning letter sent to a laboratory, in part, for failing to obtain premarket review of its test.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA were to determine that our tests are not within the current enforcement discretion policy for LDTs for any reason, or if FDA finalizes its proposed rule to end enforcement discretion or issues new rules, policies, or guidance, due to new legislation or on its own accord, our tests may become subject to FDA requirements, including pre-market review. If this were to happen, it may impact our marketing practices relating to the relevant tests, which in turn may have an adverse impact on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts. Tests without FDA clearance, approval, or authorization would not be considered covered countermeasures under the Public Readiness and Emergency Preparedness Act (PREP Act), which authorizes HHS to provide limited liability immunity protection to certain individuals and entities against a claim of loss under federal and state law &#8220;caused by, arising out of, relating to, or resulting from&#8221; the manufacture, distribution, administration, or use of a covered medical countermeasure, except for claims involving willful misconduct. Consequently, any violations of applicable laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payers, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct our business, as well as the imposition of significant fines or criminal penalties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are subject to state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory&#8217;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Louisville, Colorado and De Soto, Kansas laboratories are both CAP-accredited clinical laboratories regulated by CMS pursuant to CLIA. We also have a current CLIA certificate for each facility. To maintain these certificates, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time. Furthermore, our diagnostic tests are categorized as LDTs and are not currently subject to FDA regulation, although certain components provided by third parties and used to create and/or administer the test may be. LDTs are a subset of IVDs that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory. Failure to adhere to any new FDA regulation would result in fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal penalties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our current line of diagnostic tests is covered under CLIA and CMS, but the FDA may end its general policy of enforcement discretion and regulate laboratory developed tests as medical devices. Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, including in vitro diagnostics and, therefore, potentially our clinical laboratory tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. Although the FDA has asserted that it has authority to regulate the development and use of LDTs, such as our and many other laboratories&#8217; tests, as medical devices, it has generally exercised enforcement discretion and is currently not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. Pursuant to this enforcement discretion policy, FDA does not require laboratories that furnish LDTs to comply with the agency&#8217;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls).</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our tests, as utilized in our clinical laboratory, are and would be considered LDTs and that as a result, the FDA does not require that we obtain regulatory clearances or approvals for our LDTs or their components pursuant to the FDA&#8217;s current policies and guidance. Although we believe that our tests and test components are either exempt from FDA medical device regulations or are subject to an enforcement discretion policy, it is possible that the FDA would not agree with our determinations or that the FDA will change its regulations and policies such that our products become regulated as medical devices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, the FDA has publicly announced its intention to regulate certain LDTs and has set forth various proposals for a phased-in risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. Until recently, the FDA has articulated such policies through guidance documents, compliance manuals, website statements, and other informal issuances, but not through notice-and-comment rulemaking. On September 29, 2023, the FDA announced a proposed rule to amend its regulations to explicitly regulate LDTs as IVD tests in accordance with the agency&#8217;s regulatory authority over medical devices. If this rule is finalized, our tests that are currently offered as LDTs would become subject to statutory and regulatory provisions that are applicable to medical devices, including but not limited to, medical device reporting and correction and removal reporting requirements, quality systems regulations, registration and listing requirements, and premarket review requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the proposed rule is not finalized, Congress could take action to amend the law to change the current regulatory framework for in vitro diagnostics and LDTs to require premarket review of LDTs and other regulatory requirements. New requirements, whether imposed through legislation or administratively, could result in delay or additional expense in offering our tests and tests that we may develop in the future. Moreover, failure to comply with applicable requirements under the relevant timeframes could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial enforcement actions, which in turn may have an adverse impact on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, therefore, are or may become subject to extensive regulation by the FDA in the United States. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">test design, development, manufacture, and release;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory and clinical testing, labeling, packaging, storage, and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product safety and efficacy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">service operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">record keeping;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product marketing, promotion and advertising, sales, and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">post-market approval studies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product import and export.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The premarket submission process for medical devices can be expensive, lengthy and unpredictable. The FDA can delay, limit, or deny clearance or approval of a device for many reasons, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or conformity assessment body that the diagnostic tests are safe or effective for their proposed intended uses;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the disagreement of the FDA with the design or implementation of our clinical trials or the interpretation of data from clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data from our clinical trials may be insufficient to support clearance or approval, where required;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the manufacturing process or facilities we use may not meet applicable requirements; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity, warning letters, untitled letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">repair, replacement, refunds, recall or seizure of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating restrictions, partial suspension, or total shutdown of production;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">denial of our requests for regulatory clearance or premarket approval of new diagnostic tests or services, new intended uses, or modifications to existing diagnostic tests or services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of regulatory clearance or premarket approvals that have already been granted; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">criminal prosecution.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, we believe that our current line of diagnostic tests and their components are LDTs, which are subject to state licensing requirements and federal regulation by CMS under CLIA, although our COVID-19 testing program and select partnerships we may enter may cause us to be subject to additional FDA regulations discussed above.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we believe that we are currently in material compliance with applicable laws and regulations, it is possible that the FDA, or other regulatory agencies, would not agree with our determinations. If our products became become subject to premarket submission and other FDA requirements, we would need to comply with the applicable regulations or face significant civil and criminal penalties. In addition, IVDs and CDx tests are widely considered to be Class III devices, and it is possible that in the future, we may develop tests that fall into this category. CDx tests in particular may require further administrative procedures in the PMA process. Exposure to these additional regulatory requirements would also affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance, De Novo authorization, or PMA approval of our future diagnostic tests and failure to obtain necessary clearances or approvals for our future diagnostic tests would adversely affect our ability to grow our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is important to our business that we build a pipeline of diagnostic test offerings that address limitations of current lung disease diagnostic tests. As such, our success will depend in part on our ability to develop and introduce new diagnostic tests. However, we may not be able to successfully develop and obtain regulatory clearance or approval or certification for enhancements to our existing diagnostic tests, or new diagnostic tests for any number of reasons, including due to the cost associated with certain regulatory approval requirements, or these diagnostic tests may not be accepted by physicians or users.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of any new diagnostic test or enhancement to an existing diagnostic test will depend on a number of factors, including our ability to, among others:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify and anticipate physician and patient needs properly;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop and introduce new diagnostic tests or enhancements to our existing diagnostic tests in a timely manner;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">avoid infringing upon, misappropriating, or violating the intellectual property rights of third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstrate, if required, the safety and efficacy of new diagnostic tests with data from clinical studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain the necessary regulatory clearances or approvals or certifications for new diagnostic tests or enhancements to existing diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">comply fully with FDA and foreign regulations on marketing of new diagnostic tests or modified diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide adequate training to potential users of our diagnostic tests.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not develop new diagnostic tests or enhancements to our existing diagnostic tests in time to meet market demand or if there is insufficient demand for these diagnostic tests or enhancements, or if our competitors introduce new diagnostic tests with functionalities that are superior to ours, our results of operations will suffer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our future diagnostic tests may require FDA clearance of a 510(k) submission. Other diagnostic tests may require the approval of a PMA. In addition, some of our future diagnostic tests may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these diagnostic tests for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance, De Novo authorization, or premarket approval of new diagnostic tests. Failure to receive clearance or approval for our new diagnostic tests would have an adverse effect on our ability to expand our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Modifications to our marketed tests may require new 510(k) clearances, De Novo authorizations, or PMA approvals, or may require us to cease marketing or recall the modified tests until clearances or approvals are obtained.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Modifications to our diagnostic tests may require new regulatory approvals or clearances, including 510(k) clearances, De Novo authorizations, or premarket approvals, or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new submission is necessary. However, the FDA can review a manufacturer&#8217;s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our diagnostic tests in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our diagnostic tests as modified, which could require us to redesign our diagnostic tests and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where we determine that modifications to our diagnostic tests require a new premarket submission, we may not be able to obtain the additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced diagnostic tests in a timely manner, which in turn would harm our future growth.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our suppliers fail to comply with ongoing FDA or other domestic and foreign regulatory authority or conformity assessment body requirements, or if we experience unanticipated problems with our diagnostic tests, they could be subject to restrictions or withdrawal from the market.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any medical device that we manufacture, including those for which we obtain regulatory clearance or approval or certification, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such diagnostic test, will be subject to continued regulatory review, oversight, and periodic inspections by the FDA and other domestic and foreign regulatory bodies or conformity assessment bodies. In particular, we and our suppliers may be required to comply with FDA&#8217;s QSR (QSR codified at 21 C.F.R. &#167; 820) for medical devices and ISO regulations for the manufacture of our diagnostic tests and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any diagnostic test for which we obtain clearance or approval. Regulatory bodies, such as the FDA, and conformity assessment bodies enforce the QSR and other regulations through periodic inspections and audits. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies or conformity assessment bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, one or more of the following enforcement actions:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated expenditures to address or defend such actions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customer notifications for repair, replacement, or refunds;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall, detention, or seizure of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating restrictions or partial suspension or total shutdown of production;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusing or delaying our requests for 510(k) clearance, De Novo authorization, or premarket approval of new diagnostic tests or modified versions of current diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawing 510(k) clearances, De Novo authorization, or PMA approvals that have already been granted;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revocation of EUAs that have been authorized previously;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to grant export approval for our diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">criminal prosecution.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these actions were to occur it would harm our reputation and cause our diagnostic test sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our diagnostic tests on a timely basis and in the required quantities, if at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are required to conduct surveillance to monitor the safety or effectiveness of our diagnostic tests, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our diagnostic tests. Later discovery of previously unknown problems with our diagnostic tests, including unanticipated adverse events or adverse events of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such diagnostic tests or manufacturing processes, withdrawal of the diagnostic tests from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our diagnostic tests and services may in the future be subject to product recalls that could harm our reputation, business and financial results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our diagnostic tests and services in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations. Other jurisdictions have similar recall requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval or certification of any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. For example, the Verifying Accurate, Leading-edge IVCT Development (VALID) Act recently introduced in Congress would codify into law the term &#8220;in vitro clinical test&#8221; in order to create a new medical product category separate from medical devices that would include products currently regulated as in vitro diagnostics as well as LDTs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our diagnostic tests. For example, FDA announced a proposed rule in September 2023 to phase out its enforcement discretion over LDTs and regulate such diagnostic tests as medical devices. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future diagnostic tests. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future diagnostic tests could make it more difficult and costly to obtain clearance or approval for new diagnostic tests or to produce, market and distribute existing diagnostic tests. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new diagnostic tests would have an adverse effect on our ability to expand our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trials may be necessary to support future product submissions to FDA. These clinical trials are expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new diagnostic tests and will adversely affect our business, operating results and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initiating and completing clinical trials necessary to support any future PMA applications, De Novo requests, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our diagnostic tests or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase in costs and delays in the approval and attempted commercialization of our diagnostic tests or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or certification for or commercialize our diagnostic tests and services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not have the ability to independently conduct our pre-clinical and clinical trials for our future diagnostic tests and services and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our diagnostic tests and services on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to HIPAA and other federal, state, and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain and process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection with our clinical studies and our employees, and are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. Failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in notification obligations or enforcement actions against us, which could result in fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. These laws, rules and regulations evolve frequently and their scope may continually change, through new legislation, amendments to existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the EU and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Domestic laws in this area are complex and developing rapidly. Many state legislatures have adopted legislation relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also frequently amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California recently enacted the CCPA, which became effective on January 1, 2020. The CCPA, among other things, requires new disclosures to California consumers and affords such consumers new abilities to access and delete their personal information, opt-out of certain sales of personal information and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500 per violation, as well as a private right of action for data breaches that is expected to increase the frequency of data breach litigation. While the CCPA has already been amended multiple times, it is unclear how this legislation will be further modified or how it will be interpreted. Interpretations of the CCPA may continue to evolve with regulatory guidance and the CCPA continue to be amended, including through a ballot initiative, adopted by voters in November 2020, known as the California Privacy Rights Act, or CPRA. The CPRA imposes additional data protection obligations on companies doing business in California, including additional consumer rights, including regarding certain uses of sensitive data. It also creates a new California data protection agency - the California Privacy Protection Agency - specifically tasked to enforce the law, which may likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The effects of this legislation potentially are far-reaching, however, and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. The CCPA and other changes in state and federal laws or regulations relating to privacy, data protection and information security, particularly any new or modified laws or regulations that require enhanced protection of certain types of data or new obligations with regard to data retention, transfer or disclosure, could increase the cost of providing our offerings, require significant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to our operations or even prevent us from providing certain offerings in jurisdictions in which we currently operate and in which we may operate in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. Although we endeavor to comply with our published policies and documentation and ensure their compliance with current laws, rules and regulations, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policy and other documentation that provide promises and assurances about privacy and security can subject us to potential state and federal action in the United States if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Any failure by us or other parties with whom we do business to comply with this documentation or with federal, state, local or international regulations could result in proceedings against us by governmental entities, private parties or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of PHI and PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA, PHI) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities (CE), and the business associates (BA) with whom such covered entities contract for services. We are a CE under HIPAA when we are conducting our clinical trials. We are a CE with regard to our observational studies and clinical trials, and also a BA under HIPAA for certain other business activities, and we execute BA agreements with our clients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA requires CEs and BAs, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $119 per violation and are subject to a cap of $1,785,651 for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA CEs and BAs. With regard to BAs, those audits assess the business associate&#8217;s compliance with the HIPAA Privacy and Security Standards. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500 individuals&#8217; data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a BAs reputation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. HHS is also proposing amendments to the HIPAA Privacy Rule to modernize certain data sharing provisions and enhance patient access to their information. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, but it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may eventually operate in a number of countries outside of the United States whose laws, including data privacy laws, may in some cases be more stringent than the requirements in the United States. For example, EU and UK data privacy laws have specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States, have strict requirements relating to personal data collection, use or sharing, and have more stringent requirements relating to organizations&#8217; privacy programs and provide stronger individual rights. Moreover, we may also be subject to evolving international privacy and data security regulations which could result in greater compliance costs and in turn lead to penalties, where such compliance programs are not implemented correctly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our processing activities are subject to the EU General Data Protection Regulation and the UK General Data Protection Regulation (collectively, the &#8220;GDPR&#8221;) &#8211; including, those involving pseudonymised / key-coded data - as the GDPR applies extra-territorially. The GDPR imposes strict requirements on controllers and processors processing personal data, including, for example, requirements to: (i) identify a legal basis for the processing of personal data, (ii) provide robust disclosures to individuals, (iii) respond to requests from individuals to exercise their data subject rights, (iv) provide personal data breach notifications within 72 hours after discovering the breach, (v) limit the collection and retention of personal data, (vi) impose specific contractual obligations on processors engaged to process personal data on the instructions of the controller, and (vii) apply enhanced protections to health data and other special categories of personal data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU GDPR also provides that EU Member States may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share such personal data and cause our costs to increase and harm our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with the requirements of the GDPR may result in fines of up to &#8364;20 million (&#163;17.5 million in the case of the UK GDPR) or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. GDPR compliance may require us to put in place additional mechanisms, which may result in compliance costs and other substantial expenditures. This may be onerous and adversely affect our business, financial condition, results of operations and the profitability of our platform of diagnostic tests. Failure to comply with the GDPR and other countries&#8217; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payers, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR also prohibits the transfer of personal data from the EEA/UK to a country outside of the EEA/UK (e.g., the United States) unless made to a country deemed to have adequate data privacy laws by the European Commission (or UK Government in case of the UK GDPR) or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the EU-US Privacy Shield. However, in July 2020 the Court of Justice of the European Union (CJEU) declared the Privacy Shield to be invalid. Following an executive order on trans-Atlantic data flows issued by President Biden in October 2022, the European Commission in December 2022 announced that it had initiated the process of drafting a new adequacy decision based on a modified data transfer framework that would replace the Privacy Shield, which it completed in July 2023. Though adoption of a new adequacy decision may have the effect of making data transfers to the United States easier, it is widely expected that the updated transfer framework and the adequacy decision will also be reviewed by the CJEU. The CJEU also upheld the validity of standard contractual clauses (SCCs) as a legal mechanism to transfer personal data but companies relying on SCCs will need to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. In turn, the findings of the CJEU will have significant implications for cross-border data flows and may lead to increased transaction, compliance, and technological costs to support international data transfers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organizations operating in Canada and covered by the Personal Information Protection and Electronic Documents Act (PIPEDA), or equivalent Canadian provincial laws, must obtain an individual&#8217;s consent when they collect, use or disclose that individual&#8217;s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual&#8217;s consent.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, including any third-party vendors that collect, process and store personal data on our behalf, fail to comply with laws requiring the protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA regulations, including those laws requiring the reporting of true, complete, and accurate information to the FDA authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal and state healthcare fraud and abuse laws and regulations; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laws that require the true, complete and accurate reporting of financial information or data.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by the HHS Office of Inspector General (OIG) could result in penalties, a loss of business from third parties, and severe reputational harm.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics and compliance policies to govern and deter such behaviors, but it is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support approval of new diagnostic tests and services, or new indications. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these diagnostic tests and services. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities and conformity assessment bodies will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon development of our tests and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, may impact our ability to commercialize our tests and generate revenues.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval or certification. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions, and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and our third-party contractors are required to comply with good clinical practices (GCPs) which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities or conformity assessment bodies may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval or certification process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of these factors could be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase and we may not be able to obtain regulatory clearance or approval or certification for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that the results of our future clinical trials will support our future product claims or that the FDA or comparable foreign regulatory authorities or conformity assessment bodies will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the future product&#8217;s profile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our billing, collections and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as government payers, insurance companies and patients, all of which may have different billing requirements. We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, financial condition and results of operations. Several factors make the billing process complex, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differences between the list price for our tests and the reimbursement rates of payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare and Medicaid, to the extent our tests are covered by such programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differences in coverage among payers and the effect of patient co-payments or co-insurance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differences in information and billing requirements among payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to codes and coding instructions governing our tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incorrect or missing billing information; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the resources required to manage the billing and claims appeals process.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These billing complexities and the related uncertainty in obtaining payment for our tests could negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payers require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology (CPT) code. The CPT code set is maintained by the American Medical Association (AMA). In cases where there is not a specific CPT code to describe a test, such as with the GeneStrat NGS test, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The Protecting Access to Medicare Act of 2014 (PAMA) authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes, Proprietary Laboratory Analyses codes to facilitate implementation of this section of PAMA. In addition, CMS may assign unique level II Healthcare Common Procedure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coding System codes to tests that are not already described by a unique CPT code. The VeriStrat, Nodify XL2, and Nodify CDT tests have test specific CPT codes, but the GeneStrat NGS test does not at this time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the instance where a code used does not describe a specific test, the insurance claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our tests and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming and costly process and we may never be successful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the generation, use, storage and disposal of hazardous materials. We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Accordingly, we and our third-party manufacturers and suppliers are subject to federal, state, local and foreign environmental, health and safety laws and regulations, and permitting and licensing requirements, including those governing the generation, use, manufacture, storage, handling, transportation, release and disposal of, and exposure to, these materials, and worker health and safety.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot eliminate the risk of contamination or injury resulting from such hazardous materials. We also cannot guarantee that the procedures utilized by our third-party manufacturers for handling and disposing of hazardous materials and wastes comply with all applicable environmental, health and safety laws and regulations. As a result, we may be held liable for any resulting damages, costs or liabilities, including cleanup costs and liabilities, which could be significant, or our commercialization, research and development efforts and business operations may be restricted or interrupted.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. Compliance with such laws and regulations is expensive, and current or future environmental, health and safety laws and regulations may restrict our operations. If we do not comply with applicable environmental health and safety laws and regulations, and permitting and licensing requirements, we may be subject to fines, penalties, a suspension of our business or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success may be impaired if we are unable to obtain, maintain and protect our intellectual property rights.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our diagnostic tests, products and services and technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology and prevent others from duplicating our suite of diagnostic tests and products. However, these means may afford only limited protection and may not:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent our competitors from duplicating our diagnostic tests and products, including our Nodify XL2, Nodify CDT, GeneStrat and VeriStrat tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent our competitors from gaining access to our proprietary information and technology, including the Diagnostic Cortex platform, tech platforms such as the DeepMALDI analysis and intellectual property covering technologies that allow us to develop &#8220;test algorithms&#8221;; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow us to gain or maintain a competitive advantage.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. Consequently, we do not know whether any of our diagnostic tests, products and services will be protectable or remain protected by valid and enforceable patents. We may not prevail if our patents are challenged by competitors or other third parties. The United States federal courts or equivalent national courts or patent offices elsewhere may invalidate our patents, find them unenforceable, or narrow their scope. Furthermore, competitors may be able to design around our patents by developing similar or alternative technologies or products in a non-infringing manner, or obtain patent protection for more effective technologies, designs or methods, including for treating lung cancer. If these developments were to occur, our diagnostic tests and products may become less competitive and sales may decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have filed numerous patent applications seeking protection of diagnostic tests and other inventions originating from our research and development. Our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The scope of a patent may also be reinterpreted and significantly reduced after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with the protection or competitive advantages we are seeking.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain or maintain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. Various courts, including the United States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon, or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered unpatentable under applicable law. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing owned or in-licensed patents and patents that we might obtain or in-license in the future. Additionally, our pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. The scope of patent protection outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property rights or narrow the scope of our owned and licensed patents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize diagnostic tests, products and services similar or superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our copyrights may be limited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patent protection for the patents underlying our diagnostic tests, products and services, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information. Additionally, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or collaborators use intellectual property rights owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees have misappropriated the intellectual property rights of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors, and third parties may claim an ownership interest in intellectual property we regard as our own.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees and consultants were previously employed at or engaged by universities or other medical device, diagnostic, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize potential diagnostic tests, products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property rights we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our diagnostic tests or products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An inability to incorporate technologies or features that are important or essential to our diagnostic tests or products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our rights to either of the Nodify XL2 and Nodify CDT tests, or the VeriStrat and GeneStrat tests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property rights. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future diagnostic tests, products and services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a first-to-invent system to a first-inventor-to-file system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review and derivation proceedings. Under a first-inventor-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor was the first to invent the claimed invention. The USPTO recently developed new regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the United States Supreme Court and the United States Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered several connected to our diagnostic tests, products and services in the United States. If we apply to register these and trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our efforts to enforce or protect our rights related to trademarks, trade secrets, domain names or other intellectual property rights may be ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors or other third parties may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violations. In addition, our patents also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke those parties to assert counterclaims against us alleging that we infringe their patents or other intellectual property. In any such proceeding, a court or other administrative body may decide that a patent or other intellectual property right owned by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover such technology. Grounds for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, including opposition proceedings. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our diagnostic tests, products and services or prevent third parties from competing with our diagnostic tests, products and services. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">least part, and perhaps all, of the patent protection on our diagnostic tests, products and services. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing diagnostic tests, products, services or technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The intellectual property landscape in the field of precision oncology is in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. As we move into new markets and applications for our diagnostic tests, products or services, incumbent participants in such markets may assert their patents and other intellectual property rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success depends in part on our non-infringement of the patents or other intellectual property rights of third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, we may in the future be subject to claims that we, or other parties we have agreed to indemnify, infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because patent applications are published sometime after filing, and because applications can take several years to issue, there may be additional currently pending third-party patent applications that are unknown to us, which may later result in issued patents. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We may not have sufficient resources to bring these actions to a successful conclusion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a substantial amount of litigation and other patent challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing diagnostic tests and in which we may develop future diagnostic tests, products and services. As the precision oncology industry expands and more patents are issued, the risk increases that our diagnostic tests may be subject to claims of infringement of the patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and competitors have and may assert that our diagnostic tests or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the inevitable uncertainty in intellectual property litigation, we could lose a patent infringement or other action asserted against us regardless of our perception of the merits of the case. There is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such United States patent.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell diagnostic tests, products or services, and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs, and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, which could be significant, and obtain one or more licenses from third parties, or be prohibited from selling certain diagnostic tests, products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in diagnostic test introductions while we attempt to develop alternative diagnostic tests, products or services to avoid infringing third-party patents or intellectual property rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing diagnostic tests, products or services, and the prohibition of sale of any of our diagnostic tests, products or services could materially affect our business and our ability to gain market acceptance for our diagnostic tests, products and services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the priority or inventorship of our patents and other intellectual property rights.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property rights as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property rights. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property rights that are important to our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of our diagnostic tests, products or services. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-United States patent agencies. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property rights. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our diagnostic tests and any other or future diagnostic tests, products or services could be found invalid or unenforceable if challenged.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the United States and abroad, in opposition, derivation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our diagnostic tests, products, services or technologies, the defendant could counterclaim that the patent covering our diagnostic tests, products or services is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our diagnostic tests or any diagnostic tests, products and services that we may develop.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests, products or services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our current or future diagnostic tests, products or services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#8217;s attention and resources.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on licenses from third parties in relation to certain diagnostic tests, products and services and if we lose these licenses then we may be subjected to future litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to license agreements that grant us rights to use certain intellectual property rights, including patents and patent applications, typically in certain specified fields of use, in connection with our diagnostic tests, products and services. Some of those licensed rights could provide us with freedom to operate for aspects of our diagnostic tests, products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, royalty payment, milestone payment, insurance and other obligations on us. If we fail to comply with these obligations or other obligations in our license agreements, our licensors may have the right to terminate these agreements, in which event we may not be able to develop</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and market any product or use any technology that is covered by these agreements. If our license agreements terminate, or we experience a reduction or elimination of licensed rights under these agreements, we may have to negotiate new or reinstated licenses with less favorable terms or we may not have sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property rights. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property rights we license, other companies might be able to offer substantially identical diagnostic tests for sale, which could adversely affect our competitive business position and harm our business prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, disputes may also arise between us and our current or future licensors regarding intellectual property rights subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether, and the extent to which, our diagnostic tests, products, services, technology, and processes infringe on intellectual property rights of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether our licensor or its licensor had the right to grant the license agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property rights without their authorization;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our involvement in the prosecution of licensed patents and our licensors&#8217; overall patent enforcement strategy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amounts of royalties, milestones, or other payments due under the license agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property rights by our licensors and us and our collaborators; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property rights or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property rights or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property rights, we may be unable to successfully develop and commercialize any affected diagnostic tests, products or services, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#8217; fees, costs and expenses and royalties or be enjoined from selling our diagnostic tests, products or services, which could adversely affect our ability to offer diagnostic tests, products or services, our ability to continue operations and our financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some intellectual property that we in-license may have been developed through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for companies based in the United States. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with manufacturers that are not based in the United States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of the intellectual property that we license may have been developed through the use of United States government funding and therefore may be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied in our diagnostic tests, products and services pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). These United</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">States government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). To date, none of our commercialized products are subject to march-in rights. The United States government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the United States government requires that any products of the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit our ability to contract with product manufacturers outside of the United States for products covered by such intellectual property. To the extent any of our current or future owned or licensed intellectual property is generated through the use of United States government funding, the provisions of the Bayh-Dole Act may similarly apply. Any failure by us to comply with federal regulations regarding intellectual property rights that were developed through the use of United States government funding could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our diagnostic tests, products and services for an adequate amount of time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if patents covering our diagnostic tests, products and services are obtained, once the patent life has expired, we may be open to competition from competitive diagnostic tests, products and services. Given the amount of time required for the development, testing and regulatory review of potential new diagnostic tests, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests, products or services similar or identical to ours.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may attempt to commercialize competitive diagnostic tests, products or services in foreign countries where we do not have any patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on our diagnostic tests, products and services in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing diagnostic tests or products made using our inventions in and into the United States or other jurisdictions. Competitors may use our diagnostic tests, products, services and technologies in jurisdictions where we have not obtained patent protection to develop their own diagnostic tests and, further, may export otherwise infringing diagnostic tests or products to territories where we have patent protection but enforcement is not as strong as that in the United States. These diagnostic tests and products may compete with our diagnostic tests, products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing diagnostic tests, products and services in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries, including India, China, and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make diagnostic tests or products that are similar to our Nodify XL2, Nodify CDT, GeneStrat or VeriStrat tests or utilize similar technology that is not covered by the claims of our patents or that incorporates certain technology in our Nodify XL2, Nodify CDT, GeneStrat or VeriStrat tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own or license now or may own or license in the future;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our current or future pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive diagnostic tests, products and services for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may harm our business; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property rights.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect that the price of our common stock will fluctuate substantially and you may not be able to sell your shares at or above the price you paid for them.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">volume and customer mix for our Nodify XL2, Nodify CDT, GeneStrat ddPCR, GeneStrat NGS, and VeriStrat testing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the introduction of new diagnostic tests or enhancements to such tests by us or others in our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments with respect to our or others&#8217; intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop, obtain regulatory clearance or approval or certification for, and market new and enhanced diagnostic tests on a timely basis;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product liability claims or other litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">quarterly variations in our results of operations or those of others in our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">media exposure of our diagnostic tests or of those of others in our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in governmental regulations or in the status of our regulatory approvals or applications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in earnings estimates or recommendations by securities analysts; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">price of our common stock, regardless of our actual operating performance, and you may not realize any return on your investment in us and may lose some or all of your investment.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#8217;s attention and resources from our business.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock develops is influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a small reporting company and emerging growth company, we may be slow to attract research coverage and the analysts who publish information about our common stock will have had relatively little experience with us, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We may take advantage of certain exemptions and relief from various public reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act. We will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#8217;s report on financial statements; we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will remain an &#8220;emerging growth company&#8221; until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) until December 31, 2025 (the year ended December 31st following the fifth anniversary of our IPO).</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by nonaffiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. It is possible that interpretation, industry practice and guidance may evolve over time. If our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our officers, directors and principal stockholders each holding more than 5% of our common stock collectively control approximately 67.0% of our outstanding common stock as of December 31, 2023. As a result, these stockholders, if they act together, will be able to control the management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating as a public company requires us to incur substantial costs and requires substantial management attention.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we have incurred and will continue to incur costs associated with corporate governance requirements that are applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended (the Exchange Act), as well as the rules of NASDAQ. Compliance with these rules and regulations have significantly increased our accounting, legal and financial compliance costs and make some activities more time-consuming. These rules and regulations could make it more expensive for us to maintain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors or as executive officers. Accordingly, increases in costs incurred as a result of being a publicly traded company may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of being a public company, we are required, under Section 404 of the Sarbanes-Oxley Act to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual and interim financial statements will not be detected or prevented on a timely basis.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">faulty human judgment and simple errors, omissions, or mistakes;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fraudulent action of an individual or collusion of two or more people;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inappropriate management override of procedures; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.</span></div></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we cease to be an &#8220;emerging growth company&#8221; under the federal securities laws, our auditors will be required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. Notwithstanding the foregoing, the exclusive forum provision will not apply to any claim to enforce any liability or duty created by the Exchange Act or the Securities Act and for which the federal courts have exclusive jurisdiction. We believe this exclusive forum provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated articles of incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Section 145 of the Delaware General Corporate Law.</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as permitted by the Delaware General Corporate Law, our amended and restated articles of incorporation and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by applicable law. Such law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rights conferred in our amended and restated articles of incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not retroactively amend our amended and restated articles of incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="n1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1B. Unresolved S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">taff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="n1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1C. Cyberse</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">curity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business relies on secure and continuous processing of information and the availability of our IT networks and IT resources, as well as critical IT vendors that support our technology, research and other data processing operations. We have integrated cybersecurity risk management into our broader risk management framework. This integration ensures that cybersecurity considerations are an integral part of our decision-making processes at every level. Our IT department continuously evaluates and addresses cybersecurity risks in alignment with our business objectives and operational needs. The Company maintains comprehensive security policies and procedures. These policies and procedures include</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">but are not limited to security and data privacy training for staff, physical security, and electronic data security. Our electronic data security policies and procedures follow HIPAA, GDPR, SEC guidelines, and examples encompass data access controls, data privacy controls, password controls, data encryption, and incident response including an in-depth process for determining materiality. On top of the policies, our network is protected via firewall implementation and cyber-threat monitoring which includes 24/7 vulnerability scanning and 24/7 monitoring using extended detection and response for advanced intrusion detection.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also engages with a range of external experts in evaluating and testing our risk management systems. These partnerships allow us to leverage specialized knowledge and insights, ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaboration with these third-parties includes audits, threat assessments, and consultation on security enhancements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is also aware of the risks associated with third-party service providers. To oversee these risks, we conduct thorough security assessments of all third-party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Cybersecurity Risks</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this Annual Report on Form 10-K, the Company has not experienced any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company. In the event of a cybersecurity incident, the Company is equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents. See "Risk Factors&#8212; We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are any security or data privacy breaches or other unauthorized or improper access."</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management and Board Oversight</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for day-to-day risk management activities. Our Board of Directors, acting directly and through its committees, is responsible for the oversight of our risk management. The Nominating and Governance Committee monitors our cybersecurity risk profile, receives periodic updates from management on all matters related to cybersecurity and reports to our full Board of Directors on an annual basis or as necessary. The Nominating and Governance Committee is composed of members with diverse expertise that allows them to oversee cybersecurity risks effectively.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management is involved in assessing and managing material cybersecurity risks and incidents through dialogue with our Information Security Officer. Our Information Security Officer brings expertise to this role through his in-depth knowledge and experience in technology management and cybersecurity. Our Information Security Officer is continually informed about the latest developments in cybersecurity. This is crucial for the effective prevention, detection, mitigation and remediation of cybersecurity incidents, and allows him to regularly inform our Chief Executive Officer and Chief Financial Officer of any and all aspects of our business related to cybersecurity and information technology.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Chief Executive Officer, Chief Financial Officer and Information Security Officer regularly report to the Nominating and Governance Committee to ensure effective and efficient oversight of our cybersecurity threats and material risks, and to assist in proper risk management. Significant cybersecurity matters and strategic risk management decisions will be escalated from the Nominating and Governance Committee to the Board of Directors, ensuring that there is comprehensive oversight and the full Board of Directors can provide guidance on critical cybersecurity issues.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout fiscal year 2023 our headquarters were located in Boulder, Colorado, where we leased office and laboratory space, under an operating lease agreement that expired in January 2024. In March 2022, the Company entered into a lease agreement (the CVP Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company for office and laboratory space in Louisville, Colorado. In August 2022, CVP assigned the lease to CVP I Owner LLC, within the terms allowing for the assignment of the lease. The purpose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the CVP Lease was to replace the Company&#8217;s leased premises in Boulder, Colorado. The Company relocated its corporate headquarters to Louisville, Colorado in December 2023. We also lease office and laboratory space located in De Soto, Kansas, under an operating lease agreement that expires in October 2026. A portion of our employees are located outside of Colorado and Kansas, and others work from home. Our properties are suitable for our current business operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.514%;"/>
    <td style="width:1.62%;"/>
    <td style="width:31.514%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:14.517%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:16.057%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Location</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Use</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Square Feet</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Louisville, Colorado</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Office and laboratory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,980</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2035</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">De Soto, Kansas</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Office and laboratory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,066</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 31, 2026</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is traded on The NASDAQ Global Market under the symbol &#8220;BDSX&#8221;. The high and low closing prices for our common stock on The NASDAQ Global Market from January 1, 2023 to December 31, 2023 were $2.50 and $1.04, respectively.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 23, 2024, there were approximately 239 holders of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. We anticipate that all of our liquidity in the foreseeable future will be used for the operation and growth of our business. Any future determination to declare dividends will be subject to the discretion of our Board of Directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, and any other factors deemed relevant by our Board of Directors. In addition, the terms of our term loan restrict our ability to pay dividends on our common stock, and we may also enter into credit agreements or other borrowing arrangements in the future that will further restrict our ability to declare or pay dividends on our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities and Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 3, 2023, the Company entered into subscription agreements (the August 2023 Subscription Agreements) with all of the members of our Board of Directors, all Section 16 officers, and additional members of the Biodesix leadership team (together, the Investors) for the issuance and sale by the Company of an aggregate of 16,975,298 shares of the Company&#8217;s common stock at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $1.62 per share for an aggregate purchase price of approximately $27.5 million. The Subscription Agreements did not include any registration rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company used the proceeds for the commercial expansion of sales, research and development, and for general corporate purposes (see &#8211; Item 8. "Financial Statements and Supplementary Data").</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of 235,056 shares of the Company&#8217;s common stock at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $1.15 per share for an aggregate purchase price of approximately $270,000. The November 2022 Subscription Agreements did not include any registration rights and included lock up restrictions in effect during the period ending 90 days subsequent to November 21, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company used the proceeds to, among other things and in conjunction with a public offering, fund the repayment of the promissory note with Streeterville Capital, LLC (Streeterville), the Loan and Security Agreement with Silicon Valley Bank (SVB), and for general corporate purposes (see &#8211; Item 8. "Financial Statements and Supplementary Data").</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of an aggregate of 6,508,376 shares of the Company&#8217;s common stock at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $1.79 per share, which is equal to the closing price of the Company&#8217;s common stock on April 7, 2022, generating proceeds of $11.7 million. The three members of our Board of Directors acquired an aggregate of 3,631,284 shares pursuant to the form of the April 2022 Subscription Agreements that did not include any registration rights as they are exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act), and Rule 506 promulgated thereunder. The remaining 2,877,092 shares were acquired by others pursuant to the form of the April 2022 Subscription Agreements whereby we agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the SEC no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company used the proceeds to, among other things, fund the partial repayment of the 2021 Term Loan and for general corporate purposes (see &#8211; Item 8. "Financial Statements and Supplementary Data").</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reserved]</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biodesix, Inc. is referred to throughout this Annual Report on Form 10-K for the period ended December 31, 2023 (Form 10-K) as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion of our financial condition and results of operations should be read together with our audited financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part I, Item 1A above. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ from those anticipated.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A), is provided to supplement the audited financial statements and the related notes in Part II - Item 8 of this Annual Report on Form 10-K. We intend for this discussion to provide you with information that will assist you in understanding our financial statements, the changes in key items in those financial statements from year to year and the primary factors that accounted for those changes. Data for the years ended December 31, 2023 and 2022 has been derived from our audited financial statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a leading diagnostic solutions company with a focus in lung disease. By combining a multi-omic approach with a holistic view of the patient&#8217;s disease state, we believe our testing solutions provide physicians with greater insights to help personalize their patient&#8217;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, radiomics, and AI enabled informatics, to discover innovative diagnostic tests for potential clinical use. Our multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic treatment landscape to identify additional clinical unmet needs where a diagnostic test could help improve patient care. Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or other collaborative partnerships, to continue to advance our platform. We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have commercialized five diagnostic tests for our lung diagnostic business, each of which have Medicare coverage, which are currently available for use by physicians. Our Nodify XL2 and Nodify CDT tests, marketed as Nodify Lung Nodule Risk Assessment testing, assess the risk of lung cancer to help identify the most appropriate treatment pathway. The Nodify CDT and XL2 tests have an established average turnaround time of one and five business days, respectively, from receipt of the blood sample, providing physicians with timely results to guide diagnostic planning. The Nodify Lung Risk Assessment testing has resulted in a change in the calculated risk of malignancy in 80-85% of the cases. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient&#8217;s immune system to help guide treatment decisions. The GeneStrat targeted tumor genomic profiling test and the VeriStrat immune profiling test have an established average turnaround time of two business days. The GeneStrat NGS test is our blood-based NGS test and has an established average turnaround time of three business days. The 52-gene panel includes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify all four major mutation classes and genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the five diagnostic tests currently on the market, we perform more than 30 assays for research use as part of our laboratory services that have been used by over 65 biopharmaceutical companies and academic partners. All of our diagnostic and services testing is performed at one of our two accredited, high-complexity clinical laboratories in Louisville, Colorado and De Soto, Kansas.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have performed over 600,000 clinical diagnostic tests, and continue to generate a large and growing body of clinical evidence consisting of over 300 clinical and scientific peer-reviewed publications, presentations, and abstracts. Through ongoing study of each of our tests, we continue to grow our depth of understanding of disease biology and the broad utility of each of our tests. We believe we are poised for rapid growth by leveraging our scientific development and laboratory operations expertise along with our commercial infrastructure which includes sales, marketing, reimbursement, and regulatory affairs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, we market our tests to clinical customers through our targeted sales organization, which includes sales representatives that are engaged in sales efforts and promotional activities primarily to pulmonologists, oncologists, cancer centers and nodule clinics. We market our tests and services to biopharmaceutical companies globally through our targeted business development team, which promotes the broad utility of our tests and testing capabilities throughout drug development and commercialization which is of value to pharmaceutical companies and their drug-development process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program, which included three commercialized tests. These tests under the Biodesix WorkSafe testing program were utilized by healthcare providers, including hospitals and nursing homes, and were also offered to businesses and educational systems. We announced multiple partnerships for COVID-19 testing and maintained an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State, which expired on August 31, 2022. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two FDA EUA authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Beginning in second quarter 2021, we began partnering with GenScript Biotech Corporation to commercialize the blood-based cPass SARS-CoV-2 Neutralizing Antibody testing as a service. The test was the first surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the RBD in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors Affecting Our Performance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe there are several important factors that have impacted our operating performance and results of operations, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Testing volume and customer mix. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our revenues and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of our commercial tests, or the number of tests that we perform for patients on behalf of clinicians, as well as tests for biopharmaceutical companies. Our performance depends on our ability to retain and increase adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly impact our results of operations, as the average selling price for biopharmaceutical sample testing is currently significantly greater than our average selling price for clinical tests since we are not a contracted provider for, or our tests are not covered by all clinical patients&#8217; insurance. We evaluate our average selling price for tests that are covered by Medicare, Medicare Advantage and commercial payers to understand the trends in reimbursement and apply those trends to our revenue recognition policies.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement for clinical diagnostic testing. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. On June 7, 2022, we announced that WPS Government Health Administrators, the Medicare administrative contractor with jurisdiction for Biodesix&#8217;s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT lung nodule test. All five Biodesix blood-based lung diagnostic </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tests within the Nodify Lung Nodule Risk Assessment testing strategy and IQLung strategy for lung cancer patients are now covered by Medicare. Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a &#8220;participating provider&#8221; or do not have a contract and are considered a &#8220;non-participating provider.&#8221; Payers will often reimburse non-participating providers, if at all, at a lower rate than participating providers.</span></div></div>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. Becoming a participating provider generally results in higher reimbursement for covered indications and lack of reimbursement for non-covered indications. As a result, the impact of becoming a participating provider with a specific payer will vary. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></p>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October, 17, 2022, the Company announced that the U.S. Department of Veterans Affairs (the VA), the largest integrated health care system in the United States, awarded a Federal Supply Schedule Contract for the Company&#8217;s entire portfolio of lung cancer diagnostic tests. The VA provides care at 1,298 health care facilities, including 171 VA Medical Centers and 1,113 outpatient sites of care of varying complexity to over 9 million veterans enrolled in the VA health care program. All of our existing lung diagnostic tests will be payable when performed and partnering with the VA represents a large opportunity for Biodesix to help improve care for our Veterans by integrating our five diagnostic products and testing strategies into our country&#8217;s largest health system.</span></p>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 19, 2022, the Company announced the signing of our first four private payer commercial policies covering our Nodify XL2 test. These contracts included three Blue Cross Blue Shield plans in North Carolina, South Carolina, and Kansas City, and a contract with Capital District Physician&#8217;s Health Plan in New York. In total these new private pay contracts add approximately 4.5 million covered lives, and are in geographic regions of the country where the incidence of lung cancer is high.</span></p>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 6, 2023, the Company announced that the Centers for Medicare &amp; Medicaid Services (CMS) has designated the Nodify CDT Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023. Obtaining ADLT status is a recognition that the Nodify CDT test meets the stringent criteria established under the Protecting Access to Medicare Act of 2014. ADLT status is reserved for innovative tests with Medicare coverage that provide new clinical diagnostic information that cannot be obtained from any other test or combination of tests.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investment in clinical studies and product innovation to support growth. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A significant aspect of our business is our investment in research and development, including the development of new products and our investments in clinical utility studies. We have invested heavily in clinical studies for our on market and pipeline products. Our studies focus primarily on the clinical utility of our tests including the ongoing INSIGHT study to continue our clinical understanding of the predictive and prognostic value of the VeriStrat test. On June 27, 2023, we completed and closed enrollment of 5,000 patients in the INSIGHT study with non-small cell lung cancer. The ALTITUDE study, launched during the fourth quarter 2020, seeks to further demonstrate the efficacy of the Nodify XL2 and Nodify CDT tests. A secondary focus of our studies is understanding the economic impact of our tests in assisting with decisions related to patient management and the potential impact of our tests in reducing overall healthcare costs. On July 12, 2023, we announced the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2 experiencing invasive procedures. The ORACLE study showed patients with benign nodules managed with the Nodify XL2 test were 74% less likely to undergo an unnecessary invasive procedure compared to the control group. Additionally, the proportion of patients sent to CT surveillance with malignant nodules did not differ between the Nodify XL2 group and the control group.</span></div></div>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical research has resulted in approximately 90 peer-reviewed publications for our tests. In addition to clinical studies, we are collaborating with investigators from multiple academic cancer centers. On June 3, 2022, we announced the intent to develop a new novel molecular minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and the Company also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers and expect our investments in research and development to increase. Further we also expect to increase our research and development expenses to fund further innovation and develop new clinically relevant tests.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ability to attract new biopharmaceutical customers and maintain and expand relationships with existing customers. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business development team promotes the broad utility of our products for biopharmaceutical companies in the United </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">States and internationally. Our revenue, business opportunities and growth depend in part on our ability to attract new biopharmaceutical customers and to maintain and expand relationships with existing biopharmaceutical customers. We expect to increase our sales and marketing expenses in furtherance of this as we continue to develop these relationships, and we expect to support a growing number of investigations and clinical trials. If our relationships expand, we believe we may have opportunities to offer our platform for companion diagnostic development, novel target discovery and validation efforts, and to grow into other commercial opportunities. For example, we believe our multi-omic data including genomic and proteomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and companion diagnostic discovery and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="margin-left:8%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2022, the Company announced an arrangement with Royal Philips, a global leader in health care technology, in which our Nodify Lung blood-based lung nodule risk assessment testing will be incorporated into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data &#8211; along with the radiologic and patient history data currently used to determine treatment decisions &#8211; can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. Philips Lung Cancer Orchestrator solution is designed to enable health systems to operationalize lung cancer screening and lung nodule management programs at scale.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Motivating and expanding our field sales force and customer support team. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our field sales force is the primary point of contact in the clinical setting. These representatives of the Company must cover expansive geographic regions which limits their time for interaction and education of our products in the clinical setting. We plan to continue investing in the field sales force through select expansion and provide them with tools that maximize their education and selling efforts in order to achieve greater returns. Additionally, we plan to invest in the marketing and customer support teams to continue to provide the field sales force with the resources to be successful.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A. &#8220;Risk Factors&#8221; for more information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 Pandemic</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic disrupted, and may continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#8217; public health orders and the guidance from the Centers for Disease Control and Prevention (CDC). Employees who can perform their duties remotely have the option to work from home. Our sales, marketing and business development efforts may be constrained by our operational response to future COVID-19 variant outbreaks. We will continue to adjust our operational norms, as needed, including complying with government directives and guidelines as they are modified and supplemented.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic and the surge associated with multiple variants have negatively affected our lung diagnostic testing-related revenue and our clinical studies. Beginning in the third quarter 2020, the Company&#8217;s COVID-19 testing services began to experience rapid growth with a peak in the first quarter 2021; however, subsequent to this peak, we experienced a rapid decline in COVID-19 testing revenue primarily as a result of a few significant contracts that expired as well as the ongoing increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing. On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Part I, Item 1A. &#8220;Risk Factors&#8221; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fourth Quarter and Full Year 2023 Financial and Operational Highlights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following were significant developments affecting our business, capital structure and liquidity during the year ended December 31, 2023 as compared to the same period in 2022 unless otherwise noted:</span></p>
  <div style="margin-left:2.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.140304501956927%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total revenue of $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively, an increase of 52% and 49% over the respective prior year comparable periods excluding COVID testing revenues, and an increase of 53% and 28% over the respective prior year comparable periods including COVID testing revenues; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lung Diagnostic revenue of $12.8 million and $45.1 million for the fourth quarter and fiscal 2023, respectively, an increase of 55% and 54% over the respective prior year comparable periods, primarily driven by the continued adoption of Nodify Lung&#174; Nodule Risk Assessment tests; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biopharma Services and other revenue of $1.9 million and $3.9 million for the fourth quarter and fiscal 2023, respectively, an increase of 38% and 6% over the respective prior year comparable periods, a result of both delivering against our expanding book of business and securing new agreements; </span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.140304501956927%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gross profit was $11.3 million or 77% and $36.1 million or 73% for the fourth quarter and fiscal 2023, respectively, as a percentage of revenue compared to 66% and 63% in the prior year comparable periods, primarily driven by growth in Lung Diagnostic testing and optimization of testing workflows that resulted in improvements in costs per test, the ongoing recovery of our Biopharma Services business, and the commercial discontinuation of lower-margin COVID-19 testing;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.140304501956927%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses (excluding direct costs and expenses) of $18.2 million and $77.4 million for the fourth quarter and fiscal 2023, a decrease of 10% and increase of 4% over the respective prior year comparable periods;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Decrease in fourth quarter 2023 is primarily attributable to a decrease in research and development costs, partially offset by increased sales and marketing costs to support Lung Diagnostic sales growth, enhance product awareness and drive adoption, while the full year increase in operating expenses was driven by an increase in sales and marketing costs, partially offset by a reduction in research and development costs;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Includes non-cash stock compensation expense of $1.1 million and $5.4 million during fourth quarter and fiscal 2023, respectively, a decrease of 48% and 10% over the respective prior year comparable periods;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.140304501956927%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively, an improvement of 55% and 20% over the respective prior year comparable periods;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fourth quarter and fiscal 2023 included a gain of $0.1 million and loss of $1.3 million, respectively, from the change in fair value of warrant liabilities associated with our term loan facility with Perceptive Advisors (Perceptive);</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fourth quarter and fiscal 2022 included loss on debt extinguishment and modification of $4.0 million and $7.0 million, respectively;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.065%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.140304501956927%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents of $26.3 million as of December 31, 2023; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Company successfully drew down the second tranche of $10 million from its $50 million term loan facility with Perceptive in the fourth quarter of 2023; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash balance includes the remaining $12.2 million of the $27.5 million private placement announced in August 2023.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnostic Tests</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenue is generated from delivery of results from our diagnostic tests. In the United States, we performed tests as both an in-network and out-of-network service provider depending on the test performed and the contracted status of the insurer. We provide diagnostic tests in two primary categories: (i) lung diagnostic testing and (ii) COVID-19 testing. On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider diagnostic testing to be completed upon the delivery of test results to our customer, either the prescribing physician or third-party to which we contracted for services to be performed, which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. We determine the transaction price related to our contracts by considering the nature of the payer, test type, the historical amount of time until payment by a payer, and historical price concessions granted to groups of customers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biopharma Services and other</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Services revenue is generated from the delivery of our on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer. At times we collaborate with large biopharmaceutical companies in an attempt to discover biomarkers that would be helpful in their drug development or marketing. The performance obligations and related revenue for these sales is defined by a written agreement between us and our customer. These services are generally completed upon</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the delivery of testing results, or other contractually defined milestone(s), to the customer, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue derived from services is often unpredictable and can cause significant swings in our overall net revenue line from quarter to quarter.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements, and considering factors including, but not limited to: enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Direct costs and expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of diagnostic testing generally consists of cost of materials, direct labor, including bonuses, employee benefits, share-based compensation, equipment and infrastructure expenses associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties. Costs associated with performing our tests are recorded as the tests are processed regardless of whether revenue was recognized with respect to the tests. Infrastructure expenses include allocated depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. Under these license agreements, we are obligated to pay aggregate royalties ranging from 1% to 8% of sales in which the patents or know-how are used in the product or service sold, sometimes subject to minimum annual royalties or fees in certain agreements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect the aggregate cost of diagnostic testing to increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions. Cost of services includes costs incurred for the performance of development services requested by our customers. Costs of development services will vary depending on the nature, timing and scope of customer projects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of costs incurred to develop technology and include salaries, share-based compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, clinical studies, other outside costs and costs to develop our technology capabilities. Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with the discovery and development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">External expenses include: (i) payments to third parties in connection with the clinical development of our product candidates, including contract research organizations and consultants; (ii) the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants; (iii) scientific development services, consulting research fees and for sponsored research arrangements with third parties; (iv) laboratory supplies; and (v) allocated facilities, depreciation and other expenses, which include direct or allocated expenses for IT, rent and maintenance of facilities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external costs by the stage of program, clinical or preclinical.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Internal expenses include employee-related costs, including salaries, share-based compensation and related benefits for employees engaged in research and development functions. We do not track internal costs by product candidate because these costs are deployed across multiple programs and, as such, are not separately classified.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase as we continue to innovate and develop additional products and expand our data management resources. As our services revenue grows, an increasing portion of research and development dollars are expected to be allocated to cost of services for biopharmaceutical service contracts. This expense, though expected to increase in dollars, is expected to decrease as a percentage of revenue in the long term, though it may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales, marketing, general and administrative</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, share-based compensation, and travel, as well as marketing and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in dollars as we expand our sales force, increase our presence within the United States, and increase our marketing activities to drive further awareness and adoption of our tests and our future products. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our general and administrative expenses include costs for our executive, accounting, finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, share-based compensation, and travel, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense and Interest Income</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, interest expense consists of cash and non-cash interest from the Perceptive Term Loan Facility and changes in the value of our contingent consideration associated with the passage of time subsequent to the achievement of the gross margin target in the second quarter 2021. For the year ended December 31, 2022, interest expense primarily consists of cash and non-cash interest from the secured promissory note with Streeterville, the 2021 Term Loan, the Perceptive Term Loan, and changes in the value of our contingent consideration. Interest income, which is included in &#8216;Other income, net&#8217; in the statements of operations consists of income earned on our cash and cash equivalents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the significant components of our results of operations for the periods presented (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.75%;"/>
    <td style="width:1.121%;"/>
    <td style="width:1%;"/>
    <td style="width:9.187%;"/>
    <td style="width:1%;"/>
    <td style="width:1.121%;"/>
    <td style="width:1%;"/>
    <td style="width:9.187%;"/>
    <td style="width:1%;"/>
    <td style="width:1.121%;"/>
    <td style="width:1%;"/>
    <td style="width:8.847%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:9.667%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,087</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,212</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,875</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,010</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,154</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,144</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,988</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,102</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,114</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,387</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,925</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment loss on intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(37</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(46</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,799</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,630</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(41,342</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(50,587</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,245</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other (expense) income</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,536</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,072</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,981</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,981</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,274</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,358</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,617</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(103</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,804</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,860</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,056</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(52,146</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(65,447</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,301</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,373</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,961</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(588</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	Amounts represent share-based compensation expense reported in the Company&#8217;s results of operations above.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generate revenue by providing laboratory testing of our diagnostic tests and services. Our revenues for the periods indicated were as follows (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.31%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:8.582%;"/>
    <td style="width:1%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:9.522%;"/>
    <td style="width:1%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:8.682%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.482000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lung Diagnostic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,135</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,298</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,837</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">COVID-19</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,240</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,183</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(99</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diagnostic Testing revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,192</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,538</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,654</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biopharma Services and other revenue</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,895</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,674</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">221</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,087</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,212</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,875</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total revenue increased $10.9 million or 28% for the year ended December 31, 2023 compared to the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenue increased $10.7 million or 31% for the year ended December 31, 2023 compared to the same period in 2022. The increase for the year ended December 31, 2023 compared to the same period in 2022 is due to an increase in our lung diagnostic testing revenue of $15.8 million, driven by an increase in our Nodify XL2 and CDT diagnostic tests delivered. The Company&#8217;s lung diagnostic sales efforts continued to gain momentum during the year ended December 31, 2023 as the number of tests delivered reached the highest in Company history for four consecutive quarters. Partially offsetting this increase was a $5.2 million reduction in COVID-19 testing revenue for the year ended December 31, 2023, resulting from the expiration of significant COVID-19 testing contracts and the recession of the COVID-19 pandemic. Additionally, on January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides COVID-19 diagnostic testing services commercially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharma Services and other revenue increased $0.2 million or 6% for the year ended December 31, 2023 compared to the same period in 2022. The increase in revenue for the year ended December 31, 2023 was primarily due to recovery in testing volumes from clinical studies and services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Direct costs and expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Direct costs and expenses related to revenue decreased $1.1 million or 8% for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease in costs for the year ended December 31, 2023 was driven primarily by the overall decline in COVID-19 testing volume and reductions in inventory obsolescence as the Company began exiting our commercial COVID-19 testing services in the latter half of 2022. This was partially offset by an increase in direct costs and expenses associated with increased lung diagnostic and services testing volume.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses decreased $3.1 million or 24% for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease in cost was due primarily to a decrease in internal expenses associated with compensation and benefit costs as well as clinical trial and other external costs associated with contracted services and laboratory costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our external and internal costs for the years ended December 31, 2023 and 2022 (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.75%;"/>
    <td style="width:1.121%;"/>
    <td style="width:1%;"/>
    <td style="width:9.187%;"/>
    <td style="width:1%;"/>
    <td style="width:1.121%;"/>
    <td style="width:1%;"/>
    <td style="width:9.187%;"/>
    <td style="width:1%;"/>
    <td style="width:1.121%;"/>
    <td style="width:1%;"/>
    <td style="width:8.847%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:9.667%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials and associated costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,663</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,551</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(888</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other external costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,822</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,625</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(803</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total external costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,485</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,176</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,691</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Internal expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,503</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,926</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,423</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,988</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,102</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,114</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales, marketing, general and administrative</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales, marketing, general and administrative expenses increased $5.9 million or 10% for the year ended December 31, 2023 compared to the year ended December 31, 2022. This increase was driven primarily by increases in employee compensation and benefits associated with an increase in sales team headcount and variable compensation as well as increases in non-employee costs associated with increased spending on various sales meetings, training, and campaigns during 2023 as compared to 2022. During the year ended December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, the Company&#8217;s sales efforts continued to be impacted by the COVID-19 pandemic due to surges associated with multiple variants, restricting and delaying the Company's ability to execute our lung diagnostic sales strategy, resulting in lower sales and marketing costs in the first half of 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest expense</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense increased $1.5 million or 18% for the year ended December 31, 2023 compared to the year ended December 31, 2022. The interest expense for the year ended December 31, 2023 is primarily related to interest associated with the Perceptive Term Loan Facility of $5.5 million and interest associated with the contingent consideration of $3.9 million. The interest expense for the year ended December 31, 2022 is primarily related to interest associated with the contingent consideration of $3.3 million, Perceptive Term Loan Facility of $0.5 million, the 2021 Term Loan with Silicon Valley Bank of $2.4 million, and securities purchase agreement with Streeterville Capital, LLC of $1.8 million in 2022.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on extinguishment of liabilities, net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded a loss on extinguishment of liabilities of zero and $7.0 million for the years ended December 31, 2023 and 2022, respectively. On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which all parties agreed to restructure the milestone payments. During the three months ended June 30, 2022, the Company evaluated Amendment No. 3 to the Indi APA in accordance with applicable accounting standards under U.S. GAAP which resulted in the extinguishment of the original instrument due to the substantially different terms. As a result, during the three months ended June 30, 2022, we recorded a loss on the extinguishment of $2.9 million. Additionally, as a result of the extinguishment of Promissory Note One and the 2021 Term Loan, the Company recorded a loss on debt extinguishment of $3.6 million and $0.5 million, respectively, associated with the prepayment premium and the write-off of unamortized original issue discount (OID) and debt issuance costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in fair value of warrant liability</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan, the Company issued the Perceptive Warrant, with warrants exercisable into 3,000,000 shares of the Company&#8217;s common stock issued on the funding date of the Tranche A Loan which are equity classified (the Initial Warrants). In addition to the Initial Warrants and to the extent the Company has the ability to exercise its right to borrow the remaining availability under the Perceptive Term Loan, additional warrants will become exercisable into 1,000,000 shares of common stock concurrently with the borrowing of the Tranche B Loan (the Tranche B Warrants), and additional warrants will become exercisable into 1,000,000 shares of common stock concurrently with the borrowing of the Tranche C Loan (the Tranche C Warrants). The Company initially accounted for the Tranche B and C Warrants as liabilities as the Tranche B and C Warrants did not meet the criteria for equity classification. During the year ended December 31, 2023, the Company recorded a $1.3 million net loss as a change in fair value through the statement of operations due to changes in unobservable inputs. This is a result of changes in the probability of our ability to draw on Tranche B and C loans. On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan. In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital. As of December 31, 2023, the Tranche C Warrants remain classified as a liability.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company and, as such, have yet to generate positive cash flows from operations. We have funded our operations to date principally from net proceeds from the sale of our common stock, the sale of convertible preferred stock, revenue from diagnostic testing and services, and the incurrence of indebtedness as described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2022 (the LPC Effective Date), we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (the Purchase Agreement), pursuant to which Lincoln Park has committed to purchase up to $50.0 million of our common stock (the LPC Facility). Under the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million of our common stock. Such sales of common stock by us, if any, will be subject to certain limitations, and may occur from time to time, at our sole discretion, over the 36-month period commencing on the LPC Effective Date. As consideration for Lincoln Park's irrevocable commitment to purchase our common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, on the LPC Effective Date, we issued 184,275 shares of common stock to Lincoln Park as a commitment fee valued at $600,000 for which no consideration was received.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, we entered into subscription agreements with a consortium of investors, including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of an aggregate of 6,508,376 shares of our common stock in an offering for an aggregate purchase price of approximately $11.7 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company amended the Indi APA agreement in April 2022 in which all parties agreed to restructure the Milestone Payments whereby the Company will make five quarterly installments of $2.0 million each beginning in April 2022, three quarterly installments of $3.0 million beginning in July 2023, one installment of $5.0 million in April 2024, and one installment of approximately $8.4 million in July</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024. In addition, the Company agreed to an exit fee of approximately $6.1 million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to 10%, with such interest to be payable quarterly on the following installment payment date. Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan and commencing January 1, 2024, consent from Perceptive.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 9, 2022, the Company entered into a securities purchase agreement with Streeterville, pursuant to which, among other things, Streeterville: (i) purchased Promissory Note One in the aggregate principal amount totaling $16.0 million in exchange for $15.0 million less certain expenses. Promissory Note One could, at the Company's option, be settled in cash or shares of common stock of the Company, upon the terms and subject to the limitations and conditions. On May 9, 2022, the Company closed on Promissory Note One for gross proceeds of $15.0 million (approximately $12.8 million, net, after deducting debt issuance costs and OID).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility with Perceptive Advisors, LLC (Perceptive) for up to $50.0 million, with funding of $30.0 million on November 21, 2022, and two additional contingently issuable tranches of $10.0 million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock for $40.4 million in gross proceeds and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#8217;s management team for $0.3 million. Collectively, the Company raised gross proceeds of approximately $70.7 million ($65.7 million after deducting commissions, fees and expenses payable). Approximately $23.9 million of the net proceeds were used to retire Promissory Note One with Streeterville and the 2021 Term Loan with Silicon Valley Bank. The remaining proceeds of approximately $42.0 million were used for commercial expansion of sales, supporting the Company&#8217;s product pipeline, research and development and for general corporate purposes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $2.5 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ending March 31, 2023, recognize revenue in amounts agreed to between the Company and Perceptive.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2023, the Company entered into a limited waiver under which Perceptive agreed to waive the minimum revenue requirement for the three months ended March 31, 2023 (Limited Waiver). In addition, on May 10, 2023, the Company entered into the First Amendment to the Perceptive Term Loan Facility (the First Amendment) with Perceptive, whereby subject to the terms and conditions of the First Amendment, the minimum net revenue covenant was modified to reduce the threshold through the twelve month period ended March 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 3, 2023, the Company entered into subscription agreements with all of the members of our Board of Directors, all Section 16 officers, and additional members of the Biodesix leadership team for the issuance and sale by the Company of an aggregate of 16,975,298 of the Company&#8217;s common stock for an aggregate purchase price of approximately $27.5 million. During the three months ended September 30, 2023, the Company received $15.3 million in proceeds and issued 9,454,927 shares of common stock. On September 27, 2023, the Company entered into an amendment to delay final closing on one subscription agreement. The remaining $12.2 million in proceeds was received and 7,520,371 shares of common stock were issued during the three months ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 4, 2023, the Company entered into the Second Amendment to the Perceptive Term Loan Facility (the Second Amendment) with Perceptive, whereby subject to the terms and conditions of the Second Amendment, the minimum net revenue covenant was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending June 30, 2024 through and including the fiscal quarter ending December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the original terms of the agreement with Perceptive, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $10.0 million, which was accessible by the Company so long as the Company satisfied certain customary conditions precedent, including revenue milestones. Under the terms of the Second Amendment, the conditions precedent for drawing on the Tranche B Loan were amended to (i) reduce the trailing-twelve month revenue milestone and (ii) add the receipt of aggregate cash proceeds of at least $27.5 million from an equity offering of the Company's common stock. During the three months ended December 31, 2023, the Company met the conditions precedent associated with the Tranche B Loan and, on December 15, 2023, the Company exercised its ability to draw the Tranche B loan for $10.0 million (the Tranche B Loan).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company raised approximately $0.6 million ($0.6 million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of 376,456 common shares at a weighted average price per share of $1.66 under the ATM facility. As of December 31, 2023, the Company had remaining available capacity for share issuances of approximately $28.9 million under the ATM facility and up to $46.9 million under the LPC Facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we maintained cash and cash equivalents of $26.3 million and we have $40.0 million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technologies. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement or to obtain waivers or amendments that impact the related covenants. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined in the Perceptive Term Loan Facility, causing an acceleration of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 29, 2024, the Company entered into a third amendment to the Perceptive Term Loan Facility (the Third Amendment), whereby, subject to the terms and conditions of the Third Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2024 through and including the fiscal quarter ending December 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a period beyond one year from when the December 31, 2023 financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes our cash flows for the periods indicated (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash flows (used in) provided by:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,870</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(44,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,062</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,534</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,129</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,882</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(16,803</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,376</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cash flows resulted in a net decrease in cash and cash equivalents and restricted cash of $16.8 million during the year ended December 31, 2023 as compared to the net increase in cash of $10.4 million for the year ended December 31, 2022. For the year ended December 31, 2023, net cash used in operating activities decreased by approximately $22.1 million primarily due to the $18.3 million in tenant improvement allowances received for capital expenditures and leasehold improvements related to the CVP Lease which have been reimbursed from the CVP landlord (see cash used in investing activities below). Partially offsetting the CVP tenant improvement allowances is $2.5 million of the contingent consideration payment made during the three months ended December 31, 2023 which is now classified as a cash outflow from operating activities due to the applicable US GAAP requirements. Additionally, the Company had favorable changes in working capital that contributed to the changes in net cash used in operating activities compared to the same period in 2022. During the year ended December 31, 2022, our $5.0 million cash collateralized letter of credit under the operating lease agreement with CVP was released and the funds were subsequently transferred to the landlord as a refundable deposit to secure the performance of the Company&#8217;s obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities during the year ended December 31, 2023 totaled $23.1 million, an increase of $19.5 million compared to the same period in 2022. The increase in net cash used in investing activities was primarily due to increases in purchases of property and equipment and capital expenditures for leasehold improvements related to the CVP Lease. These leasehold improvements are tenant improvements and have been reimbursed from the Landlord, as described above in net cash used in operating activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities during the year ended December 31, 2023 totaled $29.1 million, a decrease of $29.8 million compared to the same period in 2022. The net cash provided by financing activities for the year ended December 31, 2023 primarily resulted from $28.0 million net proceeds from the issuance of common stock, $10.0 million net proceeds from the issuance of Tranche B under the Perceptive Term Loan Facility, and $0.7 million in proceeds from the issuance of common stock under the ESPP and exercise of stock options. These proceeds were partially offset by milestone payments to Indi of $8.6 million. The net cash provided by financing activities for the year ended December 31, 2022 primarily resulted from $56.3 million net proceeds from the issuance of common stock, $41.4 million net proceeds from the issuance of Promissory Note One and the Perceptive Term Loan, and $0.6 million in proceeds from the issuance of common stock under the ESPP and exercise of stock options. These proceeds were partially offset by the repayment of Promissory Note One and the 2021 Term Loan of $28.6 million, and milestone payments to Indi of $10.8 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our non-cancelable contractual obligations and commitments as of December 31, 2023 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.178%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.962999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.962999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.962999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.962999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.962999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Payments due by period </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less than<br/>1 year</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1 to 3<br/>years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4 to 5<br/>years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">More than<br/>5 years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings and interest </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,903</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,897</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,677</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,329</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,909</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,406</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,176</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,214</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,113</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">769</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">413</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,984</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,062</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,266</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,543</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,113</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Royalty payments that we may owe are not included as the amount and timing of such payments is uncertain.</span></div></div>
  <div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Includes the Perceptive Term Loan payments of principal and interest. Interest amounts associated with the Perceptive Term Loan are variable and estimated based on the interest rate in effect at December 31, 2023.</span></div></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have not entered into any off-balance sheet arrangements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Certain of these estimates significantly influence the portrayal of our financial condition and results of operations and require us to make difficult, subjective or complex judgments. Our critical accounting policies are described in greater detail below and in Note 2 to our financial statements in Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for our goods or services. To determine revenue recognition for our arrangements with our customers, we perform a five-step process, which includes: (i) identifying the contract(s) with a customer; (ii) identifying the performance obligations in the contract; (iii) determining the transaction price; (iv) allocating the transaction price to the performance obligations in the contract; and (v) recognizing revenue when (or as) we satisfy our performance obligations. The Company generates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revenues from (i) diagnostic tests and (ii) assay development, testing services, and licensing our technologies (Biopharma Services and other revenue).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach. In determining the amount to accrue for a delivered test, the Company considers factors such as test type, payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) until December 31, 2025 (the year ended December 31st following the fifth anniversary of our initial public offering).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which: (i) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by non-affiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness, including our outstanding Perceptive Term Loan. As of December 31, 2023, we had $40.0 million outstanding on the Perceptive Term Loan Facility which has an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) 3.0% per annum, plus an applicable margin of 9.0%. Historically, we have not entered into derivative agreements such as interest rate caps and swaps to manage our floating interest rate exposure.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodically throughout the year, we have maintained balances in various operating accounts in excess of federally insured limits. Our cash and cash equivalents are funds held in checking and bank savings accounts, primarily at one U.S. financial institutions. We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. We continually monitor our positions with, and the credit quality of, the financial institutions with which we invest.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, a hypothetical 100 basis point increase in interest rates would have an estimated $0.4 million impact per year on our financial position and results of operations, based on the current Perceptive Term Loan principal remaining outstanding through maturity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statements and supplementary data are as set forth in the index to the financial statements on page F-1.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain "disclosure controls and procedures," as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-K, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria established in "Internal Control &#8211; Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), using the 2013 framework. Based on our assessment, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2023, the Company's internal control over financial reporting was effective based on the criteria set forth by COSO.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This annual report does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the quarter ended December 31, 2023, there were no changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of our directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50cb6520-3ca3-4ffd-ab84-d70156078a00" contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, modified, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee5f2666-65f2-4af2-9693-53aacef49c6b" contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a Rule 10b5-1 trading arrangement during the quarter ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_foreign_jurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item with respect to directors is incorporated by reference from the information under the captions "Board and Corporate Governance Matters&#8212;Proposal One: Election of Directors" and "&#8212;Director Independence" contained in our Proxy Statement to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2023 in connection with the solicitation of proxies for our 2024 Annual Meeting of Stockholders (the Proxy Statement). Certain information required by this item concerning executive officers is set forth in the Proxy Statement under the caption "Executive Compensation&#8212;Compensation of Named Executive Officers" and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act. This disclosure is contained in the section entitled "Stock Ownership&#8212;Delinquent Section 16(a) Reports" in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to all of our officers and employees, including our President and Chief Executive Officer, our Chief Financial Officer and other employees who perform financial or accounting functions. The Code of Business Conduct and Ethics sets forth the basic principles that guide the business conduct of our employees. Stockholders may request a free copy of our Code of Business Conduct and Ethics by contacting Biodesix, Inc., Attention: Chief Financial Officer, 919 West Dillon Rd, Louisville, Colorado 80027.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, there have been no waivers under our Code of Business Conduct and Ethics. We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics or waivers of such Codes granted to executive officers and directors on our website at http://www.biodesix.com within four business days following the date of such amendment or waiver.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board of Directors has appointed an Audit Committee, comprised of Ms. Jean Franchi, as Chairwoman, Messrs. Hany Massarany, Lawrence T. Kennedy, Jr., and Dr. Matthew Strobeck. The Board of Directors has determined that Ms. Franchi qualifies as an Audit Committee Financial Expert under the definition outlined by the Securities and Exchange Commission. In addition, each of the members of the Audit Committee qualifies as an "independent director" under the current rules of The NASDAQ Stock Market and Securities and Exchange Commission rules and regulations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the information under "Executive Compensation" contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the information under the captions "Stock Ownership&#8212;Security Ownership of Certain Beneficial Owners and Management", "Executive Compensation", and "Equity Compensation Plan Information" contained in the Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the information under the caption "Board and Corporate Governance Matters&#8212;Policies and Procedures for Related Party Transactions" and "&#8212;Director Independence" contained in the Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the information under the caption "Audit Matters&#8212;Principal Accountant Fees and Services" contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibit and Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Documents filed as a part of the report. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to the Index to Financial Statements of Biodesix, Inc. included in Item 8 of Part II hereof.</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Item 15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified. </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10-K Summary.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Index</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.741%;"/>
    <td style="width:1.398%;"/>
    <td style="width:7.361%;"/>
    <td style="width:83.5%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex31_716.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Biodesix, Inc., dated October 30, 2020 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on December 10, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex32_717.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of Biodesix, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on October 12, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex41.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen stock certificate evidencing shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Eleventh Amended and Restated Investor Rights Agreement, by and among Biodesix, Inc. and the investors listed on Exhibit A thereto, dated October 10, 2018 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex43.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant held by Innovatus Life Sciences Lending Fund I, LP, to Purchase Series G Preferred Stock, dated February 23, 3018 (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-ex45_270.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Company's Form 10-K filed with the SEC on March 16, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Note, dated November 21, 2022, issued by the Company to Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 4.1 and Exhibit 10.1 in the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex4_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Stock, dated November 21, 2022, issued by the Company to Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 4.2 in the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023021238/bdsx-ex4_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Stock, dated May 10, 2023, issued by the Company to Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc. Amended and Restated 2006 Employee, Director and Consultant Stock Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1021.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Grant Notice under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2.2+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1022.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option Agreement under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.2 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2.3+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1023.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Notice of Exercise under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.3 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex103.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc. 2016 Equity Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1041.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Grant Notice under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4.2+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1042.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.2 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4.3+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1043.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Notice of Exercise under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.3 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.5%;"/>
    <td style="width:83.5%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex105.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-ex1051_388.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.1 to the Company's Form 10-K filed with the SEC on March 16, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5.2+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1052_236.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Restricted Stock Unit Award Grant Notice and Award Agreement under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.2 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex106.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1051.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc., First Amended Bonus-to-Options Program, adopted by the Board of Directors on October 15, 2010 (incorporated by reference to Exhibit 10.5.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7.2+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1052.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc., Second Amended Bonus-to-Options Program, adopted by the Board of Directors on June 21, 2011 (incorporated by reference to Exhibit 10.5.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7.3+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1053.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc., Third Amended Bonus-to-Options Program, adopted by the Board of Directors on December 31, 2015 (incorporated by reference to Exhibit 10.5.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022014433/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8.2+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022014433/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8.3+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-ex10_83.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 2 to the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.8.3 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 6, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9.1+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1061.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Grant Notice under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9.2+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1062.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option Agreement under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.2 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520268763/d937421dex107.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement, by and between Biodesix, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11&#134;+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1092.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 23, 2020 (incorporated by reference to Exhibit 10.9.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12&#134;+**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated February 23, 2020 (incorporated by reference to Exhibit 10.10.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13.1&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1011.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated October 5, 2011 (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13.2**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003495/bdsx-ex10_132.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated January 24, 2022 (incorporated by reference to Exhibit 10.13.2 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 14, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14.1&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1013.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Assignment of De Soto Facility, dated November 1, 2019 (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.5%;"/>
    <td style="width:83.5%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14.2**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023021238/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">De Soto Amendment to Commercial Lease Agreement, effective April 4, 2023, by and between Biodesix, Inc. and De Soto Investments, LLC (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15.1**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease agreement by and between Centennial Valley Properties I, LLC and Biodesix, Inc. dated March 11, 2022 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15.2**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Lease Agreement by and between Centennial Valley Properties I, LLC and Biodesix, Inc. dated March 11, 2022 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1015.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Patent Assignment between Biodesix, Inc., and Integrated Diagnostics, Inc., dated June 30, 2018 (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1015.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">IP Assignment Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1016.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">IP License Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1017.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1018.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement between Biodesix, Inc., and Oncimmune, dated October 31, 2019 (incorporated by reference to Exhibit 10.18 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1019.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (incorporated by reference to Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1020.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Co-Development and Collaboration Agreement between AVEO Pharmaceuticals, Inc., and Biodesix, Inc., dated April 9, 2014, as amended October 14, 2016 (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23.1&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1023.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Asset Purchase Agreement among Biodesix, Inc., Integrated Diagnostics, Inc., and the stockholders of Integrated Diagnostics, Inc., listed therein, dated June 30, 2018 (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23.2**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1038_489.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 2 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.38 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23.3**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_6.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 3 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.6 to the Company's Form 10-Q filed with the SEC on May 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24&#134;**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1024.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Asset Purchase Agreement between Oncimmune Limited and Biodesix, Inc., dated June 27, 2019, as amended to date (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1037_47.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021 (incorporated by reference to Exhibit 10.37 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003002/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Purchase Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003002/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.5%;"/>
    <td style="width:83.5%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.28**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Subscription Agreement with resale registration rights provision, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.29**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Subscription Agreement without registration rights, entered by the three members of our Board of Directors, dated April 7, 2022 (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Credit Agreement and Guaranty, dated as of November 16, 2022, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023021238/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Limited Waiver, dated April 7, 2023, by and between Biodesix, Inc. and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023021238/bdsx-ex10_3.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Credit Agreement and Guaranty, dated May 10, 2023, by and among the Company and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023039073/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Credit Agreement and Guaranty, dated August 4, 2023, by and among the Company and Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Limited Waiver, dated February 14, 2024, by and between Biodesix, Inc. and Perceptive Credit Holdings IV, LP</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex10_35.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Credit Agreement and Guaranty, dated February 29, 2024, by and among the Company and Perceptive Credit Holdings IV, LP.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Agreement, dated as of November 21, 2022, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_3.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Subscription Agreement, dated November 21, 2022 (incorporated by reference to Exhibit 10.3 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38**</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017023039073/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Subscription Agreement, dated August 3, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on the signature page of this Form 10-K).</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1***</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2***</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><a href="bdsx-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Policy Relating to Recovery of Erroneously Award Compensation.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Portions of this exhibit have been omitted as the Registrant has determined that the omitted information (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">** Previously filed.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*** Furnished herewith.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"/>
    <td style="width:5.04%;"/>
    <td style="width:3.04%;"/>
    <td style="width:46.46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biodesix, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  March 1, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ CHRISTOPHER C. VAZQUEZ</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Christopher C. Vazquez</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Accounting Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATTORNEY</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each person whose signature appears below constitutes and appoints Scott Hutton and Robin Harper Cowie, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file with the Securities and Exchange Commission this Form 10-K and any and all amendments and exhibits thereto, and all documents in connection therewith, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.993%;"/>
    <td style="width:1.04%;"/>
    <td style="width:49.99%;"/>
    <td style="width:1.3%;"/>
    <td style="width:14.677%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SCOTT HUTTON</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer (Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Scott Hutton</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ROBIN HARPER COWIE</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer, Secretary and Treasurer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Robin Harper Cowie</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ CHRISTOPHER C. VAZQUEZ</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Accounting Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Christopher C. Vazquez</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JOHN PATIENCE</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">John Patience</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JEAN FRANCHI</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jean Franchi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JON FAIZ KAYYEM</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jon Faiz Kayyem, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ LAWRENCE T. KENNEDY, JR.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lawrence T. Kennedy, Jr.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ HANY MASSARANY</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Hany Massarany</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JACK SCHULER</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jack Schuler</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ MATTHEW STROBECK</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Matthew Strobeck, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ CHARLES WATTS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 1, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Charles Watts, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:9.35pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;(</span><span><ix:nonNumeric id="F_cefc7cb1-ea5e-4cca-ba69-41a45656f75b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:AuditorName"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_82e670ea-e9d9-48e7-b2a8-f19af0df8eb6" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:AuditorLocation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Denver, CO</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">, Auditor Firm ID: </span><span><ix:nonNumeric id="F_a621f074-804a-452f-9e16-4ea5ddc14a76" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:2.9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:2.9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:2.9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:2.9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:2.9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying balance sheets of Biodesix, Inc. (the Company) as of December 31, 2023 and 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and needs to raise additional equity or debt capital to fund its operations. These matters raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2016.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Denver, Colorado</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.7%;"/>
    <td style="width:1.56%;"/>
    <td style="width:1%;"/>
    <td style="width:14.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.56%;"/>
    <td style="width:1%;"/>
    <td style="width:14.940000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="8" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e183e747-4142-4f33-b11d-aa34a347cf6b" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,284</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61fd9cfb-730d-4146-946d-23d85fe0283b" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,088</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable, net of allowance for doubtful accounts of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cec62bbf-68e7-4ae6-9c3f-d2aa338bc613" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9f79195-2a94-485e-a40e-a783c57614c6" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9447e57-3ea3-42dd-a3eb-581d58d036cd" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4166d85b-3856-4c76-ba1b-d3769af67f51" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aabc236-f3e8-4e4a-8ef0-80a28a04a2ef" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,720</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11f9d6f2-3300-45de-b940-dd317f1851c7" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,181</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_146c3d19-8a9a-43d7-b728-befe9771da40" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,683</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b41362d7-447c-46eb-ae93-4403ede70d5a" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non&#8209;current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1b36cc5-6a1b-4e8a-9f8b-270a90eb1b40" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,867</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a60b586-b548-4609-972c-41d2dd63cd55" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26cb3f8b-a3fc-4549-8907-eb02409dab15" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,911</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffd3ae43-00f3-48ef-a17d-0c36c3fbe253" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,797</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_691c1c36-d16e-4b70-920f-4c4a24269418" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6991f036-440e-4b0b-a109-07bdde3cf7c9" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,973</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4d0b22a-7018-4f4d-b85c-888283893360" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,031</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b367027c-d779-45a7-b3a0-a16e7279856f" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,031</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c24f891-c11f-41ff-a5a9-f94a6c321a10" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfdfb173-5cd3-4f9f-84fb-16483ed18400" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,923</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total non&#8209;current assets</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5300e302-5af5-41ad-bd27-718a459435ce" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,413</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ba9c29b-4750-4cd1-a7da-06d21d2ad5d1" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,572</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14a0ff8c-71f8-49ed-bc96-0868625aef0a" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd6dee58-328d-41c9-8a6a-8c4d610cfd81" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="8" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders' Equity</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16c80c50-7e39-45ad-b983-74c3f34f44ed" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de9a547c-a251-4e75-8cde-e9ff59149245" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bd162dc-729e-471f-9d8c-d5fa9ebaf659" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,710</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab8a9f50-6604-4cb2-a463-721a9c338fe0" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,218</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd395ae8-d9ba-407c-b8f8-a19559943afc" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eccce8e-2cbf-483d-bf1b-063e6010e6ba" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">962</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15990cf7-a132-489e-b8ac-4107a52e283e" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e545b842-ae93-4e6a-ba01-0c5d37c3cd17" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88e5dd56-fb16-4ac2-a5ac-6abc01b9b667" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9d1e250-4963-4dc4-a187-419ce5bc953f" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of notes payable</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1421636-bf6a-4666-a678-77753003edbd" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:NotesPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77bbf713-4512-475f-8053-199db6c1909c" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:NotesPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12dd6122-a8a1-4663-ba35-7350b9861a8c" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54e8c6e8-0014-4eea-a499-0f31ce8a0879" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c37190d1-68a7-4be9-941d-0256da0d6dab" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,416</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2c15498-9457-43d4-b3eb-0f609caf8bf2" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,839</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non&#8209;current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long&#8209;term notes payable, net of current portion</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c052f2-7c6f-4962-9ec6-f0a8d07f76ae" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,225</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69743a28-2dac-48b4-af78-f427e5d606a1" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,004</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8486855-1e47-4a20-93e5-edae7e92a05b" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,163</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b81fbf9-836a-4208-be55-81bfcb1b97ad" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_128272f3-09d6-4559-b2a0-a598f6a30bf6" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,645</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63697c30-59ee-470e-a967-92ba1053443d" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2843634-1b53-477e-aab7-5e2e28af46ad" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">558</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total non&#8209;current liabilities</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_628239ea-c8d4-467b-912f-8378a55309fe" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,100</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aab09d8-29cc-4fce-a2e5-eff4b3bb0bda" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,461</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5168fe7f-80dc-4a0f-8262-5999da527135" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,516</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2e2fd5e-4799-4093-bdcb-40c5de0f5a6f" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f09beae6-63bc-4fe9-8088-f12fc07a80bf;"><span style="-sec-ix-hidden:F_edf6892d-6c5b-4273-a943-cdd4ba7438d9;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d564c7c-c380-4295-9f1b-e0c0d32e9a62" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_26b72a5b-0765-41d3-9f92-bafc43391b4e" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a07dbfa-2621-440b-8a9a-d97171c75474" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8318666e-9afa-4f81-8689-f8562bd5915a" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;authorized; <br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e29ed12-b977-49f3-81e3-2fe1450cbca9" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e3c410f1-a8d2-410b-917b-8b9767b1b9c8" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9ff9bad9-f3c8-45fe-b089-95b5a623d35e" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_73f16463-4231-4168-b441-58d7e88d1cfb" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(2023 and 2022) issued and outstanding</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_e86b8b3b-a85c-44b9-8d6d-7549b1a94605;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_73a3f454-52cd-4af4-83d5-15d25b949308;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_277f4a35-7098-49a4-bc39-fa01b9b6025e" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_a4cf78c4-fa34-41cf-bd84-5c0278a390c2" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8618716b-aa14-4cf6-8fa7-f631da8d9529" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_375221e0-e3ef-4fb0-820a-3ac32cdf43b5" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;authorized; <br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_725199a2-c856-4c41-a17b-8c62cae43a41" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5a3b40b6-9a22-4c19-bb4b-4f463a4e2fea" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,235,883</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(2023) and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c72935bb-4731-4c31-9b86-22397aabe50b" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5ae7cc13-1596-4d81-8740-f43fa9814f9f" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,614,358</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(2022) shares issued and outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41dc0f28-8d6e-4949-b726-cab4fe03266e" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e56429cd-a1af-40d7-a6e9-5a4827f25ea5" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid&#8209;in capital</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77922e51-1bcc-4fd5-9b9a-216f3b59baed" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">424,050</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf60d0d7-9012-4fdf-979d-4a472fb6e61e" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387,948</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11e5bad1-2dd2-4015-8c89-63a84bf0d4cf" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">419,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac8fc07f-ee3e-4f45-8032-23bb868cd6eb" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">367,420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2848e0b9-71c0-415f-90ab-7ca208f8184b" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,580</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef183434-82a4-4c08-9438-be9761a0897e" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a68827b-2dc8-41fa-90f4-f4411a96a1df" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea7d625-d3c3-4a24-a4da-f951c0d1ee80" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3524be26-f357-4e42-aa03-25678be8206f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,087</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a922670-b997-4c75-ad24-4a734200be61" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,212</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_831fd023-e235-4b1b-8840-d3160d7d65d4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:DirectCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,010</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de719140-494b-4001-8dfe-064b89bdb88c" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:DirectCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,154</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ec58785-b0b3-42b0-9739-20a21cf15329" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,988</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fee37dc8-711a-4364-9044-e96f45a3915f" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f99e1ee-297f-435f-a4af-d797443fa428" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,387</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_944b6b5a-3d36-4e32-a18c-106f82c64903" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,462</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment loss on intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14b47f46-dcd5-4de1-8e32-04a9dc84968a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d7b37d8-e1fc-4128-988c-52c18aaeb96e" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_399dbb66-915c-450d-bbbd-ae5d35a85a7e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7d09d8f-2654-499a-bfc6-f0738b5b4989" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aa6aef4-d84e-42b8-a197-39c2191b756b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,342</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70ae9509-2bb7-4ece-af7e-9874be72e913" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other (expense) income:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df4b841-7033-467f-9f7f-91df9481adbd" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,536</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbdbd059-06f4-47e7-b4d4-f075702687df" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of liabilities, net</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c514d31b-4c8b-48c4-8c6d-49573eeea41a" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,981</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07659e0c-0d8d-4f5b-9d8f-d8714c769e39" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,274</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e667ae5b-3285-4acb-bbc6-288ed3b7b288" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da9e42fb-deb1-40be-805f-f5c6dd64b4f3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3674c21-1bb2-4bf2-8fb6-f9a0b921b062" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_042db79e-0688-4e6c-aead-d2ca818e655f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a26ee879-423b-432f-9716-e12e61a93eed" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2b20f22-f0c8-46c1-887a-b16e3f2bec20" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21f735bd-6a4b-479c-9531-d5bff1614e98" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,447</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0bf7609-688c-48b9-9b6b-5e30380105b4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2478c1f0-9a77-4ffd-b104-7c0a211dccc6" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.64</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c25fee03-361e-434c-9545-e143131c2066" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f2036274-085b-4f94-98a5-ce8f553dae4f" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.55</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95d3b2b4-4c3f-4c43-86e7-ac10dec15e4c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4b192312-c93c-4d21-a6e8-35365bc1cf2d" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,113</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88c84438-3b34-4dd0-a740-6a2f428dfca6" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_48569190-bda6-4550-8ea8-aa03bdf4fcbf" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,103</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders' Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.209%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.922%;"/>
    <td style="width:1%;"/>
    <td style="width:1.18%;"/>
    <td style="width:1%;"/>
    <td style="width:7.441000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.18%;"/>
    <td style="width:1%;"/>
    <td style="width:7.862%;"/>
    <td style="width:1%;"/>
    <td style="width:1.18%;"/>
    <td style="width:1%;"/>
    <td style="width:7.441000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.18%;"/>
    <td style="width:1%;"/>
    <td style="width:8.402000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Paid&#8209;In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Stockholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance &#8209; December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1991e22c-fc8d-41a7-9541-895b537a6721" contextRef="C_31b2a0f0-6bf1-4d74-ad13-990f695890b4" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86012fbe-42f1-49fd-ac7d-37611d37c91a" contextRef="C_31b2a0f0-6bf1-4d74-ad13-990f695890b4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_390b8f2a-8c44-4361-bb76-78f8279e765e" contextRef="C_5c930115-3fec-4523-bf83-0ba7a2e9ab92" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">321,669</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32dad6b3-dcb8-42c3-b9b4-21a6003e9b45" contextRef="C_39f4972b-0662-4c51-a7b3-8e295b8cc3f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">301,973</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_640125d7-b18c-4b0b-8281-cea297142fbc" contextRef="C_762beb25-d2a5-4129-9298-0e23686a893a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a96012f6-a180-4a4f-8287-9f80b5ecaf14" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68a445c6-ab47-42e6-9d9e-63fb2078dd71" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b01b87fd-3e82-4518-a9ab-ac0713232e1b" contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb661296-d603-47c3-bfef-3b5e5f570d03" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc55b989-9564-4def-a282-3cc724d5124e" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_660f173a-b4ee-4817-b190-80cb9d40cd9b" contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_905951b1-fe49-472e-93a8-55294aee8806" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for deferred offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f6c3aaa-c4ed-4ef5-9c9c-0872c5d4d501" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="bdsx:StockIssuedDuringPeriodSharesForDeferredOfferingCosts" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b1d66f-f027-4dd7-8852-17bff88db1f1" contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418" name="bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec6ba6db-9123-40dd-b0d8-00bf998110f7" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24b02182-aa92-44bc-95fb-99e815b98ed0" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17466085-6c84-4969-888c-a4db775e8125" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97befe96-0894-4209-bdeb-f411bad71c98" contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59748931-921c-4553-a3c8-0834c0271280" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Release of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4608a6b-93d8-4f5f-b75d-7bfb7e76eb68" contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Initial Warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02fe91be-78ed-468d-a475-5c35cefb7318" contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcd749b3-28bd-406b-94c6-6cb4cf700eca" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share&#8209;based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc62af4b-0cc0-499b-affd-3417bd9894e4" contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,961</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0f9881f-a3f5-4242-be46-bc109f6d75ac" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,961</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcdffdc1-5a25-4da3-8568-271214c17f9e" contextRef="C_f95c0d4d-7ab7-4ea8-bed2-8c4d7965b3da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,447</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dcc90fd-b0c5-4599-9f9f-347dad39d663" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,447</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fb7d11a-6578-4439-97d3-ff8f75f2b2d7" contextRef="C_854423ce-c02a-4357-a5be-bd8070c81d4a" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b3168db-a6ab-4e78-8f85-8fe9e31df17b" contextRef="C_854423ce-c02a-4357-a5be-bd8070c81d4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_671aa13f-dd71-4fb0-a2f8-c5d4ebd7087c" contextRef="C_1ecadbe3-1544-4bda-a218-b85b4bdae48a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387,948</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7718f478-0174-4c63-9986-f5df1f7a6937" contextRef="C_e1cccb8e-8913-45ca-a2a9-4d5492eb8d7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">367,420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c9333d9-a22f-4763-85d5-b9f2dcb825a0" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8512daa-9912-4c93-beef-c6abb3d31b49" contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9c4ddf1-d01c-4a3b-b83d-7c433ee668c8" contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02dfad55-ef74-4c48-9844-2391589c8d00" contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,986</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_449bf27f-d48c-4825-a3fa-ce9a36ffb13a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,003</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c6d7944-1cf7-4ab4-9bf2-be24820925af" contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">437</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e5c39d5-aba4-4091-8090-e088d14f7268" contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec80822a-3ffa-4450-a1a1-4bebb3248c13" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f5e2ab3-62db-4103-9cba-f37b67e61f0d" contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ee7cc42-78cc-4179-9d3c-7298a8f02563" contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c66bc0b-3e13-4fd3-bff5-3df06cd1df71" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Release of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec1b6ea0-f19f-44a5-a1b2-4762391d6858" contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">710</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b99a49e7-7f54-4846-b1cf-aecbd632ef04" contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74944cba-ad45-4378-8428-58f442361fbf" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of First Amendment warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e55d0f57-44ab-4145-bfe1-439b69ebcefa" contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9" name="bdsx:AdjustmentsToFirstAmendmentWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01bd8c31-d465-4915-b250-c226d9a6e5b3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:AdjustmentsToFirstAmendmentWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of Tranche B warrants to additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b45512c4-40a4-4e92-9b3e-ce6e2287bb5d" contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9" name="bdsx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08286b39-8c7d-415d-afaa-fcdf0b32ed78" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share&#8209;based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50159b81-2530-407d-aa1c-f4bd082a472a" contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11fcd2fc-8d69-4ebe-8061-ebafbb62d5f7" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8e45864-da26-442f-ba81-a41ecaeeff86" contextRef="C_e6780030-af98-4868-9310-acae4f9730f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f24359bd-bdf0-4c12-bc3b-70f892e3ed89" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c091efc6-db37-4730-bc9d-f479ffefedb7" contextRef="C_acdf8992-5bd5-4c91-833c-0190220805bf" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceec43ef-bf7e-462b-898b-faacf9036125" contextRef="C_acdf8992-5bd5-4c91-833c-0190220805bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1397405-ae74-4a46-9283-ddf8165ac6e7" contextRef="C_e430ec9b-f398-4f86-972f-96b4e020ff48" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">424,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54a189b5-e69c-4cb2-99df-6c4e48e97714" contextRef="C_b293fb96-2665-4a34-bf96-3204f1af238a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">419,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_359337ab-9e01-4807-b7a7-debdcb031ccc" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,580</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47e2f920-22f8-4238-98f5-2612e7b1257e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59597b1d-362b-4463-a165-ec7401aa3531" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,447</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted<br/>&#160;&#160;&#160;cash used in operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9f030c4-5f81-4e17-a092-95c92eab92dd" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,328</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fe45614-9ee3-4cec-814f-29e147ebe37d" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,597</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f3e3ce3-3f95-4a43-b5f1-ce7eee593620" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3eec480c-f969-4f9d-aed0-3b4b2f70e88b" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b6242f6-70d3-4fcc-b1b5-7fd318fbf272" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,981</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share&#8209;based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ee0c7bf-58c2-4957-9fd7-f2def995b466" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87a3e39d-d645-4a38-bab8-a963e050c1c3" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,961</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d595de-4579-4ff7-8c33-a01ed77269c6" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,274</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a624465a-1d35-4fd0-925a-c77a6b8e2718" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for doubtful accounts</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9efd17a-a1e3-4222-9cd5-3656cb670793" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">497</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_836a072f-1ab8-4c33-82f4-221e3e0d5a86" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest, amortization of debt issuance costs and other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61f55b14-c003-4b73-a1e2-d53a33ad8621" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_852c4c20-8952-442d-b6b5-088110580c06" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory excess and obsolescence</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d57f82d6-3221-4eb9-99e4-0070f6752a04" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f5133c4-0672-4d40-9acb-0380de14b842" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment loss on intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_370722fc-cdb3-4059-b04c-5cd6a79b09fe" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b248cb3-5367-40d5-ab05-c833c0c43db7" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10144a2f-58b0-406f-99c0-08063d4f5adf" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5f44a16-9fd9-41de-a671-be657dd16bd6" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,501</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eab4ccde-a04c-4e3c-a4b7-63610c4eecfb" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_041864c7-aa3e-44bc-902e-9e0090b19a07" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,113</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b29bcf9-3010-43f9-8397-75ff7e3dc3a9" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2f74f7b-96a0-4620-8a69-473145945991" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,504</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and other accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c11af3b0-a3d6-4991-8bed-712317e7ffd1" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">513</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c726a9b-5507-4372-b6b7-476472570080" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e2f479-379b-4d50-a5c8-069ccd06ac8e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d668301-ec45-47d6-bb12-db086be1d210" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e74a041-abf5-4cc2-aa95-3dfa0b4a1f6c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:IncreaseDecreaseInContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tenant improvement allowances received</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_239fbc15-8708-4d01-93b3-012ca1f5811d" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:TenantImprovementAllowancesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,323</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaf74361-7ae2-43de-9728-d3c08d78446a" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:TenantImprovementAllowancesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current and long-term operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d96e7aa9-3aad-43c5-83a3-908068e99368" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eeba07a1-ceaf-4c8b-aa54-77d4e12e7588" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash and cash equivalents and restricted cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3d9877b-27c4-4168-9128-39319d48907c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,870</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcc13ea8-1e61-4fd5-9698-382f5b7b11ec" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51426140-c90e-4fab-858b-f6f21cd9f12a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,919</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb02a6d7-f6f8-4721-908b-6526e8f66f03" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patent costs and intangible asset acquisition, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53072b9f-453e-4822-b288-cf95756e7e0e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85757cde-61e2-4070-a410-21ca895207cc" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash and cash equivalents and restricted cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de734fe8-ac48-4f1e-820d-cea5d9be480b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_398da69e-da94-425f-9c05-509ad4a223aa" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0550ecff-2c5b-4ade-a767-4fcf3632ee53" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b5796dc-a845-47b3-85ab-6d00a4393a78" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c3b09d6-2aa5-41a0-88e4-61bd09a1c7f9" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b010ddf-9443-4e3b-b069-b40a49b0aa67" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812b9ad2-293f-4039-b156-ecc4b726fc86" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e9f4de9-a8db-4951-aa05-9f4f9e486049" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of contingent consideration</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51605d81-8d76-4e44-a850-f1c644f84552" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,581</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25ac86c8-8849-4227-bc64-c4092413320b" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,822</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from term loan and notes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32f8a71d-90f7-4226-8638-459426b25d4c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8be6034d-0a53-45b4-88de-5268a887b411" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of term loan and notes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a13f6bc4-c2a7-4248-9eb8-8673081ad88e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d24f1a3-1421-413f-8921-c07ef64b78f5" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of debt issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb88e442-d1b3-445e-a453-b2c2a57aac47" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5e21b17-c6bc-4c5c-a208-3abd56c35b2f" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7d50074-d958-4362-80e9-e07749c0aeeb" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:PaymentOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity financing costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ddd767c-d538-4a87-98be-977eafee1180" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:PaymentOfEquityFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8320cc41-2adb-40b6-8fc6-ce6e7a48a35a" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:PaymentOfEquityFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,069</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39e4d1fc-2410-42ee-9cd5-c5aa308c8c44" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35f2f6a9-07e5-4687-b92f-1f987f67097e" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash and cash equivalents and restricted cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5812018c-ddd4-4ac9-b491-ed959b792b35" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ad61eca-5310-4b6b-bffc-23196b4278bb" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,882</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77676be8-8dc4-4f4c-b5e9-89f1cfc6ebf8" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77c9bd13-18ed-4773-9c62-aa5fc8b70117" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,376</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash &#8209; beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0554232f-aecd-4fe2-92dd-5ccbc7c3a12e" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d1be953-a394-46ce-8bc4-c341d33be8d3" contextRef="C_762beb25-d2a5-4129-9298-0e23686a893a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash &#8209; end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e31781a7-720f-4ee4-a0fd-571988bd4896" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdbda019-30ad-41f8-8bbb-91ec099e4150" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Continued from the previous page)</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock issued for deferred offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdec6021-3d3d-4d3a-b365-324ad8cb20ab" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:CommonStockIssuedForDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred offering costs amortized against Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0223a41c-6e2a-438b-980e-6f5bc13c7760" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt issuance costs included in accounts payable and other accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8743599-2ea2-4b95-bb35-e3cbccca49e8" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a19a0653-fc8e-46e7-9ae6-cc5f4365fe15" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity financing costs included in accounts payable and other accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d19d9cd6-9fbd-4393-80c4-9f9376b3d964" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_689297c0-8490-4008-944e-55eec7d7c014" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Perceptive Warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edaddda6-7ad3-4051-b347-15c8d70be5b2" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:IssuanceOfPerceptiveWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_070e932a-fe3e-4c3f-9617-877fd65c4bdd" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:IssuanceOfPerceptiveWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,051</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f99a153-f470-4234-99b5-bf57ca3e08e8" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange for lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb034cb1-eb7d-4075-ab7f-0111ba0a1816" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5a96e77-d88e-4bef-a006-b17fa25e3358" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,936</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease right-of-use assets obtained in exchange for lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3da3424-66ae-4947-82a7-f871d1f81694" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d5aa2be-a146-4f65-9b10-fa5bcdd54095" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac2b7ca9-a570-4d02-873e-05f7e69e603f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,994</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fbd2fd0-d929-447e-bada-757da4cc45b9" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of warrant liability to additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8f614d8-9e71-48ff-9fc1-7b32ad1fca2e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property &amp; equipment included in accounts payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42b1fd01-cdd8-4cb0-aa7a-4037a4d21842" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_934946fb-898b-4867-9cfa-2a23702e3cf5" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 &#8211; Organization and Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc. (the &#8220;Company&#8221;, &#8220;Biodesix&#8221;, &#8220;we&#8221; &#8220;us&#8221; and &#8220;our&#8221;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#8217;s headquarters are in Colorado and the Company performs its blood-based diagnostic tests in its laboratory facilities which are located in Louisville, Colorado and De Soto Kansas. Throughout 2023, the Company leased its headquarters and laboratory facilities in Boulder, Colorado, under a lease agreement that expired in January 2024 and the Company subsequently relocated its corporate headquarters and laboratory facilities to Louisville, Colorado. The Company conducts all of its operations within a single legal entity. Biodesix is a leading diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the use of artificial intelligence enabled informatics. We derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) prior to May 11, 2023, Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other). Biodesix offers five Medicare-covered tests for patients with lung diseases which includes our blood-based Nodify Lung&#174; Nodule Risk Assessment testing, consisting of the Nodify XL2&#174; and the Nodify CDT&#174; tests. These tests evaluate the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Additionally, our blood-based IQLung&#153; testing strategy for lung cancer patients integrates the GeneStrat&#174; ddPCR test, the GeneStrat NGS&#174; test and the VeriStrat&#174; test to support treatment decisions across all stages of lung cancer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also offered </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53a28f17-5338-42cf-b5ae-93fe84b07d4d" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:NumberOfSARSCoV2Test" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> SARS-CoV-2 tests. The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test were granted Emergency Use Authorization (EUA) by the Federal Drug Administration (FDA). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Blood-Based Lung Tests</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company offers </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e8ebfbc-0bf8-4776-92ea-2d2b56ff92d3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:NumberOfCancerTest" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> blood-based lung cancer tests across the lung cancer continuum of care:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnosis</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify CDT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">XL2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tests, marketed as Nodify Lung Nodule Risk Assessment testing, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. The Nodify CDT and XL2 tests have an established average turnaround time of one and five business days, respectively, from receipt of the blood sample, providing physicians with timely results to guide diagnostic planning. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we are the only company to offer </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9159cc9-2840-4a7e-9d74-2f3725fdff0f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:NumberOfCommercialBloodBasedTest" unitRef="U_Test" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment &amp; Monitoring</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GeneStrat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ddPCR, GeneStrat NGS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VeriStrat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient&#8217;s immune system to help guide treatment decisions. The GeneStrat ddPCR tumor genomic profiling test and the VeriStrat immune profiling test have established an average turnaround time of two business days from receipt of the blood sample, and the GeneStrat NGS test has an established average turnaround time of three business days from receipt of the blood sample, providing physicians with timely results to facilitate treatment decisions. The GeneStrat ddPCR test evaluates the presence of actionable mutations in lung cancer. The test is covered independent of stage and can be used multiple times per patient to monitor changes in mutation status. The GeneStrat NGS test is a broad 52 gene panel, including guideline recommended mutations that help identify advanced stage patients eligible for targeted therapy or clinical trial enrollment. The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#8217;s immune response to their lung cancer.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In developing the Company's products, the Company has built or gained access to regulatory approvals, product development know-how, unique biorepositories, proprietary and patented technologies, specimen collection kit manufacturing capabilities, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#8217;s testing services are made available through its clinical laboratories.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fa687f1-e9cf-47f2-a460-c495ab93b55b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9a24d59-7f0c-4f1a-a1cd-ad108d76ad60" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets pursuant to the Company's annual impairment analysis; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; fair value of warrant liabilities; leases, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the estimated incremental borrowing rates</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we maintained cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00054e17-0b03-49a1-aa99-4c20d5591168" contextRef="C_d34c69b7-5581-4027-8f30-edb22143832c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and we have </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3f2b90b-db66-4ae6-8726-ce30b449c545" contextRef="C_d34c69b7-5581-4027-8f30-edb22143832c" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in outstanding aggregate principal amount on our Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technologies. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) or to obtain waivers or amendments that impact the related covenants. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default (as defined in the Perceptive Term Loan Facility), causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. The Perceptive Term Loan Facility requires the Company to recognize revenue in amounts agreed to between the Company and Perceptive as of the last day of each fiscal quarter, which commenced with the fiscal quarter ending March 31, 2023. On May 10, 2023 (the First Amendment Effective Date), the Company entered into the First Amendment to the Credit Agreement (the First Amendment), whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold through the twelve month period ended March 31, 2024. On August 4, 2023, the Company entered into a second amendment to the Perceptive Term Loan Facility, whereby subject to the terms and conditions of the second amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the twelve month period ended December 31, 2025 (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and raised approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61841e5e-88bc-47d4-82cf-694747bc0510" contextRef="C_e0f57e5e-3320-4697-9d41-f219f5580721" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds through a private placement equity offering (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Subsequent to December 31, 2023, the Company entered into a third amendment to the Perceptive Term Loan Facility, whereby, subject to the terms and conditions of the third amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the fiscal quarter ended December 31, 2025 (see Note 16 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce8e68fc-e5d9-46a3-9b48-ce34b24d1aac" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_19d8db26-ae6e-4ab2-b567-298bf67cb775;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#8217;s revenue and all long-lived assets were derived or located in the United States for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b86beba-1ad1-4f47-a2eb-2ec3020b928b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenues from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other revenue).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price and amount to accrue related to its blood-based lung diagnostic test contracts using a portfolio approach by considering:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the nature of the payer and payer coverage;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment history;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">test type;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the historical amount of time until payment by a payer;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">historical price concessions granted to groups of customers;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether there is a reimbursement contract between the payer and the Company;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment as a percentage of agreed upon rate (if applicable);</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount paid per test; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any current developments or changes that could impact reimbursement.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharma Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Customers for these services are typically large biopharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements, and considering factors including, but not limited to: enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from contracts with customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recognizes revenue for these patients when contracts are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 11 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbf39877-757a-4332-806c-0d8ab9a90793" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:DirectCostsAndExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Direct Costs and Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9fbaedd-1639-4891-bbf6-e42eebbe76c1" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development </span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5781c26e-4bf3-447a-a6cc-ff7a76cff26b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales, Marketing, General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44b3b7dd-fcf5-4075-8f1a-b3793e9c7068" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2023 and 2022, see Note 11 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ea50ae9-9928-46b7-b62e-dffcfc8db46c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f65363c0-78d4-43bf-8f66-b032d99ea029" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card. As of December 31, 2023 and 2022, the Company had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38170f71-283a-4bef-9b1d-9244c5255363" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e650ba05-3e8b-4a5f-ae36-5ad505a2263d" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million restricted cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, which was included in &#8216;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b4950ae-8a2a-400a-848c-b12899bcf89d;"><span style="-sec-ix-hidden:F_9df9a806-ab12-4618-8e6a-94161b6cb0d5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other current assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; in the accompanying balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4640bf6a-3a03-4d40-8543-e23295b56782" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee11c39a-955c-4449-9e9f-a192e12c4c77" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:InventorySuppliesPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#8216;Direct c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">osts and expenses&#8217;. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_380b1375-6394-4e37-8a18-b126d3debb04" contextRef="C_5cc23b54-53b8-41be-ba0d-255e20378a4f" name="us-gaap:OtherInventorySupplies" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_06886c5c-4fea-463b-9fd2-84d54592beb9" contextRef="C_2c3c29e1-2f9b-4ce8-a3c1-35be4a21e942" name="us-gaap:OtherInventorySupplies" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for both years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The Company recorded a reserve for excess inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fe510c1-6ccc-47b8-b159-62313ca21979" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c1da150a-e500-48e4-aa6c-04f8156a4cc4" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for both years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50d95b90-6956-4107-9dee-62318671ac74" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6770e7b8-5725-48dc-bae5-05a5c8ac7018" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, to the statement of operations for excess and obsolete inventory.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb922b72-a621-4b88-bb99-ab24d515fc36" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_693c0deb-e916-4d0f-82f1-e7179ddec20e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9b208ef9-2e89-4c6b-beef-d077b508f0ac;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e50146c-469b-40c1-ae9b-072ddb09861b" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d1717e6d-77e2-43eb-a4ea-acd84a214394" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments for th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97ae6637-f5de-4108-a416-0e6dcdc44eae" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d32b26f3-4763-475b-b891-d05c3bf44a60" contextRef="C_642aa182-ab63-4cc2-a2bb-672f223f0786" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were immaterial impairments during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0254a35-510e-4497-b718-1df6929381e1" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2023, there</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f18d3f95-1107-40cb-897e-0107147a39d4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accumulated impairment losses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_324fee01-49c4-4c6e-8f15-36ea4a714139" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company acts as a lessee under all its lease agreements and holds various real estate leases for its headquarters and laboratory facilities in Colorado and Kansas and other various copier leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the following practical expedients as part of the adoption of ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Package of practical expedients which allows the Company to carry forward the historical lease classification;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of right-of-use (ROU) assets;</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the fair value of the underlying asset.&#8221;</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ea34298-beb1-468b-9648-47213b8647c6" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required by this standard are contained in Note 9 &#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ddf71a23-bfc1-4f3f-ba1a-5b6604bb5751" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:OtherAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1519dc09-c555-481c-a1ed-b460c0610bf1" contextRef="C_234399c4-abaf-4cff-b6b4-cf1365245c8a" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cash refundable deposit to secure the performance of the Company&#8217;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47d4a73c-1680-41ba-a310-7f12dfc33838" contextRef="C_234399c4-abaf-4cff-b6b4-cf1365245c8a" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_471af43f-3e87-4621-8b79-43a20c2053c6" contextRef="C_7ec35fb1-0374-47a3-b8d9-e1479123e997" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million refundable deposit is reported within 'Other long-term assets' in the balance sheet.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b85c163-268e-4431-9853-0d52bb8967cb" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.82%;"/>
        <td style="width:2.08%;"/>
        <td style="width:86.1%;"/>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 4 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion related to estimated fair value measurements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7bde607-595d-4d29-a4cc-da70d35bdbbe" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ContingentConsiderationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recorded as &#8216;Interest expense&#8217; in the statements of operations.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56c1c404-2040-453a-984b-7e34bd6c45ea" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:WarrantLiabilityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of warrant liabilities is assessed at each balance sheet date and changes, if any, to the fair value are recorded as 'Change in fair value of warrant liability, net' in the statement of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5daffc79-3399-456c-b869-4fe25e48096f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share&#8209;Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options, if granted, vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units (RSUs)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 12 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information related to share-based compensation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fba7876-731f-44d5-8fb1-9dfb8cc86246" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">s</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a4330dd-71d0-40a3-a63c-a2ab01b1a925" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 14 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information related to income taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67aaf853-a65a-41ed-8455-cc5cfb9fb22b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3506de10-2560-4880-a13a-e37e65a434a0" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3 &#8211; Recent Issued Accounting Standards</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea680e74-88e0-44ca-9266-009d2a88efcf" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for the Company beginning January 1, 2023. The Company evaluated the guidance and determined the overall impact of the adoption had an immaterial impact on our financial statements.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Standards being evaluated</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting: Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC Topic 280). This ASU requires all public entities to provide additional disclosures about the entity's reportable segments and more detailed information about a reportable segment's expenses. This guidance will become effective for the Company beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid by jurisdiction. This guidance will become effective for the Company beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_1c18c8a3-447e-409c-97c1-7d4b5a9e261e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4 - Fair Value</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recurring Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair value of borrowings as of December 31, 2023 and 2022 is primarily associated with the Perceptive Term Loan Facility entered into with Perceptive Credit Holdings IV, LP, in November 2022 and was determined using a discounted cash flow analysis, excluding the fair value of the Perceptive Warrant (as defined below) issued in conjunction with the transaction. The carrying value of outstanding borrowings approximates the fair value as of December 31, 2023. The difference between the carrying value and fair value of outstanding borrowings as of December 31, 2022 is due to the debt issuance costs and the fair value of the Perceptive Warrant netted against the Perceptive Term Loan Facility. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16fde6e0-4ddf-4e69-b5ed-6c477b46ee9b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" escape="true" continuedAt="F_16fde6e0-4ddf-4e69-b5ed-6c477b46ee9b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_16fde6e0-4ddf-4e69-b5ed-6c477b46ee9b_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.739%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:12.885%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:9.404%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:8.523%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:9.204%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c9c7e7f-16f5-4fc5-9004-e415da65d261" contextRef="C_c78507c9-28f4-4078-b9c2-60788d6de761" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,276</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_263fa273-e34d-413b-8e4d-419f0d6c59fa" contextRef="C_56c9ae72-9e34-4992-b029-01bdfc7ad040" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c88fcc2e-772e-4b79-b16e-781ddb116801" contextRef="C_9caae3bf-4fbb-41ab-a4e1-b00953245f32" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,053</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83cd0e95-afee-486c-a2ca-179934a06b5b" contextRef="C_944a3fdd-0063-430b-812d-8df10d978153" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi and the warrant liabilities granted as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), which were accounted for as liabilities and remeasured through our statements of operations.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8d6416c-8a70-46f0-91d1-b17648bb0814" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents the reported fair values of contingent consideration and warrant liabilities,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.412%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:17.924%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:12.903%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6502c32-0b59-42fb-a9e6-ae4822623fa5" contextRef="C_32deb686-8097-4424-ac3a-cb9f560483da" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,857</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_753a3291-50ff-49c6-a03d-0b18a89260a8" contextRef="C_e530c247-1fb1-40c9-a68a-591017a52ecf" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,341</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49b4d682-0e44-4c7e-87f2-ab04ecd5011d" contextRef="C_fb7558dc-7e0e-47e9-be24-11751dfeab98" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84594212-6cbc-4787-b4ed-4cb96eb3e3eb" contextRef="C_f5c7a2fb-eba1-497c-b9c5-a66efa1ceb59" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,857</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79807f5c-bf13-4e11-8606-f7c5168a4c42" contextRef="C_35044628-f95d-4526-999c-ceb308c83552" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,986</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c2e5df-6c5f-4f50-ae23-175e9a1e180e" contextRef="C_35044628-f95d-4526-999c-ceb308c83552" name="bdsx:WarrantLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a2cbe07-8db4-4a6b-bda0-4afe1014f7a2" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the changes in contingent consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and warrant liabilities for the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.687%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:17.537%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:12.977%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74482ff4-ad58-4e1d-a98d-260685c44321" contextRef="C_a8c71793-b3d7-4472-9294-cc317e43c263" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,792</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45549ac0-ca56-4dca-b3e2-94031e8911ba" contextRef="C_f5347cdc-ebae-4937-a95c-7a2fb92191f3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27e0c921-d1c5-45db-b52d-bdf119096115" contextRef="C_f5347cdc-ebae-4937-a95c-7a2fb92191f3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bc4ca10-d3c8-46d5-926d-a852ba3e7f02" contextRef="C_75b2228d-4f1c-40ab-9389-611290f07a73" name="bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,082</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2503d335-d695-4fa4-ac0a-45d99f7195e4" contextRef="C_75b2228d-4f1c-40ab-9389-611290f07a73" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,934</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e689fce5-a6c5-477b-892c-c845dd89f771" contextRef="C_75b2228d-4f1c-40ab-9389-611290f07a73" name="bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,822</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a56d07e2-b9ac-45c2-9fc6-6f034e986b8b" contextRef="C_fb7558dc-7e0e-47e9-be24-11751dfeab98" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,986</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3723ce93-4e28-4a82-bb47-7472f0755885" contextRef="C_cf25d082-7144-45c9-82a7-485c56547da3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e6c823f-14c9-45a2-b876-171b6dbfda5d" contextRef="C_e4c92134-cf3d-4b48-a86a-aff01ba5002e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,274</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff3c9b1d-4a5f-4f0e-8aa1-b2326c22cbe3" contextRef="C_94dfe6a6-75a6-4855-8b8a-25382e1bcc1d" name="bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,946</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8efcdf93-5750-496b-ab1a-6dd63d677044" contextRef="C_94dfe6a6-75a6-4855-8b8a-25382e1bcc1d" name="bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,075</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of Tranche B Warrants to additional paid-in capital</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3a3edd7-9ef1-4034-89f6-0fc526497f41" contextRef="C_b8e10b10-ed99-44ce-9379-a3351b13b1d3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5063d56-217d-4cdf-841c-b847cf705d25" contextRef="C_7d7940c5-ed73-407d-b4e5-5389b5b92763" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,857</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a07cfc94-0ccc-4c7f-885b-b160bb5df6e0" contextRef="C_e811ab96-e279-4509-9656-8567a594d9e7" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gross margin target of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a26c2d42-dacb-423f-8dc6-d36a6867444f" contextRef="C_d48cbf14-8cb6-4e55-8fec-7e43385ec4b8" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2de32df4-d361-4ba9-8539-af9f1184678f" contextRef="C_d48cbf14-8cb6-4e55-8fec-7e43385ec4b8" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period after the acquisition date, which was achieved during the three months ended June 30, 2021. Under the terms of the original agreement, when the gross margin target was achieved the Company was required to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3e194ca-0f16-45e7-ad8d-457fc3546f64" contextRef="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5" name="bdsx:BusinessCombinationContingentConsiderationShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,520,108</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c00809c5-a3fd-4f9d-b5f2-bcab65c880ec" contextRef="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ece330-cf19-4cf3-a184-fb5240f51804" contextRef="C_1c0d6b7f-113f-45cf-8621-8ade2e3145cb" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal quarterly installments. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20dcdfd6-cf94-430b-99ce-d3610fd1c08f" contextRef="C_42326201-3aba-4a78-8961-e432c28f468d" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98b1b48d-7ba8-4e4d-8be1-7ecdd696f3ab" contextRef="C_3f300fdd-ce4b-4d8a-b6e0-51a7c1714a99" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal and consecutive quarterly cash installments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f4ead9b-8744-4632-8247-75de225acc73" contextRef="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mi</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4a3ac985-50cc-430f-afc9-a367fa948051;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, the Company entered into an amendment to the original agreement in which all parties agreed to forgo the issuance of common stock and agreed that the Company would, in lieu thereof, make </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2837cdd6-044d-4ebd-8e0a-df77db1b8d12" contextRef="C_62ca78ec-9f39-4920-83f6-28d44aeb971e" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> quarterly installments of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52cd1025-9b9f-4e01-9e24-28914f4d4386" contextRef="C_25e96d73-e3b0-4a75-a22b-6a05aced6c60" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each beginning in January 2022 and a final payment of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59795ede-bd7f-4d84-b52d-c65f29e2c7de" contextRef="C_c37573b7-4513-43c3-9695-25908f198e7a" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in July 2023 for a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6b94559-ab9a-4f7e-bb5d-a150d266c897" contextRef="C_c37573b7-4513-43c3-9695-25908f198e7a" name="bdsx:BusinessCombinationContingentConsiderationFinalPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA, in which the parties agreed to restructure the Milestone Payments. The Company made </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7e32268-e7bb-409c-bf33-97f26167a512" contextRef="C_c3fb17ed-8bf4-45c6-95cf-234368989352" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee07eb25-32a1-4b99-8f14-549f4d60f6a7" contextRef="C_7d3ecb2f-0211-4617-a06a-2d4546f0e40f" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each beginning in April 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8774fd1c-8a59-411c-a2f6-2993340e4a59" contextRef="C_da96c3b7-099a-40dd-9b01-f364329a97fd" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fd5f731-0e3c-44df-8fa9-edf966e8885e" contextRef="C_f0a3cf0a-87dc-4d4e-85f5-ae4fff2592a5" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which began in July 2023, will make </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb6f28a-b0da-4b66-999b-d73ae68ebe6e" contextRef="C_b77a60af-bc6d-4b65-8356-5aad89c73994" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> installment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20101343-56a4-465f-a7ac-224c1f11bad0" contextRef="C_a4f1f778-0ed2-4f8c-a95b-459652dcae55" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in April 2024, and will make </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6181fd5-6664-470c-bdad-cca56be5027b" contextRef="C_ef3c2187-563e-494f-893c-b00f9a7afdcc" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> installment of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afccc2cc-c34f-4ef0-a19b-2a297c9603fa" contextRef="C_da03390b-83f8-418c-9f18-c9c25626feb4" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in July 2024. In addition, the Company agreed to an exit fee of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7905576d-5689-4fb1-baa8-a9efd428afd0" contextRef="C_5009b344-d4d5-4e3f-897a-d9f8b21265c3" name="bdsx:ExitFeePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d21dae54-c0ae-4f3d-84a9-79b7dd2ba7ab" contextRef="C_240c8f68-bf9d-46de-aa49-fa8df526c0a5" name="bdsx:PercentageOfInterestOnContingentConsideration" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, with such interest to be payable quarterly on the following installment payment date. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan Facility. We obtained consent from Perceptive and subsequently paid the contractual Milestone Payment due January 1, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d739cfe-f5a7-432e-9c78-16ed468ffaa6" contextRef="C_ccdfd811-c49b-4466-bf12-ded5e7a5e155" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34fd0fc3-a0a3-4429-be5a-b3cf31feb2b3" contextRef="C_980bcbe0-d568-4e08-a672-b071c73a3261" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. As a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate could result in a significantly higher or lower fair value measurement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ed81067-3bfb-4bc2-87b5-6463dcac4943" contextRef="C_4270ff6e-22b1-452e-a4a6-a180a3e2a6f8" name="bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac2d3921-81b1-41ad-8b1c-6f5be6cc32c8" contextRef="C_bc5a7859-ac48-440b-b875-07120eb3a782" name="bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">espectively, in interest expense due to the passage of time and fixed payment schedule.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASC 230, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statement of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) should be reflected as a cash outflow for financing activities while the remaining portion of the amount paid should be reflected as a cash outflow from operating activities in the statement of cash flows. A portion of the October 2023 and all 2024 Milestone Payments are classified as cash outflows from operating activities in the Company's statements of cash flows.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), the Company issued Perceptive a warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47ceafdd-3201-42a7-b982-4cabda038885" contextRef="C_75eae973-2f26-420e-8dcd-287d48f37677" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company's common stock (the Perceptive Warrant), including Initial Warrants and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants (as defined in Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> below). The Initial Warrants and First Amendment Warrants are equity classified (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) while the Tranche B and C Warrants were initially classified as liabilities within 'Other short-term liabilities' and recognized at fair value. The fair value of the Tranche B and C Warrants is determined using a Black-Scholes model and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the fair value of the Company's common stock, risk-free rate, the volatility of common stock, and the probability of the expected borrowing. Significant increases or decreases in the unobservable inputs could result in a significantly higher or lower fair value measurement. During the year ended December 31, 2023, the Company recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be45a9fc-f343-4b71-a0b3-90cf473b08f4" contextRef="C_c7c3261f-f9bd-43a8-901f-c9c1d238ad41" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> loss as a change in fair value through the statement of operations due to changes in unobservable inputs. This is a result of changes in the probability of our ability to draw on Tranche B and C loans. During the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c635f6ea-1a64-460e-9c68-252882d1db64" contextRef="C_4d399ad7-37d8-4601-9860-f4ed0a5dd125" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a change in fair value through the statement of operations due to changes in unobservable inputs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e61d44f9-77d2-417c-99a3-2652645aa47f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5 &#8211; Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a58affdb-6a9a-430e-8e7e-b07188411254" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_318dea6d-3288-402d-957a-3184f3166b88" contextRef="C_ef8c27b1-4741-4250-99d6-cf03e3702f8f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,089</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1892a8d-8e3b-4a7c-a114-4c8fd4d7db72" contextRef="C_7d5a6062-37b8-4fa8-a4da-c6e14c894954" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,035</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f820c3f7-0a8b-4d6f-9332-1a53882af850" contextRef="C_9312e759-444e-4716-9451-2b8b8320f87e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,713</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4835e64-9223-40ec-8356-ced315613d00" contextRef="C_e27675e3-4b86-41b3-82b6-66aeb3068eb6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3112677-90cb-4e3c-9937-79dcd9d1fa34" contextRef="C_ecb41f0c-f59d-45ea-a050-526c1d52cf1c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,221</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77403a46-2d28-4ea5-bd92-6aecef12d891" contextRef="C_b8740db4-2867-4e82-a5dd-07d9793a7524" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">749</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29d7e663-83dd-4e2a-8735-1de4165b16b7" contextRef="C_101bd2f5-f908-4988-9b9f-58f2c06e0547" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,034</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8b2e0ba-4f2a-4de0-ac3e-826762334193" contextRef="C_baaedbd4-6935-478d-9fd7-ed5496a4e509" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1030de9b-9fab-481b-a383-1798895673ac" contextRef="C_286d0721-729c-4546-81b4-7c2234ec5f19" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8315e10-e891-41a6-bc27-e8a89819eead" contextRef="C_a6b84852-36d5-4f3d-bb6a-b0b710f9dd00" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vehicles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_558f66fd-9fc1-4017-8fd7-2893cc78088e" contextRef="C_fdff4690-cd03-400e-9532-0ec16ccf2ac4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aee2fdf-cea1-4121-90c1-f8756d89b8ff" contextRef="C_30e47baf-60a9-4e0a-aa84-25a0a6d4d64d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec3a759b-aba7-46cf-b891-3abafc25bfb1" contextRef="C_51c21cd5-9bbf-406e-95cd-7db5c3f7f76f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,947</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55c13f7c-fcb7-421f-b3e0-b39b39b24c1e" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,479</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fedfa77d-ea40-4df5-9206-6b387f50270c" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,866</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a5cf9ea-da91-4c5a-9d0d-05229cc19e53" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,612</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77527404-b556-42b2-b726-f7bc8ff82e26" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,018</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a941af18-61e7-4931-92df-27bfc9a21efe" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,867</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acfbd072-d474-4638-9c5d-1d0fb0f8bc87" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f365155-7527-4353-a1d0-30901bcaf2a0" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense related to pr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operty and equipment was:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0da5be5-5c2d-4402-92b5-b71d451cd773" contextRef="C_c470b55e-4817-47fd-b1a2-60ddf9f1e696" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_526bbd8a-e97b-416a-8112-f4e4a72987b4" contextRef="C_de229b36-03e8-4ba3-9d97-4bb97a183372" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec7ec489-18e3-48cb-af2b-c68311581cc3" contextRef="C_e8071c03-dc27-49ba-8d1a-dda3eae00a0a" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">885</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a378406d-deea-4756-bd59-50c488e010d1" contextRef="C_937cac9a-b5f5-41ce-8603-758663d5645c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,031</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9fac1b0-384f-4600-9ad9-f663ff120a09" contextRef="C_4348c38b-37a4-4aad-80bf-51c279e91cbe" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,345</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e133004d-2937-4d63-be78-c5dc2c9cd766" contextRef="C_32ca7091-08cb-42b8-a3c3-0e36d7da15be" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b396b91-5a3f-4a68-b6cd-dbf5a51e3f62" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6 &#8211; Goodwill and Intangible Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3eba6ae4-63f1-47ee-9693-a95370106c32" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.195%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:6.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:8.824%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:5.702%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:8.503%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:7.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:5.702%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets subject to amortization</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_903cdff0-f390-4ef1-b4f5-6b6d6ef19331" contextRef="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,975</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31dbf65c-2cac-4f29-a3c9-2ed3d80fd160" contextRef="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f593437-ee6a-4068-a735-de62b7c8e5ce" contextRef="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,223</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba7d8107-b3fe-426a-b9c1-d09ef0e55da9" contextRef="C_1f022e96-f9de-4099-becb-8ed34b6193c3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e36ced89-134c-44da-bcea-6df1db28c4b2" contextRef="C_1f022e96-f9de-4099-becb-8ed34b6193c3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">647</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b10eb91a-7445-4acd-a4a6-41a8f3f1249e" contextRef="C_1f022e96-f9de-4099-becb-8ed34b6193c3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcde596e-fb5a-4b73-bfbd-5c95a1f92278" contextRef="C_20959b72-6f50-4526-8ce1-58ad102071d0" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,900</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa28b917-b260-4618-b8f6-eb09de524b30" contextRef="C_20959b72-6f50-4526-8ce1-58ad102071d0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,328</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e2d9b54-3714-41fa-937c-0724342a63b8" contextRef="C_20959b72-6f50-4526-8ce1-58ad102071d0" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f501e89-51b6-4d52-ae7d-213e3d035649" contextRef="C_01111575-2dc6-44fe-bdc7-2295733d2ca3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,900</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbfe89be-20a7-4bee-a17e-a67dc6b09647" contextRef="C_01111575-2dc6-44fe-bdc7-2295733d2ca3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20d8feab-9dcc-41b2-af15-af012bc0ad69" contextRef="C_01111575-2dc6-44fe-bdc7-2295733d2ca3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trademarks</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db184ade-e487-419f-8bd8-f1f0772b2bbb" contextRef="C_118e49be-c761-4dd8-a46b-5ab677d5c06f" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4803f4e5-12d2-4631-b098-e7f1ecacb949" contextRef="C_118e49be-c761-4dd8-a46b-5ab677d5c06f" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7011a18-4026-41a6-8109-05102fa086f9" contextRef="C_820acf83-d376-4b0f-8f41-f85aedc1f651" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f29be6f4-130d-4bed-acbb-03b5717f452d" contextRef="C_820acf83-d376-4b0f-8f41-f85aedc1f651" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93e115ac-2e01-4fab-9faa-c32109b30635" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,991</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c2b92ee-cfe1-4ef5-83c3-d8223fd1a80a" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc9c963f-9a1c-4da0-a567-b846fadfd7bd" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,911</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aac16d4b-0b26-470b-b89b-3d65d56c6f33" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,894</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af930c4f-4140-4bb6-a097-aef0355c2dbb" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,097</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0af753f0-bac9-41dc-954e-b2de417d6bed" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,797</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81bcb83f-586e-4bb0-a8e2-edb5a289e164" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.613%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:12.723%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:16.023%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f62a854-f3d0-4cf5-b38b-8fa903a74b86" contextRef="C_3a255c06-b8fd-42be-a476-41c0489c1cce" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_684043a2-14ff-4879-bc05-48d62b4743c1" contextRef="C_dbc0f234-0a0a-4688-a7d0-ab581da9ada6" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_566a44ce-6460-4923-a603-1f6193b2e4c3" contextRef="C_bced1c1d-85b9-42ae-8100-73aca910ab35" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,981</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a1aab1b-d251-4c17-8455-149fe53afdaa" contextRef="C_78dba0fb-71f8-42e4-a64b-0fd12fbe76a6" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,973</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fba15ab-9f38-4cef-a61a-465290dc4435" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,983</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17339b98-b697-4ba4-887f-112186c22bac" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,975</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ee70be9-083a-4ec2-ab94-70dca2999c3c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future estimated amortization expense of intangible </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assets is (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.784%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:18.476%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of <br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_987dbab1-4a23-4319-8334-d61e6a1f4fba" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,978</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5abb2d66-2d72-4f2e-8f46-d50741cbf732" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71270a33-98e9-4bdf-89e0-86a6331fcfbe" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13fadfce-2d56-4afb-97e8-1f95210fbb9d" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,007</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cbf82d0-1471-4b93-8df1-6d64e171dceb" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd8c05a-6876-4a1a-881b-ad3e935769fe" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">820</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89657b96-12bc-4d31-8c66-0713ff6c00a1" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,795</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3eb5183-13e4-4518-8696-5493877960b5" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7 &#8211; Accrued Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d798553-bbb5-4f1d-a749-0ca9ba8a2fde" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.713%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.683%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.683%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation related accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1532389c-4f5a-4b80-a692-8a90b628a398" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,855</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28499113-732d-4cb3-b3f0-2610d801bd44" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,671</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d81bb4de-59c1-402b-a795-3b51414194b9" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:AccruedClinicalTrialExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_618a4588-b6d3-476b-ab99-4c114eef5a94" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="bdsx:AccruedClinicalTrialExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b488e144-80ed-4dbf-991f-b40edad5670a" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddf7d7f2-6bc7-4172-9c0f-c6cef0de129e" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a1fe5c-48af-4a8b-9419-13c7292edf52" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,710</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11e1f4e4-ef19-40fa-beed-d40c2e35abf7" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,218</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_7eca4939-c476-49dc-a951-9ed2ccfcf854" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8 &#8211; Debt</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-term debt primarily consists of notes payable associated with our Perceptive Term Loan Facility which is described in further detail below. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3d144f7-dd8d-4305-93b8-815438dff722" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true" continuedAt="F_b3d144f7-dd8d-4305-93b8-815438dff722_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term notes payable were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b3d144f7-dd8d-4305-93b8-815438dff722_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.96%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.360000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.76%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Perceptive Term Loan Facility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_234e0b7f-69f9-4ab2-90f1-a7a42cf0f06d" contextRef="C_103305fa-0498-4e12-8c27-50a1a8d26ffb" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27c74a46-60a4-4de1-ace2-2edf1d10c401" contextRef="C_d858a437-a837-4dd7-a056-993b112468b7" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_409961e2-1f15-47cb-a313-cb14c2dfc9b9" contextRef="C_9b9a9bf1-c88b-455d-836c-503d4aebec7d" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c3e3655-166d-4a60-8cb6-5e22a334c94f" contextRef="C_e9449bbf-0db7-4011-804f-4ab3c76ffe06" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93f83049-782b-4d37-b713-b078d4dbeb63" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d74900c6-787d-4a23-9fb6-5bd2e3706c76" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d74a34ed-6b9e-4374-8218-8ac3826d6ccb" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,276</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_890af284-71a3-475d-8897-d4ec0341a0b3" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,053</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current maturities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6415d91f-6914-4456-9002-89bc7979e957" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2cdb763-b13c-49a9-bbb2-eee05686595d" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term notes payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e39e92ba-76a4-4b84-8d5b-7801b67f0d24" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_759cd0d8-033b-439c-8bdb-a507874a25be" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Perceptive Term Loan Facility</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a5d90b5-4d28-4cc7-9730-004a70b73bae" contextRef="C_7447f4c3-b576-4564-b8e9-f58111485a6f" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Perceptive Term Loan Facility). The Tranche A Loan, in an aggregate amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6430da9f-d4f2-4c46-8b28-d9499250cb07" contextRef="C_c69ea8bf-9f71-4ba2-a888-5910c8e5e8a9" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Tranche A Loan), was funded under the Perceptive Term Loan Facility on November 21, 2022 (the Funding Date). The Company's net proceeds from the Tranche A Loan were approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4e8ccf7-ec7a-4d57-a1d7-77b5949810e7" contextRef="C_ac9d67d1-000b-4fd0-b45a-e660f6627d18" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">debt issuance costs and expenses. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25825fbc-f554-4ecf-a122-dc871c31c5e3" contextRef="C_2c13b6e2-c1b8-4e30-b455-351cad2472f7" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and an additional Tranche C Loan, in an aggregate amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae5d4f95-a8d4-4009-9373-a01714f92cda" contextRef="C_6645f92e-5a21-48d7-be04-51e4d7d14345" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which are accessible by the Company so long as the Company satisfies certain customary conditions precedent, including revenue milestones. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2023, the Company exercised its ability to draw the Tranche B loan for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fb7e414-387f-4b4d-bb89-a424c125b790" contextRef="C_c641c015-2bd6-4a8d-8ea4-9455265a0578" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Tranche C loan has a loan commitment date through September 30, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility has a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_170989b9-58a0-494d-964b-cb7bea5d4fe9" contextRef="C_757ef04f-cd64-48a3-98e8-6c7d33aefba1" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 21, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Maturity Date) and provides for an interest-only period during the term of the loan with principal due at the Maturity Date.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28f18727-19ee-4f74-8973-250d70a112ed" contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum, plus an applicable margin of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fb98d23-7b3c-4cd2-8c8d-48bd4e91b8a5" contextRef="C_757ef04f-cd64-48a3-98e8-6c7d33aefba1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the stated interest rate was approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_020e2087-f260-49b8-8816-b9fe93f8b629" contextRef="C_d34c69b7-5581-4027-8f30-edb22143832c" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">14.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amortization and Prepayment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the Maturity Date, the Company is required to pay the Lender the aggregate outstanding principal amount underlying the Perceptive Term Loan Facility and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e20df0f-9a68-4b0e-9e0f-b3af32f145dd" contextRef="C_4fd25448-a781-4c46-af90-bee7da9ce5c2" name="bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ed707c3-222b-4047-9904-f737b41d59e7" contextRef="C_20fb35f1-6660-4090-b128-abf211be9258" name="bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security Instruments and Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to a Security Agreement, dated as of the Funding Date (the Security Agreement), between the Company and the Lender, substantially all of the Company&#8217;s obligations under the Credit Agreement are secured by a first lien perfected security interest on all of the Company&#8217;s assets, subject to customary exceptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the Credit Agreement, the Company has issued, on the Funding Date, the Perceptive Warrant of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_094141b7-0047-479f-9eeb-301383948a33" contextRef="C_7447f4c3-b576-4564-b8e9-f58111485a6f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including the Initial Warrants which are equity classified at a per share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82b0c374-f232-4917-ab83-18d66334ecad" contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.0648</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is equal to the 10-day volume weighted average price (VWAP) of the Company&#8217;s common stock, on the business day immediately prior to the Closing Date of the Tranche A Loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Tranche B borrowing, additional warrants became exercisable into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b38c2dba-233c-49db-9e4b-22e39243188c" contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a per share exercise price equal t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">o $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5b615f9-6068-4393-80bc-75a7b0654c43" contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.0648</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is equal to the Initial Warrant exercise price (the Tranche B Warrants) and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7314e2ef-c364-467d-9e03-fcf28de18a2e" contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 15, 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the Initial and Tranche B Warrants, additional warrants will become exercisable into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca3cc2d3-456a-41b4-8477-5ca3f01979c6" contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f57d7591-15f8-4125-a4c8-0c32401608b4" contextRef="C_886c7268-fb43-44e3-b7bd-e66c3277e3a8" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche C Loan (the Tranche C Warrants). The per share exercise price for the Tranche C Warrants will be equal to the lower of (A) the Initial Warrant exercise price or (B) the 10-day VWAP ending on the business day immediately preceding the funding date of the Tranche C loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Each warrant will be exercisable, in whole or in part, until the 10th anniversary of the date of issuance. If the Tranche C loan is not drawn by the loan commitment date, the associated Tranche C Warrants expire and will not become exercisable. The Company accounts for the Tranche C Warrants as liabilities as the Tranche C Warrants do not meet the criteria for equity treatment (see Note 4 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representations, Warranties, Covenants, and Events of Default</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting and notice requirements, maintain insurance and maintain in full force and effect all Regulatory Approvals, Material Agreements, Material Intellectual Property (each as defined in the Credit Agreement) and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the Company&#8217;s business. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s business activities; make certain Investments or Restricted Payments (each as defined in the Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that has the impact of restricting the Company&#8217;s ability to make loan repayments under the Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79dd84d3-8e51-4cdf-923b-1c8999c1abd7" contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3" name="bdsx:MinimumCashBalanceAtMaturityDate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million; and (ii) as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2023, recognize revenue in amounts agreed to between the Company and Perceptive.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2023, the Company entered into the First Amendment with the Lender, whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold of each fiscal quarter commencing on the fiscal quarter ending June 30, 2023 through and including the fiscal quarter ending March 31, 2024. As consideration for the First Amendment, the Company agreed to issue to Perceptive a warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ec93eb5-3b07-4388-96f4-c5bcca4596a3" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the First Amendment Warrants) which are equity classified at a per share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfb60323-5d09-4c9d-b054-60a986454906" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.6254</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (see Note 10 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 4, 2023 (the Second Amendment Effective Date), the Company entered into the Second Amendment to the Credit Agreement and Guaranty (the Second Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby subject to the terms and conditions of the Second Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending June 30, 2024 through and including the fiscal quarter ending December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Second Amendment, the conditions precedent for drawing on the Tranche B Loan were amended to (i) reduce the trailing-twelve month revenue milestone and (ii) add the receipt of aggregate cash proceeds of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5b53a81-e89f-46da-8212-4e4f4278a7c2" contextRef="C_63b83fa5-85b9-4152-a156-9afea82f699b" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from an equity offering of the Company's common stock. During the three months ended September 30, 2023, the Company met the amended trailing-twelve month revenue milestone associated with the Tranche B Loan. On August 3, 2023, the Company entered into subscription agreements for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26dfb21f-401b-4859-aa7e-a885cdb2f2d2" contextRef="C_fdcc9d4c-66e6-411d-9680-d5105860c125" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,975,298</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#8217;s common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a8af026-a672-4421-8508-14caae0750fc" contextRef="C_3e31ab29-a697-425a-af3d-43c74dbcb485" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a53f86f2-5ae4-43de-a8df-5a7733cd6f52" contextRef="C_e46eb83a-79be-44c5-a843-5a8c6569843c" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the three months ended September 30, 2023, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85095038-522e-4e6c-bf00-cbc4485acc49" contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eaca825-f061-470e-8b54-979213d8529b" contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,454,927</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock pursuant to the Subscription Agreements. On September 27, 2023, the Company entered into an amendment to delay final closing on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3f9baa3-a071-4a78-bf62-64bd731bd3c3" contextRef="C_532807c3-5af3-4d5a-94dc-2349407eba05" name="bdsx:NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" unitRef="U_SubscriptionAgreement" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subscription agreement. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08c342e9-8f17-4bc8-8ecc-a29b731de168" contextRef="C_76c1c45c-0a3f-4fbd-beae-7e98904be82f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds were received and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca19a70e-fc37-4053-80de-b3beabeb48d4" contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,520,371</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued during the three months ended December 31, 2023 (see Note 10 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement also contains certain customary Events of Default which include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross- defaults to material contracts, certain regulatory-related events and events constituting a change of control. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit. The occurrence of an Event of Default could result in, among other things, the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility are immediately due and payable in whole or in part.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Initial Warrants and Additional Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e91b324c-33d0-4d46-a228-7449f5564f28" contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7158cb47-644b-49b5-92f0-f4327a470e85" contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3" name="bdsx:AdditionalWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, using the Black-Scholes option-pricing model, estimated settlement probabilities and estimated exercise prices. As a result of the fees paid to Perceptive and the value of the Perceptive Warrant, the Company recognized a discount on the Perceptive Term Loan in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acc7dc83-547d-4a38-a1c9-fa5e4b1b1f51" contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The First Amendment Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a001e053-90fa-4529-946f-00269653aeec" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model which the recognized as a discount on the Perceptive Term Loan Facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company recorded the debt discount as a reduction to the principal amount of the debt and is amortized as interest expense over the life of the debt.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_def22ed6-b3f4-4142-a754-d6aff1cc2ad3" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true">
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.68%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:16.54%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_004ef27b-6261-4a7d-803c-3d1e3f9e512b" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e016ae86-b4d1-4fab-93c2-fce20d4bbd30" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1901937c-9dc4-4b10-9386-aa7efb6c362e" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dfac190-e175-438a-ae46-422d7aaab38c" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eebb9fd-bc06-4870-96f8-edf46bed1924" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,078</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7a713ee-04c4-4d15-a74c-8af42999959c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:LesseeOperatingAndFinanceLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9 &#8211; Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company acts as a lessee under all its lease agreements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout 2023, the Company leased its headquarters and laboratory facilities in Boulder, Colorado, under a lease agreement that expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6810bc43-8b88-4896-94db-50fb78cff4b9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d0f0a6d5-c980-4547-82e0-7fbd7882d4e9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company subsequently relocated its corporate headquarters and laboratory facilities to Louisville, Colorado. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17438265-7ddc-49e2-9b9c-d5c482a8ff6c" contextRef="C_62d6cec9-2f4c-4985-b1ad-fb315c4d7129" name="bdsx:AreaOfOfficeSpaceLeased" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">9,066</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet that was set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07b006c7-361d-4ea5-83e3-7a4c003eb2c1" contextRef="C_ba93e9bf-54a2-4a63-a29e-47cf3846d702" name="bdsx:LeaseExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In April 2023, the Company amended the agreement to extend the lease agreement through October 2026. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also holds various copier leases under non-cancelable lease agreements that expire in the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f032350b-436c-49d5-a43e-3d8d73323d62;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to three</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4ab91cf-5309-48b9-bf44-1a128879ae56;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Centennial Valley Properties I, LLC Lease Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space in Louisville, Colorado (the Leased Premises). The Leased Premises replaced the Company&#8217;s headquarters and laboratory facilities in Boulder, Colorado in January 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e857092-10b4-47d9-8a2b-2bc34fbfcf61" contextRef="C_05eb759d-55fd-4a20-ad8a-062b720cf18a" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The initial term of the Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96808220-dfb2-4a09-a9ae-1ab110483d9b" contextRef="C_db52ea64-8d04-4f5f-808f-473c14c90cd0" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3a4a5da-9552-4909-ad2e-8d3da7345269" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eee3338f-68f3-42ef-95ec-8c85b3993eba" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:LeaseAgreementNumberOfOptionsToExtend" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> renewal options to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9819f44-9ee0-4168-8cea-d0561631774b" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term of the Lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d101e6ae-d1d1-4191-8ad1-1ab4d344cdcb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">- or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5db12d08-8fa1-4dce-9d59-a35cc4cc982e" contextRef="C_2b4b468c-46c8-4f63-a0d6-3132df34cab5" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e1fcc6-dcef-4905-8c91-335dd36ece05" contextRef="C_f8dffbb6-3dd7-4318-8445-46c6c30532bd" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ab053d16-dbcb-4302-b42c-58b397652d34" contextRef="C_f8dffbb6-3dd7-4318-8445-46c6c30532bd" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in ROU assets and lease liabilities being recorded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, however, the Lease commenced for legal purposes on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fc31582-f9ea-4074-874d-3450c49d0e31" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Commencement Date)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Lease, the Company will lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a3a34a1-f9c6-4bca-a678-c96dac42f9b5" contextRef="C_db52ea64-8d04-4f5f-808f-473c14c90cd0" name="bdsx:LeasedPropertyBuildingCapacity" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">79,980</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac175da7-f560-44ca-83ca-765a8ab59438" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:BaseRentPerMonthFromCommencementDate" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">227,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month and escalating, based on fixed escalation provisions, to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f86a41-79e6-40a6-a30c-54c947835e27" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:RentAfterFixedEscalationProvisions" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">326,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ded8896b-a92d-4eec-844b-d684c68ffebe" contextRef="C_db52ea64-8d04-4f5f-808f-473c14c90cd0" name="bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">19,980</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0bf5463-fc3c-49bf-beab-dda1b19a2211" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5549db94-3c99-4668-8804-330e233e6e55" contextRef="C_05eb759d-55fd-4a20-ad8a-062b720cf18a" name="bdsx:AdditionalTenantImprovementAllowanceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08cf1060-a088-4995-8ac4-d541144ac5c7" contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3" name="bdsx:InterestRateOnExtraAllowanceAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability at lease commencement because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease commencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b7d603f-0dd1-45d8-9894-0a7d937caade" contextRef="C_e3ab2048-daf6-40f1-a535-fe1a3ed66ded" name="bdsx:AccretionOfLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lion by November 2024 after receiving $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d5d0fde-43a6-465d-8ae4-46b65181465c" contextRef="C_e9c98e4a-80fa-483a-9bc2-c5a38ceacbe3" name="bdsx:LessorReimbursementsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in lessor reimbursements. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilized the total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7f6b987-a7c7-4b7f-ba96-cf2f7adcc756" contextRef="C_2753e6cc-4205-46f0-b9c5-73fa3a85b6e5" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa35327-726c-4939-9477-b6e687210265" contextRef="C_05eb759d-55fd-4a20-ad8a-062b720cf18a" name="bdsx:TenantImprovementsIncurredDuringThePeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cd7ea37-9572-4cf1-88b6-0781d55ab62f" contextRef="C_2ff65011-fa8e-4a77-8fc2-78505357e43f" name="bdsx:TenantImprovementsIncurredDuringThePeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023, and 2022, respectively) in tenant improvement allowances for capital expenditures for leasehold improvements related to the Leased Premises and have been reimbursed from the Landlord.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. During the three months ended September 30, 2022, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b14c1b97-451e-487f-9e25-3afad93ed364" contextRef="C_6192e64b-6b5d-4c2e-807b-fa9c59db0323" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cash collateralized letter of credit under the operating lease agreement was released and the funds were subsequently transferred to the Landlord as a refundable deposit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#8217;s obligations. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cb83b46-7309-4014-8152-9e83b069d148" contextRef="C_d3ff8863-2403-499a-a2df-4ae38da7415d" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9bad851a-2135-42e3-9e70-fc1e672128b8" contextRef="C_b4dff87f-d0d5-422b-9f9a-13850ed49e16" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million refundable deposit is included within '</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_afd70d36-dcbf-4fdb-b7a0-f4dc56cc9f89;"><span style="-sec-ix-hidden:F_969e4251-ea3d-4fbe-a713-b5983a44c323;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other long-term assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">' in the balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense for all operating leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19745e2d-2895-4492-bdaf-73401940b696" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ba5fb26-8de5-47d4-8850-9d1c1f992703" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and 2022, respectively. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the weighted-average remaining lease term and discount rate associated with our operating leases were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_483110f5-f1cc-4f18-95bd-e194ecdaa2bd" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dfb828f-9c6c-4004-a3c6-235186647f22" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">11.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ctively.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_f9d515b3-abe3-4206-975f-095760061b9b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments associated with our operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.996%;"/>
        <td style="width:2.04%;"/>
        <td style="width:1%;"/>
        <td style="width:17.964%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1de6c824-4541-4577-b612-11f829bc7eb0" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b6fb366-8821-4ebd-a707-68423b709773" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,032</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b8beae5-0b1d-449e-9304-d1706930e520" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d0f215f-a80e-47f1-8b22-c85771101aaa" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,063</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7983e762-aca8-4769-9e9c-578794059bff" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,151</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd1344ff-17cd-44c2-a3f8-bee77e567a86" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,113</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35867c81-86f2-4b80-8c9f-77df0d35c1f9" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less amount representing interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec473b05-a8f5-4320-9828-0e3fdd3b754c" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_322029c5-a975-4aa5-b2ab-8ba314b6e373" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,415</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ab9d499-89d9-4d2a-958c-1e061400080b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10 &#8211; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74a7fcc7-deb0-4610-85dd-7d2c61853a42" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3004de32-149d-4418-9f83-8ec1016d555e" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c6a6799-bad2-4fc0-8eb1-142755867589" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holder of each share of common stock is entitled to one vote per share.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_886edb6e-4f2a-4fde-a33f-60f9622fc12c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55826e51-7bda-42f1-9d5d-278265cad747" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09ce831e-848f-4fa6-9f89-390ff1f40c43" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e3e0c9b-f53a-409c-814f-5a4809a1cc6d" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3534d81b-0eb5-48dd-9069-b30377d33718" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c05f8e86-ed56-4b68-b143-df7517a041b8" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8a0aa5b5-f2d9-4abf-a1a6-3294bac70017" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock were issued or outstanding.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Financing Programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1611393d-ed8b-46f4-a974-1840357c0c66" contextRef="C_47a08558-9395-40a3-8dcc-94e5904208d5" name="bdsx:NumberOfFacility" unitRef="U_Facility" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> facilities that enable equity financing on an ongoing basis at the Company&#8217;s sole discretion, our at-the-market offering (ATM) and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park).</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70b5b618-a4ce-460c-ae9f-ca379195b121" contextRef="C_527ecbd0-9d14-456c-8b14-6369be5c77b1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the ATM Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3, and sales of common stock, if any, will be made at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on the NASDAQ Global Market, or any other existing trading market for our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2022 (the LPC Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (the Purchase Agreement), pursuant to which Lincoln Park has committed to purchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2b19324-4847-490a-ac26-2ad149455735" contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company's common stock (the LPC Facility). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_668d34f5-2d46-47f7-94fd-ca19f6d62151" contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#8217;s sole discretion, over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17fc2087-036b-4a5d-82c8-2f232f50029b" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:PurchaseAgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period commencing on the LPC Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_053a33e3-0e41-4094-86d2-1a5c595505cb" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:SaleOfStockStockIssuablePerDayShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, but that amount may be increased up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4e2ac5d-ee2e-4666-bcd0-e456e86e057f" contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6" name="bdsx:SaleOfStockStockIssuablePerDayShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, depending upon the market price of the Company&#8217;s common stock at the time of sale and subject to a maximum limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66541bb2-4ff5-4ff0-9337-b3183220213a" contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6" name="bdsx:SaleOfStockStockIssuablePerDayValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#8217;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_416ab7ac-11d3-4ad8-aae0-2923247afe59" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:SharesIssuedOrIssuableThresholdLimitDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under applicable rules of the NASDAQ Global Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df5f870-8204-4fd5-90c6-fd078aacd80d" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the LPC Effective Date, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2a6b474-b82d-45a4-9e0f-c6922a623d86" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:SaleOfStockSharesIssuedAsCommitmentFee" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">184,275</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9557cf84-c769-4fa0-b66d-01ae0fe55b45" contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6" name="bdsx:SharesIssuedAsCommitmentFeeValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company will be required to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9f53aff-f399-4f22-9f54-4ad552e944cb" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:CommitmentSharesIssuableOnConditionalBasis" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">61,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45a5682f-496d-45df-93b8-53838f415127" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, together with due diligence expenses and legal fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_814ed7a5-33c2-4f65-9947-0fe84b08273f" contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f" name="bdsx:DiligenceExpenseAndLegalFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">129,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, reflect deferred offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d278bbd-fb1d-424c-a569-a1f9292c035f" contextRef="C_efd69ce4-92d9-4a44-8134-87ed7ac60445" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">729,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which are included on the balance sheet in 'Other long-term assets'. The deferred offering costs will be charged against 'Additional paid-in capital' upon future proceeds from the sale of common stock under the Purchase Agreement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92e64978-7a6c-4cbb-a8db-bd966def9d8f" contextRef="C_d33768d0-8007-4c23-a3e3-f26f30749f9f" name="bdsx:AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of deferred offering costs were charged against 'Additional paid-in capital'. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fe84aee-f298-4f88-ad3f-08f9211d7483" contextRef="C_87753004-7a65-4879-90a7-b55ed68ef8d1" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">654,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of deferred offering costs remain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company raised approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c69f3fcf-143e-4680-af92-09885a75ccf4" contextRef="C_47a08558-9395-40a3-8dcc-94e5904208d5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e9b087d-8ce4-4648-8bb8-aeb4e3ebde7e" contextRef="C_7feedfcd-2f75-4050-b434-093d5964efa3" name="bdsx:ProceedsFromIssuanceOfCommonStockNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_228cb171-664c-4eef-b9b0-b3839f9bb017" contextRef="C_b34059f4-8b80-437f-b778-005b358d00cf" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">376,456</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares at a weighted average price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f33d56e-934f-4b54-89a6-8e1f287338d4" contextRef="C_b34059f4-8b80-437f-b778-005b358d00cf" name="bdsx:WeightedAveragePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under the ATM facility. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had remaining available capacity for share issuances of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b425c773-c026-4a87-9e02-36baa0395eaa" contextRef="C_1b25b640-1c47-4745-9cca-376992b9713c" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under the ATM facility and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f973df37-830a-4cc6-a68a-f9c35b0e3ca6" contextRef="C_fff8f12c-e13d-40af-8269-13c52984316c" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, the Company closed an underwritten public offering (the Public Offering) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58da6e1d-a9a5-475a-9e15-d8bd78b04883" contextRef="C_ea26ef97-074e-45f4-81e8-41983d384792" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,075,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock (the Public Offering Shares), including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f85301e3-06e0-4f29-8ccd-0417c0247f3b" contextRef="C_ea26ef97-074e-45f4-81e8-41983d384792" name="bdsx:StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,575,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares purchased by the underwriter pursuant to an option to purchase additional shares. The Public Offering Shares were issued and sold pursuant to an underwriting agreement, dated November 16, 2022, by and between the Company and William Blair &amp; Company, L.L.C., as sole underwriter, at a public offering price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e210164a-2559-4e50-962f-476515e6c454" contextRef="C_50b4b982-898d-46bc-b9ea-b684abcdac48" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a4ca464-30b2-486c-873a-b852dc5e4dba" contextRef="C_8dc723fd-79de-4621-8b96-50bc34902a0e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Public Offering after deducting underwriting discounts, commissions, and offering expenses payable by the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Public Offering was made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 previously filed with the Securities and Exchange Commission on November 29, 2021 and a prospectus supplement, dated November 16, 2022, relating to the Offering.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subscription Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April 2022 Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_921a7761-db19-4c28-a6ea-a7e3fa4dec14" contextRef="C_c2c8094a-10da-431f-951a-d7eb2e067421" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,508,376</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement offering. The three members of our Board of Directors acquired an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f26ef669-a61a-460f-8ae9-b0a631ecae01" contextRef="C_26baecb2-9cae-47d3-9fff-e9ca8610e979" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,631,284</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62506747-780e-43b0-bb5f-18b73fbc7bd4" contextRef="C_0845ddd1-8e8f-416b-a225-6a579305755e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,877,092</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the April 2022 Subscription Agreements, the April 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35a4ad66-c17d-4e85-8b42-ed425e8ca2ea" contextRef="C_ed3993d6-58b6-4ff5-b5d7-5c4851329b29" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95198f5a-1743-46a9-afda-c8f9b62a5617" contextRef="C_ff6853d0-09e3-4b96-93ec-2bc31e1bfcc5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The April 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management (the November 2022 Investors), including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_487e4885-00fd-4257-92c7-643cd56cf532" contextRef="C_7f80b84d-e3ac-46dc-8317-ba012a0d08c1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">235,056</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement offering. The November 2022 Subscription Agreement did not include any registration rights and included lock up restrictions that were in effect during the period ending 90 days subsequent to November 21, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the November 2022 Subscription Agreements, the November 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9299ea7-380c-4d33-a039-23632806d311" contextRef="C_fa2e75a9-b401-42d8-9753-7018d23b85ef" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which is equal to the public offer price in the Public Offering, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_298620d5-df27-406b-bc2c-16794933461f" contextRef="C_3a9c086d-ca5a-4f0b-a935-2933e71c3b61" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">270,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The November 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 3, 2023, the Company entered into subscription agreements (the August 2023 Subscription Agreements) with all the members of our Board of Directors, all Section </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ecae9c7-561e-4588-8218-d8927d43f7ac" contextRef="C_fdcc9d4c-66e6-411d-9680-d5105860c125" name="bdsx:NumberOfOfficers" unitRef="U_Officer" decimals="0" format="ixt:num-dot-decimal">16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> officers, and additional members of the Biodesix leadership team (together, the August 2023 Investors) for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d9109ee-10ee-471e-b384-19989d8aa5d0" contextRef="C_fdcc9d4c-66e6-411d-9680-d5105860c125" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,975,298</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private equity offering. The Subscription Agreements did not include any registration rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the August 2023 Subscription Agreements, the August 2023 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8caa7903-cc0c-49fb-ba8a-80855d12432d" contextRef="C_3e31ab29-a697-425a-af3d-43c74dbcb485" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which is equal to the closing price of the Company's common stock on August 3, 2023, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41cfc315-196e-4b99-9042-5107c484f34b" contextRef="C_e46eb83a-79be-44c5-a843-5a8c6569843c" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The August 2023 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement. During the three months ended September 30, 2023, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6aef8ef-6b69-4514-8157-6bb4d804d97a" contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec50d086-6b04-46ff-8742-8ca31d210bd0" contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,454,927</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock pursuant to the Subscription Agreements. On September 27, 2023, the Company entered into an amendment to delay final closing on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_387cb83d-bd2d-4f41-a35e-e02cbdb07976" contextRef="C_532807c3-5af3-4d5a-94dc-2349407eba05" name="bdsx:NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" unitRef="U_SubscriptionAgreement" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subscription agreement. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e17ed76-34a3-4314-a4bb-0f2bc3e12edc" contextRef="C_76c1c45c-0a3f-4fbd-beae-7e98904be82f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds were received and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ad5e89e-3629-48e7-be50-46c20de67d09" contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,520,371</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued during the three months ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed1212ff-10de-4164-a9b9-a174d5ccd48c" contextRef="C_693c76f1-5bcb-4f13-8dd7-aab03824f0b6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">613,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series G convertible preferred stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06fce977-9549-4477-b9c6-b3b688aa9c9d" contextRef="C_693c76f1-5bcb-4f13-8dd7-aab03824f0b6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_491098a6-23e8-401c-b482-99a5be8ced51" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 23, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Through the effective date of the Company&#8217;s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company&#8217;s IPO, the preferred stock warrants were automatically converted to warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4613011-0d36-4095-b243-7e2e725473aa" contextRef="C_c62ec6f1-4811-4fd5-bb74-172abde325bc" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">103,326</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2576f2c-2f32-4b10-8fec-a39fb69791ff" contextRef="C_c62ec6f1-4811-4fd5-bb74-172abde325bc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.46</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and were also transferred to additional paid-in capital. All common stock warrants remain outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), the Company issued the Perceptive Warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7a6bd00-c503-490b-b812-25768be8c633" contextRef="C_7f39b903-335d-4dc6-a073-8be5fe3da6ba" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, including the Initial Warrants. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the Initial Warrants, the Additional Warrants will each become exercisable into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d40be842-9bbe-4212-a1a3-3c6feafdabec" contextRef="C_722b4124-2675-4c60-83df-552c2446203f" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The per share exercise price for the Initial Warrants is equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2101578c-3519-4b87-ab92-2de60f43272d" contextRef="C_c6dcab58-44c5-4023-bb77-3783ed60c728" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.0648</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is equal to the lower of (A) the 10-day VWAP of the Company&#8217;s common stock on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of common stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ef7e8c8-ac82-4640-83a3-bbbac20f965d" contextRef="C_82a5e47a-b63c-44b3-bca7-2b170af6b51a" name="bdsx:PublicOfferingPricePerShareOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Initial Warrants are equity classified and were immediately exercisable upon issuance and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a259352e-116d-4937-aba6-065845adc7eb" contextRef="C_5fa0d7e8-75b7-4df5-8285-781f19947e03" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 21, 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Initial Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad5b6282-cf93-42cf-b518-05c3a2306f32" contextRef="C_5fa0d7e8-75b7-4df5-8285-781f19947e03" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12854c26-e622-49ef-b4a6-3350557d9f36" contextRef="C_3d56ae6a-1cf7-4302-8a0a-2f707300fff3" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0caf9be6-a6a5-45bc-afc1-b72b66c439d0" contextRef="C_a1c1115e-2162-4e21-818c-b98821ff9dca" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="1" format="ixt:num-dot-decimal">81.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_baa7e47f-ffef-4d31-899d-7c80f738af71" contextRef="C_d94f7ed2-8768-4f75-92ef-17e38595fb19" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d5b45af-f956-4e88-a51c-de99d8988bbb" contextRef="C_d8c554b0-2f2a-45d2-827d-c5c7753bf0df" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">3.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. All Initial Warrants remain outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2023, as consideration for the First Amendment (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), the Company agreed to issue to Perceptive a warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09d762ac-9867-44b5-ad65-b2e1adff6f1c" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the First Amendment Warrants) at a per share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c9624e7-7aca-4f9c-8bdf-cf9249d7348d" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.6254</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is equal to the 10-day VWAP of the Company&#8217;s common stock ending on the business day immediately prior to the First Amendment Effective Date. The First Amendment Warrants are equity classified and immediately exercisable upon issuance and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97564638-dd54-49a5-bd09-bb3e61faa187" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 10, 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The First Amendment Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74bd223f-ab38-44a5-8650-eb9f86d56718" contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92b44a88-f862-4671-addf-9eb1b2f1a807" contextRef="C_d1ab286d-70e8-4911-8d81-5934ba62030b" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08b84bd4-a9ef-40e2-a282-e355337f9097" contextRef="C_c75f007c-cad7-4f11-be83-4e80d54a65e2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="1" format="ixt:num-dot-decimal">78.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_219c6f9c-f3ac-473d-ac15-adb6d513e666" contextRef="C_67ce5508-c2c7-4b2b-ac66-a6d8f43f57a6" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4265fde8-b8c5-4ba6-895f-e5a11b69b006" contextRef="C_c4a9239d-0ac1-4ebc-99ad-6594a4338815" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">3.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. All First Amendment Warrants remain outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital. The Tranche B Warrants are now equity classified and immediately exercisable upon issuance and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04cf4720-4696-4312-816e-9da7a45c271d" contextRef="C_fb308a59-4d7b-4ffa-b075-a3e642ac4c94" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 15, 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tranche B Warrants were value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36ae935d-58e2-451b-bbba-99a343aa967d" contextRef="C_fb308a59-4d7b-4ffa-b075-a3e642ac4c94" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de76959f-48a4-4dd2-b187-f7774b1396d5" contextRef="C_ce2a287f-cb92-4030-b3b1-332c05321abe" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7df06387-42fb-480a-bf21-4485d966bb82" contextRef="C_ea1e80b7-5077-4687-98eb-b1b280706184" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="1" format="ixt:num-dot-decimal">76.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_140f2216-d629-4e60-a924-33c1b2ceabea" contextRef="C_77f1704b-d027-4f10-90c1-a41d7fa1aa89" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e57851d5-d6de-4a8d-a32f-87c5c98e34cb" contextRef="C_1b5d3398-91f7-41ab-97d0-7393bc19f7ef" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">3.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. All Tranche B Warrants remain outstanding as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56f3fe51-09af-492d-9334-e5228d4b31e5" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11 &#8211; Revenue and Accounts Receivable Credit Concentration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f8b03e2-594c-43ad-9391-57aa17de7a78" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:PrimarySourcesOfRevenueDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and, prior to May 11, 2023, COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer, test type, and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc29a516-97e2-4080-b51b-e7b52acccd4f" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.713%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.683%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.683%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diagnostic Tests</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_075c2bf0-56c2-408a-828f-fdd211ee4bf6" contextRef="C_cc3d622b-07f0-4622-b168-11fadcf7c53f" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14e43d91-17b4-4da2-b311-cdafa3766a76" contextRef="C_7afe2c5e-ef01-4ae6-9496-8f640f10072d" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,538</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biopharma Services and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c400f5d5-49c2-4801-9cda-ddf1e40e0377" contextRef="C_495df2dc-9e4b-4eba-91de-cd835b8ec284" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,895</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9de0b07b-f372-4ac6-ad9a-b3f0eaec749c" contextRef="C_ab1111f8-759d-41b6-837c-e3d03f7a0ae9" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7feb0b7d-ea9f-49a2-9605-32c5b2b7b50e" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,087</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_288e25df-8d39-4b0e-a132-a1d0242554ee" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in 'Revenues' in the statements of operations. The Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51cd4b72-acb6-46ad-a303-4906424bc567" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in &#8216;Deferred revenue&#8217; recorded in the balance sheet as of December 31, 2022 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f79d7566-d92b-4630-8e85-8a77ddf91c69" contextRef="C_c93f4cec-77cf-4fd9-a863-07647a7dfbe6" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was added throughout 2023 to &#8216;Deferred revenue&#8217; for up-front cash payments received while $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0d056ed-efa3-4433-8e54-b86078419dba" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized in 'Revenues' during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The &#8216;Deferred revenue&#8217; of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92747a70-c705-412f-b677-cf2489247149" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">corded in the balance sheet as of December 31, 2023 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2023 and 2022, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b3c13a1-8d4a-4391-91b4-be6cd9ea8016" contextRef="C_40f12cf5-75b2-497c-a527-a856346a9ab1" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fca4e3c0-7345-4e05-a871-d1da6e6b5a35" contextRef="C_eca8f48e-2cf8-4fe3-bd45-8790ffacd616" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in non-cu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rrent deferred revenue, respectively, recorded within &#8216;Other long-term liabilities&#8217; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84bc106f-1dcd-4ea8-ac5a-f00a44f7d259" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true" continuedAt="F_84bc106f-1dcd-4ea8-ac5a-f00a44f7d259_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.16%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.16%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United Healthcare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c70317aa-ffbd-4167-9624-92da7feb67c9" contextRef="C_6c99d259-788c-49d8-9e0a-022979f1851a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The State of Colorado</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e71f4e4c-ad89-4a25-99db-efdcc7703ce0" contextRef="C_d9e2f35d-f819-4cf0-98d0-27d991f1b000" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a910f3f-06a6-4fed-a394-255443397010" contextRef="C_e89c5ad9-ee99-495b-8bf2-d125fc70e5e0" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6305b6a-c0a2-4148-be85-ad9b52a9861f" contextRef="C_5636267d-0318-4aa5-a493-1e9d911a7cf4" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company&#8217;s total revenue for the years ended December 31, 2023 and 2022, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_84bc106f-1dcd-4ea8-ac5a-f00a44f7d259_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.16%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.16%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Medicare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_346ae618-dd5b-416b-a71f-39bebf017876" contextRef="C_81062d5c-36cb-4b6f-acd2-1864d8d3f30d" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4cfac70-b3a5-4287-910d-84295d30b0a3" contextRef="C_c183917b-8a29-4963-b916-51ff5dc6f28a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AstraZeneca UK</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a8b39f5-b64d-4bca-8497-b96d9a5a5139" contextRef="C_6c326e24-3804-4962-872f-a522021fc168" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e886473-31ed-47f2-90a8-093d108b8dea" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 12 &#8211; Share Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Predecessor 2016 and 2006 Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_667925d7-5134-4ebf-a879-5b2cda2b2c76" contextRef="C_6f98ad46-d032-45e8-8dc6-864069fa3ada" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional awards may be granted under the 2006 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultants. Awards granted under the 2016 Plan or the 2006 Plan that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#8217;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efc811a1-567b-488d-a655-163afdeb1f99" contextRef="C_b7bda97d-3509-499d-a965-e2fdeb9c2460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional awards may be granted under the 2016 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the closing of our IPO, the Company&#8217;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares originally reserved for issuance under the 2020 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5baa9764-f84e-42d2-b3d4-5de40343381f" contextRef="C_04f15e86-b867-4b21-85db-2828b6000f59" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,893,395</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The 2020 Plan includes an annual increase on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccee5167-0e78-4454-9751-d5739decd757" contextRef="C_0f11691d-c0c2-4bb0-ab80-31641907e9da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#8217;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a prior plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all plans as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db558560-5b26-4389-9511-e29c676f8466" contextRef="C_b343d002-35a7-4d20-972f-2d42c271e7a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">960,305</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective with our IPO in October 2020, the Company&#8217;s Board of Directors and its stockholders approved the Company&#8217;s Employee Stock Purchase Plan (the ESPP). The number of shares originally reserved for issuance under the ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17123169-1d47-4400-a742-648ec0f35a63" contextRef="C_3b7739ff-0980-4012-9fc1-66675c283f56" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">338,106</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2beb5f2a-9b52-4387-8dd4-06e2f1968a9d" contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1143fb8b-a248-48bf-b226-a4fce40f3ff5" contextRef="C_72b4a1e8-4024-43cf-af5a-fe28f78fef95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d16c5ec0-7652-4268-b564-9b399412167e" contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f124ebf4-4541-4810-ab7a-ca569c372536" contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542" name="bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e560ed78-cf73-4698-969a-4c99f8dca0f5" contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542" name="bdsx:DescriptionOfOfferingPeriodUnderPlan"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 437,135 shares were issued under the ESPP leaving 309,012 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares remaining for future issuance.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Awards Granted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f9d1495-7e45-4c22-964c-f8408912c075" contextRef="C_4ce221be-74ad-4978-8b6b-94c91f43b705" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-statutory stock options, which may be issued to employees, non-employees and directors, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ffcfece-fe07-42ac-b730-b491438c07ee" contextRef="C_2a229531-ccdd-4632-a059-50b71306f89f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance-based options vest in three equal annual installments beginning one year after the grant date</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#8217;s common stock on the grant date. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_212fbb92-095a-4bb7-8905-f1dc330a9e10" contextRef="C_0b1fa878-d68c-49bb-adba-1cf66b1bc52e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance-based stock options outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU holders have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Exchange Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 23, 2023, the Company commenced a voluntary offer to exchange certain eligible options held by eligible employees of the Company for new options (the Exchange Offer). The Exchange Offer expired on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffc7bbf0-4f6c-4b02-b47d-7551d9291a8d" contextRef="C_b6598444-e68b-421f-8188-c98635eea90e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 24, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Pursuant to the Exchange Offer, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e9965b1-1331-4c0d-840f-7deac3708bbb" contextRef="C_b6598444-e68b-421f-8188-c98635eea90e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" unitRef="U_ShareHolder" decimals="INF" format="ixt:num-dot-decimal">83</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91497b9b-9f40-409e-94d4-71230bdfd472" contextRef="C_b6598444-e68b-421f-8188-c98635eea90e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">757,595</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66bc91ca-d36d-4e67-b58c-eb6143a35f5e" contextRef="C_b6598444-e68b-421f-8188-c98635eea90e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total shares of common stock underlying the eligible options. On July 24, 2023, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0d80fe5-2481-4876-8db7-669e90a202d1" contextRef="C_ba1bede0-706e-4693-ba5f-95a79f81fcbf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">156,868</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, pursuant to the terms of the Exchange Offer and the Company&#8217;s 2020 Equity Incentive Plan. The exercise price of the new options granted pursuant to the Exchange Offer was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7193119f-9e19-40e5-abbb-3fb1f0287ade" contextRef="C_ba1bede0-706e-4693-ba5f-95a79f81fcbf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share, which was the closing price of the common stock on the NASDAQ Global Market on the grant date of the new options. Each new option granted in exchange for the vested shares underlying an eligible option will fully vest on the first day of the month following the first anniversary of the month in which the Exchange Offer is completed. Each new option granted in exchange for the unvested shares underlying an eligible option will vest under an extended vesting schedule, with vesting commencing on the first day of the month following the first anniversary of the month in which the Exchange Offer is completed, and occurring in a series of equal monthly installments over the number of months that were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">remaining </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the surrendered eligible option&#8217;s vesting schedule immediately prior to the Exchange Offer. Each new option has a maximum term of ten years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exchange of stock options was treated as a modification for accounting purposes. The incremental expense was immaterial for the new options and was calculated using the Black-Scholes option pricing model. The incremental expense and the unamortized expense remaining on the exchanged options as of the modification date will be recognized over the new vesting schedule.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bonus-To-Options Program</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has a Bonus-to-Options Program (the Bonus Option Program) which is separate from previously described plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011, 2015, and 2022. For fiscal year 2023, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the closing market price of the Company's common stock on the grant date, as disclosed below under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;. Bonus Options issued must be exercised within a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d33792b8-c45a-491d-830e-4f5a6b5a5a93" contextRef="C_185c0faf-f292-4fd9-ace9-12ff64d5d8f1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26c148df-2043-4b10-b2e9-5ffecb26b2df" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.68%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
        <td style="width:1.1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:10.42%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; January 1, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_380fc413-1610-4861-a29e-64c64638fb97" contextRef="C_921ada3a-dad1-481f-91bb-6926ac721bcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">526</ix:nonFraction></span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93c229fc-0e43-43d8-a53a-9ef0113382fc" contextRef="C_921ada3a-dad1-481f-91bb-6926ac721bcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.69</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7ea51dcc-5da7-44bc-9d76-af27d0e7e804" contextRef="C_dbece915-caf9-4b49-8367-e61f916c83c7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d435bdb7-92c6-4256-a098-12be9584faf4" contextRef="C_921ada3a-dad1-481f-91bb-6926ac721bcf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf449979-464b-4a80-9013-6673134bf36b" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59266bfa-0686-4f5e-9424-19217b48d946" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a166088-1431-4370-8e6d-566163b7769b" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04fa2307-32aa-43ca-a691-c5c15d39162a" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2d1b873-cddc-45c1-8d04-5ddbf1c0c63b" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="bdsx:StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6b40d45-337d-4ac1-a468-496c6ce1f747" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdce4a68-92a5-4d1b-9dd4-38b8ac3ad341" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="bdsx:StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4779a37f-bf2d-4565-ba05-26db53edbadd" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c35e9a5f-a4b8-466d-9d5b-ee9923ffd8e4" contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,050</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b914e343-0714-4507-834b-775834ec0720" contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.81</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_91c2dff8-2a03-4ce1-af92-e65f4a53411f" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea95cfc3-8a89-447b-9e84-45f2e6ec2fcb" contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3947deaf-f754-45a8-a9be-f2a6203dfd7d" contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ac05ab3-6a16-487a-a8ff-3df88f609d2f" contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.86</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_da174018-7413-45f3-b0b3-a8b5d80297d7" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company record</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d8c1e22-4b37-4b82-ad24-0c5ed2e3abe4" contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af02ddaf-bc58-46a7-adda-e11cf0374ae1" contextRef="C_dbece915-caf9-4b49-8367-e61f916c83c7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million du</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ring the years ended December 31, 2023 and 2022, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in the first quarter of 2024 and 2023, respectively, by the Compensation Committee of the Board of Directors. In determining the amount of share-based compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49893e9a-39de-4c42-baab-603eded76e3a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"/>
        <td style="width:1.66%;"/>
        <td style="width:1%;"/>
        <td style="width:20.619999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.28%;"/>
        <td style="width:1%;"/>
        <td style="width:20.619999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad448474-04cd-4774-a5a9-cc2f7cb0b81c" contextRef="C_3a255c06-b8fd-42be-a476-41c0489c1cce" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_425a3cee-4905-4bc9-b13b-b57f04c17d7b" contextRef="C_dbc0f234-0a0a-4688-a7d0-ab581da9ada6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52d0e4b1-763e-4a3e-86f5-1a91e34c02e7" contextRef="C_ccfbd687-78ce-4465-b1b8-3bfc531b0880" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a87c0461-2d79-451f-aa20-034a6bae2513" contextRef="C_f01b403a-323f-485f-af41-68ca5c0839f6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_303046ef-049f-4603-95b6-5a863d2382b2" contextRef="C_bced1c1d-85b9-42ae-8100-73aca910ab35" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,989</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dee59cf-3b57-46ef-8351-ee33243673af" contextRef="C_78dba0fb-71f8-42e4-a64b-0fd12fbe76a6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b979c7-72c9-409a-83d6-31bd9eabf0c4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,373</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd5cb710-dad8-4c17-a210-8c57c1bb6f15" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,961</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unrecognized remaining share-based compensation expense for optio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ns and RSUs was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecce7236-2209-4b70-9e24-9fb66707ded7" contextRef="C_5662ec44-a16f-45a0-917c-97f0fd92ca72" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is expected to be amortized to expense over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5f64baf-8eb6-4018-a9bc-4bfa356c5cf2" contextRef="C_ce211496-7721-4eba-82cd-0d0e044cc26e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9960eed-3f80-471b-bdfc-db5827176ccb" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.68%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
        <td style="width:1.1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:10.42%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding - January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1294232-c29b-42cb-a033-dd2e81529655" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,541</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d764bce-b811-426f-9e69-2a9e8f7f4926" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_26223a05-3bea-4c10-8437-475b5ac874f8" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e716a33e-7ea4-4912-b1ba-bf01ccaceac6" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,489</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92ba33ac-b462-4c68-91cc-5a4622e5141b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04ec116f-08bf-4d21-bde7-a2bdb993b7bb" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.83</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d556fe0-444a-495c-aaa5-c3d36936af5d" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e73668e9-2976-4272-8259-305c496c99a9" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c27bd20-646d-4664-a6d1-a352196f5773" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a926e6f-4934-46b3-90de-36528a770c52" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.74</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bafcd3e2-56ad-428b-82d8-5df7a20a4f7b" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">589</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f82f4403-533e-4988-a142-56ca6093a7b0" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55cbef81-0232-4584-92e7-8efd7529fb76" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3009b578-8e37-4135-9824-34480415c012" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9953972b-af40-4cca-aef7-9879728c4fd4" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_583d9f9a-1b61-4be9-b260-1c8c1da8823d" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5e57bab7-8e83-441e-919d-178ed8c1fbd8" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2e539db-0a54-4905-9578-cc01340b63f0" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">964</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c03853e0-eaba-427b-bdc9-76796e97f9bc" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e16359d-0392-4bf7-8cd9-777ffb6fe5a8" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.04</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_79b5d3eb-cb76-4982-822d-f2e295d448c4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9fdc184-611f-44e4-90b5-64a1a42cdda4" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Company&#8217;s common stock is determined based on its closing market price on the date of grant. The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ae80642-f7ad-4d8b-a3fb-538c6ae8e810" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9b7c7ae7-862d-4e81-bd02-a1392617eb86" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_4f0d9f50-1ef2-4f5f-8a4f-4c1cb778be51" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:21.080000000000002%;"/>
        <td style="width:1%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:21.080000000000002%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e54a6219-cdb5-44ec-a853-ffb6559a45b1" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.39</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4c0e9efb-6e87-45d5-9add-cf23896e1771" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.65</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d9295d8-a683-48d7-9367-3426ca5f3ef5" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">80.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e09869a6-4a3f-4f0b-963a-8da81d182a57" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk&#8209;free rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6caffce7-71b0-46c1-9f9e-6bf79e6efa80" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9c7ddf4-c15d-4de2-bf79-6b3fec4488ab" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1991822e-01df-4d79-9a4f-55529e380694" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit activity during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 was (in thousands, except weighted average grant date fair value per share):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:21.08%;"/>
        <td style="width:1%;"/>
        <td style="width:2.28%;"/>
        <td style="width:1%;"/>
        <td style="width:20.619999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b62655dd-57b0-4434-98ba-ffba986c7893" contextRef="C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_716aa073-86e3-4789-a2e1-4073a43f0fb0" contextRef="C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e175f1c3-a147-489d-8146-b34b4e63ff77" contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,474</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_259b7219-c32c-41d2-8a1f-6ad99f7962f1" contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cceeff;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e29be295-8ee2-4176-8b34-e69dfc5c1bfe" contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4698bc95-dbba-4987-a799-199b6d8a1762" contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.52</ix:nonFraction></span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Released</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f47a044-3c5d-4510-ad54-bbbbc8f80a8d" contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">710</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_027e1381-616b-43f6-8643-aa23a6042c87" contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29d425b2-d4d8-41bd-81dd-1da569bb508f" contextRef="C_458ca6db-5494-45ba-a80b-51438237e3b3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,729</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2538eb7e-f4d5-4d0f-b1ab-c68d3fb5aaf6" contextRef="C_458ca6db-5494-45ba-a80b-51438237e3b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.91</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_088b90c0-17e0-49b4-a134-a570f622a6fe" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 13 &#8211; Net Loss per Common Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c544bf5-0756-4e08-9526-adc6d90ee286" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted loss per share as of the dates indicated were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.647%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:14.757%;"/>
        <td style="width:1%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:14.757%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a29a0e1-c02c-4338-9ddb-cfb9364d07f4" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36aa9de4-8d61-4022-9589-95d10c8db282" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c473d4d8-f4a0-4e94-8284-2fcfc9135b17" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,113</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6beaa39d-2f78-4328-970c-f28e18daaaf8" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1abdafa9-b5e0-4172-b9ca-1421b0528b3a" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.64</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a0fd1bf-46c8-4e66-b50c-360a65262521" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.55</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The potentially dilutive securities as of December 31, 2023 and 2022 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our ESPP, the terms of which are described in further detail in Note 12 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The potentially dilutive securities would be subject to the treasury stock method when dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7e33aca-9429-4802-9a2b-bde694f5b3b7" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.6%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:15.18%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:15.22%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7e45569-9277-41eb-8f33-b1e54978875b" contextRef="C_21cb25e9-02bb-4719-b5c1-a096cb7c970b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58d67fac-01ea-4df3-86cf-15322aa295b4" contextRef="C_85c18ff1-b0e9-4dde-b440-56dc6c7fe909" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares committed under ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bee2fb9-d2b9-4fff-925f-4f914ce30a38" contextRef="C_2bb7dca5-b8b4-43e7-8305-8b91be0a1148" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0965edd6-e0ff-4cc6-b4b1-65a5e4369bb7" contextRef="C_18694c42-145b-4b80-97fa-d13aaaf257c8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b60a83ba-af31-4062-bc32-50b1aeb8a3b1" contextRef="C_704abf95-1ce3-4ffb-aa7b-013f8330fca8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,603</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb67d9ee-7997-4ee2-bb42-7ff0fa647c0e" contextRef="C_d6b06b8a-9d90-4601-bafe-371bd4da5153" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e665d72c-1363-40ac-90c0-9f538d728a25" contextRef="C_e88dd606-cce8-4094-846e-9bb4b5f5df2d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,729</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cf64b33-b170-46c7-8d87-a5e5a59323f9" contextRef="C_39626716-1586-4d2d-8868-a094e33c5618" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20063d2e-416c-49fb-a226-3ed709540abe" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,482</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_695ba3c1-e07e-49da-84af-22c9ec02596e" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_9e984d7f-7b4f-43b1-8d2e-b48941c851fb" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 14 - Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has incurred net taxable losses, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eac0993e-4f9b-49fe-b6e0-66a41a32cb83" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> current provision for income taxes has been recorded. </span><span><ix:nonNumeric id="F_a8e3b60f-7f43-4528-a962-4b287da2f884" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_a8e3b60f-7f43-4528-a962-4b287da2f884_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a8e3b60f-7f43-4528-a962-4b287da2f884_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.233%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14.683%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.081999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce7f6e7a-022a-4b0e-815d-7f1ff66eba44" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcc3f915-8ca1-4df0-82c4-f5d3af014983" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0d9bcb0-da1a-43b9-a4ca-354e626f1bb7" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd962c4e-00d2-410e-85ba-c62ddabaec65" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and developments credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d054acd6-68f0-4fe0-9977-d236755eb338" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77014037-9f8e-4720-b124-ca25a6f6ff3d" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_743b6b5d-2581-4dcf-adce-980d93346612" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80437afb-7525-447b-a608-13fb8851e2e8" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b6651d0-609f-4b2c-89f4-f6669fe0312c" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c5e04b-1b7a-4f08-84dc-9e8eef21d18c" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_0340475c-01e1-4045-ac17-287d2e6a5612" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.313%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:14.103%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:12.623000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e7fb119-0d65-4e90-92f0-6f4e8d69ab78" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a218a6b5-67ae-418c-b478-cd13d2a720b9" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,822</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbc9ea26-f820-43de-8613-6092e25e9b37" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2eff594-1ba9-489f-86c2-b732c4c1d869" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_407529cb-f09c-4411-a68d-d18e0ef6a4e4" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetInterestCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,120</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffad5133-2cf1-4344-9c38-da32d6adbc8b" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetInterestCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,036</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17620c61-2d15-42d6-bd4f-ef385652a694" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d707d17-06bc-414d-9b47-4a11784b1157" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:DeferredTaxAssetsCapitalizedResearchCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_804bef59-323e-470b-b0ac-251a1fc23742" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="bdsx:DeferredTaxAssetsCapitalizedResearchCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,874</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec5e8202-f40f-4f7b-ad75-48fe5901121d" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,685</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d63fff8e-8322-4556-9c6a-8524a1b550bf" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,619</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70425032-836b-4881-ab13-ae038cf172d7" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3be4d58-2a32-4f4e-b04e-42c68312ac84" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caeabb58-434b-4ae2-ae92-dae1047056c9" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,932</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4f10cf0-7fa5-481f-b138-5c1d684a77a9" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,022</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b043e63e-762c-4ed3-a4e3-242a77d36c03" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fb787e9-f534-4883-ab2f-2b95361b3d76" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b61e54b4-fa72-4893-bd38-9c36c8e68674" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a1e8808-bd5e-465b-bc4e-45db72633eed" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e57077be-66a1-47f2-9821-c0a27077a15d" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,772</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94bd1ff5-00a9-44f8-8556-401804ed5fd3" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-Use Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a573709-4aba-443e-9bd2-37422182e726" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5490404b-2268-4b85-b967-668ef6c46fe6" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,303</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80c1b722-91ee-4163-9d70-408d0ad9a00b" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,772</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bbb9c02-2f10-4060-b466-fbb48de02bfc" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5d46df6-26fd-4639-8c8d-7ca7a8d44eda" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,772</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company ha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c301da8-83d2-44f1-b3c6-d799071bb87a" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">310.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf331762-8824-4f0b-8b08-3286892e3bc0" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6f7a977-8869-47ee-8157-7d5880625afd" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:TaxCreditCarryforwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expire beginning in 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2c92d30-4808-4b4e-ac0e-b4f048bb9347" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45c0183e-89c8-4c33-bdc4-f2a3c4fb9467" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net deferred tax assets.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The valuation allowance increased</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_758207b8-c305-4764-ba0a-c6f64ff8356d" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5531eccd-dce3-47ca-9df8-36de3e3175b8" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2023, the Company determined that it has uncertain tax positions related to its U.S. research and development credits. As of December 31, 2023 and 2022, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d37280bb-a5c4-4e2d-bf91-d215172618ae" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3ff16bba-577b-4e6f-b5f5-1e429a4535da" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest related </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a19c07b-1570-4736-8b83-f904964b9da5" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true" continuedAt="F_0a19c07b-1570-4736-8b83-f904964b9da5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_0a19c07b-1570-4736-8b83-f904964b9da5_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.22%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:14.22%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:12.6%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b106a880-2a0c-45b4-be4f-ba91973088f9" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">952</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e44aa981-9772-4538-a98b-921f223b8b58" contextRef="C_762beb25-d2a5-4129-9298-0e23686a893a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions related to the current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1614d221-a384-45f5-8547-164ef50129bd" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b02fdf2-8b2c-4b19-bb16-319d4b166423" contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions related to prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_686eea42-a4ea-482a-8576-8262dee2c541" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions for tax positions related to prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions related to settlements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions related to a lapse of statute</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38d7adba-6bbb-4c14-98f3-8053bcce3d64" contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84c7dcd1-d96e-489c-9a7a-0ebf77b2f93f" contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">952</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. As of December 31, 2023, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b56383d2-2ec0-4ace-80e1-7dfbc17d35c2" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:IncomeTaxExaminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</span></ix:nonNumeric></span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1d751d0-deaa-4630-912a-969dd8d4a789" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 15 &#8211; Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Co&#8209;Development Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#8217;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_345543ca-cbb5-4cca-bd9e-dff2f1e12052" contextRef="C_aae49741-9ea1-4f75-bfc7-d624530d36a2" name="bdsx:PercentageOfDevelopmentAndRegulatoryCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41ebba61-6547-4d0b-b4c4-571ef79d793b" contextRef="C_677ab76d-419b-473f-b103-ff9ac04bad1d" name="bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the AVEO Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ab53077-f5cb-456f-9dd7-f40ebad469bc" contextRef="C_dbf7a7b5-3d35-4435-8e39-b2016e8d14e5" name="bdsx:RemainingEstimatedObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> remaining obligations related to the AVEO agreement as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Following the AVEO Effective Date, the Company is entitled to a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d38f111d-3e06-4a5f-ae6e-29499e98b65c" contextRef="C_829c0cf6-e0e1-4b9b-b982-f1e2c2517ed1" name="bdsx:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty of net sales of ficlatuzumab and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9ab6c0b-69c4-4b38-a600-ed7928a0ff8b" contextRef="C_829c0cf6-e0e1-4b9b-b982-f1e2c2517ed1" name="bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of license income generated from the licensing of ficlatuzumab from AVEO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0d9bf39-376a-4d71-9439-12e49113f731" contextRef="C_dbf7a7b5-3d35-4435-8e39-b2016e8d14e5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b7faa5fa-aff4-4181-8c94-abf54187cb93" contextRef="C_09d39f03-6b12-424b-8512-f460834da55b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalties received or expenses related to this agreement for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#153; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66745948-7e0e-4c15-acd9-cf3aae8ce338" contextRef="C_96996321-13b7-427c-bd23-e8321fa8a247" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company no longer paid a royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8764ae5c-aef5-47c9-9da5-ee9b5915da36" contextRef="C_c2f00f89-3407-44e8-b573-6c7ef85347d0" name="bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5586ab72-6c7b-4d1a-ba67-5a4446360a6b" contextRef="C_6f68a71f-ae27-4a7e-8505-b345faef0785" name="bdsx:LicenseAgreementExpiryDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Either party may terminate for the other&#8217;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There wer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab55f8fb-b800-4f2e-b1ae-21db7dd01173" contextRef="C_6f68a71f-ae27-4a7e-8505-b345faef0785" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4c7ab6f8-b573-4819-8411-3797b0b54fe4" contextRef="C_fbe102ae-9f7e-4e28-816c-b752eedef674" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to this agreement for the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 13, 2021 (the CellCarta Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly &#8220;Caprion Biosciences, Inc.&#8221;) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332e17de-9480-4263-990f-0ede8e33b479" contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047" name="bdsx:PercentageOfFeePaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% fee on net sales made from the first commercial sale of the Nodify XL2 test to the CellCarta Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d720f663-c8e6-4d2c-b2f5-6a670451fe21" contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">0.675</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on future Nodify XL2 test net sales worldwide for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b318718-b1d9-4bc5-a659-9f46cbaf6965" contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047" name="bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the first commercial sale, ending in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc1c875f-1547-462d-8a20-8d3efb12fa6d" contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047" name="bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Royalty expense under the CellCarta License for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efa292f2-d606-48c6-90ef-8d53b0dd712d" contextRef="C_732dfeaf-3c70-43c0-9cb2-16621b310dc5" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dac6a051-70a2-4538-8ced-b972f779c30e" contextRef="C_3384de12-4804-4762-b479-c95f25937875" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respective</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2019, we completed an acquisition of Freenome's United States operations (formerly "Oncimmune USA" or "Oncimmune") including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule malignancy test, then marketed in the United States as the EarlyCDT Lung&#174; test. We renamed and relaunched the test on February 28, 2020 as the Nodify CDT test. As part of the acquisition of the assets of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to the Nodify CDT test of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5317c85c-0f3e-41ef-86b2-7a480cd728fc" contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed" name="bdsx:PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of recognized revenue for non-screening tests up to an annual minimum volume and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25b141b6-6679-430f-8d05-a0c0b39bdda8" contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed" name="bdsx:MinimumAnnualVolumePercentageThereafter" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% thereafter, with an escalating minimum</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89c1e279-f1bf-4b93-9319-fbae5baa230e" contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed" name="bdsx:PeriodOfEscalationsOfSales"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through the first four years of sales</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Royalty expenses we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">re $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc07990-0ec9-41f7-b7ef-e1b5d1b66a67" contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_357ae5d3-d1a0-4f17-b837-25861af7054a" contextRef="C_6410b666-1ca1-4444-9f01-8f35821f9a25" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation, Claims and Assessments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a9b45d2-d0f5-43e7-802c-b3de39fb0c40" contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 16 &#8211; Subsequent Events</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Perceptive Term Loan Facility Limited Waiver and Amendment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 14, 2024 a limited waiver to the Perceptive Term Loan Facility was executed (the Limited Waiver), whereby, subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 29, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024 (the Third Amendment Effective Date), the Company entered into the Third Amendment to the Credit Agreement and Guaranty (the Third Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby subject to the terms and conditions of the Third Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2024 through and including the fiscal quarter ending December 31, 2025.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>2
<FILENAME>bdsx-ex10_34.htm
<DESCRIPTION>EX-10.34
<TEXT>
<html>
 <head>
  <title>EX-10.34</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.46in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.34</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:44.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:34.194%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limited Waiver</font></p>
  <p style="font-size:10pt;margin-top:6.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Limited Waiver, dated as of February 14, 2024 (this </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Waiver&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">), is entered into by and among B</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">IODESIX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, I</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">NC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Lenders party hereto constituting Majority Lenders and P</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ERCEPTIVE </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">REDIT </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">H</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">OLDINGS </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IV, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Administrative Agent&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">).</font></p>
  <p style="font-size:10pt;margin-top:1.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:44.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:34.194%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recitals</font></p>
  <p style="font-size:10pt;margin-top:6.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Borrower, the Guarantors from time to time party thereto, the Lenders from time to time party thereto and the Administrative Agent are parties to that certain Credit Agreement and Guaranty, dated as of November 16, 2022, as amended by that certain (i) First Amendment to Credit Agreement and Guaranty, dated as of May 10, 2023, and (ii) Second Amendment to Credit Agreement and Guaranty, dated as of August 4, 2023 (as may be further amended, restated, supplemented or otherwise modified from time to time, the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Credit Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">);</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, pursuant to Section 8.01(b) of the Credit Agreement, the Obligors are required to furnish to the Administrative Agent, as soon as available and in any event within five (5) Business Days following each date Borrower is required to file its Form 10-K with the SEC, the consolidated balance sheet of the Borrower and its Subsidiaries as of the end of such fiscal year, and the related consolidated statement of income, shareholders&#x2019; equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, setting forth in each case in comparative form the corresponding figures for such fiscal year (collectively, the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Annual Financial Statements&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">), accompanied by, among other things, a report and opinion thereon of an independent certified public accountant of recognized national standing (such report and opinion, an </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Audit Report&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">), which Audit Report shall not be subject to any &#x201c;going concern&#x201d; or like qualification or exception audit;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Obligors are required to attain a Minimum Net Revenue as agreed to in writing between the Borrower and the Administrative Agent as set forth in Section 8.15(b) of the Credit Agreement;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Obligors have advised the Administrative Agent that the Audit Report that will accompany the Annual Financial Statements of the Obligors for the fiscal year ended December 31, 2023 will be subject to a &#x201c;going concern&#x201d; or like qualification or exception audit (the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Audit Report Event of Default&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">);</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Obligors have advised the Administrative Agent that they failed to attain the Minimum Net Revenue required as of December 31, 2023 (the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Minimum Net Revenue Event of Default&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and, collectively, with the Audit Report Event of Default, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Specified Events of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;);</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Borrower has requested that the Majority Lenders agree to waive the Specified Events of Default; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Majority Lenders are willing to grant such waiver in accordance with and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.46in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">subject to the terms and conditions of this Waiver.</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">OW</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, T</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the premises and the mutual covenants and the agreements herein set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:44.533%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:34.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE I D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">EFINITIONS</font></p>
  <p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 1.1. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement.</font></p>
  <p style="margin-left:44.533%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:34.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE II L</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">IMITED </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">AIVER</font></p>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 2.1.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon satisfaction of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Article IV</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, pursuant to Section 13.04 of the Credit Agreement and subject to the terms and conditions hereof, the Majority Lenders hereby waive the Specified Events of Default. For the avoidance of doubt, this waiver is effective solely as a waiver of the Specified Events of Default and does not constitute a waiver of any other Default or Event of Default.</font></p>
  <p style="margin-left:37.16%;text-indent:25.417%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:20.296%;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE III Representations and Warranties</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In order to induce the Administrative Agent and the Lenders to enter into this Waiver, the Borrower hereby represents and warrants as follows:</font></p>
  <div style="margin-left:11.333%;text-indent:7.599%;font-size:0;margin-top:11.7pt;justify-content:flex-start;margin-bottom:0;margin-right:0.935%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.263514046939672%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">After giving effect to this Waiver, the representations and warranties of the Obligors contained in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Article 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Credit Agreement and in each other Loan Document shall be true and correct in all material respects on and as of the date hereof; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that any representation and warranty that is qualified as to &#x201c;materiality&#x201d;, &#x201c;Material Adverse Effect&#x201d; or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates.</font></div></div>
  <div style="margin-left:11.333%;text-indent:7.599%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:0.935%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.263514046939672%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Default or Event of Default has occurred and is continuing or shall occur and be continuing immediately after giving effect to this Waiver.</font></div></div>
  <p style="margin-left:47.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:33.333%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE IV Effectiveness</font></p>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effectiveness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Waiver shall become effective as of the date set forth above on which this Waiver shall be executed by each party hereto.</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:33.333%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE V Miscellaneous</font></p>
  <p style="margin-left:17.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.1.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reference to and Effect on the Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <div style="margin-left:11.333%;text-indent:7.599%;font-size:0;margin-top:11.65pt;justify-content:flex-start;margin-bottom:0;margin-right:0.935%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.263514046939672%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Waiver constitutes a Loan Document. On and after the date hereof, each </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.46in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:11.333%;font-size:0;margin-top:11.65pt;justify-content:flex-start;margin-bottom:0;margin-right:0.935%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reference in the Credit Agreement to &#x201c;this Agreement&#x201d;, &#x201c;hereunder&#x201d;, &#x201c;hereof&#x201d;, &#x201c;herein&#x201d; or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to the &#x201c;Credit Agreement&#x201d;, &#x201c;thereunder&#x201d;, &#x201c;thereof&#x201d; or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement after giving effect to this Waiver.</font></div></div>
  <div style="margin-left:11.333%;text-indent:7.599%;font-size:0;margin-top:11.15pt;justify-content:flex-start;margin-bottom:0;margin-right:0.935%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.263514046939672%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth in this Waiver, the Credit Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed.</font></div></div>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.2. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The headings in this Waiver are included for convenience of reference only and will not affect in any way the meaning or interpretation of this Waiver.</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.3. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Waiver, and all questions concerning the construction, validity, enforcement and interpretation of this Waiver shall be governed by and construed and enforced in accordance with the internal laws of the State of New York.</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.4. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Counterparts. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Waiver may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Waiver. Delivery of an executed counterpart of this Waiver by facsimile, DocuSign, or a scanned copy by electronic mail shall be equally as effective as delivery of an original executed counterpart of this Waiver.</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.5.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If any term or other provision of this Waiver is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Waiver will nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto will negotiate in good faith to modify this Waiver so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.</font></p>
  <p style="margin-left:11.293%;text-indent:7.593%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.907%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.6.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Waiver will be binding upon and inure to the benefit of and is enforceable by the respective successors and permitted assigns of the parties hereto.</font></p>
  <p style="margin-left:10.907%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Remainder of page intentionally left blank; signatures on following pages.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.94in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:11.107%;text-indent:7.485%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">N </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ITNESS </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the parties hereto have caused this Waiver to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:40%;border-spacing:0;table-layout:fixed;width:38.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.579%;"></td>
    <td style="width:68.421%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biodesix, Inc.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:14.4pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:14.4pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:57.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:40%;border-spacing:0;table-layout:fixed;width:55.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.818%;"></td>
    <td style="width:78.182%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ADMINISTRATIVE AGENT AND LENDERS</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CONSTITUTING MAJORITY LENDERS:</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PERCEPTIVE CREDIT HOLDINGS IV, LP,</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Perceptive Credit Opportunities GP, LLC,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">its general partner</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SANDEEP DIXIT</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sandeep Dixit</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Credit Officer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SAM CHAWLA</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sam Chawla</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Portfolio Manager</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.63in;min-height:0.76in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.95pt;text-indent:-3.15pt;padding-left:3.15pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.0125in;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>3
<FILENAME>bdsx-ex10_35.htm
<DESCRIPTION>EX-10.35
<TEXT>
<html>
 <head>
  <title>EX-10.35</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.35</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment to Credit Agreement and Guaranty</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Third Amendment to Credit Agreement and Guaranty (herein, this </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) is entered into as of February 29, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and among </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Lenders party hereto constituting Majority Lenders and </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Perceptive Credit Holdings IV, LP, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Administrative Agent&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recitals</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	A.	The Lenders have extended credit to the Borrower on the terms and conditions set forth in that certain Credit Agreement and Guaranty, dated as of November 16, 2022 (as amended pursuant to that certain First Amendment to Credit Agreement and Guaranty, dated as of May 10, 2023, as amended pursuant to that certain Second Amendment to Credit Agreement and Guaranty, dated as of August 4, 2023, and as further amended, restated, supplemented or otherwise modified prior to the Third Amendment Effective Date, the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Existing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Credit Agreement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">; the Existing Credit Agreement as amended by this Agreement, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Credit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	B. 	The Borrower has requested that the Administrative Agent and the Lenders agree to amend certain provisions of the Existing Credit Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	C. 	The parties hereto agree to amend the Existing Credit Agreement pursuant to the terms of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Now, Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incorporation of Recitals; Defined Terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The parties hereto acknowledge that the Recitals set forth above are true and correct in all material respects.  The defined terms in the Recitals set forth above are hereby incorporated into this Agreement by reference.  All other capitalized terms used herein without definition shall have the same meanings herein as such terms have in the Credit Agreement. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third Amendment to Existing Credit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon satisfaction of the conditions set forth in Section 5 hereof, the Borrower, the Lenders and the Administrative Agent hereby agree that the Existing Credit Agreement is hereby amended as of the Third Amendment Effective Date as follows:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">		(A)	The definition of &#x201c;Fee Letter&#x201d; set forth in Section 1.01 of the Existing Credit Agreement is hereby amended and restated in its entirety to read as follows:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">			&#x201c;&#x2018;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fee Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x2019; means that certain Fee Letter, originally dated as of the Closing Date, among the Obligors, the Lenders and the Administrative Agent, as amended and restated on the First Amendment Effective Date, as amended and restated on the Second Amendment Effective Date, as amended and restated on February 29, 2024, and as may be further amended from time to time.&#x201d;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acknowledgement of Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower hereby acknowledges and agrees that the Obligations owing to the Administrative Agent and the Lenders arising out of or in any manner relating to the Loan Documents shall continue to be secured by the Liens granted as security therefor in the Loan Documents, to the extent provided for in the Loan Documents heretofore executed and delivered by the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and nothing herein contained shall in any manner affect or impair the priority of the Liens created and provided for thereby as to the indebtedness, obligations, and liabilities which would be secured thereby prior to giving effect to this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representations And Warranties.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In order to induce the Administrative Agent and the Lenders to enter into this Agreement, the Borrower hereby represents and warrants to the Administrative Agent and the Lenders as follows:</font></div></div>
  <div style="margin-left:5.87%;text-indent:9.207%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.8202485923722516%;text-indent:0;display:inline-flex;justify-content:flex-start;">(A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">After giving effect to this Agreement, the representations and warranties of the Borrower contained in Article 7 of the Credit Agreement and in each other Loan Document shall be true and correct in all material respects on and as of the date hereof; provided that to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; provided further that any representation and warranty that is qualified as to &#x201c;materiality&#x201d;, &#x201c;Material Adverse Effect&#x201d; or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates. </font></div></div>
  <div style="margin-left:5.87%;text-indent:9.207%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.8202485923722516%;text-indent:0;display:inline-flex;justify-content:flex-start;">(B)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The execution, delivery and performance of this Agreement has been duly authorized by all necessary corporate action on the part of, and duly executed and delivered by, the Borrower.  </font></div></div>
  <div style="margin-left:5.87%;text-indent:9.207%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.8202485923722516%;text-indent:0;display:inline-flex;justify-content:flex-start;">(C)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Default or Event of Default has occurred and is continuing or shall occur and be continuing immediately after giving effect to this Agreement.	</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conditions Precedent.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The effectiveness of this Agreement is subject to the satisfaction of the following conditions precedent:  </font></div></div>
  <div style="margin-left:5.87%;text-indent:9.207%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.8202485923722516%;text-indent:0;display:inline-flex;justify-content:flex-start;">(A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Agent and the Lenders shall have received executed counterparts of this Agreement and the Third Amended and Restated Fee Letter, dated as of the Third Amendment Effective Date, in each case, duly executed and delivered by the Borrower.</font></div></div>
  <p style="margin-left:14.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reference to and Effect on the Loan Documents; No Novation.</font></div></div>
  <div style="margin-left:5.87%;text-indent:9.207%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.8202485923722516%;text-indent:0;display:inline-flex;justify-content:flex-start;">(A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Agreement constitutes a Loan Document.  On and after the date hereof, words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to the &#x201c;Credit Agreement&#x201d;, &#x201c;thereunder&#x201d;, &#x201c;thereof&#x201d; or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement after giving effect to this Agreement.</font></div></div>
  <div style="margin-left:5.87%;text-indent:8.924%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.106023584404547%;text-indent:0;display:inline-flex;justify-content:flex-start;">(B)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth in this Agreement, the Credit Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed.</font></div></div>
  <div style="margin-left:5.87%;text-indent:9.207%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.8202485923722516%;text-indent:0;display:inline-flex;justify-content:flex-start;">(C)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly set forth in this Agreement, the Loan Documents and all of the obligations of the Loan Parties thereunder and the rights and benefits of the Administrative Agent and the Lenders thereunder remain in full force and effect. This Agreement is not a novation nor is it to be construed as a release, waiver or modification of any of the terms, conditions, representations, warranties, covenants, rights or remedies set forth in the Loan Documents, except as specifically set forth herein. Without limiting the foregoing, the Loan Parties agree to comply with all of the terms, conditions, and provisions of the Loan Documents except to the extent such compliance is irreconcilably inconsistent with the express provisions of this Agreement. This Agreement may not be amended, supplemented, or otherwise modified except by a written agreement entered into in accordance with Section 13.04 of the Credit Agreement. THIS AGREEMENT, THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENTS THE ENTIRE AGREEMENT AMONG THE PARTIES</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> with respect to the subject matter </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:5.87%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;min-width:8.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The headings in this Agreement are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  THIS AGREEMENT, THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER, AND ALL CLAIMS, DISPUTES AND MATTERS ARISING HEREUNDER OR RELATED HERETO, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS EXECUTED IN AND TO BE PERFORMED ENTIRELY WITHIN THAT STATE, WITHOUT REFERENCE TO CONFLICTS OF LAWS PROVISIONS (OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW).</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Incorporation of Sections 13.10 and 13.11 of the Credit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The provisions set forth in Sections 13.10 (Jurisdiction, Service of Process and Venue) and 13.11 (Waiver of Jury Trial) of the Credit Agreement shall apply to this Agreement in all respects.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart.  Delivery of an executed signature page of this Agreement by facsimile transmission, electronic transmission (in PDF format) or DocuSign shall be effective as delivery of a manually executed counterpart hereof. The words &#x201c;execution,&#x201d; &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in this Agreement shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement will be binding upon and inure to the benefit of and is enforceable by the respective successors and permitted assigns of the parties hereto.  </font></div></div>
  <p style="font-size:10pt;margin-top:20pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Pages to Follow]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.</font></p>
  <p style="margin-left:23.333%;text-indent:-4.545%;padding-left:3.333%;font-size:10pt;margin-top:28pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:40%;border-spacing:0;table-layout:fixed;width:48.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"></td>
    <td style="width:75%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biodesix, INC., as Borrower</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:14.4pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:14.4pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:40%;border-spacing:0;table-layout:fixed;width:55.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.818%;"></td>
    <td style="width:78.182%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ADMINISTRATIVE AGENT AND LENDERS</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CONSTITUTING MAJORITY LENDERS:</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PERCEPTIVE CREDIT HOLDINGS IV, LP,</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">as Agent and Lender</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Perceptive Credit Opportunities GP, LLC,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">its general partner</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SANDEEP DIXIT</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sandeep Dixit</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Credit Officer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SAM CHAWLA</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sam Chawla</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Portfolio Manager</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Third Amendment to Credit Agreement and Guaranty]</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>bdsx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:20pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-265445, No. 333-269536, No. 333-249805, and No. 333-276842) on Form S-8 and (No. 333-265448 and No. 333-261095) on Form S-3 of our report dated March 1, 2024, with respect to the financial statements of Biodesix, Inc.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Denver, Colorado<br>March 1, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>bdsx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Scott Hutton, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43%;"></td>
    <td style="width:1%;"></td>
    <td style="width:4%;"></td>
    <td style="width:52%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 1, 2024</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SCOTT HUTTON</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott Hutton</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>bdsx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.88in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Robin Harper Cowie, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;"></td>
    <td style="width:1%;"></td>
    <td style="width:4.52%;"></td>
    <td style="width:49.48%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 1, 2024</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>bdsx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Biodesix, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:1.28%;"></td>
    <td style="width:3.84%;"></td>
    <td style="width:44.88%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 1, 2024</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SCOTT HUTTON</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott Hutton</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>bdsx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Biodesix, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:1.28%;"></td>
    <td style="width:3.84%;"></td>
    <td style="width:44.88%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 1, 2024</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>bdsx-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Biodesix, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this Policy on Recoupment of Incentive Compensation (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company.  This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) rules and Nasdaq Stock Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dodd-Frank Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee.  Any determinations made by the Committee shall be final and binding on all affected individuals.  The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act.  The Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or the Committee may amend this Policy from time to time in its discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="a154254"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executives</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to any current or former &#x201c;executive officer,&#x201d; within the meaning of Rule 10D-1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company (each such individual, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Upon Financial Restatement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Committee shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No-Fault Recovery</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Subject to Recovery; Enforcement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measure that is derived wholly or in part from such measures, whether or not presented within the Company&#x2019;s financial statements or included in a filing with the SEC, including stock price and total shareholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), including but not limited to performance-based cash, stock, options or other equity-based awards paid or granted to the Executive (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting, or a bonus awarded solely at the discretion of the Board or the Committee and not based on the attainment of any financial measure, is not subject to this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Financial Restatement, the amount to be recovered will be the excess of (i) the Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) based on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation Committee.  For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, or any transition period that results from a change in the Company&#x2019;s fiscal year (as set forth in Section 5608(b)(i)(D) of the Nasdaq Listing Rules).  The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or authorized officers of the Company if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For Incentive-Based Compensation based on stock price or TSR, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to Nasdaq.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">								</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may use any legal or equitable remedies that are available to the Company to</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive.  Executives shall be solely responsible for any tax consequences to them that result from the recoupment or recovery of any amount pursuant to this Policy, and the Company shall have no obligation to administer the Policy in a manner that avoids or minimizes any such tax consequences.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy or any claims relating to the Company&#x2019;s enforcement of rights under this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exceptions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The compensation recouped under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive at any time during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because (A) the direct expense paid to a third party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the erroneously awarded Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company&#x2019;s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Remedies Not Precluded</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The exercise by the Compensation Committee of any rights pursuant to this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy, whether arising under applicable law (including pursuant to Section 304 of the Sarbanes-Oxley Act of 2002), regulation or pursuant to the terms of any other policy of the Company, employment agreement, equity award, cash incentive award or other agreement applicable to an Executive.  Notwithstanding the foregoing, there shall be no duplication of recovery of the same Incentive-Based Compensation under this Policy and any other such rights or remedies.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acknowledgment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent required by the Compensation Committee, each Executive shall be required to sign and return to the Company the acknowledgement form attached hereto as Exhibit A pursuant to which such Executive will agree to be bound by the terms of, and comply with, this Policy. For the avoidance of doubt, each Executive shall be fully bound by, and must comply with, the Policy, whether or not such Executive has executed and returned such acknowledgment form to the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date and Applicability</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy has been adopted by the Board on October 9, 2023, and shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img35377828_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img35377828_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+!#4# 2(  A$! Q$!_\0
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MF*\CI/\ A9>K8_X];;\S2?\ "R]7_P"?6V_,US7]C:E_SXS_ /?!I/[&U/\
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M6/\ H&W'_?!KN]E1[')[2J=5_P +8UO_ )]+7\S1_P +8UO_ )]+7\S7*_\
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M@   < #M734G[-<D2$N;4J66EV6G1JEI;1Q #&57D_4U<HI:Y6[[F@E+110
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MB7;G.)P,^M9\G^ND_P!\_P ZZ$>345D2+>74:A$N950<!0YQBE^W7G_/W/\
M]]FJ]+3L3SR+MI?7?VVW!NYCF5>KGUKW>+)A0G^Z*\!M/^/ZV_ZZK_.O?X?]
M0G^Z*Y<3;0]S*&VI78^BBBN8]H7%&*2B@!<4E%% #9(TE0JZ*RGJ&&:YK6O
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MY17D7_"0ZO\ ]!&?_OJC_A(=8_Z",_\ WU6?L9%>T1Z[17D?_"0ZQ_T$)_\
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M(-7T\7^(HP NL71 [%J;P4MTR?K*6Z/HNBOG?_A-?$G_ $%[G\Z/^$U\2?\
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML]134[QQYFH!TQ*0W'0^ZYK"<YQ>AI%19R5KH6K7HE^S6$TGE-LDVK]UO0U
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MSX12>S"H=.U:VMI]+G>YA\R&TEW MP&.>*7/(I8:EI[VYR TZ];R=MM*3/\
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M\CL>9^(_&8N+=M*T-6M=.4[6<</-]:X[I7L/_"H=(S@7UWCTR*7_ (5#I/\
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M_P"?NY_[Z%'_  K'3/\ G[NOS%/V\!?V9B>R/+L#OCGO1@'M7J/_  K'3/\
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M?2 T7"QQDKZY96CRRW<K+(JF1G 'E_.<[??;BI]/GN=4\/ZU&ES-.,NEO(P
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MT8/K0 M%)@^M&#ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKQJUBEL-=\-W>HVEM;0L0L;6F-SGL7KV3/>IK4U!JQ5.?,M1U%%%9&@4444
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MWVZ'_:_*C[=#_M?E0!9HJM]NA_VORH^W0_[7Y4 6:*K?;H?]K\J/MT/^U^5
M%FBJWVZ'_:_*C[=#_M?E0!9HJM]NA_VORH^W0_[7Y4 6:*K?;H?]K\J/MT/^
MU^5 %FBJWVZ'_:_*C[=#_M?E0!9HJM]NA_VORH^W0_[7Y4 6:*K?;H?]K\J/
MMT7^U^5 %FBD#!@".AI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I,#T%!ZURFJ:E>VVLW\<(EE06N0JM@1G^]32N)NQU
M>!Z"CCT%<I!XCF@M(5$0F\F)6G=WP>?3UI[^+UB<+):D,,YYZ?W?SI\C%S(Z
MCCT%&!Z"L>\UB:VLK-UM@;BZQA&; 4XSR:J7?B.YM6*"TC9XXO-F'F]![>M'
M*QW1T>![48'H*Y<^*I\-(+)3#&L;2MOY ;TJ]JNNMI=PD9MRXECW1G/WF':E
MRL+HVL#T%&!Z"N6/BYGA$D%GNWOLC+-@''7FK-[JAN/#\5YLEA9I%!56P1SZ
M^E/E8<R.@X]!1@>@KF/^$EO&D5([%2KN8HR9>K =Z0^*9W\I(+.,NT1D??)@
M+@\@>M'(Q<R.HP/048'H*YN+Q/)<>8\5IF&*+S9&+<X]!35\43+GSK-1\JR9
M23.$)ZGWHY&/F1TV!Z"C ]!7+2^+GPA@L]WF$M&6? 9!WJSJ^JW:Z/:W5K'Y
M;2R(&#G!7)Z4<K#F1T'R^U&!Z"N2M-8NK*]N#/%OMWN COOR4..@'I5W3_$<
ME]J(@^R%868JKALD$>H[4.+$I'08'H*,#T%<W?:U<RQZA'' 4AM2%>59-K9)
M[5!)X@F;S++R?+'E?+*S_,QQV]:%%CYD=7\OM1QZ"L+PYJC7VE[W3Y8%VEBV
M68CJ2*JIXIF:6/-DICFW>45D^; ]11RL.9'3X'H*,#T%<L/%4[6+3"S7S%<*
M4\S[H]_2EE\5L)XUAM1*NQ7DVOZ^GK3Y)"YD=1@>@HP/05S8\32FYN8C9X\M
M"R*7^9L#TJ./Q3<2P0^79QM/(S*4\WA<#/-+DD',CJ,#T%&!Z"N8C\5N(_,N
M+/9&\9>/:VXMC@YHC\4W#Q+_ * /-9PJ#?\ *<^]')(.9'3X'H*,#T%<J^NW
M\]Q9+%;I&3<&*5=_4CM74]J35AIBX'H*,#T%)GG\*Y7QQJ%WIT.E26C2;FO%
M5HT./,&#\M$8\SL#=E<ZO ]!1@>@KSG3_%M_:G5)9H9))Y;U(+>WF? B)!X)
M["K<GQ"DMK<//IWS@O&VQ\CS%.-H/?-:>QGT(]K$[OCT%''H*YO1?%0UBVN[
ML6ICMK= 2P.26QEE_"L]/&MV-'EU2;3X1;N0+8+,"S9.!N':I]G*]K#]I$[3
MCT%''H*X5?'=XJW$4VF1?:H9HX=J3 J2_O6OIOB*ZOM%O[EK$+>V;M&]NKY!
M(YX-.5*4=P4XO8Z/CT%''M7!P?$>*ZN!!!8,SLZJO/WO[Q'TJ[H'C.76M6%L
MVG[()0WE2J^<;?[P[4W1FE>P>TB]#K\#T%''H*XV;QM(GB*33XM/,EO%,(9)
M WS GOCTJ*U\=74TT;2Z8%M9C*D+))EG9,]NV<4>QG:]@]I'N=OQZ"CCVKA[
M/Q[)-:+-/8QQN;E8#&)<E >[>E2MXUN)KZ.SL[!)99;AH$+28!V]\_A2]E/L
M'M(G9\>@H^7VKB[3QQ-=:V+'^SB81+Y,DBOEE?N<>E1^*-7U6#79+*#:MH;%
MY"0^#Q_%]11[*5[![1'<?+[48'H*\]TSQM<Z=HZQZC:%I([-9HG5\F5>F3Z5
MO^'O$D^KV=T]Q9>1-;C)PV5<8R,&B5*4=052+.CP/04<>@K@)?%%Y?V.FZA-
M;26MM+=JL?DS<OUSD>G%!\=7-WLB-BD4%XLGV>42_,N.[#L::HS>PG5BCO\
MY?:C ]!7FVE^*=5B\/I9O /.-D\UO<&7)<*3DGTK;_X2:\TWP+;:Q=VZRW#;
M05#\-DXSFDZ4D[#51-7.NP/048'H*X<^.[F."6&;3XQ?K(B(B2YC._IENU4[
MKQEJ]W:@VUK%!+#?K;38EW ^P/O35&8O:1/1,#T%''H*\]3QA-IEK(J02W-U
M-=NBK/-\JX&3@^E69_'5WA3;:3N*VIN91))M*J#@X]:?L)WT!5(V.YP/048'
MH*X_0M>U'4_%%Q&T:"Q-NDJ+OY3(S78CI6<HN+LRU)/83 ]!1@>@I:*D8F!Z
M"CCT%(:J:F[1:9=.C%76,D,.HH%)\J;+G'H*./05PMEKMZSZ0;A9TB$#O(QY
M\[%75\7W"Q[Y+!</&9H@DF<H.N?0U?(SG6*AU9UG'M2X'H*YBQ\6KJ&HQ6D%
MJ2TK95B>/+_O5:FUNX_M=[*UMHWCAQYSO)M//H.]+D=[%+$4W'F3T-W ]!1@
M>@KE8?%<\L\&ZR06]P7$3B3+?+ZCM4^E>(Y[Z\@BGM%ACN%9HF5\DX/.?2AP
M:".(IMV3.CX]J,#':N7O?%ZV%W-!/:D&&3$A!Z)C(;^E1/XOG$L:)I^3@,X+
MX(4G@CUXHY&P>)IIV;.MP/04?+[5@:SJ2VEYI\I\[:P9MJMC.%SR.]9">(KD
M:FM[<PB.!;(R+'')NW G@GT--0;%/$0A+E9VW'H*,#T%<DGB^X-H\CZ=^]RH
M0*^58-[^M1S>(M2FEM8X[=(I%N_)F429!X/ -'(P^M4[71V)VCKBC ]!7!B]
MO;N^LH(FF\G[3*6#3?,Q4]/I[5NZ5XB;4]0-F+8H\2G[1D_ZMAT%)Q:"&(C)
MF^=H]*,#T%<7K>OW5PS16\0C@BO%A:428<L.HQZ>]/3Q'+86<92%YE>9U=YI
M?N8QWI^S=B7BZ:E:YV/'H*,#T%<LOBUI-1,4=F7ME?RVD5OFSC.<>E%OXJN)
MIX UD@AN!(8B),L=OJ*.217UJGW.IP/048'H*Y)?&,AL7D>T1;@R^6D7F=/]
M[TK=T;47U.Q\Z2 PN#M9<Y'X'N*3BUN5"O";M%FA@>@HP/04M%2;"8'H*,#T
M%+10 F!Z"C ]!2T4 )@>@HP/04M% "8YI:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!#5=K*V>664PJ9)4\MV]5]#5@U
MRVK:Q?VVJO%&XC"%?*C*$^=GKS32N)FM)I>DRSQ(UO"TL*C:O<#M5B72[&9W
M>6UC9I,;B1UQTK%T6";^U]5N93F48 R.AQFJ$6OZD$NFD8$Q."Q5<@+FJLV*
MYUEW8VM]"(;J%9$'(![56DT/3)5C$EG&PC&%Z\#TKG;OQ!?F*>:WD41+. I(
MP2N.U,E\0:@+J0)< %%C*0F,YD)ZCVHY6%T=,FEZ:T<D26\15L*ZCVZ9J>6V
MM+F6,2QQO)#\R \E?>N3&IWEOYFS9:I+<'S)MI.VG7.HW=O>RRP[6=HX@]P$
M/RJ>K8HY6%T=*^CZ=+:_96M8S"&W!<< U*;"U:T2U:!/(3&U.PQTKF8=>O4,
M+SR;K82.AG5,!QVJ%M?U,)8R%U"RGD;>3SZ=Z.5A='3BQTZ.5(Q#$L@8R(O?
M/<BJ4OAJSFU!9GBC-NL>T0X[YSFJ6M33PZNEQ;@F5+1V7BJTNOWL[D6D@VMY
M2ABG )/-"BPNCJ(["TBWF.W1?,78V!U'I44&CZ?;),D5JBK*,.,=1Z5SDFLZ
MI$3;RSH@CF:-KG9D$ 9'%6X-7O9/";7H8-<AB V..M#B]PNC7GT;3[B"*"6T
MC:.+_5KC[M3S6=M- L,L2M$F"JGH,=*Y>75]5M1)!)*K?,I-P$.(P0.U1OKF
MHM;1J\HBB9F NO+.),=!BCE871TZ6.GSH72&-U:3S"1R"P[TVVT_3H+Z6:WA
MC6Y_C*GD9]JY/3]8N=.TV-6.U'AD>,E>K[J#J5_;?:[J%3YDOE>8Y'"Y7DT<
MK%='8FPM"LR^0A68YE']X^]5QI6DO=,P@A:<+@C.2!7.3:YJ\=M9R2-&JNQ!
M9.=PS@?6M+3["-_$$UW&ZIY0RR#.YBW))HLT.]S:M]/M+5RT$"QDJ%.WN!4"
MZ%I:2M*MG&')))YK0 _*EQ478[&:-!TL0F$6<>PG)'/)IS:)IK21.;2/=$ $
M..@%:%%.["R,_P#L73O-DE^R)OD!#-W(/6EAT;3K?;Y5I&NTD@@=,\&K]%%V
M%D4AI-@%1?LL>U%*J,= >HID.BZ=!&$CM$50^\#T;UK0HI7861473;-9%<6Z
M!E<R ^C'O5JEQ10,3O5:[L+6^\K[3 LIA<21[OX6]15GO7,^,=5O=-@LQ:RB
MWCFFV37)3<(QCTJHIMV1,G979IS:!I5S'<QS6,3+<,'F!'WF[&A- TF.UAM%
ML8?)A?S(TQ]UO6O/&\9:^VCPNDD9#7$B-=%=H^4_*/;-7Q<:Y/X@TJ]FF5)6
MT^20H@)0X_QK9TIK=F:FGLCO;73[2QA>&UMXXHG8LRJ."3U-9@\.^';5I8OL
M5NAO,JRDGY_8#-9'@S6M2UBUU".]E#31<*ZC*@D'O_2N9L[?5)(M."7;"8W\
MP21U)V8[U*@[M-E.2ML>A6WA;0[1-D&G0HNY7[\LO0_A5^VL;:T\[R(5C\YR
M\F!]YCW->;7OB[Q"ME8A#'&S;U>=AM#L#P/:NFUK4]8ATW1_(,<%W>2I'*<;
ME7/>APELV$9)]#8MM&T>WN4:VL[=9H-VW:.5W=?SIEMH^BZ3?FYM[:&VNK@D
M;LX+'O@5QM_J6I:3J&IB(HK[XDFO"A.T$\MBJ U+5-=FL1]L1Y8;]XXKD1D#
M;M'.*I4I/KH2YI/8]%?0-)DU4:D]E$;W_GKW-"Z#I02.,646V,LR+Z%OO$?6
MN&AO=8U35/#TL]R4=;B6)]JD!MO<_45I>(#J$'C19[>X94CT^20+@[<C/'UJ
M>62LN8?,NQT*^%-#2TEM5TV$0S,&=>?F(Z&I;7P]I%D\3V]A%&T+%HR <J3U
M(KB;SQ!XCLO#^GWCSQL;ULO)LVB$8X'XFFW_ (HU^&VM3<31V3FU:4,L9D69
M\\ 8]N:;IS?4.>/8[E?#^DKJO]I+91"\Z^:.N?6I[G2[*[G\^XMDDE\LQ;B.
M=AZBO.C?:RVJ1ZH+EA)_97FE"IQG/3\ZD?7?$\*L[7L3*D,5P1Y)RP8C*_K0
MZ3[@IKL=VV@Z4R;6L8BHA\C!'\']WZ4_3]'T_2[5[:RM4AA?.Y1WKB#XH\0R
M>*7M4CB2,-M6!S@LN"=PI+/6O$%PT'G72&*^2:,+Y9!B*]#2=*75A[1=$=O_
M &+IHM(+86D0A@;?"F.$;U%<W8^ U@UW[?<RV[Q*6(CBB*EL_P!XYYJ'1;K4
M]-^&K74>ZXND1FC#@DJ,_KBL>'Q;K(2]\J]6[2".-Q(L14@'[W'M5QC/5)BE
M*.C:.^;1]'A6%6M84"QF",'CY3U4?6JOB#1+:\\/+IXDCM+:-T;+#Y0H/2N2
MF\07.JZK$519[:.^C$#%2.,=1^-0WFL:CJNA:NEY>+YNQPUB(B&BP>.:E4Y7
M6H.:ML=F/#_AZVTT6+6ENMO<,#M)_P!8W8@U/'X?T2RM3&EC#%"L@E([!AT:
MN&2]O-2T[1!<RD7L=VJM$$(\G@8^OUK0MM0U'66U.QU15^SZ?$PGQP)7R2/P
MQBAPEU8<R['3OH&@ZG9&,V=O-;O(9?E.06[G(JP-"TL?\N4?^I\CIUC_ +OT
MJAX.TG^RM%&)ED^T-YH" A5![ &N@Q6<FT]&:12MJBG:Z78V4IEMK9(W*",L
MH_A'05=I,4M1=E)!0:*#0 P]1]:22-)HVCD4,C#!![BG-VJKJ<SV^FW,T7WT
M0E?K03)\L6V']FV:B#%N@\@%8AC[H/85#;:)IEFTI@LXT,HP^!U'I7)VWB+5
M&M)F2X2X;[*96*QD>2^> ?K5F_U/5K+RHY[U(MT?F+)Y9(D;^X*OE9S>VA:_
M*=1;Z78VKI)!:QQO&GEJP'W5]*;<:1I]W=I=3VJ/.GW7Y!XKD-2\1ZI$DKM,
MEHZ1*R0NF3(3UJ[_ &GK#0ZE=QN&2V^6.+;R?E!R:?(^XE7IO1(W4T#2H[@W
M"648E))W<]^M6(M-LX&B>*V1&B!$9 ^Z#UKC8]=UIM$GN#)"=KKMEW>O4'TJ
M<>(-1-WIQ+CR9E 9=OS$DXZ=Q[T<K!5Z:>D3IWT_3KYI9WMXIC(OENW7< >E
M-FT33+F6&::TC9X@%0G^$#I7(KJ]];6B(CI9QYE=7*$AW#'"U9EU?6I%>X5E
MB$*QLT1C.6SC-'*^X>V@_LZG73V=O</')-"CO'G83VSQ52W\/Z5:L[0V,:,Z
ME6ZG(/:LKQ-K%_8V]F;15C67EY'X"\=,UFW>O:O'%'YTL=JXMS(N$WB5NP%)
M1;14ZM-2LXW9T\6AZ5;0-'':1I%N#L.V1WI\=GIDLGF110N^\2Y4_P 79JYZ
MWO=4U%;GS)0D"6BNR;>69D.169;:C?:=I6^U@'F+;0@NP.5!'4T^5]S-UX*W
MNZ';QZ7912K)';(KHS,K =">IJKI-C#8W5X6GCDNKB4R/C@A>PQ7/VFK:W="
MRA\V)1/(R^</FRH_K5^TTE&\423QRJH@&Y\9WNS=<GT]J5K;FD9J33C$UIM
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M&8HR #$I Z J.*4QH008U(/48I]% $9BC(4>4F!T&WI3@JAB0H!/4@=:=10
M@I:** "BBB@ HHHH **** "BBB@!#6?K&CP:U:K!.\B!6W*R'!!K1HH3L#5S
M-TW1;+3-/6RAB5H@2Q\P9W,>I/O5[RDR,(HP, XZ#TJ2BFVV))(C2&.($1QH
M@/4*H&:/*0=(UXYX6I**0R%K>%@%:&-E!S@H*>8U.,JIQTR.E/HH"QGZII-O
MJMHUO,&0$AMZ<'(J/2-"L]&M#!;H6W.79Y.69O6M2BG=VL*R(_*0$$(O'(^6
ME9%8Y* G&,D4^BD,B:&-T\MHD9/[I4$?E08(F #1(0O0%0<?2I:* (_)C_YY
MITQ]T=/2@PQ_\\T/&/NBI** (O(B,@D,2%P,!MHS^=+Y,8QB-..GR]*DHH"R
M&!%"[0H"_P!T#BJ$6BVD.JS:@B8DFC$3)@;<#VK2HH3:"R(EMX5P%AC&.F%
MQ2&"'+-Y*;F^\=@R:FHH"R(O)CW;O*3/KM%4]-T>VTN*=(@S^?(9)&DY+$^M
M:-%.[%9"*H50   .@%+112&%%%% !1110 A%0W,"W5M) ^=KKM./2IZ*!-7*
MMI8PV=LD$<:A5&.@R?KZU*\*2 ;XU;'3*YQ4M%.X**2L8]_X>M-1NEGG:3'
M:,?=8#UK46%$3:J #&,8J2BB[)4(K5(B^SPA"GDIL/5=HQ1Y$>0?+3*]#MZ5
M+12N59$301, &B1@#D J.M.\M"?N#GKQ3Z* LB-XTD7:Z*R^C#-(88VQNC0X
MZ97I4M% 61&(U&<(HSP>*/*CP08UP>",5)10%D1K#&F-L: #IA>E."*&)"@$
M]2!UIU% [!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img35377828_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img35377828_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'V!:H# 2(  A$! Q$!_\0
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MK6?M92^"-T=7U*G32^L5.63Z6O\ >>4;*-E=]XVN/#.HV=O>Z8 +^4Y81+M
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MN#[CH?S[UROP<\K^W=?SCS<+M_W=S9_7;7;^"_%UMXE\/Q7,LL<=Y'^[N4)
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M?& J)D]>,\T2>NFX)::GS_1116Q 4444 %%%% !1110 4444 %%%% !1110
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MN[7[-;)Y2Q+)\QC&#AB!7GGBWQOX1UGPW<V.E:'):WDA0I*;2) N&!/*L2.
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M!*L13**  DDDDY)[T444 *K,C!E8JPZ$'!I9)9)G+RNSL?XF.33:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&BBBOH3YX***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^(_^?W2O^_LG_P 11_PI?Q'_ ,_NE?\ ?V3_ .(KW6BCVD@Y4>%?\*7\1_\
M/[I7_?V3_P"(H_X4OXC_ .?W2O\ O[)_\17NM%'M)!RH\*_X4OXC_P"?W2O^
M_LG_ ,11_P *7\1_\_NE?]_9/_B*]UHH]I(.5'A7_"E_$?\ S^Z5_P!_9/\
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M5_W]D_\ C='_  I/Q)_S^Z5_W]D_^-U[S11_:%?R#ZC1/!O^%)^)/^?W2O\
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MUK_\*\U7_GXLO^^W_P#B:]*HJ'C:K=V<E7(\)5FYR3N_,\U_X5YJO_/Q9?\
M?;__ !-'_"O-5_Y^++_OM_\ XFO2J*7URJ9_ZOX+L_O/-?\ A7FJ_P#/Q9?]
M]O\ _$T?\*\U7_GXLO\ OM__ (FO2J*/KE4/]7\%V?WGFO\ PKS5?^?BR_[[
M?_XFC_A7FJ_\_%E_WV__ ,37I5%'URJ'^K^"[/[SS7_A7FJ_\_%E_P!]O_\
M$T?\*\U7_GXLO^^W_P#B:]*HH^N50_U?P79_>>:_\*\U7_GXLO\ OM__ (FC
M_A7FJ_\ /Q9?]]O_ /$UZ511]<JA_J_@NS^\\U_X5YJO_/Q9?]]O_P#$T?\
M"O-5_P"?BR_[[?\ ^)KTJBCZY5#_ %?P79_>>:_\*\U7_GXLO^^W_P#B:/\
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M***Y3VPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%<CI/BT?V_>Z3J#A=MU(EO*>!C<<*?Z&NNJYP<'9F&'Q-/$1<J;VT?D%%%%
M0;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17%?$G_D%V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/E7+C]Y&6QN/MV.?0U,)I5+R=W;<UKX:<\&E1IN,>:[CN[>E_P -#A[N318
MDVCS:I%=(P*F<)C\"IR/UKU70-0?5-"M+R3'F.F'([L#@G\Q7+VUGXZN[F/[
M3>BU1#G<?+/_ (ZHY^AKN5!5%#-N(&"?6IQ$TTEN_6_Z&V48><)RG9Q3Z./+
M\[<S%HHHKD/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4C)X)X/>JNNKX\TVS3Q#>:HT2,RDV\,Q BST#)C:?3O[UJ?%O_6Z%_UTD_\
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M=.JGY(VR.1C[H'.>@Z<5HHW<U;J]=/Q(;MRNYV>NZE?0_%?2;.*]N4M72,O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5QGQ(_Y UI_U\?\ LIKLZXSXD?\ (&M/^OC_ -E-73^)
M$RV.<EU;6O$R0:#Y%O&05XP4.%'4[CZ<\<UT'B[[3H?A?3;>TNYHVB=8S)&Y
M0L I].U4_$]A+IXTSQ#9+AXTC$N/4 8)^O0_A4WC>^AU+PMIUY <QRS CV.T
MY'X'BM=VK;$;)C_%NL:A9V>EP0W#V\-Q&#+<+G=GC//7OGCDU>\*IJ0N96.L
MQZCINT%7+%GW'MSRN/0^WX,UW518Z;I\-UI)O-/DB7SI",A>!C'H>_./;VQO
M",#2^*I+O2H+B'2MI#>:>V/NY[_-]>*FWN#^T1:=JEMH_C/6[RY;"J)@JCJ[
M>8, >];'AR/5]=U!M9OKJY@LMV8;:.5E5\>P[#]36)9Z1!K?C'6K.<E?]<R.
M.JL)!@^_6M30]9NO#FH?V#K9Q$.+><G@#MS_ '3Z]NGTJ6VFXEYG=UROC[4O
ML>A?948"2Z;9COM')_H/QKJJ\XU>"3Q;XT>PBF\N"U0H9-NX+CJ<9'\7'6LJ
M:UN^A<GH0ZOH;^'=,T;5(5Q<0L///^T3N&?U'Y5W5[J3_P#".2ZE8J)'\CS8
MQU[9_3^E<C+\-62)V35-[A257[/C)],[JL^$-9G3PQ=P1V[7%U8Y*0K]Y@>1
M^1S6DK25T[DK1F1H]UK.I.EQ:^(LWYD^:TG<A=I/4 _*?7 %;GC?5=1L/L-M
M#<-;0S?ZVXC!!R",XQR/7CFN6U2XL]8>$6&D3VVKE_WJ1#Y3]!U!S@]!WSFN
MOU[4IM-T^PM]3THWULT0%W*>0&QC@]CGG)Q['T;6J=A+9CO"J:D+F5FUF/4=
M-V JY8L^X]N>5QZ'V_#"U+Q'J.MZM-:6&H0:=:1$@223B+=CC);K^ I?",#2
M^*I+O2H+B'2MI#>:>V/NY[_-]>*H:CH__"/:I</?:3]OL'),;B1T"C/'S+T/
ML1]*$ES!=V+":WK'AVXB>75[75+9FPZ1W0E/Z_,/KTK9\::W>01Z>EG<-;6E
MTNYKA,YQQT(Y'!SQ6#I::?J]_'%:^%"T).';[7*=ON6Z#OQWKJO$M]%I%M:6
M4NCM=:7MVR,?F" <  ]B/4X^OH.W,M-06PWPJFI"YE8ZS'J.F[05<L6?<>W/
M*X]#[?ASD^J:EJ>N7D,^MMI;Q.5ABW,B$@G@D<#ZFIO",#2^*I+O2H+B'2MK
M!O-/7C[N>YW?7BF>(=6LKV2[@U71)K>^4E;:5.&/IN]1],CGCUH2]X+Z'1:K
M+JEIX#EEN[K%^%4F6 [2,N.X[X[BN<LXO%FL:(MS!?ND$(;;^^99)<$Y.>I]
M.2!Q5P6U]:_#&[COE=#N!C1^JIO7 QVYS70^$?\ D3[/_<?_ -"-3?E3]1[L
MY32]3\3>)+/[!:7(B\CF6Z9BK,#]T$@9SUZ?C5_PGJFJP>(;C1=2G><J&Y=]
MQ5AZ$\D$4[X;?\>VH_\ 71/Y&FV/_)4[S_</_H"TY6NU8%T92U+Q'J.MZM-:
M6&H0:=:1$@223B+=CC);K^ J%-;UCP[<1/+J]KJELS8=([H2G]?F'UZ57U'1
M_P#A'M4N'OM)^WV#DF-Q(Z!1GCYEZ'V(^E/TM-/U>_CBM?"A:$G#M]KE.WW+
M=!WX[U5E;;0G6YL>.]5N8%TN:PNYHDE5G_=2%0P^4C.#SUK.U7_A+=,ABUBZ
MU!E#L/W22'"$C@%,;?YU;\?PQVS:-!$NV.,,BC). -H')K:\=@'PK)[2)_.I
MB[***>[,'Q<;[4M"L-6\X):/$GF0!VP7.>=O3^M;O@>SOK;1_-NKGS89U5H$
MWLWEK@\8/3\*R=9_Y)E8?2+^M=3X9_Y%G3O^N"TI/W+>8U\1JT445B6%%%%
M!1110 4444 %%%% !1110!Y7X^T&]\0^/K*RLDR38H7D/W8U\Q^37?>'O#UE
MX;TU;.S7)/,LI'S2-ZG^@[5J!%#EPHWD %L<D#.!^I_.G5M.M*4%#HB(TTI.
M74****Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \1UW_ )&'4_\ K[E_]#-=CX.\([/+U34H
M_F^]!"PZ>C-_05<TKPD'\07VJZB@*&ZD:"$]_G.&/]!78UVUL1[O) ^;R[*/
MWKQ%==79?J_T"BBBN(^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?
M'T,5MJFG:DYCFVX5[9S]]0<]/3D@_A4O@C3FN+^ZU[RX[>&4LD,$1X'//';&
M/\\5EZQ=06?CNXGUNU>XM@N(T !&W'RD \$=?QS6%_:<EE-=1:1=74%C,PR&
MX8#WP3S[@\UZ4:<I4E%=MSXZKBJ=/&2KR6BD_=ZW2LGZ/U/:JQ_%?_(K:A_U
MR_J*NZ8XDTRV9;O[6#&/W^ -_O5+Q7_R*VH?]<OZBN&"M42\SZ?$RYL-.7>+
M_(\\M/$<G_",G08M.\YWW 2;MQY.>%QU].:VYY-5\+>"++RY?(N7N"6&T-M4
M@G!R#SP*W? W_(J6O^\__H1JE\1O^0%;_P#7P/\ T%JZG-2J^SMI<\..&J4\
M%]:=1N7(DK:66G;?U)-$U?5Y(+K5]7Q#I@@WPHH7GWXY[=\9S62NO^+->=YM
M'MA#;*V 0$Y]B7X)^E='+82:GX(CLXB!)):1[,G&2 "!^E<QX?\ %T6@6!TO
M4K.X62!VQY:C/)R002/6IBE).48IOMY&E>4J;ITZM648-7YNK?:_1=C5T+Q3
M?'5AH^N6XBNFX23&W)[ CISV(IOB+Q/J*ZO_ &-HD6ZY& S[0QSC. #QP.I-
M9EK--XN\9V]_#;O#:6FTESZ*21D^I)Z4NI7$WA;QQ+J4T#2VUR"01W!QG!]0
M1T_QJO9QY]M;;>9D\56^K_&^3GMS]>7_ (?J1ZEX@\7:1:+%?H(9'?*7 1&R
M.<KQE?3T/%7]=\2:GIVFZ%<PS_-<0B2<;%_>'"GTXZGI67XK\5PZ[I\=O9VL
MRPI('>24 8.#@#!/O^5'B?\ Y _AC_KW'\DJU!/EYHI;_D85,1**K*C5E))1
MLV_-'266L:KIVC7FJ:^NT%E-O H4=1P..><]^1BL>+5?&VK+]LL(!';,?E4+
M& 1_P/D_45T7C#3)]4\//%;*7EC99%0=6QU'Y&O.K7_A'1;A;^/5DN5X<1-&
M5S^(!'TJ**C.+E97]+F^/J5J%2-%S?+;?FLV[][/[CO?#7B6YU"\ETS5+?R+
M^(9X! 8#KP>A[^]8S^(O$&K:O=6^F7%M:B D);R;=\N">!N!R>/:I/!>G:5<
M7AU"SCU*-[?(S,R-&V01C(4$G'.*SM>N_#FIR7LNRXL=1B9@A"'$Q'J.QS]#
M]::A#VC2C^&WR"=>N\)"4ZEM7ULY+UMNOQ.JO-<U+3O"(U&[LT2].%\OG:N3
M@$CM],UE:+J?BFYFM+CS;6^M)VQ(J[1Y(Z_-@ @X^M.TS5W@\"-<:S;RW<1<
MQHK+DNG&"3Z9SR?05S<LMG::Q9S^%[BY,LK?- RGY3D?+GN/SZ=:4*:]Z-N^
MO3_@!B,7).G4]H[66E[2U>]K6E?L=?J>LZA;^.;'3HKC;:2JI>/8ISG=WQGL
M.]1:]XIOEU;^Q]$@$MT.'<KNP?0#IQW)XJKK/_)2],S_ '$_FU5;V6?PEXTG
MU*:W::TNMV&'HQ!.#Z@CIZ4HPB[::V^\NMB:T?:+G:CSV;WLK=.Q(VO>+=!*
M3ZQ:B:V8X.0G'_ DZ'ZUK>*/$$\'ARSU'2KCR_/D7#;%;@J3C!!YR*Q?$'C"
M'7=/.F:=9W#23L ?,49X((  )R>*=XFT^32_ FF6<IS(DP+\YP2&)'X9Q3Y$
MW%RBD[[>1F\1.-.M&C4<H*-[O=.^U].A%/X@\7-IT>J)$(K)57+>6AW]MQ!Y
MY/H *[70-5.LZ-!>L@1VR'4=-P.#CVK.OU'_  KPC' L4X_X"*3P'_R*L'_7
M1_\ T*LZG+*FVE:S.["*K2Q482FY*4+Z][].QTM%%%<I[04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !6?KO\ R+VI_P#7I+_Z :T*S]=_Y%[4_P#KTE_] --;B>P:%_R+VF?]>D7_
M * *T*S]"_Y%[3/^O2+_ - %:%#W!;!1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RWA7_
M )#_ (H_Z_A_Z#74URWA/G6?$['K_:!'Y**ZFM*OQ?=^1$/A"BBBLRPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K/UW_ )%[4_\ KTE_] -:%9^N_P#(O:G_ ->DO_H!IK<3
MV#0O^1>TS_KTB_\ 0!6A6?H7_(O:9_UZ1?\ H K0H>X+8****0PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .6\)?\ (7\3?]A$_P#H(KJ:Y;PE_P A?Q-_V$3_ .@BNIK2K\7W
M?D1#X0HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *S]=_P"1>U/_ *])?_0#6A6?KO\
MR+VI_P#7I+_Z ::W$]@T+_D7M,_Z](O_ $ 5H5GZ%_R+VF?]>D7_ * *T*'N
M"V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#EO"'.I>)6[_VFX_("NIKEO!__ !_^)?\
ML*R?R%=36E7XR(?"%%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110
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M5Z7/,(99);28]([J,QG\SQ^M;8((!!R#W% !1110 4444 %%%-9U7[S ?4T
M.HH!!&0<BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMMX!RJN#CMPPX]<T 7Z*** "L_7?^1>U/_KTE_\ 0#6A6?KO_(O:G_UZ2_\
MH!IK<3V#0O\ D7M,_P"O2+_T 5H5GZ%_R+VF?]>D7_H K0H>X+8****0PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH Q/%?B6V\*Z%+J-P-[_ '(8LX,C
MGH/ZGV%?/<UUKOCCQ"N_S+R^F.(XUX6-?0#HJCU_.NH^-&JO<^*+;30Q\FS@
M#E>V]^2?^^0OYUV/P^T2/PMX,&K20!]3OU5E4]2&.(XQZ9R"?K[4 8%C\+HQ
M.NGS733Z@5#W#Q\0VBGI[NY[#@=SQC/H%KX!\,6MND0TF"4J,&24;F;W)K8T
MRP&G6>QG\R=V,D\IZR2'J?Z#T  HGON2L7_?1H PKOX=^&;E"%L3;-_>@D*_
MIT_2L'_A']?\&2-=:'=G4+$<R6C_ 'L?3^HY]JZ]G=SEF)^IIO2@!=*U33/%
MFCLPC62,_+-;R@$HWH1_(U7B\[PS/'#+(\VCRL$CD<Y:U8]%)[H>@/:L74K>
M30=1'B'3EPHXOH%Z2)W;'J.M=@DEKJMDR,JR0S1_,IY#*10!<HK)T.66..?3
M;AR\UDP0.W5XR,HQ]\<'W!K6H ^<]"'_ !>N/_L+3_S>OHPD 9)P!7SGH7_)
M:H_^PM/_ #>O:?'NI/I7@;5[J-MLGD&-#Z%R%'\Z /'_ !KXNU/QSXC&B:07
M:P\[R8(8SC[0V?OM[=<9X YKK-*^!^FI:+_:NHW,ER1\PMB$13Z#()/UK#^"
M&DI/KE_J;J#]DA6*,GLSYR?R7'XU[G0!\]^,/ >I> ;B'6=)OIGM5< 3K\LD
M#'H&QP0>F?P(KU?X?>+QXNT#SI@JW]L1'<HO )QPP]B/US6[KNF1ZSH-]ITJ
MADN(63GL<<'\#@UX7\'=1DL?''V)CA+R!XW'^TGS#^3?G0!ZQ\1?^13?_KO'
M_.HOAK_R+4G_ %\M_):E^(O_ "*;_P#7>/\ G47PU_Y%F3_KY;^2T =C17 :
MYXOU6P\7MID!@^SB2)?FCRV& SSGWKOZ "BN+\;>)]1T"\M8K(P[98V9O,3=
MR#]:ZG3+A[O2K2XEQYDL*.V!@9(!- %NBO-].\?WJ:K<IJ;0_985D.$3#,P/
M '/>H)O%WBZ[1KRTL7BM.H*6Q<8_WCUH ]/HKA?"GCJ35+U-/U*.-9I/]5+&
M,!CZ$=C7<LP52S$!0,DGM0 M%><:M\0+ZZOS9Z!;AANVK(4+M(?9>PIUMXO\
M1Z1-&VOZ?(;1S@R>5L*_0C@_2@#T6BN T[QGJ&H>,ET^*2![!YF5&"<E "1S
MGVKK+J>[ADG,3[]ICV(4&.3R,_04 :=%5+"Y>[$\C#$?F8BXP=FU3S^)-6Z
M"BBB@ HHHH **** .6\&?\?'B3_L,3_R6NIKEO!G_'QXD_[#$_\ ):ZFM*OQ
MLB'PA1116984444 %%%% !1110 4444 %%%% !1110 5RGCGQK;^$-.4A1-?
MSY$$)/'^\WL/UKJZ^:?%%]=>+O'TZP$N9;C[-;+V"@X']3^- "Q?\)+X^U<K
MNFO)LY.3MBB'\E'ZUUFA?"U[^Z)N+\&SCRKRPKP[]PF>H'=ORKOM/T"WT/2K
M7PYIWR/,N^[G7[Q7^(Y]2>!Z#-=,JPV=ND:*L<4:A54#@ =A0!P;?"31]N([
MR[5O4D&H%\'>)?#3>?H.J_:(UY-O)QN_#I_*NXEOG8XC&T>IZU7,TIZR-^=
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MT6N^$=1M)%!<1&6(XY#J,C'Y8_&O,_@?JSQZEJ.D.W[N2,3H#V8'!Q]0?TH
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M7J7C*^EM-'5(F*F9]C$?W<9/]*\MT7_D+6?_ %V3^8KTCQY_R#;;_KK_ $H
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M).2223U))Y)J:B@ HHHH *S]=_Y%[4_^O27_ - -:%9^N_\ (O:G_P!>DO\
MZ ::W$]@T+_D7M,_Z](O_0!6A6?H7_(O:9_UZ1?^@"M"A[@M@HHHI#"BBB@
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M<C)51Q@?CFG_ !'L89= 6\*+Y\,B@/CG!X(J]X!_Y%"T_P!Y_P#T(U'\0O\
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M_P#1C5Y1J?F^ ?BL;QHV-N+@SKC^.)\YQ] 2/J*]P\.Z*GAW0;72HYFF2W#
M2,,$Y8MT_&JOBCPCI?BRR6"_1EDCSY4\?#IG^8]J $/C;PTNG?;O[:L_)V[L
M"0;_ *;>N?;%>"7>M'Q#\18]4VE5GOHRBGJ%#*%'Y 5Z!#\#K=;G,VN2O!G[
MB6X5L?7<1^E<CK6E65C\5+32M)BVP0W-M$!G)+?+DD]SDF@#Z(HHHH ****
M"L_7?^1>U/\ Z])?_0#6A6?KO_(O:G_UZ2_^@&FMQ/8-"_Y%[3/^O2+_ - %
M:%9^A?\ (O:9_P!>D7_H K0H>X+8****0PHHHH *ANKJ*SMI+B=ML<8R34Q.
M!DUS?/B74^_]E6C_ (3N/Y@?YZT 2Z/:RZC=G6[Y"&88M8F_Y9IZ_4UOT 8&
M!THH J:CIUKJ5N8KI 0.5?H4/J#7.:9K\]D7CNO,NM.24Q1WP7I]?4>]7]7N
M9=2O/[$L7*EAFZE7_EFGI]36Q#9V]O9K:)$OD*NW81D$>] $L<B2QK)&P9&&
M58'@BG4B(L:!$4*JC  & !2T %%%% !1110!C^*/#\'B;P_<Z9,0ID&Z*3'W
M''*M^?Z9KS#X8:JWAO7M0\+:NGV>>>0",L>!(!C;]&'(/?\ &O9Z\X^)OA:+
M5[O2;M)%M9GE-J;C'&YAF+<1SC<,9[;A0!UA!!(/4<5;L"!*P[D<5YUI7C"^
MT6Y71_&4$EM<K\L=Z1E)1ZDCK_O#\<5W-O.DB)<6\J2(>5=&# _B* -RBJT5
MY&XPYV-[]*DEN(((6FFFCCB499V8  ?6@!\DB11M)(P5%!9F/0 =ZPK,EK)[
MEP5>]F-QM/4)C" _\! J*6^&O,%C5AI2G+,PP;HCH .R>I[]!Q4U_?PV%E-J
M5Z<0QCA1U=NRK]30!';#[3XLC0<K86A9O:24\#_OE?UKHJQ?#5C/;:>]U>C%
M]>R&XG']TGHOX# K:H ^<]"_Y+5'_P!A:?\ F]?1,T4=Q!)#*H:.12K*>A!&
M"*XRT^&&D6?BD>(([N]-T+A[C8SKLW-G(QMSCGUKMJ /F^YM]1^%OCY)HXV>
M!&)A)X6X@/5<^H'Y$ U[/IOQ$\*ZE9+<+J]O;DC+17#B-T/H0?Z9K8UK0M,\
M0V)L]4M$N(>HW<%3ZJ1R#]*\^N?@=HTDQ:WU2^AC_N,$?'XXH Q_B7\2K/5=
M.?0]"E,T,I'VFY (4J.=BYZY[FMWX-^&QIVA2ZW,4:?4,"/:<[(E/3ZDY)'L
M*E_X4OX>32KB!)KI[R1,1W,K_P"K;L0HP,>N>U<WX%3QCX)UF73[K1+ZYTF2
M4K+Y*;U1NGF(>X]1W'O0!Z!\1?\ D4W_ .N\?\ZB^&O_ "+,G_7RW\EKH-:T
M>WU[339W#R)&65\QX!X^HINA:';Z!8M:6TDKHSE\R$$Y./0#TH \V\>12V7C
M$W6WB18Y8SV.W _F*[^T\8:'<V2W+:A#"2N6CD;#*?3'?\*N:QH=AKEJ(+Z+
M<%.4=3AD/L:Y=/ACIPF#/?731Y^YA0?SQ0!R'C'6AKNJBZA1A:1KY4+,,;L<
MD_K_ "KUC0CG0-./_3M'_P"@BLO4?!&E:A:VEL/-MX;4,$6$CG.,DY!R>*W;
M*T2QL8+2-F9(4"*6ZD 8YH \J\(_\E!'_72?^35ZY7-Z;X+L-,UD:I#/<M,&
M=MKD;?FSGM[UTE 'D7B;_DHQ_P"OB#_V6O1O$^FMJWAV[M(QF4KNC'JP.0/T
MQ5*_\%V&H:W_ &K+/<K-O1]JL-N5QCM[5TE 'EG@+Q%;Z1-<:?J#^3%*VY'?
M@(XX(/IV_*NRUOQ=IFFZ?))#>0W%RRXBCB<,2W;..@J+6_ ^EZS<-<_O+:X;
MEWBQACZD'O4>C^ =*TJY6Y=I+J9#E/-QM4^N!WH X/P@DL7C:S292LH=]X/4
M':<YKV:O)=#D%Q\33+'\RM=3,#[8;FO6J "BBB@ HHHH **** "BBB@#EO!/
M_,Q?]ARY_P#9:ZFN6\$<KXA;LVMW)'_CM=36E7XV1#X0HHHK,L**** "BBL?
M6]2EA,>GV/S7]SPN/^6:]V/I0!5U&5]<U$Z3;,1:Q$&[E7O_ + _S_*M^**.
M")(HD"1H-JJ.@%5=+TV+2[%+>+D]7<]7;N35V@!&574JRAE(P01D&N3O1)H.
MK11Z/NE,^6DL1R !_$#VK?U74HM+LFGD^9R=L<8ZNQZ"JVB:;+;B2]O3OO[D
M[I"?X!V44 6=,U6WU2 O#N5UXDB<89#Z$5>IBPQ)(\B1JKO]Y@,%OK3Z "BB
MB@ K@/BCX/?Q!I*ZA91[K^S!(4=9(^Z_4=17?T4 >?\ @+Q-#KWA>*S<A+^P
M41RQGJ5' 8?U]ZZ6O/\ 5O"%['XUU&ZT&Y^S:HN+N&(\)/&W# >X8=.G-:NF
M>-H3*+'7X'TK45X99@1&Q]0>U 'H-NP:!"/2I:R+2\ 4-$ZR1MS\K9J_]MMP
MNYY @'7?QB@"Q63<2BXUA0#F.R4NY[>8PPH^H&3^-07'B!+IC;Z01/)T>XQF
M*+\?XC["G6\"PV_EJQ$:Y>260\L>[,: *.K9DM(K-?OWLZ0@?[.=S'\A74]!
M@5S.A_\ $YU9]8VD64"F"RS_ !_WY/QZ"NFH ^?OBY_R42/_ *Y0_P Z^@!]
MT?2N:UOP%X?\0ZH-1U&VDDN0%4,LS*,#IP#734 > >,]$O\ P#XUCU[34(LY
M)O.A<#Y58_>C;V//X&O1]*^*_A:_L4ENKX6,^/GAF4Y!]B!R*[*[M+:_MGMK
MN".>!QAHY%R#^%<3=?"'PG<3&1+>X@R<E(ICM_(]* .&^(_Q*@U^R.CZ-O\
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MTD$:LTD32C#32'^+Z#).?7%>JP>&M"MI?-@T>PCDSG<MNH(/Y5J=* "BBB@
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M;_;^C;,>?O?_ +XQS6[63IFD26UR]]?7'VF]<;=^,*@]%%:U !1110 4444
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M5E\/0[@0I9R@/]W<<4Q]$U"_8+JFI>9;CDPPIL#?4UN(B11K&BA44851T H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<^$&H^,9A+S%81*40]-[<Y_SZ"N@KGM08Z-KXU1E)L[E
M!%.P&=C#H: .AHJ.*XAGB$L4J.A&0RMD5B:KJ;WLPTG2W#W$G$TJG(A3OSZT
M 13D^)-3-JG_ "#+5OWK=IG_ +OT'^>U=(!@8%5[&RATZSCM8%PB#\2>Y-6*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFH=S>*+Y<*ZZ1 V26&//?_ ?Y]ND    & .@% "T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !3719$*.H96&"I&0:=10!BOX5TEW9A
MZ!NJI(0/RK1L["UT^+R[6%8E/7 Y/U/>K-% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?KO_(O:G_UZ2_^
M@&M"L_7?^1>U/_KTE_\ 0#36XGL&A?\ (O:9_P!>D7_H K0K/T+_ )%[3/\
MKTB_] %:%#W!;!1112&5KO3K.^ %U;1RXZ%EY'XTRUTFPLGWV]I%&_\ > Y_
M.KE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!RW@/_ )!%]_V$;C_T*NIKEO ?_((OO^PC<?\ H5=3
M6E;XV13^%!111698V2-)4*2(KH>JL,@UGKX?TE7#"PAR#GIQ^5:5% "*JHH5
M0%4<  8 I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCAGCN(_,B;<N2,U)0 4444 %9^N_\B]J?_7I+_Z :T*S]=_Y%[4_^O27_P!
M--;B>P:%_P B]IG_ %Z1?^@"M"L_0O\ D7M,_P"O2+_T 5H4/<%L%%%%(844
M44 %%%% !1110 4444 %%%<WXY\6#P5X;;6#9&\"S1Q>4)?+^\<9S@]/I0!T
ME%,AD\Z".7&-ZAL>F13Z "BBB@ HKF+[Q>++X@Z9X5^PES?6SW'VGS<;-N>-
MN.>G7-3ZAXG^P^)+72/L,D@G(!F#8VD].,<C\?6@#H**** "BBB@ HHHH **
M** "BBB@ HIDLL<*%Y9%1!U9C@5%!?V=TQ6WNH96'9'!- %BBBJ=WJVG6$R1
M7E_:V\DGW$EF5"WT!- %RBHDN8)9GACGC>5 "Z*X+*#TR.U5KG6M+LKA;>ZU
M*S@G;[L<LZJQ_ F@"]14<L\,,!GEE2.)1DR,P"@>N:K3ZSI=M)%'/J-I$\P!
MC5YU4N#T(R>: +M%'6J,FMZ5%>"SDU.S2Z)P(6G4/^6<T 7J**SCX@T877V4
MZM8BXSCROM";L_3.: -&BN&^+>K2Z7\.]4ELM0>TO0J&)X9C'(/G'*D$'UZ5
MT/AO48;S0=-S>QSW#6D;/^]#.3M&2><]: -BBH5N[9HGE6XB,:'#,'&%/N>U
M2+(CQB175D(R&!R"/7- #J*BCN()F*Q31N1U"L#BO./B9KL]AXE\%P6>JR6R
M2:LJ7<<-P4#)E>) #R/8T >F45%!<V]R"8)XI0O!,;AL?E1'<P3.R131NR?>
M56!(^M $M%1B>(S&$2IYH&2FX9Q]*2:X@MEW3S1Q+ZNP _6@"6BHH+F"Y4M!
M-'*!W1@?Y4Q[^SCF\E[J%9/[AD /Y4 6**3<N[;D9/;-+0!RW@/_ )!%]_V$
M;C_T*NIKEO /_(!N/^OZ?_T*NIK2M\;(I_"@HJC<:UI=I/Y%SJ-I#+G&QYE!
M_(FKB.DB!XV5D89#*<@BLRQU%-DD2*-I)'5$499F. ![FJT6JZ=/ 9X;^UDA
M#!3(DRE0?3(.,T 6Z*CGN(+6%IKB:.&)>KR,%4?B:9:WMI?1&6SNH;B,'!:&
M0.,_44 3T57>^M(UF:2Z@18?]:6D \O_ 'O3\:=;7=M>PB:UN(IXB<!XG#+^
M8H FHJO=WUI81B2\NH+="<!II @)^IJ2">&YA6:WECEB;[KQL&4_0B@"2BJM
MWJ=AIY47M];6V[[OG2JF?IDT];RU>W%PES"T!Z2!P5_/I0!/17F?PEU^?4+#
M7CJ>JO</'JTT</VBXW%4XP%R>GTKTGS8_-\KS$\S&=FX9QZXH ?13$ECE+".
M17*G#;3G!]#2&>(2B(RH)#_!N&?RH DHKC?BGJ<VE_#K6)[.]>TO%A!B>*79
M(/G RI!S^52VTMYK/@+3HK'4Q_:,MG"[N)OWC'8-W.<@Y[T =;15#1;>\M-(
MMH-0G\^Z1</)G.?Q[TMGJ]C?WEW:6TXDGM&"S( ?D)H O452U75['1;,7>H3
MB& N$W$$\GH.*?-J5A;,$GO;>)B-P6255./7!- %JBFQRQS1B2)U=&Y#*<@_
MC5>YU*QLF"W5[;P,>@EE52?S- %JBJTFH64,*32WEND4GW':4 -]#GFGV]W;
M7:EK:XBF4<$QN& _*@":BBB@ HIDLL<,;22NJ(HR68X K-7Q)H[2>6+Z/.<9
M(('YXQ0!JT4BL&4,I!!Y!'>LS6_$FC>&[=)]9U*WLHW.$,K8+'V'4_A0!J45
MB67C#P[J/V(6>L6DYO69+<1R9,C*,D >H'8T[7/%OA_PUL&LZM:V;2#*)(_S
M,/4*.<4 ;-%4-(US2]?L_M>DW\%Y;YP7A<-@^A]#]:S+GQ[X4L['[;<:]91V
M_FM!N,G5U^\H'4D9&: .BHJEI6KZ=KEBE]I=[#=VS' DA<,,^GL?:L[6_&WA
MGPY<+;ZOK5I:SL,B)WRV/4@9(_&@#>HJKIVIV.KV27NG7<-U;2?=EA<,I_$5
MBZMX_P#">AWK6>I:]9P7*\-$7W,OU SC\: .DHK#NO%6@)X>&KOK%FNG392.
MY,H",V#P#Z\'CVKS;X+^+/#^G^$FT^\UFR@O)=0E\N"28!VW,-N![T >RT51
M.LZ:NHRZ<U];B\AB\Z2$R ,B?WB.P]Z73=7T[68'GTV^M[N*-S&TD$@=0PZC
M(H NT5B-XQ\,I??86\0:6+K=M\DW:;L^F,]:YGXPZUIEI\/=7TZXO[>*\NK;
M-O \@#RX9?NCO0!Z#17%_#_Q3H-]X:T/2K35[.?4(]/A#VT<H+J50;@1[5U4
MFHV<-XEI).JW#XVH<Y.: +5%5[F]MK1HEGE"&5MJ ]S3[BY@M(3+<2I%&/XF
M.* ):*S[;7--NYEA@NT:1NBD$9^F13[S5["PD$=S<I&Y&=O)/Y"@"[15=+^U
MDMTG6=#$_P!UL\&K ((!!R#WH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"IJ>HV^DZ;/?7+;8H5W'U)[ >Y/%>#W6HS:M
MJ<]].<R3.6(]!V'X#BM3Q]XQ_M[4SI]FY_L^U<C(_P"6KCC=]!V_.N?M>U '
MHVAZ'IUSX6&H7#-$R2GS) <_*.P'J<XK4TRVTC4/,;21/;7MN-Z,[9SC\>G^
M-9]C_P DVE_Z^/ZBI/!'_(7F_P"N#?S% '5?V]"N@+J;+R1M\L?W^F/S_2J*
M3^)9K7[:@MPA&]8-O)7_ #[US;2,WAXHQ.Q;T_\ H->CQX\I,=,#% &?I6L1
M:CIK73 1F//FK_=P,_EBLJVU#7-7,EQ8B"&V5B$$@^]^E4-/W#3?$ C^X =N
M/^!?TK?\,;?^$?MMO^UGZ[C0!D:5<27/C&5YHO*E$15T[ @ ''MQ6G:ZG<R^
M)[JP8KY$:;E&.<_+W_$U3M]O_">7.WKY7/UVK18_\CS??]<OZ+0!G:@NL_\
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M4-0TV2V:0?:+>./!5>^TXY(^M8-[IT&@_$/P=8Y)M8;5H8G?N_S<_4DBO4*
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M#!MQXTF_9]O;6>WOH=<@1H5$BE9WA##D=R=A(]>*@\ :/\*?%.BVUC#IMO\
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M$X!P?<&K*@']I1B1TT3C_OH4 =!I_@3_ (1?P;J.D>%KV6"^N@66[NW+D2$
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M-NE:,=26'7]:UM6U'1;FVN;:\D4O%E=K*=P;_9_^M0!;DTFTGMH4MR(XD.Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIOQU_P"28W/_ %\P_P#H5=)=>+-$\+Z3HXUJ^6T6ZA58G=&*DJJY!(!QU[T
M<3X=^,;VM^-%\>:=)HVH# %P8R(G]V'5<^HROT%>K2NLEH[HP96C)# Y!&.M
M>3_%#QKX&UKP7=62WEKJ=_(G^A) N]XY3C# X^7WY&1D<UVW@'3;W3?AYH^G
MZB'6[CM=KJYY3))"GZ @?A0!Q_[/G_)/;K_L)2?^BXZJ?'RS;4+;PQ9*P5KB
M_,08]BP49_6LWX-^,-%\*Z'JF@>(+U--OK>^>0K< J"-JJ0#Z@H>/<5O_%QU
MEU/P)(ARC:Q&RGU!9* /2=*TNST72[?3K"%(;:W0(B*,?C]3U)[DUQNH^*/
M7P[OKF%%AAU&Z(>>WLHB\LAY(W8X!Y/4CK7?5\^_"?6=!\-:WXA;Q;<1VGB
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MZ0FO_$?P9I4N?*N69),==F]2WZ UZ+:_$'PE?75O:VNO6<UQ<N(XHXV)9F/
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M</\  _\ Y!'B/_L,R_\ H*UF_M 1S&S\.S3+,^CQW;?;!'ZG;M_':) /K[T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3
M0QW$$D$J[HY%*.OJ",$444 $,,=O!'!$NV.-0B+Z # %/HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y36=,M=
M5\<Z;#=+)A=,N71XI6B=&\V 95E(8<$C@\@D=#6Y!HFG6R620VP1;)F> !C\
MK,"&)Y^8D,V2<\G/6BB@"OJ'AC2-3NGN;JV=I)%"2A)G19E'02*K!7_X$#QQ
MTJS<:19W.HVVH.DBW5LI2-XI73*D@E6"D!ER <-D444 0VOAW3+&]%W:PRQ.
MI=EC6XD$2EL[B(]VP$Y/05'!X7T>VU 7L5JPD61ID0S.T4<C9W.L9.Q6.3R
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M+T>TT>-TM#<E7QGS[J28C P "[' ]A110 C:+8-JDNHF)_/FB$4P\UO+E49
MW1YVL0"1DC/-5[;PQI5I!+##'<"*2+R=C7<K!$_NH"WR#_=QBBB@!8O#&DQ6
M-[9_9Y)8[X;;EIYY)9)1C !=F+<#ISQVK1M+9+.UCMXWE=(Q@--*TCGZLQ)/
MXFBB@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img35377828_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img35377828_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +L!SH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9AF*5' _NL#3\B@@6BC-% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWH14N9/L>3FM>='V4HW^)72W?EYGG?PJ\.:3XDUN^M]6M/M,45MO1?,=,-N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXJ?\\-5_\%*__&Z/9ON',>ZT5X5_PDOQ4_YX:K_X*5_^-T?\)+\5/^>&J_\
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M2O\ \;H_X27XJ?\ /#5?_!2O_P ;H]F^X<Q[K17A7_"2_%3_ )X:K_X*5_\
MC='_  DOQ4_YX:K_ ."E?_C='LWW#F/=:*\*_P"$E^*G_/#5?_!2O_QNC_A)
M?BI_SPU7_P %*_\ QNCV;[AS'NM%>%?\)+\5/^>&J_\ @I7_ .-T?\)+\5/^
M>&J_^"E?_C='LWW#F/=:*\*_X27XJ?\ /#5?_!2O_P ;H_X27XJ?\\-5_P#!
M2O\ \;H]F^X<Q[K17A7_  DOQ4_YX:K_ ."E?_C='_"2_%3_ )X:K_X*5_\
MC='LWW#F/=:*\*_X27XJ?\\-5_\ !2O_ ,;H_P"$E^*G_/#5?_!2O_QNCV;[
MAS'NM%>%?\)+\5/^>&J_^"E?_C='_"2_%3_GAJO_ (*5_P#C='LWW#F/=:*\
M*_X27XJ?\\-5_P#!2O\ \;H_X27XJ?\ /#5?_!2O_P ;H]F^X<Q[K17A7_"2
M_%3_ )X:K_X*5_\ C='_  DOQ4_YX:K_ ."E?_C='LWW#F/=:*\*_P"$E^*G
M_/#5?_!2O_QNC_A)?BI_SPU7_P %*_\ QNCV;[AS'NM%>%?\)+\5/^>&J_\
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M_P"E1-&Y'?;@J?R;]*\HJ:L.2;B;X'$_6</&J]WOZ[,****@Z@HHHH ****
M"BBB@ HHHH *** "3@#)H *UM!TJ34K]$ (0<LWH*=I'A^ZU.487;&#\SGH/
M\?I7J&@>'X[6-8H4Z_>8CEC79A\.[\TCY_-LWA2@Z5)WD_P.C\-6Q4K@84#
M%=S&,(*R=)T\6\0R.:V!Q7H'Q04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7COQD\1[YK?P];O\L>)[G!_B/W5_+G\17L5
M>'_$SP5'HUJVO-J,]U<WE[M=70 #<K-QCTV@?2KA:^I,MCIOA!XC^WZ-+HL[
MYGLOFBR>6B)_H?T(KTJO)_ACX*C^Q:9XIBU&>.=_,#P! 490S(0?J!GZUZQ2
MG:^@X[!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#%\4>'8O%&D?V;/.\,1E5V:, L0.PST^O-.T+PMH_AR'R]-LDC<
MC#3-\TC_ %8\_ATK8HIW=K!8****0!1110!Y[\2-,EBFLM8L;Z2TN9F73I3&
M!\\<A[_3FNTT;2X=%T:TTVW.8[>,("1C=ZG\3DUA_$&QN;OPLTUI&9)K*>.[
M6,=6"')'Y9K<TC5K36]+@U"RE62&50>#RI[@^XK-)*;.VI.4L-#LFU_E^MB]
M7&_#/_D6KK_L(W/_ *'71ZUK%IH6E3ZA>RJD42D@$\L>RCU)K&^'VGW%AX2@
M-TACGNI)+IHSU3>V0/RQ3?QHB"MAI-]6OPN=1116#XNUZ30='$EK&);^YD6W
MM(C_ !2-TS[#K5-V5V84X2J24([LT-3UK3-&A\W4;Z"V0]/,< GZ#J:YFY^)
M&E31/%I-K?:G<L"L20VS;7;MEB.!5C0_ ]G:,+_6<:IK$GS2W%P-X4^B*> !
M75JBHH5%"J.@ Q4^\_(WOAZ;M9R?W+_/\C \%:/<Z'X5M;.[P+CYI)%!X0L2
M=H^F:Z"BBJ2LK&%2;J3<Y;L****9 4444 %5=1U&TTJPEO;V98;>)=SNW^>3
M4EW=165G-=3DB*%"[D DX R>!UKS_2 /B)J@U7498QI%K(?LFFB0$NP_CE'\
MA_DS*5M%N=%&CSISGI%;_P"2\RQ8:?>>/-0BUC687@T2%MUC8/UF/:20?R'^
M3WH 4    < "J%_K6E:1"7OK^VMD4='< _@.M<M+XIUCQ.QM?"=DT5N>'U6[
M0K&H]44\L:FZCZFLHU,1JERP6W9?YO\ %FOXE\60:'Y=G;1->ZO<<6]E%RQ/
MJWHOO4/A+PS<:3)=ZIJ<XEU?4&WW'E\1IZ*H[X]:L^'/"EEH'F7'F/>:E/S/
M>SG,CG^@]JWZ:3;O(B=6$(NG2V>[[_Y+^F%%&:*LY0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV2,8 %38Q6QY(BJ%&!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5YS\:/^1.M/^P@G_HN2O1J\Y^-'_(G6G_803_T
M7)50^)"EL:_PO_Y)UI7_ &V_]'/77UR'PO\ ^2=:5_VV_P#1SUU]*6[!;!11
M12&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7)7?@*V%])>Z+J5[HTTIW2K:,/+<^I0\5UM%)Q3W-*=
M6=-^XSDK/P':B_COM8U&\UFXB.8A=L/+0^H0<5UM%%"BEL%2K.H[S85E:IH4
M&K:CI=Y-+(K:=.9D1<8<E<<_SK5HH:ON3&;@[Q"BBBF2%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N=\=W+6O@76)%.";<Q_\ ?7R_UKHJY/XE_P#)/-6_W8__ $8M..Z$]CF/
M@E:JNDZK=_Q23I%^"KG_ -GKU.O./@L!_P (?>'N;]Q_Y#CKT>G/XF$=@HHH
MJ1A1110 4444 %%%% !2$ TM% $3P(XY JI-I<,G\(K0HH YRX\/1OG"US]]
MX'LIR2]G$Q/<+@_F*]#Q32BGJ*"HRE%WB['C=[\-K)\[$EC/^RV1^N:PKKX:
MR+DQ7'X,A'ZY_I7OK6\;=5%0/IT+_P (J'3A+='73S+%4_AFSYRN/ 6J1?<"
M2?[K?XXK-F\*ZO#G=:2'_=&[^6:^EI-&A;^$54D\/1-T45D\-3?0[H9_C([M
M/Y'S-+I5["<26\B_[RD?SJN8)1_ :^EI/#:GH*I3>%(Y/OQ(W^\H-0\'#HSK
MAQ+57Q01\Z&-QU1ORI"I'4&O?)?!%FW6Q@/OY8JG)X"L3_RY)^&14/!+HS>/
M$L/M0/#J*]FD^'MAGBU8?1V_QJN_P[LCG]U*,^C4OJ3[FRXDH=8,\AHKU=_A
MS9D8Q./Q'^%1GX<6G_3Q_P"._P#Q-3]3EW+7$6&[,\LHKU+_ (5S9_\ 3Q^:
M_P#Q-'_"N;/_ *>/S7_XFCZG+N'^L6%[,\MHKU+_ (5S9_\ 3Q^:_P#Q-2K\
M/+,'.R8_B/\ "G]3EW$^(L-T3/***]=3X?V0_P"6$A^K&K$?@.Q7_ES)^KM_
MC3^I/N0^)*'2#/&PC'HI_*G"*0_P-^5>UQ^"+,=+*/\ $9JY%X/@3[MG"OTC
M JE@UU9C+B5?9I_B>%K:S,<!":M1:)J$WW+64CU"'_"O>8O#)48" #V%64\-
M>HJE@X'//B2L_A@D>%Q>$=5E_P"6!4?[1 _K6C!X#O'P99(U'U)/\J]NC\-H
M.HJW'H$2]5%:+#4UT.2IGV,GLTO1'C5M\/HN/-F=O]U,?SS6W:>![*/&+4N?
M5R3^G2O5(](A7^$592QB3^$5JH1CLCAJ8[$U?CFS@+/PNL(Q%;I&/]E0*U[?
MPWTW"NO6!%Z 4\*!VJCE;;=V85OH,28RHK1BT^*,<**NT4"&+&J]!3Z** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KSGXT?\ (G6G_803_P!%R5Z-7G/QH_Y$ZT_[""?^BY*J'Q(4MC7^
M%_\ R3K2O^VW_HYZZ^N0^%__ "3K2O\ MM_Z.>NOI2W8+8****0PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]?%=#!"EO;QPQC"1J%4>P&*O:/J3NR2BBBH*"BBJU_?VVFVK7%U($0=/5CZ
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M% !1110 4444 %%%% !1110 5R?Q+_Y)YJW^['_Z,6NLKD_B7_R3S5O]V/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?0G:1T]%%%04%8WBO_D6;SZ+_P"ABMFL;Q7_ ,BS>_1?_0Q51^)"EL6M$_Y
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M:>.;$1RSD:K*))]S#Y2SX.WCC\<U>^(&DP:%>>#],M7D>&W9E1I2"Q_>(><
M#OZ52Z6%W/8W=(8B\CJJ*,L['  ]2:IVNN:1?3F"TU2RN)AUCAN$=OR!KR'X
MJZ[)=>*DT2YN)X=+MU1I5A7<79AG=@D!L# '/'-<K?\ _"&+9EM*F\01WJ\H
MUPD)0D?[K CZ\X]#4J%T-R/I&ZN[:QMVN+NXBMX%QNDF<(HSP,D\54DU_1H;
M:*YEU:P2";/E2M<H%?'7:<X/X5YC<:[<Z]\#[R6\D,ES;RI \C'E\.A!/O@B
MLWP_\-X-:\#-K5S?7(NC%(UO&F"BA2< @@DY(/0CK2Y5U"_8]<UZ^L[;P[>3
M3W4$44D#JCR2!58E3@ GJ37G_P %KVU32[ZS>YA6ZDN-R0F0!V 09(7J169X
M-TY?$WPRU2PO[B?R+*X::#RV *D)G'(/&23CWI?A)X=AO8;S64GFBOH"\$."
M-@W)U(QG(SZU5DDT*]VCUF76M*AO192ZG91W9( @>=0Y)Z?+G-7J^<$T_3]*
MN;O3/&&GW]O>RN6CU"-RVSWVGAU)SD@D_C7T!HBVB:'9+87#7-HL*B*9G+EU
MQU)J)1L4G<OT445(PHHHH **** "BBB@ HHHH **** "BBB@#$U33[JY\3:%
M>11;H+5IS,^X#;N3 XSD\^E00VFH:#J5])9V;7VGWLIN#%$ZK+#*<;L;R%93
MC/4$'/!KHJ*=PL<E<6VNZGXJT2_DL1:Z=:22EHFE1I 6C8;GP<#D@ *6ZDFK
MD%I?:!?WSVED]_8WDQN/+A=%EBD8?-PY52IP#U!&3P:Z&BBXK&58R:O=:@UQ
M=0K96*Q[8[9BKRNQ/WG*Y"XZ  GJ23VJ#PKI]UINF7$-W%Y<CWMQ*HW Y5I"
M5/![@UN447&8VD6-S:ZQKL\T>V*ZN$>%MP.Y1$JD\=.0>M4-(TB^M? $NF30
M;;QH;A1'O4\L7*\@XYR.]=111<5CE[G2+Z3PKH5DL&;BUFLVF3>ORB-E+\YP
M<8/3\*N:KI]S<^)="NXHMT%JTYF;<!MW)@<9R>?2MRBBX6.;TVWU#PU;MI\.
MG3:A8I(S6SV\D:NBL=VQP[*."2 03D8X%7[)M9;[9=7<42!E_P!%LE<$K@'[
M[X^\Q],@8[UJT47&<O'875_XIL=5_LF33#;I(+B1Y(RUQD85/D8[E!YRV,8&
M!S3?B'H]_KOA&:QTV#S[EI48)O5<@')Y8@5U5%%];BL<)JGAW5;CQ1X1O(K7
M=;Z?$%N7\Q1Y9P.V<G\,U2;P%+J_BGQ,^K6FRQOE4VMP'4LKC'S  Y&/?&>E
M>D44^9A8X72M$UZ_\.:AX7\2Q%H GEVVI)(K>8H/RY7.[((!&1R.#SR>7A\)
M^+]-A&F1>&/#=\B_*FH2V\1?'8G)!)'NI_&O8J*.9A8\Z\1^$-2GT70K:QTZ
MQ^T07BSW8L42"/I@L 2,] /4XZ#I2?&"& Z%87"NR:C'= 6OE_?8GJ!CGL#]
M0*]&K,U#P_I>JZA9WU]:^=<6;;H&:1@$.<YV@X/('4=J%+74&BKX.T%?#GAB
MTL-H$P7?.1WD/+?ET^@K)\5:%J6I>,O#-_:6WF6ME*S7#[U&P94]"<GH>F:[
M.BE?6X6.,\5:%J6I>,O#-_:6WF6ME*S7#[U&P94]"<GH>F:/%6A:EJ7C+PS?
MVEMYEK92LUP^]1L&5/0G)Z'IFNSHI\P6/-]2\/>*_#WBN]UGPI';7<&H'=/:
MS,!ANY.67/))!!SR1BF^'M \6#XB#7=>@A*/;,I>&1=L>1P@7.>/Q^IKTJBC
MF86/--,\*:U;^&?%]G+9;9]0F=K5/-0^8#G'.<#\<5#K?AQXO 7A^*YU"STK
M6M-^>#[5<(@+ Y*ALXS]TY&>GO7J-5-1TNQU>S:TU"UBN8&.=DBYP?4>A]Q1
MS!8\,\7>)?$&MZ+%:ZG=:0$$HVP6$Z2R3-C[S;&8 #\.3T/;T+6O#NJ7FO\
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MU&U6YM)EEB;(W#L1U!'4$=P>17.^ [:&'3=2F1 ))M3N3(W=L2$#]!5GP_\
M+KOB6->$%ZC!>P)A0D_C3:0(Z&BBBI&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:O.?@O\ \B==_P#80?\ ]%QUZ-3G\3!;!1114C"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'F2^(/&/C/4;P^%9[33]-M)#$)YP&,Q_%6[<XP,9ZUJ^%?%FIWEWJ>A
M:Y#'%K%A&7WQ?=E7^]CIW4^^>@K*3P_XQ\&:C>CPM!9ZAIMW*95@G8 Q'\67
MZ=3G'2M7PIX4U2TN]4UW798I=7OXRFR(_+&N.F>G8#VQU.:T=K$JYR>BZ_\
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M16NKP87&VU$,T3'J'4< <'''/7-9_A[PYKGAGP*]DEC9ZC=SSF6:SGEP@C(
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M@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/B9,=@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N3^)?_)/-6_W8_P#T8M=97)_$O_DGFK?[
ML?\ Z,6G'=">QB_!?_D3KO\ ["#_ /HN.O1J\Y^"_P#R)UW_ -A!_P#T7'7H
MU.?Q,%L%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HILD
MD<2[I'5%'=C@5EW'B32K;(-T)&](QN_7I6<ZM.GK-I%PI3G\";-:BN4G\;1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O.?C1_R)UI_P!A!/\ T7)7HU><_&C_ )$ZT_[""?\ HN2JA\2%+8U_
MA?\ \DZTK_MM_P"CGKKZY#X7_P#).M*_[;?^CGKKZ4MV"V"BBBD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M .2=:5_VV_\ 1SUU]*6[!;!1112&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '+^ _\ D!S_ /7RW_H*UU%<OX#_ .0'/_U\M_Z"M=15U/B9,=@HHJK>67VS
M9_I-S!MS_J9-N<^M046J*S/[%_ZB>H_]_P#_ .M1_8O_ %$]1_[_ /\ ]:G9
M=Q:FG169_8O_ %$]1_[_ /\ ]:C^Q?\ J)ZC_P!__P#ZU%EW#4TZ*S/[%_ZB
M>H_]_P#_ .M1_8O_ %$]1_[_ /\ ]:BR[AJ:=%9G]B_]1/4?^_\ _P#6H_L7
M_J)ZC_W_ /\ ZU%EW#4TZ*S/[%_ZB>H_]_\ _P"M1_8O_43U'_O_ /\ UJ++
MN&IIT5F?V+_U$]1_[_\ _P!:C^Q?^HGJ/_?_ /\ K467<-33HK,_L7_J)ZC_
M -__ /ZU']B_]1/4?^__ /\ 6HLNX:FG169_8O\ U$]1_P"__P#]:C^Q?^HG
MJ/\ W_\ _K467<-33HK,_L7_ *B>H_\ ?_\ ^M1_8O\ U$]1_P"__P#]:BR[
MAJ:=%9G]B_\ 43U'_O\ _P#UJ/[%_P"HGJ/_ '__ /K467<-33HK,_L7_J)Z
MC_W_ /\ ZU']B_\ 43U'_O\ _P#UJ++N&IIT5F?V+_U$]1_[_P#_ -:C^Q?^
MHGJ/_?\ _P#K467<-33HK,_L7_J)ZC_W_P#_ *U']B_]1/4?^_\ _P#6HLNX
M:FG169_8O_43U'_O_P#_ %J/[%_ZB>H_]_\ _P"M19=PU-.BLS^Q?^HGJ/\
MW_\ _K4?V+_U$]1_[_\ _P!:BR[AJ:=%9\&E^1,LOV^^DVG.V2;*GZC%:%)C
M"BBB@#E_ ?\ R Y_^OEO_05KJ*Y?P'_R Y_^OEO_ $%:ZBKJ?$R8[!1114%!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<G\2_^2>:M_NQ_P#HQ:ZRN3^)?_)/-6_W8_\ T8M..Z$]
MC%^"_P#R)UW_ -A!_P#T7'7HU><_!?\ Y$Z[_P"P@_\ Z+CKT:G/XF"V"BBB
MI&%%%% !1110 4444 %%%% !2$A5+,0 .23VJM?ZC;:; 9KF0*/X5'5CZ 5P
MFKZ_<ZJQ3)BM@>(P>OU]:XL7CJ>'5GK+L=F%P53$.ZT7<Z#5?%L%ONBL )I.
MGF'[@^GK7'W5Y<7LQEN96D?U8]/H.U045\UB<95Q#]]Z=NA]!A\)2H+W5KW"
MBBBN4Z0HHHH ***EM0#=P@\CS%_G32N[ W97(J*[+QE#%%8VYCC1"9#G:H':
MN-KHQ6'>'J.FW<PPU?V]-32L%%*JL[!54L3T &:?+;S0@&6&2//3<I%<]G:Y
MO=7L1T4H!8X )/H*&4J<,"#[B@!**4*Q4L%.!WQ0 2< $GT% "44K*R_>4CZ
MB@ L< $GT% "45W6OQ#_ (1==L8W8CZ+SVKA>AKIQ6&^KS4;WTN<^&Q'MX.5
MK:V"BI5M;ADWK!*4_O!#BHJYFFMSH33V"BBBD 4444 %%%% &AIVLW>G,!&^
MZ+O&W3\/2NRTOQ!;7X"[MDO=&Z_AZUY[2@E2""01T(KT,+F%6AIO'M_D<6)P
M%*OKL^YZTK!AP:6N'TCQ,\)6&\)9>@D[CZUV,%S'.@9&# \@@U])A\33Q$>:
M#/GJ^'J4)<LT3T445T& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %><_&C_ )$ZT_[""?\ HN2O1J\Y^-'_
M ")UI_V$$_\ 1<E5#XD*6QK_  O_ .2=:5_VV_\ 1SUU]<A\+_\ DG6E?]MO
M_1SUU]*6[!;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+^ _^0'/_
M -?+?^@K745R_@/_ ) <_P#U\M_Z"M=15U/B9,=@HHHJ"@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC/WEKO\ 3]0CNX5=6!!%?58+&1Q,>TENCYG%X26'EW3V9H44=:*[3C"BBB@
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MMWH#,3;%/M-F6.=JDX*_G_(GO0!U%%%% !1110 4444 %%%% !1110 4444
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MS#%O"*L2Y9F/89('8]3VK(MOB+HEU+H\:+=J^JDB$-&/DPQ3Y^>,D$<9_"N
M\;^(KCQ9X TS4X_+@B2\:&[M^I\[;\I!QTQN/7^(=<5O7%SK>G>)?!FGZK<6
MES=.9/.E6WC;C=QM8H"ORX!QCIWJN7345]3M=/\ $UEJ7B#4=%ABN%N;  RL
MZ@(<_P!T@Y[]P*V:\V\/W,5E\2O&=U,<10PB1SZ  $_RK&C\:^)_$,DM[8Z]
MH6BVJN1%;7<\8=Q[[@3^/RCTI<O8+GL5%<EX#\72>*=/N4NTB2_LY/+F\ELH
MX.<,IR1@X/0GIGO76U+5M"@HHHI %%%% !1110 4444 %%%% !1110 4444
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MMCR.$"YSQ^/U-:_@'0M2T637#J%MY(NKUI8?G5MR\\\$X_&NSHH<KA8XG6-
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MUQ^M;*\=S-V>Q4@\1:M:P*MYI$LVWY3/$3ASV(P,<^H-9=YJ<L^HV]QJC#=
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MMA-,_P"1WU?_ *YK_):Z6N:TS_D=]7_ZYK_):Z6B>Z"(4445!04444 %%%%
M!7D/QJUA3_9VC1ME@3<R@=OX4_\ 9J]5U'4+;2M.GOKR01V\"%W8^G^/;%>&
M^&[:X^(/Q(DU*Z0_98Y!<2J>0J*<)'^@'X$U<%U)EV/7_!VE'1?".F6++MD2
M$-(#V=OF8?F36Y114/4H**** "BBB@ HHHH Y_Q9J1M-/%M&V);C(..R]_SZ
M?G7!UIZ_?&_UB:0'*(?+3Z#_ .OD_C697R&/Q'MJ[:V6B/JL#0]C12ZO5A11
M17$=84444 %%%% !1110!I:?H5[J<#36ZH4#;<LV.?\ )K/DC:*5XW&'1BK#
MT(KT+PQ#Y.@6^1@N6<_B>/TQ7+>*K/[-K3R 82<"0?7H?UY_&O3Q&!5/#0K+
M=VO\SSZ&,=3$2I/9;?(H:=I=UJDCI;*I*#+%C@5'>V4UA=-;S@"1<$X.1R,U
MVGA"S\C23.PPT[9_X".!_7\ZQO&<.S58I0.)(A^8)_\ K45<"H815NK_ "?]
M(*>,<\4Z/3]3G**N:?IEUJ<WEVT><?><\*OU-;A\%7(CRMW$7_NE2!^?_P!:
MN6EA*U6/-"-T=-3%4:3Y9RLSEZ*L7MC<:?<&&YC*..1Z$>H-3:;I-UJLI2W4
M!5^](W"K62I3<^1+7L:.I!1YV].Y1K7N?#UQ;:2-0::(QE5;:,Y^;'M[U>F\
M&7<<)>*XCED ^YC&?H:UM91H_!H1U*LL40(/8Y6O0I8"485'6C:RNCAJ8V+E
M!4I7N[,X2BK-E8W&H7 @MDW.>3Z >I-= O@FXV9:\C#^@0D?G7'1PE:LKTXW
M1U5<32I.TY69RU%7M2TFZTJ4)<*-K?==3E6JY;>&;R[TZ.\A>-A)C"<YZX_^
MO2CAJLI."CJBGB*2BIN6C,6BM35]%?1UA\RX21Y,_*H/&*M:?X5O;V%9I&6W
M1N5#@EB/7%4L)6=1TU'5$O$TE!5'+1F#3HT,DBHO5B ,UT$O@^^2Y2-)(WC?
M/[SD;>.XID'ARYCUM+0S1%TC$Y/.,;L8Z=:KZE73M*+WL3]<HM74NEREJ6AW
M>E1))<&,J[;1L;//Y5FUZ'XCTN74[)%B=$\IBYW9Y&*XG3=*NM4F,=N@POWG
M;A5^M:XS!NE64*:=GL983%JI1YZC5UN4J*ZD^"9]F1>1E_0H<?G7/WUA<:=<
M&&Y3:V,@CD,/4&L*N$K45>I&R-Z6*HU7:$KLK4445S&X4444 %%%% !1110
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MU5#3M(MM+:4VV\"3&0QSTS_C5^NBDZC@O:6OY;&%7DYG[/;S"BBBM#,****
M"HIKF&W ,TJ1@]-QQFI:Y_Q3_J+?ZM_2FE=B;L;R.LB!T8,K#((Z&G54TO\
MY!=M_P!<Q5ND,**** "BBB@ HHHH **** "BBB@ HHHH **** "L;7-!&J-%
M=6TYM=1M^89U_P#06]1_GU%;-% '+Q^)-0TW,6N:5.NWC[3:KOC;W/I_GBG'
MQWH[#$(NII#P(XX3NS^-=-10!R<HUSQ-F%H7TK3#Q)O_ -=*/3'8'_.:Z6RL
MX-/LX[6VC"0QC"@?YZU/10 4444 %%%% !1110 4444 %%%% !1110 4444
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M *]T_P#017)67_)/+K_KI_[,M=;I/_(&L?\ KW3_ -!%:U/U(C^A<K-\0?\
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MI.F;YM6D"[W;RH2QX7/&<<FKYT'1=6M3+I[!'' =&)P?<&NC"4,31E>$E?\
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M=<%DY@@4/-W)Z+6:-4UD_O C[/\ KEQ^>*Z.5F%T=715&POC/I@NK@JN 2Q
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M^ K7I %%9&A:I/J;:F)DC7[+?26R; 1E5 P3DGGFM>@ HHHH **** "BBB@
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MC_A='AS_ )\M5_[]1_\ Q='_  NCPY_SY:K_ -^H_P#XNM?_ (5?X._Z _\
MY,S?_%T?\*O\'?\ 0'_\F9O_ (NB\ ]XR/\ A='AS_GRU7_OU'_\71_PNCPY
M_P ^6J_]^H__ (NM?_A5_@[_ * __DS-_P#%T?\ "K_!W_0'_P#)F;_XNB\
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M:\#%U74EY'V&#PBPU.S^)[E^*O1OAS]S4/\ MG_[-7G,5>C?#G[FH?\ ;/\
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M!*PUW6.-I'.%4$D^@%8G_"9:!_S_ /\ Y!D_^)K:EC$T+Q,2%=2IQUYKEO\
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M+M(K2ZBNH%:2%=K2J\BJRN1RX(/?/.#4EU_Q(/&4-Z/EL=8Q;S^B7"C]VW_
MAE?J!6QK6E_VQIWV3SO)_?12[MN[[CAL8R.N,5E^-PEWHB:0J![O4IE@MQ_<
M8'<9/^  %OP%"8#]'4:OK]YKC?-!%FSLL]-JG]XX_P!YACZ)[UI:QH]KK=D+
M>Y\Q"CB2*:)MKQ..C*>Q%3Z?8P:9IUO8VR[88(Q&@]@._O574]*DO+BVO+2\
M:TO+;<$?;O1E;&Y73(W X'0@@@<TKZ@9^CZA?K<7NAZNR2WMK")8[J--JW$3
M9 8C^%L@@CIZ5E>#_#&F7O@_3YM1MH[RXE@!$LR[FB7^%4/\&!C[N.>>M='8
MZ/)#=W-]>70N;ZXC$1D6/RT1!DA57)(&22<DDU-HFF_V/HMGIWF^=]FB$?F;
M=N['?&3BG?L%CGO#&E0:YX=AN-=5-3FW/&C7*A]BHQ08ST8XR6'))Z\"J5OJ
ME]_PB=K917,D<DVJMI@NBV9$B$C#.3_%M7 /KCO76Z)I?]C:5'8^=YVQG;?M
MVYW.6Z9/KBJ-MX7MX]%N=,N96F2:YDN1(@V-&S.74J<G!4XP?;IVHN%A9/"&
MBFV*0VBV]SCY;V([;@'^]YOWB?J3GOFN4U/Q%<+X7\.ZU=P/=7$%\XD6!>92
MB2KN&.@.,^PS76OI>M30FUFUU/LY&UI(K,)<$?[^XJ#[A![8J2;P_;E-(BM2
M+:#39Q*D87.X!&7;G/'WLYYH3[A8IZ!I@O)(_$-_=17U[,F8&B.8;=#_  Q_
MU;J?;I6#-_R)OCG_ *^[O_T!:Z>W\/C3=7-WI=S]EMIB6N;+R]T4C?WU&1L;
MU(R#Z9YJ!_"^_1M<T_[9C^U999/,\K_5;P!C&?FQCVHN%B"T\*:;)H,37<(N
M+]H QOI.9E?;G*/U3!Z 8 JC!J-YK.E^%K*:>2,:C"TEW+&Q1W6- 2H8<C<2
M,XYP#7810>79I;[L[8PF['7C&:YJZTNVT?P_I%G</>,;%@(]0M8AF!@I&]ER
M3M()!X8<\XZT)@1>*?#.F6_A74YM-MX=.N([61O-MD"%P%.5?'W@1D<YZYZU
MTFD_\@:Q_P"O>/\ ]!%<?K-Y_;FB7>G1:]9:I//&8XK;3(]I9CP#(0[X4'DG
MY1QSZ5VUI!]FLH+?.?*C5,^N!BA[ CD/#,.KN=;-C?6,,/\ :]S\L]F\K9W#
MN)5_E5F"/4(_B#:_;[FVG8Z9-M,%NT0 \R/KEVS^E;.C:1_9"7R^?YOVJ\EN
MON;=N\YV]3G'K3I-+W^(H-6\['E6KV_E;>NYE;.<_P"STQWHN%CF;&TO;_0_
M%MKI\_DW<NI3K&^2.<+QD<C/3/;-7?#?]B2M<V"Z*NEW_DA;JPDC #ITW#'R
MR*>1N[]ZT;/1)["WU-;:_P!DUY=O=+(801'NQ\N"?FZ>W7M3K+1YTU=M5U"[
MBN;OR/L\?DP&)$3.X\%F))..2>W2BX'.>'K:PT>S\3ZG;:;:K/9WESY12%0P
M15!" @9 ]JU-'\.Z??Z3;7VK00ZE?7,:S23W*B0@L,X3/"*,\!<=/7FM/2M'
M731J(:43K>W4EP5*8"A@!MZG/3K56WT74=-B^RZ5JD45DO\ JX;JU,QA']U&
M#KP.V[=CZ<47"QRVMM<0:1X@T(74LD-I+9O;32-YCQK)(IV$GKM(XSS@BMW5
M_"<":*[Z7$HU>!UNHKMP#+-,F3\[=3NR1Z8;C JS/X6BET:YLA=2&XNIHY[B
M[E4,\C*RMR!@ 84  8 'Z[TDB11M)(P5$!9F/0 =31?L%CD;S5(O%FFZ7I]H
M65-37S;L \Q0(?WBGW+?)^)]*Z]55%"J % P .PKE/!6F0 :AKZ0>4=5F,L*
M'^"')V_3<27/^\/2NLI/L""BBBD,**** .7\!_\ (#G_ .OEO_05KJ*Y?P'_
M ,@.?_KY;_T%:ZBKJ?$R8[!1114%!1110 4444 %-D_U3_[IIU-D_P!4_P#N
MF@#B++_DGEU_UT_]F6NMTG_D#6/_ %[I_P"@BN:T2REU#P1/:PE1(\AV[NG!
M4_TJS!#XKMK>*!!I^R- BYSG &*VFKW7F9QT.HIDL231/%*H>-P593T(-<_G
MQ=Z:=^M&?%WIIWZU'+YE<WD6?^$4T7_GT/\ W]?_ !JZVDV+:<+ VZ_91T3)
M]<YSUS63GQ=Z:=^M&?%WIIWZT[-]1:=BU_PBFBY!^QG_ +^O_C5R\TFQOX8X
MKFW5TB^X 2NWZ8K)SXN]-._6C/B[TT[]:+/N&G8NP^&=(@F25+3YT.Y<NQ /
MT)J:^T33M2F$UU;AY -NX,5./P-9F?%WIIWZT9\7>FG?K19[W#3L:-GH.FV%
MP)[:V"R@8#%V;'YFM*N<SXN]-._6C/B[TT[]:3BWNQIVZ'1US>L?\C;HO_ Z
M7/B[TT[]:BATW7+K6[*\U$V@2WS_ *HG/(IQ5M;B;N/TS_D=]7_ZYK_):Z6N
M:TS_ )'?5_\ KFO\EKI:4]T.(4445!04444 5[VQM=1M7M;VWBN('^]'(H8&
MO'?%WPRO-$F.L>&7F:&(^8848^;#CNIZL!^8]Z]JHJHR:$U<\U^'WQ)&M,FD
MZTZ)J!XAGQ@3^Q[!OY_7KZ57CWQ/\"BS+>)-'C,:AMUU%'QL.?\ 6+Z<]?S]
M:ZWX<^,/^$GT4PW3@ZE: +-V\Q>S_P!#[_44Y)-<R$GT9VE%%%04%%%% !11
M10 5SGC*(OI<4@'W)1GZ$'_ZU='6;KUM]JT:YC R0FX?4<_TKGQ</:4)Q78W
MPL^2M&7F>:T445\6?7!1110 4444 %%%% !1110 4444 %%%% !1110!9T^%
M+G4;:"3.R255;![$UV<GA32%P&,B$]/WG7\ZY#2/^0S9?]=T_F*['Q)H]SJW
MV7[,8QY6_=O..N/;VKV,!3BZ$Y\G,TUH>5C:DE6A'GY4T8VM^%Q86K75K*[Q
MI]]'QD#UR*D\,:?I=W8S/=*CS!L$.V-JXZ_SYK7ND_LKPE)!=2B1Q"T8/J3G
M 'TS^E9/A;2[*_LYWNH!(RR8!)(P,>U;/#PABH*$5JKM/I^9DJ\Y8:3G)Z.U
MUU_(YNZ2*.\F2!MT*NP1O5<\5#6]H.CPZEJ=P)L^1 >4!QGG@?3BMN>'PU+Y
M]JPABDAR&(!5@1Z'O^M<%/ RJQ]I=13O:YVSQD:<O9V;:WL<QH%M#=ZW;P3H
M'B;=E3WPI-6?%%E;V&IQQ6T0C0PAB 2><MZ_2F^' @\36XC8L@+[21@D;6[5
MH^)K*:_\16]O NYV@'T W-R?:M*=)2P3LKRYK>?0B=1QQ:N[+EO^9RM%=CJ.
MGZ/H>FH)8%GNB,+N8@L?4X/ KCR<DG&/I7)B,.Z#49-7\NATT*ZK)RBG;\Q*
M***YS<**** "BBB@ HHHH **** "BBB@ HHHH ***0]*NG!SFHKJ3.:A%R?0
MW_#B9E!KNX^$%<AX:AZ&NQ4845]RE;0^,;N+1110 4444 %>:_&*]>+2M-LE
M)"SS-(V.^P ?^SUZ57G7Q>TY[C0K*^12?LLQ5O97 Y_-0/QK*M_#9W9:U]:A
MS?UIH>2PUH0UGPUH0UXE0^ND7XJ]&^'/W-0_[9_^S5YS%6SIVI7E@&%K<21;
M\;MIQG'3^=<]*LJ-55'T_P CCQ=%UJ3II[FEK/\ R&KW_KL__H1K9\$?\A6;
M_KB?YK7,M*\[M+(Q9W)+,>I-36MY<64A>VE:-B,$J<<5R4JZIXA56M+W)JT7
M.@Z2>MK'375L;KQ\$QD!T<^P"@_TJ?Q9IDJW"ZE "1@"3'52.A_SZ59\*V<\
M@EU6\9GFF&U"W7;Z_H/RKIB 001D'J#7NT<(J]"3EISNZ\NQXM7%.C6BHZ\J
ML_/N<[9^+K)[9?M>^.8## +D$^U8FIWLWB34HH+2)O+7A0?U)]*Z>?1]%>;$
MD$*R'^$/M_0&K<$-AI_[J%882W;(!/\ 4U4L+BJT53JS7+Y;LF.)PU)NI2B^
M;SV0^VM([>PCM!RBIL.>_K7$6\LWAC7'$J,T1RI_VE/0BN\DECB&9)%0'C+'
M%5[V&QN(U6\$+*>5WD#\C6^)PCJ*+INTH[&&'Q2IN2J*ZEN95QXML5@)MA)+
M,1\J%<8/O_\ 6KFK".:#Q- MR,3&568'KDX//YUV5OIND696>&.!>?E=GSS[
M$FI7L]->7[<\<)?(;S2W<=.?PKGJX/$5G&522NGLMO\ ASHIXNA24HTXNS77
M?_AB#Q)_R +K_@/_ *$*S_!?_(-N/^NO]!6_,EO=6VR;9)"^.IX//'ZTVVM;
M6Q7RX(TB#G.!W-=,L/)XJ-:^B5OS.:->*PSHVU;O^1D^+O\ D"?]M1_(T[PG
M_P @-/\ ?:M6YAMKJ K<JCQ*<G<> 11:0VT, 6T""+.1L.1FCZO+ZU[>^EK!
M[>/U;V-M;W)F4.I5AD$8(KS.Z,NGS7FGC[CN%;/< Y!KTVN$OHUU/Q@85 VF
M4*V.X P?Y&N3-H<T8./Q7M]YU97.TIWVM?[CK-%M?L>D6T1&&V;F^IY_K5_K
M3))8H0/,D1 >FY@*3[1!LW^='L)QNW#&:]6G!0BHKH>;.;G)R?4Y2[MY]$U,
M3PC]V3E#V(]#6FOB>V,>6AD#^@QBM:1[:2 F1HFA/!+$%35)],TE<2ND:AN0
M3(0#].:TNGN9V:V(G+:WHLC!0'W$H![=ORK,TG6!IR-;7*/M!R".H_.NFMU@
M6(+;[/+!_@QC-17&FVETVZ:!2WJ"03^5%PL<YJ^K_P!H((;='$2_,Q/4UJ>&
MCG37'I)_05H1Z?:0Q-&D"A6&#ZG\>M206T-JA6&,(I.2!ZT-JU@2=[G->(-T
M&KQSE<KM!'X5LV>LV][<+#"KY());'%7+BVANDV3QAU[9[5#;:;:6DF^&+:W
MKN)_G2NK#L[ENBBBD,**** "BBB@ HHHH **** /+OC+(XMM'B&=C/*Q^H"X
M_F:\QA[5[/\ %/27U#PL+F)=SV4@E(']PC#?T/X5XQ#VKS,6K3/J\JFI85)=
M+_YFA#6A#6?#6A#7E53N9Z9X-OK2#PY-'-=0QN96(5Y #]T=C7'#I52$D#K5
MM>@KFQ-=U(0@U\)RTJ"ISG-/XCMO!MY;6^G3K/<11,9<@.X!/ ]:=X+M2!=W
M9Z,0BG]3_2N.M;>6ZN8X(06=S@ 5ZGIUDFG6$5JG.P<GU/<UZ>6N5=PNM*=_
MFV>7F"C14K/6=ON1S6MZ)=VVH?VEIJL<MO*H.5;N<=Q4+^(]9GB\B.V"RG@L
MD9W?A7:U5@OHYV0!)$\P90NN WTKME@'S-TIN*>Z....7*E5@I-;,Q?#>A2V
M3M>78Q.PPJGJH[D^]:NKZ<NJ:>]N2 _WD8]FJ6"^CG9 $D3S!E"ZX#?2E2^B
M>0* X5F*K(5^5CZ UTT\+3ITO8I:'/4Q-2=7VK>IQEG?:OH#-:M;EDSPKJ2,
M^Q%27MIJFK6<M_>1LOE@"&%5.3DC/'7I77K>!KCR?(F##DDJ, 9QGK[4L=V)
M9"JQ2X#%=^WY<C@UR++7R^SE4;CT7]=CJ>8>]SQ@E+JS+\*1R1:04EC=&$IX
M92#T%9%Q:W!\:"402&/SD._8<=N]=4M]$TH0*^UF*K(5^4GT!I\5U%,9@K?Z
MEBCYXP<9K:6"4J4*=_A:?W&4<8XU)U+?%?\ $FKC-!M;B/Q++(\$BH=_S,A
M_.NKAO(9T@="<3 E,C' I$OHGD50'"LQ59"ORL1V!_.M:V&56<)-_"[F5'$.
ME"44OB5BS7(>-+8K);7:\$@H2/;D?S-=?7(>,[@-+:VBG)&78?7@?R-<^9\O
MU:5_+\S?+K_6(V\R_P"$+;R=(:8CF9R1]!Q_/-=!52SA^PZ9!%L9C'& 0HY)
M[_K0FH1O;R3F*940')9>N#C KIPU+V5&,.R.?$5/:593[LP9()]6UL-)%(L
M/5E(^4?Y_6NFDB26%HF7*,NTCVJ+[6HB:1XI4"D##+RQ/  Q0MVK(Y$4N]"
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M .2>:M_NQ_\ HQ:<=T)[&1\&I#)X+G4DXCO74>WR(?ZUZ'7G/P7_ .1.N_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ^XK*\0?$:'7?!EUI4&BW:W?E*MSN0>5  1DYSGJ,#('--UD$?#_ ,#9&/\
M28_ZT[>0KG?>*?&]EX9FALDMIK[4IAF*T@ZD=B3SC.#T!/M530?'EQJ>JQZ;
MJ7AO4M+GE!,1>-G4@=R2JD#WQCW%8OB47GA/XA_\)7)837^FS6_E.T0RUN0
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MG6J_]L?_ $<E..Z$]C(^"_\ R)UW_P!A!_\ T7'7HU><_!?_ )$Z[_["#_\
MHN.O1J<_B8+8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$1-?R%8(_P#GG$">GU/_ *"*](HI7TL%@HHHI#"BBB@ HHHH **** "BBB@
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MB/J!5^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E_
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MVD7@BR!A1S=PAIRXR9,]CZ@#@#T%.\"V<:^%XY),S22-)$SR_,?+1V54Y_A
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M&1#';I&. *E  I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL[71?G1+O^S+N"TO
MF8YYQ\D>.23D'C&>QJ73'F_L>U>\NH;B;R5:6>'B-SCEA['K0!<HK(GU[3[B
MQOO[-U.SGN8('?;#,DC(0#R0">_K4GA^\EO/#.FWMU(&FFM(Y97( R2H)/'
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M%9A\1:&MLMRVLZ<('8HLINDVLPZ@'.,UI*RNBNC!E89!!R"* %HHHH ****
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M=B_>YYW8S^M"3$SLZ*JQZGI\U])8Q7UL]Y&,O;K*ID4>ZYR.H_.K5(84444
M%%%% !1110 5R?Q+_P"2>:M_NQ_^C%KK*Y/XE_\ )/-6_P!V/_T8M..Z$]C%
M^"__ ")UW_V$'_\ 1<=>C5YS\%_^1.N_^P@__HN.O1J<_B8+8****D84444
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MTFU>?<(D49!D8Y)QW"Y ]SCUK7^'_A1O#^F/>7^7U>^_>7+N<LN>=F?U/O\
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M_O-HW=..N>G%9?C>_NM+\&ZE>V4QAN8D4I( "0=P'?V-=!7+?$?_ ))_J_\
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M; 7[0-."06@4JK#L<$DCZ9/UJQ2&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <OX#_P"0'/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JO?V::AIUS92$B.XB:)B.H# @_P ZL44
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M,<L>3W)JS10!7M[&VM;BYN(8]LMTX>9MQ.Y@H4'GIP!TJQ110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6+%U+&L3R;CRJDD#&<=2:62QMI;^"^>/-S C)&^X_*K8W#'3^$58HH ****
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M@21=LDF96![9Z?IBMFBBI;N[C2L@HHHI#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y/XE_\ )/-6
M_P!V/_T8M=97)_$O_DGFK?[L?_HQ:<=T)[&+\%_^1.N_^P@__HN.O1J\Y^"_
M_(G7?_80?_T7'7HU.?Q,%L%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
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M%7:*+L+(I?V-I?\ T#;/_OPO^%']C:7_ - VS_[\+_A5VBB["R*7]C:7_P!
MVS_[\+_A1_8VE_\ 0-L_^_"_X5=HHNPLBE_8VE_] VS_ ._"_P"%']C:7_T#
M;/\ [\+_ (5=HHNPLBE_8VE_] VS_P"_"_X4?V-I?_0-L_\ OPO^%7:*+L+(
MI?V-I?\ T#;/_OPO^%']C:7_ - VS_[\+_A5VBB["R*7]C:7_P! VS_[\+_A
M1_8VE_\ 0-L_^_"_X5=HHNPLBE_8VE_] VS_ ._"_P"%']C:7_T#;/\ [\+_
M (5=HHNPLBE_8VE_] VS_P"_"_X4?V-I?_0-L_\ OPO^%7:*+L+(I?V-I?\
MT#;/_OPO^%']C:7_ - VS_[\+_A5VBB["R*7]C:7_P! VS_[\+_A1_8VE_\
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M7.PHKGX?&&E38Q*0?J#_ "-:$6MZ?+C;<H/][Y?YT6871H45%'<0RC,<J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %175M'>6
M<UK*,Q31M&X]01@_SJ6B@#PGX:7;^&_B#<:/>$IY^^U;/ \Q3E3^."!_O5[M
M7BWQ;T&;3=;MO$MEN19F42.O5)E^ZWX@#\5]Z],\(^)(/%'A^"_C($P&RXC'
M\$@Z_@>H]C6D]?>)CIH;M%%%9E!1110 4444 %%%% !15.\U2SL%)GF4$#.T
M<FN2U+X@Q1[DLT!/][K_ /6_G3L*YW!(4$D@ =S6?=:[IUH"7N58CLG/Z]*\
MJO\ Q1J5\Q+2E1]<_P#UOTK(EFEF.99&<_[1S1H&IZ=>>/[&'(@3>?<Y_E_C
M6#=?$&]DR(4V ^@ _P :XRBBX6-FZ\3ZI=9WSG'U)_G6>]_=R?>N)/P;'\JK
M#&1GI70Z[X7_ +'TVTOX;S[5;W&,-Y6S&1D=SU&:+A8Y\L6.6))]325IZ#HT
MFNZHEDDGE@J6>3;NV@=\9'? _&H=6L4TW5+BRCG\\0MM,FW;D]^,GH>*0RE1
M110 4444 %%%% !1706OAG[3X6GUK[7M\K=^Y\O.<''WL_TKGZ "BBB@ HHH
MH **** "BNSTCP%_:NE6]]_:7E><I.SR-V.2.NX>E4?$'@V[T.V^U+,MS; @
M,P7:5STR.>/QH YJBNHNO#5C!X-AUA;YC</M)0D;6)."H'7(^O8\5R] !3TE
MDC_U<CK_ +K$5H^'M-AU;7+:QG9UBEW;C&0#PI/<'TI?$>F0Z1KD]C;M(T48
M7!D()Y4'L!ZT 5HM5OHB"MPQQ_>YK5MO&.J6^,R%@.VX_P!<BN>HIW8K'=VG
MQ"D&!<19]\?U'^%;]GXUTZYP&;:Q[ Y_P/Z5Y+11<+'NMOJ5I<X\J=&/IG!_
M*K08'O7A$-]=6^/+F< =B<C\C6_I_C2^M,+(2ZCWS^A_Q%&@:GK-%<IIGC6S
MO"$D.Q_;_#_]==)!=PW";HI%8>H-*P[D]%&<T4 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_Y\M*_[]2?_ !='_"Z/$?\ SY:5_P!^I/\ XNO=:*.:/8+/N>%?\+H\1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1WZ?UK3\&ZUJFMR7L>I*)8%'#F,* 3U3CKQ^-><7L<<5_<1Q',:2LJ'V!.*
M/2+S6-2T*RTW2XIX-0UB1ML@?+<=LG(/H,GK@FLGQEX@G2U711<"6? -Y(@P
M,]=@]A_A[U4L$7PKHG]J3*/[4O%*VL;?\LT/\9'^>WJ:M?V;X=TF"T774N;J
M^O5$K2*QPF[Z$9_4T <YX=U:31M9@N58B,D)*/5#U_Q_"MKX@Z:EKK$5Y&,+
M=IEL?WAP?T(K&\1Z0NB:S):)(7BP'C9NNT^OO75?$#G1=(+??YS_ -\C- 'G
M]%%% !1110 4444 %%%% !1110 4444 %%6;?3[FYY2/"?WVX%:5OIUO <M_
MI$GIC"C_ !IV%<S[33Y+KYR?+A'5V_IZUN6]N'"00(5B4_BQ]35JWL)[MUW#
MY1T ' KJM+T18@&9: 'Z'IWDQAB*Z$# ID48C4 "I*0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JGJMK]LTV:(#+8W+]15RB@#+T"[^TZ8B
MD_/%\C?TI-<LWGMEN(.+BW.]2.I'>LGSCHGB"4'/D2'+#V/.?PKJE974,I!4
MC(([U3T=R5JK%73;Y-0LUF7 ;HZ^AJRZ+(C(ZAE88((X-85Y:SZ3=M?V2[H6
M_P!=$/YBM:ROX+^$20OG^\IZK]:375#3,Z3PY$'9K6YFM\_PJ>*A'AA=^_[;
M+OZ[L<YJQ-J&JI.ZQZ9N0'"MOZBF?VEJ_P#T"O\ QZGJ+0/[!F_Z"EU_WT?\
M:/[!F_Z"EU_WT?\ &C^TM7_Z!7_CU']I:O\ ] K_ ,>HU#0/[!F_Z"EU_P!]
M'_&C^P9O^@I=?]]'_&C^TM7_ .@5_P"/4?VEJ_\ T"O_ !ZC4-!'\//(I5]1
MN&4]0QR/YT+X?D50JZE<JHX !P!^M+_:6K_] K_QZC^TM7_Z!7_CU&H:%[3[
M%[)7#W4L^X_\M#TJ[5+3[F[N%<W5KY!!^7YLYJ[4LI!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %,>-7&"*?10!DW>D13 _**P
M+S07 ("AE_NL,BNUIC1JW44 >5W?A^+)_=/$?5.1^594VASJ3Y4B2>Q^4_K7
MK\VGQ2CE167<Z!&^<**=Q6/)I;2X@_UD+J/7''YU#7I<V@RQ_P"K)%9=SHC$
MGS+:-_?;@_G1H&IQ%%=)-H5O_P \I8_]UL_SJF^A@?<N,>SIC]:+!<QZ*T7T
M6Z'W&BD_W7_QJ%],O4ZV[G_=Y_E19A=%2BI'AEC^_$Z_52*CI#"G([1R*ZG#
M*00?0TVB@#T'QI$-9\.Z?K5L-RH/GQV#8SGZ$8_&O/JT[/Q!JEA8O96]SBV?
M.Z-HU<'/7[P/%9E #HY)(9%DB=D=3E64X(^AK8T'Q+>:#<R21XFBE.98W/WC
MZY['WK%HH [+5/B'>7MH\%I:K:%QM:3S-[8]N!CZUSFCRZ?!J4<VIQRR6\?S
M>7&H.\]@<D<50HH OZQJL^LZE)>3\;N$3LB]@*W-/\:FVL8+>]TN"^>V&()7
M(#(.W8_F,5RE% &U#]L\5^)8S+S).XW[1PB#KCV K:^(M^DNHVUA&01;(2^.
MQ;''Y ?G7,Z;K%]H\CR6,PB=QM9O+5CCTY!Q56XN);JXDN)W+RR,69CW)H C
MHHHH ** "3@#)J9+2XD^Y!(?HIH AHJZNDWK<^3M'JS 5*NC2?\ +2>%?8')
MIV8KHS:*V4TBW'WYY'_W$Q_.K,>G6R_<M"Y]78G]*+!<YX L< $GT%6HM,O)
M>1 RCU?Y?YUTD-G<=(HDB!_N)BKD6B7$Q!<L?K1H&IS4>D1K_K[@$_W8AG]:
MO06D49_T>V!;^_)\QKJ;;PWTW"MBWT.*/&5%%PL<?#I=S=,"Y8UN6/AT#!9:
MZ:*SCC'"BK 4#H*0RC:Z=' !A15Y5"C %+10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '/^);=?\ 1[MERJMLD^A_R:;9WDFC
MSK:73%K1^89NP%;&HVWVO3YH<<LO'U[5GZ4(M4T18+A=_E_(P/48Z&JOH3;4
MV00R@@@@CJ.]9%WH?[XW.GRFWGZX'W35;;J&A,=@-U9>G=*U+/5;2^4>5* _
M]QN#2VV'ON9PU>_L?EU"R9@/^6L?0_TJU'XATZ0<S%#Z.I%:E026-K+R]M$Q
M]2@HT#4K?VYIO_/VGZT?VYIO_/VGZU+_ &78_P#/I%_WS6-?V=M'K]C"D*+&
MX^90.#S35@U-3^W--_Y^T_6C^W--_P"?M/UJ7^R['_GTB_[YH_LNQ_Y](O\
MOFEH&I%_;FF_\_:?K1_;FF_\_:?K4O\ 9=C_ ,^D7_?-(=+L,?\ 'K%_WS1H
M&I8@N(KF(20R*Z'N#4E8/AY1]IOGA!6VWX05O4,$%%%%(84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K"L?]!\17-KTCG'F)]>O^-;M8?B!# ]KJ"#Y
MH7 ;Z?Y_G30F;E9MYH=E=L7V&*3^_'Q3/^$BT[_GJW_?!H_X2+3?^>K?]\&B
MS"Z*XT_6+/BUOEE0=%EI?MFNQ</81R>ZG_Z]3_\ "1:;_P ]6_[X-'_"1:;_
M ,]6_P"^#3U["T[D/]IZO_T"O_'JKA=0O=9M+B>R:%8C@D'(Q5[_ (2+3?\
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MIR.A'(K/^&5[=7_@FVN+RYFN9C+(#)-(78@,<<GFG;2XKZV.PHHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO:ZE8:O]JL9)0DD14HK-R<,F2.0#R#GZ52^(6G1ZCXNTR_BN"(]<BAD4%/\
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MR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Q'Q!\':AXKDTMK&:UC%H[M)Y[,,YVXQA3_=-=O133L[@U<0#  I:**0!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8\T\&6EOK/C>36X/$TFH7%LA68C2OLRS*5P,L#CJ1U&3M]!FL_1O^1,\?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img35377828_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img35377828_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,F!QD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9!<O_P!K3_W(_P C_C1_:T_]R/\ (_XU0HHL@N7_ .UI_P"Y'^1_QH_M:?\
MN1_D?\:H44607+_]K3_W(_R/^-']K3_W(_R/^-4**+(+G3 AAQ2U4L9#)"I-
M6ZS*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K,U7_5CZBM.LS5?]6/J* ,NBBBM2 HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** -G3?^/9?I5ZJ.F_\>R_2KU9%A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:K_ *L?45IU
MF:K_ *L?44 9=%%%:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ;.F_P#'LOTJ]5'3?^/9?I5ZLBPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-5_P!6/J*TZS-5_P!6/J*
M,NBBBM2 HHHH ***;O7.-PS]:+@.HHH)QUH **** "B@'/2F/+'%CS)$3/\
M>;% #Z*0$, 000>A%+G'6@ J*YNK>SA,UU/%!$#@O*X51^)I[R)&A=W55'4L
M<"L3Q9X?C\6>'9-,-UY"2LCB51NZ'- S:BECGB66*19(W&5=#D$>H-/JAHNF
MC1]$L].64RBVB6,.1C=@=:N/+'$,R2*@_P!HXH$/J*XN8+2$S7,\<,2]7D<*
MH_$U(KJZ[D8,/4'-<1\6_P#DG6H?[\7_ *,6AC1VD,\5S"LT$J2Q.,JZ,&5A
M[$5)7,_#W_D0-%_Z]Q_,UTV<4 %%(S*BEF8*HZDG %".LB!T8,IY!!R#0(6B
MHFN($?8TT:M_=+ &I: *]U?6EBBO>74%NK':K32! 3Z#--N-2L;,Q"YO;: R
M\1^;*J[_ *9/->:_'$@Z!I7/_+X?_03757?ADZJ;"\6>-=MLB,DD>X<8/K^G
M2E<=CJJ*BMH!:VD-NK,RQ(J!F.2<#&34M,04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!LZ;_Q[+]*O51TW_CV7Z5>K(L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI/$$<>CZQ(J:J@Q'*>!<@?\ L_MWZBO3*^-$D>*19(W9'0AE93@@CH0:]_\
MAK\2T\01QZ/K$BIJJ#$<IX%R!_[/[=^HJZ]"WO1)IU+Z,],K,U7_ %8^HK3K
M,U7_ %8^HKD-S+HHHK4@*1E#*589!&"*6B@#FK[39+:0LBEHL\'T^M#W[_9!
M;Q1B->C$'DUTM,\F+.?+3/KM%>5++'&3=&7*GY&3I=F<[8Z=+<R!G!6,=6/?
MZ5TBJ%4*HP ,"EHKKPF$AAHVCJWU+C!1.)^*6@MK7@Z:2!"UU9,+B+:.>/O
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M>C>&],T%YFT^%HS* 'RY;.,XZ_6M*>"*Y@>&>-)(G&&1QD$?2B^MPMH<VGQ
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M6DI (:*#10 4444 )1112 2BBB@8E%%%(!**** $I#2TAH *2EI*0Q#10:*
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M]9W;VLEM%Y!4('5XL@[>>G3K18#7HHHIB"BBB@ HHHH **** "BBB@ HHHH
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M@B*69C@ #))H 159W"(I9F.  ,DFO;/ WPW_ +#M8M8UF('47P88&Z0#U/\
MM_R^O30^&?PS714BUO6X@VI,-T$##(MQZG_;_E]>G?ZK_JQ]17#6KW]V)T4Z
M=M69=%%%8F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &SIO_'LOTJ]5'3?^/9?I5ZLBPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@-;?D?\ &C_A!O#'_0%M?R/^-=!11[6?\S#DCV.?_P"$&\,?] 6U_(_XT?\
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M:*/:3[ARQ['-?\*^\)?] *T_(_XT?\*^\)?] *T_(_XUTM%'M)]PY8]CFO\
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M4BUK6H@VI,-T$##(MQZG_;_E]>GJ-77KW]V)-.G;5A69JO\ JQ]16G69JO\
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M%K^SKK_GE_X\/\:/[.NO^>7_ (\/\:JT4:@6O[.NO^>7_CP_QH_LZZ_YY?\
MCP_QJK11J!:_LZZ_YY?^/#_&C^SKK_GE_P"/#_&JM%&H$\MG/"F^2/"^N14%
M%% @HHHH **** "BBB@ HHHH V=-_P"/9?I5ZJ.F_P#'LOTJ]6184444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH V=-_X]E^E7JHZ;_Q[
M+]*O5D6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !117G/Q(\5ZQX>U_PY:Z9<K##>S;9U,2MN&Y!U(..">E#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKX:U+5FLUC:S#D1B3(;"[NN.*5F.YU=%>>6_Q%O]2\B'3M&\RY9P).69$!(
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M]9^('D:DVG:-8-?W"$JS $C<.R@<M^E1Z;\1'74$LM>TU[!WP Y! !/]Y6Y
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M!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_IUIJ<"PWD7F1JV\#<1S@CL?<U479W%)75AG]LZ7_P!!*S_[_K_C1_;.E_\
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M-K<\&NPK$_X1'0_^?'_R*_\ \56W1)JR2!)WNPHHHJ"CE_'G_(#@_P"OE?\
MT%JZBN7\>?\ (#@_Z^5_]!:NHJW\*)6["BBBH*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-
M5_U8^HK3K,U7_5CZB@#+HHHK4@**** "BBB@ J.X\S[-+Y/^MV'9_O8XJ2B@
M#R2#QS\0]' MM7\'R7LB\>=;J1N]_EW#^55[;1/%7Q&\4V.I^)-/.F:-8MOC
MMFR"YR#C!Y.2!DG' XKV.BE884444Q!1110 4444 %%%% !1110 4444 %%%
M% !1110 5'-/%;Q&6>5(HQU9V"@?B:DKA?$UK#K7Q%T#1]003:<MK/=&W?[D
MD@P!N'?&<XH&=M'<0RMMCFC<[0V%8'@]#]*;%=VT\CQPW$4DD?#JC@E?J!TK
MR#48U\+ZE\0/['S (=/M_)5#_J=_4+Z 9)'I5[2='O(M3\,W.D>$[C3/L[JM
MW=M-$?/A9?FW[6RQS@\TKA8]/:_LU*AKN %V*KF0<D=0/>I)IXK>,R3RI%&.
MK.P4#\37CUAX:TF_\#^,-2NK19KR&[OC!*W)AV98;/[O//'6M2VB3Q)XE\*:
M=K'^E6::"M\89>5EF.U=S#^+ YYHN!Z9]I@-O]H\Z/R<9\S>-N/KTI!=VS22
M(+B$O&-SJ'&5'J?2O(]6@CTFS^(>A60V:;#:PW,, ^["[C+!?0' .*M:KX4T
M:WU?P5'#9A!?%H[PJQ!N5\L-B0Y^;)'>BX'I%_=ROHMU<:3-:23B-C"\C_NM
MPZ;B.U2VMQ(FE03ZA) DOE*9G1OW8;'.">V>E>77-I!I<7Q*TRQC6"QCLTDC
M@3A$9H3NP.V:M);1:[K_ (0T+45\W3(]$6\-NQ^260!5&X=\#G%%P/3H9X;B
M,202I+&>C(P8'\163%XHTV;Q)/H:RK]IAB65F+KM.3@*.>6XZ5>TW2K#1[7[
M+IUK%:P;B_EQ+A<GJ<5P=GH.D)\7-6<:9;$PV$5U'^['RRER2X_VCZTP/0C=
MVRW(MS<1"<C(B+C<1].M$]Y:VS*MQ<PQ%_NB1PN?IFO$-,M-0U_P=+?6WA>Z
MN=<NKA[B/6!-&&602'&"6W!0!MQTKHM?L?[*\27FO>)M &KZ1<P0CSE D:PV
MJ PV'^$G)R*5P.ZN?$^FVGB*WT6651<31/+N+J%0*0,'GJ<]*V:\WU+1=#U+
MXIZ/*VGVL\-WITMPS-&")&!7:Q]2!TKTBF 4444""BBB@ HHHH *P_$7A;3_
M !)$GVD-'/&,1S1_> ]/0BMRBF!YU'\)X!+F35I&C_NK  ?SR?Y5W&E:59Z-
M8)9V47EQ+SUR6/<D]S5VBAML+!1112 **** "BBB@ HHHH **** "BBB@ HH
MHH IZII=IK%B]G>Q>9"W.,X(/8@]C7#2?">W,N8M6E6//W6A#'\\C^5>BT4T
MV@L8?AWPKI_AN-_LP:2>08>:3[Q'H/05N444 %%%%( HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#9TW_CV7Z5>JCIO_'LOTJ]6184444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5F:K_JQ]16G69JO^K'U% &71116I 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QGCH
M:&EQI=QJ6L2Z-?Q,[6=]&OW> &4D@C!!'!KLZ:Z)(NUU5E]&&10!YGX*TNSU
MC6?$]RK7%_I%[#%;-=W0(-VX!\QAP..0!CCTKJ-'\*76D7%N!XCU*XL;;B&T
MEV;0N, ,P&6 [9]!72@!0 H  Z 4M%AG/6GA*UM- U72%N)FBU*2>21SC<IE
MZX^G:H+SP5;SV>DK:W]U97VE0B"VO8<;]FT*0P(PP..E=1118#E8_ EDN@:K
MILMY=3W&J\WE[*097/;M@ =A6A=^&[>\O-$N7GE5M(8M$!C#Y3;\WX5M446$
M<Y=>#K2ZF\02M<S ZW"L,P&/W852N5_/O3-1\%VE]8Z7'%>7-I>Z7&([6]@(
M$B@* 0<C!!QR*Z:BBPS/T?3[C3+'R+G4KG4)2Y=I[C ;GL   !6==^%A-XKB
M\06NI7-I/Y:PW$484I.BG(!R./J*Z&B@1R2>!VL[N8Z7KVHZ?8SS&:2SAV%0
MQ.3M)!*@^@J76_!\VN7%PLOB'4HM.N<">QC*;&& "H8C*@XY ]374446&<WJ
MWA"*^O\ 3;ZRU"YTVXL(S!&T 4@Q'&4(8'TZUTE%% @HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#9TW_CV7Z5
M>JCIO_'LOTJ]6184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)
M>,->-O'_ &9:,?M$HQ(R]5![?4UK^(-:CT73S)P9W^6)/4^OT%<]X2T62[N#
MK5_EF9BT0;^(_P![_"M())<S(D[Z(U_"V@C2;/SIES=S#+?[(]/\:Z"BBHDV
MW=E)65@HHHI#"D9@JEF(  R2>U+7&>+]<=W_ +'L26D<@2E>O/\ #51BY.PF
M[(S]5O;CQ7K:6%D?]%0\-V/JQ_I_]>NZL+&'3;*.UMUPB#KW)[DUG>&]#31K
M ;P#=2#,K>GL*VJJ<D]%L**ZL*,8Z445F4%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%0->0)>):-(%F="Z*?X@.N* )Z*** "BBB@
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M_P"K'U%:=9FJ_P"K'U% &71116I 4444 %%%% !1110 4444 %%%% !1110
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M,G X'N:E.S&]CRC^QM4_Z!MY_P!^&_PH_L;5/^@;>?\ ?AO\*]#_ .$NT/\
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MJVPG:1S@'N/<5,JDK:H:@KZ,M4445@:G+^//^0'!_P!?*_\ H+5U%<OX\_Y
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M_/&'_OD_XT?VSJ'_ #QA_P"^3_C1S(+'045S_P#;.H?\\8?^^3_C1_;.H?\
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M +Y/^-',@L=!17/_ -LZA_SQA_[Y/^-']LZA_P \8?\ OD_XT<R"QT%%<_\
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M(?[H_*C^Q(?[H_*M>B@#(_L2'^Z/RI\>D11MD**U** &1QB-<"GT44 %%%%
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M3FY,WC&P4445!04444 %%%% !7+^%_\ D.>(?^OG_P!F>NHKE_"__(<\0_\
M7S_[,]7'X62]T=1574;"+4["6SF9UCDQDH0#P0>_TJU67XBNY[#0;FYMGV3)
MMVM@'&6 /!]C4J]]!O8R_P#A ]+_ .>]Y_WVO_Q-'_"!Z7_SWO/^^U_^)KE_
M^$NUS_G^_P#(2?\ Q-'_  EVN?\ /]_Y"3_XFNCDJ=S+FAV.H_X0/2_^>]Y_
MWVO_ ,31_P ('I?_ #WO/^^U_P#B:Y?_ (2[7/\ G^_\A)_\31_PEVN?\_W_
M )"3_P")HY*G<.:'8ZC_ (0/2_\ GO>?]]K_ /$T?\('I?\ SWO/^^U_^)KE
M_P#A+M<_Y_O_ "$G_P 31_PEVN?\_P!_Y"3_ .)HY*G<.:'8ZC_A ]+_ .>]
MY_WVO_Q-'_"!Z7_SWO/^^U_^)KE_^$NUS_G^_P#(2?\ Q-'_  EVN?\ /]_Y
M"3_XFCDJ=PYH=CJ/^$#TO_GO>?\ ?:__ !-'_"!Z7_SWO/\ OM?_ (FN7_X2
M[7/^?[_R$G_Q-'_"7:Y_S_?^0D_^)HY*G<.:'8ZC_A ]+_Y[WG_?:_\ Q-'_
M  @>E_\ />\_[[7_ .)KE_\ A+M<_P"?[_R$G_Q-'_"7:Y_S_?\ D)/_ (FC
MDJ=PYH=CJ/\ A ]+_P">]Y_WVO\ \31_P@>E_P#/>\_[[7_XFN7_ .$NUS_G
M^_\ (2?_ !->H5$W..[*CRRV1%;0):VL-NA)2)%12W4@#'-2T45B:'+^//\
MD!P?]?*_^@M745R_CS_D!P?]?*_^@M745;^%$K=A1114%!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-3O
MX],T^:[EY"#A?[Q["N9M-$O?$<0OM8O)4BD&8X(N !V// _6K7CMB-"B [W"
M@_\ ?+5TRJ$4*HP ,"M$^6-T3N[',?\ "!Z7_P ][S_OM?\ XFC_ (0/2_\
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_KY;_T%:ZBBBID[NXTK*P4444AG+^ _^0'/_P!?+?\ H*UU%<OX#_Y <_\
MU\M_Z"M=15U/B9,=@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+^/
M/^0'!_U\K_Z"U=17+^//^0'!_P!?*_\ H+5U%6_A1*W84445!04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '+^ _P#D!S_]?+?^@K745R_@/_D!
MS_\ 7RW_ *"M=15U/B9,=@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH KWME;ZA;-;W,8DC;L>WN/0UQESX/U+3IS/I
M%TQ'8;MK#V]#7=T549N.Q+BF<$+OQE&-ABE8^IC4TW^Q/$NM,!?S-'%GD2,
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MKE_'G_(#@_Z^5_\ 06KJ*M_"B5NPHHHJ"@HHHH **** "BBB@ HHHH ****
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M)=H?_/\ ?^0G_P#B:/\ A+M#_P"?[_R$_P#\31[27\H<B[GE]%>H?\)=H?\
MS_?^0G_^)H_X2[0_^?[_ ,A/_P#$T>TE_*'(NYY?17J'_"7:'_S_ '_D)_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?QY_P @.#_K
MY7_T%JZBN7\>?\@.#_KY7_T%JZBK?PHE;L*X/Q%X=U6_UZYN;:UWPOMVMYBC
M.% /!/J*[RN7U?QA_96J367V#S?+V_/YVW.5!Z;3ZTZ;DG[H3M;4Y?\ X1'7
M/^?'_P BI_\ %4?\(CKG_/C_ .14_P#BJV_^%@_]0S_R8_\ L:/^%@_]0S_R
M8_\ L:UO4[&=H=S$_P"$1US_ )\?_(J?_%4?\(CKG_/C_P"14_\ BJV_^%@_
M]0S_ ,F/_L:/^%@_]0S_ ,F/_L:+U.P6AW,3_A$=<_Y\?_(J?_%4?\(CKG_/
MC_Y%3_XJMO\ X6#_ -0S_P F/_L:/^%@_P#4,_\ )C_[&B]3L%H=S$_X1'7/
M^?'_ ,BI_P#%4?\ "(ZY_P ^/_D5/_BJV_\ A8/_ %#/_)C_ .QH_P"%@_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9]B@\KS,;_G9LXSCJ3ZFN7^'W_,1_P"V7_LU=K6,[I\K9I&S5[!1114%'+^
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M_I3:M_98OHC?9*^1GYL@9_E6E18 HJO>WUKIUL;B\N(X(00"\C8 )Z<UF_\
M"7^'/^@W8_\ ?X4[-A<VJ*BMKF&\MTN+:5)89!E'0Y##V-2T@"BBB@ HHHH
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MC*3>J-ZBBBLBPHHHH **** "BBB@#E_ ?_(#G_Z^6_\ 05KJ*Y?P'_R Y_\
MKY;_ -!6NHJZGQ,F.P4445!04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.H#X@^-]&M(@?LJ1(9%[#C?+_P#$_A7LX  P!@"HE'E2[E)W84445!04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_BCPE:>*X[9+JXGA
M%N6*^5CG..N0?2O(?"GA>UU_Q1=Z5<3S1Q0I(RO'C<=K!1G(]Z]^KQ[X;_\
M)1-3_P"N4W_HQ:UA)\K(DE='ID(L/"WAZ*.XNO+M+.,)YLIY([=.I]A7*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?QY_R X/\
MKY7_ -!:NHKE_'G_ " X/^OE?_06KJ*M_"B5NPHHHJ"@HHHH **** "BBB@
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MW,+ETL%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %%%% '+^//^0'!_P!?*_\ H+5U%<OX\_Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN7\!_P#(#G_Z^6_]!6NHJZGQ,F.P4445!04444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!+147VF#_GO'_P!]"C[3!_SWC_[Z% $M%1?:8/\ GO'_ -]"C[3!_P ]X_\
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M/_OH4 2T5%]I@_Y[Q_\ ?0H^TP?\]X_^^A0!+147VF#_ )[Q_P#?0H^TP?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "$X&:P]0D\RYSZ+BMN3[AKG9CF=_K51W$QE%%%62%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5_3)-DCK_>Q5"I[,_P"E
M+2EL-'0#D44B]*6LR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HK#\8:A=:5X5O;VRE\JXCV;'VAL9=0>"".A->5?\+ \4?]
M!/\ \EXO_B:SG54'9GGXK,:6%FH33O:^EO\ ,]QHKP[_ (6#XH_Z"?\ Y+Q?
M_$T?\+!\4?\ 03_\EXO_ (FH^L1.;^W,/_*_P_S/<:*\-_X6#XH_Z"G_ )+Q
M?_$U[!X?NIK[P]I]U</OFE@1W; &21SP.*N%53=D=>$S"EBI.,$]._\ PYI4
M445H=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3[AKG9O\ 7R?6
MNBD^X:YV;_7R?6JCN)C****LD**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)]PUSLW^OD^M=%)]PU
MSLW^OD^M5'<3&44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %3V?_'TOTJ"I[/\ X^E^E*6PT;Z]!2TB]!2UF4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\0/^1(U'_ME_Z,6O
M#37N7Q _Y$C4?^V7_HQ:\--<>(^(^5SS_>(^B_-A1116!XXAKZ \*?\ (IZ5
M_P!>J?RKY_-?0'A3_D4]*_Z]4_E71A]V>YD?\67I^IL4445UGTP4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M Q'Y4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:^('_(D:C_ -LO_1BU
MX::]R^('_(D:C_VR_P#1BUX::X\1\1\KGG^\1]%^;"BBBL#QQ#7T!X4_Y%/2
MO^O5/Y5\_FOH#PI_R*>E?]>J?RKHP^[/<R/^++T_4V****ZSZ8**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ;)]PUSLW^OD^M=%)]PUSLW^OD^M5'<
M3&44459(57OI#%8S.O4+Q5BF31B:%XVZ,"*BHFX-1WL#V./SSFMFV/\ :5BT
M,@^>,95S67- T$YCD&,&KL]Y##9BVM2>?OL1@FOE\*U3<O:;6LUW\O\ @]#E
MCI>Y5LV:&^CVG^,#CZXJ]XRT8:_X2U'3\ R/$6BSV=?F7]146DVCS7(F8?(A
MSD]S715ZV4PDJ3;V;T-:-TKGG_@#Q.C_  S:[N7_ 'FE1O%+N//R#*Y_#%5O
MA1:2P^%M1U^92;G49I)<GNJYQ^NZN%\6->>&=>\1>&[1#Y&M/%)$!VRV<#\R
MOX5[GHFFQZ1H5EIR#Y;>%8\>I Y_7->FC=GAWPX\,7GB1-4FMM?NM,DCE4.L
M SOSDY/(KL;WX27NI0"&]\77UQ$&W!)8]P!]<%O>N;T>^?X7?$.^LM21UTJ\
M)V2!<C;G*./ID@UZ^GB;0I+<3KK-@8B,[OM"_P"-"2&VSE/B/9G3_A/+9&4R
MF!8(_,(P6PRC-:_PZTR'2_ FEI$F&FA$\A[EGY/\\?A5#XK.LGPWO71@RLT1
M!'0C>*Z'PK_R*6D?]><7_H(I]1=#E/C/_P B$?\ K[C_ )-6GK?A=/%O@"TT
MTRB&400RPR$9"N%XS[8)'XUF?&?_ )$(_P#7W'_)JZ>#6-.T;P]I4NHW<5M'
M+#%&CR' +;,XS^!HZAT/--/\:>*? ,D6F>*M.DN=/3"1W*<L%'3#=&^AYKUC
M2-8L-=TV._TZX6:WDZ,.H/<$=C[5GZMKOAA])G_M'4=.FLV0[T,JON'L <D_
M2N+^"T$B6.LSQI(FGRW(^S!^X&<X_#:*-G8-U<CU;_DX+2/^O7_V22O5J\B\
M57<.C?'#1M1OG$-H;<*96Z#(=<GVR17JEKJ-C?%A9WEO<%0"WDRA\ ],X-"!
MGE/PGTR*7Q?XEU-U!D@G:*,GMN=B3_XZ!^->MW A\AS<"/R0,OYF-H [G->:
M?"/_ (__ !7_ -?_ /5ZV/BT;L?#^\^RE@-Z>=M_YYYY_#.*%L#W*UU\5M"M
MK@V6D6-YJ;)QBSA^0?3_ .L*Y.SUN77?C5I5Y)IMQI[>5L\J<88C8W-=5\/M
M7\+:3X%M9DO;*VD$>;LNX$AD[Y'4^WM7(:?KI\1_&RPU*.)TM'W);%UP7148
M;OQ.:0T=#\;?^0!I/_7\/_037ID'_'O%_N#^5>;?&V*0^%["=$+)#>@N?3*M
MC]:[;1_$6D:I9VK6>HVTC2H-L8E&_..1MZYI]1=#7HHHIDA1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y9\+O\ D.ZC_P!<?_9A7J=>6?"[_D.ZC_UQ
M_P#9A5+9B>YUI\>Z&E[=6LTDL+6Q8.SIP2IP0,').?:HK'XAZ%?WZ6BM<0ES
MM229 $)[#()(_$5Q&C:3;ZS\1[VWNTWP)<3RLG9L,< ^V2*M_$O1K#3)=/GL
M;:.W\X.KI&H53MVX.!WY-.RV"[.LU'XAZ%IUZUJ6N+AD.UV@0%5/IDD9_#-;
M^G:I9ZK8+>V<HDA;/(Z@CJ".QKEHO".DQ^!2#9Q-<M9^:9V4;P^W=D'L,]JS
MOA8['3=53/RAT('N0?\  4K*P&U#\1= F@FE:6:(18^5X_F<G/"@$YZ5+I/C
MS1-7O#:QO+;R8)7[0H4-CT()_7%<)\.M$L]7U:XDO85FCMXP1&PRI8GN._0\
M4WQ]H]K8>)X(;&)(4N8E8H@PH8L5X';H*=E>P79VD_Q*T"&[, -S*H.#-'&"
MGZD']*Z-]5M%T=]523S;18C-NCYRH&>/>N4\5>%=(L?!EP;6RB2:V1668*-Y
M.0#ENIR,U2\,,TGPKU52>$2X ^FS/]32L@.PT+Q#9>(K>6>R$H2)]C>8H!SC
M/J:KOXLTY/$?]A%9_M>X+G8-F2N[KGTKG?A4?^)1?C_IN/\ T$5ES GXS#'_
M #V7_P!%"BVH7.UU?Q?IFB:G%87GG"6158,JC: 21R<^U9TOQ)\/Q77DAKF1
M<X,R1?)^IS^E<K\1H/M/C6S@SCS8(TSZ9=A6]XR\+Z18^#II;2RBBEM=A211
M\S?,%.X]3P3UHL@NSMK:YAN[:.XMY%DAD4,CKT(KG]7\=Z)H]RUM)+)/,G#K
M;J&VGT)) S^-8.@:C/8_"FYN8F(DA\Q8V'5<MC/X%LURGAK4[?3(9)9?#9U2
M9VXF<Y"CT V$9Z\T)!<]3T3Q9I&O.8K.<K..?)E&UB/4>OX5MUXAJEY-<:M!
MJ6E:#-I<T1W$1 LI8="!M 'OZU[9#)YT$<F"N]0V#VR*&K F1WMW'86,]W-N
M\J"-I'VC)P!DXKFU^(F@&Q:Y,LRX?8(BGSMQG( /3GJ:UO$W_(K:K_UZ2_\
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M ,?2_2H*GL_^/I?I2EL-&^O04M(O04M9E!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '-?$#_D2-1_[9?^C%KPTU[E\0/^1(U'
M_ME_Z,6O#37'B/B/E<\_WB/HOS84445@>.(:^@/"G_(IZ5_UZI_*OG\U] >%
M/^13TK_KU3^5=&'W9[F1_P 67I^IL4445UGTP4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 V3[AKG9O]?)]:Z*3[AKG9O]?)]:J.XF,HHHJR0HHHH
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MMHV!"P*A]B.#^HKHP_Q,]S(W^]EZ?J;E%%%=9],%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3W!'8BNNE/F/;P^)5:/F6J***V-PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *GL_P#CZ7Z5!4]G_P ?2_2E+8:-]>@I:1>@I:S*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*://M?\ GS_\BFJM%%@+7GVO_/G_ .131Y]K_P ^?_D4U5HHL!:\^U_Y\_\
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M4MAHWUZ"EI%Z"EK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "LW5]!TW7(?+O[5)<#"OT=?H1S6E12:3W)E",URR5T
M>::A\)U+%M.U(@=H[A,_^/#_  K%D^&/B",X4VDGNLI_J!7LM%9NA!GG3RC"
MR=TK>C/%O^%:>(O^>5O_ -_A1_PK3Q'_ ,\K?_O\*]IHI>P@1_8N&\_O_P"
M>*_\*S\1_P#/*V_[_"C_ (5GXC_YY6W_ '^%>U44>P@']C8;S^__ (!XI_PK
M/Q'_ ,\K;_O\*/\ A67B/_GE;?\ ?X5[711[" ?V-AO/[_\ @'BG_"LO$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ>S_ ./I?I4%3V?_ !]+]*4MAHWUZ"EI%Z"EK,H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIJ%A-Y-U!$&CDVAMIW =""#UJ#X>:O?:[X'T_4=2G\^[FW[Y-BKG#L!PH Z
M47&=11110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "I[/_ (^E^E05/9_\?2_2
ME+8:-]>@I:1>@I:S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<>B6NI_VCHUU((XV&0%9ONL >ASP1T.?I4J?<PACKM<R5GYW^]'MC,%4LQ
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M_A_PAHPU*[MR5FE<G8I'!P 1P#QDD<U/\)?">N^$[75+?6(HXTG>-X@DH?D
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9/B?6%T'PW?:D2-\49\L'NYX4?F16M56_TZ
MRU2W^SW]K%<P[@VR5=PR.^*3)FFXM1W/"_"GP\O/%VG2ZDU^MLAE**7C+F0]
M2>H[G^=6?$7PKN]!T.XU-=12Z$&"\:PE3MS@G.3TSFO;K.RMM/M4M;."."!,
M[8XUVJ,G)X^IJ2:&*Y@D@GC62*12CHPR&!X((J/9JQPK+J7)9_%W\SSC3&E\
M<?"*6QC8-?0((<$]6C(9?S4 9]2:Q/ GQ!L_#6E/HNM07$1@D8HZIDC)R58=
M00<UZQIVCZ=I*R+IUE!:K(07$2!=V.F<56U'PQH>K7'VB_TNVGFXS(R?,<>I
M'7\:?*]UN4\/57+.,O>2MY,\/\<^*X_%>OV\]M"\=G OEQ>8,,W.23Z=N/:O
M>]4T^'5M+NM/N!F*XC:-O;(ZCW'6JDWAC0ITA272+-T@7;$IA7"#.<#TYK6H
MC%J]RZ&'E"4W4=^8^;-,T+4+_P 3V_A:=G"Q7;B1!T3IO8?\!0?I7N?B[0CJ
M_@V\TJS15?RU\A.@RA!"_CC'XUJ1Z3I\6I2:C'90+>R#:\X0;V''4_@/RJY1
M&%DT*A@U3C*+=[_D>->!/B#9^&M*?1=:@N(C!(Q1U3)&3DJPZ@@YKGO'/BN/
MQ7K]O/;0O'9P+Y<7F##-SDD^G;CVKW#4?#&AZM<?:+_2[:>;C,C)\QQZD=?Q
MHF\,:%.D*2Z19ND"[8E,*X09S@>G-)PE:US&6$KRI^RYE9'#?&G_ ) ^E_\
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M]JWK#PEH&EW N+/2;6*8'*R;-S*?8G./PK9JK-K4U5*I.,HUG>_8\,\.ZIX
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M'<8S2ZE\%Y]0LDFFUPW&LR3^;<WEPK$,N,!%&>!G_(J;:#.M^(O_ "2_5O\
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M^O04M(O04M9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,YSQBFI-%("4D1@.N&!Q0,?14$E[:0PF:6ZA2('!=I !GTS3Q/$S*HE0EAD
M,.10*Z)**A@N[:ZW_9[B*;8<-Y;AMI]#CI1<7EK: &YN880>AD<+G\Z NK7)
MJ*;'(DJ!XW5T/1E.0:1YHHR!)(BD]-S 4#'T57FOK.WF6&:Z@CE;[J/( 3]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&S?9)Q)( .0A!!/X'%#2Y7RESC1]A45 Z+3_P#DGUK_ -@I/_10KSOX4?\
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MFO\ A2_T^#'GN@:+)QEE(8#\<8_&O(?"U[X.M;22Q\4Z2Z7L+L/.*N=PST8
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M"WN=O"F6,$K]#U%7Z*8VDU9F5IGAK1=&D\S3],MH),8\Q4RV/]X\UJ,H92K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5/9_\?2_2H*GL_P#CZ7Z4I;#1OKT%+2+T%+6904444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 -D^X:YJZFBBG?S)$3G^)@*
MZ9AE37,ZOI37+D@4T[ 5_MUI_P _4'_?P4?;K3_GZ@_[^"LX^')/2C_A')/2
MGS"L:/VZT_Y^H/\ OX*/MUI_S]0?]_!6=_PCDGI1_P (Y)Z4<P6-'[=:?\_4
M'_?P4?;K3_GZ@_[^"L[_ (1R3TH_X1R3THY@L:/VZT_Y^H/^_@H^W6G_ #]0
M?]_!6=_PCDGI1_PCDGI1S!8T?MUI_P _4'_?P4?;K3_GZ@_[^"L[_A')/2C_
M (1R3THY@L:/VZT_Y^H/^_@H^W6G_/U!_P!_!6=_PCDGI1_PCDGI1S!8T?MU
MI_S]0?\ ?P4?;K3_ )^H/^_@K._X1R3TH_X1R3THY@L:/VZT_P"?J#_OX*/M
MUI_S]0?]_!6=_P (Y)Z4?\(Y)Z4<P6-'[=:?\_4'_?P4?;K3_GZ@_P"_@K._
MX1R3TH_X1R3THY@L:/VZT_Y^H/\ OX*/MUI_S]0?]_!6=_PCDGI1_P (Y)Z4
M<P6-'[=:?\_4'_?P4?;K3_GZ@_[^"L[_ (1R3TH_X1R3THY@L:/VZT_Y^H/^
M_@H^W6G_ #]0?]_!6=_PCDGI1_PCDGI1S!8T?MUI_P _4'_?P4?;K3_GZ@_[
M^"L[_A')/2C_ (1R3THY@L:/VZT_Y^H/^_@H^W6G_/U!_P!_!6=_PCDGI1_P
MCDGI1S!8T?MUI_S]0?\ ?P4?;K3_ )^H/^_@K._X1R3TH_X1R3THY@L:/VZT
M_P"?J#_OX*/MUI_S]0?]_!6=_P (Y)Z4?\(Y)Z4<P6-'[=:?\_4'_?P4?;K3
M_GZ@_P"_@K._X1R3TH_X1R3THY@L:/VZT_Y^H/\ OX*/MUI_S]0?]_!6=_PC
MDGI1_P (Y)Z4<P6-'[=:?\_4'_?P4?;K3_GZ@_[^"L[_ (1R3TH_X1R3THY@
ML:/VZT_Y^H/^_@H^W6G_ #]0?]_!6=_PCDGI1_PCDGI1S!8T?MUI_P _4'_?
MP4?;K3_GZ@_[^"L[_A')/2C_ (1R3THY@L:/VZT_Y^H/^_@H^W6G_/U!_P!_
M!6=_PCDGI1_PCDGI1S!8T?MUI_S]0?\ ?P4?;K3_ )^H/^_@K._X1R3TH_X1
MR3THY@L:/VZT_P"?J#_OX*/MUI_S]0?]_!6=_P (Y)Z4?\(Y)Z4<P6-'[=:?
M\_4'_?P4?;K3_GZ@_P"_@K._X1R3TH_X1R3THY@L:/VZT_Y^H/\ OX*/MUI_
MS]0?]_!6=_PCDGI1_P (Y)Z4<P6-'[=:?\_4'_?P4?;K3_GZ@_[^"L[_ (1R
M3TH_X1R3THY@L:/VZT_Y^H/^_@H^W6G_ #]0?]_!6=_PCDGI1_PCDGI1S!8T
M?MUI_P _4'_?P4?;K3_GZ@_[^"L[_A')/2C_ (1R3THY@L:/VZT_Y^H/^_@H
M^W6G_/U!_P!_!6=_PCDGI1_PCDGI1S!8T?MUI_S]0?\ ?P4?;K3_ )^H/^_@
MK._X1R3TH_X1R3THY@L:/VZT_P"?J#_OX*/MUI_S]0?]_!6=_P (Y)Z4?\(Y
M)Z4<P6-'[=:?\_4'_?P4?;K3_GZ@_P"_@K._X1R3TH_X1R3THY@L:/VZT_Y^
MH/\ OX*/MUI_S]0?]_!6=_PCDGI1_P (Y)Z4<P6-'[=:?\_4'_?P4?;K3_GZ
M@_[^"L[_ (1R3TH_X1R3THY@L:/VZT_Y^H/^_@H^W6G_ #]0?]_!6=_PCDGI
M1_PCDGI1S!8T?MUI_P _4'_?P4?;K3_GZ@_[^"L[_A')/2C_ (1R3THY@L:/
MVZT_Y^H/^_@H^W6G_/U!_P!_!6=_PCDGI1_PCDGI1S!8T?MUI_S]0?\ ?P4?
M;K3_ )^H/^_@K._X1R3TH_X1R3THY@L:/VZT_P"?J#_OX*/MUI_S]0?]_!6=
M_P (Y)Z4?\(Y)Z4<P6-'[=:?\_4'_?P4?;K3_GZ@_P"_@K._X1R3TH_X1R3T
MHY@L:/VZT_Y^H/\ OX*/MUI_S]0?]_!6=_PCDGI1_P (Y)Z4<P6-'[=:?\_4
M'_?P4?;K3_GZ@_[^"L[_ (1R3TH_X1R3THY@L:/VZT_Y^H/^_@H^W6G_ #]0
M?]_!6=_PCDGI1_PCDGI1S!8TOMUI_P _4'_?P5<L)$DN5,;JP]5.:P1X<D!Z
M5T&CZ:UKC(H<KA8WUZ"EI!TI:D84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %-* ]1110 GEKZ4>6OI110 >6OI1Y:^E%% !
MY:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI1
M10 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'E
MKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110 >6O
MI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'EKZ444
M'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E
M%% !Y:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>
M6OI110 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:
M^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110
M >6OI1Y:^E%% !Y:^E'EKZ444 'EKZ4>6OI110 >6OI1Y:^E%% !Y:^E."@=
*!110 M%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img35377828_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img35377828_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $B \(# 2(  A$! Q$!_\0
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MY?\ OLT>?/\ \]Y?^^S1[+S#G/4MI]#1M/H:\M\^?_GO+_WV://G_P">\O\
MWV:/9>8<YZEM/H:-I]#7EOGS_P#/>7_OLT>?/_SWE_[[-'LO,.<]2VGT-&T^
MAKRWSY_^>\O_ 'V://G_ .>\O_?9H]EYASGJ6T^AHVGT->6^?/\ \]Y?^^S1
MY\__ #WE_P"^S1[+S#G/4MI]#1M/H:\M\^?_ )[R_P#?9H\^?_GO+_WV:/9>
M8<YZEM/H:-I]#7EOGS_\]Y?^^S1Y\_\ SWE_[[-'LO,.<]2VGT-&T^AKRWSY
M_P#GO+_WV://G_Y[R_\ ?9H]EYASGJ6T^AHVGT->6^?/_P ]Y?\ OLT>?/\
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M_P".T?V)_P!/'_CM&@:E&UOKFS)-O*R9ZCL:2>]N;J59)I6=E^[GM5_^Q/\
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M #_C_OW_ /7HYH!:1S]MJ5Y9V\T%O.T<4W$B@#YNU5:ZK_A"S_S_ (_[]_\
MUZ/^$+/_ #_C_OW_ /7I\\0Y6<K175?\(6?^?\?]^_\ Z]'_  A9_P"?\?\
M?O\ ^O1[2(<K.5HKJO\ A"S_ ,_X_P"_?_UZ/^$+/_/^/^_?_P!>CVD0Y6<K
M175?\(6?^?\ '_?O_P"O1_PA9_Y_Q_W[_P#KT>TB'*SE:*ZK_A"S_P _X_[]
M_P#UZ/\ A"S_ ,_X_P"_?_UZ/:1#E9RM%=5_PA9_Y_Q_W[_^O1_PA9_Y_P ?
M]^__ *]'M(ARLY6BNJ_X0L_\_P"/^_?_ ->C_A"S_P _X_[]_P#UZ/:1#E9R
MM%=5_P (6?\ G_'_ '[_ /KT?\(6?^?\?]^__KT>TB'*SE:*ZK_A"S_S_C_O
MW_\ 7H_X0L_\_P"/^_?_ ->CVD0Y6<K175?\(6?^?\?]^_\ Z]'_  A9_P"?
M\?\ ?O\ ^O1[2(<K.5HKJO\ A"S_ ,_X_P"_?_UZ/^$+/_/^/^_?_P!>CVD0
MY6<K175?\(6?^?\ '_?O_P"O1_PA9_Y_Q_W[_P#KT>TB'*SE:*ZK_A"S_P _
MX_[]_P#UZ/\ A"S_ ,_X_P"_?_UZ/:1#E9RM%=5_PA9_Y_Q_W[_^O1_PA9_Y
M_P ?]^__ *]'M(ARLY6BNJ_X0L_\_P"/^_?_ ->C_A"S_P _X_[]_P#UZ/:1
M#E9RM%=5_P (6?\ G_'_ '[_ /KT?\(6?^?\?]^__KT>TB'*SE:*ZK_A"S_S
M_C_OW_\ 7H_X0L_\_P"/^_?_ ->CVD0Y6<K175?\(6?^?\?]^_\ Z]'_  A9
M_P"?\?\ ?O\ ^O1[2(<K.5HKJO\ A"S_ ,_X_P"_?_UZ/^$+/_/^/^_7_P!>
MCVD0Y6;NB_\ (#LO^N0J]4%E;?8[&"VW[_*0+NQC-3USO<T"BBB@ HHHH 2B
MBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH >_\ JHOH?YTRGO\
MZJ+Z'^=,I %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P _$OZ?X4 2T5%Y+?\ /Q+^G^%'DM_S\2_I_A0!+147DM_S\2_I_A1Y+?\
M/Q+^G^% $M%1>2W_ #\2_I_A1Y+?\_$OZ?X4 2T5%Y+?\_$OZ?X4>2W_ #\2
M_I_A0!+147DM_P _$OZ?X4>2W_/Q+^G^% $M%1>2W_/Q+^G^%'DM_P _$OZ?
MX4 2T5%Y+?\ /Q+^G^%'DM_S\2_I_A0!+147DM_S\2_I_A1Y+?\ /Q+^G^%
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M^G^% $M%1>2W_/Q+^G^%'DM_S\2_I_A0!+147DM_S\2_I_A1Y+?\_$OZ?X4
M2T5%Y+?\_$OZ?X4>2W_/Q+^G^% $M%1>2W_/Q+^G^%'DM_S\2_I_A0!+147D
MM_S\2_I_A1Y+?\_$OZ?X4 2T4B@JH!8M[GK2T %%%% !1110 E%%% "T444
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M=;4R=+UK4YK74;=<W4\$>^WF:,KO^H/>H_#^IWUU?I!+JA9Y$/F03Q[65O\
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MH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-?RJ2B@"/R(?^>:_E1Y$/_/-?RJ2B@"/R(?^>:_E1Y$/_/-?RJ2B@"/R(?\
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M_P \U_*CR(O^>:_E4F1C.1C&<YXI%99%#(RLIZ%3D4 ,\B'_ )YK^5'D1?\
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M )YK^5.5T<D(ZL5.#M(.*!(C;L.AV_>PP^7Z^E #?(A_YYK^5'D1?\\U_*I
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MBLH\6[>5]E<MG@YSFN*L])\,MX&ANKC6'CNUM_,\O[;D!QR!Y><=>V*2TO\
M+]1O6WS_ $/2HK^%],BOYG6")XUD)D; 7(SR:+?4["[$9MKVWF\PD)LD!W$=
M<5P]]<_;T\(R^(E$>GS(6N%8;8S+CY-X["GS1:'%\2]#_LG[.)2LAG6W(V=.
M.G&:?+K;U$GH=J=2L1>BR-[;BZ/2$R#=^5+>:C9:>JM>WD%N&X7S7"YKSF<6
M.FRSWH_L[5K&340[$DI>0R%L8'<X/Z5/=?:)?'.K_:(-(ED 3R!JDA4"+'\
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M*'TKI:EJP)W"BBB@84444 %%%% !1110 4444 /?_51?0_SIE/?_ %47T/\
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M\\(?^_:_X53O[JVL/+W6#3;\_P"I@#8^O%:%9FNWTEGIQ2#)NKAA#"!ZGO\
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M_?%344 0_:%_YYR_]\4?:%_YYR_]\5-10!#]H7_GG+_WQ1]H7_GG+_WQ4U%
M$/VA?^><O_?%'VA?^><O_?%344 0_:%_YYR_]\4?:%_YYR_]\5-10!#]H7_G
MG+_WQ1]H7_GG+_WQ4U% $/VA?^><O_?%'VA?^><O_?%344 0_:%_YYR_]\4?
M:%_YYR_]\5-10!#]H7_GG+_WQ1]H7_GG+_WQ4U% $/VA?^><O_?%'VA?^><O
M_?%344 0_:%_YYR_]\4?:%_YYR_]\5-10!#]H7_GG+_WQ1]H7_GG+_WQ4U%
M$/VA?^><O_?%'VA?^><O_?%344 0_:%_YYR_]\4?:%_YYR_]\5-10!#]H7_G
MG+_WQ1]H7_GG+_WQ4U% $/VA?^><O_?%'VA?^><O_?%344 0_:%_YYR_]\4?
M:%_YYR_]\5-10!#]H7_GG+_WQ1]H7_GG+_WQ4U% $/VA?^><O_?%'VA?^><O
M_?%344 0_:%_YYR_]\4?:%_YYR_]\5-10!#]H7_GG+_WQ1]H7_GG+_WQ4U%
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MB@"'SHR03$Y(Z$QT?:%_YYR_]\5-10!#]H7_ )YR_P#?%'VA?^><O_?%344
M0_:%_P"><O\ WQ1]H7_GG+_WQ4U% $/VA?\ GG+_ -\4?:%_YYR_]\5-10!#
M]H7_ )YR_P#?%'VA?^><O_?%344 0_:%_P"><O\ WQ1]H7_GG+_WQ4U% $/V
MA?\ GG+_ -\4?:%_YYR_]\5-10!#]H7_ )YR_P#?%'VA?^><O_?%344 0_:%
M_P"><O\ WQ1]H7_GG+_WQ4U% $/VA?[DO_?%'VA?^><O_?%344 0_:%_YYR_
M]\4?:%_YYR_]\5-10!#]H7_GG+_WQ2_:%_YYR_\ ?%2T4 0_:%_YYR_]\4?:
M%_YYR_\ ?%344 0_:%_YYR_]\4?:%_YYR_\ ?%344 0_:%_YYR_]\4?:%_YY
MR_\ ?%344 0_:%_YYR_]\4?:%_YYR_\ ?%344 (K;E# $9[$8-+110 4444
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M.T)$4K#J%;O6]1884444 %%%% !1110 4444 %%%% #W_P!5%]#_ #IE/?\
MU47T/\Z92 ****8!7.>*;K6M,M)+^PO+9($V+Y,D&XDDXSG/O71UC^*+*XU'
M0)K:TC\R9G0A<@9 8$]?:A;AT&B34[/["E]JEHTD]P%X@*^8N,[%YX/O5F'7
MM+N-1:PBO$:X4D;<'!(Z@'H2.]0ZS97%U=:*\$>Y;:[664Y VJ%(S^=8UCIV
MJV^M@6]A);VADE>=)9%>!MV<&/\ B4D]:>XMC<M_$>D7;3B"]1C AD?@CY1U
M8>H^E6CJ-HJVC&=<79 @/]\D9&/PKE-.T?5<W%DMK-9V#6LD1CN)%D5'/3RB
M.0OKFI(+?6[F3P_;S:.UO%ITH\^9I5(.%(!4#M3L@NS=E\1Z1!?_ &*2^19P
MVPC!VJW]TMT!K4KSUO#6JQK=:6T-]/;SW#2>9'<(L)4MG+ \@BO0$79&B DA
M5"Y/L*5M ZCJ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ANY6@LKB9,;HXV89]
M0,U-4%Y&\MA<QQC+O$RJ/4D<4GLQK<Y.'6M?M=*TS5[VYLKBVO)(T:W2'8XW
MG'RG/.*Z"Y\1:1:7YLIKY%F#!6&"0I/0$] :YG2?"4FD7.BZ@E@9Y$C$=W;O
M)N\EO^>B9.,COBJ\_AS58GO[#R;ZXM[NX:0217"+$RL<_.#R"*T=KF:O8["Z
MU[2[*^2RN;Q([A\?+@D#/3)Z#/;-3C4;1ENF$ZE;0D3G^X0,\_A7,:GI>IQ:
MIOTRRF64K$@N%E5H957&?-5NX'0BG7=KK-H^NVMKI9NTU++Q3K*JJI*X(8'F
MIMH6MR[-K_DZQ<-YP;3TTT7287.6)X/K3K#Q;ITV@VNI7DZPF;Y2BHQ.X=0!
MC) ]:KV&D7T%XLDD&%&CK;9W#_6#^&JLVDWT6@Z+&;"Y:ZM(BI>UF5986([9
MX93WINW]>K)3;_KR1UT$\5U;QW$$BR0R+N1U/#"I*HZ-'>Q:/:IJ 0783]X$
M  S^'%7JEZ,I;!1110 4444 )1110 M%%% !1110 4444 87BK2KK4M-AEL-
MIOK*=;B!6. Y'5?Q%4_^$\M/)VOIFIC4.AL_LS9W^F[ICWKJ:7)SG//K0NP'
MGU_H]];^ =:FO(BVHZC,MQ+#&-VS+#"\=<#K6MXOMV;0])2&!F,5Y;D!$R4&
M1GITKJ@2#D&@$CH:=_T_ 5OU_$Q=3T/4+V_DGM_$5[9QMTAB12J_3-9VJVEQ
M_;/A6S>2:Z\B=Y9;ADZX7@MC@5U=&3C&>*2=AM7.+U'PM?S^(G@MRJZ#?3+=
M7BYP1(O\('HW%6+BSF/CC4(X49$OM*\M9 IVJRY Y_&NLHR<8SQ1?2P=;G :
M?K<>G^$SX>GT>\.I10M ;9;<E)3@_-NZ8/6H8K&63PUX)AEMI#Y=R#(A0_)C
M/4=OQKT;)]:,GGD\]:KFUOZ?@3RZ6.1\?Z<^KQ:19J9E66^VM)$"3&"IYXZ"
MLNXM]0N?"5]X3:S\G4+1 T+0IB*YC!SE3TW'N#WKT$$CH:7)QC/%2G96*MK<
M\Q!_MP66G'4=?NG\U&>VDM%C6 KW+8Z#VKJH(Y1\1KR0H_EG3T42%3M)STSZ
MUTF3^=)DXQGBGS"Y11U%<QX.BDB?7?,C=-VI2,NY2-PP.1ZBNFH))ZFDG8;.
M$EME9_& O-.NKJVDNHR4A&URNT?,A[X]J?H-Y=7%Y?V\3WFK:4MF</=P^7)O
M_P">08_>XKN<GCD\=*3-%]+?UM85M;GGWA^ZEAUG3;+29-1EL?F%Q:7T'%FN
M/X7(]>,4_2]7'A^SU;1KNQO6O6N)G@6* LLJOT(;I7?Y/K1D^M-NX)6/+SI]
M^GA;PQJ %W"MB7^T""/=+%N_B"GKBM;0(UU3Q1#?K?:M?+:1,!<74 B3YOX>
M@)KNLG.<G-)GC%/F%RG.OX<U1K@R#Q5J"H7W>6(TP!GI]*R?$$]G9>/;>ZU*
MPFN;3["4^2U,P#9],5W%*&8="1]*E,JQPVD1C4_$M[=Z/8S:?ICV1@<R0F$2
MRGH0GMZU!I6M1Z3X7/AZZTF\.I11O#Y"0%DF)S\V[I@UZ 23U)-&3ZTV[JPD
MNIYU;P01>!= &HVNH0F%V87-JIWVC9."5ZD=J9<0ZSKWA&_4&>Y6WO$EMYGA
M$<MS&O4E>Y';/7%>D9.<YI,FARU;"VQYS;D:[J>G0#4]=OO)F69EFM5B6 KW
M)('TP*T--U1/">HZM::I9W9>XNFN(9X8#()U;H,CN.F#7;9-+D^M'-_7]>@6
M.0\!+*+;5Y);.2T\V_=UA==I -6=9BD;QQX<D6-V1!-N8*2%^7N>U=,23U.:
M3)QC/%%]4_ZVL%M&CSZXT>[TGQ]H\5M$[Z1+>-<IM4D0.5(8>P/6M)Y9_"7B
M"_NY+2>XTC47$ID@3>T$O0Y4<X-=AD@$9ZT@)'2BXWJ><2V.F^)=?M7T33;N
M("X$]Y?S!XUP.=J@GDFMG5=9LX=1NK+Q-HQEM@<VD\=L9A(GID<AJZ[/&.WI
M1GC%%^@K=3F? ]M<VVCS^9%-!:R7#/9P3'YXXNP.>GTJ7QS')-X/O4BC>1SL
MPJ*23\P["NAZ]: 2#D4F[NXTK'&^,K&\EL]%OK<W 2Q</-]G0-(@*@;@IZD5
M4TA!J_B.VNTOM8U$6<;L);J!8D!(^YT!.:[W.#D49IW%8\WT^YDM-2LK71!J
M2![H_:-+NX-T<"D_,ROCCVQ71Z='*OC7Q'(879'AB"Y&!)P> >E=-D^M)DXQ
MGBBX6/.-,N9+34["TT4:DJ-<G[3IEY!NCMEYW,KXX]L5Z.>M+D^M)0W<$K!1
M112&%%%% !1110 4444 %%%% #W_ -5%]#_.F4]_]5%]#_.F4@"BBBF 4444
M %%%% '+2^*=1C\83:,F@W$UM''N%Q'U;CKSQCM6G_:]Y_T K[\U_P :ULFB
MK<HO[([KL9/]KWG_ $ K[\U_QH_M>\_Z 5]^:_XUK44N9=@N9/\ :]Y_T K[
M\U_QH_M>\_Z 5]^:_P"-:U%',NP7,G^U[S_H!7WYK_C1_:]Y_P! *^_-?\:U
MJ*.9=@N9/]KWG_0"OOS7_&C^U[S_ * 5]^:_XUK44<R[!<R?[7O/^@%??FO^
M-']KWG_0"OOS7_&M:BCF78+F3_:]Y_T K[\U_P :/[7O/^@%??FO^-:U%',N
MP7,G^U[S_H!7WYK_ (T?VO>?] *^_-?\:UJ*.9=@N9/]KWG_ $ K[\U_QH_M
M>\_Z 5]^:_XTW6[C4;&&6\@NH([>-?N.F6+>@^M7M--W)IT,EYC[0Z[G"C &
M>U)278VE1Y:2JW5GIYE/^U[S_H!7WYK_ (T?VO>?] *^_-?\:M:A_:.(H[ 1
MJS-\\LG1!ZX[UCKXAN(]&FGE$3W"7'V>-P<1N?[WTHYX]BZ6%G5BI0L];6OK
MJ7O[7O/^@%??FO\ C1_:]Y_T K[\U_QI-%O;J[>437=I=1J!AX."I]"/3WJ/
M49K^37[>PM+S[,CP&1CY8;D&CG78/JTO:.FVE97OKVOVO^!+_:]Y_P! *^_-
M?\:/[7O/^@%??FO^-)IU]=Q:C<:=J,B2211B9)U7:&3W'8U3TC5KV[U%DNFV
M6]VK/9D+RH4X_'UHYX]BOJ<[2>EDD_5/73Y7?R+O]KWG_0"OOS7_ !H_M>\_
MZ 5]^:_XUGOK6H6R2:7(OF:L7V0.%^5U/1_PI+V^OH=1%A+JB6>R$,LTD8Q.
M_?GH!2YX]BU@*C=KKOUU7=65[?UT9H_VO>?] *^_-?\ &C^U[S_H!7WYK_C3
MH[J_2734N&@_? B4)SD@9R#Z5J57,NQRU*;A:_\ 6MC)_M>\_P"@%??FO^-'
M]KWG_0"OOS7_ !K6HHYEV,[F3_:]Y_T K[\U_P :/[7O/^@%??FO^-:U%',N
MP7,G^U[S_H!7WYK_ (T?VO>?] *^_-?\:UJ*.9=@N9/]KWG_ $ K[\U_QH_M
M>\_Z 5]^:_XUK44<R[!<R?[7O/\ H!7WYK_C1_:]Y_T K[\U_P :UJ*.9=@N
M9/\ :]Y_T K[\U_QH_M>\_Z 5]^:_P"-:U%',NP7,G^U[S_H!7WYK_C1_:]Y
M_P! *^_-?\:UJ*.9=@N<CX@\7:GI$-L\'AN[E,LH1MYR /;;W^M=:I+(K%2I
M(!*GM[4N311*2:22L#84445(@HHHH **** "BBB@!**** %HHHH **** "BB
MB@ HIC^9QY84^NXTW-Q_=B_[Z- $M%19N/[L7_?1HS<?W8O^^C0!+146;C^[
M%_WT:,W']V+_ +Z- $M%19N/[L7_ 'T:,W']V+_OHT 2T5%FX_NQ?]]&C-Q_
M=B_[Z- $M%19N/[L7_?1HS<?W8O^^C0!+146;C^[%_WT:,W']V+_ +Z- $M%
M19N/[L7_ 'T:,W']V+_OHT 2T5%FX_NQ?]]&C-Q_=B_[Z- $M%19N/[L7_?1
MHS<?W8O^^C0!+146;C^[%_WT:,W']V+_ +Z- $M%19N/[L7_ 'T:,W']V+_O
MHT 2T5%FX_NQ?]]&C-Q_=B_[Z- $M%19N/[L7_?1HS<?W8O^^C0!+146;C^[
M%_WT:,W']V+_ +Z- $M%19N/[L7_ 'T:,W']V+_OHT 2T5%FX_NQ?]]&C-Q_
M=B_[Z- $M%19N/[L7_?1HS<?W8O^^C0!+146;C^[%_WT:,W']V+_ +Z- $M%
M19N/[L7_ 'T:,W']V+_OHT 2T5%FX_NQ?]]&C-Q_=B_[Z- $M%19N/[L7_?1
MHS<?W8O^^C0!+146;C^[%_WT:,W']V+_ +Z- $M%19N/[L7_ 'T:,W']V+_O
MHT 2T5%FX_NQ?]]&C-Q_=B_[Z- $M%19N/[L7_?1HS<?W8O^^C0!+146;C^[
M%_WT:,W']V+_ +Z- %A_]5%]#_.F5&SW!1%V1_+G^(TF;C^[%_WT: ):*BS<
M?W8O^^C1FX_NQ?\ ?1H EHJ+-Q_=B_[Z-&;C^[%_WT: ):*BS<?W8O\ OHT9
MN/[L7_?1H EHJ+-Q_=B_[Z-&;C^[%_WT: ):*BS<?W8O^^C1FX_NQ?\ ?1H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img35377828_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img35377828_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &]! H# 2(  A$! Q$!_\0
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MV]S%?:\D]L6>&.V=&?:0 Q92!D]\ TFTPG4A*RB[ZHUZ***LV"BBB@ HHHH
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MM\RYOI%#!MDER[*2#D9!/J*EIV,W";@HV5UL[_\  -6BBBK.H**** "BBB@
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M0@HHHH **** ,>XC6^\2);SJKPVUL)EC89!=V*@D=\!3C_>J'^R]1SQ'HO\
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M'=W"'E%._"Y_A#'@MV_'(ZIM(L7BO(G@#)>_\? +$[_E"^O' '2@Z38D7 :
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MD=U;VAF;R9(05=G8D$@DC@$C\<TDWA:(I?PVDL=K;79A;R8X0%1T8$D8('(
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MCSK!N8-;O[.1X5N'M(WD7AH P"O]".1GL>:W8[?2M+URRMHM&:WFD+)#=QA
M'Q&20Q#;VX!^\.O/O6G#H^GP/>,EJG^FMNN V660^X/'<U';:%86D\,T23%H
M 1$)+B1UC!&/E5F(''' Z47"QHT444AA1110 4444 %%%% &)XB9G?3+-F9;
M:[NA%.02-R[6(0D=F( /KTJKK=C::=9PQ642V45Y=0V\_P!G_=C86YX' )Z9
MZX[\"MZ\L[>_MFM[J(21-U!XP>Q!'(/N.:K#1-/\B>&2%IDG4)(;B5Y691T&
M6)( ))'H3FBXK&7>6-KI&L:.^F6\=L\TYAEBA7:)(]C$E@.NT@'/O6)H%_\
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M11=A8I_8/^FO_CO_ ->C[!_TU_\ '?\ Z]7**+L+%/[!_P!-?_'?_KT?8/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJZ20'(##G]/;@T5(+N30Q#YVW&WXJVQZ3XP\/_V!K3)%DV<X\VW;_9/;\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&_^A@TK_P #8_\ &CV<^S#GCW-BBL?_ (2WPW_T,&E?^!L?^-'_  EOAO\
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M"MD'_:#C/?M7M'_"6^&_^A@TK_P-C_QH_P"$M\-_]#!I7_@;'_C3C&I%W2_
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M7_0:T[_P*3_&C_A)-"_Z#6G?^!2?XT70>UI_S+[S4HK+_P"$DT+_ *#6G?\
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M[K\?\@_M"EV?]?,^D:*^;O\ A:7C/_H,_P#DK#_\11_PM+QG_P!!G_R5A_\
MB*/[,J]U^/\ D']H4NS_ *^9](T5\W?\+2\9_P#09_\ )6'_ .(H_P"%I>,_
M^@S_ .2L/_Q%']F5>Z_'_(/[0I=G_7S/I&BOF[_A:7C/_H,_^2L/_P 11_PM
M+QG_ -!G_P E8?\ XBC^S*O=?C_D']H4NS_KYGTC17S=_P +2\9_]!G_ ,E8
M?_B*/^%I>,_^@S_Y*P__ !%']F5>Z_'_ "#^T*79_P!?,^D:*^;O^%I>,_\
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MI.E1>'M-U*YFM4N;NXO8MY?<2"$_N\J?IQP:T?#.G&^\%+J&B^%=(OKJ;5)
MT5[&C^5 <G =L'CY1W[\5S"^/[*]TVQMM?\ #5OJMQ9($AN&N&C8@= P .[\
M3@^E9UQXSE?P]'IEK9K9R1:FVH130R8$9(;"*N. -W7/;I3]C4<;6UOJ[Z/\
M0]K34KWTMHK?\ M^/$T'3_%NH6VG6<;1^4J%8F(2&;^(#].G?(]:Y6\FMIO*
M^SVWD[4 ?YL[CZUJ>+/$,7BC5UU(6 M)VB5)]LFX2..-W08XP,<]!6%751@U
M%<V_J<U6:<GR[>@4445J9!1110 4444 %%%% !1110 5](_"W_DG&D_]MO\
MT<]?-U?2/PM_Y)QI/_;;_P!'/7GYG_"7K^C._+_XK]/\CL*\)^(?_(]:E_VR
M_P#125[M7A/Q#_Y'K4O^V7_HI*^=K?"/.O\ =UZ_HSF****YCY@**** "BBB
M@ HHHH **** "NJ^'MI;7OBV*&[MXIXC$Y*2H&4G'H:Y6MCPSKO_  CNLIJ'
MV?[1M1E\O?LSD8ZX-.+2:N;8:48UHRGLF=A)X;L+[Q=IVI0P11:+<6GVZ2,*
M BA -RXZ8R5R/<U1\7:1;WWB_1K/3;.*U2]M8F*0QA0-S-EL#T'\JRK?QC<V
M_@Z;P^L ^<E5N-_*H3EEQCG//.>]6E\<!==M=5.F*TMK8"TB4S=&&?WGW?0D
M8]^M:7BT=\JV&E'EVNTWI]Z_KN:?BZQTJ_T*ZN](LH;=M*O#;3>7&%WI@#<<
M=?FQR?>LGQ;9VUMHGAJ2"WBB>:R#2LB!2[87EB.I^M/A^(6J36MY::N!J%O<
MPF+;A(BA/\0*KS3)O%FEWNDV-GJ'A[[3)9VXACE^VLG8#. /84-Q8JM3#U5)
MIV;2W5M4_*_0V=1U+3M L/#R/X?TNYAN;"*6X9[=?-)VC)#>O?FK%QX:T[2[
MOQ7"EM%)%'IXGMQ(H<PDANA/(.1U^E8J>-=.-OIOVKPXES<Z? D,4SW38^4
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M_H%_^3$O_P 573T4N2/8/JF'_D7W(YC_ (5YX6_Z!?\ Y,2__%4?\*\\+?\
M0+_\F)?_ (JNGHHY(]@^J8?^1?<CF/\ A7GA;_H%_P#DQ+_\51_PKSPM_P!
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M )[U3N_$VCV)N!/>@?9HDFE*HSA4<@*<J".21QU[]*.1=@^JX?\ D7W(SO\
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MR%8CAABMXQ'#&J(.BJ,"I*C>XABFBBDFC264D1HS %R!DX'? YJ2I*"BJ?\
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MM8DG(/F Y &,'KUHY6%T=E17#WFJ7][';P7D1*QZC8NDXLIK96)F&5VR\DC
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MZ,;/,%?$C <D8!49'ZBM2\O?[,N;[3GN;EK87D:QM<:@\*Q@P[R'GY=5R,@
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M0.&UT21(ZC/ERK*RNWM^Z.?^V==)X<_XE_A[5?LEN9#;WEYY,"_Q;9&VJ/R
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MQ^5-E7\Q9?M4OFJVW;Q)NW@8XQG&*H?\)/<S7<5I:::DDTMS<6Z^9<;%'DD
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M<\$ETDD\UXZ$X=Y%"C;QT "CG' JZ^O2):P74NEW-O!)/%$6G>/A7. XV,W
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M+#_6=-K.-_3OLZ>_6J-KXOD>W@N[O3#!:7$$TL31S^8Y\H98%=H R V.3TY
MS3U%H:,GA?1Y9$=[5_E\O"B>0*2@ 0E0V"0 .2,\5++X>TR8W6^!R+EQ+(HG
MD WC!#J V%;@<K@\57T76KO4[VXM[FQ@MQ##%+NBN3+GS 2!]Q>P.?P^M0Z;
M)J6L&:_34FMXDNI(HK98D9"D;E3OR-V3@]&&,CCU-1Z%ZW\/:7:LC0VQ#)<&
MY#-*[$RE-A8DGDE>N?KUYJ3^Q[,7S7B">.5G\QA%<R(CM@#+(&"D\#J.<5B-
MXS2.>_B:"V=[:TGNE2&\61OW?5) !A&.?5N_I4Q\4SP+,MUIGESF&&6VCCG#
M^;YK[%4G VG=C.,CJ03BBS"Z-:RTFSL)I)X5F::10C23SR3-M!) !=B0,D\"
MKU<WJ'B>;3'@MKRUL;>\EWL!/J CAV+CD2%<DDL %V@\,>@R7V'B675;VTAL
MK%3%-:)=R2RS[?+5F*E0 IW,,<= >>1QE6871T-%<=XEUF[LM9G@CU&YM433
MUFA6*W5T:8NRCS&9#M4D*,EE'N*LS^([BPEOO/AS)#]E5A),J01-(#N)8(2J
M@CDG=VZ4<K"YU%%<C+KMQ#XKM[=0L\UY81&"VBN282Q=RS[B.@49W;<D   \
M"MW4M2EM+BTM+6W2>ZNBVQ9)/+0*HRQ9@&/H. >3^-%@N:-%<=<:G?:OJ>C0
MQPF",S3I<Q+>O$1)'PPW(OS*.HYPV1D"G^)M7N+'5S -2NK.!;!YP;>W60>8
M&P-Y*-M7W)4>XHY0N==17)7WC3^S-L5W#9BXAM8Y[M7O%C.6&2L2X/F$8/&1
MV&3FM!=>N9I;N2VTY9;&V=HWF,^URRKN)"8^[G SG/M19A=&[17-W7BO[-9I
M<?8MV[2GU';YN,;=GR=/]OK[=*E37-3?4K6Q_LJ 33P&X)-X<1Q@@<_)RW/0
M9'OCFBS"Z-^BN0MO'EO<AGCBMG1H)IX4BO \N(QNQ(@'[O<!QRWO5D>+)H8)
M'O-,\IC:I<VZ1SAS('?8JMP K9*],CGKQ1RL+HZ:BN=U#Q+/I9MX+ZUL;:ZN
M'<(9K\) 455);S"F<Y8#&W.<]N:O6=W_ ,)!H=O>6MQ/9^<-VZ+8S#!((RRL
MI&1UQ18+FI17&6&OW&G^&['4]0U W4]]((D2Z>*"%&RQ)+*@(&%/7=S@8YJT
MGC$306C0PV>Z>:6 RRWFV ,A'"R!#NW9RO R >F,4<K"Z.IHK T/4-3N]8UF
M"\2#[/;7'EQ%),E?D0A<;!D<DY)R"<<CFM^DQA1110 4444 %9>OP:Q<:6T>
MA7<%K>[P1),N5V]QT/\ (UJ44 1P"5;>)9W5Y@@$C*, MCD@?6N,O+W3([WQ
M;97TL+RW#QK':DAI)B;= H5.K'.,8[UV]%-.PFCSUYKS3X-7M2KRZE<6UC9J
M%(+&5HV5CDG&1\QR3CBMKPLYLM0U'2&LYK.)2MS;0S%"VQAAN4)7 <$]?XJZ
MBBFV%CS.]U,V>L7^H,J7$RW4I324)WQ2HN([AD!RZE5RQ' !!&2,UU'B:[@.
MB:;=M<0&#[?:2-,KCR]OFJ2V>F.^:Z2BBX6//_$,]M=MK&HV$L;V7V:V2>XB
M(\N243 CYAPQ5>I[ @>PMZCJUNNKW6L:.Z7(AT]H9);?#I+.SH(4W#@D$GW
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ML6>G66G1M'8V=O:HQRRP1*@)]2 *3:'9EFBBBD,**** "BBB@ HHHH ****
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M-3E>&*.-&$D1PS(2Q;#9"'/RC!(ZXY=F&A%HGA,KH=I#J<]UYL=M)"(#(A6
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M !1110 4444 %9/B'P]:>)=/2SO)+B.-9!(# ^TY&>N01W]*UJ* $50B!1G
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MMQMS#\_F9W8W[L;=_P V-N>V:;:^%_*^RVUS=1W.FV;2-!;-;\G<&4!V+$,
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MP3"1(S',T0/SJ6!X<@\ G ^;VI:AH.N/#]G>:^-4NXH+C;;K#''+"&V$,6W
MGH>?3M3+G0?M"ZZ/M.W^U8?*_P!7GROW>S/7YO7M5M=:TI[>:X34[-H8"!+(
M)U*QDG #'.!^-0P>(=*FB65KV"*-YFAB:65%$Q4X)3GYAFC4-"E+X7\VWU"+
M[9C[8]N^?*^YY008Z\YV?AGO3=1\+&^NKJ<746)[F.<PSV_F1'9'LVNNX;A_
M%U&"!UQ6G)K6GI(T<=U;S2QRK%+&D\>Z,DX^8%AC&#QUX. :M0W=M<DB"XBE
M(17(1PWRM]T\=C@X/?%%V%D8FC>%QI$M@XNUD%I%<1A5A"!O-D#\ 'C&,8_E
M3=!TMK?7];OF658GG\NW65<8!P\A7U5G8\^U7X-?T^>6_7S1%'9$"2>4A8SD
MD9!)Z!E9<G'(-6$U?3998HH]0M'DF3S(D69273GYE&>1P>1Z&C4-#.N/#GGZ
MC-=_:]OFWL%WM\O./*4+MSGOCKV]Z#X<SN_TO[VIC4/]7Z8^3K[=?TK0MM7T
MR]=4M-1M)V;HL4ZL3U]#['\C3K;4K:[NY+>%PY2))@ZD%71BP!4@\\H?THNP
MT,VQ\.?8_P"RO]+W_P!GO.W^KQYGF;O?C&[WSBJT7A6XM8;=;74UCD2&:WD=
MK?<&21]_ W?*P[$Y'J*Z:BB["R.<M_"GD65Q;_;=WG:5'IV[RL8V*R[^O?=T
M]NM-C\(PPZH;M$TV57=)'^U6 ED#* #L?<-N=N>0<$D^U=+11=A9&?>:6M[J
MEE>.XV6RRHT3)D2!P!S^7H<UB-X+39:9FL[E[:%K=/M]EYZ^5NW(,;P0RCC.
M>1VKJZ*+L+&&^@22:K8W;2V<4=GM$8M[3RY-H0C9OWG]WDD[<>@]ZQM"\,7%
M]X<TV'5YV$,=D\2VWD>7(AD7:=Q).2!D#Y1UYS7:T4786.:NO#%UJ-M<+J&I
MI+.]I]DCDCMM@52P9F(+G<Q*KW XZ5<O=$DN+N^GCEM&%W%#$\5U:F9-L9<\
MC>N<[Q],=\\;-%%V%CE#X*B46C"2RN)H;9;=S?V(G4@$D%1N!3&XC&3QM';-
M=3$@CB2,!0%4 !%P!CT'84ZBANX6"BBBD,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MLZ#0M,MM8GU:&T1+Z==LDH)Y'';.!T'05HU E[:R7<EHES"US& SPK("Z@]"
M5ZCJ* *FOZ?+JNB7%E R+))MP7) X8'L#Z5AWWA*ZNGUD)/"8;B*464;$CRI
M)0/-+8'0D<=?O-70:SJ7]DZ5/?>5YOE;?DW;<Y8#K@^M5;CQ3HUK<RP3791X
M9/+D/DN51L9 +;< D=.>>U4K]!.QGR>'K]-1EU"![9I5NH;B&.1V"N%A\I@Q
MVG:<%B" >@JXFDWMQJEQ>7K0(+BP^RLL+,=IWN>"0,@!@,\9(/ J8^)M)6WC
MF:XD"R3&W53;R!S(!DILV[@<#ICGC'44EKXFTB]F2*WNF=I VTF%P"5&67)7
M&X#DKU'I1J&AG0:)J;1V<=[%I\L=A:O!&BRMBYW*$^?*?(-HZ#=R?:H5T'7$
MLTB2Y7REN&<68U"90L>S"KYX7S#ALG&,<XSQ6Z^O:;';P7#7.(KBV>[B;8WS
M1*H9FZ<8##@\\U'%XDTF6&>87>V."(3.9(W3,9SAEW ;E.."N0>U%V&AD:9X
M:OM/&G*SV\JQV4MG<XD92 SAMR?*<G@\''UJLGA"[_L:>QDCA,ZV+VMO=-J$
M\@Y '^J8%8P0 3M)Q@ 5U5CJ5KJ*R&W=]T3;9$DB:-T.,C*L 1D$'I69IVO7
M5WI[:G<V4%OIRB1BZ3O+( C$9V"/V/0FB[%9%9_#EXVJ&Y$D&PWUO<XW'.V.
M+8PZ=<]/:JY\,Z@+"U@S"6L;N66$I=RP^<DA?(9D7=&P#CIN!P1T-;4WB32(
M%9GO 0K1KE(V?+.I9 , Y) R .>1ZC+7\3:2D,,K7$G[Z1HDC%O(9"Z]5V;=
MP/L1GO1=A9#8M(9/#-WI\<,=O/<1S K]I>==[YY+N-QSG)X]:SI/#-Z^GZQ;
MB6#?>Z?#:QG<<!D1E)/'3+#UK877]->]^R"X82;S'N:)PF\+N*;R-NX#/RYS
MP>.*:OB+37LS=B2?R-RJC&UE'FEON^6-N7SU^7/'/2C4>A1DT6]FU>ZE00V=
MI<1RI,(KAY//+*%5C&5"HPQDD$DXQ5&YT#7;G2+2R:2W58K-K5HX[Z6--V%
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M]L@:WBB3[3<"!XFC=F1E:.+D@G//)).32W?A_6KI;H"XMXWGM!#/()F(NW
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M\+?_ .H%_P"3?_V%'_"W_P#J!?\ DW_]A1[6'</[4PG\_P"#_P CTZBO,?\
MA;__ % O_)O_ .PH_P"%O_\ 4"_\F_\ ["CVL.X?VIA/Y_P?^1Z=17F/_"W_
M /J!?^3?_P!A1_PM_P#Z@7_DW_\ 84>UAW#^U,)_/^#_ ,CTZBO,?^%O_P#4
M"_\ )O\ ^PH_X6__ -0+_P F_P#["CVL.X?VIA/Y_P '_D>G45YC_P +?_Z@
M7_DW_P#84?\ "W_^H%_Y-_\ V%'M8=P_M3"?S_@_\CTZBO,?^%O_ /4"_P#)
MO_["C_A;_P#U O\ R;_^PH]K#N']J83^?\'_ )'IU%>8_P#"W_\ J!?^3?\
M]A1_PM__ *@7_DW_ /84>UAW#^U,)_/^#_R/3J*\Q_X6_P#]0+_R;_\ L*/^
M%O\ _4"_\F__ +"CVL.X?VIA/Y_P?^1Z=17F/_"W_P#J!?\ DW_]A1_PM_\
MZ@7_ )-__84>UAW#^U,)_/\ @_\ (].HKS'_ (6__P!0+_R;_P#L*/\ A;__
M % O_)O_ .PH]K#N']J83^?\'_D>G45YC_PM_P#Z@7_DW_\ 84?\+?\ ^H%_
MY-__ &%'M8=P_M3"?S_@_P#(].HKS'_A;_\ U O_ ";_ /L*/^%O_P#4"_\
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M3BUS*U]>_P#EL<O1114'"%%%% !1110 4444 %%%% !1110!Z?\ "#_F,_\
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M>2#YW;: 82'W GDG<0/3!J*2'Q(]K;EX+ERDTH#C[*;H1E0$#%LQ@$[MVWG
M7WKL:*+A8\\&BWEJF@:7(BJU];+:WZ;@?EA829XX/&]/^!"NDTZWOK?7I_(M
MKFWTV5I995N6B93*2N&BV$L ?F)#>HP!TK;:")YDF:)&EC!".5!90<9 /;.!
M^0J2FV%@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%X
MW\$:EXEUJ&\LY[2.-+=8B)G8'(9CV4\?,*[VD)"@DD #DDTI14E9F->A"O#D
MGL>/?\*GUW_G[T[_ +^/_P#$4?\ "I]=_P"?O3O^_C__ !%>MVMY:WT GL[F
M&XA)($D+AUS]13=2N_[/TN[O=GF?9X7EV9QNVJ3C/;I6?L8G#_9&&[/[SR;_
M (5/KO\ S]Z=_P!_'_\ B*/^%3Z[_P _>G?]_'_^(KM-/\=1ZA;:8ZV)26[O
M#:2Q&7F XR#T^8$8/;K6Q;^)=(NKI;>*[RS^9L=HW6.39]_8Y 5L=\$T_8(/
M[)POG]YYG_PJ?7?^?O3O^_C_ /Q%'_"I]=_Y^]._[^/_ /$5V-UXU674Q!ID
MD#6YL)[GSKB&50&0?*W0$IP>5!S@X-1)XY":K%#=21Q645A'<W,Z6<[AV8?P
M?W4Y&"P/IUI^P0O[)POG]YR?_"I]=_Y^]._[^/\ _$4?\*GUW_G[T[_OX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUQY)950FTE#2$\C8NW+\<_*#QSTHNQV1:M=/LK)Y7M+.WMVF.Z1HH@A<\\G
MYZGKZUFSZ/<2>,[76 \7V>*S>!E).\L6SD#&,?C5JWU[3+E=T5T"/(-QRC+B
M,$J2<CL001U'<4MIK=A?3K#:O-*Q4-N6WDV+E0P#/MVJ<$'!(/(XI:AH<S8>
M#9K)_+EMK6[2*:66WFFO9L)NSC,&-AZX.",BHCX-U0Z7-;)-;Q(EU;SVED;F
M26*(1_>&]EW#=DG&#C'OQW=%/F8<J&QES&ID55D(&Y5;< >X!P,_D*=114C"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **1G5%+.P51W)P*6@
MHHHH **** "BBB@ HHHH ***:'1F958%E^\ >1]: '44U'61 Z,&4C(93D&G
M4 %%,,T01G,B!%)#-N& 1US3Z "BBB@ HHHH **** "BD#J7*!AO !*YY .<
M']#^5('1F90REE^\ >1]: '44QIHD<(\J*QQ@%@#R<#]>*5W2, NRKDA1DXR
M3T% #J**:KH^[:RMM.#@YP?2@!U%,6:)W*+*C.,Y4,">.#3Z "BBB@ HIH=&
M=D5E++]X \CZTZ@ HHHH **;O7>4W#>!DKGG'K3J "BBFNZ1H7=@JCJ6. *
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MT4@(90RD$$9!'>FO-%$R+)*B,YP@9@"Q]!ZT /HI'=8T9W8*BC+,QP /4TM
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M1D;&CV!<;C]_E@ /I55-!UN.T:&&6*"V$Z,EE'J$V!&J$%1-MWH"=IV@8&W
MQDUUU%%PL<!>^'KFSTC1-.:>,7DUU-;2&,L^Z"5GDD )Y.% .3W%=$NE7B>)
M4OH(X+6U&1-Y5R[&X4)M4-%M"J1Q\P).% Z5NT47"P4444AA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %:_L(-1MO(N%)3(;@X.:RKO2[
MGSKAK5/D;RTV;A\R#'J>H([]B:W$;>BMC&1FG4[BL8TVF?+=*899(RP$*Q[#
MM7(8\-QC=G@]@*?);7LFFI&\<&T!-UK$FW(!&5SNQC';IVSBM:BBX6,>*"6&
MZ5XM/>.%XFC"*Z?NR6SR-W [X&:JP:1(VG6UO]E6-EE#2F>*-E_U;#.$(SR>
M,\\YKHJ*+A8R=2MKQ;."&R$KM&A7>)"#D  9^=<_CGZ&J4S7FV_GC>X58S,"
MYF^4\_*%&>"/7 KHZ*+A8QHK6]:12/M$48=V59+@L5^5=NX@G(W!CC)XIB6^
MI);M)$LZRKLQ'-.'W-@ACU(QR#C_ &>@K<HHN%C$-IJ:W4H264J(RL;EL@_N
M\#.7X.[G[OXU:TNWEADN7>*:-9&4J)I=[<+@Y.3W]ZT:*+A8QA ]SX7AAC0N
MS)'\HVY(# G[W'3UJ!+*_C@CB2.9$&_R@DJIY9+Y!<*<$8[#(]JZ"BBX6.?N
M["]=)8Q%*R.TA54E"@$OD%N1D$=N?I5V^CO'U"W:!7\I2A9E<@8W?,"-X'3_
M &6Z]JTZ*+A8P'L]36&U"R3[L$R$2%B'R,'EU&,#IR/;FK]U'<-?*R),R>7A
M"DNU4?)Y89&X=/7H>*T**+A8Q(;.]<1J_P!JCC+IY@:YRQPK;B"&R 25XSVZ
M"DBL;\11QO)<$-Y)D)G.<\^9@YX'3I^%;E%%PL8(L]4CM&17F+,B;MTQ8DAC
MD#YACY<="/KFI!::@82?,GWK;@*#+MRVYLC 8\[2 "2>QSFMJBBX6,:>&\,3
M""&X"%8P$><EU(9]QR)!GJO\73'IBGVUM?):W18$7,D"!6+#)<)@\_6M:BBX
M6,9;6X^T++##<1+B-3YLP9N) 6YW'C;GO38+748S%EICN*-)NFW<B3G'/ V]
MAUK;HHN%CGYK?438*D4-T+CG?(UR3EL=5Q(,#/\ ^R:N"WNELKL!&$DD^\!'
M )7*YP<\$@$=:U**+A8P$M+^*&01Q3!6WD(TV6Y=2,D.,G;G^+\>:@AEGCU*
MS@NYYPZA08UEY)+-C(W\CIGANG45TU%%PL8B6E]% BM]IE!2(S*+CYRWS;PK
M$\<[.A&0*CDLM0EC\J03ONMF0EIL '!QT;D\@'(_&M^HIYO)0-MSDXZT7"QD
M"VO01F*[-N"N8EN,28V$==WK[U-J%I<O=B>V63?]F>-6$F K=1D9&>_KSCI@
M&K7V_P#Z9?\ CW_UJ/M__3+_ ,>_^M3U#0SXK:_VVP<7+8E)8&3: I(ZD2DG
M')'+=<8'%)96=W;FR3R;@+&2)0T_R?48?/X$$?2M'[?_ -,O_'O_ *U'V_\
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MSTZ&EDL+TO?+''*%E$W64;'##Y0%SP<]\#ZUI_;_ /IE_P"/?_6H^W_],O\
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M8WGY$?SDG?S\WR[1T/0_6F7%IJ(M(_)$[3EG9F\\G'/R_P 8&,?7Z5I?;_\
MIE_X]_\ 6H^W_P#3+_Q[_P"M1J!FFRNHO-5(;IHVG=B([G:6!SM();@#OT[=
M:L+:7PD#O)(SB2($B4A2H"[SC..H/:K7V_\ Z9?^/?\ UJ/M_P#TR_\ 'O\
MZU&H:&4EKJ@LW$GVAYMR_*), D!LG=YN<'(Z8Z#Y>HK2NR]]I\Z0QMO#[,'
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M19A<N453^W_],O\ Q[_ZU'V__IE_X]_]:BS"Y<HJG]O_ .F7_CW_ -:C[?\
M],O_ ![_ .M19A<N453^W_\ 3+_Q[_ZU'V__ *9?^/?_ %J+,+ERBJ?V_P#Z
M9?\ CW_UJ/M__3+_ ,>_^M19A<N453^W_P#3+_Q[_P"M1]O_ .F7_CW_ -:B
MS"Y<HJG]O_Z9?^/?_6H^W_\ 3+_Q[_ZU%F%RY15/[?\ ],O_ ![_ .M1]O\
M^F7_ (]_]:BS"Y<HJG]O_P"F7_CW_P!:C[?_ -,O_'O_ *U%F%RY15/[?_TR
M_P#'O_K4?;_^F7_CW_UJ+,+ERBJ?V_\ Z9?^/?\ UJ/M_P#TR_\ 'O\ ZU%F
M%RY15/[?_P!,O_'O_K4?;_\ IE_X]_\ 6HLPN7**I_;_ /IE_P"/?_6H^W_]
H,O\ Q[_ZU%F%RY15/[?_ -,O_'O_ *U'V_\ Z9?^/?\ UJ+,+G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>bdsx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-29T14:25:22.1496+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://biodesix.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:bdsx="http://biodesix.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100040 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandards" id="DisclosureRecentIssuedAccountingStandards">
        <link:definition>995475 - Disclosure - Recent Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinations" id="Role_DisclosureBusinessCombinations">
        <link:definition>995485 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue" id="Role_DisclosureFairValue">
        <link:definition>995495 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>995505 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>995515 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>995525 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>995535 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3" id="DisclosureLeases3">
        <link:definition>995545 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>995555 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock">
        <link:definition>995565 - Disclosure - Warrants to Purchase Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>995575 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" id="DisclosureRevenueAndAccountsReceivableCreditConcentration">
        <link:definition>995585 - Disclosure - Revenue and Accounts Receivable Credit Concentration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>995595 - Disclosure - Share Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1" id="DisclosureNetLossPerCommonShare1">
        <link:definition>995605 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995615 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995625 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995635 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" id="Role_DisclosureDefinedContribution401KPlan">
        <link:definition>995645 - Disclosure - Defined Contribution 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995655 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables" id="Role_DisclosureFairValueTables">
        <link:definition>995665 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>995675 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>995685 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>995695 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>995705 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995715 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables">
        <link:definition>995725 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationTables">
        <link:definition>995735 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>995745 - Disclosure - Share Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>995755 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995765 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" id="DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Recent Issued Accounting Standards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" id="Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
        <link:definition>995815 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails" id="DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails">
        <link:definition>995825 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" id="DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails">
        <link:definition>995835 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" id="Role_DisclosureFairValueAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Fair Value - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
        <link:definition>995855 - Disclosure - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
        <link:definition>995875 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
        <link:definition>995885 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
        <link:definition>995895 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails">
        <link:definition>995905 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>995915 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" id="DisclosureDebtSummaryOfLongtermNotesPayableDetails">
        <link:definition>995925 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" id="Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
        <link:definition>995945 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995955 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails">
        <link:definition>995965 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>995975 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
        <link:definition>995985 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails">
        <link:definition>995995 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>996005 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails">
        <link:definition>996015 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails">
        <link:definition>996025 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails">
        <link:definition>996035 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>996045 - Disclosure - Share Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>996055 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails">
        <link:definition>996065 - Disclosure - Share Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
        <link:definition>996075 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" id="DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
        <link:definition>996085 - Disclosure - Share Based Compensation - Summary of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>996095 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
        <link:definition>996105 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996115 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>996125 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996135 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>996145 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>996155 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" id="Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail">
        <link:definition>996165 - Disclosure - Defined Contribution 401(k) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="bdsx-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="bdsx-20231231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="bdsx-20231231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="bdsx-20231231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="bdsx-20231231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="bdsx-20231231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="bdsx-20231231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="bdsx-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandards" xlink:href="bdsx-20231231.xsd#DisclosureRecentIssuedAccountingStandards" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinations" xlink:href="bdsx-20231231.xsd#Role_DisclosureBusinessCombinations" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue" xlink:href="bdsx-20231231.xsd#Role_DisclosureFairValue" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="bdsx-20231231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="bdsx-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="bdsx-20231231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt" xlink:href="bdsx-20231231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3" xlink:href="bdsx-20231231.xsd#DisclosureLeases3" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="bdsx-20231231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:href="bdsx-20231231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquity" xlink:href="bdsx-20231231.xsd#Role_DisclosureEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:href="bdsx-20231231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="bdsx-20231231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:href="bdsx-20231231.xsd#DisclosureNetLossPerCommonShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="bdsx-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="bdsx-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="bdsx-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" xlink:href="bdsx-20231231.xsd#Role_DisclosureDefinedContribution401KPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bdsx-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureFairValueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="bdsx-20231231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:href="bdsx-20231231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:href="bdsx-20231231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="bdsx-20231231.xsd#DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="bdsx-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails" xlink:href="bdsx-20231231.xsd#DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:href="bdsx-20231231.xsd#DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20231231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:href="bdsx-20231231.xsd#DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:href="bdsx-20231231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:href="bdsx-20231231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20231231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:href="bdsx-20231231.xsd#DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:href="bdsx-20231231.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:href="bdsx-20231231.xsd#DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20231231.xsd#DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:href="bdsx-20231231.xsd#Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2" xlink:href="bdsx-20231231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#axisDefault" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AstrazenecaUkMember" xlink:label="bdsx_AstrazenecaUkMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentOfEquityFinancingCosts" xlink:label="bdsx_PaymentOfEquityFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OtherAssetsPolicyTextBlock" xlink:label="bdsx_OtherAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalWarrantsMember" xlink:label="bdsx_AdditionalWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CO" xlink:label="stpr_CO"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsLeaseLiability" xlink:label="bdsx_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LessorReimbursementsReceived" xlink:label="bdsx_LessorReimbursementsReceived"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IncreaseDecreaseInContingentConsideration" xlink:label="bdsx_IncreaseDecreaseInContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToFirstAmendmentWarrants" xlink:label="bdsx_AdjustmentsToFirstAmendmentWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FirstAmendmentMember" xlink:label="bdsx_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_UnitedHealthcareMember" xlink:label="bdsx_UnitedHealthcareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TenantImprovementAllowancesReceived" xlink:label="bdsx_TenantImprovementAllowancesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BiopharmaServicesAndOtherMember" xlink:label="bdsx_BiopharmaServicesAndOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockOptionExchangeProgramMember" xlink:label="bdsx_StockOptionExchangeProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NetProceedFromFinancingTransactionsss" xlink:label="bdsx_NetProceedFromFinancingTransactionsss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecuritiesPurchaseAgreementsMember" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ExitFeePayment" xlink:label="bdsx_ExitFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventorySuppliesPolicy" xlink:label="us-gaap_InventorySuppliesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_GrossProceedsFromFinancingTransactions" xlink:label="bdsx_GrossProceedsFromFinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OffsettingDeferredRent" xlink:label="bdsx_OffsettingDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LPCFacilityMember" xlink:label="bdsx_LPCFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TheStateOfColoradoMember" xlink:label="bdsx_TheStateOfColoradoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfInterestOnContingentConsideration" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TrancheBWarrantsMember" xlink:label="bdsx_TrancheBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:label="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentOfDeferredOfferingCosts" xlink:label="bdsx_PaymentOfDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PromissoryNoteTwoMember" xlink:label="bdsx_PromissoryNoteTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMarketFacilityMember" xlink:label="bdsx_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalWarrantsAmount" xlink:label="bdsx_AdditionalWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfFacility" xlink:label="bdsx_NumberOfFacility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IssuanceOfPerceptiveWarrants" xlink:label="bdsx_IssuanceOfPerceptiveWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseExpirationMonthYear" xlink:label="bdsx_LeaseExpirationMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TenantImprovementsIncurredDuringThePeriod" xlink:label="bdsx_TenantImprovementsIncurredDuringThePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsAndRestrictedStockUnitsRSUsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsRSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PromissoryNoteOneMember" xlink:label="bdsx_PromissoryNoteOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CommonStockIssuedForDeferredOfferingCosts" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="bdsx_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CashCollateralizedMember" xlink:label="bdsx_CashCollateralizedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ThirdAmendmentToApaAgreementMember" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccretionOfLeaseLiability" xlink:label="bdsx_AccretionOfLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AreaOfOfficeSpaceLeased" xlink:label="bdsx_AreaOfOfficeSpaceLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ExistingShareholdersMember" xlink:label="bdsx_ExistingShareholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfOfficers" xlink:label="bdsx_NumberOfOfficers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_KS" xlink:label="stpr_KS"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DefinedContributionPlanNameExtensibleList" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DiligenceExpenseAndLegalFees" xlink:label="bdsx_DiligenceExpenseAndLegalFees"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PublicOfferingMember" xlink:label="bdsx_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WeightedAveragePricePerShare" xlink:label="bdsx_WeightedAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanFacilityMember" xlink:label="bdsx_PerceptiveTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EquityFinancingProgramsMember" xlink:label="bdsx_EquityFinancingProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MinimumCashBalanceAtMaturityDate" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Description of Acquired Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining life of outstanding performance condition options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AstrazenecaUkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZeneca UK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AstrazenecaUkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Astrazeneca UK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AstrazenecaUkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Astrazeneca UK.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfEquityFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfEquityFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Equity Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfEquityFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of equity financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Assets Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than OptionsVested In Period Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than optionsvested in period amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase agreement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Contingent Consideration and Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instruments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Testing Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Testing Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Testing services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation tax carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research and experimentation tax carryforwards subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled under the Option Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Cancelled under the Option Exchange, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Cancelled under the Option Exchange, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful Lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CO_lbl" xlink:role="http://www.xbrl.org/2003/role/label">COLORADO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of tax credit carryforward expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diagnostic Tests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diagnostic Tests [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Diagnostic tests.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of license agreement and royalty payment related to Nodify CDT test recognized revenue for non-screening tests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income , net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LessorReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessor reimbursements received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LessorReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Reimbursements Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LessorReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor reimbursements received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseDecreaseInContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseDecreaseInContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase decrease in contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseDecreaseInContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Annual Principal Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal balance outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BDX004</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B D X004 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bdx004.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock allowed to purchase by counterparty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage of Common Stock Allowed to Purchase by Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock allowed to purchase by counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturities of Long-Term Debt [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToFirstAmendmentWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of First Amendment warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToFirstAmendmentWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To First Amendment warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToFirstAmendmentWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments To First Amendment warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreements Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2029 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Six and Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, to be paid, year six and thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted under the Option Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Granted under the Option Exchange, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Granted under the Option Exchange, Weighted Average Exercise Price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Outstanding - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options, Outstanding - January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of outstanding stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, warrants or rights exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refundable deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets after valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual volume percentage thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Volume Percentage Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual volume percentage thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining available capacity for share issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Amount Awarded to Other Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final settlement payment to third parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining estimated obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Estimated Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining estimated obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement number of options to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement number of options to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease agreement number of options to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation Expense Related to Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation and amortization expense related to property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A2 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory, Supplies, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnitedHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Healthcare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnitedHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United Healthcare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnitedHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">United healthcare.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowances received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowances Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowances received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less amount representing tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amount representing tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, operating lease, liability, amount representing tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, amount representing tenant improvement allowances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BiopharmaServicesAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biopharma Services and Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BiopharmaServicesAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biopharma services and other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BiopharmaServicesAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biopharma services and other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional warratns exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Additional Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, additional warrants or rights exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tenant Improvement Allowance Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tenant improvement allowance amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up Front Cash Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up-front Payment Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount withdrawn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for doubtful accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockOptionExchangeProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Exchange Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockOptionExchangeProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Exchange Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockOptionExchangeProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option exchange program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lung Diagnostic Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lung Diagnostic Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lung diagnostic revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited/canceled, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series F Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest related to uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Lease Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development and regulatory costs exercised using opt-out right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs exercised using opt-out right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax examination, likelihood of unfavorable settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Likelihood of Unfavorable Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance, deferred tax asset, explanation of change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Explanation of Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of ending royalty payments from first commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year Of Ending Royalty Payments From First Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of ending royalty payments from first commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Patent costs and intangible asset acquisition, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for proceeds from patent costs and intangible asset acquisition, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Convertible Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Convertible Preferred Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series E convertible preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire license rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments to Acquire Businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity financing costs included in accounts payable and other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financing Costs Included in Accounts Payable and Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financing costs included in Accounts payable and other accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedFromFinancingTransactionsss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds after deducting commissions, fees and expenses payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedFromFinancingTransactionsss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceed From Financing Transactionsss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedFromFinancingTransactionsss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceed from financing transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable to Bank, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross proceeds from an equity offering of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued or issuable, threshold limit description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued or Issuable, Threshold Limit Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued or issuable, threshold limit description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital expenditure for leasehold improvements related to leases premises which are tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding - January 1, 2020, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding - December 31, 2020, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">First Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term notes payable, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExitFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exit fee payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExitFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exit fee payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of valuation allowance equal to net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of valuation allowance equal to net deferred tax assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Share Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of Tranche B Warrants to additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue share expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus-To-Options Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonus To Options Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonus-to-options program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bio-Rad License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bio Rad License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bio-rad license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount and debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Applicable margin rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Other Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common stock for purchase under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, Interest Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Landlord contribution towards cost of construction and tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Landlord contribution towards cost of construction and tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Landlord contribution towards cost of construction and tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Estimates Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of Presentation and Estimates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from the sale of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense related to definite-lived intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant under all plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional stock awards granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 200,000,000 authorized; 96,235,883 (2023) and 77,614,358 (2022) shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount used to retire outstanding debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of term loan and notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ficlatuzumab</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ficlatuzumab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ficlatuzumab.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Supplies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Test Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Diagnostic Test Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 diagnostic test revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted under the Option Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock issued during period shares stock options Granted under the Option Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options granted under the option exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions for tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Contingent Consideration Liability, Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of blood based lung cancer test</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Cancer Test</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of cancer test.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of common stock underlying eligible options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current and long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration arrangements, common shares, redemption amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration arrangements common shares redemption amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets subject to amortization, Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Convertible Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Convertible Preferred Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series G convertible preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2006 Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue and Accounts Receivable Credit Concentration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial warrants amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial warrants amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial warrants amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions and offering expenses payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions And Offering Expenses Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding - January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Intrinsic Value, Outstanding - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding - December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - January 1, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_GrossProceedsFromFinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross proceeds from financing transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_GrossProceedsFromFinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from financing transactions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument, aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to the current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in fair value, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OffsettingDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offsetting Deferred Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OffsettingDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offsetting deferred rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to additional paid-in capital deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid-in capital deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding - January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax examination, period under examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Period under Examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax examination, period under examination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of performance-condition options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for deferred offering costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, For Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, for deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid&#8209;in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity for Convertible Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LPCFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LPC Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LPCFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">L P C Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LPCFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LPC facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheStateOfColoradoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The State of Colorado</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheStateOfColoradoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The State of Colorado Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheStateOfColoradoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The State of Colorado.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of interest on installment payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of interest on contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public offering price per share of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering price per share of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding - January 1, 2020, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price,Outstanding - December, 31, 2020, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Other Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TrancheBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TrancheBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TrancheBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche B warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration number of installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Number Of Installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration number of installments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial blood-based test</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Commercial Blood Based Test</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial blood based test.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited/canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LongT erm Debt Maturities Repayments Of Principal In Year Four And Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal in year four and thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Excess and obsolete inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory excess and obsolescence</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Write-down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased property building capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leased property building capacity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leased property building capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Additional Paid In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to additional paid-in-capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, Marketing, General and Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Initial Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination contingent consideration final payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Final Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration final payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from term loan and notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Term Loan And Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of term loan and notes payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and developments credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory note two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Gross Margin Target Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration gross margin target period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Exercisable - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Values, For Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, values, for deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional warrants amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional warrants amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest, amortization of debt issuance costs and other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Amortization Of Debt Issuance Costs And Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest, amortization of debt issuance costs and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scheduled Principal Repayments (Maturities) of Long-term Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Portion of Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Portion Of Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right-of-Use Assets Obtained in Exchange for Lease Liabilities at Adoption of ASC 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued as commitment fee, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued as Commitment Fee, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as commitment fee, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateral Held [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about liabilities measured at fair value on recurring basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Preferred Stock Converted Into Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of preferred stock converted into common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Condition Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Condition Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance condition options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable2018 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes payable 2018 notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating leases, Less amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct costs and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well Known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fee payments on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fee Payments On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fee payments on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES act.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board of Directors Chairman [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license income generated from licensing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of License Income Generated From Licensing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of license income generated from licensing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Issued Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite lived intangible assets excluding goodwill gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Contingent Consideration Excluding Accretion Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of contingent consideration excluding accretion expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Responsible percentage of development and regulatory costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options And Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options and restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining capacity under the tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Capacity Under the Tenant Improvement Allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining capacity under the tenant improvement allowances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount reclassified from non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Reclassified From Non Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability reclassified from non-current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of offering period under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Offering Period Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of offering period under plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized to expense period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of SARS-CoV-2 test</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of S A R S Co V2 Test</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of SARS-CoV-2 test.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private placement in net equity proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IssuanceOfPerceptiveWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Perceptive Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IssuanceOfPerceptiveWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Perceptive Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IssuanceOfPerceptiveWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of perceptive warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent per month from commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Base rent per month from commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base rent per month from commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series H Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">POC Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">P O C Clinical Trials [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Poc clinical trials.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Gross (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Gross (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A3 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A3 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-3 preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Sixteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution 401(k) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales, Marketing, General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, Marketing, General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants For Convertible Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants for convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on extinguishment of liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss on debt extinguishment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain (loss) on debt extinguishment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of voting power or value of stock for employee participation in offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of voting power or value of stock for employee participation in offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of property &amp; equipment included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of property &amp; equipment included in accounts payable and accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments not required on net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments Not Required To Pay On Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments not required to pay on net revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating leases, Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, stock issuable per day, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Stock Issuable Per Day, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Collateralized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateral Held [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Outstanding Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Long-term Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest expense due to passage of time and fixed payment schedule</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense due to passage of time and fixed payment schedule.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax Aassets capitalized research costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Centennial Valley Properties I, LLC Lease Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Centennial Valley Properties I, LLC Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net of allowance for doubtful accounts of $65 and $118</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementsIncurredDuringThePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements incurred during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementsIncurredDuringThePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements Incurred During The Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementsIncurredDuringThePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvements incurred during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of subscription agreement for which final closing to be delayed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of subscription agreement for which final closing to be delayed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of subscription agreement for which final closing to be delayed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, expires period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of royalty payments from first commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Royalty Payments From First Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of royalty payments from first commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to a lapse of statute</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options And Restricted Stock Units R S Us [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options and restricted stock units (RSUs).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory note one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal contingency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for deferred offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, marketing, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent after fixed escalation provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent after fixed escalation provisions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent after fixed escalation provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes payable, total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement with Unobservable Inputs Payments of Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs payments of contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-Money Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Money Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Money Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Industry Sector [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Collateralized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Collateralized [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash collateralized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln Park.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CellCarta License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cell Carta License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CellCarta License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Estimated Amortization Expense of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Amendment to APA Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Amendment to APA Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third amendment to APA agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Life and Patent Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Life And Patent Life [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product life and patent life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of escalations of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Escalations Of Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of escalations of sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating and Finance Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating and finance leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of Tranche B warrants to additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital Reclassification of Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to Additional Paid in Capital Reclassification of Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash &#8209; beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash &#8209; end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expiry Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement expiry date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights outstanding, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer and Chief Financial Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer and Chief Financial Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief executive officer and chief financial officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs included in accounts payable and other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Included in Accounts Payable and Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt issuance costs included in Accounts payable and other accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimate of Fair Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets, Excluding Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Office Space Leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space leased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2023 and 2022) issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from net of debt issuance costs and original issue discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from debt, after deducting debt issuance costs and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Debt, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased by underwriter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues Shares Purchased by Underwriter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares new issues shares purchased by underwriter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining unrecognized share based compensation expense for options and restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Forfeited/canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExistingShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existing Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExistingShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">existing shareholders member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExistingShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">existing shareholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment premium percentage of aggregate outstanding principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment premium percentage of aggregate outstanding principal amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of officers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Officers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of officers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_KS_lbl" xlink:role="http://www.xbrl.org/2003/role/label">KANSAS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible assets amortization expense year six and thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets subject to amortization, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Weighted average exercise price, Forfeited/canceled, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Accumulated Amortization Excluding Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accumulated amortization of intangible assets, excluding goodwill.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate on extra allowance amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate on extra allowance amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest rate on extra allowance amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock may be issued under incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes/Loan payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan principle amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use assets obtained in exchange for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Perceptive Term Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Perceptive Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Perceptive Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Perceptive term loan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares committed under ESPP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Committed Under E S P P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Committed Under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Industry Sector [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of earnings used for purchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trademarks</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trademarks [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes and Error Corrections [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit subject to contingent reduction over the term of the lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairments loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation claims and assessments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Claims And Assessments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Claims and Assessments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Three Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of eligible holders elected to exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vehicles [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vehicles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer discretionary contributions amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Exercisable - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AVEO Oncology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A V E O Oncology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aveo oncology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Indi</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Integrated Diagnostics, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Integrated Diagnostics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrated Diagnostics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk&#8209;free rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Name [Extensible List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name Extensible List</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment shares issuable on conditional basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment Shares Issuable on Conditional Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment shares issuable on conditional basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased premised obligated to pay base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased premised obligated to pay base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of leased premised obligated to pay base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of Stock, stock issuable per day, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Stock Issuable Per Day, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiligenceExpenseAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diligence expenses and legal fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiligenceExpenseAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diligence Expense and Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiligenceExpenseAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Diligence expense and legal fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options, Cancelled under the Option Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Cancelled under the Option Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock issued during period shares stock options cancelled under the option exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options cancelled under the option exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, shares issued as commitment fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Shares Issued as Commitment Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as commitment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary sources of revenue description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary Sources Of Revenue Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Primary sources of revenue, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchased Technology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchased technology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NSCLC POC Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N S C L C P O C Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nsclc poc trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuable during period, value, committed shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuable During Period, Value, Committed Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable, committed to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, Weighted-average remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding - January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Perceptive Term Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Perceptive Term Loan Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Perceptive term loan facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Liability, Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financing Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financing Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Financing Programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation related accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs amortized against Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Amortized Against Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs amortized against additional paid-in capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum cash balance at maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum cash balance at maturity date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oncimmune Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oncimmune Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oncimmune Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AstrazenecaUkMember" xlink:to="bdsx_AstrazenecaUkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentOfEquityFinancingCosts" xlink:to="bdsx_PaymentOfEquityFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesMember" xlink:to="bdsx_DirectCostsAndExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OtherAssetsPolicyTextBlock" xlink:to="bdsx_OtherAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchaseAgreementTerm" xlink:to="bdsx_PurchaseAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TestingServicesMember" xlink:to="bdsx_TestingServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdvanceDeposits" xlink:to="bdsx_AdvanceDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalWarrantsMember" xlink:to="bdsx_AdditionalWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CO" xlink:to="stpr_CO_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiagnosticTestsMember" xlink:to="bdsx_DiagnosticTestsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsLeaseLiability" xlink:to="bdsx_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LessorReimbursementsReceived" xlink:to="bdsx_LessorReimbursementsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncreaseDecreaseInContingentConsideration" xlink:to="bdsx_IncreaseDecreaseInContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BDX004Member" xlink:to="bdsx_BDX004Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdjustmentsToFirstAmendmentWarrants" xlink:to="bdsx_AdjustmentsToFirstAmendmentWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FirstAmendmentMember" xlink:to="bdsx_FirstAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SubscriptionAgreementsMember" xlink:to="bdsx_SubscriptionAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SecondAmendmentMember" xlink:to="bdsx_SecondAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:to="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerFunds" xlink:to="us-gaap_CustomerFunds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumAnnualVolumePercentageThereafter" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingEstimatedObligation" xlink:to="bdsx_RemainingEstimatedObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA2PreferredStockMember" xlink:to="bdsx_SeriesA2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventorySupplies" xlink:to="us-gaap_OtherInventorySupplies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_UnitedHealthcareMember" xlink:to="bdsx_UnitedHealthcareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TenantImprovementAllowancesReceived" xlink:to="bdsx_TenantImprovementAllowancesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:to="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:to="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BiopharmaServicesAndOtherMember" xlink:to="bdsx_BiopharmaServicesAndOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:to="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockOptionExchangeProgramMember" xlink:to="bdsx_StockOptionExchangeProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LungDiagnosticRevenueMember" xlink:to="bdsx_LungDiagnosticRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:to="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseCommencementDate" xlink:to="bdsx_LeaseCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NetProceedFromFinancingTransactionsss" xlink:to="bdsx_NetProceedFromFinancingTransactionsss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SecuritiesPurchaseAgreementsMember" xlink:to="bdsx_SecuritiesPurchaseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ExitFeePayment" xlink:to="bdsx_ExitFeePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareAgreementMember" xlink:to="bdsx_RevenueShareAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareExpenses" xlink:to="bdsx_RevenueShareExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BonusToOptionsProgramMember" xlink:to="bdsx_BonusToOptionsProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BioRadLicenseMember" xlink:to="bdsx_BioRadLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:to="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiclatuzumabMember" xlink:to="bdsx_FiclatuzumabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventorySuppliesPolicy" xlink:to="us-gaap_InventorySuppliesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_COVID19DiagnosticTestRevenueMember" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" xlink:to="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCancerTest" xlink:to="bdsx_NumberOfCancerTest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanMember" xlink:to="bdsx_TwoThousandSixPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InitialWarrantsAmount" xlink:to="bdsx_InitialWarrantsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_GrossProceedsFromFinancingTransactions" xlink:to="bdsx_GrossProceedsFromFinancingTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationPolicyTextBlock" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OffsettingDeferredRent" xlink:to="bdsx_OffsettingDeferredRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:to="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:to="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LPCFacilityMember" xlink:to="bdsx_LPCFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TheStateOfColoradoMember" xlink:to="bdsx_TheStateOfColoradoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfInterestOnContingentConsideration" xlink:to="bdsx_PercentageOfInterestOnContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TrancheBWarrantsMember" xlink:to="bdsx_TrancheBWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCommercialBloodBasedTest" xlink:to="bdsx_NumberOfCommercialBloodBasedTest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:to="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeasedPropertyBuildingCapacity" xlink:to="bdsx_LeasedPropertyBuildingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredRevenueMember" xlink:to="bdsx_DeferredRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:to="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMarketOfferingMember" xlink:to="bdsx_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentOfDeferredOfferingCosts" xlink:to="bdsx_PaymentOfDeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyOneTermLoanMember" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OtherMember" xlink:to="bdsx_OtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PromissoryNoteTwoMember" xlink:to="bdsx_PromissoryNoteTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMarketFacilityMember" xlink:to="bdsx_AtTheMarketFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:to="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalWarrantsAmount" xlink:to="bdsx_AdditionalWarrantsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CurrentPortionOfContingentConsiderationMember" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" xlink:to="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesIssuedAsCommitmentFeeValue" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeExtensibleEnumeration" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerformanceConditionOptionsMember" xlink:to="bdsx_PerformanceConditionOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NotesPayable2018NotesMember" xlink:to="bdsx_NotesPayable2018NotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpenses" xlink:to="bdsx_DirectCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfFeePaymentsOnNetSales" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CARESActMember" xlink:to="bdsx_CARESActMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityPolicyTextBlock" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsAndRestrictedStockUnitsMember" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:to="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfFacility" xlink:to="bdsx_NumberOfFacility_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LossMember" xlink:to="bdsx_LossMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfSARSCoV2Test" xlink:to="bdsx_NumberOfSARSCoV2Test_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IssuanceOfPerceptiveWarrants" xlink:to="bdsx_IssuanceOfPerceptiveWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BaseRentPerMonthFromCommencementDate" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationMember" xlink:to="bdsx_ContingentConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_POCClinicalTrialsMember" xlink:to="bdsx_POCClinicalTrialsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA3PreferredStockMember" xlink:to="bdsx_SeriesA3PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityMember" xlink:to="bdsx_WarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandAndSixteenPlanMember" xlink:to="bdsx_TwoThousandAndSixteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseExpirationMonthYear" xlink:to="bdsx_LeaseExpirationMonthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockStockIssuablePerDayShares" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:to="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:to="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TenantImprovementsIncurredDuringThePeriod" xlink:to="bdsx_TenantImprovementsIncurredDuringThePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" xlink:to="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsAndRestrictedStockUnitsRSUsMember" xlink:to="bdsx_OptionsAndRestrictedStockUnitsRSUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PromissoryNoteOneMember" xlink:to="bdsx_PromissoryNoteOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CommonStockIssuedForDeferredOfferingCosts" xlink:to="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RentAfterFixedEscalationProvisions" xlink:to="bdsx_RentAfterFixedEscalationProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MilestonePayment" xlink:to="bdsx_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsToPurchaseCommonStockMember" xlink:to="bdsx_OptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:to="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="bdsx_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMoneyOfferingMember" xlink:to="bdsx_AtTheMoneyOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CashCollateralizedMember" xlink:to="bdsx_CashCollateralizedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LincolnParkMember" xlink:to="bdsx_LincolnParkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CellCartaLicenseMember" xlink:to="bdsx_CellCartaLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ThirdAmendmentToApaAgreementMember" xlink:to="bdsx_ThirdAmendmentToApaAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProductLifeAndPatentLifeMember" xlink:to="bdsx_ProductLifeAndPatentLifeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccretionOfLeaseLiability" xlink:to="bdsx_AccretionOfLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PeriodOfEscalationsOfSales" xlink:to="bdsx_PeriodOfEscalationsOfSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LicenseAgreementExpiryDate" xlink:to="bdsx_LicenseAgreementExpiryDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:to="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:to="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AreaOfOfficeSpaceLeased" xlink:to="bdsx_AreaOfOfficeSpaceLeased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:to="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ExistingShareholdersMember" xlink:to="bdsx_ExistingShareholdersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:to="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfOfficers" xlink:to="bdsx_NumberOfOfficers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_KS" xlink:to="stpr_KS_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RepurchaseMember" xlink:to="bdsx_RepurchaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InterestRateOnExtraAllowanceAmount" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerceptiveTermLoanMember" xlink:to="bdsx_PerceptiveTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesCommittedUnderESPPMember" xlink:to="bdsx_SharesCommittedUnderESPPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_EquitySecuritiesIndustryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LitigationClaimsAndAssessmentsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AVEOOncologyMember" xlink:to="bdsx_AVEOOncologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntegratedDiagnosticsIncMember" xlink:to="bdsx_IntegratedDiagnosticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationShares" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DefinedContributionPlanNameExtensibleList" xlink:to="bdsx_DefinedContributionPlanNameExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockStockIssuablePerDayValue" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiligenceExpenseAndLegalFees" xlink:to="bdsx_DiligenceExpenseAndLegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" xlink:to="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedClinicalTrialExpenseCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PrimarySourcesOfRevenueDescription" xlink:to="bdsx_PrimarySourcesOfRevenueDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchasedTechnologyMember" xlink:to="bdsx_PurchasedTechnologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PublicOfferingMember" xlink:to="bdsx_PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WeightedAveragePricePerShare" xlink:to="bdsx_WeightedAveragePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NSCLCPOCTrialMember" xlink:to="bdsx_NSCLCPOCTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerceptiveTermLoanFacilityMember" xlink:to="bdsx_PerceptiveTermLoanFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:to="us-gaap_RegulatoryLiabilityAmortizationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EquityFinancingProgramsMember" xlink:to="bdsx_EquityFinancingProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" xlink:to="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MedicareMember" xlink:to="bdsx_MedicareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumCashBalanceAtMaturityDate" xlink:to="bdsx_MinimumCashBalanceAtMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA1PreferredStockMember" xlink:to="bdsx_SeriesA1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OncimmuneLimitedMember" xlink:to="bdsx_OncimmuneLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_DirectCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToFirstAmendmentWarrants" xlink:label="bdsx_AdjustmentsToFirstAmendmentWarrants"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_18"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_AdjustmentsToFirstAmendmentWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CommonStockIssuedForDeferredOfferingCosts" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IssuanceOfPerceptiveWarrants" xlink:label="bdsx_IssuanceOfPerceptiveWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IncreaseDecreaseInContingentConsideration" xlink:label="bdsx_IncreaseDecreaseInContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TenantImprovementAllowancesReceived" xlink:label="bdsx_TenantImprovementAllowancesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentOfDeferredOfferingCosts" xlink:label="bdsx_PaymentOfDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentOfEquityFinancingCosts" xlink:label="bdsx_PaymentOfEquityFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_CommonStockIssuedForDeferredOfferingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_IssuanceOfPerceptiveWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bdsx_IncreaseDecreaseInContingentConsideration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bdsx_TenantImprovementAllowancesReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_PaymentOfDeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_PaymentOfEquityFinancingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandards" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="bdsx_LesseeOperatingAndFinanceLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventorySuppliesPolicy" xlink:label="us-gaap_InventorySuppliesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OtherAssetsPolicyTextBlock" xlink:label="bdsx_OtherAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventorySuppliesPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_OtherAssetsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMoneyOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanFacilityMember" xlink:label="bdsx_PerceptiveTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_GrossProceedsFromFinancingTransactions" xlink:label="bdsx_GrossProceedsFromFinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NetProceedFromFinancingTransactionsss" xlink:label="bdsx_NetProceedFromFinancingTransactionsss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanFacilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_GrossProceedsFromFinancingTransactions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_NetProceedFromFinancingTransactionsss" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWriteDown" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CustomerFunds" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OffsettingDeferredRent" xlink:label="bdsx_OffsettingDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="bdsx_OffsettingDeferredRent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_WarrantLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TrancheBWarrantsMember" xlink:label="bdsx_TrancheBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_TrancheBWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ThirdAmendmentToApaAgreementMember" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalWarrantsMember" xlink:label="bdsx_AdditionalWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfInterestOnContingentConsideration" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ExitFeePayment" xlink:label="bdsx_ExitFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="bdsx_LossMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_ThirdAmendmentToApaAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_AdditionalWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_MilestonePayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfInterestOnContingentConsideration" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ExitFeePayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanFacilityMember" xlink:label="bdsx_PerceptiveTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_OtherMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecuritiesPurchaseAgreementsMember" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PromissoryNoteOneMember" xlink:label="bdsx_PromissoryNoteOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FirstAmendmentMember" xlink:label="bdsx_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PromissoryNoteTwoMember" xlink:label="bdsx_PromissoryNoteTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MinimumCashBalanceAtMaturityDate" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalWarrantsAmount" xlink:label="bdsx_AdditionalWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SecuritiesPurchaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_FirstAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SubscriptionAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_SecondAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MinimumCashBalanceAtMaturityDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_InitialWarrantsAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_AdditionalWarrantsAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:label="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CO" xlink:label="stpr_CO"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AreaOfOfficeSpaceLeased" xlink:label="bdsx_AreaOfOfficeSpaceLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CashCollateralizedMember" xlink:label="bdsx_CashCollateralizedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_KS" xlink:label="stpr_KS"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseExpirationMonthYear" xlink:label="bdsx_LeaseExpirationMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccretionOfLeaseLiability" xlink:label="bdsx_AccretionOfLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LessorReimbursementsReceived" xlink:label="bdsx_LessorReimbursementsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TenantImprovementsIncurredDuringThePeriod" xlink:label="bdsx_TenantImprovementsIncurredDuringThePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CO" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfOfficeSpaceLeased" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralDomain" xlink:to="bdsx_CashCollateralizedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_KS" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseExpirationMonthYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CollateralAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseCommencementDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeasedPropertyBuildingCapacity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RentAfterFixedEscalationProvisions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AdditionalTenantImprovementAllowanceAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_CustomerFunds" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AccretionOfLeaseLiability" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LessorReimbursementsReceived" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_TenantImprovementsIncurredDuringThePeriod" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMarketFacilityMember" xlink:label="bdsx_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EquityFinancingProgramsMember" xlink:label="bdsx_EquityFinancingProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ExistingShareholdersMember" xlink:label="bdsx_ExistingShareholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LPCFacilityMember" xlink:label="bdsx_LPCFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FirstAmendmentMember" xlink:label="bdsx_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PublicOfferingMember" xlink:label="bdsx_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TrancheBWarrantsMember" xlink:label="bdsx_TrancheBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfFacility" xlink:label="bdsx_NumberOfFacility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DiligenceExpenseAndLegalFees" xlink:label="bdsx_DiligenceExpenseAndLegalFees"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WeightedAveragePricePerShare" xlink:label="bdsx_WeightedAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfOfficers" xlink:label="bdsx_NumberOfOfficers"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SubscriptionAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_EquityFinancingProgramsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_LincolnParkMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ExistingShareholdersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_LPCFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_FirstAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_PublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_TrancheBWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfFacility" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PurchaseAgreementTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DiligenceExpenseAndLegalFees" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_WeightedAveragePricePerShare" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_InitialWarrantsAmount" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfOfficers" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BiopharmaServicesAndOtherMember" xlink:label="bdsx_BiopharmaServicesAndOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BiopharmaServicesAndOtherMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_PrimarySourcesOfRevenueDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_UnitedHealthcareMember" xlink:label="bdsx_UnitedHealthcareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TheStateOfColoradoMember" xlink:label="bdsx_TheStateOfColoradoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AstrazenecaUkMember" xlink:label="bdsx_AstrazenecaUkMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_UnitedHealthcareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheStateOfColoradoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_AstrazenecaUkMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockOptionExchangeProgramMember" xlink:label="bdsx_StockOptionExchangeProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsAndRestrictedStockUnitsRSUsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsRSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_StockOptionExchangeProgramMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsRSUsMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_SharesCommittedUnderESPPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription_13"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_IncomeTaxExaminationPeriodUnderExamination" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_RegulatoryLiabilityAmortizationPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="bdsx_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsLeaseLiability" xlink:label="bdsx_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="bdsx_DeferredTaxLiabilitiesRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="bdsx_DeferredTaxAssetsLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_CellCartaLicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DefinedContributionPlanNameExtensibleList" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="bdsx_DefinedContributionPlanNameExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToFirstAmendmentWarrants" xlink:label="bdsx_AdjustmentsToFirstAmendmentWarrants"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_AdjustmentsToFirstAmendmentWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMoneyOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanFacilityMember" xlink:label="bdsx_PerceptiveTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_GrossProceedsFromFinancingTransactions" xlink:label="bdsx_GrossProceedsFromFinancingTransactions"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NetProceedFromFinancingTransactionsss" xlink:label="bdsx_NetProceedFromFinancingTransactionsss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_GrossProceedsFromFinancingTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_NetProceedFromFinancingTransactionsss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CustomerFunds" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_WarrantLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TrancheBWarrantsMember" xlink:label="bdsx_TrancheBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_TrancheBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ThirdAmendmentToApaAgreementMember" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalWarrantsMember" xlink:label="bdsx_AdditionalWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfInterestOnContingentConsideration" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ExitFeePayment" xlink:label="bdsx_ExitFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="bdsx_LossMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_ThirdAmendmentToApaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_AdditionalWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_MilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfInterestOnContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ExitFeePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanFacilityMember" xlink:label="bdsx_PerceptiveTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_OtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecuritiesPurchaseAgreementsMember" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PromissoryNoteOneMember" xlink:label="bdsx_PromissoryNoteOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FirstAmendmentMember" xlink:label="bdsx_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PromissoryNoteTwoMember" xlink:label="bdsx_PromissoryNoteTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MinimumCashBalanceAtMaturityDate" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalWarrantsAmount" xlink:label="bdsx_AdditionalWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SecuritiesPurchaseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_FirstAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SubscriptionAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_SecondAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MinimumCashBalanceAtMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_InitialWarrantsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_AdditionalWarrantsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CO" xlink:label="stpr_CO"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AreaOfOfficeSpaceLeased" xlink:label="bdsx_AreaOfOfficeSpaceLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CashCollateralizedMember" xlink:label="bdsx_CashCollateralizedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_KS" xlink:label="stpr_KS"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseExpirationMonthYear" xlink:label="bdsx_LeaseExpirationMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccretionOfLeaseLiability" xlink:label="bdsx_AccretionOfLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LessorReimbursementsReceived" xlink:label="bdsx_LessorReimbursementsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TenantImprovementsIncurredDuringThePeriod" xlink:label="bdsx_TenantImprovementsIncurredDuringThePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CO" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfOfficeSpaceLeased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="bdsx_CashCollateralizedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_KS" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseExpirationMonthYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CollateralAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeasedPropertyBuildingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RentAfterFixedEscalationProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AdditionalTenantImprovementAllowanceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_CustomerFunds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AccretionOfLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LessorReimbursementsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_TenantImprovementsIncurredDuringThePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMarketFacilityMember" xlink:label="bdsx_AtTheMarketFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EquityFinancingProgramsMember" xlink:label="bdsx_EquityFinancingProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ExistingShareholdersMember" xlink:label="bdsx_ExistingShareholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LPCFacilityMember" xlink:label="bdsx_LPCFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FirstAmendmentMember" xlink:label="bdsx_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PublicOfferingMember" xlink:label="bdsx_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TrancheBWarrantsMember" xlink:label="bdsx_TrancheBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfFacility" xlink:label="bdsx_NumberOfFacility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DiligenceExpenseAndLegalFees" xlink:label="bdsx_DiligenceExpenseAndLegalFees"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_WeightedAveragePricePerShare" xlink:label="bdsx_WeightedAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfOfficers" xlink:label="bdsx_NumberOfOfficers"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" xlink:label="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SubscriptionAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_AtTheMarketFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_EquityFinancingProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_LincolnParkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ExistingShareholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_LPCFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_FirstAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_TrancheBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfFacility" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PurchaseAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DiligenceExpenseAndLegalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_WeightedAveragePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_InitialWarrantsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfOfficers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BiopharmaServicesAndOtherMember" xlink:label="bdsx_BiopharmaServicesAndOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BiopharmaServicesAndOtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_PrimarySourcesOfRevenueDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_UnitedHealthcareMember" xlink:label="bdsx_UnitedHealthcareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TheStateOfColoradoMember" xlink:label="bdsx_TheStateOfColoradoMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AstrazenecaUkMember" xlink:label="bdsx_AstrazenecaUkMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_UnitedHealthcareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheStateOfColoradoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_AstrazenecaUkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockOptionExchangeProgramMember" xlink:label="bdsx_StockOptionExchangeProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsAndRestrictedStockUnitsRSUsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsRSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_StockOptionExchangeProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsRSUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" xlink:label="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_SharesCommittedUnderESPPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_IncomeTaxExaminationPeriodUnderExamination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_RegulatoryLiabilityAmortizationPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_CellCartaLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_Goodwill" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_DirectCostsAndExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_PaymentOfEquityFinancingCosts" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_PaymentOfDeferredOfferingCosts" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_IncreaseDecreaseInContingentConsideration" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="17" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_TenantImprovementAllowancesReceived" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="21" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="22" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentOfEquityFinancingCosts" xlink:label="bdsx_PaymentOfEquityFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_PaymentOfDeferredOfferingCosts" xlink:label="bdsx_PaymentOfDeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IncreaseDecreaseInContingentConsideration" xlink:label="bdsx_IncreaseDecreaseInContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_TenantImprovementAllowancesReceived" xlink:label="bdsx_TenantImprovementAllowancesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_LongTermNotesPayable" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" xlink:label="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="bdsx_DeferredTaxLiabilitiesRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bdsx_DeferredTaxAssetsLeaseLiability" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="bdsx_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts"/>
          <link:loc xlink:type="locator" xlink:href="bdsx-20231231.xsd#bdsx_DeferredTaxAssetsLeaseLiability" xlink:label="bdsx_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" name="NumberOfPreferredStockConvertedIntoCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" name="ProceedsFromIssuanceOfTermLoanAndNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_FiclatuzumabMember" name="FiclatuzumabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DiligenceExpenseAndLegalFees" name="DiligenceExpenseAndLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" name="InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_TrancheBWarrantsMember" name="TrancheBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" name="PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LeaseExpirationMonthYear" name="LeaseExpirationMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PurchaseAgreementTerm" name="PurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_RemainingEstimatedObligation" name="RemainingEstimatedObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_MinimumCashBalanceAtMaturityDate" name="MinimumCashBalanceAtMaturityDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" name="NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessAbstract" name="OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_FirstAmendmentMember" name="FirstAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" name="PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantLiabilityMember" name="WarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AtTheMoneyOfferingMember" name="AtTheMoneyOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" name="PercentageOfDevelopmentAndRegulatoryCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SaleOfStockStockIssuablePerDayShares" name="SaleOfStockStockIssuablePerDayShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_TwoThousandTwentyOneTermLoanMember" name="TwoThousandTwentyOneTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_RevenueShareExpenses" name="RevenueShareExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AreaOfOfficeSpaceLeased" name="AreaOfOfficeSpaceLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OncimmuneLimitedMember" name="OncimmuneLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" name="LandlordContributionTowardsCostOfConstructionAndTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_CashCollateralizedMember" name="CashCollateralizedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DescriptionOfOfferingPeriodUnderPlan" name="DescriptionOfOfferingPeriodUnderPlan" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" name="PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" name="BusinessAcquisitionContingentConsiderationNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PrimarySourcesOfRevenueDescription" name="PrimarySourcesOfRevenueDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" name="StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" name="RemainingCapacityUnderTheTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_InitialWarrantsAmount" name="InitialWarrantsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AstrazenecaUkMember" name="AstrazenecaUkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TenantImprovementsIncurredDuringThePeriod" name="TenantImprovementsIncurredDuringThePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_WarrantsForConvertiblePreferredStockTextBlock" name="WarrantsForConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" name="ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandSixPlanMember" name="TwoThousandSixPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessLineItems" name="OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" name="FairValueMeasurementWithUnobservableInputsInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_NumberOfSARSCoV2Test" name="NumberOfSARSCoV2Test" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BaseRentPerMonthFromCommencementDate" name="BaseRentPerMonthFromCommencementDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_NumberOfOfficers" name="NumberOfOfficers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessTable" name="OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" name="StockIssuedDuringPeriodSharesForDeferredOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" name="PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NSCLCPOCTrialMember" name="NSCLCPOCTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" name="LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_MedicareMember" name="MedicareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" name="ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_UnitedHealthcareMember" name="UnitedHealthcareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_EquityFinancingProgramsMember" name="EquityFinancingProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" name="DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" name="StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BiopharmaServicesAndOtherMember" name="BiopharmaServicesAndOtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" name="CentennialValleyPropertiesILlcLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ProductLifeAndPatentLifeMember" name="ProductLifeAndPatentLifeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_NumberOfFacility" name="NumberOfFacility" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PerformanceConditionOptionsMember" name="PerformanceConditionOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" name="BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DeferredRevenueMember" name="DeferredRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OtherAssetsPolicyTextBlock" name="OtherAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_IncreaseDecreaseInContingentConsideration" name="IncreaseDecreaseInContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SeriesA3PreferredStockMember" name="SeriesA3PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" name="LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" name="StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DirectCostsAndExpenses" name="DirectCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" name="FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LungDiagnosticRevenueMember" name="LungDiagnosticRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_CellCartaLicenseMember" name="CellCartaLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AccruedClinicalTrialExpenseCurrent" name="AccruedClinicalTrialExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PaymentOfDeferredOfferingCosts" name="PaymentOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_LeasedPropertyBuildingCapacity" name="LeasedPropertyBuildingCapacity" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OffsettingDeferredRent" name="OffsettingDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" name="ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_CommonStockIssuedForDeferredOfferingCosts" name="CommonStockIssuedForDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AdditionalWarrantsAmount" name="AdditionalWarrantsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PurchasedTechnologyMember" name="PurchasedTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_StockOptionExchangeProgramMember" name="StockOptionExchangeProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" name="DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" name="SaleOfStockSharesIssuedAsCommitmentFee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AVEOOncologyMember" name="AVEOOncologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" name="TermOfRoyaltyPaymentsFromFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" name="PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DefinedContributionPlanNameExtensibleList" name="DefinedContributionPlanNameExtensibleList" type="xbrli:tokenItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WeightedAveragePricePerShare" name="WeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" name="PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" name="FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_LincolnParkMember" name="LincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" name="FairValueLiabilitiesMeasuredOnRecurringBasisTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" name="BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_LossMember" name="LossMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationShares" name="BusinessCombinationContingentConsiderationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AdditionalWarrantsMember" name="AdditionalWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LicenseAgreementExpiryDate" name="LicenseAgreementExpiryDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfFeePaymentsOnNetSales" name="PercentageOfFeePaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" name="SeriesEConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" name="PercentageOfRoyaltyPaymentsOnNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandAndSixteenPlanMember" name="TwoThousandAndSixteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BonusToOptionsProgramMember" name="BonusToOptionsProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" name="OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" name="RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" name="MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OptionsAndRestrictedStockUnitsRSUsMember" name="OptionsAndRestrictedStockUnitsRSUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_NumberOfCancerTest" name="NumberOfCancerTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BDX004Member" name="BDX004Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" name="PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_MinimumAnnualVolumePercentageThereafter" name="MinimumAnnualVolumePercentageThereafter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BioRadLicenseMember" name="BioRadLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AtTheMarketFacilityMember" name="AtTheMarketFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_IncomeTaxExaminationPeriodUnderExamination" name="IncomeTaxExaminationPeriodUnderExamination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AdvanceDeposits" name="AdvanceDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" name="ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" name="PercentageOfRoyaltyPaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DiagnosticTestsMember" name="DiagnosticTestsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SharesIssuedAsCommitmentFeeValue" name="SharesIssuedAsCommitmentFeeValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SaleOfStockStockIssuablePerDayValue" name="SaleOfStockStockIssuablePerDayValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PromissoryNoteTwoMember" name="PromissoryNoteTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" name="SeriesGConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_PeriodOfEscalationsOfSales" name="PeriodOfEscalationsOfSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_CurrentPortionOfContingentConsiderationMember" name="CurrentPortionOfContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_InterestRateOnExtraAllowanceAmount" name="InterestRateOnExtraAllowanceAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" name="PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OtherMember" name="OtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationFinalPayment" name="BusinessCombinationContingentConsiderationFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ThirdAmendmentToApaAgreementMember" name="ThirdAmendmentToApaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" name="PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_COVID19DiagnosticTestRevenueMember" name="COVID19DiagnosticTestRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" name="DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_IssuanceOfPerceptiveWarrants" name="IssuanceOfPerceptiveWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfCommercialBloodBasedTest" name="NumberOfCommercialBloodBasedTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_RevenueShareAgreementMember" name="RevenueShareAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA2PreferredStockMember" name="SeriesA2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ExitFeePayment" name="ExitFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_CommitmentSharesIssuableOnConditionalBasis" name="CommitmentSharesIssuableOnConditionalBasis" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DirectCostsAndExpensesMember" name="DirectCostsAndExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AdditionalTenantImprovementAllowanceAmount" name="AdditionalTenantImprovementAllowanceAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_TestingServicesMember" name="TestingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" name="LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" name="DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ExistingShareholdersMember" name="ExistingShareholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" name="AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_POCClinicalTrialsMember" name="POCClinicalTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PerceptiveTermLoanFacilityMember" name="PerceptiveTermLoanFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SharesCommittedUnderESPPMember" name="SharesCommittedUnderESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PerceptiveTermLoanMember" name="PerceptiveTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" name="BasisOfPresentationAndEstimatesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" name="ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_NotesPayable2018NotesMember" name="NotesPayable2018NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SecuritiesPurchaseAgreementsMember" name="SecuritiesPurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_RentAfterFixedEscalationProvisions" name="RentAfterFixedEscalationProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LPCFacilityMember" name="LPCFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PercentageOfInterestOnContingentConsideration" name="PercentageOfInterestOnContingentConsideration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LitigationClaimsAndAssessmentsMember" name="LitigationClaimsAndAssessmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" name="ChiefExecutiveOfficerAndChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_GrossProceedsFromFinancingTransactions" name="GrossProceedsFromFinancingTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" name="AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" name="PercentageOfLicenseIncomeGeneratedFromLicensing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NetProceedFromFinancingTransactionsss" name="NetProceedFromFinancingTransactionsss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_PromissoryNoteOneMember" name="PromissoryNoteOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TheStateOfColoradoMember" name="TheStateOfColoradoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AdjustmentsToFirstAmendmentWarrants" name="AdjustmentsToFirstAmendmentWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LessorReimbursementsReceived" name="LessorReimbursementsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" name="SharesIssuedOrIssuableThresholdLimitDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_RepurchaseMember" name="RepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_TenantImprovementAllowancesReceived" name="TenantImprovementAllowancesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AccretionOfLeaseLiability" name="AccretionOfLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_OptionsAndRestrictedStockUnitsMember" name="OptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DirectCostsAndExpensesPolicyTextBlock" name="DirectCostsAndExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantLiabilitiesFairValueDisclosure" name="WarrantLiabilitiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" name="StockIssuedDuringPeriodValuesForDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_StockIssuableDuringPeriodValueCommittedShares" name="StockIssuableDuringPeriodValueCommittedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_IntegratedDiagnosticsIncMember" name="IntegratedDiagnosticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LesseeOperatingAndFinanceLeasesTextBlock" name="LesseeOperatingAndFinanceLeasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" name="EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LeaseAgreementNumberOfOptionsToExtend" name="LeaseAgreementNumberOfOptionsToExtend" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PaymentOfEquityFinancingCosts" name="PaymentOfEquityFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" name="UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" name="IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_CARESActMember" name="CARESActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightWarrantsOrRightsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PublicOfferingPricePerShareOfCommonStock" name="PublicOfferingPricePerShareOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" name="DeferredTaxAssetsCapitalizedResearchCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" name="YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" name="AreaOfLeasedPremisedObligatedToPayBaseRent" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504181052384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biodesix, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3986492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 West Dillon Rd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Louisville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-0500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDSX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,942,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Denver, CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Company&#8217;s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504181236704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,284<span></span>
</td>
<td class="nump">$ 43,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $65 and $118</a></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">5,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">39,683<span></span>
</td>
<td class="nump">53,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non&#8209;current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">27,867<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">7,911<span></span>
</td>
<td class="nump">9,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,031<span></span>
</td>
<td class="nump">15,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">6,859<span></span>
</td>
<td class="nump">5,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non&#8209;current assets</a></td>
<td class="nump">59,413<span></span>
</td>
<td class="nump">39,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">99,096<span></span>
</td>
<td class="nump">92,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,929<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,710<span></span>
</td>
<td class="nump">8,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">21,857<span></span>
</td>
<td class="nump">10,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,416<span></span>
</td>
<td class="nump">22,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non&#8209;current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable, net of current portion</a></td>
<td class="nump">35,225<span></span>
</td>
<td class="nump">25,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">25,163<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non&#8209;current liabilities</a></td>
<td class="nump">61,100<span></span>
</td>
<td class="nump">49,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">94,516<span></span>
</td>
<td class="nump">72,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2023 and 2022) issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 authorized; 96,235,883 (2023) and 77,614,358 (2022) shares issued and outstanding</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">424,050<span></span>
</td>
<td class="nump">387,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(419,566)<span></span>
</td>
<td class="num">(367,420)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,580<span></span>
</td>
<td class="nump">20,606<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 99,096<span></span>
</td>
<td class="nump">$ 92,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183317792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">96,235,883<span></span>
</td>
<td class="nump">77,614,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">96,235,883<span></span>
</td>
<td class="nump">77,614,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504181992000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 49,087<span></span>
</td>
<td class="nump">$ 38,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DirectCostsAndExpenses', window );">Direct costs and expenses</a></td>
<td class="nump">13,010<span></span>
</td>
<td class="nump">14,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,988<span></span>
</td>
<td class="nump">13,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, marketing, general and administrative</a></td>
<td class="nump">67,387<span></span>
</td>
<td class="nump">61,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">90,429<span></span>
</td>
<td class="nump">88,799<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,342)<span></span>
</td>
<td class="num">(50,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9,536)<span></span>
</td>
<td class="num">(8,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability, net</a></td>
<td class="num">(1,274)<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income , net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(10,804)<span></span>
</td>
<td class="num">(14,860)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,146)<span></span>
</td>
<td class="num">$ (65,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">82,113<span></span>
</td>
<td class="nump">42,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">82,113<span></span>
</td>
<td class="nump">42,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183035904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 19,727<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 321,669<span></span>
</td>
<td class="num">$ (301,973)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">56,235<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">56,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts', window );">Issuance of common stock for deferred offering costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts', window );">Issuance of common stock for deferred offering costs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Release of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Initial Warrants</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(65,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,447)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">20,606<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">387,948<span></span>
</td>
<td class="num">(367,420)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">28,003<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">27,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount', window );">Release of restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdjustmentsToFirstAmendmentWarrants', window );">Issuance of First Amendment warrants</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant', window );">Reclassification of Tranche B warrants to additional paid-in capital</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Release of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(52,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,146)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 4,580<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 424,050<span></span>
</td>
<td class="num">$ (419,566)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital Reclassification of Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdjustmentsToFirstAmendmentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To First Amendment warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdjustmentsToFirstAmendmentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than optionsvested in period amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, values, for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504187840112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (52,146)<span></span>
</td>
<td class="num">$ (65,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,328<span></span>
</td>
<td class="nump">3,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of lease right-of-use assets</a></td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">5,373<span></span>
</td>
<td class="nump">5,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability, net</a></td>
<td class="nump">1,274<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther', window );">Accrued interest, amortization of debt issuance costs and other</a></td>
<td class="nump">5,111<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory excess and obsolescence</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,718)<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(3,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">513<span></span>
</td>
<td class="num">(773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(755)<span></span>
</td>
<td class="num">(1,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IncreaseDecreaseInContingentConsideration', window );">Contingent consideration</a></td>
<td class="num">(2,494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_TenantImprovementAllowancesReceived', window );">Tenant improvement allowances received</a></td>
<td class="nump">18,323<span></span>
</td>
<td class="nump">2,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Current and long-term operating lease liabilities</a></td>
<td class="num">(503)<span></span>
</td>
<td class="num">(937)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and cash equivalents and restricted cash used in operating activities</a></td>
<td class="num">(22,870)<span></span>
</td>
<td class="num">(44,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(22,919)<span></span>
</td>
<td class="num">(3,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet', window );">Patent costs and intangible asset acquisition, net</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and cash equivalents and restricted cash used in investing activities</a></td>
<td class="num">(23,062)<span></span>
</td>
<td class="num">(3,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">28,126<span></span>
</td>
<td class="nump">59,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(8,581)<span></span>
</td>
<td class="num">(10,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable', window );">Proceeds from term loan and notes payable</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">45,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan and notes payable</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(28,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(833)<span></span>
</td>
<td class="num">(3,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PaymentOfDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PaymentOfEquityFinancingCosts', window );">Equity financing costs</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(3,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and cash equivalents and restricted cash provided by financing activities</a></td>
<td class="nump">29,129<span></span>
</td>
<td class="nump">58,882<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents and restricted cash</a></td>
<td class="num">(16,803)<span></span>
</td>
<td class="nump">10,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; beginning of period</a></td>
<td class="nump">43,174<span></span>
</td>
<td class="nump">32,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; end of period</a></td>
<td class="nump">26,371<span></span>
</td>
<td class="nump">43,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_CommonStockIssuedForDeferredOfferingCosts', window );">Common stock issued for deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital', window );">Deferred offering costs amortized against Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities', window );">Debt issuance costs included in accounts payable and other accrued liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities', window );">Equity financing costs included in accounts payable and other accrued liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IssuanceOfPerceptiveWarrants', window );">Issuance of Perceptive Warrants</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842', window );">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance lease right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities', window );">Purchases of property &amp; equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest, amortization of debt issuance costs and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_CommonStockIssuedForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_CommonStockIssuedForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs included in Accounts payable and other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs amortized against additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity financing costs included in Accounts payable and other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IncreaseDecreaseInContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IncreaseDecreaseInContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IssuanceOfPerceptiveWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of perceptive warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IssuanceOfPerceptiveWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentOfEquityFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of equity financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentOfEquityFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from patent costs and intangible asset acquisition, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of term loan and notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of property &amp; equipment included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to additional paid-in-capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TenantImprovementAllowancesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowances received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TenantImprovementAllowancesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183265312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (52,146)<span></span>
</td>
<td class="num">$ (65,447)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183210208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504186451824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract', window );"><strong>Organization And Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 &#8211; Organization and Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biodesix, Inc. (the &#8220;Company&#8221;, &#8220;Biodesix&#8221;, &#8220;we&#8221; &#8220;us&#8221; and &#8220;our&#8221;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#8217;s headquarters are in Colorado and the Company performs its blood-based diagnostic tests in its laboratory facilities which are located in Louisville, Colorado and De Soto Kansas. Throughout 2023, the Company leased its headquarters and laboratory facilities in Boulder, Colorado, under a lease agreement that expired in January 2024 and the Company subsequently relocated its corporate headquarters and laboratory facilities to Louisville, Colorado. The Company conducts all of its operations within a single legal entity. Biodesix is a leading diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the use of artificial intelligence enabled informatics. We derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) prior to May 11, 2023, Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other). Biodesix offers five Medicare-covered tests for patients with lung diseases which includes our blood-based Nodify Lung&#174; Nodule Risk Assessment testing, consisting of the Nodify XL2&#174; and the Nodify CDT&#174; tests. These tests evaluate the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Additionally, our blood-based IQLung&#153; testing strategy for lung cancer patients integrates the GeneStrat&#174; ddPCR test, the GeneStrat NGS&#174; test and the VeriStrat&#174; test to support treatment decisions across all stages of lung cancer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also offered </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> SARS-CoV-2 tests. The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test were granted Emergency Use Authorization (EUA) by the Federal Drug Administration (FDA). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Blood-Based Lung Tests</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company offers </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> blood-based lung cancer tests across the lung cancer continuum of care:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnosis</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify CDT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nodify</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">XL2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tests, marketed as Nodify Lung Nodule Risk Assessment testing, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. The Nodify CDT and XL2 tests have an established average turnaround time of one and five business days, respectively, from receipt of the blood sample, providing physicians with timely results to guide diagnostic planning. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we are the only company to offer </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment &amp; Monitoring</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GeneStrat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ddPCR, GeneStrat NGS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VeriStrat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient&#8217;s immune system to help guide treatment decisions. The GeneStrat ddPCR tumor genomic profiling test and the VeriStrat immune profiling test have established an average turnaround time of two business days from receipt of the blood sample, and the GeneStrat NGS test has an established average turnaround time of three business days from receipt of the blood sample, providing physicians with timely results to facilitate treatment decisions. The GeneStrat ddPCR test evaluates the presence of actionable mutations in lung cancer. The test is covered independent of stage and can be used multiple times per patient to monitor changes in mutation status. The GeneStrat NGS test is a broad 52 gene panel, including guideline recommended mutations that help identify advanced stage patients eligible for targeted therapy or clinical trial enrollment. The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#8217;s immune response to their lung cancer.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In developing the Company's products, the Company has built or gained access to regulatory approvals, product development know-how, unique biorepositories, proprietary and patented technologies, specimen collection kit manufacturing capabilities, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#8217;s testing services are made available through its clinical laboratories.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504186721104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets pursuant to the Company's annual impairment analysis; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; fair value of warrant liabilities; leases, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the estimated incremental borrowing rates</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we maintained cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and we have </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in outstanding aggregate principal amount on our Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technologies. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) or to obtain waivers or amendments that impact the related covenants. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default (as defined in the Perceptive Term Loan Facility), causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. The Perceptive Term Loan Facility requires the Company to recognize revenue in amounts agreed to between the Company and Perceptive as of the last day of each fiscal quarter, which commenced with the fiscal quarter ending March 31, 2023. On May 10, 2023 (the First Amendment Effective Date), the Company entered into the First Amendment to the Credit Agreement (the First Amendment), whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold through the twelve month period ended March 31, 2024. On August 4, 2023, the Company entered into a second amendment to the Perceptive Term Loan Facility, whereby subject to the terms and conditions of the second amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the twelve month period ended December 31, 2025 (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and raised approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds through a private placement equity offering (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Subsequent to December 31, 2023, the Company entered into a third amendment to the Perceptive Term Loan Facility, whereby, subject to the terms and conditions of the third amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the fiscal quarter ended December 31, 2025 (see Note 16 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_19d8db26-ae6e-4ab2-b567-298bf67cb775;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#8217;s revenue and all long-lived assets were derived or located in the United States for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenues from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other revenue).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price and amount to accrue related to its blood-based lung diagnostic test contracts using a portfolio approach by considering:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the nature of the payer and payer coverage;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment history;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">test type;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the historical amount of time until payment by a payer;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">historical price concessions granted to groups of customers;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether there is a reimbursement contract between the payer and the Company;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment as a percentage of agreed upon rate (if applicable);</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount paid per test; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any current developments or changes that could impact reimbursement.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharma Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Customers for these services are typically large biopharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements, and considering factors including, but not limited to: enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from contracts with customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recognizes revenue for these patients when contracts are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 11 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Direct Costs and Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development </span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales, Marketing, General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2023 and 2022, see Note 11 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card. As of December 31, 2023 and 2022, the Company had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million restricted cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, which was included in &#8216;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b4950ae-8a2a-400a-848c-b12899bcf89d;"><span style="-sec-ix-hidden:F_9df9a806-ab12-4618-8e6a-94161b6cb0d5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other current assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; in the accompanying balance sheets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#8216;Direct c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">osts and expenses&#8217;. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for both years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The Company recorded a reserve for excess inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for both years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, to the statement of operations for excess and obsolete inventory.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_693c0deb-e916-4d0f-82f1-e7179ddec20e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9b208ef9-2e89-4c6b-beef-d077b508f0ac;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments for th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were immaterial impairments during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2023, there</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accumulated impairment losses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company acts as a lessee under all its lease agreements and holds various real estate leases for its headquarters and laboratory facilities in Colorado and Kansas and other various copier leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the following practical expedients as part of the adoption of ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Package of practical expedients which allows the Company to carry forward the historical lease classification;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of right-of-use (ROU) assets;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the fair value of the underlying asset.&#8221;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required by this standard are contained in Note 9 &#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cash refundable deposit to secure the performance of the Company&#8217;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million refundable deposit is reported within 'Other long-term assets' in the balance sheet.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.82%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:86.1%;"></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 4 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion related to estimated fair value measurements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recorded as &#8216;Interest expense&#8217; in the statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of warrant liabilities is assessed at each balance sheet date and changes, if any, to the fair value are recorded as 'Change in fair value of warrant liability, net' in the statement of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share&#8209;Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options, if granted, vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units (RSUs)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 12 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information related to share-based compensation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">s</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 14 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information related to income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504186644352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Issued Accounting Standards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3 &#8211; Recent Issued Accounting Standards</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for the Company beginning January 1, 2023. The Company evaluated the guidance and determined the overall impact of the adoption had an immaterial impact on our financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Standards being evaluated</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting: Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC Topic 280). This ASU requires all public entities to provide additional disclosures about the entity's reportable segments and more detailed information about a reportable segment's expenses. This guidance will become effective for the Company beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid by jurisdiction. This guidance will become effective for the Company beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504186647872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4 - Fair Value</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recurring Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair value of borrowings as of December 31, 2023 and 2022 is primarily associated with the Perceptive Term Loan Facility entered into with Perceptive Credit Holdings IV, LP, in November 2022 and was determined using a discounted cash flow analysis, excluding the fair value of the Perceptive Warrant (as defined below) issued in conjunction with the transaction. The carrying value of outstanding borrowings approximates the fair value as of December 31, 2023. The difference between the carrying value and fair value of outstanding borrowings as of December 31, 2022 is due to the debt issuance costs and the fair value of the Perceptive Warrant netted against the Perceptive Term Loan Facility. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.739%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.885%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.404%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.204%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi and the warrant liabilities granted as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), which were accounted for as liabilities and remeasured through our statements of operations.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents the reported fair values of contingent consideration and warrant liabilities,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.412%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.924%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.903%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the changes in contingent consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and warrant liabilities for the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.687%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.537%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.977%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,946</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,075</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of Tranche B Warrants to additional paid-in capital</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gross margin target of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period after the acquisition date, which was achieved during the three months ended June 30, 2021. Under the terms of the original agreement, when the gross margin target was achieved the Company was required to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,520,108</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">eight</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal quarterly installments. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal and consecutive quarterly cash installments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mi</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4a3ac985-50cc-430f-afc9-a367fa948051;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, the Company entered into an amendment to the original agreement in which all parties agreed to forgo the issuance of common stock and agreed that the Company would, in lieu thereof, make </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> quarterly installments of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each beginning in January 2022 and a final payment of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in July 2023 for a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA, in which the parties agreed to restructure the Milestone Payments. The Company made </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each beginning in April 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which began in July 2023, will make </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> installment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in April 2024, and will make </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> installment of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in July 2024. In addition, the Company agreed to an exit fee of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, with such interest to be payable quarterly on the following installment payment date. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan Facility. We obtained consent from Perceptive and subsequently paid the contractual Milestone Payment due January 1, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. As a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate could result in a significantly higher or lower fair value measurement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">espectively, in interest expense due to the passage of time and fixed payment schedule.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASC 230, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statement of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) should be reflected as a cash outflow for financing activities while the remaining portion of the amount paid should be reflected as a cash outflow from operating activities in the statement of cash flows. A portion of the October 2023 and all 2024 Milestone Payments are classified as cash outflows from operating activities in the Company's statements of cash flows.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liabilities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), the Company issued Perceptive a warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company's common stock (the Perceptive Warrant), including Initial Warrants and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants (as defined in Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> below). The Initial Warrants and First Amendment Warrants are equity classified (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) while the Tranche B and C Warrants were initially classified as liabilities within 'Other short-term liabilities' and recognized at fair value. The fair value of the Tranche B and C Warrants is determined using a Black-Scholes model and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the fair value of the Company's common stock, risk-free rate, the volatility of common stock, and the probability of the expected borrowing. Significant increases or decreases in the unobservable inputs could result in a significantly higher or lower fair value measurement. During the year ended December 31, 2023, the Company recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> loss as a change in fair value through the statement of operations due to changes in unobservable inputs. This is a result of changes in the probability of our ability to draw on Tranche B and C loans. During the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a change in fair value through the statement of operations due to changes in unobservable inputs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184468016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5 &#8211; Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">749</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vehicles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,947</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,867</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense related to pr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operty and equipment was:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504186451824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6 &#8211; Goodwill and Intangible Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.195%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.824%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.702%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets subject to amortization</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">647</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trademarks</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,991</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,097</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.613%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.723%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.023%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,981</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,973</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future estimated amortization expense of intangible </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assets is (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.784%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.476%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of <br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184553280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7 &#8211; Accrued Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.713%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation related accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,671</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504185490704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8 &#8211; Debt</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-term debt primarily consists of notes payable associated with our Perceptive Term Loan Facility which is described in further detail below. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term notes payable were as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.96%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.360000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.76%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Perceptive Term Loan Facility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current maturities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term notes payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Perceptive Term Loan Facility</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Perceptive Term Loan Facility). The Tranche A Loan, in an aggregate amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Tranche A Loan), was funded under the Perceptive Term Loan Facility on November 21, 2022 (the Funding Date). The Company's net proceeds from the Tranche A Loan were approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">debt issuance costs and expenses. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and an additional Tranche C Loan, in an aggregate amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which are accessible by the Company so long as the Company satisfies certain customary conditions precedent, including revenue milestones. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2023, the Company exercised its ability to draw the Tranche B loan for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Tranche C loan has a loan commitment date through September 30, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility has a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 21, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Maturity Date) and provides for an interest-only period during the term of the loan with principal due at the Maturity Date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum, plus an applicable margin of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the stated interest rate was approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amortization and Prepayment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the Maturity Date, the Company is required to pay the Lender the aggregate outstanding principal amount underlying the Perceptive Term Loan Facility and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security Instruments and Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to a Security Agreement, dated as of the Funding Date (the Security Agreement), between the Company and the Lender, substantially all of the Company&#8217;s obligations under the Credit Agreement are secured by a first lien perfected security interest on all of the Company&#8217;s assets, subject to customary exceptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the Credit Agreement, the Company has issued, on the Funding Date, the Perceptive Warrant of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including the Initial Warrants which are equity classified at a per share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0648</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is equal to the 10-day volume weighted average price (VWAP) of the Company&#8217;s common stock, on the business day immediately prior to the Closing Date of the Tranche A Loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Tranche B borrowing, additional warrants became exercisable into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a per share exercise price equal t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">o $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0648</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is equal to the Initial Warrant exercise price (the Tranche B Warrants) and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 15, 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the Initial and Tranche B Warrants, additional warrants will become exercisable into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche C Loan (the Tranche C Warrants). The per share exercise price for the Tranche C Warrants will be equal to the lower of (A) the Initial Warrant exercise price or (B) the 10-day VWAP ending on the business day immediately preceding the funding date of the Tranche C loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Each warrant will be exercisable, in whole or in part, until the 10th anniversary of the date of issuance. If the Tranche C loan is not drawn by the loan commitment date, the associated Tranche C Warrants expire and will not become exercisable. The Company accounts for the Tranche C Warrants as liabilities as the Tranche C Warrants do not meet the criteria for equity treatment (see Note 4 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representations, Warranties, Covenants, and Events of Default</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting and notice requirements, maintain insurance and maintain in full force and effect all Regulatory Approvals, Material Agreements, Material Intellectual Property (each as defined in the Credit Agreement) and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the Company&#8217;s business. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s business activities; make certain Investments or Restricted Payments (each as defined in the Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that has the impact of restricting the Company&#8217;s ability to make loan repayments under the Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million; and (ii) as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2023, recognize revenue in amounts agreed to between the Company and Perceptive.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2023, the Company entered into the First Amendment with the Lender, whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold of each fiscal quarter commencing on the fiscal quarter ending June 30, 2023 through and including the fiscal quarter ending March 31, 2024. As consideration for the First Amendment, the Company agreed to issue to Perceptive a warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the First Amendment Warrants) which are equity classified at a per share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6254</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (see Note 10 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 4, 2023 (the Second Amendment Effective Date), the Company entered into the Second Amendment to the Credit Agreement and Guaranty (the Second Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby subject to the terms and conditions of the Second Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending June 30, 2024 through and including the fiscal quarter ending December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Second Amendment, the conditions precedent for drawing on the Tranche B Loan were amended to (i) reduce the trailing-twelve month revenue milestone and (ii) add the receipt of aggregate cash proceeds of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from an equity offering of the Company's common stock. During the three months ended September 30, 2023, the Company met the amended trailing-twelve month revenue milestone associated with the Tranche B Loan. On August 3, 2023, the Company entered into subscription agreements for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,975,298</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#8217;s common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the three months ended September 30, 2023, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,454,927</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock pursuant to the Subscription Agreements. On September 27, 2023, the Company entered into an amendment to delay final closing on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subscription agreement. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds were received and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,520,371</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued during the three months ended December 31, 2023 (see Note 10 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Credit Agreement also contains certain customary Events of Default which include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross- defaults to material contracts, certain regulatory-related events and events constituting a change of control. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit. The occurrence of an Event of Default could result in, among other things, the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility are immediately due and payable in whole or in part.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Initial Warrants and Additional Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, using the Black-Scholes option-pricing model, estimated settlement probabilities and estimated exercise prices. As a result of the fees paid to Perceptive and the value of the Perceptive Warrant, the Company recognized a discount on the Perceptive Term Loan in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The First Amendment Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model which the recognized as a discount on the Perceptive Term Loan Facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company recorded the debt discount as a reduction to the principal amount of the debt and is amortized as interest expense over the life of the debt.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.68%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,078</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184315712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LesseeOperatingAndFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9 &#8211; Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company acts as a lessee under all its lease agreements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout 2023, the Company leased its headquarters and laboratory facilities in Boulder, Colorado, under a lease agreement that expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6810bc43-8b88-4896-94db-50fb78cff4b9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d0f0a6d5-c980-4547-82e0-7fbd7882d4e9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company subsequently relocated its corporate headquarters and laboratory facilities to Louisville, Colorado. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,066</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet that was set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In April 2023, the Company amended the agreement to extend the lease agreement through October 2026. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also holds various copier leases under non-cancelable lease agreements that expire in the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f032350b-436c-49d5-a43e-3d8d73323d62;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to three</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4ab91cf-5309-48b9-bf44-1a128879ae56;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Centennial Valley Properties I, LLC Lease Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space in Louisville, Colorado (the Leased Premises). The Leased Premises replaced the Company&#8217;s headquarters and laboratory facilities in Boulder, Colorado in January 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The initial term of the Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> renewal options to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term of the Lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d101e6ae-d1d1-4191-8ad1-1ab4d344cdcb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">- or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in ROU assets and lease liabilities being recorded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, however, the Lease commenced for legal purposes on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the Commencement Date)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Lease, the Company will lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">79,980</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">227,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month and escalating, based on fixed escalation provisions, to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">326,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,980</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability at lease commencement because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease commencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lion by November 2024 after receiving $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in lessor reimbursements. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilized the total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023, and 2022, respectively) in tenant improvement allowances for capital expenditures for leasehold improvements related to the Leased Premises and have been reimbursed from the Landlord.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. During the three months ended September 30, 2022, a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cash collateralized letter of credit under the operating lease agreement was released and the funds were subsequently transferred to the Landlord as a refundable deposit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#8217;s obligations. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million refundable deposit is included within '</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_afd70d36-dcbf-4fdb-b7a0-f4dc56cc9f89;"><span style="-sec-ix-hidden:F_969e4251-ea3d-4fbe-a713-b5983a44c323;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other long-term assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">' in the balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense for all operating leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and 2022, respectively. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the weighted-average remaining lease term and discount rate associated with our operating leases were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ctively.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments associated with our operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.996%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.964%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,063</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,113</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less amount representing interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LesseeOperatingAndFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LesseeOperatingAndFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504186647872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10 &#8211; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holder of each share of common stock is entitled to one vote per share.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock were issued or outstanding.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Financing Programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> facilities that enable equity financing on an ongoing basis at the Company&#8217;s sole discretion, our at-the-market offering (ATM) and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the ATM Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3, and sales of common stock, if any, will be made at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on the NASDAQ Global Market, or any other existing trading market for our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2022 (the LPC Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (the Purchase Agreement), pursuant to which Lincoln Park has committed to purchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company's common stock (the LPC Facility). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#8217;s sole discretion, over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period commencing on the LPC Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, but that amount may be increased up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, depending upon the market price of the Company&#8217;s common stock at the time of sale and subject to a maximum limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#8217;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under applicable rules of the NASDAQ Global Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the LPC Effective Date, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">184,275</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company will be required to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, together with due diligence expenses and legal fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">129,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, reflect deferred offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">729,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which are included on the balance sheet in 'Other long-term assets'. The deferred offering costs will be charged against 'Additional paid-in capital' upon future proceeds from the sale of common stock under the Purchase Agreement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of deferred offering costs were charged against 'Additional paid-in capital'. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">654,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of deferred offering costs remain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company raised approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">376,456</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares at a weighted average price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.66</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under the ATM facility. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had remaining available capacity for share issuances of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under the ATM facility and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, the Company closed an underwritten public offering (the Public Offering) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,075,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock (the Public Offering Shares), including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,575,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares purchased by the underwriter pursuant to an option to purchase additional shares. The Public Offering Shares were issued and sold pursuant to an underwriting agreement, dated November 16, 2022, by and between the Company and William Blair &amp; Company, L.L.C., as sole underwriter, at a public offering price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Public Offering after deducting underwriting discounts, commissions, and offering expenses payable by the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Public Offering was made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 previously filed with the Securities and Exchange Commission on November 29, 2021 and a prospectus supplement, dated November 16, 2022, relating to the Offering.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subscription Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April 2022 Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,508,376</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement offering. The three members of our Board of Directors acquired an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,631,284</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,877,092</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the April 2022 Subscription Agreements, the April 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The April 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management (the November 2022 Investors), including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">235,056</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement offering. The November 2022 Subscription Agreement did not include any registration rights and included lock up restrictions that were in effect during the period ending 90 days subsequent to November 21, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the November 2022 Subscription Agreements, the November 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which is equal to the public offer price in the Public Offering, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">270,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The November 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 3, 2023, the Company entered into subscription agreements (the August 2023 Subscription Agreements) with all the members of our Board of Directors, all Section </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> officers, and additional members of the Biodesix leadership team (together, the August 2023 Investors) for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,975,298</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private equity offering. The Subscription Agreements did not include any registration rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the August 2023 Subscription Agreements, the August 2023 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which is equal to the closing price of the Company's common stock on August 3, 2023, for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The August 2023 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement. During the three months ended September 30, 2023, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,454,927</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock pursuant to the Subscription Agreements. On September 27, 2023, the Company entered into an amendment to delay final closing on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subscription agreement. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds were received and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,520,371</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued during the three months ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">613,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series G convertible preferred stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 23, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Through the effective date of the Company&#8217;s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company&#8217;s IPO, the preferred stock warrants were automatically converted to warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">103,326</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.46</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and were also transferred to additional paid-in capital. All common stock warrants remain outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), the Company issued the Perceptive Warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, including the Initial Warrants. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the Initial Warrants, the Additional Warrants will each become exercisable into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The per share exercise price for the Initial Warrants is equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0648</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is equal to the lower of (A) the 10-day VWAP of the Company&#8217;s common stock on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of common stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Initial Warrants are equity classified and were immediately exercisable upon issuance and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 21, 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Initial Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. All Initial Warrants remain outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2023, as consideration for the First Amendment (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), the Company agreed to issue to Perceptive a warrant to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the First Amendment Warrants) at a per share exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6254</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is equal to the 10-day VWAP of the Company&#8217;s common stock ending on the business day immediately prior to the First Amendment Effective Date. The First Amendment Warrants are equity classified and immediately exercisable upon issuance and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 10, 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The First Amendment Warrants were valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.49</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. All First Amendment Warrants remain outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital. The Tranche B Warrants are now equity classified and immediately exercisable upon issuance and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 15, 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tranche B Warrants were value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">76.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. All Tranche B Warrants remain outstanding as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184315712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue and Accounts Receivable Credit Concentration</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11 &#8211; Revenue and Accounts Receivable Credit Concentration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and, prior to May 11, 2023, COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer, test type, and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.713%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diagnostic Tests</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biopharma Services and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in 'Revenues' in the statements of operations. The Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in &#8216;Deferred revenue&#8217; recorded in the balance sheet as of December 31, 2022 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was added throughout 2023 to &#8216;Deferred revenue&#8217; for up-front cash payments received while $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized in 'Revenues' during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The &#8216;Deferred revenue&#8217; of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">corded in the balance sheet as of December 31, 2023 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2023 and 2022, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in non-cu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rrent deferred revenue, respectively, recorded within &#8216;Other long-term liabilities&#8217; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United Healthcare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The State of Colorado</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company&#8217;s total revenue for the years ended December 31, 2023 and 2022, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Medicare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AstraZeneca UK</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504188995728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 12 &#8211; Share Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Predecessor 2016 and 2006 Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional awards may be granted under the 2006 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultants. Awards granted under the 2016 Plan or the 2006 Plan that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#8217;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional awards may be granted under the 2016 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the closing of our IPO, the Company&#8217;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares originally reserved for issuance under the 2020 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,893,395</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The 2020 Plan includes an annual increase on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#8217;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a prior plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all plans as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">960,305</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective with our IPO in October 2020, the Company&#8217;s Board of Directors and its stockholders approved the Company&#8217;s Employee Stock Purchase Plan (the ESPP). The number of shares originally reserved for issuance under the ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">338,106</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 437,135 shares were issued under the ESPP leaving 309,012 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares remaining for future issuance.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Awards Granted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-statutory stock options, which may be issued to employees, non-employees and directors, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance-based options vest in three equal annual installments beginning one year after the grant date</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#8217;s common stock on the grant date. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance-based stock options outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU holders have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Exchange Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 23, 2023, the Company commenced a voluntary offer to exchange certain eligible options held by eligible employees of the Company for new options (the Exchange Offer). The Exchange Offer expired on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 24, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Pursuant to the Exchange Offer, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">757,595</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total shares of common stock underlying the eligible options. On July 24, 2023, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">156,868</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, pursuant to the terms of the Exchange Offer and the Company&#8217;s 2020 Equity Incentive Plan. The exercise price of the new options granted pursuant to the Exchange Offer was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share, which was the closing price of the common stock on the NASDAQ Global Market on the grant date of the new options. Each new option granted in exchange for the vested shares underlying an eligible option will fully vest on the first day of the month following the first anniversary of the month in which the Exchange Offer is completed. Each new option granted in exchange for the unvested shares underlying an eligible option will vest under an extended vesting schedule, with vesting commencing on the first day of the month following the first anniversary of the month in which the Exchange Offer is completed, and occurring in a series of equal monthly installments over the number of months that were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">remaining </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the surrendered eligible option&#8217;s vesting schedule immediately prior to the Exchange Offer. Each new option has a maximum term of ten years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exchange of stock options was treated as a modification for accounting purposes. The incremental expense was immaterial for the new options and was calculated using the Black-Scholes option pricing model. The incremental expense and the unamortized expense remaining on the exchanged options as of the modification date will be recognized over the new vesting schedule.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bonus-To-Options Program</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has a Bonus-to-Options Program (the Bonus Option Program) which is separate from previously described plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011, 2015, and 2022. For fiscal year 2023, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the closing market price of the Company's common stock on the grant date, as disclosed below under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;. Bonus Options issued must be exercised within a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.42%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; January 1, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">526</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.69</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,050</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.81</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company record</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million du</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ring the years ended December 31, 2023 and 2022, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in the first quarter of 2024 and 2023, respectively, by the Compensation Committee of the Board of Directors. In determining the amount of share-based compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.619999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.619999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">331</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,961</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unrecognized remaining share-based compensation expense for optio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ns and RSUs was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is expected to be amortized to expense over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.42%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding - January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,489</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">964</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,298</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.04</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Company&#8217;s common stock is determined based on its closing market price on the date of grant. The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.080000000000002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.080000000000002%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.39</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.65</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk&#8209;free rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit activity during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 was (in thousands, except weighted average grant date fair value per share):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.619999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cceeff;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Released</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504188995728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 13 &#8211; Net Loss per Common Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted loss per share as of the dates indicated were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.647%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,113</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The potentially dilutive securities as of December 31, 2023 and 2022 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our ESPP, the terms of which are described in further detail in Note 12 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The potentially dilutive securities would be subject to the treasury stock method when dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares committed under ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184481168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 14 - Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has incurred net taxable losses, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> current provision for income taxes has been recorded. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.233%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.683%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.081999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and developments credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.313%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.103%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.623000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,120</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,685</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-Use Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,303</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023, the Company ha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">310.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expire beginning in 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net deferred tax assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The valuation allowance increased</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2023, the Company determined that it has uncertain tax positions related to its U.S. research and development credits. As of December 31, 2023 and 2022, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest related </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.6%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions related to the current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions related to prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions for tax positions related to prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions related to settlements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions related to a lapse of statute</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,037</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. As of December 31, 2023, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184481168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 15 &#8211; Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Co&#8209;Development Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#8217;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the AVEO Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> remaining obligations related to the AVEO agreement as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Following the AVEO Effective Date, the Company is entitled to a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty of net sales of ficlatuzumab and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of license income generated from the licensing of ficlatuzumab from AVEO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalties received or expenses related to this agreement for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#153; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company no longer paid a royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Either party may terminate for the other&#8217;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There wer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to this agreement for the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 13, 2021 (the CellCarta Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly &#8220;Caprion Biosciences, Inc.&#8221;) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% fee on net sales made from the first commercial sale of the Nodify XL2 test to the CellCarta Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.675</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on future Nodify XL2 test net sales worldwide for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the first commercial sale, ending in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2034</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Royalty expense under the CellCarta License for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respective</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ly.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2019, we completed an acquisition of Freenome's United States operations (formerly "Oncimmune USA" or "Oncimmune") including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule malignancy test, then marketed in the United States as the EarlyCDT Lung&#174; test. We renamed and relaunched the test on February 28, 2020 as the Nodify CDT test. As part of the acquisition of the assets of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to the Nodify CDT test of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of recognized revenue for non-screening tests up to an annual minimum volume and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% thereafter, with an escalating minimum</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through the first four years of sales</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Royalty expenses we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">re $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation, Claims and Assessments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184374624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 16 &#8211; Subsequent Events</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Perceptive Term Loan Facility Limited Waiver and Amendment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 14, 2024 a limited waiver to the Perceptive Term Loan Facility was executed (the Limited Waiver), whereby, subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 29, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024 (the Third Amendment Effective Date), the Company entered into the Third Amendment to the Credit Agreement and Guaranty (the Third Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby subject to the terms and conditions of the Third Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2024 through and including the fiscal quarter ending December 31, 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504187964912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock', window );">Basis of Presentation and Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets pursuant to the Company's annual impairment analysis; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; fair value of warrant liabilities; leases, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the estimated incremental borrowing rates</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we maintained cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and we have </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in outstanding aggregate principal amount on our Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technologies. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our Perceptive Term Loan Facility (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) or to obtain waivers or amendments that impact the related covenants. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default (as defined in the Perceptive Term Loan Facility), causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. The Perceptive Term Loan Facility requires the Company to recognize revenue in amounts agreed to between the Company and Perceptive as of the last day of each fiscal quarter, which commenced with the fiscal quarter ending March 31, 2023. On May 10, 2023 (the First Amendment Effective Date), the Company entered into the First Amendment to the Credit Agreement (the First Amendment), whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold through the twelve month period ended March 31, 2024. On August 4, 2023, the Company entered into a second amendment to the Perceptive Term Loan Facility, whereby subject to the terms and conditions of the second amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the twelve month period ended December 31, 2025 (see Note 8 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and raised approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds through a private placement equity offering (see Note 10 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Subsequent to December 31, 2023, the Company entered into a third amendment to the Perceptive Term Loan Facility, whereby, subject to the terms and conditions of the third amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the fiscal quarter ended December 31, 2025 (see Note 16 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_19d8db26-ae6e-4ab2-b567-298bf67cb775;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#8217;s revenue and all long-lived assets were derived or located in the United States for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenues from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other revenue).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price and amount to accrue related to its blood-based lung diagnostic test contracts using a portfolio approach by considering:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the nature of the payer and payer coverage;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment history;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">test type;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the historical amount of time until payment by a payer;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">historical price concessions granted to groups of customers;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether there is a reimbursement contract between the payer and the Company;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment as a percentage of agreed upon rate (if applicable);</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount paid per test; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any current developments or changes that could impact reimbursement.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharma Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Customers for these services are typically large biopharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements, and considering factors including, but not limited to: enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from contracts with customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recognizes revenue for these patients when contracts are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 11 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DirectCostsAndExpensesPolicyTextBlock', window );">Direct Costs and Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Direct Costs and Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development </span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Sales, Marketing, General and Administrative Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales, Marketing, General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2023 and 2022, see Note 11 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card. As of December 31, 2023 and 2022, the Company had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million restricted cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, which was included in &#8216;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b4950ae-8a2a-400a-848c-b12899bcf89d;"><span style="-sec-ix-hidden:F_9df9a806-ab12-4618-8e6a-94161b6cb0d5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other current assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; in the accompanying balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventorySuppliesPolicy', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#8216;Direct c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">osts and expenses&#8217;. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for both years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The Company recorded a reserve for excess inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for both years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, to the statement of operations for excess and obsolete inventory.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_693c0deb-e916-4d0f-82f1-e7179ddec20e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9b208ef9-2e89-4c6b-beef-d077b508f0ac;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments for th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were immaterial impairments during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2023, there</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accumulated impairment losses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company acts as a lessee under all its lease agreements and holds various real estate leases for its headquarters and laboratory facilities in Colorado and Kansas and other various copier leases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company elected the following practical expedients as part of the adoption of ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Package of practical expedients which allows the Company to carry forward the historical lease classification;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of right-of-use (ROU) assets;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the fair value of the underlying asset.&#8221;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required by this standard are contained in Note 9 &#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.82%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:86.1%;"></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 4 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion related to estimated fair value measurements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recorded as &#8216;Interest expense&#8217; in the statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of warrant liabilities is assessed at each balance sheet date and changes, if any, to the fair value are recorded as 'Change in fair value of warrant liability, net' in the statement of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share&#8209;Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options, if granted, vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units (RSUs)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 12 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information related to share-based compensation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">s</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 14 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information related to income taxes.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OtherAssetsPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cash refundable deposit to secure the performance of the Company&#8217;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million refundable deposit is reported within 'Other long-term assets' in the balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for the Company beginning January 1, 2023. The Company evaluated the guidance and determined the overall impact of the adoption had an immaterial impact on our financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Standards being evaluated</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting: Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC Topic 280). This ASU requires all public entities to provide additional disclosures about the entity's reportable segments and more detailed information about a reportable segment's expenses. This guidance will become effective for the Company beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid by jurisdiction. This guidance will become effective for the Company beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of Presentation and Estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventorySuppliesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventorySuppliesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183269456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of Fair Value of Outstanding Borrowings</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.739%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.885%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.404%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.204%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below presents the reported fair values of contingent consideration and warrant liabilities,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.412%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.924%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.903%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Contingent Consideration and Warrant Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the changes in contingent consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and warrant liabilities for the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.687%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.537%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.977%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,792</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,946</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,075</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of Tranche B Warrants to additional paid-in capital</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance - December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184341904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">749</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vehicles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,947</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,867</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock', window );">Schedule of Depreciation Expense Related to Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense related to pr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operty and equipment was:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation and amortization expense related to property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504181980176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets, Excluding Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.195%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.824%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.702%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets subject to amortization</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">647</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trademarks</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,991</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,097</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.613%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.723%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.023%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,981</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,973</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization Expense of Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future estimated amortization expense of intangible </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assets is (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.784%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.476%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of <br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184559680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.713%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation related accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,671</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184341776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes Payable</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term notes payable were as follows (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.96%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.360000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.76%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Perceptive Term Loan Facility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current maturities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term notes payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Principal Repayments (Maturities) of Long-term Obligations</a></td>
<td class="text">
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.68%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,078</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184502944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments for Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments associated with our operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.996%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.964%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,063</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,113</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less amount representing interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504189001440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.713%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diagnostic Tests</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Biopharma Services and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United Healthcare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The State of Colorado</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.16%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Medicare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AstraZeneca UK</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182033152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.619999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.619999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">331</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,961</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.42%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding - January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,489</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">964</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,298</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.04</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.080000000000002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.080000000000002%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.39</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.65</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk&#8209;free rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit activity during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 was (in thousands, except weighted average grant date fair value per share):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.82%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.619999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cceeff;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Released</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.42%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; January 1, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">526</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.69</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted under the Option Exchange</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8209; December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,050</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.81</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8209; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184298368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted loss per share as of the dates indicated were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.647%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,113</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares committed under ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504188415184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.233%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.683%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.081999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and developments credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.313%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.103%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.623000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,120</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,685</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-Use Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,303</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.6%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at January 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions related to the current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions related to prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions for tax positions related to prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions related to settlements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions related to a lapse of statute</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,037</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183267184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>Test</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfCancerTest', window );">Number of blood based lung cancer test</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfCommercialBloodBasedTest', window );">Number of commercial blood-based test</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfSARSCoV2Test', window );">Number of SARS-CoV-2 test</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCancerTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of cancer test.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCancerTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCommercialBloodBasedTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of commercial blood based test.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCommercialBloodBasedTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfSARSCoV2Test">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of SARS-CoV-2 test.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfSARSCoV2Test</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184149120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,284,000<span></span>
</td>
<td class="nump">$ 43,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Description of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Amount used to retire outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">28,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolete inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember', window );">Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Refundable deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal balance outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum | Two Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum | Three Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanFacilityMember', window );">Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement in net equity proceeds</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182069584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Issued Accounting Standards - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">$ 1,745<span></span>
</td>
<td class="nump">$ 2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 25,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Description of lease</a></td>
<td class="text"> For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184330112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504181915184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details) - Fair Value, Recurring - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 35,276<span></span>
</td>
<td class="nump">$ 25,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 35,506<span></span>
</td>
<td class="nump">$ 26,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182307280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities (Details) - Fair Value, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">$ 21,857<span></span>
</td>
<td class="nump">$ 28,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Portion of Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">$ 21,857<span></span>
</td>
<td class="nump">10,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504187957376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 28,986<span></span>
</td>
<td class="nump">33,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense', window );">Interest expense</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration', window );">Payments</a></td>
<td class="num">(11,075)<span></span>
</td>
<td class="num">(10,822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">21,857<span></span>
</td>
<td class="nump">28,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value, net</a></td>
<td class="nump">1,274<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Warrant Liabilities | Tranche B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Reclassification of Tranche B Warrants to additional paid-in capital</a></td>
<td class="num">$ (1,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504177387696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th"><div>Apr. 07, 2022</div></th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,274<span></span>
</td>
<td class="num">$ (84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule', window );">Interest expense due to passage of time and fixed payment schedule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember', window );">Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfInterestOnContingentConsideration', window );">Percentage of interest on installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Contingent Consideration | Scenario Forecast | Third Amendment to APA Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ExitFeePayment', window );">Exit fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount', window );">Contingent consideration arrangements, common shares, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationFinalPayment', window );">Business combination contingent consideration final payment</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Contingent consideration cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeExtensibleEnumeration', window );">Investment, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Repurchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock | Contingent Consideration | Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration number of installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements common shares redemption amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration final payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ExitFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exit fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ExitFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense due to passage of time and fixed payment schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfInterestOnContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest on contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfInterestOnContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column C)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_ThirdAmendmentToApaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_ThirdAmendmentToApaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182338816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 33,479<span></span>
</td>
<td class="nump">$ 12,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(5,612)<span></span>
</td>
<td class="num">(7,018)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">27,867<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,089<span></span>
</td>
<td class="nump">6,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24,713<span></span>
</td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183097552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details) - Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,345<span></span>
</td>
<td class="nump">$ 1,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Selling, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 885<span></span>
</td>
<td class="nump">$ 1,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184081584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 7,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, Cost</a></td>
<td class="nump">18,991<span></span>
</td>
<td class="nump">$ 18,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(11,080)<span></span>
</td>
<td class="num">(9,097)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, Net Carrying Value</a></td>
<td class="nump">7,911<span></span>
</td>
<td class="nump">9,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross', window );">Intangible assets not subject to amortization, Cost</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization, Net Carrying Value</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(752)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember', window );">Purchased Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(10,328)<span></span>
</td>
<td class="num">(8,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 6,572<span></span>
</td>
<td class="nump">$ 8,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets excluding goodwill gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504185015584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 1,983<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 1,981<span></span>
</td>
<td class="nump">$ 1,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504185451664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter', window );">2029 and thereafter</a></td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 7,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets amortization expense year six and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504176911584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation related accruals</a></td>
<td class="nump">$ 3,855<span></span>
</td>
<td class="nump">$ 4,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">2,872<span></span>
</td>
<td class="nump">2,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 7,710<span></span>
</td>
<td class="nump">$ 8,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183023344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long-term Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="num">$ (4,802)<span></span>
</td>
<td class="num">$ (5,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, total</a></td>
<td class="nump">35,276<span></span>
</td>
<td class="nump">25,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Less: current maturities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable</a></td>
<td class="nump">35,225<span></span>
</td>
<td class="nump">25,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanFacilityMember', window );">Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504175351680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2023 </div>
<div>SubscriptionAgreement</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 16, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount withdrawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,126,000<span></span>
</td>
<td class="nump">$ 59,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,520,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed', window );">Number of subscription agreement for which final closing to be delayed | SubscriptionAgreement</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,454,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,975,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,508,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember', window );">First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 10,  2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche B Loan | Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Applicable margin rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MinimumCashBalanceAtMaturityDate', window );">Minimum cash balance at maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdditionalWarrantsAmount', window );">Additional warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Tranche A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt, after deducting debt issuance costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Tranche B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount withdrawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 15,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Tranche C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount', window );">Prepayment premium percentage of aggregate outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount', window );">Prepayment premium percentage of aggregate outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum | Tranche A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum | Tranche B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum | Tranche C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdditionalWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdditionalWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, additional warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InitialWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InitialWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumCashBalanceAtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance at maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumCashBalanceAtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of subscription agreement for which final closing to be delayed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment premium percentage of aggregate outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504181234896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter', window );">2027 and thereafter</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 40,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal in year four and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504178620912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>RenewalOption</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseExpirationMonthYear', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,745,000<span></span>
</td>
<td class="nump">$ 2,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, Weighted-average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Current<span></span>
</td>
<td class="text">Other Assets, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccretionOfLeaseLiability', window );">Accretion of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember', window );">Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial term of the Lease is twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023. The Company has two renewal options to extend the term of the Lease for an additional seven- or ten-year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $2.0 million in ROU assets and lease liabilities being recorded, however, the Lease commenced for legal purposes on April 1, 2023 (the Commencement Date).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseAgreementNumberOfOptionsToExtend', window );">Lease agreement number of options to extend | RenewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeasedPropertyBuildingCapacity', window );">Leased property building capacity | ft&#178;</a></td>
<td class="nump">79,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BaseRentPerMonthFromCommencementDate', window );">Base rent per month from commencement date</a></td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_RentAfterFixedEscalationProvisions', window );">Rent after fixed escalation provisions</a></td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent', window );">Area of leased premised obligated to pay base rent | ft&#178;</a></td>
<td class="nump">19,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements', window );">Landlord contribution towards cost of construction and tenant improvements</a></td>
<td class="nump">$ 18,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdditionalTenantImprovementAllowanceAmount', window );">Additional Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InterestRateOnExtraAllowanceAmount', window );">Interest rate on extra allowance amount</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Capital expenditure for leasehold improvements related to leases premises which are tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_TenantImprovementsIncurredDuringThePeriod', window );">Tenant improvements incurred during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember', window );">Centennial Valley Properties I, LLC Lease Agreement | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LessorReimbursementsReceived', window );">Lessor reimbursements received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember', window );">Centennial Valley Properties I, LLC Lease Agreement | Letter of Credit | Cash Collateralized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Refundable deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets | Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Refundable deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CO', window );">COLORADO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseExpirationMonthYear', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_KS', window );">KANSAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AreaOfOfficeSpaceLeased', window );">Area of office space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseExpirationMonthYear', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccretionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccretionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdditionalTenantImprovementAllowanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional tenant improvement allowance amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdditionalTenantImprovementAllowanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased premised obligated to pay base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AreaOfOfficeSpaceLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AreaOfOfficeSpaceLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BaseRentPerMonthFromCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent per month from commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BaseRentPerMonthFromCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InterestRateOnExtraAllowanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate on extra allowance amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InterestRateOnExtraAllowanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Landlord contribution towards cost of construction and tenant improvements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseAgreementNumberOfOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease agreement number of options to extend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseAgreementNumberOfOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeasedPropertyBuildingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased property building capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeasedPropertyBuildingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LessorReimbursementsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor reimbursements received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LessorReimbursementsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RentAfterFixedEscalationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent after fixed escalation provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RentAfterFixedEscalationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TenantImprovementsIncurredDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvements incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TenantImprovementsIncurredDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=bdsx_CashCollateralizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=bdsx_CashCollateralizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_KS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_KS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504185646624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating leases, 2024</a></td>
<td class="nump">$ 2,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating leases, 2025</a></td>
<td class="nump">4,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating leases, 2026</a></td>
<td class="nump">4,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating leases, 2027</a></td>
<td class="nump">4,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Operating leases, 2028</a></td>
<td class="nump">4,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter', window );">Operating leases, 2029 and thereafter</a></td>
<td class="nump">28,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating leases, Total future minimum lease payments</a></td>
<td class="nump">46,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating leases, Less amount representing interest</a></td>
<td class="num">(21,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 25,415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, to be paid, year six and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504168351200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2023 </div>
<div>SubscriptionAgreement</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>USD ($) </div>
<div>Officer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 16, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder of each share of common stock is entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuable per day, number of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,003,000<span></span>
</td>
<td class="nump">56,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,520,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,126,000<span></span>
</td>
<td class="nump">$ 59,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed', window );">Number of subscription agreement for which final closing to be delayed | SubscriptionAgreement</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PublicOfferingPricePerShareOfCommonStock', window );">Public offering price per share of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G Preferred Stock | 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuable per day, number of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche A Loan | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche B Loan | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 15,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche C Loan | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfFacility', window );">Number of facility | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuableDuringPeriodValueCommittedShares', window );">Common stock issuable, committed to purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PurchaseAgreementTerm', window );">Purchase agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayShares', window );">Stock issuable per day, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SharesIssuedOrIssuableThresholdLimitDescription', window );">Shares issued or issuable, threshold limit description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under applicable rules of the NASDAQ Global Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty', window );">Maximum percentage of common stock allowed to purchase by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockSharesIssuedAsCommitmentFee', window );">Shares issued as commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_CommitmentSharesIssuableOnConditionalBasis', window );">Commitment shares issuable on conditional basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DiligenceExpenseAndLegalFees', window );">Diligence expenses and legal fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts', window );">Adjustments to additional paid-in capital deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs | Lincoln Park | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuableDuringPeriodValueCommittedShares', window );">Common stock issuable, committed to purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayShares', window );">Stock issuable per day, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayValue', window );">Stock issuable per day, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SharesIssuedAsCommitmentFeeValue', window );">Shares issued as commitment fee, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfCommonStockNet', window );">Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter', window );">Shares purchased by underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Perceptive Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,454,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,975,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,508,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfOfficers', window );">Number of officers | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements | Private Placement | Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,631,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements | Private Placement | Existing Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,877,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements | Private Placement | Chief Executive Officer and Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_AtTheMarketFacilityMember', window );">ATM Facility | Equity Financing Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_WeightedAveragePricePerShare', window );">Weighted Average Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_LPCFacilityMember', window );">LPC Facility | Equity Financing Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember', window );">First Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 10,  2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember', window );">First Amendment [Member] | Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember', window );">First Amendment [Member] | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember', window );">First Amendment [Member] | Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember', window );">First Amendment [Member] | Risk-Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember', window );">Tranche B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 15,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember', window );">Tranche B Warrants | Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember', window );">Tranche B Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember', window );">Tranche B Warrants | Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember', window );">Tranche B Warrants | Risk-Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid-in capital deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, additional warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_CommitmentSharesIssuableOnConditionalBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issuable on conditional basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_CommitmentSharesIssuableOnConditionalBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DiligenceExpenseAndLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diligence expense and legal fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DiligenceExpenseAndLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InitialWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InitialWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock allowed to purchase by counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of officers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of subscription agreement for which final closing to be delayed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PublicOfferingPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PublicOfferingPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockSharesIssuedAsCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, shares issued as commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockSharesIssuedAsCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockStockIssuablePerDayShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, stock issuable per day, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockStockIssuablePerDayShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockStockIssuablePerDayValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, stock issuable per day, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockStockIssuablePerDayValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharesIssuedAsCommitmentFeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued as commitment fee, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharesIssuedAsCommitmentFeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharesIssuedOrIssuableThresholdLimitDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued or issuable, threshold limit description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharesIssuedOrIssuableThresholdLimitDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuableDuringPeriodValueCommittedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuable during period, value, committed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuableDuringPeriodValueCommittedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues shares purchased by underwriter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bdsx_ExistingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bdsx_ExistingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_LPCFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_LPCFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_TrancheBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504178611232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 49,087<span></span>
</td>
<td class="nump">$ 38,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember', window );">Diagnostic Tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">45,192<span></span>
</td>
<td class="nump">34,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_BiopharmaServicesAndOtherMember', window );">Biopharma Services and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="nump">$ 3,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_BiopharmaServicesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_BiopharmaServicesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183981440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PrimarySourcesOfRevenueDescription', window );">Primary sources of revenue, description</a></td>
<td class="text">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Minimum | Customer Concentration Risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Long-term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember', window );">Up Front Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PrimarySourcesOfRevenueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary sources of revenue description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PrimarySourcesOfRevenueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184098320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk - Minimum<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | United Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | The State of Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | AstraZeneca UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_TheStateOfColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_TheStateOfColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_AstrazenecaUkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_AstrazenecaUkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182508336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2023 </div>
<div>ShareHolder </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,041,000<span></span>
</td>
<td class="nump">2,541,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,373,000<span></span>
</td>
<td class="nump">$ 5,961,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_StockOptionExchangeProgramMember', window );">Stock Option Exchange Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 24,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of eligible holders elected to exchange | ShareHolder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of shares of common stock underlying eligible options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="nump">526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsRSUsMember', window );">Options and Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Remaining unrecognized share based compensation expense for options and restricted stock units | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Amortized to expense period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Performance Condition Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Performance-based options vest in three equal annual installments beginning one year after the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Stock Option Exchange Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="nump">156,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember', window );">2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember', window );">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of earnings used for purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Percentage of fair market value of common stock for purchase under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod', window );">Description of voting power or value of stock for employee participation in offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DescriptionOfOfferingPeriodUnderPlan', window );">Description of offering period under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. During the year ended December 31, 2023, 437,135 shares were issued under the ESPP leaving 309,012 shares remaining for future issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfOfferingPeriodUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of offering period under plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfOfferingPeriodUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting power or value of stock for employee participation in offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_StockOptionExchangeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_StockOptionExchangeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183197104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - January 1, 2023</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange', window );">Stock Options, Cancelled under the Option Exchange</a></td>
<td class="num">(589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange', window );">Stock Options, Granted under the Option Exchange</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - December 31, 2023</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable - December 31, 2023</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - January 1, 2023</a></td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">8.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled under the Option Exchange</a></td>
<td class="nump">20.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted under the Option Exchange</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - December 31, 2023</a></td>
<td class="nump">3.36<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable - December 31, 2023</a></td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable - December 31, 2023</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - January 1, 2023</a></td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2023</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">$ 1,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2023</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - January 1, 2023</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange', window );">Stock Options, Cancelled under the Option Exchange</a></td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange', window );">Stock Options, Granted under the Option Exchange</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - December 31, 2023</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable - December 31, 2023</a></td>
<td class="nump">1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - January 1, 2023</a></td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">4.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled under the Option Exchange</a></td>
<td class="nump">20.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted under the Option Exchange</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - December 31, 2023</a></td>
<td class="nump">2.81<span></span>
</td>
<td class="nump">$ 10.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable - December 31, 2023</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable - December 31, 2023</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - January 1, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2023</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Cancelled under the Option Exchange, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Granted under the Option Exchange, Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options cancelled under the option exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options granted under the option exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184836064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 5,373<span></span>
</td>
<td class="nump">$ 5,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,989<span></span>
</td>
<td class="nump">$ 5,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182051520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 4 months 20 days<span></span>
</td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.10%<span></span>
</td>
<td class="nump">72.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk&#8209;free rate</a></td>
<td class="nump">3.98%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182359152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Outstanding - January 1, 2023 | shares</a></td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Shares, Forfeited/canceled | shares</a></td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Released | shares</a></td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Outstanding - December 31, 2023 | shares</a></td>
<td class="nump">2,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, January 1, 2023 | $ / shares</a></td>
<td class="nump">$ 2.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="nump">1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled | $ / shares</a></td>
<td class="nump">2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Released | $ / shares</a></td>
<td class="nump">2.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, December 31, 2023 | $ / shares</a></td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504184223056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (52,146)<span></span>
</td>
<td class="num">$ (65,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used in computing net loss per share, basic</a></td>
<td class="nump">82,113<span></span>
</td>
<td class="nump">42,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used in computing net loss per share, diluted</a></td>
<td class="nump">82,113<span></span>
</td>
<td class="nump">42,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183293616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">11,482<span></span>
</td>
<td class="nump">9,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember', window );">Shares Committed Under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="nump">5,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182359568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">310,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration', window );">Research and experimentation tax carryforwards</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Description of tax credit carryforward expiration</a></td>
<td class="text">expire beginning in 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Valuation allowance, deferred tax asset, explanation of change</a></td>
<td class="text">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets', window );">Percentage of valuation allowance equal to net deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="nump">$ 15,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination details</a></td>
<td class="text">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax examination, likelihood of unfavorable settlement</a></td>
<td class="text">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income Tax Examination, Description</a></td>
<td class="text">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research and experimentation tax carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance equal to net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482669/740-10-15-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504183020576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and developments credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504182300208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 72,722<span></span>
</td>
<td class="nump">$ 70,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense limitation</a></td>
<td class="nump">5,120<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsCapitalizedResearchCosts', window );">Capitalized research costs</a></td>
<td class="nump">4,281<span></span>
</td>
<td class="nump">2,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">6,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">1,932<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">95,022<span></span>
</td>
<td class="nump">84,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(93,023)<span></span>
</td>
<td class="num">(82,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-Use Asset</a></td>
<td class="num">(692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,303)<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (1,999)<span></span>
</td>
<td class="num">$ (1,772)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsCapitalizedResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Aassets capitalized research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsCapitalizedResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504175338928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to the current year</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior years</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140504178695168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,988,000<span></span>
</td>
<td class="nump">$ 13,102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember', window );">Revenue Share Agreement | Oncimmune Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests', window );">Percentage of license agreement and royalty payment related to Nodify CDT test recognized revenue for non-screening tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MinimumAnnualVolumePercentageThereafter', window );">Minimum annual volume percentage thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PeriodOfEscalationsOfSales', window );">Period of escalations of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> through the first four years of sales<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember', window );">Bio-Rad License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue', window );">Percentage of royalty payments not required on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LicenseAgreementExpiryDate', window );">License expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember', window );">CellCarta License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="nump">0.675%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfFeePaymentsOnNetSales', window );">Percentage of fee payments on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale', window );">Term of royalty payments from first commercial sale</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale', window );">Year of ending royalty payments from first commercial sale</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_RemainingEstimatedObligation', window );">Remaining estimated obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology | NSCLC POC Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts', window );">Responsible percentage of development and regulatory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember', window );">Ficlatuzumab | AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight', window );">Percentage of development and regulatory costs exercised using opt-out right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales', window );">Percentage of royalty payments on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing', window );">Percentage of license income generated from licensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LicenseAgreementExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LicenseAgreementExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumAnnualVolumePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual volume percentage thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumAnnualVolumePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs exercised using opt-out right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfFeePaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fee payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfFeePaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of license income generated from licensing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments not required to pay on net revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PeriodOfEscalationsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of escalations of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PeriodOfEscalationsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RemainingEstimatedObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining estimated obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RemainingEstimatedObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of royalty payments from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of ending royalty payments from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M4%<%J*OC0(T)BZAL,$($S8[RKCN@M'MXUSZ]M?5-H1D2JT"[+J!='P=M&/$
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MU-^;4JMR*QV^K;?H17 /*(/[,8_N9V@JX'F&*$,^S:!]@&8"H"AAZM7[ R5
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M)?'8(GPJ;[N<!WF$;GWL&Y,-?=9=B96P*7M(!7P\*Z855+DP,2F#.$*G#&F
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M').H>:J"6:VI0GQ,3"U;=:-:6$ZO)XHP'CH/[.X\/J0IUX*G:MJ&\K0KQ;P
M"=UP5>FL8,T>PD>^1\8EV&*'HS">.FG$0[.!]V[&Z[S.J%3!3=F*)]QZT(C-
MGN'<AS$)C,A:#'$0^FBJ$@_]!7;W%ZU:5(?6)K,G\$EDA-6T0EXP=:R#A\X!
MNSL'0]F:A7LP]LCX'F0[D[*96<ZD%EM?+_6GXS]H^<"+2K64*S7.NP@5^[+]
M&MO>2+%I/FC>"RE%WERN&56@M8'Z?2548]W=Z&^D_3?QY7]02P,$%     @
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M>@TS3%4["%P+U/T%8_)MHAN.NL&,_@)02P,$%     @ :C%A6+1<3M/?!
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MID 3X%I ?5\S)H\#/4%[&[7X%U!+ P04    " !J,6%8&8#1P*$&  !&+
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M,P^U^S.(%(0F(3A5;W1KZ\]D$^W91&>Q =M*/)\ *3<%_45(^^5F6V=KL6(
M&S%MV-+5&G1HND8:19@$"FF7 5-'8KT!B?<#$K_4@)@&(M;GUU!-9&N#!K);
MG! P=12PQW>ZYSL]CZ_P W+Q2^I:+#'H2GS(JWM1A'%FRW1KM*&9/M4S?:IF
MNLN J2.QWD@D^Y%(G(^$:002#5KD*0N(N;4E0U/\A("IHX ]L-#K_(9G19O^
M)'66LP;MCBG=R)6XR&1V-)/MFD-3N57K301:+CL-F;I2ZT,_,'GP/.A&V%##
M@U0',&\+]2R'2M"D,U62T=[P<\%T)@O:7=8M*0C><1'RO,XSZ>*>GFHYMV>E
M57MP5B+#XRE6F;H,F;I2Z\/OW!ZTV[W#6?:3@)T+-_X5US6NS+,IU!T92KQ(
MS4R7CFQQ4LS45<P^R,ZY0;MU:Y8 8[E?MI2/JPVI&):WMQ&B[K#")((J1)<.
M:W%2S-15S#[$SHE!NQ7[AW"1A0(? :__HHR],=+3;=,X"H- W6JQQQK,SZ5:
M^GP?^@0[OP;MANW8EA4RDM2M$_(B_6Z.M.=,/%4G15W*G\9)H#UK]')C/XH#
MY!WI>6>,H-T9#=FX,M-P:73F4'<Z<1Q!;8GC,FCJ2JT_!)UW@N>9IV>WK^RZ
M@]$;?%+LATA%[]0JN5+KH^_,$CS/+1W=Q(*Z34%3S_/5>S_1UYC:@L@@%2=3
M[0']$J8'=:8'V4W/"VUEV:,.35VDVZ+ 5WD[#9FZ4NL/2V>+D-T6.=[00KHG
MB@(UJ>U-&KHR0+K'TD*FKD+V*1^\R+)[K+,</]+=$$0:RQ,*+>RM&YRQ+V&9
M4&>9D-TR#3+RK=9A/B;J0M\>;W ZZFY)C9BZBM@GV'DE9/=*SSI^(TG=P&@@
M@V<W1.PM&YR)+V&74&>7T.EOKC[D->/@?4FJI3Q* !XM)A[I[D,LP5683NW3
M*2%35R'[.#OOA.S>Z99D!68L7^598]TEUL\"8K8FX'H/%' *<'=T8=,>7<B.
M'EVX1H8W5+[VOM#>N,&\3XF9NHK9!]Y9-F2W;/]KY\^N/7CA9;!K4#UGX#1D
MZDJM#[\S:\ANUH9L6"'=485^K"T%7!JJQ4DQ4U<Q^Q [VX7LMNND#2ND^Z-Q
MB*!Z'&!NCS68GTNU]/D^]$\;=;;,M]NR8QM6OO%LD:<?J@BGZML\0ZE$/7IA
M4D*!%ZHOZ@SEQ@%,PNA8QSOCX]N-SY#]*C,,ERYF[NLN)HF0KW%S&31UI;8;
M@LG!$4QYPO9O7-_G%0,%60EY[VTL.E?O#JWN+CC=-*<ROU'.:=E\7!,L;*<L
M('Y?4<J?+N1!S_W1X=E_4$L#!!0    ( &HQ85@<=1%QO@D  .,N   8
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M3B8@.$Y X!I]]4\H-P5OC4[V=T;=G;*F/*SF(?:#Y=7B80S?8+8,@R ZFIT
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M2VWQ&8S(2$^=^J5D!7'+BE._V!-KTKPO@3UV7LNZ8=[ZU@5#,FW.#39XF5A
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MZ3Y..9J ]U.+?$@/M$'[7>GBOU!+ P04    " !J,6%8]9\2')TI  "OA0
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MO #9#]G#WKF,;=@WWH:]<JLA(Q7_=UT!C3NRE/612B(-B@/I*\@B_MF;^5J
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M=QXTND%4G *&89JS1#/1_6'@3SQJ7O>MT%#')_[OZ $:7$*NI'MSB4AX;+
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MKC&U;#U%83F_D)"47!@_'(?$[.'D@^B+I#R[O!\Z(LH8^"V->-46;EU;)0_
M&*VR.'Q2 0.]*Z&/V8-HUQZ<.PO%FJS[8^6+G",3^J1M$:4B Z@U$K5FPR,&
MO"&EQ23O3C'O>FP*A2$Q3)M<&&%?JN<(E=^.:&G)0!'^FY3?:DW=!!624)8
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M[[ C_0EKSJ7L4 >Y[J0NB?YTIX'BZK+XO+P7-YE+UGG<!]$GYL7I\+YGTHB
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MX<.;%OI![TA(;HUWPJ2,GK/&K]FA<G74:A5UYF?HOAEZMFHL)'2VU[:85A9
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M _3YNJ73UE\P =[EP<M[^7]02P,$%     @ :C%A6-F.%@5Q!   3PL  !D
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M'Y^=!&#J\:U>.%WZD6FI'0U@_C.CB1<-"]#Y2M.;V"S80#M#3_\!4$L#!!0
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M/63R&90V S,>PNFH92"F5F(+ BL/$6@#&LM*5Q<9/*&*4DZ;. O.[")N60&
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MU<)^G N.>H$6X/U4@7/_A0ZH?_7W]E]02P,$%     @ :C%A6(O8#U)A P
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MEL:7%[?T>P&U,Z#]M:+.TBW< ?TOD/D74$L#!!0    ( &HQ85CV[XORG@(
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MGA!*S)U'X+0\X@U*Z8&(QN\6,^BN](F'^SWZ^UH[:<FXQ1LM?XC"E=,@#:#
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M$7[WK\#XI*T](\N2+,5.G&3&<9(V;7+B<<[EH=,'B(0D-B2A J04GU_?;Q<
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M:# :C?!PP0]'7YB_RRLQGEP>_9S+3)LB^0W<,U8Q5$B7>2' @?N26%O*/%(
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M^T'R7AS[_SU(03Z^$$T?:@E5<JD\8G.;+G%M;_VVWKJ+ WNQ#P;=G5D%I)8
M4/?[_./F]"D2 ?F3MZ=-$R$;$&U'?T#)*?4-9KWP/J0?A=1I^7L)M?'BJ+=0
M2X(S_.U*I\P;GM?2P'TA'B6I9Y.T-<_AF(PEA^A7"JN&V@<JT\L"5#;7!6?4
M>2@$^C)CYP4;C9P>$7B5)07DK1#AKG*U2C]*1RBZVD.BI6(_<>D_E1^^+ND9
M&&M>,Z/^,PV)$&:0,TLF[GUI04DI;^O$*B6XRS6MNEP?9&+$+S)%E@M=O%?<
M#LL+%_H&825P,< .4--XT\*.WV\XN'.2R6W<_I8#;(9JI[J(,NTU''J-9>0"
M031SC8VH7C*GC&7GVR+!0T3J';5Y:Y1GQ4JZ.!U"*'7NJG24<+():B=I K5\
M:9W$]C""[(A,@_M>Q8J&#P*]5I2%17+F4,AO2FRPKBXI#UY3)DW%)MB$[,@(
M_6Q.E@:"S@(8*(!6&B[C:6SC,RP-R@;6_4]J08D&9Q3W:EFFLM"PBQM*Y3<R
M!<G/DK4BK<72_$B544I]?O(C=T;#&5&[2I&E2FI( AC7CNSO8!$+#@Y#8=4.
MJCS'D@V[;$:<;%?*82;S)5?A;-_A[10H2 MG/8=X$ 3A;LBX@Y$04UY?]H3G
MX*2<[+K:(H@A^+R"UDTA<F<QH<AN4X7P^@3-6VUF95ZEZYPLJ/M^O#@9*@TX
MW.*)VC4J)KZO8;Q4/7+R:#E#9."NX8R7E*-0_\&O1YY6$C'6? .5HHG1"E@J
MSAN=Y#)EEG"2+(0(*F83;]7XX =7&<H>--VY#[NA:Z@@-#GP\#'? %"7X(/>
MO4<7&[\+I="35>C:L\-MCT5B(^SK04ESS;5BG%"+((_! 5<:7B2!D3:(7;#(
MC-.$>QVP)BLYO\)(\I"DIQS[2=J*]-AP;0Y/0+VE/*PE*[MQ_F3E77("U").
MC(-VA6#8R>GK9@[#R"&G*IP.%1FMW*>=R&=P:>(D.>4D&=9/I:%MIYZM6K9V
M(I).PY(,A6(D[4K,9<J.!AMY)B;#6>@F7;L>1$)+5):'W+S@5 #O+&$O,>0A
MAO"D0*K8D88$8F> SRX^2X/)=6,"R81>YLEOJNJ>$:.9BY8L 6X?[*OSZH*%
M6VV?P>!XU-ME:W;MN?CAHNV&%(!#5I79A;)Q2QT Y H-TP_-*+L;;T+1VJ;I
M./CL,?\1X?K>[S%$57'R%%_+/1HBZK PU/=U8<>H5&VXKEY!%Y% Q?^M?/Y:
MYBIT R^J1B%MMUW./4&ZTP.U:B]2E6 KL7/!2@^-PE16F22UE4HL*)'9^AKU
M4(7:6]3YKOV.,M1%RO^H2GT^F4T;J=AX5.5B[QW94];?FW))UCWU\(>^!Q2M
MP=Q[COP$Q6.G4[W3@_-__-QJ=VKWW.H)!U2A&^,9'- <5SS]3B/;Y>K_8F7_
M>\?8-+SI?VQXNRW?V5#\7 47A^9!^/J.-MA8J61J\-X^Z_%G535H%)8:P$$3
M$ #IK':K4FB$ZX-WCDD:\2:./>*12M8<8^N^)0>MZOB,?BJ@?00_GX]5\<N=
MK($[;[$:]L)G"0<;5D/QKG'B $%[=JUPN^N<E>P$F,Q78Q4:3]W[SJV!+LI-
MSW#Q:&RC;B<JPK7KVM<I3/"\U3$AI[6R>S!&P#8/V_ ^?CYX<3D;3%Y</<FE
M.K\8/+/O.2R\'VPX3'_\TS@P[LSI.0>=U:=>_YW$6,DV& C&9L.+2GVH_Q"T
MC.V/NZ;BQ6 ZFPY>3"[W-8K6C28W6UI3$G41QN*L>9M</BI2PJCIOOG(GBM7
M5 *^RX@E2)OZI>_*(Q2;R )I,#8\&4YZ-\P672%#V[\<S":CP<7E>&\KD:9X
MD.*#$NG>17DD)/8V%U#=ZFZ'H6Z6=WL4OF_ICJ];-1[U&'1^%@Y2^&##GXC4
M%2W73@M%5=8FT:G+9!B%JC\ 640H\&3TX.J"P]V.N<R_F7)=1 _>P5L-%Y'C
M56U"/\#7Z?\LXZ6OW2.CK3T+]^>LJRK\,(*#KFK1L*KE$KH"9PA@[& <==<^
M<(^4G15)4;KN1*C(>&\@J--'CA2#NE+L3+B;MD;51=[%]9=1GE0U4JLNW_5Z
M5 /6+55FL'W-AHMW&BVI!TCJ_D'-34GR'D]#T-1/."%T%V8\M5^9&A3MZ]/S
MC_;<02L=JA)7"H3,:@<3(M&U@[[T):!5AT='T07(JGODBE/Z>...J.^YW<00
M:6Q_/#K[6^7]J< ^VV>,G,,ATX#.(#CJ-7ABM^+SCM!VXW-D%U0H>X/<X1BJ
M1FCKD!*JL=0D46JB*Y.[-@PJ8<J-D41'WI9,W4UQ'#C3UY'KO/M8D#O3;EIV
MI$MD8] Q>DGR_D8==XH5$G=?A+CN(!W%]9^$YHW#XJ?>"*)XUNR2\YT$NNO@
MKZ;U-+C='COG8C3KIC[%J%O_Y&8WU+3ERH-*]NI*$$]Z)D;#<7T)!NRO79V0
M(NLN;?#+;U,9?3O[&A$W)&5:YXP"+@W(-(++0&#G''/I&+,HTNH>V;S1GR8;
MK8:U:Q]W2BF#7+SAD <5?*B]4]#Y"H'W%@9W3R([P=OU#0!&?>/0ZVJOJ'SB
M7]\=>B9F=1!TPMA7!W;!'PTO*_#_$VQ]+/));K4%^]1=M*\2--$PG'6RJK<N
M83I!\%6Q^ABM[VI>-=<E/:*^ULG>W1N$OU,F],;;!>Q8-:?#F?9<E6ATO4[J
M^YQ\[EI?M6T>P#]VKY7CTA'[?;I-2$\S,1G3W^?B\H@O('G-,LI=F'/76(]^
MTM1"=;=:+Z]$WWWD\\;M<&ZHTAUXBI: RET4K[Y6U^QOW.WR>KB[H_^9[^A0
MG;S 5*C-[-BUS,-+H==\UWRN"R0P_+A2$EZ'!N#WA49ZY%]H@>H_'[SY-U!+
M P04    " !J,6%8&FR8 @@*  !?&@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6RE66UOVS@2_MY?07B[VP1P'-MQW*1- J3I%M>]=AOT9>_#X3[0
M$FWS5A)5DK+C^_7WS)"2)<?Q]G! T<@R.2_/S#PSI*_6QO[IEDIY\9!GA;ON
M+;TO7YV>NF2I<ND&IE0%OID;FTN/CW9QZDJK9,J;\NQT/!Q.3W.IB][-%;^[
MMS=7IO*9+M2]%:[*<VDW;U1FUM>]4:]^\5DOEIY>G-Y<E7*AOBC_K;RW^'3:
M2$EUK@JG32&LFE_W;D>OWDQH/2_X0ZNU:ST+\F1FS)_TX7UZW1N202I3B2<)
M$G]6ZDYE&0F"&=^CS%ZCDC:VGVOI[]AW^#*33MV9[!\Z]<OKWD5/I&HNJ\Q_
M-NN_J>C/.<E+3.;X?[$.:T=8G%3.FSQNA@6Y+L)?^1!Q:&VX&#ZQ81PWC-GN
MH(BM?"N]O+FR9BTLK88T>F!7>3>,TP4%Y8NW^%9CG[_YH."2NSKUD$5O3I.X
M[TW8-WYBWV@L/IK"+YWXM4A5VA5P"B,:2\:U)6_&!R6^5<E G(WZ8CP<GQV0
M=]9X=L;RS@YZ)OYY.W/>(OC_VN=D$#'9+X(*XI4K9:*N>\AXI^Q*]6Y^^6DT
M';X^8."D,7!R2/H!Z _NVV_5[\8K<2E^^>EB/!J]%M'Y3Z6RTNMB4;_XNE3B
MSN2E+#94$$Y(_!.9<DXI42&25L@L$QK?9+1#R(55"D6(RL=F:ZK%$J7-,>H+
MWY+&RU/>N00Y?*^D]<I">I&*3,X,[#!V(^8RT9GV&K;H0KPQ50:=?4C)L"(U
M_=J(7?70);U0#Z6VI*40O\D"*C9DR825M(UQU<RI[Q7V91M01V82Z:-QB;$E
M&:-^U$QOQ =3:;?26::VE@ZZ6&;.!)-=6PQ)-?.Y3I3@B)'A;Y7X8CP\_;LL
MG'1;CPM3G"2R2!0$9.H1 "!@(<O2F@<-,E)P[+(_G$[!8_!!B3DQ.(.T1DP=
M?3 1+]+Z*?%F!C44.#$0[PMQ6UJ=[0FDA#94-+]KP4_"O(HX/PX.9T9;RW0/
M0$N3I4ZLI-6FHDB4&FLC:@&%PQBX=A:05V1+ ;N$*129"#N0QQLE$=&!N,,6
M511:9N(/9+7:B'N+;F8YK._[XL.'NU 7XK;QY%,A/DJ;+,4H,-&X"PY)# D(
M;?+1[B-:RR^/P>-^^2,F]"&G3BJ1Z5Q3IF9:SB@!-T I: ZBD5!8F1YS-L3,
MVDG=)M'V96W+PA2FJ%P#^^,0JIVWJ)LR@ZA.93&_O'S]?]7X;O4&[;K #L $
M@3D\$XV=0B/L:Y6MZL"R"^_C\J]8#C2LR7D'T$(@DA"-%&72%^NE1CA)"+Z'
M@(R2SLQ?B2-]W(EM8HJT2I@MK5JIHE)BH8J:0&>5 P\[J$=YH>WC0UJG8(AX
M7R F1QI20VG%5B:ZA;"4Y(Z!BD*MX8 I:3IQ.P7V& 4N?TPQ::II W8Z,E*<
MD%;L.R%P>)_CM4K"ZZAD(-Y6EIQ@T5PC>6C>H=1_JU ^9\-VPH?*J^%,@_HD
M,57!:)056#0DB</\0Z^ Q7,Q'@PQI609#5QX\?G3-W08D%',$19:YS;EQTP%
MN,'*9$@?%+&&6[;?\KQK1*86\+W1;XH=M(]B2+=I@+D(Y3@0WYAA&KG=PE[#
MZ)IN.B3[\K)_>3'LL*ST8D\5=</,\DJYX9&1X@".6D7UF9ZK;G!G:J'!$H "
MLKOZ@>GX97\X' K01@@;8ZE<(C-.S3[K2 F*N7Y0VZ_P I)6F@9H]!EBK!W1
M9^-I5W1?E!E1,Q@* [TPS?P SL4DKD(<O7S8\?<%(C'+]")HA::NZVY)4\4,
MV,ZH$??KF++'KL;B4=2"HT5*RVB"+ZCBDJQ*ZURF"@\] ?6-D31FM9S["/5C
MD9P?MVR&^$QO[Q7:40H.?%=9?&<[>?$7?C''HP1*G#$87X'9@I=&EY SLAOJ
MAEXQGQ#=&3%ZG&$[> 6C[\&V1'DMXX^?0#*%E5L0%$\A8K_C_QO&F+5^%.,]
MYFZQOJ^LJV010:.#&XK/D\2ZP\XV++R4MFXDX.<BGN48]YU*KGMC*#TL]E;/
M*DXB3!!HT0LR#3@\%Z.+P45#4]ZLI4UC]W">5F SS@Q5/#<2(CD54IQ!B(7V
MU/^C(50]*)OH>B@./+^'QL'=!$1+!8W@, J0!G/;I,K0_OJ $XVX;5;=YL3+
MQWL8"#U<!B#W[Z%# -(09#"ON!5$V!LP@7M(5 X[UD%>@(%C((GF*6  SD9\
MI^)G)A1N2 WIM1LVH*DSC"RE&!](4"#V="[5_3U4C/,DBG(J22SZMREV4KCC
MVUQ;F)UJ-T,V*G< IBZRN4Q#5K7ZH<ET@I#7EPV>&CRF"<5"+5T-G)CY247M
MA?KAGG:X(>[OMEU.AIE*).W;4@C1C9Y354BZ"M!YE6/C2F4$HE4Z9W^:0\/C
M!',1-.(;O)SQK(V]H1NC_"M+)4@V4I3CE+.E1"XNPV-%'+O5P31V=<ML(;;'
MT[2F?.96ICY^7W*D:>IR"6J:+)M!Q\YD_D D[%K#RQ;8F!#*JVX3%+'!G@_.
MJ< $5Q@JX'?R()YC)I'I,*,HO2++L6'8X@^@0^=G8[O0HS_>,A^_Q4865M]M
M=.VF>;#RL/,_<=+VQB/3=Y0<,6F=-9\))2*&\^9-NIWPPI@<1KL]VFEO&/1B
MY])(G<TQ#[,'@TC)E,A2DWT\#X##*AN_8,SI@-=--!R^N61CENSCS*5<T02D
MBBV Z7:BKZNU=4:)#4JUCY(KMAQ3CH;;><'39;^^GJ/A![2CB]#&N1Q= ,)0
MRV^-2?'.C<XFC5<"E("C>A(&=28JM$((@_-_-5I_4:6/ 6CF:XG0G;<X/9%N
M"1<R0LK*D FQ&U(S0BEJ'\_'I&4[E.T>P^GD#\ #QG4[(F)'P8.CN]<B[-1<
M<:77T:F9D6^%K**MS VIPK0-(XX@X=]QUB$2@!&DEZDNC#TUW;</,%DX$&./
M4Z"60&5P@J^48Y?;=\;<3EYQV.S"ML<^[>K<:)CKA?C$(<Y,L3AAJ^*!Y$5]
M>IMA6"8KPB6XW%^T3=4,6I=J ?\X&H?6GF6[\7$<EN=BLJ=\IYTW]6#!C?.)
M\GVB>I\D&Q'89LVWTRH]0:U9N:#QE6[LMTX$9" ;[9 Y.K1S8&42S17,_=Y4
M=H]_E%NCX> R,@^)&8T&DZ'X.5HI&C/?550U=),=VQ8I;V:*'U<GB76(FG @
MYSB"!J#7';]ZQD@\8^H&QOW)<$H?SL6D/SP;T^,4CZ/)A!Y?TMOI&3U>T-OS
M$3U>UL6#Z9W)?WS1'XW.GGUE:IX?=&$R[5\.+Y]]H*L"&68L#&%T3UO$8W(<
MEX[$>-2?7$[$<93[^'1,K:D_&9V+?;?-IZU+_US9!?^T050(E>'^OWG;_'IR
M&WXTV"X//[U\E!;G3[KRG6/K</#RO!=(LO[@3<D_(<R,!SGR(UT *4L+\/W<
M&%]_( 7-;THW_P502P,$%     @ :C%A6(9MW+L#%   GT8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&ULU5Q9<QNY$?XK*,5>2U4CBK>D]5$ER7;B
ME!TKEK-^2.4!G %)K.=@!C.DE%^?[L8QF(NBO)NMRL.N>6" /K^^0+W:9?EW
MM1:B8/=)G*K71^NBV/Q\=J;"M4BX&F0;D<(WRRQ/> %O\]69VN2"1_10$I^-
MA\/Y6<)E>O3F%7UVF[]YE95%+%-QFS-5)@G/'ZY%G.U>'XV.[ =?Y&I=X =G
M;UYM^$K<B>(?F]L<WIVY72*9B%3)+&6Y6+X^NAK]?#W%];3@%REVRGO-D)-%
MEGW'-Q^BUT=#)$C$(BQP!P[_;,6-B&/<",CXM]GSR!V)#_JO[>[OB7?@9<&5
MN,GB;S(JUJ^/+HY8)):\C(LOV>XOPO SP_W"+%;T?[;3:R?G1RPL59$EYF&@
M()&I_I??&SEX#UP,>QX8FP?&1+<^B*A\RPO^YE6>[5B.JV$W?$&LTM- G$Q1
M*7=%#M]*>*YX\^[?I2P>7IT5L!=^<A::YZ[U<^.>YT9C]BE+B[5B[])(1/4-
MSH (1\G84G(]WKOC6Q$.V&04L/%P/-FSW\1Q-J'])CW[W159^'V=Q9'(U0NF
M^61_RPK!_GFU4$4.]O"O+K[UKM/N7=%'?E8;'HK71^ $2N1;<?3FIS^-YL.7
M>VB>.IJG^W;?HXW]SQ%;HR'[Z4\7X]'HI>7V)DL2L'R2!/NZ%OC!AJ</M.S\
MI6)?A"IX(2)V(_)"+F4(;UBV9!_2,,LW6<ZUYY3%.LOE?X1B1;4)*S(FE2H%
M*S?X&F @&.K_F%IS$ [N%&H2%)&PD\6:<;;A.=ORN*2CGK'A8#@<L8W(]6,#
MHE0K#A<('J[U-ZW]I&(B+601 P= 098*MD5)-/:RS^ GQB 8;N<_&\FMC$0:
M*;9;BU1L88=EB6]Y&C&NE"CT,[%8\3A^8'S+9<P7L: %^ R]D$N A#"&E1%;
M/)"XKC.>1TCZ6YD#%&6Y&OBZ0";",L^!&-A6E8M?81%2! (L<DG8!9),::\-
M?P! +'"WBN!C)80V[ MG &_%HF G1%+J,[?F6\$6 JAU9'+2$WB?2!; M?7
M ;L%?!0Y+OEC#&C683X;1\.3+.BJFR>2![P8LP#%LN<8 :HFVD!S8(5E 6RF
MD4Q7 ^M;[V7*TQ ^ 3EEJYPGJJ95C(<%_ <<[S*VY*&,92%) +P RR/3$7JK
MI=L*997"_U<9OH-H \8!RXL.R:L,-HBD"G.!,@Z R!S6GL+:4PBOWP5:"3"%
M&QU???VDC0$7U5QH4^;A&J(:XZM<"#(NDO%'"1J,4W8+6[$;OI$%C]E[\(B
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M5X0M8'5@5BB2.P%\:C^Z"@D&1Y<3Y ($#;Q!(@)DIV%<HJL:OHCLB+ 7I&.
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M\]"8D5,1FNO!W(6F6FS,J=DDF$-$'5],/3BLV3E>W".O[=&3CB(V'3/5$],
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M0:NS+B9 P;'4\R%9W;WK6AEEE"@F>&>"DAZ:*$BNKR'KG+/(!=?@5EG U%G
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MQXPL-Q-/QXW'CV3:3C]@L2 7]7*Q ;"BF5_?<_'8ATC)::=?1'(7N,]SS[V
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M 4)O&EXK:4/Z*5<*ID +=] FJK:00T,HG=R(,NMM./#(&45_@]$98G '0FQ
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M_V-*FW7(<3"-.D 3NZD=-Z^2%W!_?C*CHJY\MZW#*>KYQ7WG_>,7%]X<4_0
MR7GEW0M7-=SK&R;3Y]%GY'LV.WG>:=I2"RN*OCQQGO#3+<'\&S:L/%,=(^B
M_S@17>319BKIO5N.=(XA/HA<T78SU(YP*?=P&<P+(?R&A0@"N=NK]I3TW\9M
M2?6Z/[@/[.^JE\Y:@9OD5U "#E&H^$VXV^"/@<VG9M348J^ED?[F ;-H#^5U
MC-0 IZ'7*>VG0X#5&$A$RQ V9.\^G#.RDAR&==4NZ^%&=-:C\Q=?W96NU\=$
M?^!-GL?9/*7@4)QMG#Z,])<=1*2Q-QT*+D9*#,6>QD;Q#)<"I1R8>B^=!:IO
M5&K1*#O@B)&"^>R)US.BJ#B"*+,WXE#M4)[H_H*OY?[6+5)+JP+WVC]#M9]K
MWWE^EN#XD@X^,(H]"0%?7!R1,Q^)54C9+=J=X85.;\/2- LP2G2<6="B$1U'
M70RCGTSC-@Q5F[PU-@Q@6)_+DE>KT5D#BP-$,;;UI[%XU@WW.C1-@ Q.EU!/
MX5J^8$]2W[D?^G&$4M>G6K</%GL/]"$LQRR*&K5M_F_R"DZ+<+EDE/T2@$+G
M#9YNH4Q_"S4XY.U?KL23W^#8=0A,_MAZ'(ZM8$ :*?K6]SC2#EB4'0#<(<,?
M!-^AQ7M ])1RM!_IO9YQE%+.%G,D%4N>8#/&T']@Z!:<??YKC[YS]N30;>5T
M</^,2*S]+3O!"E:&J^CN:7>1?Q/NK_OEX;\ [[A9XZ#/*KG"UMG)B[-)F,K2
M#Z<;?YN=:X>P^Z^EY!CX: '>K[1VZ0<IZ/Z]<?T?4$L#!!0    ( &HQ85AJ
MW[I),10  %Q"   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;.U<67/;
M2))^UZ^HT'3/2!$0Q5NDKPC9EGL]$=W66G9/3&SL0Q$HDK4&4.@"($K]ZS<S
MZT"! &G9W3&S#_MBDT =>>>7646]V"G]I=P*4;&'+,W+EZ?;JBJ>75Z6\59D
MO!RH0N3P9JUTQBOXJC>79:$%3VA2EEZ.A\/Y9<9E?OKJ!3V[U:]>J+I*92YN
M-2OK+./Z\;5(U>[EZ>C4/?@H-]L*'UR^>E'PC;@3U>?B5L.W2[]*(C.1EU+E
M3(OUR]/KT;/74QQ/ WZ58E<&GQERLE+J"WYYG[P\'2)!(A5QA2MP^.]>O!%I
MB@L!&;_9-4_]EC@Q_.Q6?T>\ R\K7HHW*OV'3*KMR]/%*4O$FM=I]5'M_D-8
M?F:X7JS2DOYE.S-V.CEE<5U6*K.3@8),YN9__F#E$$Q8# ],&-L)8Z+;;$14
MON45?_5"JQW3.!I6PP_$*LT&XF2.2KFK-+R5,*]Z=;?E6K#7P%?"WJ@,=%UR
M%->+RPI6QS&7L5WIM5EI?&"ET9C]K/)J6[*;/!%)>X%+(,O3-G:TO1X?7?&M
MB =L,HK8>#B>'%EOXGF=T'J38[Q>&%YO^2.85L6NM>;Y1M#G_[I>E94&._GO
M/N[-VM/^M=%WGI4%C\7+4W".4NA[<?KJKW\9S8?/CU ^]91/CZW^35HZNE(_
MG;^H2C#0WU__LAB/1L_9H>W8K1:)B$59*@U*&<T9SQ.&_L]N?JME]<C>YS%(
M$OR,W:8\+]EG, 7-JJTX,HJ=T3O\>![16-R3YX]LQTO&ZVJKM/P=2*D4VX"V
M*B;]?/"/^ M3!5)71BQ7^459\:JNE'[<?VF^\@+XCJ7A1Z//PBN01*5E7,$F
M=M2.ZZ0D]C[>?2X'[!?%>))(G,53]SKCCVPE#%$PM6XSBPP-@%?V3JQT#1&/
M1-;FD"= 'K)&DT9')#2R$F(H$XBAL54#" 6IC,'U9%X;MM2:%BRT)#UY6CZY
M76C10JM["9[*ULI0;80+D_]5\HU(N!$QH( "W98^L)9(6 PV@T$B*U+U*(0=
M#PR7$'F!8M#.M9G0IPC'K=K3#'SC%=L),/0:5)JJF,-4V.:A@#T3'$\D[60I
M6"4TQ%XS %[0+)#:6DAZ%',06)K:MUH4M8ZWY#VKQU#=$5A+S#/!^#V7*5^E
MM I;UU4-"\JRK'&A/O+)CIP!@JC104NP@M7_@'B,#1BI&=IVLMIN14HN@ZY;
MKL'46,%U)6,)E%3DZ5?/0<;\P8Q6:2+S#5.K5&ZXU:AC%;)]#':I.PRA,:(B
MP(RTT;BS)?$@=(RB@^].'&B0P!X8& \5S7A:JN^23-M+OMU)O7 AP0P/N-[-
M>BT(.;"Z4#E-C%-5DJS63-6:O;_]T')J+]O7"KF#46^=%9-WJ'OO\ =W/:-W
M-B3NMC+>HEFE$+>3?=H_N95"IR[__4Y="$V8$?46A-.NGP_8A_4:# .=O-_?
M U\'Y]\(\S\L)D&9D)T2S-X8 3%YHYAW6^4DP3#'P>H43D+31;N S01*Q!&"
MLD1?+\E(4V]#F XWH#>=&Q= ;]MH86##2E0[(?*V7^1&3RBU0EJ"89T$PH@L
M80M8!\=X>PC\RF=;^)+)JA+"!?2N09U#[,/M;,#$D&8"&/H=#Z/4H:#8!$3P
M0-7QP%[7L\9FY)77V0K> %4V*D&VWD@,J2A?0AC)5Y>B5#^*%LM)-%G.V+Y5
M@^VF-5HU"CZ'-)?B(PA+&&",Y-=2EQ5+0*E "<2K+43E%$R#:_8HN,;0"U3E
MZ+<8[XPCAR,8?,2W@#H%<621YS@*$RR.J.%3Z@P0"8.'T9,7G P-=_M\["38
M&P0J\1L^ML::0I(WPCV3YVS*?G2FT)6Z"4:@P@PD8OP+)6X-#>HQ\'%#$*?1
M 5EEY9:56282\',!RD.7%S2AS18N=R:!'  A6T<ASQ2(!>HADRH;B^[:++"O
M;(ZHT'] I\($09,.^B*U,X0S$S[ T-$0'C$#EI6$T&5]^!Q-NKT #C.S["X%
M+H3U:L4=H75I!YM0&WA]5VY$N4\*"<C*/0W(Q*^W!+\(!Y];KRP/P(J2;!+V
M8EM^CUNM,*"X'$I@I. 2S0U28II29I:0_T55 >K QS$OM\8&N]B ]&31@3&R
M'D>WJ=:DBUYG;R&0JJ7"(WB$_TEPI$F_(;0P$J PC*[0,/HD0P%R"O[87K2#
M44PJ/&J5&&LMVD;CB@PA5BA_1.24CU0%\:#C[^VEPC4P;Q54?74<W932%&R7
M\V$T&6*HO;&)EMT1O[<.K>W!'XJ:%N^@Q7T 9\95D=RGXQ^,F55I1(M*%ON@
M:'^1H]21G]W<W=Z>__%<A,N09":3132"I&B6S/B#S.KL:0&W4<K^NF@$4,JJ
M#(PY)GKZ$QA &#+\@XG,P0\3;X\DBU&3++X]1<#[[\T/49,@&CK;>0&IZ,L+
M=V'\L($ZE8"!7$'BY8D%VZYD J*#1'%[L(AS"0G*%?@Z@EN H"CN:JM5O=FB
MPVL%RH#"MX[MLG6!TT8S+S$)R8)K! L-D/95C!7%OJ&V#0'2&H#9,D;N@6D3
M50I$OJ@+8UKF(5:AE'7V],*:*G+/F."=U_NB(9JM.="=<?U%5.R>I_732&V9
M'_":\@9'X0L%$4"CEH%ZJ1);C@@ PT@(J$%HJKR<"@A8^]@.\59B!-Y?ADF;
M2=TLM8. -?L1*<B4]J2;Z <$K\AX[E5%:^"N./0HF\2?$37)K54;V0X*U4/R
MX2+#UN4^D64 &D%,=Z*HC$N@1Z"5_\Q!1<SZ!_DJ>L" O:UI%23*(4$@OA.(
M(S:=7$6CR<SG"F&KW:[24V&0P62XC(:CL9NA!2(9?-%3+P,AHHRU+%Q7R/9)
M?K*Y[%-0L8"E^1SW?:5B4/!=K,AN]P8TW;3WAS8PGH 6I/*4ZG8KC4JU&D"Z
M*>BY09#M_.T]K1TA7>5NG<3G^J<ZB4FSB/D,-_<"58^N4$E,[V4/ .XOZ:*F
M_4956V4K3^]U1B(DBEQA51<+' NP$"T*;%BKC$8Z!$JT03D(9IUB-T88\@R[
M(,\XAJ@K+82ZMX@)'9-V$N)O2#ROMEB$EWPE4\#*D<>K9@HU0H^80*.^0YI#
M"VJ"-<HP*/G_7ZW_-K7>'G=>4DWU6%CLXI2D\J BAVFR]+U9:8(B[PD+.,1V
M9>P34 J@>X&,4F(,6D<5UQM1E5XOA#=4;NH0$\K#'?RK%N5F%SH$W$I@V14,
M8'EJD]/A@D9)U'Z_/HFX%<D\2.1:.$OTU3SX1IKB^NWD81,!7U="[]D<P]!I
M8%<L(&VN0<@N8+>:: 'MQ]M%0;]">%$;T1)&\%FS7W*V_ 5E>KG]N5Y&I(!:
M4#6Y^EKB.-Z[,)ET0(DE:+NEY"FFEV?%X4P&=R46390A9P.DID5X=M(O6=J&
MN;H%:G58R3<>4?_4&\6PY#N+-E[!LBV9[+;@\FA((K&T?W_0,53YAJ2)+J[]
MB0[">X)')V18PNI<5I;#@Z$#1:6M$^T'D@\0C@Z8)9)EV]$]AST8+EN^2AM9
M/:HC-8PMM[&]:I9JU6@MJ?OD J:M\MJ8!L;ALEUY= --A$?]0FMOG"@GWQ_W
MM8'KC5.(^VK5);&\$;4;$IR]N-8$MG6"/E;L!(NYMW"MA^8(>V"KY \&\=T\
M %7PBMUJ!:QG[$/._EY#+$+H:0!HV+1&$D6.1PP<@'8*E0L>6A(FIBSN5L,H
M!:"SJ;Z<HU*/!TRUIRQKQPFRRESL_$Q3R+L-/N"6MJ1O/VR.YY 3R$3CJ>UI
M#+ U@+"W<JB@/3-BBTE#F'-ANAUB08H='ODHXIOYX#YT2HM4V[,^;MI@'1&@
MWIPQT"D!>.7&IO*KV54T6\X"P_A:Z,1#%CJFS\D<J5'R(#-3?R^73>EGRJ0#
M5D_VDSZZBF2?YH$QBT"84:O.7RLLMOUL5$#KF'E?SJ'HG,.%N@Y%-)K-H\5\
M<8#R" >V=.H/9[H;[ZO-"_3P,9NQL&[KCQKL <6.BWUJ]@C YM$/;#2 [3Q0
M=9@8WX5)M+577[;\Y?KN[?5_LI]2M0+-_FQR;B>3]E [8#=8B#9/@K*N\6'7
MU3 IR,D_L!3>\6_3Q,+^\Z--5CTG+_C U-)MLS&# "6!['5IXDHP&$@S<NH1
MJR2?*%)!N?);F*OS;V:/&',!U[2WDR!KXJ6XI$Y1K=@.;?($14[;)_A7"\5>
MH,!*0-O4SA'U2>-1!J#2DM1V#!"J@1NMQFEF[G UMR.:#H.%#"5L@U+!,+PG
M0^]S^_+::QQ*TWSO\M75[Y;NN[@NK*^E7,'D7-@N@JF_A1W)[[3@-NO#2BII
M$+8%1]BD(Z>L=:%*81>E!BW*":0'40_RKJ#E@!583DMX[ PM#!:H"QP&E5)<
M&_A2ET[CKU,>?[FXBR'_H'(,BQ@+"%BK1*2']W;QK<YYIJ!.P*K%O6N4Y ])
MC$2:JJ4YO6J)@**(.WL,ZJ'&-("W?74.V&N$3Q>?U,4'N[R#&&%/B2YV& 6:
M\55W_)DY)$0P9E&+?7-NC9_.N0J.Z-54QY 0[Z6J2["DA-I;*PS-YL##RAY$
M44FJ5-T%JX.GD6C5X^%P83%;O2K!7T#P.#<SSH\O\+(#MW%F/!P-,5&.J/@8
MS2)[#6X\'K!WV(6#:@+T1@5?@[+Z>"3F&N@9].K]:<7!<Z&^]:)&9M0W-\BF
M:<:&!0X4DVOP/A'7E _M'0QW!0.!!QA9<VNB?SAQ_BNFLEN@6"8FJK2 3>2:
M]<%YG[FA <9!^,OV[,'@L&N.VS9T2NU*:X+"!K7+'&8TB0@C(/:5,,Z!87?J
MQQ!P'(!(9Z$TR_->8."<W2W;:*97M11VVTG_2.7\MR=TIDJJ4V$MM&>\3FU)
MP*@['CYG[["V_]75]F_,<J8@H"&CYX,6J:6K0[*ZK.CJ@3]PQNQ&:00"[049
M,D;>0<N[,5CHQ![;-8F-[EDCU@J*MX-"2I[6*&=GE'O Z<'>\&[0@T7D.[IU
MC3X*UL,W'9U10-@?$Q;L8##B_-G)+S[__<.-OK:C.P^N':8_^1 T)E#"P^5S
M]G>>TUU/1_EL/$=0.!S,E^QJ@)_')Z[_OKB:L_%@.#07;\?/W?\G[]RMG4M3
M;L#8,P:9E9VSZ6 V[HR_\8K;>],9^<9=50S,=[]:/&,C(/8<Z!_,KSHK_-0Y
M"-^?/YD:$+P_LT]<756/HN%LB&(:+$9L,9CBQ['CD,Y6C\X=S<W<.<R=P$='
M1-=R&3#Q QO"#AFD/VI\Y0D!^)%_DM2L9:#E00MU*8#NQ17FS#S%X%>6"F_.
M6:<RR1FR:6;1>Q"DP ,! " 6M!6I U>MR/F5L$,6;TH.$;3390A+(3+IRI@[
MD#QUM$_V:?_.2VET5<0UKYST[$&PZ\T$C5^_M&F;&0#R%3;;5::3IXFVMK-3
M88^">E0N</O;2[ZQ5KJ2UG0!&A3\K5H9L.LG8#O,RW5IEO$TM"PBV6O0_FGD
MH?E_$=B:L3U"V551+Q'VZAW:<9T53=/]7F$/Q+0$J>4JRR\7:VR(0W86")>8
MIK3ER4\D-B1S>P\4[XY^L6$Z8C4N];LC)!,<B@S38"1\ZA*H[;91:*=;>$V2
MM'U=_VN! 0M_[M$RX1L+FN\.&6*#JA&,--[3/6 &XC*'>51A+T&;JJ.5LB#%
M_!.M[Z83/4XH>F#D.#$.!*24]KS#TH%=A1G&LOGLY"/@0CIT-G8,?JH*DM-D
M,F+3\=7)'4_QG,U #;J8N!$Y$)::^Z;V BH2"BAN&BT72S:+IO/ER2=J(<%.
MT>1J0O\OYR.RFSIOG9.X2N.@'SOQH9F0I;*\^2F%^5%'JY$%>PV631 ^<&F)
MK@Z5C3D9VV]*(6KAF8V#VN6A@F0P<[5BV!TM[3?KJ!ZV/!&2$ @Q=S^/P!M?
MG_ 5$!5U#<-AF?]#2.:B@V'&T6PZ C5!-AX"B,&4/(JFBZ7' M,9IOS%Y&E
M9C*? ;I8#)9=<-$ &0 AL/,YY.>KZ7>BF-G"HIAIE["OHQC<_@_ F'$T))E-
M!I,YFX-]_\"6\^F3<<QXN8 9T\%P2L[Q [N:+HX!_.[9WE>/Y63[A,D=N^#U
MO/Z")>\[F/[42AQ!9[)-3;<K\^3^R$4KAT;M0\F@[F@2U#-3[\R?4ZBG:/$)
M&T?/;%GG(@@^\PUV@P7L[21_>+_? J:[!^T0%!Y/-IR4,BML-9H)<'>PZ!;A
MF4PN"B7W?C_@&BTD0=?P$7G2=(H;AT?RH5+ML/JKS\R680>3ZM+>H+?NOX5$
M ,D2>Q5A8D5MN7,1C.M<D[72QYQZBBZ\MB5I2727I\L61$L43,23-CHT+6ML
M'^#O(OR%1T.,.1DB$PQ,M6'R(Z*,=X@RWCN4\1%%U</H$5#R%0Z<SMNGWPH;
MIT P&#ID"*QOK2-\'MR!&VC"+(\@NAA?2WNG&^U IER[:?B\Z<2%+7SK3QUU
MOK6PB?U3XO%:FU-L U,[%OM502?)_3;'G)\;#@K[DU?8KX%B9R4(AW[_N8#
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M C]==03,_4_SJWGRCXN+#P_F!!E/Q7##.D8!@Y&RND)^5G1[AL(/ WSFC[Z
MU<,1JX IX1M)5\.GSRYQ'@F(DK0%1K;#F5J +.V2=+4"3D-0 A1U@W"F6UP=
MX12>=QV_6A;ILBB+KI"A\J+-RKKM<5YX$J!#A.#4QU[B:7( !E_ OT>7BN\=
M@Z=QUZ[J'3WCO@"3;V'@O&]P*\([M#&N*>I\'O$'V(5M"ZQ\^3NMN88_LXW!
M$&QEV>?NN9^F<5D-KR.^SFE\>59VBI:0%DURG98]+6I=U_E-498$8 V_-S!H
MEU;K8EDZ1<RN;]H^Y3WJ F5^ATNO>D!& 9^+AK81-K3< X&?#R8"%IM]3FK>
MRG.$O-ZZI$N_)#V0:=.!9$.DSV1-B)&4WI;C48)@(X(&DD)YX!JD=7R?@1S.
M=Y,V#8)L-O0\*1U(EF@.@R,B_ZRA384U+>L&N 4^TQ"NSPE%GFJ0<\WM.26I
MA40*A]IL$<"^*6#Q#>PH8QF@ KZWHPF!%D&N 41=XZH<_L<'KE.@A+Z5[3@X
M 9V=TY4%;#UL1(.;G[9UE>+&]<#^&WHR*YJLWP*U NYB[)IQTQ:W=M5W<#@2
M)*6.UQ:M!,\R#;DD!H;[  <6A_J]S]=R%):@DO"\@/\]_D@[<MO9%+K])Z%D
MY,3PT0?@JKK#=>8%<JT=,CS8XU53;P5;;=TW&>[,1=8A90J"8=_Z$ED <(^&
MG^\V=3O!;>;)NP*85([<"W^Z3'<%DL5')U,D%[0H$)!NNX1!54C.DAN7H**&
M) WKR=)VPZ2#?R#C XPX80_?)HNG\T>@<92E"@%XFYCZM\GCT_FI_PGX*: 6
M]Y%W;[UNW!HYDS!T)"YB.TAQ &'RP37(U$$92WYQL'/OZK1*WJ09HGV?W&^=
M2_ZGAO>_3TC"G)W#4I9= BS^-X$ QNWIE+6&)0$'Q0UI"SR+^,].Q=<,R2@5
MC,_\.E9(BSF!!$HN2PTBMUR@!\4(=[/;-'6_WA#QM( AYM';+0Q.O&,V^*6Z
M!JY!7 K$D; #\V#1(LO*Z&$@&@!YE^[Q;/ 98Y(!F+J;6H#8>]*3'7Z>W"\>
M ,VDZZH&,LF2#JFE6L/:-@7P8>&^;5+VL".'SS%28' X*;#>]^D^.?-$<OGS
MKV]?G9S]$ 9%L.X7,..NJ:\+VN5E4>\V*6C%F>L[8B 9'7P\-B12<X"XK'?"
M>7,_,RI"1>;TL&6HW\/7M&"7;:JZK-?$P-X>*@M&1;M"<DN;O$T^[6B[%J=G
MCT_.GB3W+ZXNDU_J'2QV<?KDY/'I@UFLS@#6WWA9>15DY4GRCQI'OJR1ZU?/
MDU=>*N,[GZPL$&X"9/L:/G=!$[I8,A$#4B^)'R.[0-J+QDYF$:L$EB5J1XXO
M.I8ML.:-(\Z!_R#9H+C%8]8AY'G=PYE@. KB;W[F+)IY33-G,K-+@3R&HMTR
M7U@@?+>57W@?!"*52D/U[VY3SZQ*!82$B@,*-F2!R']6($:5OIG%"AY8A8%1
M\D)D OU(FT;<ESEHDQ; -8^AZ,_#3:2'/*YRR=ZE(/96G4@P(CR5?.T1'>R&
M-Z_M':A0[P,*8/BV %DHZQL"1PPN8(H6CAHM2T*/,1"<^F28W>-JYA$*KY:1
MU,B1I=;+LE@+WT.I"2M!1:0+BQ6!%'1-R[T +VV"MG%R=GKRWZ)8TZ(0?TJ^
M10?LEM0/B_$M>AQP\PT,\^1G8 /#AX@_&T!YK'U":EK>HTA#=8-4/2*IY9[>
M,>. ZI02=-L=R'? %;$3BS @IU2,@[\BHA)FJ/42.05H>C! T^*7*>QYO@TT
MR\"*HET2E7L@YL<%N&4;-ZG8,KPH;U&5I%MTH-81_&%MH$/4L%R<BYY$[ ==
MDDX5'G[2-F$1*5#,EJPM7@>*[S=NV?0HD,X>$TB/5?&^!6'XR#L9[3<:#:3Y
M5; >\'>8>MNJ*JMG74R#^-V9G2X%=8,9)\I$ O4 )SC$ 3:3]T55;/MM\C]
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M%3O:BXITK)ZC#I0KU2IK11L$63?IHDB4F,S1'L!$CHT&N5?Q3R]#!3OP(:"
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MEU7,EX7&5*=.Z?B O9. E;R&\2=DTVPX='(#IBF^&^(LQYS=)#]D;L5CR/X
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M<G]H_/J8'#U(";>[&AVXK!91;JS*/44*>H3%G!X$"0>-AA1='J9@6X<"GC&
M)54KY-!@K10(6DR_P]^Y49%'T6@FS2QD4?"YN@&FM2$C;D8A;/5:VAX_H=B#
M8O:'1:^SP\CU)*V'9FEGTXW-WE987E0W^U'JO>.[2?C+<Z+(GE0/D/=_VHP;
MLBNV4>@\"E:.M4?AL _1A+ .B>-EB3<TU*H0]C$W4&+'$']4*# GY<?<"TSZ
M6LC(8SQIP)(B+L3A 6!PWR9G\\>>,2)I+L%LO&LV<<PX#V/M'.9)1*:RIY.5
MW,*OD[H56>[\E4 ,87@5"L?OO(IN#&Z$:A&U4,)O?M!OAD)#1)A/X1_4DIBU
MDVV^!'T1V$U Q.19"4GT9],I\!\:G%-*ZEYK9'7TX/R9@9+H:Q^Y'3!VHE92
M6]#%N94(H@T!8]J!"0ACZ@J@OX]#B.@3P>28$X0MV;IN4^<FT.8YH(^T73M?
M0\E'8&:RU$*B&ZI7U*L)_2U,(_/DW9'P<A3PNRMLI 5BQ<[J&*@A*,@9/9*J
M1%4Y6EGN2+U[GU)Y4ZH9D%@-4C0,F6$Q/I(:_*?BQAE&RSEM,BQ/ZH\XLOH;
MA@RUH1IE#774V4C#I3=8?@>V!B8NYMZ@]NSIV'[+6-O:IXF-LR0^@!JC6)/)
MV; 11?'+52E]AZKXL+6#TQ9G.+%XQ.6].RBVX-2<C2LYFX]<E.20]OV+\.2:
M1H045)4&1F@91S(2$S<S%?YQJSI2 @ZJ/<B33G]06C&ND@Y.MTEY"5A*VI(:
MH-HJ-0X*2,34+]]3"?/X>'<XP%>KH<H]=! 80X*#S"[T&G"0B!.Q)?5QR1F>
MJ6>K( FYOE*[0/U%& ?GP*)#M)T8D^J01CZ-)&UWATEE-8;_ K.X,3^N.8+=
M@^Y,6E9)!3E5;>;1Y,+D7U)X<Q8J;\ZFJV;>AAZ:%T2_HYS]*\=(WAYVYO2:
MD;%M#QMX<BX-1VVHS _K)30< $2S+"IU2+LXAGV0^T"I$9JY;ONR<@ANR>6?
MOH46MC^HMZ",!E^RY-3D#MWC&M%]4Z [44Y<6$ [(K%FI$JS?\0S,9N%-#@N
M(A6H@>[8'(JD.PJ-HID0:6>G0F>SH-H'F^F[8 ^8=+]"!V<U5J88XLU7]RJ3
MG&GB 4LIUNEI<X1E*(I;KQE+(S1@?HYQD0B'DQH9JN%5(3H?(3>6#FBEC?-;
M]$U:GBO%"!B!'F>_J:F_Q0ZDH87K$CN9"S(\@Y!$YNB\%UMO$=ASGW^U>CEY
M\D,VX=ET#N _I*'NZ(&_VZN)_Z-Q.VZJ*!%@[WA6KY)4P!#Y^ 8Y/BA"!43^
MY(\W7VV]O33*$/@L'4I(WS<8ZT2.B6#?Z([;!)<4C]YB"OZJX918^&I23E-B
MLR47;]D/YF(X#]L1^S0L-@2]/R+J!T0MC. ?X&_B9YB# BT9L";;*\6?,3E8
M0H"^/?%,4[[;5DT*CF7P@YIM+NT< BR1+\-T\@. "4W84(Q"&3 \'D[?#RWN
M=<R9>%I+VU>4T<Q-60ZE,I4,$#51!ZXH]=L6IV%]Y!0D8U1!L6XNW!W  ^.(
M(YV&B%TC836S&,.^+-1N8%!RO DH/8:-5\<.RK$)0Q24ED?G2GK%#O625OMR
M^72^</08V3*Q/P9>@2NP)UXT/9(FUS^,-[(QBHN5: .@;HEHAI2_L^F</[*?
MQM61N[P8BU:I"TA)%W;:=AH#D8@*,HQL+B?U1:-XG0;84)A1TGXG=A0K; 4U
MX$MS.8T'J6^2-%:P;+FL2_@AK^FI_\:"2EM%JE-E]:[ AA,TRR A2ZP5.EDU
M.@"I0P)F#GF/7,XU!T:!(F4XYX[F^!E;XG[_>#%+!%.AHO)#FGV67-S10<5_
M59(R;@\D^E;QD"%2;M(F']9.,H8SX&6MK[T(E83_"7RSI:J5D5DG)T4[8./?
M+BK/&52D\L0</BF4]1'25#!)IW=-43"/&,+&@!LI6O7J!.>\__'G3P]\0W==
MQY6/U<B\7[N<8#D#]R<NAN5\0F\:XT&%2+/;:'MM(T,57'$A)M+0&"Q<N$L>
M9<K:YG, +U9U=2)[%N*V]T-2!'6[!B4KY<"TD^R/OA-JGW&<V?L8NO2+X^H[
MWS!A,#P73V /BC+E:/.*3VG)"A6A.O+"&R$@I4RADHH+964]G6G_K95K6UL$
M1(:TIN#-]5B0,BH4*\GE!2? ^.Y*M>F),I.,Q8C&)=*JU AZ;T<M.%?>O6(N
M0KC-"2'.%$OB/CE;UDK+EF0<^0K1:ILKTK<S90*ABDJ]\:3^< %5DC4%::RQ
M_$<8B;).SSG]0AE-\ EXJ\ ZIH;;26.<&4H]/3]:JG2H1PQ'F^MP;SPE#_9"
M5R":4-Q\F3J1M,I3L/_#LR?_CLCS)OZ8"A2S&$9_C!.6PE^%E\0WC/CA]&X@
MB)(0(XB\*BOE1)K 6DS4@]T!R0DP/E71O=(_3)#0 D3VTARNS]=1>LS)H8LT
M_F/#A_QB?Q7+8(WA4@EQ>?X<4[]=Q(&=$5<VBAKKF17UW&3V$^6ICN[" "SO
MS;7K?GLHLVX9)XXN8":<,B:B-02+=+NLZ)2C>$Y0</'!D;M#^&($7^L_BY=G
MT_=" RTQG4:0,_!N2 U [+Z>NL>$4FMH[)/E7J11B1FA,5C^2+GJNFCJ2AH;
MQ-X@0PL(5'V,'J(DR9:3GT22NX!_<>L(RZ54%/2KS)/+8UE-(L(U^[+6:U)J
M<F-5Y Y7YN0LM!?^7=\.0U,[AIE&[#8)*JL:<RJU#QK^^:PVGR?/WO+*W4@J
MJ>&7 69J\@0&(K61&^=)VD^*QCJR-B(VA(TZKH6PRJ#'E()C!K'02)^T<*(D
MO4SJS#1KN8RXRWZFUI(.0^H8=I6+&@:KY$4COH3EBO^:0IW.WO*B9?R:U:;K
M=U^PDTWK)-_,SS9LXSC&8*+C\]V(D2*(0MG%S3'W(>0,'(2[/3 /68-Y@NU&
MN"'B:#MXY<"JEP1],/"OU?#@#)L(T)&-G9)\!X]G?2/QJ%^&W(Q^.XBK&&U\
MC9T/J16A)3ZK25$%!UO&JK^#( K'/ RFC41B.'PR*$59;_<3TJ'07B ID83Z
M6. ,CY8$<^V"N>K+7_JQ1,6?H_54LJYN44ENA,DI;>X'GS4G"NNDW1W*&\ZF
M"P_>H!+PJXJ><#?*VY!N-FJ4_^51S;5KB'6CC(1B^9::)@(-@O&V9ZQ3!7@A
MCO/PCMG].,$G]%4IJEU/[G1Q".*/RCS#A5Z4J5[\@<KA?6&ARHIG>CM8^()K
MFMKP#%]31(;1/QV9&=YGR4DB/"+9GM%8K(R*#M /<YP%9]SW+_PTH=1X1Q&'
M#V3Q/J+&46R2K^V(/NB1/D_>'$$RAWX[MX;MT(I0T3_&!I)-\1U>@ $[BO*C
MA!< J)FC;:UCMRPZ_+$7:WPY86H5?)HM*,-2;+X5STK[_)MW!,M;^O&;L^13
MY9L%_=%3?TAR:A,[T"[YM)WB&\I1+\B.[LK\F\77#MD66U"[FB,#GG]S=+@8
MGL.1J&0[T$M1^6FC"\T8I'-X_!O&BF_^#]PUGM&_5R\Q5X=T13UD/C+K!?+\
MFT> "_.HDN?Q-V)_O[G)4(7PZ($Q-2M'<]=G8WER,U8!"W/76W#=Q7E2VMZ&
M9!@)//W>CRM7?)FZRL&!#?W,[>'QI?<8;"+BI5PA3@]1Q;"(>EH\]E+"L&#B
MKQA&P*STD.=MDF?'W-/1<9\2-HM0MK*XM9Q$[[:\M,U(QB3,GQR*:T(CR];<
MJ!FW0"E:35H@RX_*'^.<$K+Z)!D/58'0ATS2M<Q,:DIJ;P))K7NK[:&%D 9I
M=4>]/U,(#UGNB^DL]]_DMLEW>HY&,?V58XR@>.16R[\9N]]=<@M$//F3H.S)
M@/ON -^#C)])?(<T^,5T$OL5U:'Q13J7I@YM%.UW& J)Y?2'\\,!DRNZM_1G
M,3&L,DNM!GUKI6  <BC>))Z&7Z)+4.<RMC=?L%F;M"\DZ]J;.<+[L?]V&6V9
MJ#E1_,W>F:BZF18CT/#,XNE/_B'>5Z(?7P)H(8Y[ HX-;7(H7I9I]OGD*MO4
M5/5( YS@0O"!;9UC-2'[[*-;8-"W5:_L19P'M[7Z?IW&YN'Q9^''ZQJYN%23
M<5R25D*H-,]I[_ID7[C2=(O'BIP3;" >VLZ+*R=<SB.=O36C _9[Y<P%/*PS
MB(T:%6]+([?H!;EN+73RHAS!<$4K9LR7="DG1@P1U5$I8,#1N#_"U'1NTFL*
M;:LF$7P$VI/V6!4A=\R9:Y_%8X0=%XI'1L)1JB-MY(8:B=TU>9/H!NL6_1'4
M*Y0_A,-W<@1&8H%RVF8)]E,W32[CIH=;S'+<4?]U!,;%AWM=4_LEW(LH\F&?
ML0,N0]V;YS&76!C==<YCXF6-]BG6SE F.EC,OCT).=1]FRVN*MO=9;VV7->[
M(^!$]W2S9^Z+EOW1L"M@\R'%1,^XGQ*O7UTOY');';O^4F]-)4)N0S_/5 Y%
MW&I2U$T[%U! 0PV*3<T2\U L1@5#\N/5I_;!!),VV,%')SBAZ6^!3Q))1Y2,
M_@5SW"0/YS@+#K/\K5SCR$H'%'Y 1]H69(1$OLH/=?Q,AFYP"Z\Z'Y/B$QW?
MHL911XK1)U6,4+FUF*ZG>LM^@U\PQ#JJ5MSY]628-2'6RHIK3.4>=+5.!Y?Q
M7ETFSQZ?SA(+3C*36 R?*'\;>C38(.(2._>#&<)IFEA\[RBFRG5_=$\V7WAB
M&\^.W("@<6BY_KP^>LWW&FPJ#>C4UT6KA>ZNXOM$<8PRO;&=#LTE\>8=SHV7
MK,CH7/KFQW6P;@^,<'+-T$40\!C^3\&BT$-^>+^\.Z@]UH@ PM6X-3G$S;50
MOX.UV.9%N''$YW7Z,5@?IEX+X:+XE=D,,=9Q^<SYS>TOB V\_(\*F;!8U\E5
MSJLA1+/#,N295C"8FS0PK"7W;:9?3D;&IL8^L_A.BOI("IA%W3%2D#PX]<S.
MDPOC& P%>.($)TN$L@1ORXQ+1V:7BZCX L]08/"+S>(Z,KFG*^LJBYLWJ0R3
M_H;JW\ODB]B;S>0Y$X?HX91<3J[!!HQ[T O^DFYIN8H$&I0_;#T0'?S#*BGI
MI'KL &MC2$K7(.KR&?\5%;5W5&1O@ZFIOU-7+BU#;/>@GE%M] VO8VR;6B"@
M5(L^=)J0<I7Z.U)1K;&PM'1+L2J&1TA ;DYC#$A)YV$[W=%K7 J)CU 'R( 3
M6BI?2!+5)#PY_7>>O]C4->D\W'M "8S]KZ@XDI#'>QWDB/FXZ3CRCO;!]68(
M6Y>5=(54+U?-D:J^,NLEKNP99<M><DD+(C^]YZXBZZV4#@ZN2/+<33);>IR4
MQJ&V=#%='XK7Z;W#W$QLB7_)^A6I#Z.B>7*L\38"1R? ZWJ+C(+3I?ZN"MZ&
MKPJR_3=!OR>;$JG!OR-*OQH0)RG?GY!4/:6#DN\LC-A&9;LFD=TKTD!#V-<D
M]K*944CQC-J&O.+KT&Y9AM;V_0L6$35>L.M1W[,NIECQ76T%7@D5;+^N(:_H
M7A;#QA^8=J:R6U^S=[E)&8ST$S4) 3XQT>)HIEZLJ4=8_]=65*V]C<^_8>Y)
MCCTG(5$?Q"KG^;HOTJO !XE\6)UW,;]UKY8.KSYVXK%FQ4W8+M[_!@@Z\<C1
M!$!MIB=I,+>T;5N$2M;%= $JES0?KW+ZBM='KH'Z-GDR/_7%O112:!S>VTBZ
MD/2G(&. +G94RAITJ#YP9<0WW1\FM0PS6<(]#/3()2(0M"3@@+\";L$"DWI;
M),&WL^3=NTMS%^</_BI.B2@_N+TUAA0[Q\L?63GI2'&I^7<_CX9)O&<V\@U/
M<N=0[K:X[9*HC(LY+C ?VHUWB!\ECCN.F\JX1@UJ?>=Y4(_^JP=;='%Z]I31
M]N;BZJ5<X086U"?8ACG]>G+V:#8>)3^1%CCO*-7^>?(^SG*(?J7[YT=#[=CV
M/OFEWH&\>+1X^D#N+40(O)/3ID]H>:2F5TC^*C<\X1FE1]2J/@Q'R^@^:P.9
M @A=Y^^85DZK)VH)RCRK]O^55CVVL/"W5]N#%\IYR&^APW-/2'\[()T2:D55
MZ@TSPYQX;.A"59]1@18^.+PU/"AB<W.C *M4 9RWF*%QS0<F7 ,\OM>+1R>G
MSV;)P4USSY.WMLX:& ?_1(=*GWYETD?,EBZ^/QW=4N*N?)TIRJ9.^@5+A]#H
M8E4S<+CDD%[B%E@>%+GMC@4/J;N >S !7=SOCP=)1][\+G23'1**5!*2BO;U
MU/)8,K+!<M:#B9#LD#"Z;GC?%6H5',4-_4Q9Q%N(R,+U!0)CI,4E0^,4 W3A
M&>EQNF":^&'@2;G/6_OL\>F#0]((3T8D86A BO;-95YX!63%O6*-@FTW?JD7
MWU.TG/45BIE*DH>8EFIOP*OI>HVM9)5'6 (0GD[IJ<A**BR,"8E0D4>(PNPP
MNW50_&MIX\G_-=H8DVX/2?"]2KOTQ8];!_;>I2M+ND2V B&$(5__+4I<3.UZ
M?K&X]Q#>#(^_^'$'NN][,!>+"I,(5_#JZ?P9Z#J4IJT?NGJ'0V*?E*[>TI]8
MU^0:? !^7]6@(,@'G  OIB7P7OPO4$L#!!0    ( &HQ85@NJ S5.@0   L,
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*U6VV[;.!!]]U<,U*)(
M #76Q;>DMH'8V6 +I-@@29N'Q3[0TM@B2HE>DHJ3O]^A;G8:6W6+?;&'(N?P
MS,P98L8;J;[K!-' <RHR/7$28]87W:Z.$DR9/I-KS&AG*57*#"W5JJO7"EE<
M.*6B&WC>H)LRGCG3<?'M5DW',C>"9WBK0.=IRM3+#(7<3!S?J3_<\55B[(?N
M=+QF*[Q'\W5]JVC5;5!BGF*FN<Q X7+B7/H7LX$]7QSXQG&C=VRPD2RD_&X7
MG^.)XUE"*# R%H'1WQ/.40@+1#3^K3"=YDKKN&O7Z-=%[!3+@FF<2_'(8Y-,
MG)$#,2Y9+LR=W/R)53Q]BQ=)H8M?V%1G/0>B7!N95L[$(.59^<^>JSP<XQ!4
M#D'!N[RH8'G%#)N.E=R LJ<)S1I%J(4WD>.9+<J]4;3+R<],KQE7\(V)'.'D
M@2T$ZM-QUQ"PW>Y&%<BL! D.@/@!?)&9233\D<48OP;H$J.&5E#3F@6MB%<8
MG4'HNQ!X0=B"%S9AA@5>^/,PK[B.A-2Y0@U_7RZT4:2,?_8%74+V]D/:;KG0
M:Q;AQ*%VT*B>T)E^>.</O$\MA'L-X5X;^O2^;!*02]CA3JN_<J,-RV*>K6 F
M%<&2I??1;[U@/_V'!,%8%<#"MBL4.YG18&@C8DJ]V&OI=EA:4D^6E+:LY ZK
M1</*A4W"HP28(F_!M.9+CC$P#3?XA ("U]KD;N%C9@B+$T9$5@PG/*/O,M<$
MJT\O.I?V9(>$@>D"52,.^/%+T)G71,ND[>3OX$YGFTIX#V'?#8:#TNA[U@CZ
MKM</K3%PAZ,^M%2XWU2XWUYA>E_C7!1%O<.U5#;HZ]=IG5-7$2<J@34UCU&Q
M\C&C$CQ2,(QV;CA;<,$-Q[TR:&7Q&S)0-=<?)!!MN49ON&XJKF++]6?B"*$0
M .[< PDG4!4E+[\BG"O4D>+K@LM1\LF5LE'8,*U/6VPD"-\=]8=D^)X;]OS.
M_-#1#^]&@1]\ G_D#GK]SH,T3!P%'(S<\]&@\_@VA;19H[Z'@=^FRD&CRL'1
MJIPGC*C9U/XO0FR]^+ 0EU*(HC,K2;Y^D[84?U5_!*R.TD\MQSLB0CX$%1_.
MQYY<=&9,L"Q"^/A&;+Y]8T)W>!YL2]FYC&-NL?16,J27G6)L&\*%C.:V^M@)
MC'IPVOF<&:0<&<!G&MTT0NAZHZ"!OY&:6B>C71M!SG62VC"HWKO)"=SSL-?X
MW+*7M,CYB97Y* C@M-D['%U029>D>0Q]GQ[=WC[VY[W!7B:^ZPW[.TSNL'Y'
M(E9W[@-5@R0-L[HRI!L)K$HQ=>":\?BCE0];<]N1VV3Z;A@2?$N X6Z;UH[[
MFK"[,Z"EJ%;%&*I)IWEFREFM^=I,NI?E@+<]7H[)7YA:<=*&P"6Y>F=#>M]5
M.7J6"R/7Q;BWD(:&Q\),:%I'90_0_E)*4R_L!<W\/_T/4$L#!!0    ( &HQ
M85@*6!&9@@,   H(   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)55
MVV[;.!!]UU<0:E$D@!!)U-6N;2"W8A=H 2/NMB@6^T!+8XN()*HD%:=_OT/*
M4>R%ZVV!..)EYLR9"V=F.R$?506@R7-3MVKN5EIW4]]7104-4U>B@Q9O-D(V
M3.-6;GW526"E56IJGP9!ZC>,M^YB9L^6<C$3O:YY"TM)5-\T3/ZX@5KLYF[H
MOAP\\&VES8&_F'5L"RO0?W5+B3M_1"EY ZWBHB42-G/W.IS>)$;>"GSAL%,'
M:V(\60OQ:#9_EG,W,(2@AD(;!(:?)[B%NC9 2./['M,=31K%P_4+^@?K._JR
M9@IN1?V5E[J:N[E+2MBPOM8/8O<'[/VQ! M1*_N?[ ;9-'-)T2LMFKTR,FAX
M.WS9\SX.!PIY\!,%NE>@EO=@R+*\8YHM9E+LB#32B&86UE6KC>1X:Y*RTA)O
M.>KIQ5)B?J7^05A;DOOO/>\PXII<?&;K&M3ES-=HQ(CZQ1[P9@"D/P$,*?DD
M6ETI<M^64!X#^,ANI$A?*-[0LXAW4%R1*/0(#6AT!B\:78XL7O0_+GMD63/T
M]=CSOZ_72DLLEG].^3X@QZ>1S0.:JHX5,'?QA2B03^ NWKT)T^#]&=[QR#L^
MA[Y8X8,L^QJ(V)#3:3O%^"SF:<9'X#!&IA#X%)4VYG4%9"-J?-&\W9(+WN*)
MZ!7*J\NI@PF#9@UR3!KY[PEU/K+U ?1;DGI!/AF^4>)\!'QHE:A+PIM.BB<P
M4HK0V,O"B% O2A/G5C1=KQ'S%2;T* U)%D^<#[ULN>XE6!\V_-FL%0H$44PB
M%%B)C=XQO(]H@K_8^0(5+[#DR23#/T1OL0SZH76@?\BB *7(NS<Y#>E[Y#")
M,R>*O#B;D)!Z>9HB:Q1@1=$W?<TTE-@=,*@%9Q;D@B1>BJ_C$E>9%X0YN70^
M"\UJ@WTBWAYIP42&9@B>X2+Q\C@G9PHI&0LI^>5"NCND>/^,O5X!>8"!OQ:_
M46AG;9XNM"/CL#<N7XUWDIRLQ!U34^<;,#GTF*/R<FS!V1J[XXANZE9A[5B$
MP83"8,9I8$(Z"9T53@2L8@^[JGP$;9=;:$%B9HP2*['M<M,3S/P@>9[8,@KW
MR7N+NRA.[#>E]&1^_(/^W(#<VBFDD%C?ZJ%5CZ?CH+L>^ONK^# E/S&YY:TB
M-6Q0-;C*,.QRF#S#1HO.=ONUT#@[[++"80W2".#]1@C]LC$&QO&_^!=02P,$
M%     @ :C%A6/+*6)@)!   (0H  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&ULG59M;]LV$/[N7T&H0Y$ 6O1F6U)J&W!>NA58"R/).@S#/M#2V>9*
MD2Y)U<E^?8^4K#BS:@3[8.MX/-X]Q^=XY&0GU1>] 3#DL>)"3[V-,=O+(-#%
M!BJJ+^06!,ZLI*JHP:%:!WJK@)9N4<6#. S'0469\&83IUNHV436AC,!"T5T
M7554/5T!E[NI%WE[Q1U;;XQ5!+/)EJ[A'LSOVX7"4=!Y*5D%0C,IB(+5U)M'
MEU=C:^\,/C/8Z0.9V$R64GZQ@P_EU LM(.!0&.N!XN<;7 /GUA'"^-KZ]+J0
M=N&AO/?^WN6.N2RIAFO)_V"EV4R]S",EK&C-S9W<_0IM/B/KKY!<NW^R:VS3
MU"-%K8VLVL6(H&*B^=+'=A\.%F3A#Q;$[8+8X6X".90WU-#91,D=4=8:O5G!
MI>I6(S@F+"GW1N$LPW5F]HN4Y8YQ3J@HR0=AJ%BS)0<RUQJ,)F</%$?Z?!(8
M#&:7!$7K^*IQ'/_ <123CU*8C2:WHH3RI8, 4790XSW4J_BDQQLH+D@2^20.
MX^2$OZ1+/7'^DO^7^@W3!9>Z5D#^FB^U45A ?_?M0Q-EV!_%'JI+O:4%3#T\
M-1K4-_!F;]]$X_#=B1R&70[#4]YG]WA(RQI!R]5Q"CZY?2QX73*Q)OMD^Q(X
M&:(_@8-8M(T%7:QU&\LGA<33JXU%9S9 5I)C$[ F9TR@1M8:]UZ?7PZ06ZB6
MH#I^R7\U\>!:HJ=Y4=15S:F!DGS"GG5-E7JR'C]37@-YA<W@"#MVI.4_V"6(
MD8164AGV+[4M8[! %P+G?R*1GZ<C_)Z1=!23<Z>)$:7]9EGH9L;#=#^3)(-%
MK8H-MHN2&"@V0G*Y?B+1V,_#$&VCT$_B#,W'_BB-G_69/QR%J';?'J1"F@.T
M@P=%2VS2V,!)%(W)VS=9',7OG!Q%PX/Q</ @#>467>;G>>0 1Y$?9J'#G/IY
M%#6S63YTL[D?YDU"N9^B=*):1UVUCEY=K?.#C<8ZQ4M& [F#AC4DX@963# #
M/_^&7;OG?/85\LGH_87\ @:T,-0SC'(/@SL8[(B1'=5'U?PG4-6TO1=E/'"%
M[6KYABE+88'EJEW_:4/;6HOM;W!/L>_ZQ)(+!HO7)VL0H&C3KFB)=P&S3<E>
M:K8\L\@5:?),-.J2KG1/L#?NV!N_FKWWM;&-\58;5KFMZJ6SKRGU\78R;C]O
M+0#H - ^(A' ,6/LF+"Y1E-+S[#=L,P.1DZ,K3BVXBBW8HIB&*96S$BCRATG
MV.'P6;0R2'86AQT/*9Z>_OT/#J[M"M3:/4XT%D4M3'.#=]KN_3-OKOUG\^;Q
M])&J-1.:<%CATO BQ:.@F@=),S!RZQX!2VGP2>'$#;[A0%D#G%]):?8#&Z![
M%<Z^ U!+ P04    " !J,6%8Z.(/99\"  "U!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q]5%%OVC 0?N=7G+)J:B74) X4QB 2M*LV:=50VVT/
MTQY,<A"KCLULI[3_?N>$9$RBO,3V^>Z[[WSY;KK3YLD6B Y>2JGL+"B<VT["
MT&8%EMQ>ZBTJNEEK4W)'1[,)[=8@S^N@4H8LBJ["D@L5I-/:MC3I5%=."H5+
M [8J2VY>%RCU;A;$06NX%YO">4.83K=\@P_HOF^7ADYAAY*+$I456H'!]2R8
MQY/%P/O7#C\$[NS!'GPE*ZV?_.%+/@LB3P@E9LXC<%J>\1JE]$!$X\\>,^A2
M^L##?8M^6]=.M:RXQ6LM?XK<%;-@'$".:UY)=Z]WGW%?S]#C95K:^@N[QC=)
M L@JZW2Y#R8&I5#-RE_V[W 0,([>"&#[ %;S;A+5+&^XX^G4Z!T8[TUH?E.7
M6D<3.:%\4QZ<H5M!<2Z=9YFI,(>O@J^$%$Z@A?-'OI)H+Z:AHPS>+\SV:(L&
MC;V!%C.XT\H5%CZI'//_ 4*BUO%C+;\%.XEX@]DE)'$?6,22$WA)5V]2XR5O
MX"WY:UT<<)5#73R7%G[-5]89^D-^'ZNY01P<1_2JF=@MSW 6D"PLFF<,TO?O
MXJOHXPF^@X[OX!1Z^D JS"N)H-=PI%?'Z)X$/$ZW198'?T&F27G6^<2N0%AK
M20(6:@/G0I%%5Y:>T%Y,>G/K?:A16*[0^&;U?+-\QUCO6I<T/RQWC8@E=Y2&
MM^]^!DE_/!S2.NA?C>)>RR,CUB+C$IP1],47CX'P89Q W&<)ZWTC2J:U6V#]
M\8C1-XF'O4?M*(0?J>@,1OU1'-$Z[K-X#,?:$QY(J42SJ0>&?XQ*N495G;6;
M2?-&BO_<FX%VQ\U&* L2UQ0:78Z& 9AF2#0'I[>U,%?:D<SK;4%S%8UWH/NU
MUJX]^ 3=I$[_ E!+ P04    " !J,6%8&Q8?*QL#  #Z!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q]5=N.TS 0?<]7C )"5"J;-$W:W=)6V@L(
MI%VH]@(/B <WF3;6.G:P'<KR]8R=;EA0-R_Q^#)GSOAX)O.=TO>F1+3PJQ+2
M+,+2VGH6128OL6+F2-4H:6>C=,4L3?4V,K5&5GBG2D1)'$^BBG$9+N=^;:67
M<]58P26N-)BFJIA^.$.A=HMP%#XN7/-M:=U"M)S7;(LW:._JE:99U*$4O$)I
MN)*@<;,(3T>SL\R=]P>^<-R9)S:X3-9*W;O)QV(1QHX0"LRM0V T_,1S%,(!
M$8T?>\RP"^D<G]J/Z.]][I3+FAD\5^(K+VRY"(]#*'##&F&OU>X#[O/Q!',E
MC/_"KCT[.0DA;XQ5U=Z9&%1<MB/[M;^')P['\3,.R=XA\;S;0)[E!;-L.==J
M!]J=)C1G^%2]-Y'CTHER8S7M<O*SRPM<6WA]R]8"S6 >68)T&U&^=S]KW9-G
MW$<)7"EI2P/O9('%OP 1<>D()8^$SI)>Q O,CV \&D(2)^,>O'&7X-CCC?L2
MO. F%\HT&N';Z=I838_A^Z%L6ZST,)8KD)FI68Z+D"K H/Z)X?+5B]$D?MO#
M-.V8IGWHRYNV+D!MX%+)[1N+NH)/RJ*!%7MP"AUBW(MYF/%?=.G1ZQ8==DCW
MPPQLE*!:-?":2["E:@R3A1G, I(&JS7J3A[X?R4)5JASK%VEP:V+<*F8A/<L
MYX+;!W@):3R,XYB,L3>"S[8D]^DQC))I<"=9I;3EO[&@RB+="M)--=(",6A7
MN#$-DSE"KHPEBI .C^,$!F1EPWB:PB 89\-D.H&$YMDXN$1C9E1)6B/A4!DW
MFEM.66<C2$^"Y^Z""!),DI'A@.(4>A3..H6S?H6II1:-H.Q6FLN<UTS -5)(
MZG(NF:N.W>#?5_!Y+?B6N39F#KV!WJB'W\"IH0@!2992AEGLK R2D1LG,'7#
MU%^ZDP?9AECLI0MNE27:K9*DVZ%KB9[THPKUUG== U[*MC5UJUUC/VW[V=_C
M[5_ABNDMEP8$;L@U/II2KKKMM.W$JMIWM[6RU"N]6=+/";4[0/L;1;KN)RY
M][M;_@%02P,$%     @ :C%A6+ +@'&_ @  ]P4  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL?51-;]LP#+WW5Q#>,*Q 4'_$29,L"9"T*S:@Q8*V
MVP[##HK-Q$)ER9/DIOWWHV3'RX T%YNDR,?W;)'3G=)/ID"T\%(*:69!86TU
M"4.3%5@R<Z$JE'2R4;IDEER]#4VED>6^J!1A$D7#L&1<!O.ICZWT?*IJ*[C$
ME093ER73KTL4:C<+XF ?N.?;PKI .)]6;(L/:+]7*TU>V*'DO$1IN)*@<3,+
M%O%DF;I\G_"#X\X<V."4K)5Z<L[7?!9$CA *S*Q#8/1ZQBL4P@$1C3\M9M"U
M=(6']A[]QFLG+6MF\$J)GSRWQ2P8!9#CAM7"WJO=%VSU#!Q>IH3Q3]@UN<,D
M@*PV5I5M,3$HN6S>[*7]#@<%H^B-@J0M2#SOII%G><TLFT^UVH%VV83F#"_5
M5Q,Y+MU/>;":3CG5V?DMDB0#'Q_96J YGX:60-U1F+4 RP8@>0,@3N!.25L8
M^"QSS/\'"(E-1RG94UHF)Q&O,;N ?MR#)$KZ)_#ZG<2^Q^N?EOAKL396TRWX
M?4QD Y$>AW"3,3$5RW 6T-4WJ)\QF']X%P^C3R<(IAW!]!3Z_*$9"% ;N*EM
MK1'NN.1E78*G#BOV2F-@#= ,PK<*-;-<;IM#<TS,R7;'Q;2-R[:Q\(VK?6-F
MC,HXLYC3];0%J%J#ZHB(Y@/OD "88REHU.E.<0FV4+5A,C?GD[.%(85G]%-3
M> ])+XV&SAE VHOZB3.'9,9IZLQ+%QWVG3ERT4'LS#$0%&%2([:QJ"$9]>*X
M?_:H+!.P.2DA'?;&T?CL%@W)*54M+>T4KU]Z$5P2(!H+'R&)>^DXA?,6MP$2
MG*VYX):34J(_Z*7Q ([]_/!@&$O46[]R#&2N93.77;3;:HMFF/^E-ROQCNDM
MEX88;*@TNK@<!*";-=,X5E5^M-?*TJ+P9D&;&;5+H/.-4G;ON ;=KI__!5!+
M P04    " !J,6%8RV<QLX$#  !\"   &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6R55FUOVS80_NY?<5"7H@6\Z,5VXB2V =M9T6((&L3.AFW8!YHZ
M6T0E4B/I./[W.U*RXK:*UWVQ^7+WW'//\4B-=DI_,1FBA><BEV8<9-:6UV%H
M>(8%,^>J1$D[:Z4+9FFJ-Z$I-;+4.Q5YF$3115@P(8/)R*_=Z\E(;6TN)-YK
M,-NB8'H_PUSMQD$<'!8>Q":S;B&<C$JVP07:Q_)>TRQL4%)1H#1"2="X'@?3
M^'HV</;>X#>!.W,T!I?)2JDO;O(I'0>1(X0Y<NL0&/T]X1SSW $1C7]JS* )
MZ1R/QP?T#SYWRF7%#,Y5_KM(;38.A@&DN&;;W#ZHW4>L\_$$N<J-_X5=;1L%
MP+?&JJ)V)@:%D-4_>ZYU^!&'I'9(/.\JD&=YRRR;C+3:@7;6A.8&/E7O3>2$
M=$596$V[@OSLY &?4&X1F$QARKG:2FO@ 3F*)[;*$>8:4V%AKB1':37S4KY;
MNCWS?A1:HN" 0EZ'FU7ADE?"Q0G<*6DS [_(%-.O 4+BWB20'!*8)2<1;Y&?
M0R_N0A(EO1-XO4:0GL?K_8<@:ZT*ES;ES"T5Q68P]^5 #7]-5\:O_]VF0(7?
M;\=W379M2L9Q'% 7&=1/&$S>OHDOHIL3[/L-^_XI],FBZBU0:Z@3:6-X$J.=
M88UF@"MJ2&,Q=3%L1D*IG#I;R V\$Y)6U-;083+OKSM_(--5G8&JA,6*I*-*
M=5RE7+F2SJU@&ZF,%1R6:.CD_03]03>^2FC0ZW<'O6%G)E29,>H_6! 3P8F"
M.ZN*0A-:=W@UH-^+RWYGJ2S+Z9ZHRD= 5]UH>.F AMV$SMT)=0>-NH/_J>ZK
M?;/:PS(3.OVY9-KNX9[ME:Z8?_;,#V?)M-7G-(LEB3Y71<GD_NV;81)?WICZ
MIB XH!K@,ZED',LX.O-E^DH:1X(X"$TK.7.5;':((92H7:O3C?R]ZPZUMZIJ
M;GZDQ(]2N! ?D>4VXXS\XPC.P#-/;CHNF84E%BX87:U*LU0==BO3MGSMD;;E
MB[;5J3@M!CM42S?5ZK9HTF+VNCYMQM]I-74L.L<R^3L+OEU).G=TYWJIDICR
M)Y,S<J8+YT^4R!D\_OHBT!#.V@YV>/0BD!(;_^ZYYB66U>/0K#9/Z[1Z45[,
MJW?YCNF-D 9R7)-K='Y)IU-7;UTUL:KT[\M*69+=#S/Z/$#M#&A_K90]3%R
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M%WCXO4?_R6LG+2MF\%:))U[8<AI<!E#@FC7"/JCMS[C3XPGF2AC_A.UN;QQ
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MP3,*;*? 7-S>D8OR@AN^.%%R"\I*DS6[<%"=-@4G2EN4:Z/HJR ]L_A0)K)
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M8FC_Y QY=9@PP;"J\5V]4!9GA-_6.)1!.P>\7RIEMX8CZ,9\_A=02P,$%
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MYWCXO4=_Y[63EA4SN%#B"T]M/@M>!9!BQBIA;]3V/39Z1@XO4<+X)VP;VUX
M266L*AIG8E!P6;_9KR8.CW&(&H?HGD-_^(##H'$8>*$U,R]KR2R+IUIM03MK
M0G,?/C;>F]1PZ4[QUFI:Y>1GXQM,4%JX-*;"%.9)HBIIN5S#K64R93HU\!+F
M:<I=T)F 2UG?''<$)TNTC MS2B:?;I=P\O04G@*7\#%7E2%W,PTM<70[A4G#
MYZ+F$SW IQ_!E9(V-_!6IIC>!0A)7*LPVBN\B(XB+C$Y@T'_!42]:-!!:/%X
M]^@(G4$;\(''&SR =Q#B1<[D&@U0I."MUDK#0FE=WV\#7^<K8S5=\V]=4:PW
M&79OXE+_W)0LP5E N6U0;S"(GS_ICWMONB+PG\#NQ&/8QF-X##WV=0-4!I5!
M8,:@[;PU-<C$@[C*M(G[D^%H&FX.=?QM%+V>#%JC._Q&+;_147X?2M3,'Y=
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M?<]]UPK_F->]_XKI-:<2)C CU][9A&Z\KOMI/;"J]"UII2PU./^9TR\(:F=
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M3552:=!2*JAF034;JCE0S85J'E2C4,V':@%4"U&:G/RNJDI3EU7=+KEXA8O
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M$Q[7=5ND/J?'25/JU;NM@-9P034+JME0S8%J+E3SH!IMM=W[).[<9,2'=AI
MM1"ER1N!KM;+5-=Z?8R>_\KX'7H_+*AF034;JCE0S85J'E2C4,V':@%4"U&:
M'."N1LP\?U/C=^C=LJ":!=5LJ.9 -1>J>5"-0C4?J@50+41I<O*[4C-376KV
M]L?OT)(VJ&9!-1NJ.5#-A6H>5*.MMCM^W[TN"MII -5"E+;:"(SYG+'*BJKH
M^BIC(FYW+$WK^F\1MWH,L/4J*=FL?@CC^QM]--Y[W=;>>UK/ZU1['S2OCSO^
M^FHA-B(?FY!SDK*9Z&IR<BX.3,KD8;[YH2H68E6-R'U15476?#MGD=BLU!.(
MW\^*HEK_4'?P5)1?F\6Y_C]02P,$%     @ :C%A6*T+4YE!!   1QD  !D
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M'M_SW-FYSHJ+%YD */2:4B:[3J+4_,IUY22!%,M+/@>FOTRY2+'24S%SY5P
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MR7@!I>:R) J68^?:OYI$%E\#?G#8ZKTQL4D64C[8R9=L['C6$ A(C55@>-O
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M@WVQ'N;XYP)E ;B^E-+L)K8Y=O_"Y"]02P,$%     @ :C%A6.0 :!]$ P
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MU1)*4V.E[:F.]#W5VWVAQ'C,RN4\3Q^[UU#02BJJV:CFH)J+:AZJ^:@F4"U
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M+W=O<FMS:&5E=',O<VAE970U,RYX;6R]G5MOX[@=Q;\*X2Z*&2 72[XETR1
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M:&.*\O:B;"A>V N .5?ZF]H^ID 2$&: ?K_@7&T;9H+Z#FGR/U!+ P04
M" !J,6%8\.J%DIH,  "/A0  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6S%G5N3HS8:AO^*RLFFDJJ9-D>[/>EQU72#E-G:)%W3F>S%UE[0MMRF!H,#
MN ];^?$K ;8LC.4F\Z9\,V.[T2/!]Z+#RP=</67YEV+)>4F>5TE:O!\LRW+]
M;C@L9DN^BHJ+;,U3\9=%EJ^B4GS-'X;%.N?1O"JT2H:.98V&JRA.!].KZK?;
M?'J5;<HD3OEM3HK-:A7E+]<\R9[>#^S!]H=/\<.RE#\,IU?KZ('?\?+S^C87
MWX8[RCQ>\;2(LY3D?/%^\,%^Q_R)+%!M\7O,GXJ]ST3NRGV6?9%?/L[?#RS9
M(I[P62D1D?COD=_P))$DT8X_&NA@5Z<LN/]Y2Z?5SHN=N8\*?I,E_X[GY?+]
MX') YGP1;9+R4_;T$V]VR)>\6984U;_DJ=G6&I#9IBBS55-8M& 5I_7_T7-S
M(/8*N,Z1 DY3P&D7<(\4<)L";JO T29Y30&O5<"9'"G@-P7\=@'[2(%14V#T
MV@+CIL"X"E9]=*O0!%$93:_R[(GD<FM!DQ^J^%:E143B5$KQKLS%7V-1KIS>
M+:.<DVL1S#FYR59"X454:>0M^3"?Q_)CE)"/:2UZ^8?O UY&<5+\<#4L10,D
M9CAK*@OJRIPCE=D.^3E+RV5!PG3.YSI@*%J^:[ZS;?ZU8R3^<Y-<$,=[0QS+
M<<FW9$@*N4-%\U]'$V]. 5,!=!M@=71^RI(YSX\3 S,QX+,+XMH-\?-=0+[_
M]H=7-35\/=C9@8_2J)GVZZS<T:SC%&:F4'XO#M]$4NQ1)T4+L[M3J5MAW;XJ
M_9#G4?K 1=]8DNL7LK_=;?12_?SA*<KGY#__$DCRL>2KXK\=NW5=U^]UUR_'
M@W?%.IKQ]P/1X1<\?^2#Z7??V"/KQRZ)(6$!$A8B810)8R"8)B]O)R_/1)_^
MLEG=BS,\6Q Q6!=EE,[C](&(OG?VA61K*;2"/ BAE>T^J]:.$=Y7.TA84,/\
M"B8G)8]3Q_)LR[*NAH_[LNC8SN_8CB(;QT P+>+^+N*^,>+A,\]G<<').H]G
MO(J\'F?RYUX7W15T([]OT)&PH(9-]H)I7URZK8@C:Z1(& /!-%F,=K(8&65Q
M5YWRL_T1AC_+SUSJH4L&1EY?&2!A00T;[\G =\?NX;G?L=UDU''N(QO'0# M
MR.-=D,?&( ?Q8SSGZ;PX%E-C\;XQ1<*"\4&LVM$\N05%-HB!8%H<+W=QO'S%
MR?IKU6^3\'FVE#-!<IMGH@M?=<75B.L;5R0L0,)")(PB80P$T]0RV:EE<N8E
MQ 0I+R0L0,)")(PB80P$T^1E6\I(L4Y,*==Q7DMJ'I6\2R%F0E^)G&C/SAJI
MC(=.LP;9G!!*HU :0]%T:>QY;/8KUY<\B1_B^X23964J%:3R9$574V9BIMD,
M87_N^TZ=.C)6UUM']L'JK[U<"* UAE :A=(8BJ9+Q5%2<<R3FMH3C(MBTVTV
MF,OWCKUS$/NQ/_8G?CO^R%I#*(U":0Q%T^.OC$[;:'1-;WD^$U..Z*$R)1J'
M6'P2:]*5&%EJ3VJ3BHXA>9$FU:Y#:?R+3LE S<V&)KM4M<:XF$S:BH'ZEE :
MA=(8BJ8K1GF7MMF\O,[23?'VM^SMKXV#95@!F5&]E0#U*J&T$$JC4!I#T73!
M*.O3]L^\$K*AYBB4%D!I(91&H32&HNDR4U:J;?92O_*BBIG>6T-0:[6A[<^:
M;,NW#KW5C@U]9W3HK4*;QU T/?#*7K7-_NK77ULQ5] []E +UCYT6)UVU)$5
M4BB-H6BZ-I1E:[_&L^US@<4,[*T%J&W;T/:UX%E=W<#A=K;=L2&%-H^A:'JL
ME>%J&PVWZ78^*GI^\HD7I>@-Y,E?2^!S&I<%^?[3W>?.1*)K,[MWV*%V*I06
M0FD42F,HFI[;I2Q5QSKS3-6!.K)06@"EA5 :A=(8BJ;+3-FSCMF>_<1ESJZ<
MG6[2G,^RAS3^GU!2-3^I\ESGW2/6(LMW4QO9R>6JD]OZ-+*3.S*PF1O56WI(
M6M#0]*2 KI$-6BV%TAB*IJM*.;F.V<G]L,KRLA)2Y>W7DEGS/,XZUSMF6F\Y
M(&G!B3UUR N/\H*,R*K*[NWL?J"6+Y3&4#1=*,KR=<R6[\_1<[S:K$0_T<?*
M,T-[ZP6:L@JEA5 :A=(8BJ9+1WF_CG?N"1+4,8;2 B@MA-(HE,90-%UFRC%V
MS-FR38X55QD.AG$,ZOU":<&)W;2M>B#K5 ?4Z(72&(JFJT,9O8[9Z*UN& G_
MV,3E"_F8RJN7\2,GMTF4=NH#ZNM":0&4%D)I%$IC*)HN&641.^-SCUM0"QE*
M"Z"T$$JC4!I#T729*;?9,;O-ZA)4DTC15#*OENXRQR82_56G?*"N,Y06-#3M
MZM/EQ'7;23LAM%H*I3$435>&\J8=LS=]?,P2R[!;GE>WNXK?1>^4UG?!-HGF
MG=>KS)7U5@O4K(;20BB-0FD,1=/O4%5FM7MNL]J%FM506@"EA5 :A=(8BJ;+
M3)G5KMFL_IT7I;2J2YYW^D+FXKU% K653^S:7K_[MK;=M^[ZH]AI$J>D7.:<
M$_[')DI(E*;ROS@MRBA)Y&E4D'O^$*>5DY^),TDNYDBT$$=*%.1U]L&QW/P0
MNJ<42F,HFBXYY62[9G_W*S-YS/3>BH0ZV^YA_G/[$@>T0@JE,11-%\;>4QG,
MSK5Q%M7[]CQS9;UU@GT( _8I#-C',&"?P_!W.-JN<K3=<SO:+M31AM("*"V$
MTBB4QE T76;*T7;-5N_)VVR:\MHBVQ]=CB[UT>'&7$_O^$.3DZ$T"J4Q%$V/
MO_*L7;-G_?4YJDT%HWV!7#AM=4#M:2@MA-(HE,90-%T=RIYVS1G,QGE-<[F^
M4Q-0TQE*"Z"T$$JC4!I#T73Q*-/9O3SW# 9J3D-I 9060FD42F,HFBXSY6"[
MK\FN?MTU>3.JMV"@_O2)W31=DX<VA$)I#$73GV>GS&C/_/ 'XPAV4]]+7"W0
MN^1B9O>5"Y060&DAE$:A-(:BZ0I2/K-GGWD8\Z!.-9060&DAE$:A-(:BZ3)3
MWK)G]I;UYQVD[0OV[2<?U OV*MM^SXON5!?4=8;2@H;6>H2"Y;6?R@EUGJ$T
MAJ+ILE'.LW?*>;9&1U/,S&5[AQYJ)$-I(91&H32&HND*V7ND[[F-9 ]J)$-I
M 9060FD42F,HFBXS921[9B-Y[R'Y]0@52>V8'Q<-S9"&T@(H+832*)3&O$.#
M7UWYU<6@7&7O5":T;1B5H(G/4%H I850&H72&(JF*T0YR]ZY$Y\]J <-I050
M6@BE42B-H6BZS)0'[9D3G__*J 0UE:&T $H+H30*I3'O,+?[V*BDG&+O5*YS
MLU9JWLI2N8!R!=WOQAUS+;T% C61H;002J-0&D/1]+=F*%_9/W>2LP\UGZ&T
M $H+H30*I3$439>9,I]]<R;P7QB_S,3>NH&ZR5!:Z!\^KWDRLERK=?L/A=;*
M4#1=$<HG]LT^<;A:)]D+YTU:Z>TFGRU%[W)TM#+C>LL!:O]":2&41J$TAJ+I
MHE$NL7_NU\;Y4*L92@N@M!!*HU :0]%TF2FKV3=ZC%]QFZD9W%L^4 L92@NA
M--K0]H= U[VTK9$^!#)4K;HP]EXR9S:'_[:+F^9Z>^L&^_HYO_/BIMU^ 1WV
M#7385]#]'<G)OK*1?;.-K,N&1[F\HZT@FZ+I4=;;R4]+0)U*@;K.4%K0T%I*
ML=NWL4,KI5 :0]%TI2@[V3<G*NM*641Q3E91_H67Y#%*-@<"T=53O46"K(]-
MH*$^,I06-+26<"X/A ,UB*$TAJ+IPE$&L6\VB ->S/*X3B$5(GG,JGN*U]F3
M'*!RI1XE&[Y=@*VCO(QG\;J>2<>R_(+G5?&C":CFUO06$]1</G&D?LG4KJ^B
ME[W=YW+GHX/])_&BNMUX5RI[2@OB_T,>UU665X=5_KW,RBB1I^>]J'%^/ 1R
M6[EXB=*7[[ZY=.SQCT4=EHO.>1;4W(;2&(JF:U[YX+[9!V]IOAVV$]TAU/V&
MTH(3^_V;$%!X=WM+UGDFWWQ:5.=SL9G->%%(Q[^(G]]63^YL'Q/]AGIRQ]=B
M(2SGL'915M/4GR,QEE3?JHF*^"R3M2](L*DH4KK53?A<'-LY"?BL+MZ\9MY]
M0SQW_,9V_>V,6&B?;Z?!=3S*;>,3'CU*IFM-WEBVHY9:VV?WRIU:;,I-0Y!+
MKNXS!.KN0VD,1:O/D&&QY+P,HC*:7JUX_L!O>)(4HLO9I (OK;?=K^(X+N03
MW=]]< ;#@]\#^UUHR]^'"C.]6HMIAQ" $$@AHK,02.MB+&;.>?RPW'TIL[48
MJ ?D/BO+;%5]7/)(1%9N(/Z^R+)R^T56\)3E7ZIF3_\/4$L#!!0    ( &HQ
M85@1?^!=L08  %0K   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;,5:
M:X_:.!3]*Q9;K5JI [$=0IAED(#I[G;5JJ-.'UJM]H,G&(B:!TW,,//OUWD0
M)W'&) :T_= A(;[WGFO[WI.#)_LP^A%O*&7@R?>"^*:W86Q[/1C$SH;Z).Z'
M6QKP;U9AY!/&+Z/U(-Y&E"S30;XW0(9A#7SB!KWI)+UW%TTGX8YY;D#O(A#O
M?)]$SW/JA?N;'NP=;GQVUQN6W!A,)UNRIO>4?=W>1?QJ4%A9NCX-8C<,0$17
M-[T9O%Z89C(@?>*;2_=QZ3-(H#R$X8_DXOWRIF<D$5&/.BPQ0?B?1[J@GI=8
MXG'\S(WV"I_)P/+G@_7?4_ <S .)Z2+TOKM+MKGIV3VPI"NR\]CG</\GS0$-
M$WM.Z,7I_V"?/VOT@+.+6>CG@WD$OAMD?\E3GHC2 &2], #E U!]P/"% 3@?
M@%.@660IK%O"R'02A7L0)4]S:\F'-#?I:([&#9)IO&<1_];EX]CT?D,B"N8\
M$4NP"'V^.F*2YO<*W&<S"\(5N&>A\P-\VJ;?S)+,N^P9O+ZEC+A>_(8__/7^
M%KQ^]0:\ @,0)S9CX ;@:^"R^&WIQI=-N(M)L.0W7U6N)P/&T20Q#9P\\GD6
M.7HA<HC QS!@FQB\"Y9T634PX&DH<H$.N9@CI<5;ZO0!AF\!,A!N"&C1?CA2
MA(.+J<&I/:R:FJN&J9E%$0G6E&\F!AZ>0?FY._*<WI[M2;0$_WS@)L%[1OWX
MWZ8$9_[-9O]) ;F.M\2A-SU>(6(:/=+>]-=?H&7\UI2<,QFKI,HL4F6JK$_+
MZY,OK4\[%C.^JMQ@S9?F7R38)>OXY8F=9]:'J?6D\#U.T="$D\%C&: R!$V
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MD"+S;++4$:'NB".[E;B6YT1MZJ#3C0ZFK&,RG2G8D]GQ)\.SRG1'G!]RA _
MH/URCBXA6IF"IYEG$JW:G!.2U:AZQ5-'HXNV=!#J3,)6NU4@2UE( MSP3*W(
M#4KG$WT:K=-CFS%PPEW LN-YQ=WB:.@L/1!9NS^'UXOL@*<PDYTW_4BB-4<+
M/+KB)HW^B/.K*#O"F5VP<)N>@GP(&0O]]..&$M[PD@?X]ZLP9(>+Q$%QD';Z
M'U!+ P04    " !J,6%8H)I0)($#  #J#@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6S-5]MNVS@0_15"6Q0MD$8W6XY36T!LIQ>@18.XW7U8[ ,C
MC2TBDN@E:3O=K]\A)2N2(PL;K KD)2:IF:,SAX<*9[+GXEXF (H\9&DNIU:B
MU.;2MF640$;E.=] CD]67&14X52L;;D10&.3E*6VYSB!G5&66^'$K-V(<,*W
M*F4YW @BMUE&Q<\9I'P_M5SKL'#+UHG2"W8XV= U+$']V-P(G-D52LPRR"7C
M.1&PFEI7[N7<]76"B?B=P5[6QD27<L?YO9Y\CJ>6HQE!"I'2$!1_=C"'--5(
MR./O$M2JWJD3Z^,#^@=3/!9S1R7,>?H'BU4RM2XL$L.*;E-UR_>?H"QHJ/$B
MGDKSE^S+6,<BT58JGI7)R"!C>?%+'THA:@EN<"+!*Q.\XX3!B02_3##*V04S
M4]:"*AI.!-\3H:,130^,-B8;JV&YWL:E$OB489X*EPD50&8H1$SF/$-W2&KT
M?4>6Q<X2OB(FZMW=TZCK!ST&\F8!BK)4OL6\'\L%>?/J+7E%6$Z^)WPK:1[+
MB:V0KGZI'9749@4U[P0UUR-?>:X22:[S&.(F@(UU5L5ZAV)G7B?B J)SXKMG
MQ',\OX70_+^G>QUT_$I[W^#Y)_"NLTW*?P*0)8@=BX"<W(RK-.51,?RV(K<0
M\77._L&H&Q",ZV"I)/GS"[Z ?%:0R;_:Y"[8#-K9Z._%I=S0"*86?A D4@(K
M?/V;&SCOVZ3J":PAW* 2;M"%'G[GBJ9$UDP9U=6"PI1M$A2X(X.KOW"[<.B/
MT J[>FDM0>/ K8(:E(<5Y6$GY043^.$J-PK/P^'DM)Z+3JCG;E1/8(VJ@ZKJ
MX$4Y/.A3N)[ &L*-*N%&O\CA!>ZPX? C?S\-"8;M[KZHZ%YTTKU% :B($N/L
M!>SP=K#!__6JC6 GTG/WJ">P1M'CJNCQBS+WN$_A>@)K".<ZCY<.YQ?9NP2N
MF]?WW2.#MP0-O%&[Q=W:3<GM)+VD*<@S\I6*>U L7Y^1CY"#P$*TZZ]BO)TQ
MJ035]])6ZIWPS]W OM":8GB/8G@OROPEG;[$ZPFM*=[CO<_MO!W]'_O[3^XF
M@_'%^-C_3Z.&@V!\= #L6M>0@5B;9DHBE6VNBCMUM5HU;%>F33E:G^E&SG0C
MCS!%%XAG9<UR25)8(:1S/L(C*8K&JI@HOC&]R1U7V.F888+-* @=@,]7G*O#
M1+^@:F_#?P%02P,$%     @ :C%A6'"]/.?; @  J0<  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C(N>&ULK55-;^(P$/TKHU2JNE+;? &E+40"VFKW4 D5
M;7M8[<$D XGJQ%G;0/GW.W9"%JH4<=A+8CLSS^\].S.#C9#O*D74\)'S0@V=
M5.ORSG55G&+.U+4HL: O"R%SIFDJEZXJ);+$)N7<#3ROY^8L*YQH8->F,AJ(
ME>99@5,):I7G3&['R,5FZ/C.;N$E6Z;:++C1H&1+G*'^64XES=P&)<ER+%0F
M"I"X&#HC_V[2,_$VX#7#C=H;@U$R%^+=3'XD0\<SA)!CK T"H]<:)\BY 2(:
M?VI,I]G2).Z/=^A/5CMIF3.%$\'?LD2G0Z?O0((+MN+Z16R^8ZVG:_!BP95]
MPJ:.]1R(5TJ+O$XF!GE65&_V4?NPEQ!TOT@(ZH3@U(2P3@BMT(J9E?7 -(L&
M4FQ FFA",P/KC<TF-5EA3G&F)7W-*$]'LY1)A#$9D<!$Y'0Y%+/^7L&L.E@0
M"WBS;E#(:(V2#A=&BHZ]-($*+AY0LXRK;P-7$R.#Z\;U[N-J]^"+W?T GD6A
M4P6/18+)(8!+4AH]P4[/.#B*^(#Q-83^)01>$+80FIR>'ARA$S;VAA8O/&;O
M58N](RE9L43Z'S3,M[ ?-V5;NSS:,)E<PA/+)+PROCITG14)/*-.12*X6&[A
MUVBNM*2_XG?;,50L.^TL3:6X4R6+<>A0*5 HU^A$YV=^S[MOL_ _@1T8VFD,
M[1Q#CQX_2BH Y))&F<-%5L 6F6R_>\>1NE4F=""OKF#@0<*VJDWQ:4@W#5*G
M!>E ;K>1VSU-[EIPNC@\T]LVI16(7]UJ4[C7D7?=]_R!N]Z7T1IV$_2:L ..
MO89C[RC'ETR]GY_U ^_V?B$103*-;21[;;M[X6W_$\OV.#\,/M%T]ZI>CG)I
MFX&"6*P*716,9K7I-R-;9C^MCZD/56WC'TS5Q)Z97&;TLW%<$"1Y10[*JC%4
M$RU*6UOG0E.EML.4>BE*$T#?%T+HW<1LT'3GZ"]02P,$%     @ :C%A6$GP
MFQ]M P  -PL  !D   !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULK99?C]LV
M#,"_BN -PP;<Q;:<O[<D0'*WKBW:+KBL[<.P!\5F8N%L*9/DI ?TPY>2$\=;
M'-]NNY?84D3R1XJD.=Y+]:!3 $.^Y)G0$R\U9GOC^SI.(6>Z([<@\)^U5#DS
MN%0;7V\5L,0)Y9E/@Z#OYXP+;SIV>PLU'<O"9%S 0A%=Y#E3CW/(Y'[BA=YQ
MXYYO4F,W_.EXRS:P!/-QNU"X\BLM"<]!:"X%4;">>+/P9AY&5L"=^,1AKVOO
MQ+JRDO+!+MXD$R^P1)!!;*P*AH\=W$*664W(\==!J5?9M(+U]Z/V5\YY=&;%
M--S*[#-/3#KQAAY)8,V*S-S+_6LX.-2S^F*9:?=+]H>S@4?B0AN9'X21(.>B
M?+(OAT#4!")Z08 >!*CC+@TYRCMFV'2LY)XH>QJUV1?GJI-&."[LK2R-PG\Y
MRIGI,F4*R!S]2LBMS/&R-7/ANB;+\J*(7)-[T$;QV."AI9'Q _DHN-%D9D/*
MS2/Y\0X,XYG^"<4NG-76D"9<D-]366@F$CWV#7I@.?SX0#LO:>D%VI"2]U*8
M5)-?1 +)WQ7XZ'KE/SWZ/Z>M&N\@[I HO"(TH!'YGOA'T/+18B&J(APY"U%;
MA*\;(CQ3BHD-8(H;LGHD]7,+]NBV9WNF$O+'.U1)WAC(]9]-,2OM=YOMV[*^
MT5L6P\3#NM6@=N!-?_@N[ <_MWC7K;SKMFF??BCR%2B;(XY?7Y'?"J,-7B\7
M&\R&MTP4-HF.$?[:&-C2C])2SUFRW62']QV&8W_7P->K^'K/Y/L5HVZ3LXVD
M=T9"NX-N,TF_(ND_DP3;RAHXLO@Q$S$VJG:H_AG4->WVFZ$&%=3@F5#WR.%R
ML UE<(XR"(-FE&&%,OQ?F825"NY$]&]R:7A^@P,Z:B8<582C5L+/KL5C:&8[
M4/C)*E.)8-\%\HIQ13ZQK "R0$;GPE5#]I\Z3!-U:7]4I^Y$%ZXX#$XM/GAA
M[E.-M/,>#(?=>LUV1O0"<>VC%+XP,=82G!?3$_3A.3WM]"[1TQ,]?6'Z6M$]
M@4R;D+O#"\BG;U38^I'X#\A-Y?@$>W26W9@K_^SO?FV6R4%MW,2F22P+8<JQ
MIMJMIL)9.0N=CI<CY7NF-EQHDL$:18/. -N!*J>T<F'DUDU&*VEPSG*O*4ZV
MH.P!_'\MI3DNK(%J5IY^ U!+ P04    " !J,6%8X+0E]CT#   U"@  &0
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MTQ,;OD3DROZ2[<[6<TA2*2V*'1@]*!BO_^G/71Q: +]_ A#L ,$Q(#H!"'>
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ :C%A6-AW-GB.!0  )RX   \
M  !X;"]W;W)K8F]O:RYX;6S%FEM/XSH0@/^*U9>S^\!IFQN[B"(!A=U*'$"
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M E!+ 0(4 Q0    ( &HQ85@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ :C%A6("$:_KO    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ :C%A6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !J,6%8/C;W\6,(  ! -0  &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ :C%A6 8^.""G!@  'Q\  !@              ("!IQ   'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &HQ85BR^_^_%0,  &P*   8
M              " @807  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " !J,6%8M%Q.T]\$  "9$@  &               @('/&@  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ :C%A6!F T<"A!@
M1BP  !@              ("!Y!\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( &HQ85@<=1%QO@D  .,N   8              " @;LF
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !J,6%8O87!
M>TL"  "D!0  &               @(&O,   >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ :C%A6&JM*4$D @  304  !@
M ("!,#,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &HQ
M85@!B[[=? H  &,:   8              " @8HU  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " !J,6%8]9\2')TI  "OA0  &0
M        @($\0   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( &HQ85C9CA8%<00  $\+   9              " @1!J  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ :C%A6+A?R;<5#0   2@
M !D              ("!N&X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " !J,6%8B]@/4F$#  !/!P  &0              @($$?
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &HQ85@TW^\+
MP0,  (T(   9              " @9Q_  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ :C%A6/;OB_*> @  PP4  !D
M ("!E(,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !J
M,6%8WH;L23 0  "(,   &0              @(%IA@  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &HQ85@:;)@"" H  %\:   9
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M970R,2YX;6Q02P$"% ,4    " !J,6%8=\!#.WH(  "P%0  &0
M    @($\V   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M &HQ85@(CW9(/0L  $@<   9              " @>W@  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ :C%A6'9@A$;Z P  00D  !D
M             ("!8>P  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " !J,6%8<AKW2L0L   RF   &0              @(&2\   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &HQ85@NJ S5.@0
M  L,   9              " @8T= 0!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ :C%A6 I8$9F" P  "@@  !D              ("!
M_B$! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !J,6%8
M\LI8F D$   A"@  &0              @(&W)0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( &HQ85CHX@]EGP(  +4%   9
M      " @?<I 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ :C%A6!L6'RL; P  ^@8  !D              ("!S2P! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !J,6%8L N <;\"  #W!0
M&0              @($?, $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( &HQ85C+9S&S@0,  'P(   9              " @14S 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ :C%A6/9_+[#I
M!0  8!(  !D              ("!S38! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " !J,6%8O2=UL[L#  #'"   &0
M@('M/ $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &HQ
M85B"9 /\0P4  $L-   9              " @=]  0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ :C%A6)>D$N=Y @  \@4  !D
M         ("!648! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " !J,6%8MBP=FJH)  !B6@  &0              @($)20$ >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &HQ85A/XN]C5P,  . (
M   9              " @>I2 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ :C%A6%"%,VHH @  $P4  !D              ("!>%8!
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !J,6%8Y:\V
M3*D"  #J"   &0              @('76 $ >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( &HQ85C[R?W)"0,  !T,   9
M  " @;=; 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M:C%A6!$O2)9K!   I10  !D              ("!]UX! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " !J,6%8]6(+=+\-  "0M@  &0
M            @(&98P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( &HQ85BM"U.9000  $<9   9              " @8]Q 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ :C%A6/,C2889 P
M80L  !D              ("!!W8! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " !J,6%8XME1OOX#  #?$P  &0              @(%7
M>0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( &HQ85@/
M(40S+P,  -\+   9              " @8Q] 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ :C%A6,[Z4!/8 @  >@<  !D
M     ("!\H ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &HQ85AC=4-KS@T  *V,   9              "
M@>6> 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ :C%A
M6+Q'2U_] @  RP@  !D              ("!ZJP! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " !J,6%8)@(2.[4F  #AN0( &0
M        @($>L $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( &HQ85@,/1O&" ,  /4*   9              " @0K7 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ :C%A6!\,ND[7!   (1(
M !D              ("!2=H! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " !J,6%8/R%JJ*,#  !/$@  &0              @(%7WP$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( &HQ85CPZH62
MF@P  (^%   9              " @3'C 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ :C%A6!%_X%VQ!@  5"L  !D
M ("! O ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !J
M,6%8H)I0)($#  #J#@  &0              @('J]@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( &HQ85APO3SGVP(  *D'   9
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M970V-BYX;6Q02P$"% ,4    " !J,6%8"\$\0P #  #-"   &0
M    @($\#@( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M &HQ85B9N\:1- 0  /(/   9              " @7,1 @!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ :C%A6/NP-%H) P  8P@  !D
M             ("!WA4" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " !J,6%8[X0 9%T)  !"9   &0              @($>&0( >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( &HQ85B1?2I 7@,
M +(6   -              "  ;(B @!X;"]S='EL97,N>&UL4$L! A0#%
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K @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !. $X 614  ',Q @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>248</ContextCount>
  <ElementCount>461</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Recent Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandards</Role>
      <ShortName>Recent Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Revenue and Accounts Receivable Credit Concentration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Recent Issued Accounting Standards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails</Role>
      <ShortName>Recent Issued Accounting Standards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails</Role>
      <ShortName>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value - Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Fair Value - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails</Role>
      <ShortName>Fair Value - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails</Role>
      <ShortName>Debt - Summary of Long-term Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails</Role>
      <ShortName>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Share Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Share Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share Based Compensation - Summary of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Share Based Compensation - Summary of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share Based Compensation - Summary of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bdsx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996155 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="bdsx-20231231.htm">bdsx-20231231.htm</File>
    <File>bdsx-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img35377828_0.jpg</File>
    <File>img35377828_1.jpg</File>
    <File>img35377828_2.jpg</File>
    <File>img35377828_3.jpg</File>
    <File>img35377828_4.jpg</File>
    <File>img35377828_5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="688">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bdsx-20231231.htm": {
   "nsprefix": "bdsx",
   "nsuri": "http://biodesix.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "bdsx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "bdsx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 346,
   "keyCustom": 115,
   "axisStandard": 35,
   "axisCustom": 0,
   "memberStandard": 47,
   "memberCustom": 50,
   "hidden": {
    "total": 20,
    "http://fasb.org/us-gaap/2023": 15,
    "http://biodesix.com/20231231": 2,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 248,
   "entityCount": 1,
   "segmentCount": 98,
   "elementCount": 920,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 688,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 2
   },
   "report": {
    "R1": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets",
     "longName": "100010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations",
     "longName": "100040 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:DirectCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_762beb25-d2a5-4129-9298-0e23686a893a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_762beb25-d2a5-4129-9298-0e23686a893a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_47cf66b1-0604-4cd3-8aee-7a4e96842346",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47cf66b1-0604-4cd3-8aee-7a4e96842346",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandards",
     "longName": "995475 - Disclosure - Recent Issued Accounting Standards",
     "shortName": "Recent Issued Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue",
     "longName": "995495 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "longName": "995505 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "longName": "995515 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "longName": "995525 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt",
     "longName": "995535 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3",
     "longName": "995545 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquity",
     "longName": "995575 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration",
     "longName": "995585 - Disclosure - Revenue and Accounts Receivable Credit Concentration",
     "shortName": "Revenue and Accounts Receivable Credit Concentration",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "longName": "995595 - Disclosure - Share Based Compensation",
     "shortName": "Share Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1",
     "longName": "995605 - Disclosure - Net Loss per Common Share",
     "shortName": "Net Loss per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995615 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995625 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995635 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995655 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables",
     "longName": "995665 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "longName": "995675 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "longName": "995685 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "longName": "995695 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables",
     "longName": "995705 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995715 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables",
     "longName": "995735 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)",
     "shortName": "Revenue and Accounts Receivable Credit Concentration (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
     "longName": "995745 - Disclosure - Share Based Compensation (Tables)",
     "shortName": "Share Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "longName": "995755 - Disclosure - Net Loss per Common Share (Tables)",
     "shortName": "Net Loss per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995765 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:NumberOfCancerTest",
      "unitRef": "U_Test",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:NumberOfCancerTest",
      "unitRef": "U_Test",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Recent Issued Accounting Standards - Additional Information (Details)",
     "shortName": "Recent Issued Accounting Standards - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Business Combinations - Additional Information (Details)",
     "shortName": "Business Combinations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails",
     "longName": "995815 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "shortName": "Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_c78507c9-28f4-4078-b9c2-60788d6de761",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c78507c9-28f4-4078-b9c2-60788d6de761",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
     "longName": "995825 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities (Details)",
     "shortName": "Fair Value - Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_f5c7a2fb-eba1-497c-b9c5-a66efa1ceb59",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5c7a2fb-eba1-497c-b9c5-a66efa1ceb59",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
     "longName": "995835 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)",
     "shortName": "Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8c71793-b3d7-4472-9294-cc317e43c263",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Fair Value - Additional Information (Details)",
     "shortName": "Fair Value - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4270ff6e-22b1-452e-a4a6-a180a3e2a6f8",
      "name": "bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
     "longName": "995855 - Disclosure - Property and Equipment - Property and Equipment (Details)",
     "shortName": "Property and Equipment - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
     "longName": "995875 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_4348c38b-37a4-4aad-80bf-51c279e91cbe",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4348c38b-37a4-4aad-80bf-51c279e91cbe",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
     "longName": "995885 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
     "longName": "995895 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails",
     "longName": "995905 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "longName": "995915 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
     "longName": "995925 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)",
     "shortName": "Debt - Summary of Long-term Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Debt - Additional Information (Details)",
     "shortName": "Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_63b83fa5-85b9-4152-a156-9afea82f699b",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails",
     "longName": "995945 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "shortName": "Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995955 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails",
     "longName": "995965 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)",
     "shortName": "Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
     "longName": "996005 - Disclosure - Equity - Additional Information (Details)",
     "shortName": "Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
     "longName": "996015 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cc3d622b-07f0-4622-b168-11fadcf7c53f",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
     "longName": "996025 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:PrimarySourcesOfRevenueDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "bdsx:PrimarySourcesOfRevenueDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
     "longName": "996035 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_6c99d259-788c-49d8-9e0a-022979f1851a",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6c99d259-788c-49d8-9e0a-022979f1851a",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
     "longName": "996045 - Disclosure - Share Based Compensation - Additional Information (Details)",
     "shortName": "Share Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b6598444-e68b-421f-8188-c98635eea90e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "996055 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Share Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
     "longName": "996065 - Disclosure - Share Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "shortName": "Share Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3a255c06-b8fd-42be-a476-41c0489c1cce",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails",
     "longName": "996075 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "shortName": "Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
     "longName": "996085 - Disclosure - Share Based Compensation - Summary of Restricted Stock Units Activity (Details)",
     "shortName": "Share Based Compensation - Summary of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "996095 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
     "longName": "996105 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996115 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "996125 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996135 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55007458-a47c-4577-8a1f-a5b74438afae",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "996145 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_762beb25-d2a5-4129-9298-0e23686a893a",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "996155 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_07be75b0-fbf4-4119-a2ba-55afe4ef7386",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bdsx-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "bdsx_AVEOOncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AVEOOncologyMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVEO Oncology",
        "label": "A V E O Oncology [Member]",
        "documentation": "Aveo oncology."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r782"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable",
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $65 and $118",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "bdsx_AccretionOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AccretionOfLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of lease liability",
        "label": "Accretion Of Lease Liability",
        "documentation": "Accretion of lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AccruedClinicalTrialExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expense",
        "label": "Accrued Clinical Trial Expense Current",
        "documentation": "Accrued clinical trial expense current."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AccruedInterestAmortizationOfDebtIssuanceCostsAndOther",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest, amortization of debt issuance costs and other.",
        "label": "Accrued Interest Amortization Of Debt Issuance Costs And Other",
        "terseLabel": "Accrued interest, amortization of debt issuance costs and other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued liabilities",
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r207",
      "r593"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "terseLabel": "Additional paid\u2011in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r782",
      "r986"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r626",
      "r901",
      "r902",
      "r903",
      "r960",
      "r988"
     ]
    },
    "bdsx_AdditionalTenantImprovementAllowanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdditionalTenantImprovementAllowanceAmount",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Tenant improvement allowance",
        "label": "Additional Tenant Improvement Allowance Amount",
        "documentation": "Additional tenant improvement allowance amount."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AdditionalWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdditionalWarrantsAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional warrants amount",
        "documentation": "Additional warrants amount."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AdditionalWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdditionalWarrantsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Warrants",
        "documentation": "Additional warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to additional paid-in capital deferred offering costs",
        "documentation": "Adjustments to additional paid-in capital deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of Tranche B Warrants to additional paid-in capital",
        "label": "Adjustments to Additional Paid in Capital, Fair Value",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r164"
     ]
    },
    "bdsx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of Tranche B warrants to additional paid-in capital",
        "label": "Adjustments to Additional Paid in Capital Reclassification of Warrant",
        "documentation": "Adjustments to Additional Paid in Capital Reclassification of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r421"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Initial Warrants",
        "terseLabel": "Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r79",
      "r164"
     ]
    },
    "bdsx_AdjustmentsToFirstAmendmentWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdjustmentsToFirstAmendmentWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of First Amendment warrants",
        "label": "Adjustments To First Amendment warrants",
        "documentation": "Adjustments To First Amendment warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AdvanceDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AdvanceDeposits",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance deposits",
        "label": "Advance Deposits",
        "documentation": "Advance deposits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r818",
      "r828",
      "r854"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r821",
      "r831",
      "r857"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r822",
      "r832",
      "r849",
      "r858",
      "r862",
      "r870"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "verboseLabel": "Stock compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r466"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for doubtful accounts receivable",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r304",
      "r310",
      "r311",
      "r313",
      "r982"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortization of Intangible Assets, Total",
        "terseLabel": "Amortization expense related to definite-lived intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r69",
      "r74"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent": {
     "xbrltype": "areaItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AreaOfLeasedPremisedObligatedToPayBaseRent",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of leased premised obligated to pay base rent",
        "documentation": "Area of leased premised obligated to pay base rent.",
        "label": "Area of leased premised obligated to pay base rent"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AreaOfOfficeSpaceLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AreaOfOfficeSpaceLeased",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space leased",
        "label": "Area of Office Space Leased",
        "documentation": "Area of office space leased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r211",
      "r239",
      "r279",
      "r292",
      "r296",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r507",
      "r511",
      "r539",
      "r586",
      "r669",
      "r782",
      "r795",
      "r920",
      "r921",
      "r969"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r217",
      "r239",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r507",
      "r511",
      "r539",
      "r782",
      "r920",
      "r921",
      "r969"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non\u2011current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r507",
      "r511",
      "r539",
      "r920",
      "r921",
      "r969"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non\u2011current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AstrazenecaUkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AstrazenecaUkMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca UK",
        "label": "Astrazeneca UK [Member]",
        "documentation": "Astrazeneca UK."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AtTheMarketFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AtTheMarketFacilityMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ATM Facility",
        "terseLabel": "At-The-Market Facility",
        "label": "At The Market Facility [Member]",
        "documentation": "At the market facility."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_AtTheMoneyOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "AtTheMoneyOfferingMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Money Offering [Member]",
        "label": "At-the-Money Offering [Member]",
        "terseLabel": "At-the-Money Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r814"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r814"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r814"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "bdsx_BDX004Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BDX004Member",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BDX004",
        "label": "B D X004 [Member]",
        "documentation": "Bdx004."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108"
     ]
    },
    "bdsx_BaseRentPerMonthFromCommencementDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BaseRentPerMonthFromCommencementDate",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base rent per month from commencement date",
        "documentation": "Base rent per month from commencement date.",
        "label": "Base rent per month from commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BasisOfPresentationAndEstimatesPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Estimates",
        "label": "Basis Of Presentation And Estimates Policy [Text Block]",
        "documentation": "Basis of Presentation and Estimates."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_BioRadLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BioRadLicenseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bio-Rad License",
        "label": "Bio Rad License [Member]",
        "documentation": "Bio-rad license."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_BiopharmaServicesAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BiopharmaServicesAndOtherMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biopharma Services and Other",
        "label": "Biopharma services and other [Member]",
        "documentation": "Biopharma services and other."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "bdsx_BonusToOptionsProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BonusToOptionsProgramMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus-To-Options Program",
        "label": "Bonus To Options Program [Member]",
        "documentation": "Bonus-to-options program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r773",
      "r774"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r104",
      "r502",
      "r773",
      "r774"
     ]
    },
    "bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition contingent consideration gross margin target period",
        "label": "Business Acquisition Contingent Consideration Gross Margin Target Period",
        "documentation": "Business acquisition contingent consideration gross margin target period."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BusinessAcquisitionContingentConsiderationNumberOfInstallments",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration number of installments",
        "label": "Business Acquisition Contingent Consideration Number Of Installments",
        "documentation": "Business acquisition contingent consideration number of installments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition description",
        "label": "Business Acquisition, Description of Acquired Entity",
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "terseLabel": "Total consideration amount",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r14"
     ]
    },
    "bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration arrangements, common shares, redemption amount",
        "label": "Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount",
        "documentation": "Business combination contingent consideration arrangements common shares redemption amount."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_BusinessCombinationContingentConsiderationFinalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationFinalPayment",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination contingent consideration final payment",
        "label": "Business Combination Contingent Consideration Final Payment",
        "documentation": "Business combination contingent consideration final payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r106"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r106"
     ]
    },
    "bdsx_BusinessCombinationContingentConsiderationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationShares",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration shares",
        "label": "Business Combination Contingent Consideration Shares",
        "documentation": "Business combination contingent consideration shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r503"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_CARESActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CARESActMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CARES Act",
        "label": "C A R E S Act [Member]",
        "documentation": "CARES act."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CO": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CO",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLORADO"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_COVID19DiagnosticTestRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "COVID19DiagnosticTestRevenueMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19 Test Revenue",
        "label": "C O V I D19 Diagnostic Test Revenue [Member]",
        "documentation": "COVID-19 diagnostic test revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash purchases of property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition contingent consideration gross margin target",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r205",
      "r744"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r178"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2011 beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2011 end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r147",
      "r235"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r147"
     ]
    },
    "bdsx_CashCollateralizedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CashCollateralizedMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Collateralized",
        "label": "Cash Collateralized [Member]",
        "documentation": "Cash collateralized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "bdsx_CellCartaLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CellCartaLicenseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CellCarta License",
        "label": "Cell Carta License [Member]",
        "documentation": "CellCarta License."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CentennialValleyPropertiesILlcLeaseAgreementMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centennial Valley Properties I, LLC Lease Agreement.",
        "label": "Centennial Valley Properties I, LLC Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "label": "Change In Fair Value Of Contingent Consideration Excluding Accretion Expense",
        "documentation": "Change in fair value of contingent consideration excluding accretion expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ChiefExecutiveOfficerAndChiefFinancialOfficerMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer and Chief Financial Officer",
        "label": "Chief Executive Officer and Chief Financial Officer [Member]",
        "documentation": "Chief executive officer and chief financial officer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r212",
      "r213",
      "r214",
      "r239",
      "r266",
      "r267",
      "r269",
      "r271",
      "r277",
      "r278",
      "r305",
      "r336",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r377",
      "r378",
      "r381",
      "r384",
      "r391",
      "r539",
      "r619",
      "r620",
      "r621",
      "r622",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r657",
      "r678",
      "r697",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r878",
      "r897",
      "r905"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r277",
      "r377",
      "r378",
      "r379",
      "r381",
      "r384",
      "r389",
      "r391",
      "r619",
      "r620",
      "r621",
      "r622",
      "r762",
      "r878",
      "r897"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expiration date",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional warratns exercisable",
        "label": "Class of Warrant or Right, Additional Warrants or Rights Exercisable",
        "documentation": "Class of warrant or right, additional warrants or rights exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant, exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Warrant Or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant issued to purchase shares",
        "terseLabel": "Warrant issued to purchase shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant issued to purchase shares",
        "terseLabel": "Warrants to purchase shares of common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsOrRightsExercisable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable",
        "label": "Class of Warrant or Right, Warrants or Rights Exercisable",
        "documentation": "Class of warrant or right, warrants or rights exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_CollateralAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollateralAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Collateralized",
        "label": "Collateral Held [Axis]",
        "documentation": "Information by category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_CollateralDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollateralDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Domain]",
        "documentation": "Category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_CommitmentSharesIssuableOnConditionalBasis": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CommitmentSharesIssuableOnConditionalBasis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment shares issuable on conditional basis.",
        "label": "Commitment Shares Issuable on Conditional Basis",
        "terseLabel": "Commitment shares issuable on conditional basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r121",
      "r587",
      "r656"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r328",
      "r329",
      "r729",
      "r915"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "bdsx_CommonStockIssuedForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CommonStockIssuedForDeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for deferred offering costs",
        "label": "Common Stock Issued For Deferred Offering Costs",
        "documentation": "Common stock issued for deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r789",
      "r790",
      "r791",
      "r792",
      "r901",
      "r902",
      "r960",
      "r985",
      "r988"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value",
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "terseLabel": "Common stock, authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r657"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "terseLabel": "Common stock, issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r136",
      "r657",
      "r675",
      "r988",
      "r989"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 authorized; 96,235,883 (2023) and 77,614,358 (2022) shares issued and outstanding",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r589",
      "r782"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r115",
      "r116",
      "r301",
      "r728"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r115",
      "r116",
      "r301",
      "r614",
      "r728"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r115",
      "r116",
      "r301",
      "r728",
      "r883"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r189"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r115",
      "r116",
      "r301"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62",
      "r63",
      "r115",
      "r177",
      "r728"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r115",
      "r116",
      "r301",
      "r728"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Process",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration estimated fair value",
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "bdsx_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "documentation": "Contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ContingentConsiderationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ContingentConsiderationPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r405"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current deferred revenue",
        "terseLabel": "Non-current deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r405"
     ]
    },
    "bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount reclassified from non-current liabilities",
        "label": "Contract With Customer Liability Reclassified From Non Current Liabilities",
        "documentation": "Contract with customer liability reclassified from non-current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r349",
      "r379",
      "r566",
      "r745",
      "r747"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_CurrentPortionOfContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "CurrentPortionOfContingentConsiderationMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Portion of Contingent Consideration",
        "label": "Current Portion Of Contingent Consideration [Member]",
        "documentation": "Current portion of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r301"
     ]
    },
    "us-gaap_CustomerFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerFunds",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable deposit",
        "label": "Customer Funds",
        "documentation": "Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r237",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r361",
      "r368",
      "r369",
      "r371"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Principal balance outstanding",
        "documentation": "Amount of the total principal payments made during the annual reporting period."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r129",
      "r130",
      "r180",
      "r182",
      "r243",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r551",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r898"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Applicable margin rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes/Loan payable",
        "terseLabel": "Loan principle amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r182",
      "r372"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt instrument, aggregate principal amount",
        "terseLabel": "Aggregate loan amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r120",
      "r346",
      "r551",
      "r758",
      "r759"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r118",
      "r375",
      "r551"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r347"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r551",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r898"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, maturity date",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Debt instrument maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r757",
      "r962"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r243",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r551",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r898"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r85",
      "r88",
      "r117",
      "r118",
      "r120",
      "r122",
      "r162",
      "r163",
      "r243",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r551",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r898"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, discount",
        "label": "Debt Instrument, Unamortized Discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r120",
      "r923"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "negatedLabel": "Unamortized debt discount and debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r357",
      "r373",
      "r758",
      "r759"
     ]
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs included in accounts payable and other accrued liabilities",
        "label": "Debt Issuance Costs Included in Accounts Payable and Other Accrued Liabilities",
        "documentation": "Debt issuance costs included in Accounts payable and other accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r181",
      "r485"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs amortized against Additional paid-in capital",
        "label": "Deferred Offering Costs Amortized Against Additional Paid-In Capital",
        "documentation": "Deferred offering costs amortized against additional paid-in capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DeferredRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DeferredRevenueMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue",
        "label": "Deferred Revenue [Member]",
        "documentation": "Deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest expense limitation",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "bdsx_DeferredTaxAssetsCapitalizedResearchCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchCosts",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research costs",
        "label": "Deferred Tax Assets Capitalized Research Costs",
        "documentation": "Deferred tax Aassets capitalized research costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "bdsx_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets and liabilities",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets after valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r958"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation tax carryforwards",
        "label": "Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration",
        "documentation": "Deferred tax assets research and experimentation tax carryforwards subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r958"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r958"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r958"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r958"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r958"
     ]
    },
    "bdsx_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Asset",
        "label": "Deferred Tax Liabilities Right of Use Asset",
        "documentation": "Deferred tax liabilities right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer discretionary contributions amount",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DefinedContributionPlanNameExtensibleList": {
     "xbrltype": "tokenItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DefinedContributionPlanNameExtensibleList",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan Name [Extensible List]",
        "label": "Defined Contribution Plan Name Extensible List",
        "documentation": "Defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution 401(k) Plan",
        "label": "Defined Contribution Plan [Text Block]",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r76"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r76"
     ]
    },
    "bdsx_DescriptionOfOfferingPeriodUnderPlan": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DescriptionOfOfferingPeriodUnderPlan",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of offering period under plan",
        "label": "Description Of Offering Period Under Plan",
        "documentation": "Description of offering period under plan."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of voting power or value of stock for employee participation in offering period",
        "label": "Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period",
        "documentation": "Description of voting power or value of stock for employee participation in offering period."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DiagnosticTestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DiagnosticTestsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diagnostic Tests",
        "label": "Diagnostic Tests [Member]",
        "documentation": "Diagnostic tests."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DiligenceExpenseAndLegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DiligenceExpenseAndLegalFees",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diligence expenses and legal fees",
        "label": "Diligence Expense and Legal Fees",
        "documentation": "Diligence expense and legal fees."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DirectCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DirectCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct costs and expenses",
        "label": "Direct Costs And Expenses",
        "documentation": "Direct costs and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DirectCostsAndExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DirectCostsAndExpensesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct Costs and Expenses",
        "label": "Direct Costs And Expenses [Member]",
        "documentation": "Direct costs and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_DirectCostsAndExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "DirectCostsAndExpensesPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct Costs and Expenses",
        "label": "Direct Costs And Expenses Policy [Text Block]",
        "documentation": "Direct costs and expenses policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r423",
      "r454",
      "r455",
      "r458",
      "r776"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Common Stock, Total",
        "terseLabel": "Dividends",
        "label": "Dividends, Common Stock",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r164"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r814"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r814",
      "r850"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r264",
      "r266",
      "r269",
      "r270",
      "r271",
      "r275",
      "r523",
      "r524",
      "r583",
      "r597",
      "r749"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r266",
      "r269",
      "r270",
      "r271",
      "r275",
      "r523",
      "r524",
      "r583",
      "r597",
      "r749"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r272",
      "r273",
      "r274"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r474",
      "r498"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r959"
     ]
    },
    "bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "negatedLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "documentation": "Effective income tax rate reconciliation permanent items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r959"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and developments credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r959"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Compensation related accruals",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized to expense period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining unrecognized share based compensation expense for options and restricted stock units",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r200",
      "r221",
      "r222",
      "r223",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r260",
      "r276",
      "r306",
      "r309",
      "r393",
      "r459",
      "r460",
      "r461",
      "r491",
      "r492",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r522",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r564",
      "r606",
      "r607",
      "r608",
      "r626",
      "r697"
     ]
    },
    "bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity financing costs included in accounts payable and other accrued liabilities",
        "label": "Equity Financing Costs Included in Accounts Payable and Other Accrued Liabilities",
        "documentation": "Equity financing costs included in Accounts payable and other accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_EquityFinancingProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "EquityFinancingProgramsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Financing Programs",
        "label": "Equity Financing Programs [Member]",
        "documentation": "Equity Financing Programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesByIndustryAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector",
        "label": "Industry Sector [Axis]",
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r642",
      "r645",
      "r705",
      "r707",
      "r712",
      "r716",
      "r754",
      "r787"
     ]
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesIndustryMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector",
        "label": "Industry Sector [Domain]",
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r642",
      "r645",
      "r705",
      "r707",
      "r712",
      "r716",
      "r787"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r818",
      "r828",
      "r854"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r815",
      "r825",
      "r851"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r538",
      "r758",
      "r759"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "bdsx_ExistingShareholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ExistingShareholdersMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existing Shareholders",
        "label": "existing shareholders member",
        "documentation": "existing shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ExitFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ExitFeePayment",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exit fee payment",
        "documentation": "Exit fee payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrant liability, net",
        "terseLabel": "Change in fair value of warrant liability, net",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r9"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r535"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r535"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r530",
      "r570",
      "r571",
      "r572",
      "r758",
      "r759",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r175"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r110",
      "r359",
      "r758",
      "r759"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r532",
      "r533",
      "r536"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r758",
      "r759"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r409",
      "r414",
      "r530",
      "r571",
      "r758",
      "r759",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r530",
      "r572",
      "r758",
      "r759",
      "r770",
      "r771",
      "r772"
     ]
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Table]",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Table]",
        "documentation": "Disclosure of information about liabilities measured at fair value on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reported Fair values of Contingent Consideration and Warrant Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r176"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r112"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Contingent Consideration and Warrant Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r112"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsInterestExpense",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Fair Value Measurement With Unobservable Inputs Interest Expense",
        "documentation": "Fair value measurement with unobservable inputs interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "terseLabel": "Payments",
        "label": "Fair Value Measurement with Unobservable Inputs Payments of Contingent Consideration",
        "documentation": "Fair value measurement with unobservable inputs payments of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in fair value, net",
        "terseLabel": "Changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r570",
      "r571",
      "r572",
      "r758",
      "r759",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r536"
     ]
    },
    "bdsx_FiclatuzumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FiclatuzumabMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ficlatuzumab",
        "label": "Ficlatuzumab [Member]",
        "documentation": "Ficlatuzumab."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible asset, useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets subject to amortization, Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r323"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortization Expense Related to Definite-Lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "documentation": "Finite lived intangible assets amortization expense year six and thereafter.",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r322",
      "r323",
      "r325",
      "r577",
      "r581"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "terseLabel": "Intangible assets subject to amortization, Cost",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r581"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Intangible assets subject to amortization, Net Carrying Value",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r577"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_FirstAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "FirstAmendmentMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Amendment",
        "label": "First Amendment [Member]",
        "documentation": "First Amendment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r858"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of liabilities, net",
        "negatedLabel": "Loss on extinguishment of liabilities, net",
        "negatedTerseLabel": "Loss on extinguishment of liabilities",
        "label": "Loss on debt extinguishment",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Gain (loss) on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r80",
      "r81"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "totalLabel": "Goodwill, Total",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r316",
      "r582",
      "r756",
      "r782",
      "r911",
      "r912"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r319",
      "r756"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairments loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r317",
      "r318",
      "r319",
      "r756"
     ]
    },
    "bdsx_GrossProceedsFromFinancingTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "GrossProceedsFromFinancingTransactions",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from financing transactions",
        "documentation": "Gross proceeds from financing transactions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IPO",
        "terseLabel": "Initial Public Offering",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r814"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total",
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss on intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r913"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r75",
      "r158"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r681"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r681"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r101",
      "r170",
      "r171"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r469",
      "r475",
      "r482",
      "r489",
      "r496",
      "r499",
      "r500",
      "r501",
      "r624"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax examination details",
        "label": "Income Tax Examination, Description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax examination, likelihood of unfavorable settlement",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r169"
     ]
    },
    "bdsx_IncomeTaxExaminationPeriodUnderExamination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "IncomeTaxExaminationPeriodUnderExamination",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax examination, period under examination",
        "label": "Income Tax Examination, Period under Examination",
        "documentation": "Income tax examination, period under examination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r195",
      "r259",
      "r260",
      "r283",
      "r473",
      "r497",
      "r598"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r471",
      "r472",
      "r482",
      "r483",
      "r488",
      "r490",
      "r618"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable and other accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "bdsx_IncreaseDecreaseInContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "IncreaseDecreaseInContingentConsideration",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Increase decrease in contingent consideration",
        "documentation": "Increase decrease in contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r894"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and long-term operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r894"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r324"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance",
        "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance",
        "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Total",
        "terseLabel": "Intangible assets not subject to amortization, Net Carrying Value",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets not subject to amortization, Cost",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill Gross",
        "documentation": "Indefinite lived intangible assets excluding goodwill gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r155"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r822",
      "r832",
      "r849",
      "r858",
      "r862",
      "r870"
     ]
    },
    "bdsx_InitialWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "InitialWarrantsAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial warrants amount",
        "label": "Initial warrants amount",
        "documentation": "Initial warrants amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r874"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r874"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r874"
     ]
    },
    "bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "IntangibleAssetsAccumulatedAmortizationExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets, Accumulated Amortization",
        "label": "Intangible Assets Accumulated Amortization Excluding Goodwill",
        "documentation": "Amount of accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible Assets, Gross (Excluding Goodwill), Total",
        "terseLabel": "Intangible assets, Cost",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, Net Carrying Value",
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r72"
     ]
    },
    "bdsx_IntegratedDiagnosticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "IntegratedDiagnosticsIncMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Indi",
        "terseLabel": "Integrated Diagnostics, Inc",
        "label": "Integrated Diagnostics Inc [Member]",
        "documentation": "Integrated Diagnostics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r185",
      "r224",
      "r282",
      "r550",
      "r682",
      "r793",
      "r987"
     ]
    },
    "bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense due to passage of time and fixed payment schedule",
        "documentation": "Interest expense due to passage of time and fixed payment schedule."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense",
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r233",
      "r234"
     ]
    },
    "bdsx_InterestRateOnExtraAllowanceAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "InterestRateOnExtraAllowanceAmount",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate on extra allowance amount",
        "documentation": "Interest rate on extra allowance amount",
        "label": "Interest rate on extra allowance amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventorySuppliesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventorySuppliesPolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Supplies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for inventory",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r890"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Excess and obsolete inventory",
        "terseLabel": "Inventory excess and obsolescence",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r640",
      "r641",
      "r643",
      "r646",
      "r702",
      "r705",
      "r707",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r787"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r640",
      "r641",
      "r643",
      "r646",
      "r702",
      "r705",
      "r707",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r787"
     ]
    },
    "us-gaap_InvestmentTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeExtensibleEnumeration",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Type [Extensible Enumeration]",
        "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r643",
      "r703",
      "r705",
      "r706",
      "r707",
      "r708",
      "r712",
      "r715",
      "r716"
     ]
    },
    "bdsx_IssuanceOfPerceptiveWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "IssuanceOfPerceptiveWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Perceptive Warrants",
        "label": "Issuance of Perceptive Warrants",
        "documentation": "Issuance of perceptive warrants."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_KS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "KS",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "KANSAS"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LPCFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LPCFacilityMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LPC Facility",
        "label": "L P C Facility [Member]",
        "documentation": "LPC facility."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LandlordContributionTowardsCostOfConstructionAndTenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Landlord contribution towards cost of construction and tenant improvements",
        "documentation": "Landlord contribution towards cost of construction and tenant improvements",
        "label": "Landlord contribution towards cost of construction and tenant improvements"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LeaseAgreementNumberOfOptionsToExtend": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LeaseAgreementNumberOfOptionsToExtend",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease agreement number of options to extend",
        "documentation": "Lease agreement number of options to extend",
        "label": "Lease agreement number of options to extend"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LeaseCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LeaseCommencementDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease commencement date",
        "documentation": "Lease commencement Date",
        "label": "Lease commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LeaseExpirationMonthYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LeaseExpirationMonthYear",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Month Year",
        "documentation": "Lease expiration month year"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LeasedPropertyBuildingCapacity": {
     "xbrltype": "areaItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LeasedPropertyBuildingCapacity",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased property building capacity",
        "documentation": "Leased property building capacity.",
        "label": "Leased property building capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "bdsx_LesseeOperatingAndFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LesseeOperatingAndFinanceLeasesTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeases3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee Operating and Finance Leases [Text Block]",
        "documentation": "Lessee operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of lease",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease description",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Description",
        "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]",
        "terseLabel": "Lease option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less amount representing tenant improvement allowances",
        "terseLabel": "Less amount representing tenant improvement allowances",
        "label": "Lessee, operating lease, liability, amount representing tenant improvement allowances",
        "documentation": "Lessee, operating lease, liability, amount representing tenant improvement allowances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating leases, Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, 2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, 2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, 2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, 2029 and thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Six and Thereafter",
        "documentation": "Lessee, operating lease, liability, to be paid, year six and thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating leases, Less amount representing interest",
        "terseLabel": "Less amount representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, expiration term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "bdsx_LessorReimbursementsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LessorReimbursementsReceived",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor reimbursements received",
        "label": "Lessor Reimbursements Received",
        "documentation": "Lessor reimbursements received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r239",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r508",
      "r511",
      "r512",
      "r539",
      "r655",
      "r750",
      "r795",
      "r920",
      "r969",
      "r970"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r183",
      "r591",
      "r782",
      "r899",
      "r909",
      "r963"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r204",
      "r239",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r508",
      "r511",
      "r512",
      "r539",
      "r782",
      "r920",
      "r969",
      "r970"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "terseLabel": "Total contingent consideration",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non\u2011current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r126",
      "r127",
      "r128",
      "r131",
      "r239",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r508",
      "r511",
      "r512",
      "r539",
      "r920",
      "r969",
      "r970"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non\u2011current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LicenseAgreementExpiryDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LicenseAgreementExpiryDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License expiry date",
        "label": "License Agreement Expiry Date",
        "documentation": "License agreement expiry date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Rights",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "bdsx_LincolnParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LincolnParkMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park.",
        "label": "Lincoln Park Member",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term Line of Credit",
        "totalLabel": "Long-term Line of Credit, Total",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Letter of credit subject to contingent reduction over the term of the lease",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r182",
      "r980"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining available capacity for share issuance",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "bdsx_LitigationClaimsAndAssessmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LitigationClaimsAndAssessmentsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation claims and assessments.",
        "label": "Litigation Claims And Assessments [Member]",
        "terseLabel": "Litigation Claims and Assessments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Final settlement payment to third parties",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount withdrawn",
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r182",
      "r358",
      "r374",
      "r758",
      "r759",
      "r980"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r243",
      "r363"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r243",
      "r363"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r243",
      "r363"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails": {
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Noncurrent",
        "totalLabel": "Long-term notes payable",
        "terseLabel": "Long-term notes payable, net of current portion",
        "verboseLabel": "Long-term notes payable",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "bdsx_LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 and thereafter",
        "label": "LongT erm Debt Maturities Repayments Of Principal In Year Four And Thereafter",
        "documentation": "Long term debt maturities repayments of principal in year four and thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r78"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r335",
      "r916",
      "r917"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r335",
      "r916",
      "r917"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrued legal contingency",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r879"
     ]
    },
    "bdsx_LossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LossMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss member.",
        "label": "Loss [Member]",
        "terseLabel": "Loss"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_LungDiagnosticRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "LungDiagnosticRevenueMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lung Diagnostic Revenue",
        "label": "Lung Diagnostic Revenue [Member]",
        "documentation": "Lung diagnostic revenue."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r765",
      "r925",
      "r983",
      "r984"
     ]
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-Term Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r417",
      "r574",
      "r605",
      "r647",
      "r648",
      "r704",
      "r706",
      "r709",
      "r710",
      "r715",
      "r739",
      "r740",
      "r753",
      "r762",
      "r775",
      "r784",
      "r922",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of common stock allowed to purchase by counterparty.",
        "label": "Maximum Percentage of Common Stock Allowed to Purchase by Counterparty",
        "terseLabel": "Maximum percentage of common stock allowed to purchase by counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Term",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Volatility",
        "terseLabel": "Volatility rate",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-Free Interest Rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "MedicareMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare",
        "label": "Medicare [Member]",
        "documentation": "Medicare."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_MinimumAnnualVolumePercentageThereafter": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "MinimumAnnualVolumePercentageThereafter",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum annual volume percentage thereafter",
        "label": "Minimum Annual Volume Percentage Thereafter",
        "documentation": "Minimum annual volume percentage thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_MinimumCashBalanceAtMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "MinimumCashBalanceAtMaturityDate",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum cash balance at maturity date",
        "documentation": "Minimum cash balance at maturity date."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r417",
      "r574",
      "r605",
      "r647",
      "r648",
      "r704",
      "r706",
      "r709",
      "r710",
      "r715",
      "r739",
      "r740",
      "r753",
      "r762",
      "r775",
      "r784",
      "r922",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "bdsx_NSCLCPOCTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NSCLCPOCTrialMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NSCLC POC Trial",
        "label": "N S C L C P O C Trial [Member]",
        "documentation": "Nsclc poc trial."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r765",
      "r925",
      "r983",
      "r984"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash and cash equivalents and restricted cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash and cash equivalents and restricted cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash and cash equivalents and restricted cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r149",
      "r184",
      "r202",
      "r218",
      "r219",
      "r223",
      "r239",
      "r249",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r268",
      "r279",
      "r291",
      "r295",
      "r297",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r524",
      "r539",
      "r596",
      "r677",
      "r695",
      "r696",
      "r751",
      "r793",
      "r920"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_NetProceedFromFinancingTransactionsss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NetProceedFromFinancingTransactionsss",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds after deducting commissions, fees and expenses payable",
        "label": "Net Proceed From Financing Transactionsss",
        "documentation": "Net proceed from financing transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Issued Accounting Standards",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r197",
      "r201",
      "r247",
      "r248",
      "r251",
      "r252",
      "r261",
      "r262",
      "r307",
      "r308",
      "r493",
      "r494",
      "r495",
      "r518",
      "r521",
      "r525",
      "r526",
      "r527",
      "r540",
      "r541",
      "r542",
      "r552",
      "r553",
      "r565",
      "r578",
      "r579",
      "r580",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r849",
      "r858"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Notes payable, total",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r182",
      "r980"
     ]
    },
    "bdsx_NotesPayable2018NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NotesPayable2018NotesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Notes",
        "label": "Notes Payable2018 Notes [Member]",
        "documentation": "Notes payable 2018 notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails": {
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Notes Payable, Current, Total",
        "terseLabel": "Less: current maturities",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableToBankCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of notes payable",
        "label": "Notes Payable to Bank, Current",
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "bdsx_NumberOfCancerTest": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfCancerTest",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of blood based lung cancer test",
        "label": "Number Of Cancer Test",
        "documentation": "Number of cancer test."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_NumberOfCommercialBloodBasedTest": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfCommercialBloodBasedTest",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of commercial blood-based test",
        "label": "Number Of Commercial Blood Based Test",
        "documentation": "Number of commercial blood based test."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_NumberOfFacility": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfFacility",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of facility",
        "label": "Number of Facility",
        "documentation": "Number of facility."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_NumberOfOfficers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfOfficers",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of officers",
        "label": "Number of Officers",
        "documentation": "Number of officers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "bdsx_NumberOfPreferredStockConvertedIntoCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfPreferredStockConvertedIntoCommonStock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of preferred stock converted into common stock",
        "label": "Number Of Preferred Stock Converted Into Common Stock",
        "documentation": "Number of preferred stock converted into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_NumberOfSARSCoV2Test": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfSARSCoV2Test",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of SARS-CoV-2 test",
        "label": "Number Of S A R S Co V2 Test",
        "documentation": "Number of SARS-CoV-2 test."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of subscription agreement for which final closing to be delayed",
        "label": "Number of subscription agreement for which final closing to be delayed",
        "documentation": "Number of subscription agreement for which final closing to be delayed."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OffsettingDeferredRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OffsettingDeferredRent",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Deferred Rent",
        "documentation": "Offsetting deferred rent."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OncimmuneLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OncimmuneLimitedMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oncimmune Limited",
        "label": "Oncimmune Limited [Member]",
        "documentation": "Oncimmune Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open tax year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r291",
      "r295",
      "r297",
      "r751"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability",
        "totalLabel": "Total lease liabilities",
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "terseLabel": "Right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842",
        "label": "Operating Lease Right-of-Use Assets Obtained in Exchange for Lease Liabilities at Adoption of ASC 842",
        "documentation": "Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r781"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r781"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesRentExpenseNet",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Leases, Rent Expense, Net, Total",
        "terseLabel": "Rent expense",
        "label": "Operating Leases, Rent Expense, Net",
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "bdsx_OptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options and Restricted Stock Units",
        "label": "Options And Restricted Stock Units [Member]",
        "documentation": "Options and restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OptionsAndRestrictedStockUnitsRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OptionsAndRestrictedStockUnitsRSUsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options and Restricted Stock Units (RSUs)",
        "label": "Options And Restricted Stock Units R S Us [Member]",
        "documentation": "Options and restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to Purchase Common Stock",
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OrganizationAndDescriptionOfBusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OrganizationAndDescriptionOfBusinessAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization And Description Of Business [Abstract]",
        "documentation": "Organization and description of business."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OrganizationAndDescriptionOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OrganizationAndDescriptionOfBusinessLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Description Of Business [Line Items]",
        "label": "Organization And Description Of Business [Line Items]",
        "documentation": "Organization and description of business."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_OrganizationAndDescriptionOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OrganizationAndDescriptionOfBusinessTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Description Of Business [Table]",
        "label": "Organization And Description Of Business [Table]",
        "documentation": "Organization and description of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Description of Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r174",
      "r615",
      "r616"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r782"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "bdsx_OtherAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OtherAssetsPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets Policy Text Block",
        "documentation": "Other Assets Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInventorySupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInventorySupplies",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Other Inventory, Supplies, Gross",
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r782"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "bdsx_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "OtherMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other [Member]",
        "documentation": "Other member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Long-term Assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Long-term Liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income , net",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPaymentsToAcquireBusinesses",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire license rights",
        "label": "Other Payments to Acquire Businesses",
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r820",
      "r830",
      "r856"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r823",
      "r833",
      "r859"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r823",
      "r833",
      "r859"
     ]
    },
    "bdsx_POCClinicalTrialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "POCClinicalTrialsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "POC Clinical Trials",
        "label": "P O C Clinical Trials [Member]",
        "documentation": "Poc clinical trials."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "bdsx_PaymentOfDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PaymentOfDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs",
        "label": "Payment Of Deferred Offering Costs",
        "documentation": "Payment of deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PaymentOfEquityFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PaymentOfEquityFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity financing costs",
        "label": "Payment of Equity Financing Costs",
        "documentation": "Payment of equity financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Patent costs and intangible asset acquisition, net",
        "label": "Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net",
        "documentation": "Payments for proceeds from patent costs and intangible asset acquisition, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r504"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "terseLabel": "Contingent consideration cash payment",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfDevelopmentAndRegulatoryCosts",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Responsible percentage of development and regulatory costs",
        "label": "Percentage Of Development And Regulatory Costs",
        "documentation": "Percentage of development and regulatory costs."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of development and regulatory costs exercised using opt-out right",
        "label": "Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right",
        "documentation": "Percentage of development and regulatory costs exercised using opt-out right."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfFeePaymentsOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfFeePaymentsOnNetSales",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fee payments on net sales",
        "label": "Percentage Of Fee Payments On Net Sales",
        "documentation": "Percentage of fee payments on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfInterestOnContingentConsideration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfInterestOnContingentConsideration",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of interest on installment payments",
        "documentation": "Percentage of interest on contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfLicenseIncomeGeneratedFromLicensing",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of license income generated from licensing",
        "label": "Percentage Of License Income Generated From Licensing",
        "documentation": "Percentage of license income generated from licensing."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range",
        "label": "Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range",
        "documentation": "Percentage of probabilities of contingent consideration successful achievement milestone discount rates range."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests",
        "documentation": "Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.",
        "verboseLabel": "Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of license agreement and royalty payment related to Nodify CDT test recognized revenue for non-screening tests",
        "label": "Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests.",
        "documentation": "Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalty payments not required on net revenue",
        "label": "Percentage Of Royalty Payments Not Required To Pay On Net Revenue",
        "documentation": "Percentage of royalty payments not required to pay on net revenue."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfRoyaltyPaymentsOnNetRevenue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalty payments on net revenue",
        "label": "Percentage Of Royalty Payments On Net Revenue",
        "documentation": "Percentage of royalty payments on net revenue."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalty payments on net sales",
        "label": "Percentage Of Royalty Payments On Net Sales",
        "documentation": "Percentage of royalty payments on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of valuation allowance equal to net deferred tax assets",
        "label": "Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets",
        "documentation": "Percentage of valuation allowance equal to net deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PerceptiveTermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PerceptiveTermLoanFacilityMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Perceptive Term Loan Facility",
        "label": "Perceptive Term Loan Facility [Member]",
        "documentation": "Perceptive term loan facility."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PerceptiveTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PerceptiveTermLoanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Perceptive Term Loan Facility",
        "terseLabel": "Perceptive Term Loan",
        "label": "Perceptive Term Loan [Member]",
        "documentation": "Perceptive term loan member."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PerformanceConditionOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PerformanceConditionOptionsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Condition Options",
        "label": "Performance Condition Options [Member]",
        "documentation": "Performance condition options."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PeriodOfEscalationsOfSales": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PeriodOfEscalationsOfSales",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of escalations of sales",
        "label": "Period Of Escalations Of Sales",
        "documentation": "Period of escalations of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value",
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r377"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized",
        "terseLabel": "Preferred stock, authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r657"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, issued",
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r377"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r657",
      "r675",
      "r988",
      "r989"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2023 and 2022) issued and outstanding",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r588",
      "r782"
     ]
    },
    "bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment premium percentage of aggregate outstanding principal amount",
        "documentation": "Prepayment premium percentage of aggregate outstanding principal amount."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PrimarySourcesOfRevenueDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PrimarySourcesOfRevenueDescription",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary sources of revenue description.",
        "label": "Primary Sources Of Revenue Description",
        "terseLabel": "Primary sources of revenue, description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Private Placements",
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from net of debt issuance costs and original issue discounts",
        "terseLabel": "Net proceeds from debt, after deducting debt issuance costs and expenses",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of common shares",
        "verboseLabel": "Proceeds from the issuance of common stock",
        "label": "Proceeds from the sale of common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "bdsx_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock net.",
        "label": "Proceeds From Issuance Of Common Stock Net",
        "terseLabel": "Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock under employee stock purchase plan.",
        "label": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Private placement in net equity proceeds",
        "terseLabel": "Aggregate purchase price",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ProceedsFromIssuanceOfTermLoanAndNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from term loan and notes payable",
        "label": "Proceeds From Issuance Of Term Loan And Notes Payable",
        "documentation": "Proceeds from issuance of term loan and notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Funding amount",
        "label": "Gross proceeds from an equity offering of common stock",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "terseLabel": "Gross proceeds from sale of common shares",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r619"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from exercise of stock options",
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26"
     ]
    },
    "bdsx_ProductLifeAndPatentLifeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ProductLifeAndPatentLifeMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Life and Patent Life",
        "label": "Product Life And Patent Life [Member]",
        "documentation": "Product life and patent life."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r576",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r742",
      "r763",
      "r783",
      "r885",
      "r918",
      "r919",
      "r925",
      "r983"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r576",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r742",
      "r763",
      "r783",
      "r885",
      "r918",
      "r919",
      "r925",
      "r983"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r218",
      "r219",
      "r231",
      "r239",
      "r249",
      "r259",
      "r260",
      "r279",
      "r291",
      "r295",
      "r297",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r506",
      "r509",
      "r510",
      "r524",
      "r539",
      "r584",
      "r595",
      "r625",
      "r677",
      "r695",
      "r696",
      "r751",
      "r779",
      "r780",
      "r794",
      "r891",
      "r920"
     ]
    },
    "bdsx_PromissoryNoteOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PromissoryNoteOneMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note One",
        "label": "Promissory Note One [Member]",
        "documentation": "Promissory note one."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PromissoryNoteTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PromissoryNoteTwoMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note Two",
        "label": "Promissory Note Two [Member]",
        "documentation": "Promissory note two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r206",
      "r594"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r585",
      "r594",
      "r782"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r190",
      "r191",
      "r592"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful Lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for doubtful accounts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r312"
     ]
    },
    "bdsx_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PublicOfferingPricePerShareOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PublicOfferingPricePerShareOfCommonStock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price per share of common stock",
        "label": "Public offering price per share of common stock",
        "documentation": "Public offering price per share of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PurchaseAgreementTerm",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement term.",
        "label": "Purchase Agreement Term",
        "terseLabel": "Purchase agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PurchasedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PurchasedTechnologyMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased Technology",
        "label": "Purchased Technology [Member]",
        "documentation": "Purchased technology."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases of property &amp; equipment included in accounts payable and accrued liabilities",
        "documentation": "Purchases of property &amp; equipment included in accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r408",
      "r417",
      "r449",
      "r450",
      "r451",
      "r573",
      "r574",
      "r605",
      "r647",
      "r648",
      "r704",
      "r706",
      "r709",
      "r710",
      "r715",
      "r739",
      "r740",
      "r753",
      "r762",
      "r775",
      "r784",
      "r787",
      "r914",
      "r922",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r408",
      "r417",
      "r449",
      "r450",
      "r451",
      "r573",
      "r574",
      "r605",
      "r647",
      "r648",
      "r704",
      "r706",
      "r709",
      "r710",
      "r715",
      "r739",
      "r740",
      "r753",
      "r762",
      "r775",
      "r784",
      "r787",
      "r914",
      "r922",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of warrant liability to additional paid-in capital",
        "label": "Reclassification Of Warrant Liability To Additional Paid In Capital",
        "documentation": "Reclassification of warrant liability to additional paid-in-capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r815",
      "r825",
      "r851"
     ]
    },
    "us-gaap_RegulatoryLiabilityAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegulatoryLiabilityAmortizationPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Liability, Amortization Period",
        "documentation": "Amortization period for the recovery of regulatory liability, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received",
        "documentation": "Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_RemainingCapacityUnderTheTenantImprovementAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RemainingCapacityUnderTheTenantImprovementAllowances",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining capacity under the tenant improvement allowances",
        "label": "Remaining Capacity Under the Tenant Improvement Allowances",
        "documentation": "Remaining capacity under the tenant improvement allowances."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_RemainingEstimatedObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RemainingEstimatedObligation",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining estimated obligation",
        "label": "Remaining Estimated Obligation",
        "documentation": "Remaining estimated obligation."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_RentAfterFixedEscalationProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RentAfterFixedEscalationProvisions",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent after fixed escalation provisions",
        "documentation": "Rent after fixed escalation provisions.",
        "label": "Rent after fixed escalation provisions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount used to retire outstanding debt",
        "totalLabel": "Repayments of Long-term Debt, Total",
        "negatedLabel": "Repayment of term loan and notes payable",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r622"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r349",
      "r379",
      "r566",
      "r746",
      "r747"
     ]
    },
    "bdsx_RepurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RepurchaseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase",
        "label": "Repurchase [Member]",
        "documentation": "Repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r468",
      "r977"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r816",
      "r826",
      "r852"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r817",
      "r827",
      "r853"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r824",
      "r834",
      "r860"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r896",
      "r978",
      "r981"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r164",
      "r590",
      "r609",
      "r613",
      "r623",
      "r658",
      "r782"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r260",
      "r306",
      "r309",
      "r459",
      "r460",
      "r461",
      "r491",
      "r492",
      "r513",
      "r515",
      "r516",
      "r519",
      "r522",
      "r606",
      "r608",
      "r626",
      "r988"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and Accounts Receivable Credit Concentration",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r407"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r741",
      "r748"
     ]
    },
    "bdsx_RevenueShareAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RevenueShareAgreementMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Share Agreement",
        "label": "Revenue Share Agreement [Member]",
        "documentation": "Revenue share agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_RevenueShareExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "RevenueShareExpenses",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue share expenses",
        "label": "Revenue Share Expenses",
        "documentation": "Revenue share expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Revenues",
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r239",
      "r280",
      "r281",
      "r290",
      "r293",
      "r294",
      "r298",
      "r299",
      "r301",
      "r305",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r539",
      "r584",
      "r920"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use assets obtained in exchange for lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r781"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r781"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty expense",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SaleOfStockSharesIssuedAsCommitmentFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SaleOfStockSharesIssuedAsCommitmentFee",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, shares issued as commitment fee.",
        "label": "Sale of Stock, Shares Issued as Commitment Fee",
        "terseLabel": "Shares issued as commitment fee"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SaleOfStockStockIssuablePerDayShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SaleOfStockStockIssuablePerDayShares",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, stock issuable per day, shares.",
        "label": "Sale of Stock, Stock Issuable Per Day, Shares",
        "terseLabel": "Stock issuable per day, number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SaleOfStockStockIssuablePerDayValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SaleOfStockStockIssuablePerDayValue",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, stock issuable per day, value.",
        "label": "Sale of Stock, Stock Issuable Per Day, Value",
        "terseLabel": "Stock issuable per day, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r882"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r418",
      "r904"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r418",
      "r879",
      "r904"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r104",
      "r502"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Outstanding Borrowings",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Long-term Notes Payable",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r85",
      "r88",
      "r117",
      "r118",
      "r120",
      "r122",
      "r162",
      "r163",
      "r758",
      "r760",
      "r900"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation Expense Related to Property and Equipment",
        "label": "Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]",
        "documentation": "Schedule of depreciation and amortization expense related to property and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r577"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Lease Obligations",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets, Excluding Goodwill",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled Principal Repayments (Maturities) of Long-term Obligations",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r422",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r162",
      "r163",
      "r164",
      "r212",
      "r213",
      "r214",
      "r277",
      "r377",
      "r378",
      "r379",
      "r381",
      "r384",
      "r389",
      "r391",
      "r619",
      "r620",
      "r621",
      "r622",
      "r762",
      "r878",
      "r897"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity for Convertible Preferred Stock Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r956"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Estimated Amortization Expense of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62",
      "r63",
      "r115",
      "r177"
     ]
    },
    "bdsx_SecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SecondAmendmentMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment.",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SecuritiesPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SecuritiesPurchaseAgreementsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement",
        "label": "Securities Purchase Agreements [Member]",
        "documentation": "Securities purchase agreements."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r639",
      "r642",
      "r644",
      "r705",
      "r707",
      "r712",
      "r716",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r743",
      "r764",
      "r787",
      "r925",
      "r983"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r299",
      "r752"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "terseLabel": "Sales, marketing, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales, Marketing, General and Administrative",
        "terseLabel": "Selling, Marketing, General and Administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, Marketing, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "bdsx_SeriesA1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SeriesA1PreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Preferred Stock",
        "label": "Series A1 Preferred Stock [Member]",
        "documentation": "Series A-1 preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SeriesA2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SeriesA2PreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A2 Preferred Stock",
        "label": "Series A2 Preferred Stock [Member]",
        "documentation": "Series A-2 preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SeriesA3PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SeriesA3PreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A3 Preferred Stock",
        "label": "Series A3 Preferred Stock [Member]",
        "documentation": "Series A-3 preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SeriesB1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B1 Convertible Preferred Stock",
        "label": "Series B1 Convertible Preferred Stock [Member]",
        "documentation": "Series B-1 Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Preferred Stock",
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "bdsx_SeriesEConvertiblePreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SeriesEConvertiblePreferredStockWarrantsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Convertible Preferred Stock Warrants",
        "label": "Series E Convertible Preferred Stock Warrants [Member]",
        "documentation": "Series E convertible preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Preferred Stock",
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series F Preferred Stock",
        "label": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "bdsx_SeriesGConvertiblePreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SeriesGConvertiblePreferredStockWarrantsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series G Convertible Preferred Stock Warrants",
        "label": "Series G Convertible Preferred Stock Warrants [Member]",
        "documentation": "Series G convertible preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesGPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series G Preferred Stock",
        "label": "Series G Preferred Stock [Member]",
        "documentation": "Series G preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesHPreferredStockMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series H Convertible Preferred Stock",
        "label": "Series H Preferred Stock [Member]",
        "documentation": "Series H preferred stock."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r924"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "terseLabel": "share-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fair market value of common stock for purchase under plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "documentation": "Discount rate from fair value on offering date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, December 31, 2023",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance",
        "terseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Released",
        "terseLabel": "Release of restricted stock units, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Release of restricted stock units",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than OptionsVested In Period Amount",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than optionsvested in period amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk\u2011free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r422",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of earnings used for purchase of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/canceled, warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Shares, Granted",
        "terseLabel": "Granted, warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs outstanding",
        "periodStartLabel": "Outstanding - January 1, 2020, warrants",
        "periodEndLabel": "Outstanding - December 31, 2020, warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease), Total",
        "negatedLabel": "Reclassification of warrant liability to additional paid-in capital, warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)",
        "documentation": "Increase (decrease) in the number of shares under non-option equity instrument agreements."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted average exercise price, Forfeited/canceled, warrants",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding - January 1, 2020, warrants",
        "periodEndLabel": "Weighted average exercise price,Outstanding - December, 31, 2020, warrants",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant under all plans",
        "verboseLabel": "Additional stock awards granted",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Exercisable - December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable - December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "negatedLabel": "Stock Options, Forfeited/canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited/canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of performance-condition options granted",
        "terseLabel": "Stock Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding - January 1, 2023",
        "label": "Aggregate Intrinsic Value, Outstanding - December 31, 2023",
        "verboseLabel": "Intrinsic value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding - December 31, 2021",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - January 1, 2021",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stock Options, Outstanding - December 31, 2023",
        "periodStartLabel": "Stock Options, Outstanding - January 1, 2023",
        "verboseLabel": "Number of outstanding stock options granted",
        "terseLabel": "Number of outstanding stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding - December 31, 2023",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding - January 1, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of number of shares of common stock issued and outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of eligible holders elected to exchange",
        "label": "Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected",
        "documentation": "Number of grantees affected by modification of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued",
        "terseLabel": "Number of common stock may be issued under incentive plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised, warrants",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted, warrants",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled under the Option Exchange",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Cancelled under the Option Exchange, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Cancelled under the Option Exchange, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted under the Option Exchange",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Granted under the Option Exchange, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangements by Share-Based Payment Award, Option, Granted under the Option Exchange, Weighted Average Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of options granted",
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "First Tranche",
        "terseLabel": "Tranche A Loan",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three Tranche",
        "terseLabel": "Tranche C Loan",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Two Tranche",
        "terseLabel": "Tranche B Loan",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r427",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares of common stock underlying eligible options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Contractual Life (Years), Exercisable - December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Contractual Life (Years), Granted",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1",
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Outstanding - January 1, 2023",
        "periodEndLabel": "Number of Shares, Outstanding - December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited/canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, January 1, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Contractual Life (Years), Outstanding",
        "verboseLabel": "Remaining life of outstanding performance condition options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "bdsx_SharesCommittedUnderESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SharesCommittedUnderESPPMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares committed under ESPP.",
        "label": "Shares Committed Under E S P P [Member]",
        "terseLabel": "Shares Committed Under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SharesIssuedAsCommitmentFeeValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SharesIssuedAsCommitmentFeeValue",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued as commitment fee, value.",
        "label": "Shares Issued as Commitment Fee, Value",
        "terseLabel": "Shares issued as commitment fee, value"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SharesIssuedOrIssuableThresholdLimitDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SharesIssuedOrIssuableThresholdLimitDescription",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued or issuable, threshold limit description.",
        "label": "Shares Issued or Issuable, Threshold Limit Description",
        "terseLabel": "Shares issued or issuable, threshold limit description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Common Stock Balance, Shares",
        "periodEndLabel": "Common Stock Balance, Shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r236"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r212",
      "r213",
      "r214",
      "r239",
      "r266",
      "r267",
      "r269",
      "r271",
      "r277",
      "r278",
      "r305",
      "r336",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r377",
      "r378",
      "r381",
      "r384",
      "r391",
      "r539",
      "r619",
      "r620",
      "r621",
      "r622",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r657",
      "r678",
      "r697",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r878",
      "r897",
      "r905"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r47",
      "r200",
      "r221",
      "r222",
      "r223",
      "r244",
      "r245",
      "r246",
      "r250",
      "r258",
      "r260",
      "r276",
      "r306",
      "r309",
      "r393",
      "r459",
      "r460",
      "r461",
      "r491",
      "r492",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r522",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r564",
      "r606",
      "r607",
      "r608",
      "r626",
      "r697"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r639",
      "r642",
      "r644",
      "r705",
      "r707",
      "r712",
      "r716",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r743",
      "r764",
      "r787",
      "r925",
      "r983"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r276",
      "r576",
      "r617",
      "r637",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r676",
      "r679",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r788"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r418",
      "r879",
      "r880",
      "r904"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r276",
      "r576",
      "r617",
      "r637",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r676",
      "r679",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r788"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r819",
      "r829",
      "r855"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_StockIssuableDuringPeriodValueCommittedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockIssuableDuringPeriodValueCommittedShares",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuable during period, value, committed shares.",
        "label": "Stock Issuable During Period, Value, Committed Shares",
        "terseLabel": "Common stock issuable, committed to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r135",
      "r136",
      "r164"
     ]
    },
    "bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesForDeferredOfferingCosts",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for deferred offering costs, Shares",
        "label": "Stock Issued During Period, Shares, For Deferred Offering Costs",
        "documentation": "Stock issued during period, shares, for deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net, Shares",
        "verboseLabel": "Shares of common stock issued and sold",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r135",
      "r136",
      "r164",
      "r619",
      "r697",
      "r722"
     ]
    },
    "bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares purchased by underwriter",
        "label": "Stock Issued During Period Shares New Issues Shares Purchased by Underwriter",
        "documentation": "Stock issued during period shares new issues shares purchased by underwriter."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options, Cancelled under the Option Exchange",
        "negatedLabel": "Stock Options, Cancelled under the Option Exchange",
        "label": "Stock issued during period shares stock options cancelled under the option exchange",
        "documentation": "Stock issued during period shares stock options cancelled under the option exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercise of stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r135",
      "r136",
      "r164",
      "r433"
     ]
    },
    "bdsx_StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Granted under the Option Exchange",
        "label": "Stock issued during period shares stock options Granted under the Option Exchange",
        "documentation": "Stock issued during period shares stock options granted under the option exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r135",
      "r136",
      "r164"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net",
        "terseLabel": "Stock issuable per day, number of shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r135",
      "r136",
      "r164",
      "r626",
      "r697",
      "r722",
      "r794"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r47",
      "r164"
     ]
    },
    "bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockIssuedDuringPeriodValuesForDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for deferred offering costs",
        "label": "Stock Issued During Period, Values, For Deferred Offering Costs",
        "documentation": "Stock issued during period, values, for deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_StockOptionExchangeProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "StockOptionExchangeProgramMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Exchange Program",
        "label": "Stock Option Exchange Program [Member]",
        "documentation": "Stock option exchange program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets",
      "http://biodesix.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r139",
      "r140",
      "r151",
      "r659",
      "r675",
      "r698",
      "r699",
      "r782",
      "r795",
      "r899",
      "r909",
      "r963",
      "r988"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r238",
      "r376",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r520",
      "r700",
      "r701",
      "r726"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "bdsx_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreements",
        "label": "Subscription Agreements Member",
        "documentation": "Subscription agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r569"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary Of Significant Accounting Policies [Line Items]."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of tax credit carryforward expiration",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, outstanding",
        "periodStartLabel": "Temporary Equity Balance, Shares",
        "periodEndLabel": "Temporary Equity Balance, Shares",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "bdsx_TenantImprovementAllowancesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TenantImprovementAllowancesReceived",
     "crdr": "debit",
     "calculation": {
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowances received",
        "label": "Tenant Improvement Allowances Received",
        "documentation": "Tenant improvement allowances received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditure for leasehold improvements related to leases premises which are tenant improvements",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "bdsx_TenantImprovementsIncurredDuringThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TenantImprovementsIncurredDuringThePeriod",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvements incurred during the period",
        "label": "Tenant Improvements Incurred During The Period",
        "documentation": "Tenant improvements incurred during the period."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TermOfRoyaltyPaymentsFromFirstCommercialSale",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of royalty payments from first commercial sale",
        "label": "Term Of Royalty Payments From First Commercial Sale",
        "documentation": "Term of royalty payments from first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TestingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TestingServicesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Testing Services",
        "label": "Testing Services [Member]",
        "documentation": "Testing services."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TheStateOfColoradoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TheStateOfColoradoMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The State of Colorado",
        "label": "The State of Colorado Member",
        "documentation": "The State of Colorado."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_ThirdAmendmentToApaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "ThirdAmendmentToApaAgreementMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Amendment to APA Agreement",
        "label": "Third Amendment to APA Agreement [Member]",
        "documentation": "Third amendment to APA agreement member."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r968"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks",
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TrancheBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TrancheBWarrantsMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B Warrants",
        "label": "Tranche B Warrants [Member]",
        "documentation": "Tranche B warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "bdsx_TwoThousandAndSixteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TwoThousandAndSixteenPlanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan",
        "label": "Two Thousand And Sixteen Plan [Member]",
        "documentation": "2016 Plan."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TwoThousandSixPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TwoThousandSixPlanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2006 Plan",
        "label": "Two Thousand Six Plan [Member]",
        "documentation": "2006 Plan."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2006 Plan, 2016 Plan and 2020 Equity Incentive Plan",
        "label": "Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "documentation": "2020 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_TwoThousandTwentyOneTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "TwoThousandTwentyOneTermLoanMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Term Loan",
        "label": "Two Thousand Twenty One Term Loan [Member]",
        "documentation": "Two thousand twenty one term loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions and offering expenses payable.",
        "label": "Underwriting Discounts And Commissions And Offering Expenses Payable",
        "terseLabel": "Underwriting discounts and commissions and offering expenses payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "bdsx_UnitedHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "UnitedHealthcareMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Healthcare",
        "label": "United Healthcare [Member]",
        "documentation": "United healthcare."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1",
        "periodEndLabel": "Balance at December 31",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r477"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reductions for tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reductions related to settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions related to the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest related to uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reductions related to a lapse of statute",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_UpFrontPaymentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UpFrontPaymentArrangementMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Up Front Cash Payments",
        "label": "Up-front Payment Arrangement [Member]",
        "documentation": "Category of deferred revenue by arrangement wherein all amount due is received from customer before delivery of goods or services, and revenue will be recognized upon customer acceptance of delivered goods or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetExplanationOfChange",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, deferred tax asset, explanation of change",
        "label": "Valuation Allowance, Deferred Tax Asset, Explanation of Change",
        "documentation": "A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VehiclesMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "bdsx_WarrantLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "WarrantLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liabilities",
        "label": "Warrant Liabilities Fair Value Disclosure",
        "documentation": "Warrant Liabilities Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liabilities",
        "label": "Warrant Liability [Member]",
        "documentation": "Warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "label": "Warrant Liability Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r789",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants expiry date",
        "terseLabel": "Warrants, expires period",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expected term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "bdsx_WarrantsForConvertiblePreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "WarrantsForConvertiblePreferredStockTextBlock",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Convertible Preferred Stock",
        "label": "Warrants For Convertible Preferred Stock [Text Block]",
        "documentation": "Warrants for convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share, diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r271"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20231231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share, basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r271"
     ]
    },
    "bdsx_WeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "WeightedAveragePricePerShare",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Price Per Share",
        "documentation": "Weighted average price per share."
       }
      }
     },
     "auth_ref": []
    },
    "bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://biodesix.com/20231231",
     "localname": "YearOfEndingRoyaltyPaymentsFromFirstCommercialSale",
     "presentation": [
      "http://biodesix.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year of ending royalty payments from first commercial sale",
        "label": "Year Of Ending Royalty Payments From First Commercial Sale",
        "documentation": "Year of ending royalty payments from first commercial sale."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(19)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a)(1),20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482669/740-10-15-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715-70/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000950170-24-023513-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-023513-xbrl.zip
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M*/[^=S^8Y,><@A%>%*DD41Q$E_1 KE8D19A*7 4GG:#V#E-X2()B+MD4N";
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MDHN82:285BV4P4SFC*8]-31:EF1O-^*6Q^N8E38:=F)S5=@C&E4H!<4%9",
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M$<=S(0R@WBJG2F"]A9?O;SR%D0FQ(ZF/.("T!\OV )&ECY$\N1C/0-0I^J"
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MXZ,'<0#K7J4K),*<,-%'YPE:U1A#EHG55 #I6ZU%4AK$VPK0>C_K19^CX6
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M61)74EKT'0%B1JF)+XZ2D+-)WL6L8F^/71]4H#YBI^/'4+2X@/UR41(??$'
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M0CD\4VIFB*<@#'F2"L.WLZ2]Q8D>1!,^Q3+(BSD=O*56![<*N@B!%[1R%FV
MK+%H/^C_Q#*+];RM%BIG[_I;B/:JO,;NR&>:R+C].1ZAG?!@E?LUX;>M47/Q
MUGMMG\U@S3%*<G(.A%/,Q GCB!="L<!$8&D5'$UKI?QAE/);#^D13T5Z8 5H
M$:PH7LU:##/%B6=*$^=+]I87[5QOJ_<\OA5P+>WL9UCFM,2BO5<4#9.W!.2+
MM]ZO:!@7/((\Q0(A ,B<DF#!;K II&)EXK*_36A[G='\.$XO6AC3CB42:>1$
MAH .;XL59K1DCIKL^AM/_LA5)]:I)E- 2$K[K+O&: :/ CFQ>(+"BZ%&4%I*
MZ:V&]OV1&GAR$L%R0I_"VJMTDS?=@865I2>6%D^D%9ZX ! 3E1<V9A]#[BU9
M]*7EUCIJ9.LPQE22!;*,$OM52ZU)* !>*2>5C5>9J=Z>YO4LC/]!RJ@_CA!2
M@EMJHB#*%P&JJ0*TD2D2+J23H,4$3Y=.)7=8*4>XN=U*7;KU7@H?@_^4482G
MJ#&Y-Y.0HB%8?,P(D7CTO<7E[R\!.:^_"O(Z'@V77IUQH?$HHA1KM2!< IA*
M;)#L>2I$^BQL\@:L]MZ%.?9-@/X@G0H"=Z)@ZA+7F#SAA009"1\%I[(P7S )
MIJ^DTINDX"4UD6"1LY@4*+\!>)?JC"F^B9@45!3%%-/?PLC?U4<!M9=Q,XG(
M6CO#[D@BMRO32,&#EFF=XT0%;! <'2-6B B*C(/W4$M5Z.TV]<$/L23FT='Y
M;#AQ&2!-XOX$RAWL2D@E&I^H[&TEJG64<9_.A7I#TD[Y'"7EQ B%385"(M[)
M M:M3QR$=3+]/<]<G<(L%\NK?2/.X.*M][&K/&Q>P:J4%,NQR&(C;"S69%-.
M*["U?%[[*7ZP@)EOOKUW_KW;QN?(Q<7G6$8U3X"%0D>L8*@+ 64,5#NK9;)@
M! O:6S-WJ[\=0W_-J8Y^<7K#%5.]IIOG9HR8$X^B.=<??1C<>PP_F"]3^A D
ME@L'"Q$]WDQAZ@HG-BAOE%'HS.R!+W-1AMAD6$]G_MOA":AU9S,[GJIYO\R>
M 7_.'S"_,O^,3[CB:>V_ROBKITW&S0N\\)W/NK*<RE</O[[RRG>^;AY;<O4;
MYE>_\Z&_H?,T=?*F!34.  ,0XO5H,/!-V\7/G+TMU1^!&"X^XMWD& 7^J/ER
M0'4[DIR9%[_MO[YI.%_]'K]\G8>CXWIXU6-G#-=5/+CIN9<>\?SRZ&]>C=U2
MZIB;JU=X=O$[%_@@M]?0!%[Y7NKMYGX--WQ[8:ZBX2D,7D.UTXO?2U+[K[]Z
MW"TIXHJG[2!N# ;7#_+"#=_YZ+T\S)_\8!HW>_7#+]WRO4N+^_'OHT&ZCJ N
MW'#SHY_7GU_ UHXF3<SM].-1]JG#9"#L7_ZMJOX,_Z_:\>D T/W$IP1:.1F/
M3E[0#54/7P(WD*-<?S@:S[X(H\^DK?\+[GH11@T\B< W+V&8)_.'% !DO"6_
M8/1D_!)$^@=X2/?(E]VUXH_KP>F+ Q#);?4N?ZKV1L=^.+\QC,:@?L"]B.K$
M#^H/PQ>#7,;XCO;$#^>O^70$^$/@FYA?G#29?&K\R<LOWGWCZ^!=G^HT/GI1
MZC'II,@07_*__L T??GGY_@N6*63"RMU-L79S'%.?(.KDW&51A-035Y>7$ V
M'\#RUP(;A34O_D"[_UY^8V7$'1>F^F_5?[NP+)<6I!][?M>9?;7ERYX;ZKZY
MN>LN?IKR8P#^OTA@^HZS_^W=SL'VZVK_8/-@>W^^"#T85_6C;LC^]M9O>SL'
M.]O[U>:[U]7V?VS]^^:[OVY76[N__KJSO[^S^VZ]2XN;^%WEQ#]\>P10/QX-
M?ZY>;VQM5)PJZ9:P,W<=X+4[,UMA!-@7DO[/,Z$U6_)%RJTS%6'^Y*H=#>HT
MOZ_I)HQC6-@NWT_$?3\Q\V^]ZH')V=YQZF]V]WZMKJ+>[W@VS 04S.%HV-EG
M=>S4V3>'05OMM7(D)PPXL0EK-AE':(E,6!^+#_%9-;/C]W+IXHI,R$8%2DHH
M$EO1PV]X\$0I7[+,Q0BKGU5#CSZ)E.L7KT=QTOES3T]R/Q:44?*W,W*ZM"R_
MW <D[C>H-28\!"9\\U7+T>ZO)N [D\I/O_KF]VIWF/^T>*&V*/H=HT/X"ZL,
M1X'F*:PK7B4#?SJ:C.%!GW-Z.7THHW0#"&SV@XA.JY,VOVCSB<=S&7@1/!R>
MWLP?_;%NZ^E!UHOYW;.;X*YT9IYT#Y?_\^6SY]=<<_KLXI^?CYLO7S.SM'%U
MKES13S!@$IKL?W_1_4OPBRL&,N?>CIUAJ@P,]X]X?AK]8$9H0*=G3-[,[/ON
MOD<PY2_3Q3521'F38[:9F.03D2IGD @:"\6E$+3FA=FT*"FR.1Q._& OGXR:
M\;.J:_PZ_LNS&B;1Y@BT/!H$/QB,QF'T>0&\>KU9ZHS4+[\A1#H/Q3@]  W8
M'G@P;K-NF^_>_;;YMMK;?K^[=U"]_VUO_[?-=P?5P6X%EM4!F$\5$]7N7L74
M3^E/U>Z;ZN#?MZL+1M>9P;6Y=8"7F1-R41!X&V [V\XY1,#_$<E6526]JP'S
M9M14XZ-<E;H%FJU.LV^J/$PY?4M/_=8+KT$8$7DL(DC"@L&6V4Z0P)0BRF.;
M5LV#BPM#F/?=(=;V]%SO$L2\2/ -.8:W'.'/2/*G!*=.\O!:V+SKC)U(7!N:
M",_.$NF\)]:D0!1+W'G%E>'^OC/>FH9 O^DV\3]A(K>=]%?S?20R? UBISM#
MQB/)A>OS"Q[LSTOB#5NDY=%JHA4/1 KX)P2FB8S<:PXR6&:Q*-XX)Y4W\$W;
M#RK 0_EO2>)K!?0/!MR[>SWBB+7)T!.38<%6\:V,AIBI%]I*XI5"D:X!@AC(
MN^*ST%2:&();F.NI\<-IK%\O# ?96\/A'C"W;-/A8&_SW?Y.9R,LU'RHWL /
M\+X++WB_O;>S^[IZL[?[:W7E?P>[2[<ZKOIO;8E\M4Y=EY06PP>K-S5(#V E
M5 B7HVI1H66@RA!7I"+2<$Z<!J4\T,QH,=YP:N^+6=M=)![.93J5?BPSI8P(
MIY7KOYZ]=J2OY.':^:OXMYY]W6&68*Q@LHVS*1,9HB-6FTRRBI&[Z)*@;#'<
MN9<_U.T8J\9A5:*%<N@W)W_='KZJ1RFW]>>?JYUAW%B8X?,T(@)^VO[LX[C;
MQVI4JO/]JWQ;M2<Y8C1TJNIA58_;:NO(-S#V)1RNK$&MUZ"V@I%_-YG0%VG#
M3\:CEXNSJ2_M>??L>UG9BMY@9E^X>(.9W>WE=]C97^_>EV__PK*:[ONCG,Q=
MYJ*KI5^*-,B4$TF%2TQ&#,3*D@A3GEIEDC*,+D;Z80^:!LSH+D.HRS+H>F,V
MIUL@@;XVK5N\XZ09?<3G+,1S?+T[>. _>4P?N9-UO5K[S8Q+4<A$M.&,2&L]
M"<6ZKJ\\RS'FK.\=NC/=[P/_>6>6,30MJ+(PP^1ZCRX8&U9+Q[]C*V_ !M,[
M:#"]T[*N59TZ#J]&337"RCG5/R=-W::Z*_\!NM3%G5CP/#>,@E\_Z&3KB]#6
MS;GYX(?U?W6?_[1T %DAJMC9V-O8WZBVCT\&HU/,=5D:&3SLQ"XC7?5NM''E
MMO] BL@MV?#*&=\^D^>!1WVU3)4Q,B:-!,V)@DPM"?U[#D1LS$9HJQ4S9C$R
M=3,EK)HT^]_;>IC9$HG:,5?]([?CZG4]& !5[Z4EN_&N&\C&S[W;<\&R=3G"
MUAFOB?0L$I<"*,^!^N0Y35R'A>[Y%ORYVQR,/BU3%7X[FM3M1]CM;RG#RQK
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M?NU\-?=ZE4MDW5RHRHH;+NJ-6W771/D6?/S]0S.:#!.9$>>TQ=VR [2/ZY0
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M2@#S!"OGL@NP<K'C\T/ RCF6;%UX\QHVUK#QM&#CZ16W8OQP7HKN</1I"%K
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MWY8*ACT>-:@35M@+NYT/-"<L*S*^>58_PSUQ,$E?S*,Y2]S#293)>-+DZLP
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MR^>^9F"L7M9%VQS29Q=MI_.R;5U;/*>G['KMS65P#=__G+]^?GY^\MF59'!
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MIR_2 ITPGQX., B$VXFC?9A*RU ,>HRHXLP^^8#)/!<(R36B]SBOKE%J0HN
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MYDV2&91UDG3B&9G5;^>2B[CGSCGG%I4I$PPU9;X3=O+1[U&-4IMDDPC.D##
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M^8U9KE8.RHYG@4,C0-F@7Q<Q[ZWR7/I6;Y_N0@T.!+78R^.]AY;Z6GNIGIO
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M=<=:U>:JF4ZK4DJZF M.?JWL0F!<[S(N)1&BQQQI;9<GLUFH$2M<7 <TH#N
MV_(%B@@P)L/C/)GSL1C_PS $0H[J H"KNLC-K7R3 7G]39#7!P/R^H= 7G^F
MZ>9X0]/-<2^WR^.0V^7@ 3?=7+NZF",@UY+Z>E+>%^.$5GGEY]]84K!4.;@5
M*.?ZP$ORD23"X\2NYEN9HRN]*NJP1T\1W)UQ-&W/U7.1V9("TZ$!%J34M0R
MYS(;(.*2[';SH1S("9GILN!<+F-LVVL8T5?R&<//T;4FONZ^$-CBQT-;/$//
M8QO19#/&RV+I'$A+],Z1;<H 2&Z<1"8;H72+ !ZTQ6TNNU\<6[WL!@^,3RN'
MA[KI?=$M.*\O]RH]->U*B6G3\L9Z9E"AXIY-?95L /E-,NNR47P.5J?0"RY+
MQ'6,U8WC_*.P&@>F52'(\J&%<!USOBY$YO!F8(M<V;,G(D%JO[4$CC&81Q>
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M@(J,E<D9^;O&-4V*LL4FBFER+9IV4H%J^991[TU/W"[:#^0&:;<PA]H>_<!
MOL3232H:+^3[Z R#&$6<FA8U'P/2J((5<AAH]F 1_X.4_;RHEN!^K]IC14F.
M:@ &G1I>BX,&)3DHR=L=^#8+CRL!"QEFI1R96C;M-% &[=!TG*J82PB2%-?Y
MY.EB3!&G<8Y:P83M]KQT$F:=_F1Q3T?,W*-]C*R57;_GG0;H(:\V=C/5P2%%
MN+?F$PCU>8.@PZQU<:E]6SD8^8UI?TLS)F%US&@U-^,!X;;_5J??\%O1@@=K
MF9)W?>I2CD@NZD69QLB5/BPW$IG/K%B)9QQ4:^SP^DYD$U9^UBO+Y$KRR]N-
M+NC_U#MW=1A0 R?ZKIG-Z@HX/2-V9HXG%H86R0TQ8(S'LI?-PJI9OCW33#%;
ME%#5\OQJ25-8!BJAG=JH%!\6WNI"HXD'A; BL8'N"*BPJ^MT6H\Z/,N25'(S
MS5UE[P;GPYK@=FI .(;8<2'G$@S?CL#:'2I'(@X^ Q%S[X^.7/'%U0E[8!?2
M'LVH#\]HA((AER80%?)"!IS8X 5TSL09GP<[%8VD_AIT6A06C5S88VD^0R/.
ME7,N9&T(B<:>5/5VKN?CW<>/OYO0'=TMY=S!T^,G!\^.G^T_)<G[#>)6? ]!
M^SJY:K-OD(\A47&HV'J!$#;2L;8:8GA5)'&R@F_3+"L_3@T_K40K6J"90Z(4
MY8P4XC^MCRE4)7Y8 E*,E?-&>0X9MJK]-9O%\[0Z %\(XPA3EE2A'U/]-,C[
M Y9WX<VP>)QEDRT*%39IC)E(7!1Q@UV7!;0T#A;J!CTZ14P.,EEW>F_"!;M@
MOUP94MVGY>*< [=Q%_TQ89H44&0%ZQ%QKORP"'&H6=0#BE:;QLTI0+#7YK$A
M;E1U.]%["_$?^G&^23_.T="/\WWZ<09-_A T>8A'0,+^BL>\BG[T%-%J^6]0
MZJYJ9N+%X!L\9(EJ%X:LP]@BO^1!4D$013[NG(GN[*B'(L$$I*N4'% 2R^7.
MI+C.@T9X'GX,'@7,6Z_Z0S(E;L_@,Y!(MX$_<Q-G($<0K_LGW'>0V0<LLYJ;
MM@+;CH% &1B#1DF;S#47(!RK7 Q3N4VO>!XDAVF..'3 C@XIJ1M34ABREV\J
MB"I8Z+/-9Y[B#,5V^[<V/'#(4CUP+4>O(',JCD'RM1^?R0C6-=I+9F?=G(&_
M-1IY< D?LN %YM5\2L49)#?O'SR24J=@!IH/B1\A.Y: P[75W$(;#K[<0Q<V
MR1)R?[A34T$#H5#@@8LG& $@.(OU$8LBH6,$$.@@"%H!;+\\W+QUNO?;< L-
M+N'@$O9+\"O')N6P??W,M0S;EE#6T->Y3:];K1EJE8-^[.1GKC0? S2HS^!U
M84\>BV&1G&UXIS*6D4*<WE9>AP+B((0BA()'8N3X77>C#![C((Q6& 'OS%9=
M0)S38[T"J @YRP*\CI3#J"%,-V&QM!\3LYT(_T8UM/<,WN FZ3RWA0ZA>_E<
M?^;@WCUL96;RF61:@JS)S6P\^$&FGBNN3/ =-_+TT(:0FB0E-G&SG[L3H@))
M532-'0[7&0X=\EH'W.!]/;&#T_BP15NGX]K,3=+FRF*)OR%;?0OH9$BJ)I!Y
M>PZ$FRL0:G?9P8%\Z((9I!>16'0 ! >*F9O6<$P[1%+'M1>8"L:#'Y5KSK7@
MVG'TMIA\JQ%A@P<Y>) M\7P9D &&'#8GYSZ/K9V-EO<KU(..TF)P+1^VFMN$
M%=S(B(EF1VYM3:62+//M0ZHCU(_;])2=:PP>WT.6N("-="2\5V6;.<NH=V:I
M8"Q)J0"W5DL+-KQ!]0T2]I E[',QA?:Y=FF>E,W$V\:@O;QWL"\8BM% $-9+
MN#RW05V.0I)F(07HD%+:9O91Q&1*SG0K=,<!>X;PY*'+N+1(0\C9A]W[Z>4G
M6E,JR>V3<_[E_D\\L]0',NODSPAX=1P<RG\%(-H,Q9X8.D,+=!0JR<WZ^&_O
M:"[BCPS(L)1:"&ULSMS.7TL\SX&FT=U O@$X,00Z&P7]M/!3WE4C<O7%,H\$
M'/%#,// E:+(A]5T0A_#OB5RV<68GH[;45WGDTP?<'VA\"\K4[=&#<S+HIEI
MSCT<1:=]+8%;,?B<#UGTA(]8+*KUYMI(?<'^._BB#KFVQ"C,G([*,8.L*7R6
M,=_MIFRKYV!?26)3<C>O\\UQMG54!V_QH4OGHLB-#E?78?,;I/2.B*6^\IU_
M VZIP-N]M#7Y,W^T'A#EE"6TFQ40EFDT3<7$>O;CC7.W J[UVS >=V /HWZL
M:V>J@_+[M2<.=FFB?H#W(Q_%E9^#729--I<&XC);[5SPE X>3\VEJ8.?/J35
M1[S #T9Z+C!"^\//'[9_O+W:&$M8FFY,$BB%HQ\V.+'<N%S4X^E2L-84IVH[
M,0D?_:Z,)ZD"Q70:N1#\16L#V7$BF$PZ.I=7X"A_=J,_%]>(74;1P1X.QM'>
M(QZ%I>L!)0K.ATR'L!/'>1(]CSK!D'/W^I1-G$G15^1)D%<!>@R^&/D#N]$K
M]+/J<">7T<>W[G#N\V8&MX%=Y9NPJQP/["KW9MKQ'U5S>OJEE)FO23F6<4)J
MD56-8RCC$8=P$_+$?Q;\C5+S27FP>SBMJ<=M8.49MZ8'6!I_ >=:7%F_@G6!
M% :Z,LL4R&75] 6Z4YBF5K:W1EK_8W)'\-79#$,<H%:=G6#8QH2)A6E]_.G<
M%/'D'PWF3>%W[F=G,SS3?_2"'X1-1UKITP:N#1Z<=\H&<T9R$IMLM@Y"<%-N
M8R13=U3OM_;.48+K5R8&^V\'FWTFL2OS*Y&DI5L9+G#$_?O.<UIOVN\EW6%G
MW>KN1G_)94@T;TR(QC;P8Y2M#A-]K%GCUY;,XWRFQ.WN%64Q)YC_$];WAHD/
M=HK0IO>GUMUN+\^MQ(W\_![:E](P?E>\!2'\59R/#!&F'2^+'7K-<87\>A(.
M6]$GJ[ I53H&KS!B#GJQ(NI^HJ^,FR"/&X0"$'S-6DF>"O>[UH&/;@()Z-0=
M5E3(UQU$#JS#::UN^R;&];"<95<BGI$)0>T_C+=X>\_Z#>U$CV-]CN&CA?4)
M+YW$O6YH[_C(OC]_2&[V>4Z^[?ZQS&F9IB40)>$66:WN-@I3S.B'Z!HZA$%S
M0B*,[[\Z.V&+@(%<-D"T(W$"?QZ7EI/PS Z#3>8F^2CS,M)\GHX19D9;YZ?G
MV_:&5;2E\PGIE8H2D+F/DN+%YSA10B?/K>?=Z>D[S[<IP:]_$DQ[PP!"L"!W
M'?]7;->@E33:<"9+/?Z1)F?0M5SQZ B9.L.<]('1# 8;<0U:VT](#UZE5Q8<
M6UH5#V6>YLU"=YUV9>%D52")U0]XJ#?)YN7<A.\X(G'PTE 94JRH3'9V>&E*
M-DL,N+OB@9.!U- E1M$8L2+8N V%:4D=3"<FD2257&D/'!J#Y)=J*NLY1OP6
MZ]?<C>@<6>P\&C<3MF(H4K!%JN9(_LK@>GKW8[((+:$*9AJP4R-$^-8*T?K$
MQX$HRC:TQ2:4$^;6EU2T^B4W^PS6B>$$SGL=O7(NI_*#J98D<JH4Q:9$]*-X
M,9L]%^^X"/4Y=M>W /Y[U;;.BZ+A_)+5!:6]JU"(I:4=[B08#W%QR*FMC-_
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M.I;O:X3>W2IE=DNXQ;9 IH/*@RS7(]+\G" I.1QM^8">1SP1(22KYIZBQN0
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M+<<&S2;S7R++Z5QX5.3EZ4OH!&5BXP1,4S?*QI%R6=#'W8!!?B-QJ%&:4WI
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M-I[@4E-A9;VDXP>[ORJ["%Y'XJ[EZ]V7X4C<E8UCP?^TU;8D9.Q,]PR\A5=
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MX?.]OCG$GY]_^S+HCGB)42;X, Z0V<YT'DVD.B<E/;/(!'1;9)TQ/)+0!-3
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M,?3DMM ;)6RY+$Z7EW\EF?QKD!GZQQNQ W2WGBQQ'IRV]_CHQ7.LC@\:/<'
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MG(!B-$MR(5@[+&54L%0^(<4/C <^C/(QZ&7QF"BGR/YQ]2;A"K^Q@6XZOPW
MQJH40$C2&9,0^FAQO-)"E>*9UCS/ #G/OAWZVQ"@X2]4*%^573C)L)G*4J W
MMF*EU2B/9U=TJO4]FP%W" 5W=*.*<&0O7ENP%MBE)%3;!D&:$R@IO-<BR(_P
M_ND:=-(19,<S5Z9J)+GRGG*IF]79P>HS*?VNK(JI#TSP:$A4S)0+KR9"D/R[
M3L@C/^;PN#0<,2B/;S3/=<2&#:A(9UIDIDKD% %F1^NPJ$N3#S(;<4?B,)6P
MG=L5A8MMC'!_;,O\\>SUIWX4RF;KQN2ESEG'8&34CSY#Q ),8YK#=SIW@--'
M&Q\>N?*>'Q;W%D3X]&>1_%3> 29!"H!":;5U7QKLLBJ78;7#VI1XJ[_JR._"
M&"FU,32O@T#O9$+LETB5TDWTX(5(1+5YOSM+"BNX;F'&>@OBETG!S$0),G,,
M#K7H>;+=;*L-9\:9XWEKE_8WR(]G'*S$W!H@>[D_Q^;[&B$ 3[D9>()\ZW%V
MK&5D$K@GUP_AS+PM6&M13]>&/2B2><DGY:#,3?U[!N/@#X;I N)JF5':H$3U
M&1_RS/28Q: ZDHY&'8?>Z77%O>1WZO*!*9SS@U7[D:_WY>S@])#G;[)T,.Q]
MM2K:>=*A0W_C1K-.*N)R-,U_O#C7&"J:D<.OZ#$/S@YCS(0VHRB8Y_K[@]??
MG<O''QV&)R8MTHSR4^P[,DWB?P13QJ99A+IP+GC7#.$]\BL@7L",L,3Z3TP:
M+>J;_G:3^;**312@.47N[83W1U.-?I(R^?V>&\V1\6L]BMZ!V?!I61,.],AQ
MR8I^PAO('./Y%%"O[#ZU;@9K@@ZJ:A-/R-B\',_.MTT.!HAN?57^J#DY,66Q
M]R+(:["'Q\5Q!AAB_#"EH2<6(M3L@)]^GLU.OWCZV>R WA?F5+(+R)<Y'(VV
MP[UT#8JZ'M^5"D?715&[%)&6/*-%]'F>L)R7HJK&JU^32]@,':&,FX%8PG?:
M\"FW3VSU6W2!?>3U9?;^;GG(7=/%O8<P\<1)..NK(M6H$AZ/7RB?:&%@3;^.
MHI]EX^:W.1770B!)R:ENU_5HDW 9!O;CN3]\'7%]VKSL'C"9>X3)?/* R7S
M9/[,IXY*YM\#P5,D22>I"O)0DTR%ST^/3-WK29/;.0"FQH\8C)VY6269)-R*
M!$L3XJ\$6A-,4IP-Y-M])9KT=B/J?%K:RR6&<GHH _Q3LL1C)]*F.Z65+XQ/
MICS!R'7F,=>8(!T=.,K$\N3/"73;KJWECG"A)<"-J IBXT?;],;6;)&X_ FF
MB(,">[ L]64]/Z(V[NUAC]6SC01JA9\UGH@7#]7M>:BXI*\05XCH)/DF:0K_
MXB3([ 9'*3)R.+?%?T>&=<IH<,XV]X2L<%R607W7U,N#QOX@#VTVRJ"1OT9X
M#"T!T*0=27BA.^^#63*M0(>+21&X&?H4V!9WQP_V6PXMW!X'2TQFPXVNT. 0
MP07L*0BL-1M]D[<+9L.:/,%^IF!ZS(+\TGY(M1*OQCS"E\L8$% 1O)OR]W=Z
MBL23 $C,34LAF:OV-2YD-:<[2>"Z.^N33M^=W+8?$W%L^YZDK):CJX9SWM#+
M8*T[!A8XM(#[6K<.8M"TK@5I.51+>GX$792\PYS<MKQI@A../LX.##)0D.&T
M'?$,-GJ-%$"X,5%<Q0![6?%NNZB<J*W$Q[\L9O]#<;F^TOU12[!84Z$C24Q^
MEY<5)47CH40QF^,)EWR#EI))=K:715]J+J/LXL!>O<3(4-XCU<HYUA\M83Q:
M H[%;-'<UT?;;YYTZJA@[:_AX2T*:6$LY/@TK6DD"46U5-5G:QEQ!5E27V?M
MI1K9[9<5"V/JB"6YBJK:-E(?S&J]N13JUE, WQSIO<'>"S+D4FJR"H]-%M?1
M#O87 KNM5FSJ/P*TT:M_6K4IFUYVN,$U+BLH]=&WB(*F9LQ%&V'D]B7:\HX_
MDVHFC&W/8_=IA@ILBJ!V$S+(3TQ*7;Q!1/81"0(BLC8A>;DF$Y8\9SW&:A\$
MS1F+U(?'25GZIJ$K=BS"7++:>O5B[$^?G.AG8/01;(WL?CQVYX(&,/_!']B6
M$SV,)*&$86P%PO4EWRAFCPY<-#6RJLZW[T_V"\@S;P];^P,KU+=-Q-7:%MM&
M)(E$R 9/^HR;ER8.?_ZYLS C\> GYO1TX8[=DL?B!N&9$XM06 (L+]335GQ%
M]8+!LH@8HHHSFKFI-=.')CIBLDC7H_:I\YW:TOR]9,13ZB/&>1#:_U9K!6!>
M-:B8)Z(K_1$3S11$YE76YL9POP3#R$;*FU^RJDY,Q)QU<ZJ70]<6].M:$Y-N
M-&;WL=="XS=_'8'8HP/Z"K%W6;&!<(=49YR=?BXQ5=3(]&?^RNA5NW*_4Y[H
MVDDE@EQ:#JX:H@KKF! L'T49''*1)2IYUBOYNS364YR(TN)"_LAVL(0AJM-J
M&:0J>9MZ1=Z254&X%AL5W$7L,M4;,,&,)@P(L4Y2/0_K+BB05/$U;9?IDM0X
MV5],O FFV]2=3(F5"Y;HZERMAAI>J:_\[Y&@OM;:RI:GF+YV9>3S UTA@9LI
M;3FE16D">CI<?.):J9(U')T@V+A,&:?XD?^ @;(RE7T&@:DW'W9[&>]+=V,]
MEY!W44G7J3%Z=+([Q -U2Q.22?TEV:Z/J=.O4,+%)6ECX+8D!D>;XL(S_C6A
M)&(:$4EF<2UIJ%OJB@,;"^4INF')TMS[S*$-"D$Y."TS"N^;QK"RPV71V:."
MNL:A'3U@B"F5#QX?2B(/Q@H1F\7'X&]EYJA\T9@;3LD[3PKK\RY.E2!3NC^G
MSZ56TD9<*ULN\[NF3:-CY'%82\9)B?8"6$MR<=)^3>]1_P!O'#DYNA&GHI11
MD%8FF>1Z("XZ:95?"&,94T9*.^^*FXR,<+<C:LU"VO_]">S9>SF>@98-ONA2
M4$_NVJ@2H@HKN9H8BB7N203=BMM[ ^O@=B5/4S9B-S1?S,2;AM)(V*=\A#5"
M4KJ5-LMX<;5>T#\BVW&VNL%,1HN)*@Q86W 5:&J--]F=">-X&ZL&2G,:4#.+
M-,Y$AJ:;OI45UP'<2V2P[A"R!^=0&/G!;DB7J?@*[DYB 61LO=4P$&4(H(8$
M3@ORNF^P).+PBDQ3P$C4#$KJ'Z^!(%LO;8FAZ/^JYI+ T8%2J!6$6QT</(42
M'%&.%>@7L>B6;](],B! 1]Y63RX!=RY+0T8A8LK):7R2OYL"!]G B%P=0P^,
M;% GP3$S4KDF?4O5@\J6+**KDYCO/JG/,^19UPS!,=4>!$/Y.Y0FUK)DH,XD
MIB2IHB3S[,+FEH)<7P!K'J,<R[)R8D?1]^%OE.-C_I.$"$LB+\[@30$O;!=]
MPM2]\3VR"2B?F+:A/1O[+W$"L/?0$M0^8,%,&+ED8'0R'0$%NUUX:5 RMX7(
M<\PJB +HP!I-Z=6C81VOQK_JK.-(P=LWX7VN.V%FCH>1%0UW.% =B$.-$+B.
M^)KIZ9H1+1I*7!)PDA&Q'D"HCPA=Y]1BKY7+]1"4\EQ9U]GKU?C9J5N"\")"
M.B*%O#O>97=.-)OGG$A>B CVA!>*M!EKE_0%.4MCT?-/@=X;.>ST0.PQ8Z@;
M:IG.C)X8&;U?P?Q;JW1FEC05];V%G70F28P0;UC-Y8\^VC,?,&R5[=70J6/&
MQ5+)>5(+;!"(TS,QW)PAHP54>7#-6'KY)N;J+R5AR$Q+8HAC(8S+7[)4:QI4
M>,0N#",/8N:\?[I(ZO?%"::UXJS#":#&)BOY6@:7\@]>US DH)-DB'5@H?4B
M(7_G!XD+4'X/R5''3#L]?BVP@[88.U+'X:UVZU+:1&DUF-RN4T)H;QQB,(:$
M#^BT_4&G??: 3GM I_W,IS8G%[$<PU-\6]EYO>'PC-WWLH*]MU)/=&Q<_X7I
MY,Y#H#I!<=WF0AFNM/O'LQ<,<B$]F+$^#L'X/0\6 #BD6'S"]>%Z;H2"FW%P
M'O+OHV%E.:\7DF<=.@G"O*L2(3&<R>,H![[IR,?:VXZD"R,%N#12@,C*%@&+
MK_>M2>D'RAM597$G4:60C9#<RX0J;;L.PKDH%ZB">='-IPD7N)U'PG,Z=^YO
M!T*-%CP]XH:X?'^(!COSZ-#>ND U;N,#E(:I^*@AM2K?%4QM+; $)5DC,L%R
M3MUY]&;#)A4#W5(>(INXKK_4+ >*@W+;=)2I-7_I9BV"R]XH_3I4^XBF#;$#
M-3DB?R U_8^M! Y57?8\@,!J+#_R.G;"E;T;K? 0*2KIV,5 ^GV+]TP3.J!*
M=^!/V?MU,%)J?E1.J'#=]<"4@:7C_)8<8!#O6_N*GJZ)5:?!GN6RZZU2@UZ+
MWTY7K//6*%^AU]KAQB70K<47MRY5E=ODITJ-1))7E/H)I=GU>K:(N(;,9)J1
M6%- 0R_%, K.O;Z1;0MR$V%18_X?EPB+)!#:CP/)YQKE*,$Z!;/;LR"3X;K=
M$';8>MQ+(20[.SG]+"('FB.'8*"7'YM[Y<A-G3.DWOGZ><W9@$4;W-7D;I?!
MS4"6)MSQ\PC> HD3;<7-)MXLG@%D_<O_%"*SVY<]7[=E1>P_)_23P$0O^2&4
MI.);/88ARKO#9($IFV<,09Q3NM(5_HTR3;07KW2=;]T>O!9B">7UP\KC @FW
ME[..H5\6ZG&,]UCY*=1C(>G620/A5!!'#QLAS2SYXK?VPQ5&Z*HO%&7%))_C
ME=>D]CG'>LI.3I.L5=+S4ZXF9(T&N>1UP0UJ%EJ[&\2"_$A[4K+_QRM.3/ E
MRZ!4T]L/\@.J#66O]<MNO%(_4<:#_CLEL6O9?<WA/[OROBPR0M*Z-&6J3)&D
M>CP4GAX@O"Z:*,7MSEN0!\/K2<7E$U7T]HY\2&'O>&SW4J#/<9#ORZ[XF&8'
MV<OV(=;4590@X,KN<YN@QS2N9<P1RM$SY7"C1\^N/O&FNQ2W2K"4^J::ENZ]
M=?)?4RI81N60F,91*OMC"I]+5#H5AGZH[\>7EX*VDF@V/?(\ FLJ0$58RD#)
MA=7;TEJARP!>B^X3?<LI<P]G,KZR%0KJSMGQ@?*.B47'QE!EU.9\3^N);NIJ
M8];CXTO?^)Z8N(=L(-18!)L"K&]N4;D;/JH/Y&EE:%/'M#D9Z- GYK)D5/TI
MJ-LBJ3SMFMD$XMD4'89J8=ODQF/ 8U6%=8(^-IHQ-M[&$3_>B !HJ".GH(<F
MC?Q9I;+FFFBCF-&)&52ZRI)!ER"][";)Q?YQ]<9=.P'?.'8SV0O,1(O+\X'L
M=FW8 7PD1) 92#3$\$7,,6%5XA%LWW_K[<S1>("X,9@%S_LA*(VX:3ZW8[FB
M7"C-M$3U93 W/#F/ 1+A:<FG0E'Y7Y'_C)IRF*)YCA8HI.?+N^!8KHM@EGM,
M?:?W&&Q)N8:C@H),L-M<[HX"G0X(H\KI.B];$+*1\&:*QPIQRV"^3#<B^4<9
MC>#*W ]4_F=H+?6@5N^K6;"IAK2.-;>,HV*J9PX=BD9B^9N>?G<[]-1D@OHM
M7PE@LC'4C);7L>ZCFQIJGD[_N*H4JU=IYTJFU2S!:45[/>9AZ<:=FQU3& O7
M2GSD7<LD3DY@=.:1"+KS(]PBU7+GJ%AEDJ&1PRUEWA;P1WTRB9,A:@HQH55M
M%=?X:3N%(%!U5E"IP")H%A3"U9:KDB<'-H1O8MSZ2YFO>&<3&VRT&"=NNV1N
M[]2)]YM#/EQX=PK3\))I@RB9BJ'A#RTWT@YK-^4Z%3FA).]M">AWJ@G@D28I
MG_WULEX4"P"?:-M _3-[T>8#O_+S:PI\OLWO]RN#.AZI*#NTM'W)L2\T@CL9
M.JL?Q+39;W0^_15W(<\.SK^Y.LR2#[H1J+.<QH)3&\/MIJ.9X^&QBVIYQ#2>
M1&P4KM.^HY<A%WE>E=QH&P1:;X;(Y$V!"3T8=#L[>/[-&\QF%,6MMWZ!6=X7
MQ"/5\0=?7)P?8OJV3>9,'#4FQ(>M3XS\U*[L6:XJO-CP>AI@*&6H.F\^U?:>
M?C4[/3W[_-G!]>&AO? .8ZS1[2,ZNJIHM@01(X?WS="3?(/_=X 1<XC=^.ZS
MH!>'NFB5  EU[FK#:&C]*4/?@_QZ+O\&/G*>=[<RO?%=B?$3Y,8$!<F96L8$
ME01S*EC(@R[MF%,,,CD#:>4B+&4Q$/Y*0$1#.P^^*2 ?^!]JMD'\@@P3VX%2
MEEG;HWX#CT??$>I ?$_ZB(*SA,GQR-Q'Q)QQ&_" 648& _G95#:8,O@5F3".
MY2;\C'N:YUP."49N%:='LYO<X@+\[W*!W)YF5AQR*S+!%>]I1D&I [Z=KXAT
MUFW>7E,_D^1W26"2S)A@LZR9CSY X':&_)/#S/OG9KBRN# <.(&GC8'J>W08
M2=?-#DX_GWU_=:&'[^SLY%/.G3]E=L0R.XX ">) ?N*Q2T\3IZ!$DR,V5TP@
M=>^QJ 81NM4SDAZNV=!93S,?@(30O)#Q\=ZE#P$Y39QO9"#[,OTR8YAMBENN
M0$#(O5;@Y&1P7AOX/\E4?^##;D8-HM-J8QEAG"](+MX2S_KH3)VT.9JA958T
MEH4D:G2"M2$QXM7[V[)='-$1I_K?!G$<+NXZMS]R6#]X"G&M> QE%W<<,YTK
M-CYN#WBD7QN/]/0!C_2 1_H%W#ASL#_LS'W^].FAJP2;:9F&%AN^TFMDGSQK
MCBAI$C2>:%?N#T"^1A2MJFU5KJKO64D%Y80RA/DMVBVQ^T*1P"$&&^IO>4,A
MG5.;H-9,B<(3U&]9V%ZNJ/*-4C[V/4.",G?]WQA,2"KWMEQ'9\M(3)SUE!9P
MF5L9SBMS<6BYOJ@[@?Y'ERCF$G0WL$<;\OPJ9C<KDL]38U_'W+AB"AS5A89D
M;/FB5" FBIZ$[8*\B!4/9,>C19,&=I\/O I>:.)@(O1*XBU$FIQ<P0PR-"68
M=VKMDM$RLC7$Y:[1/K9'3B#*\,0B_.C4^X&/GIY]<2@UCR[F2"WNCNY6Q_S-
M>L@H8IDZV=&3%(8:C=#FN?AK#3-ZX(]4:IASM+UD7])WAKFI:C9N9XD(G>"/
M%&$/S%T5?HSW98G+Q#W<NO,J7^#[S,TBUZ/ JT6I Z+%IT'ZD[AQED[FU,UY
M^:,EA&V?!XF6^Z?.-8!)(6JD'^^:<B']4H!CV5[%[Y,2NJYTC";F65'+5UUL
M=)<T?(N[)5Q'0O0F)Y1Z!WLF7BOOZ/@X3YI2\G0O^K,HW.#"S?KHN@:Q[/JJ
MN*9Y+@AIKZ$6\]@=<EW<YM52L]_;BR+"I8(:QV9W9:--OMJJ><&5$]KI6YYZ
M)*UM==$SGI63-\?XJ',^NZ2F[@MG4MIW02V%[5U/$RL*$@GIE)%-$F]7<*=M
M 0[^?)7?%-J$5"\X=(V')*S^SZ>/LB<GG]/*_WSV-"- S!HI7A(4YB-/A I2
M'D\9"CXDARBKV12L$YTM.)XAYK>."!SX)>#+_Q,VB%$Y].73)WNDVUY! ZG(
MR1M%QY@VM(2M<X(P3L[YXA@7BTSPXKLRVD0N5GW$P:%+(4J>.;4&=L08)K,5
M-'MEF14+((/1:@5B8==K](H%*Q8FFKM%9I]^IB,1P9YEO:P&87D97;61OFQ+
MGA5(^\>LT59Z:1M\*H>FS83-D9Y*6LNU\"!$5 U/6J5WP17$)))7R^(>5O)J
MNQXQ>"CTRH2#FY=$]3SA"ATGM68^JS7J$=)/6B7'!&B.D1X&P9?Q<B]K);QY
MW;0VY1J%@3F*3/HKY(^_?OGZ_#RF6CYF--/T2_$>%24V(]213Y,46)SY3_3.
MNOEML5+F$I'LC1?W438">41N&+C> -0&339EV\(A)08EKF**R8[=R01I*!E8
MH":)?TL';T-C>'GOR-@:V[VV&$NM^0/+1%VLKB7U8+[LHJA*Y/&IH!G/%BG6
M[8M1EB?L6N?$>)\R?T[.Q5OHHFDF]SESX#C!W(Y*&GUY]$YK-BAP1,O6.0\\
MLG*Q+SY.SH;HI:DD/R_9++PVY-EPKR.JH@>!\?J03\GD$7Y%J\WDD; .(M(J
M@'G!I$,&']8W0WZC*,6R]0_/%>&B)>71I0Q*(4QLF'H2.9$1S;U+E*'*'#/9
MT"SHK.[BN)!NO(U8K80L(_M.0 &.4A)>V7$(LT<B?#[*52K!0K#+H)J((FA#
M1JBG*2QCZ(VN;<2X&;D:J @O[0E<H& 4 >N4\ YNRF7O\Q*)^48D01YY#'GC
M)]-B"JPD W20!$]D)*(X/11E9*7B-Z)]$JA:,_0M)M->Y^R*:PH\83;E1TF7
MN^N(+0N 8>, 0!M,RDIC-$510H;\YH88]7KP/M0+#1W"3>0#M 3]+5\HW)"*
M08X&&: >22HS)HU]WKT*UI^CM[A+FOJI;<GUZ:7J5:QC&6)8^$*4S:)>EAV@
M+2><K(QB<0YJC:ERH+*+Y.T0P(D_'KD5\[H>T"G-OK:@[BM#' 6GI6HV!L82
M3Y"U)7]"X$]*S,U,5ARMEW6,>=1G2(11DW$LQTE=Q#^1E4;-/ T1.G-=[$)?
M(AK(HFN(F&$1_BU#.^^*&"%D&B]&9%H(]<O@Q3*))%S6SLHH6SYK7+N:PNV"
M;#=1D:4UJ=$$$\--T[)<9+;; YBS9'5!RPWLQH'0IEW1M_!,MYBETX  %\:>
MF^,*1MZ1_HH =S>7M'73L6.RHI.^T6LJ:B<[3-UT+8'W>V;TOT$V&:3ERDTC
M.$?[%0IB'>01>828/P"C[@1^*@A'Q'>$4#EHQ$JO#I3=H+BG9BR%F8J9Q^[+
MZ-4XZX"^XVK1_/5B=$C)'@!UQPAYNI7=A@<UF$!_0#&G9B1)Q.%Y[V^#0-W3
MN,MX:Z)'< >)O)D)I)E3"N8/;B8.A9Z 3 )DD+<EY\ 0F]YS,9F7;/ GR?C^
MHLX D;IHVG98[Q>@G[/3KSD+J"$(RARU*JIK&@D<G 4H?<Q5"+'B4(<?:;HQ
MY]4H99 >#YW!H"[=-)*44BMT\BJ%89=27(F,*$@!,EP37-W6+J_=913\"-\<
MO45=+DYMER8[7Y];/D#._Q(Y%%YCIH&U9'NYWN2XZ: K8DK)(N]P*204Z)?$
M%<BCL.N-;$PFK&V2;)"4.B.3<QU9;=4LN^KHDMHBBS53^OZ&&FI=.F"Q&_T!
MU:^[KUN.Q 7H<AH9:[? ?,8<-:_4^E-6&W%^.UL,_4;A5<(K"$B49-=)7=,H
MU9LB82"<>K6P!^/WJF@O4I*XC0 4W$>R='L3?]TX:#\N"EF2AD:N/I(L<D)I
M"XW.E3/VO]7N4+X[2&FQ<A/)I^]^/+L0E$L,A!)F.1M<$H3^75&L9]=-\TZ]
M1"J4:-F-4M#AWI*W6N9EBR;@9:6,6L$XU%T^3Y+]?-.-LFR779&<+KS[15@*
M HE-AR3D4I5!Y?=$QP4<SWX 5=8PUAG.L53:./I0BI!I^Q#140&6'4*V]L&$
M#>D(40Y,T,H3/3['56L^HE4G,G& ".\][J 07LZMMT1G<<=+3V2&$@\?59/'
M,S1*Y31<-!QJZO$C73F_)1>JOK%&A GWR9(JV TNEPP=IY1I9W00/5.F:0(T
M8?B@(8TB,]P1BN !6-JX&*H3YBB!T$(JGJ ,#>D6)6V*03:H*L)KK!MZ(^1D
M;/D+#]BB7QM;]/D#MN@W@RWZ@[B^KZDJ/6<U<DG$B:\C['"_6BW^1YL@EZX'
MQ2%>1LD:'VZAV 2KE,OPG''I*E(-O-4AJ]PE^CPL(#A@<US>!A'*]PZ^?OGV
M^<77AU32RL1O%EO.'#>,^0UZ7(><9>R4,=I(+'RXPY*9:;B-B1O7Z"5'!) G
M0SAX_?7+0[&XY&&E@P2LR2J8J):)"(30#TZ=C\*##9:"U]2%_ :&.QY#W+92
M8HS4XMK;FF4U8X;/B(^U6F='K] #9\F]*K0"DB2!B8I9._U05(U5 1I.0K>K
M"\)<<'B^'9DGG *E K/A%%#Y3E,-/&\: H)5\AMEY_/KKZ^XZ:[;SID9577P
M(4KPQ5(R<)&3$\B"H"&)#@#P&&P2CK:IC505<7[B%+KQX.SF+)NX<QKL.-V@
M8@7:VZ]?9HSC@8..42HL\Q?/C?>J;'TS<\S,=!VA&2F-?O#LO#L\GCT35,B]
M=C2,DN)(OLBFV',QK24]$- U_BN)B*&N6QA8#L!JW25#O=$<L.?F9Z,D'Q[1
M>(!6F:VMG_%84*5W#]_C,.X9'W^%EX>MP"L_GKTB=W:X=NE7?A2N<2NZO\C,
M#\_LL5(*"67VI)515$8'C:$_M#(6L&?G IHA(G@)::+OZ[2499_V*+D_/H,)
M_&12U-NAPI2C\*KFM^G\S11K3WGY>.3<.8N'5EE?^39T93G&G1(%<& 6!Q/I
M09L ]]I7XOF+WY Z*;UG!I^!VL^  '3KS$&KBL@,3275FP$J9LS0+.OF.TP\
M"\-$"]8CL"<&,D&-S"70L0CDK$$;I@,O8#EM*1KO2DAN4-9X74/[8I,X(:%\
M,&,&Y9W;]8%K\D,FLA!I;%5=T(&C1(ANG"ID;V^SF&OG?1?Z_%*-\0ZMUA<"
MC&PH-T O]D"8Q),B8 %K?8T4#!/BP=8E2>),<MPZ%L&F<L4WGE@JVX=)T6<!
M(M4'/8,_;CQBE:W;%6$K >8*SQA,729$&&)_RW8^K.AXS*5>CVIQ[LT8WYT!
M?R&21K:)=X)2C7CO/F\YM5B7^[$*E%Z>7EX\%Z(4SG\2Q\WO52>^-I@=F?_E
M#M8)K^WP,L>:] X<C 6*Z.0$\HD3  %]+CBG<N+H#PY-F<LH2H*Y-JWXIC3X
M*'XFDFA?IURF+$ZLPT?P0<+R&D& /N.Q+)Q@;,R+87[Z)7'_]?9\[$W@ 8>P
M?4&46R&5>$794^YJN, MWXAVX]W OH!=7EV?3A$]X<VW=;'I;!PG9<0I+]P-
M9.I'0-X2M2MH$7XW<3\HC3BTTN*%"A(I@GO2/E9JC/5BNZ^<Z1#=%)VEAD;0
M5GVU=$@'F5?2*0\8_VG1%#SPCQT8AVMFG4ZU8O&]"0[$/G'$LB</374Q;"*%
M$OWH,6TU&<;51>\WCJ/1,9_ 6&):*UV",M30(N@KI"? \^ M\.WHYKY7GL <
M],VZN E'LA FBF""WE&[!E?UZICB'JB36 P7X)S;-G@$(N&M,WMK8,NQBC1?
MWH8NN&Q<'D*EWKVD8(.B41TB"TT0'=)LRV8RP2A?GO1WXA[3KW?I?JJ?BG?9
MYS2 E1;.R56-69B7:%6$K5UPJ*N#*ZCL72P2D2#JU?M"!BC<D=5>X2EW:W^F
M]53L;-@K2LI%N-DTEI@2GJ4=>):SIMTC79](Y#0" V?$HNSYYIIRS9I.L.%"
M4X+!47+D$]J1J\#1<:=%&+HT7*=2$W3OD2JH".R:SD5<$.E*4'!EGD'BB_<Y
MN4'<\:58-5K%Q7821"FH?'8&B18\!E(%OJZT'<,[?S<>'0$&@(*RJMP")^/:
M3F*UZ_ #*?8@"/FBF5B]_$'3=5@GK>6?)4D;77W[@3D=,L[JX:OH9C:D!0XS
M]&I\CF2B&"N2./,A[]U\I)F2MHS2,B/&KZN82E/.-.*=)4^]OD']%4W:!=K/
MNWE0M0B  >:_@;%IM\.*+20GZ0>P&&JTFR;Q,- +V1H.[R')+&"E#J;EZ&="
MW"+CL1=UQ^WH]"V/J2 J+Q1CV=%E/]>)A+TD]UYG!Q<7K\\/T2VS*ASO:%B
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M!6@A8K1=PY58^V.UWR.G[^R4=^%9"6Q5ZH%1_1U#Q]!@@[D$O= +KX/+/A"
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MER5WN?AEIJTB02 1&1F/'7MSF+@D_3W28M=.E5Z#C14O)&V^  2B.9>]&HD
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M)V73D:9!V(HL ..C4>D!!*@ASY?@>1!LS<L5AT07%P0>AH!C5:=2MC)7*:.
M#>_T87W)2+Y-#5TT<U-+]VBM]\U:X?-NFCB-3+AE^D?QTT+:J0=*DFI>ML-\
MZZ8KG"9%M'/.V)^W@N-"-T2Y="*<U";$&ZA0D74AWAK0J,M^7^R=L^3O]F-'
MZS]:?PJ.$B>MAVEXH!UC&[K=V;(NSYLV//I"]0VD=:VZ$#9%H(/*UD@7&KY^
M-EQ2JV:K* 3H[1$^2#5L46E98$!,V@ <&Z=\0QP8Y_^422?\FU*SRXDRK]O+
MBS(DH(MJ$ !XG+T\VOO1WF-L@KB P']4^M.8MW:?PY?+<ZM)BOD:^X]XW/ 4
MW7"Y'6FN'RWL:&%:+EE) B<RJ-)X-4GL3,M*YDN:"I."2Q67H,45\=LFBB:0
MBHEK+,I+.?%9O.SB4.R\:\L1-@*7V'/>;.Q"YN<D*<>&AVO0UID.H97]OAJY
M^*/]'^W?V[\*!4058!]-^.YI+XU#NF)*)F,J:O0!5CEN.-V++.0(@0()\BU"
M3HIV1QL]VF@VHS2.>@43DT6N:"<I\"5Q22NF>5EM5)RE,"H$E;!TC)G%I..U
MD&(D!5,:&3WTJ5B<PW6'1EE8MKNC"1]-. :R&+5RV(X>+<]S8X380U0%IUJ[
MZD#TS(33@U3#5[;?P<Z.PSOO97CGR7%XY\,,[QQ=YCUTF7*&2QV*JHLGP ;L
M.'"[KEE=2J@D$**L,5@,PBG_D8T,E@[][&I8(QV*[0526P</'/YA8W/](.58
MK8-+'HZE@J-!>H/\KI3)MI !A8^=4%P]W!=4X#JF\X*2Z>MP5;#,7K$?@:3<
M54[7NZPDE7K3L#YK'Z2)A_PSJ:L ?D;/X<3V->L&QQK7T7 G\J=:H0$SXAMB
M"A-^H5ZJ2%9>.(W<AZ8%VT<*QKVZU'5D2\G["Q&3W\[#5:IM:@.' 'AHS!'G
M_61'RJ+L*M/%L,E?$LTO/L :J-$$O^>N9=." /[C[CCN#L6 -SM6<%655 P6
M18034JQKN 'TH3'XW&R*I+:=PB%E=3(IDR6Y]\/NOZLN!V-1TAZ;BL&[R9LN
M$SUX"PSJ>(P<-\J_WHP3L%O2)$<_HB\( 1*A=E;DBJQ=;+4,EG]1%[;!TWG'
M;LJRLEK<T,>1.B/+%'UOU[(V2[9(BLH!*P5X" =QE#'8L<]2;DO1KUGL9LC&
M%Q>5B]C"231L+]HNK,Y2Z:,[; "VMWN'13U65SYL=>7IL;KR;T.-\@>9^/+@
MUS\>J/K=I[='BNF3<.AQO\/D0J=Z'5&=Z9V V!,12#$=?BB-;W\Q6X%3]W3V
M/,=@0T"C7W3U'(,DA$XG##;H0< "BRGH!F1?,K-R7LDTBZ&QY1"8EEW21M&!
M895\^.6^SRQDV/3V$#;]'BS2N^_"NX"]OE-F_=M X;FP<!:ZMCT(#12RJXSX
MD5SV%J_E[S9P6BW=2X<)?/3L\>E94FP)/_71)\].G\9_P15%@$?4!O=XL?F=
M\#\>TZU>"E9HO9N2^^NK9&UO(]FFDN2P&62;0[IH(83N.?WV1T_//CO]Q.[V
M?AF0V80I8D_@P/A.PMM;7'AI!"#5"^7^I"M(5)2X9M.3HF"]'MN:0,X$CQ8^
M:)C>A#JK5BL.-;]3^:*P:U1OZEX5"O?*%@(/TLI:H9.U_M87X,,J27N,"5(8
MQQ7F<U6BQI&0KCCC*[2SPM03Y[[Q*_$NW@YD1B2!3OIJZ+AH(X6%?;H0?5-$
MCJJL#5']R_!V:S+C 5\7U]ZO]G*(--'C3#B\B;Y=U-P@7"QH*!E"-6:NHP#'
M&. !$%R0Q:\G(1'^OW 2E2.1=M_YTKM95^?D-(J2FOA,/W0BP5#9"/Q:5U36
M;',9<G-^P#1LT@N?L,#,@11O.YKT*<./J6N3;1 .&W!+31](23+, !,1P^@K
M"F[9#0,$W!KR-D)S]-*T$CW*1C_S9?@6R@8WGHP*C*/,:5?%@3\O:69?6E="
M=H/:@YLO4?57^-K@1.PL7K8R6*@_C K'U%U2*XL_-J]&*J3\L8%F*=%TE5N8
MT,W("^XO5 #*V!XC?1'V>\TW3!T$BC@R?-:PQ$;K+:"?51K.-[>I*=ZI$^%#
M!($JG'5(>]00QQ!R*9+*ID4I6:7-1RQYM,(O[:IMMJ>,9,WE6"H9F]X6!TT]
M&*FJ%%"?5-UP>V1T"/<L_E&E:J62G=2/W'5T YD3VHJ_])84MF@I0UW"V5QU
M?*!PNS]5W6;V31L6[2M1S=A%Y_*O#5D%S\:=&W: W+(A4O=V0K.<V TZF+R8
MU.>[4_9^^U[CY%Q>J70=RQ@2JV<\%,%>HYH;;NVR[(28@J=MWP^B0)]\,=_2
MC6]6R%TF;VM9+XV10L8&L=V66$*GZ;"!!S"[BHK+[;"EL1M5A0-^\I@\&$H;
MF*_2RD8L<8#;Z8HZ6Y(%//[D]$F6!=C6_^CIH].DZ,A3PV;BC1#2ZS6U-VR?
M!TZ#E 64AXE#_U=Z&&'4\<$!K[(:^(;S"1SRT],!=2%KZ.KU+K*FB^; 6BAW
MO/!>>$[R:U%3[;J#V%DS%N*-,!XVD2EPYK6U>W 'R28-;QWL\.4.1[=DVN+X
MP/IXW>J-[6)XH4IV?Z'PZ"@<9; EQZ<:4C];#_MAJ\9=F(\C@U\[^S8XK+-H
M'"^^_]O++T[./DL7%;7C\(M)@O4&;+UX4$]MZZ/++%P.BQ8B.@M,(RW@[M_#
MV^-EW>SM9?DT];@NJ3;!9,-Q1V'O:B<U\L!AT]DOW2.__!]& ^='.U)\#F;$
M(FPL:EL20I%B^:ZL^SS/477'!]3FQD (:1\?9OF CY3G'NV1#9E,O7YN[SS[
M6^/5E^==)?/<JIR+=]J$]0W;M5I33KW97O0YC"4% Z"*O5(QGR^J58E_?I +
M,+_5ZL(C+LJA5YV**+2>@MW@3DPP2(^(Z(35,8]3*,G5&R/)O> =J6['\GU,
MKH.-\,#2I;.-KGE[^-B\ECN"S#M*\ML+>F[S^- %AGU7EY(V.QC/N@ZVLI34
M)B:PYOEA:4QH85>1['!G!E>D,)9\C#04_2TE*PX_I*JLFY"H#UWE>.NFI:VC
MIJS-\&,KR-$L5L[4-]PQ+\:C6D5VT^ZQ[+APJ9W?![*0HJ #%IFV21NC'Y#0
MU961B-Z\.495C#JBJ9A-Z@[SZYUN4C.Q5/#5]'H-@;KQZ>SL;#V1DA]T";J)
MT$H1DG7O(/9F)*,QA$32F7G3,LYCX6+/D<0"-?K[VNI'T(XH0[0IN4WBHH9W
M#H)6U+Z,EE-4S_!E&5_7*PZ]9><''\\,E<^EKX='?SP 7;LL>30N,8]:5%="
M&EXOMG;RNEU+.6T4:Q%JF;D44;Y3HC'ZGG1GN),(<9XT6<Z9+M9E)V4TH(6:
M9>\*$6]]6@NQNAA7Z?N,09=L(R&U!<FJD?9:,A0=.0,Y)?"-KW19KX=P+A<1
M8!C94V7C](G($:MLH;I8CW)O&);C,G;G[#U/=2(G[T>%@&8=HOVP0%])(1%E
M%W,39?024?'9ZH!)GA=ISLCG)BJ2O&581 J&RY8*4-Q"[^;(BPC4E,1T/8'[
M^N-DI>]?;.->4&O<J7?^7J9&]0T4S)I+;$$K+:0%/S1_G[]A*\U#OL!F]@R_
MV8<S6 O"FVK)=Y (!%BK+Y5$:(!&GO4J0'^Z#LZ)&6D\COGOV-GAO]:5))!,
MGK2UYTCF%4EJMH*.Q"QR!?P;*4X>L7/O&SOW[(B=^[?!SMU5%_KWV  +5PU>
M+*2G[?4L1%V+UY  @ZHDQ<Z+&PXG]4<*61>="WK:=SM',:V/W^%7$"/B#E9=
M"$"%]IY5J%ADZ!.5-R!?VQ "RQ!66,5<]'C2OPOV?UXU55B'7C)E"2L3&7BY
MIN( FV?WZ#3]B0P*Y\J$OA^C_*MQD@5$"(<<G8)2*KLBP5^.1*7W?/[@^J+2
MRHV5PY;!#2 =#5'N6M4ZDMP53&V^4S=4E\BD;ZJ<.^%7L/QO55 XZ6<PEXI9
MFJ@/=]3B93\PA.[A1#W,W:1EM[;WN1BE>8*='X=LCD8N1KYE&MJ$I+&NC M$
MZF4K/QNS9UZ6>R3!C"0-H\8K3OMH:D=32Z86<T//.S=%7:<@PJ/U'*U'K&=4
MNS8%.-;W55*18W>,MGM$[71M!LJ,0;; $'V9(O$AN I(_$)QR 4>3?-HFOX,
M14/PW IS]68^=+WJD.YE+7'2U*<F1WLZVI/8$SHH!$E !&3HJDPA&AUSI@JF
M$"E]OJ0?V,\>_/6'[_N'!:4/V>Z.N!73C^P-F;$7UV7I1WC<M=*^SH-M://@
MLKV6I!D?"3]E2H)' SX:L!APE"603BZ.["[\4Q?5_'0RQ&6DU@R=2#0 (XBF
MOZQ6E<[H5UUW3&6/5I<=PQ@7Z\"ZD)5E]I/58TGD:$>'CU^A2%V7J. +BL;^
MK6Y"N 9H]C^&NE-LVIQ=@=E77SQ/L! _5B=<'\;!'GX':"49NNK# <\8<=XN
M(42!@/!HAT<[I!T2Q:4A73"<Z[)K"#A/; &*?HN&RC%(X921&4@!1O]&UGF(
ME^8/W(5Z'D%JZ#]6.L$WC=70T;IPF:J_I!S?7M>JD/:AC;]'\*4,?>SWN%C"
M#[>*']6C:FHTM75X>C(>)?9PSO#EY0Y:1P=TF383^)E5>=6"J30\)OX8;HP>
M#_W-KQ)9F9L?C#<_@1]JEO][1'^G4S,)^^E*.7N:$9P\.4X%?O"IP/<B?7.G
M5OF6WN)M= 89:4%(=V9@BU' 0K<]X5:O-I?K=E<!M_]]AIPWR#EY&&X8A<[)
M7R/^F=>)_6Z"4NV7(@ZV7X3W9G].K[#@[<$6RHZ7%/P:KHL/LWQ?N-K]7@FL
MB/'30>Z!U:JL.]\57:F**78]?BDK@L@ <CY[;NR)'#;":/KI+'??V8HYYH+I
M87B'Y0M&D4&@1_[W=/93JR,5XMK"#6$VCI*!@DF(VZ42:$@VN@[D7IR=\EAZ
MN28<7P;.RY[434OL>L1QA7^TE<R16+\YF[*I%MU0Z\!61ZK_](C\A55=+1.*
M\'3VA7Q1@/2;D2)B\+ RKW:(X$47B$T@W&#OFN=N$("(]5]W9SIL,Y8HD@';
M#-VL]Q"GG>FU0FZXT]NJ%H/OZ<?9=HQH"+!]TL6Y,9&WC>V^ RW5'^.\NITG
M?;5/@)/F.[&).W:K0^R"\PG(U\5NL18TA$FS8/WC3HPL'?K7.G\5V?0Y-9FS
MC:NF<CELR6F +S=:QTIU5\X+Y5P>XYY2W:RZ,OP5;.]Y63>$\"#\(B.3\[NV
MT[$R71M^P%A0K&L@'03V3_V]N DO#M,<),V0L^$B1*MTI++GVME%;;$CQT/H
M D<[CF,WLDA)FRQ;U/TQ'O_C^(G"]C=;O]R;DUN]YVA-+;R?::7B_1#\9QY4
MSX0$^7(?2ZN5=YM#;KA:9?Y7_NZ&H]+$JK8?PV77.^_WQ58XZ(+_A%05'K(W
MK9799=MVBF.,G-0*$P^! !8U?)YG&9>%_RM&7<(,MZW.=;Q*1E7P(^D<!Y=H
M-J&57UW4YBR$BS,I\?M%OB=TP@@ II &W!_G\_<#YU=,UJJX+]M.MQ;L>^B:
ML@NFMV3.=AB9E=,?@8HEO-%^M4N;6Z6C,(-%7-CU!"?&V.Z222I9#"M4RM@R
MBC?&TWKBO-)IE/8CXQ+U/GWA:8*4*KKM9 -)\&$4T<$U8Q:,V%C)8/54DQC!
M[FZ9QS_)I*<O-_.D!SI!GW)3#GI7'".M5;H0O[R6.*F* WH2';S#,-,HCQE%
MDVFC^8<1+;E$XI3--7J>NW&$[8(F&6D-"W<QA'MUJ^:M\.WGV'$"X@-/0'QR
MG( X3D"\_T+-_520O5_Q1\+2=I4 :F5UX;+U/86(<J&#Z6 H/K#X.$9^;IBK
MO\),L +=RER#8EKM;^+G-)J/LA&WEWN0$$$1),F,]G[9*6TR.%:NY$N2 V7G
MK$3J!/TQ4PRQ592:"29G4SDA1EB@[[$0%@'="3+M'N4Y)]=U\I:S1=Z[\S+X
M!2R=*^[A&J9A((%/-K#I.M-%;-Q<RZ.\AY<P)9.CKN7 "TEWRY(-F8_P(!L9
M%:T;COX/9.%<.::IJ=?#.]-T;V$149;,I+M**0U+D>&UK-="63!U868]D97)
MIX+U5EDI?LMUO#].ZJ4COXPN>[_:B<K9. '1^J34:14U>>C\R2LFP4ZAL!L>
M.I6962O$?[IRP=L.PYA?B\&&5TJ\,-/Z3;N=%H#BX'8)E;^%D&]6R\CA2KZ%
MV;J\-I5@%K83IZE1 W*4;QV\%E!1U5Y^HYE$G\WG(XDI+*,0[[WE5%#;A/4
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M:%VHF?MBEM%R>(%%U-(V(>TQIC-?!K&GD"GFZ5M;,(N1G-729A>HH;9GKT"
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M[JI.>%<PP*U%,;2>RLC@E+# 3NQH0?K5))#HYW1'8^7:-+A;;^-VV^<KK0L
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M_#A*^HL4E:)<NR2\.H*<R]2>J)ON_Y6Z-2%PW@6#1$B'F_BF'>H^[#302+Z
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MBR*:+[PP=K%JRMGW^G,0ZT:0?EU'0'^T\7E5-1I=]TSZ9+BN7KJKH62&.0Y
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M21+]":0.P)YXGR%(>>N7C;[*866=4@%@#QLO[L: DO@1(<6-\G#S:M>J)=L
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MBF@/G@D,%S!+$]R_\C?5%&$P:L:<S,EQ'"SK-2FJ3F?/&\S(FICSWL4B*:5
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MD(O*<K <]F:K] _YZPP1W;G?V9Z27GM?P8( LY$P>$4&NQXML&U=J5BGEP%
MHT)%TDV@9O+%+:KU>B"'F#-7L8SK1$V<68=CJANSR2'Z:3PU+>GCPT^,6-KF
MU:(<U%HF[D]M:GR_765X".P];M9R<2&<\S)0*87'6):L.4=BV$B:/%@;38Q0
MX9,2\2GY<XF))YDR0HL2$T,A]KV>M'S;10A2?VEKK@CY;TV/<V)C16XWCAPO
M.:NJDQ#>'B*-GK@'B9^1;+I,R)KVNL66I[-7;#(<@BA[D$@_S#&;A0N!$C%L
MGM25)3WC7F<6'U->"C7BL.J)^$ZJ,(=^6E0@:[(!7@A3+KU=1610H>!6" $
MH7@)_MER 0:<IEK5*D*@7'?R=7S00V+;[KQL5!2O5_4$7<]EOKGL]SW0",8Q
MA/=H.93M//UH=,,\5*P/'2<X1TUJ)B'YVPQ;E[9E5,."O>P=]S XER+78P66
MX;!_^D,D>TG\:<]#]^ HO &D#@KH8'CA+K]4HKST=)%B?RG3?^GV1@U]H0ER
M-P;RZEG5B+AF+@$<&UG9$0?KIY!8IG8@RH85F;/L#.RJX%@:R_72V)'0Z>S>
M[5E?)&))<13^<8++6O:+X/OX1!QY+!R+ ,88ZV65#DKE/S0%!QV'5:)/ R]<
MU>;V#]S@_3H).YJ7SYIC-$1>P1CC;M\U=HM!FPF.0XHMN'_R;<IF_J>ZS4-1
M'0^E/1GG0N!S_EY#=%/W4C:80PMB/Q3+)Q&UT5LM8>25N+_M[E)=ZR;8ME'#
MOOCV52%$<15TV7%J!!O]^NM7I_@3?QA,;79(J![>-8YG]<+E> H2VTQ_.9*M
M<1VC1'MTC#)^^RT^3<<+;\<]''SN"I4/.>67U9JL8;TH(IBK%(?5XNBV2\R>
MY_#-%]@L@D.</?CV^8O^X>GLASRLV5;R3*)QFJ[$PI [IL)=H#P4WAG]:92X
M$9EQ?&LKZX)UTZ,.BR<GL<KMBI/9>WEA=2;"(_*SEI1"#:;R/-8F<1*.'&(Z
M/*3.M91ACMF7 Q2QC<V-E,.@3PE^2=:'Y-'AAH60M7I3 EE=X)T.)%U(XQ_+
M;CCOI8 G,@AFU*MV'#O4$T:MW&=7E7KL&Z_ XVGBI\1<'/- 8M$H/'>!/'79
MB'I-5]\QG9+;PG;EN)CP*_M'3UC8J L!<K\UW<45</69YA ]E2QK$<_.29_(
MK<_=PJ,/6T5"ML5ZZ(5:#WU6&^G'W^+K"K<+!LHO?WX8MB'M3^[<D4QGGW\1
MCKN:JICXF23D@'NC0+=,"'C"]7FUO89-\3H_YS^#,UXCKE@[W7&BH.\%//C@
MZY^>/XR#_4U?:\P)'[BEJH0]TNC2RA0TBUU!OV.QCKIEX29P7<0\V!;A]P25
M+O$]H1"J7J7R$HLVEI_!+C322E*)M?"##.BRQ\>UY6='VL\]*P-P9?1 3!3Z
MB;>=3B5S\R%YJ2ZWJ1(\4V10EH,P/A53C'TKOQSB/GHN0!6,</;+T-7]THKN
M8'S76V) ]WILTQ#P ,M"7J-.H1&2"Y4KO9)5/G"CA2J3,<V)-167 67$SA9G
M:=-.GP.I6?1"*?DRHDFGYH6^CRE[PX*=!X[?Y[E4OL:?:TRS\QJ]*<E U@LW
MZ#*4^; \K[89QST2I9/%L,VG2AL[L^6Q^ 2%'?=EL)ZP"SH]\HOQ)B]BW)X(
M->J.U:WJI!L:?T?]KD=#FCV;2'QE=V^W(R3HC&O9Z$*R>>[)DL)>6X<X:SYL
MW3DA]8BN#9[1'4-?_CP^.YFBI$4U4FDY9L)3.<2<WA^WN'5CYQ4,<T:.\(;'
M*M$A$NL%S[P4DP[)/7]#NV^P%#05H[H2&[1X[5\)^W-8[95IV[B?1KRCYQ\5
M<T7;+A-D"!9:(P1+'+EVJY!$7.P6T.I[J5,9\;D+_:3X<KV&TNW.PVHCV.0-
M);Q@V[DKQ]:5+5NX4W:+9"$87'[)+^,O5D8@@YLUL)E>3NT\;7]I:=(!%NVW
MA)75;B:E6E(93;52?=R=F$JXIX;+[]NNL=N^?SHFB^A&;/CR;KI8_K:*E9.F
M'^5CDB6,G(2[\["'VAZ.7Z3*UU5SOKU073YY*R,A'^="7 88O95*-9LOCG50
MRD5$&Z.I"RWUQ$K*G_86\QX%4TFPR7EF\U)3-=/]<DQQ.!XNYUU;+EGL#IY!
MBD9D9W/^4NI:%)]DQ9)'<E9MBF4;J:)E*:N<^GO57LT84;S93UD+QM'"5YAE
MKQK1C5)+:I/Y/1V>=1=K,[P;=1R$*,2ZBK%&&WIXL@PK1>4>U'1AM0\&%%GR
M4@O+[^-'9Y].K+LKQ('_KD0:6AH%^7P]5&"*VA;&/]ZRH=X4(^H\P^LP*\)9
M%EQ<_/(^S]4F_ ZG#;FC0G:=A-H0-0KK#+;Q6O,?GPBC+":NH8K?C\R3+H8*
MOVTA%,U%%#,2P]5_A.5O1F7'X(ZWJD"#=T)S*<+_.Z_[=:D#DE3^,N-?PZQ[
M;@/[E)6VX^W+>9)<X[)"+B'E%3OIM<3*<K]NG7D=,9=Z*OF)"#V(.VLX[-6K
M&SQ33?Q$/'J+/;R&O1%S>&72Q4O'#-\N+K)N>Q-(I 9<V-<LD]C[=&4ZVIU$
M%E+2]T\=OA2LEC7.#:+V,FD"FW1J#/&P$L/ZM1&1AONY1_XV4T=TI[2%*>B_
MR$[2>NRDUW#^8KJ!Y/2EMYW4?Z#S(L)9)W,Z!9_EFD\MM#P8CX*Z685O:"Z[
MWU@8.6HE!#*(6=Q 5Y%D4:!,R_:ZX?W8XZ;,U)T)M1,KR[K#^%9(@F1B@QX*
M1*2=;:V0\2_CZ+,V$:PK%3XIGHE20^&A=VS"-'TU"MPRC\#J^[SLPLOJ>A4<
MYD'9B4ZQ+G6%X$'KIF\M1Q]!0^\;-/39$33T;P,:^@.#8;Z-L4][8WA[,:A8
MZCU4./J)8C6_2%/#^GSD1C6'ZI9,(^D.79G6^NG#)439#D,Z]!B+Z:C3!9<V
M")-.<#I9O3_YYW"<#E9[LX;FWU7TQ-UT'F='7 C;'_[*U@L*]Y<Z/^2ZMM9+
M_AQ,6VN*8VKTA*R!31V5EM65BD&Q%2:E"'D#:HAI4Q\+(9(V:_#<G4>MO<TI
M2\V'E@Y?(!@;=.[;Z=/;LIV.BS->[(0*22O\7'8+#_%Z_&[?<AF]IRCU6^J4
MDS<K*TD[_AS:"+-,/+0$KB@L,!Y.=Y-G,VQ!,TROY#-6A HQ^*75^.M.YO[*
MC=2=P(Z>"JGK7?KFLMJ0;.3 3.F=<@KOW;=^G;Q"5Q'T'=^-\@[73/^8?XOP
MSZ@L9<+@1Y# ="N>MIIJS%&&W;(4_GE"#C[OH?I(7_HH,6LWR5&-D?<JY>26
M1H4R;K8HCJV0MZQ!D;<DK&7QMDTU^ZI:1@8D+064U^BM=%9BD,2BY4"$U'RV
M+$Z2/!Y.PI<#7#$T\71[0,/;GKJ(.**$@V$BLDQE!$6MCJHRO6]"QEZ,P  C
M&D=QJX[5R+\A><S@T06%:MJ,W%_N3M]2KI.27*S&88,%;PU]B(EBG!;M8V:6
MCSGSST-_$%<E66,:946=_V+/-:2.42K5).$(78<X^%+J>6$HO[VZ\0%#\I4X
M?/SYB^=%*HCY3<$XIJ_'[,MLF4G@PARRZ4+J;KB"E=II'@[IN3*J"*F)\25W
MY;#4DBO6,=5OR!._\M* ^NR1$WP/N9?]JOB#FAVJG) ^C>QIQFM?N4<^]:?<
M>\Y^&5 VQE3=15CXRER %>5*8F1BDX^FXV2P7=T=?_ZI&S:7>S#*\#I>M(TP
M###CN*Q0( G_G]*O*&BOK<T6MT%I U"'[V2,D.E9<[$/_/3B/\.]QA^NL/D;
M@91=4)E\%J+T\,/H/F)2E;HH93, GD!=D[//"H4";57B+U-6"3<0HUM(B8<$
M %)!TFT474#.*6H)*H:HXAFTPXC["[%\O>2-/4==/T2]6IMZ+J[C\:/'CXK9
M#\/\=/;-Z>R[]G1V=O;)R6=/BYE6,\D0&PZ'),SR^%%\@$%".2RY/KJ_<2VR
MORB78;^4B]E/Y9M89D^561233AAQ5F$9VA!AGQ 3T8K^3XR]UV6C/<RR:; 8
MJZK2B;UE=KW1DKC\20I]K748593I@3R ^E.ZRP;K<O:PB =JW@ 'N@4#?WC/
MX6I-VYR$5&!SN1TWRN_1UL]%T6E^$_5.YQLTN% W#<*9"J#K1L_V8$B4,F*P
MP;;Y^*3Y#\$ZO- .0S3HL[-IS1M-6I8ILZ'' 'S/!&.DU6OF@JM]3/4NE2J"
M!'N4E943"CE3U/1X'K;76O?W$XF:M/(,7*' &_/8T,2?8F3$"2&*U\H9LQ%)
M'?L1&RY]_.C)H]G0K-G+2!5F<TB*.=)DLJ=80E,D]Q+LMTH$/^$L1YY-$-C0
M@__2J:>'%5@,/.9BNAY7BS$"%38IU?0HWEZFXO98]>A=1JG7QH4A&/NQ7,DM
MW^/'\5I>3NKQ&-I!2PFY#:),^!?AAOLQ^.-JY2SB\;1%2#BWW#.!'M@S"2?%
M%'S $N(53HHK7,:4 Y;^]3$'0#RHSE9A%A;YN1"#1Y8T3>/ZXK^F+5*#LJZB
M4:U@0K#)^^1G?CK0V<PC =9T7()F<B*'4Q*;;7,Q7SCU^G0$3/XHFB<XGQ<\
M8FMV:6Q6I4>KZ9P8%'-HDI0M!K:SLN*)-9C3SQ.DMT(,DY#K=2S"$"^C(2BM
M8M,N^63:^>ST6+;T0'=<BL&SH"M9]XAN8K&?.863+NQ;F![K^EI8\TYMH;/Q
M/V7:78J-TU4/SZ_=N@2O2XYTXL@-JQS,#M!!W*&H+_U?]MZNRVWCRAK^*[R8
M6<M>"^KQ1YQ,QE>*9,>:L6,]EA*_MR!9[$9$ AR Z!;SZ]\Z^WS4J0+(;D66
M8TWS9B96DR!0.'7J?.RS=^-'P\;V3=O="9U"\7*Q]O1&FS>!YUY8H*FU^VLE
M^9E16TJ3%Q,4W_TJ3F=$G!P(,\.3LX\ZE7OX1CO.B'AE3(UM@3+SF9ZHHFL.
MU?6^ZZ^8K3R+++/C3E)N_<UY;,M#Y*Q^*VI6_W+G)6ZIT/C(CX4J&TDAQ<E&
MYD1L:FVFU<R&(T7JS)=8+62^EF)UE&S6C2M/%P[GQ\Y<5$Q8$QZ[%GB.CNTN
M*>"Z#8S*;_H+0^3%J-[-J,JQ?<X8A"T\G^-T]>X+P]K%I'*&M8S_ ,-LR-4>
M*?49A;W9X+W$Q9S0W-59UX!\-PMGH%4/;/%)B@@=3*]D5-Z-CDE(/<CX-$?M
M-/7 _88T&.TCW&[;K([:C/!:?!R:U,P@ #0^3WF[HH=KKF4:%:Y;?0A]/^[]
M4) $3@E\,<ES# 7Q+O<.6$#&3>(=FB0;@[(FG*96GKF?C[I5^VOHP.Y(39YK
MZ5SI(JN/'\&K%T'=^ _+OEF&_BC_M>O:P"/=:["R9]0/5 #XJ);YO<&XR!5R
M#?MOG[U\JD5/P9]R:_BF63:'(>4G\[DABA.0&V?\[$+6?V&2K'HIIRS.\]D\
M#=B!L(&ZL]8X'?N]L 3RQ)#,*O5!_T,S4=EA< K^3J$7KN1'0L 2/5[W1K\1
MK68]>$Z2K2+9.6_'J WM]6PLRSF?!,//E^-UCU;D<?$\4#^)/FS]DA_I2?%8
MW_*S_W;DRR_HW ^\X%]]=D'G7M"Y[_G43R&&IQVQJG ])H*C'IB.-U<X.GM<
M<D(V>V+BE%S\?--L ]4"4%E%4*3C+0[H0AD<^O)^6H9&>+L#5[JV#8I>.+\Q
M^L9%>*BV<WN8Y\#EEJ\-_-C&VXK_AHX8CIL@C,IZME EDB: S#,/7.''L:(]
M/9TWLR+WD)A9X\77?F ?<^WG;XR.B4TW\E0U%H9O#2@<&;:G<OE*.<$01!)'
M4>BY"Q4$2*!KJ>-#+;<35R$#BMT*E1%PH*Z>?JG./F3["&R"6%.J4B7*P-GH
M+#D^.L M9[G:0H-WQ4<EC?E2),0CC=K;K%WW@PD?"+,Y@AJ'<8?W!&1S89@T
MK)J>GX'Z*#5&S;A/Q'0"%FE%0[QMNJUE0P3UB#]$F(:3@Y3O%9)AY'@U2K"M
M"M8Q-2*2CYZ,-[J9N$>N%C\B?1*/@-X#@]_!14$]N&8Y8KP+54D"=LWAO@M2
M.<%&4A,)8TS,\D,W?MM<QZB_Y5%H#0]5G$FRO/J:8&TZ)-WLK2DB?E.U2XZ)
M<I ]37:_1K:W)OKIM4R]HB0F?H-?OGVN=#VZ[O$=6[?M1ZQC_LXFL7G15),Q
MS&(X<],$Y>ZF_N.:&#9VS!1AOBC%MV2./)]/?$K2SVSL49B;L;%1]-I@2"$Y
M/[J]=9>9B6(5AN  4*>#;TW9LC,+[EV>/"<5(9"MN7SXNN"[H/@B'4OC]AJ=
MW>5Q\>,WSYZ[N<W9*RB#TXNAK\-6.2_XG.WE@ MO.:NO^R<QFEO=2%K4UK;O
MB_EJQQ7)XP7';K3*.X-NA<C%N,-SC"<(\@@#%X](%%.)SL*("?05L!&JW*X[
MAMU1*9R0JXS=SOV1IR7C3^UIXPLT.!YBW8;;LN9IM.<U:)>=[0?]5?DKUC)]
MH9+=$#<2-EI.Q$XO[[;;WN8M?L?7B/W'>V7^LZG0I!*PF4'$.P/B3(8F"J@S
M#<: @V9[[^$;K8JQAO]4NS@5F4X$"?ZF;=OBEHELWW\NKLAUUSN%]TYPSS@P
MMH:9_:@"@'])G<D5 TO@\2.K(/U-M#8V<^,%0P;N)5?!;F-CI1['5:.!3582
MHFJRP -9+@.CT#PW#XY3F7T1Z'P.H>#! ,?2Z8M#Y<&8E8H8V2\#-?#0_P$O
M&H_:KJ_D,DS.I6P#[J;G&$*4YU5N;:.0/:FG2TCDCST^24Y;FF1K;YK5FV6]
M>D/+LHQV+#>FA<WZ.@8[=*(M!DP1\LF4H"RH3%>>@"?!"I"D)6"A"+0M9?!!
M<4PQN%SS.S7GEFM=)/?$9? $Y[\+*8N9#!&FB3D'RG-0O/W-<:"8M'5)F"/N
M$AOI!S&/'-*GLXO5'*%=/DKRFLA.X(!%+,0U(@HI<9G U+-T.4;S; 7Y!'ZF
M-,1?^7/4. ;F08M$#GU'2,,^&C2F#4T[=%9:5,DQ?*JIZ8RRRL5D)6Z/A*,#
MLP;S+SCHD:TQ\D_"'646HD1"_GUG(9#M::-),3O+V,V4QHTU7[A>0'@5W174
M40*+'8NOW 4AML>!",80ZOGX0),=AX!64\IRPF^<HO?%0HLE5/H/F=@P]G/H
M5Z$A AU@ T_<1I7%]RZ076WK9J?QM6H774X8TZCP_"Z\2$[YJF@]3$ZA MPY
M =3I7"N"YT[RF0L"ZH(L2"C*IW3,_H\<L[ TP/7K%&U'RTKQRS#OQ*.3&!2V
M1V?4P>HS!&)EEA6=-.,I&_7M4''"_Q]08SU8I86\CA958A0_MI(Z5*D$U7%4
MP?_%%+HU$Z7'_TE'=^7"+%R4!]N-FHBXHN1_P&O*_Q(O2+^^H9"(HS/]([73
M=C3I8'2%YGI!R&4>F#&HUUVW]L1TJ3ZK0_5*;UROF8:)T<#\%'2H5N(9SDP/
M6JINJ'M:;OZ/9GW!J5VV?MKZW\AT'YFO[GP4/W[BR8TC39I,*[*G=G+:MU7:
MM95M<(E@F%3M@;M8- LTM-'D2'A,A4#MT%6R1\);(8M#V:[U$X;,&8M1%DV3
MW)BDNJJ\5B8T6_SOF_S+',<9 4B=I3XJMR&;\K+K+KLN[;H_P3ABNA'WUPL+
MG-.)6VXWB-7@6*TR;#R,'H8K+9AK.R9Q&J/T3SQPS'R<GQD+?VB(O?(M(4MI
M!C=2DH[-Q!)'#^*^95"/U4TG4 ]-9RO)S^B6Z;\Z3LZV36 XM6XBW5F7S7+9
M+-/HE*N\W];;F!D^XTS2G4T2-X4V&M0**%"1*L6WXF>&PS8LF;,BFMR'AQ\]
MO.[ZOV.S.,0M^*^#1$FCC4%A="K&?Z>*@1!^8DD7]V8*KEYR3S):285I*$OW
MY=0<*RTHO^A9Q@QM7[K2HGG'A@FFYO.5%,N((IK&]M3C%#I;:(SACX'S"+\8
M?K9)2AP;#G1X#%9K/AN8+@D,4IUCW :1&V3J?U9ZX,\P2,^FVB0QD"X,N?)V
MT2VC\ZE506$O)-W36])?R",V;4G3?]YVS1J/+-A>B=.B=:Q(0@K'R<S/,5;F
MY%)<?/C%A[-S,?^M1009)!],WR\&S]^]>/GTJ=:=4[G!A+\>L'OS3$103FS+
M]8%H  ZRF?E/@2215C=Q<W$?7XN/V>! $<47),YI7,#3>'1@6,>5=O3#O?1D
M>8.?N_ATGZ;G$0^A7H P-^0JJ-/*D=7(=5OG6\QW#-SZ;EL1;S2NA'7<*4CR
MF-')TYC/Y#+# V>2+BC:#X*B_?R"HOUU4+27(^JQ'5%U/&RZ:^I&<2]%" ;1
MN)^/7[7$JI]W_6F!0%$<)]$@ P1 8[K?<T(M34VO2)-WVZC!RM].IX>?:"-#
MRCK^N48K81RS";=Y,8_9PRQXTI5',U3(&,/W1W=,YXA.IR1Y4^2AZ<<TQP 8
M(X_Y'2^JBD.>R4,J31.F=B5H/)$>,W&LN!"X#Z*O^D:X'I L)L4U#P[+K5L"
MD(;Z+P04"(/RCKH)M]3ZO*^UR5R'"GQS,I< OJG*92X\DH]_.LDV)4#5;FGY
M( E5F'1ATEU/9>0UVJVR6\;[Y1:W#P_3,Y>]<$-^W+,8AMQ/\+H<JL] R P7
MG4AT"C D_V*V5!.=J,RMC0GKDK?^,S@BY?Q5#N$K\"4>RU?O8F##D,+ E8.^
M&3K)MU.%@.N-&(.(O[(&,Z 3^'&H%ZZ4VD,]V8R@8IVM*IQMI>5 0Z8&)>N@
M9H/==A_VXT&Q]@1&IF_A86^"<MP.&0E1#;901\\4C>I0-UO=VM"! 4!&2KSY
MZ[Y:)*4G>HDL\ZS9.VC=<G0L0S48T:T03X98*>^NR<IA1TEN0HRY3X"6V7%#
M!Q!N'AU!P7H&MC1+_>Y=(C;1W4U\07=>/F7=>4^BUDR;[R2TU^TE=N$'U7(J
M0"EBAI74HLCT<V,<XD4-B:LGIAG>N]C3(P*S_%"W(Q';L\8[4=@!6:: ?\KL
MMV$ZL,0]MB-><IH@$+9-F*C2;*(5-RY5-)4.XYGZFIR5RZ/8&P.RTEQL=/96
M[Y(_$L&P5;IL.*8JKJ$S'0D+F"&@W"",-AAE>LKPA8SWY\I$>732_M%[8ZS=
MY.;N; N=I*2AZ2W"-OPC<-32!E$H=ELS0T'*AL0(\9N0#:7\?5Q?R[/!3^@*
MPGD['-C,7>.)>'OJ#B>J8K=!F=I0!^O8\:V[U2CUTP1AM2?@.0P39J@'?Q-7
MT3[C;I21N:KD)=1SF^"B_3I;Z]#W7>\.-D%BT+LO="R ?R-G>5",.8LQUJ38
MR>P(H'%K,\/+;"N[8E6^%'LV%&*90#JUW YEJ=R3<V,(0C7',:50[W]EI<.Y
M5/XW W3_]OE3S_LF)ZBQ\*4(7O:52)C'PP@A#,A&;,R)9S8@0-X]5LV7'Z?Q
MICMAH;0+O6S)KBI.K2H1O+\_VT['+KVZ^<]D[.?%'3 D))]9*G*(<H:IN$(Q
M^;-43=2QEYU8*-1$&UJICU<&,9UK8@& U-"91"Y;K9%W_='?Z(0&QKE0";Y%
M&I8Y;^I%C)3?2 [CYJ-F;E0,FLAT$>51($LZC-W0&-" 3R:K%7 M@;^WH0'I
M86S<"/)"VYI37DY-LLM>+F(O&W>S]/MJ\0I"H2M.KE:22T7?O16Y#SX-NO%
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MXO^2C'+P:-HRGLTRK5:2(RZRTP/8J!+-Q=G/^T?,1G4DBH"Q9:%.7,L8@:)
M(+MI'-B24T6!;@V3.G!W/"RGTKONT<LGB*D7V>234TOT,GWTJ7X4X?M&$,.'
M>GC#YNYEIZ)'5<]&1B+!<<HN4X/5V<FPZL=H$M@A[E;<>:5]:_JN[2/_-*[D
MQV^2':J8;;$E]MV!2RU;!DAMZOX)]B1886Y4QE<SJ!S-M./!1FLRNP*H2PS
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M$%MH+K+.5J",73%53WC=+?<^-024_-R]BWO67'B*3R;M,X0C$A.XJG5YF\M
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M3H00!? H3LP=';.H].2Y%=F.:RNXO=*R+BJN)7;,T?\QD;Y<]F+'%SN>^DG
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MY[#J&X*4X#%3R3N)<(4VO*+FZ.(O?WXE'[)5$60CV:-)7F#<F>IP\5]VW3:
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M!1%OQ3Y,)#+*!LJQ&5$HP6BUUU5,^6"WJS]AOW1OVXI9TM>U5;X=8*LE2Z$
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MNE?^ZI<7QHM[NZC,KG,_V%L5@-98!;JVH:J/L!@IEFH563H&ZT'T[5Z]KL]
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M!WPFZ"<V1(^.F<#!:VZ7W7;9A?,T8J E V?IGTV7#/[M0UE=[DRK2\.EY1O
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M"QV#)3T&/Z_;\]YF[Y<J?<,W04IG;,G6GN("-H/+[]C+4R6W>4@GY2LB+5R
MN73JHIV^_N/5RYW]YY@#(%<GC5:"2<^S1?VQJ';>9KD<)5%.-V),^U=5?SC+
M)LZ_=9CM\SHL' _EX>1$]U)\@#!HCU=08#2^]A[<#$[K\'_8WS,P *G%Q_CC
M:=40'8CL,3#Y_-NY:Q2?6$L=G-)]7'74W2'+#'$%F6QWSD])^;PL*X07YJ$
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M=94Y$)\71T(-Q158,>,Q)ZN_WE"NF\4J4Y8$H#[[I!;^(2Y8#7QQE1^]&+(
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M%R]FC5NUY&,Q$TTH"AX\U;.,VXN(%YU==U3TQ P1A0WZ5HZIF3<P!?!#QP]
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M]X&(*YW.4;'Y*WN<C>O%M/PKW/$(*>4=.0^0QD <WL#XZEH7+/7)18/"ZDO
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M#0\:'C0\:'@H2> ;G>;F<O@:'30Z:'38'W387!EM19&ARA5 ^QGA^8)E/,/
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M4W2P#C;E'H>$&>] ?G==_T%>" H/>.E7P=UHQ,['(K@3'CS/%I;+U2MBF$/
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M%W\6!N+YWG%N,&')BS-ZAO \&]:!P0/Q-7X<JG&,!2T0+!8L!ZP*KA4.QN)
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MD\8AB.<$/;=[X4YK[-)CIR#)+NL:;,YX9.0."<(;GYW"L&P:VC>_QIH)E%Z
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M++R G_D92E$IS!DL$W7C>E.NL6O 'I7YF[55!V#&@WPZ0WCOU$@,W_SL+8
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MF_?$ R6A)J4#DD0WF?Z%2%1Y3A\UTD,A59-5/+HR<4_Z(Y(I&<5O]5G_I"1
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M=J;_%;7^5SQ3)Z#BL2_\01KO-S7V-P&FJ T?_A;49/GMIZ!&UO@(IG$=!?Y
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ML,/'8_'8-&^[9J<VBL8IDQS#$^$;BG2?*&]U\8HL4A@T 1L/=*.<S F5C<H
M]*($T5@V.9*;/]1Y2[@_Q!G2\6J8:[U(JT!5AY_9/A4VW75I13ZU2:I3FZ0Z
M.UI<Y!KY:9T2<$N2&E8'5J3'U_Q=-I)UIR7'$_U]KN73^1E^GW9K,M4PWF?Q
M,ZXA86N0T-"0\"0D-  2NM6%A(]3ES^4E6>L*N2-30IY C5F0\MX962\I=5^
M(N-FOVDVVL"9W6:ST__%[C>[K89IB\>660D1O\;36D',X26X,]G*Z7N!1W]Z
M&/!DX8@'LA\*]C;!MG1T]6H2WUJLUK_3$4C*G,C*=A*YOSXV?SE=(O@-4PM^
MA01?*_=9P>\T6HU&7O ;)/AO(-OG+K7C'[%2/7[AP>AQ3^MWI&_(3N\"H0Y-
MIKZ1<#E(^FPKNN105^:HVT/FXBEF=#9<(O&G2477K$,@+7&SMS)R++05EB/'
M,MS0L%$AV&AJV%@&&\U*V M_4(U=Q$;");F]\#S_GD=QR+XX0Q RRT$AAK\
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M]KN'O4T>>& 7H_<( O+C\GC>)A!@-IZ70X!%.PY.XSM8M&2SA(: +4) 1P/
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M%?V=:ECXS]G>-P,),D!P,Q<@>$92\2#V^NT<QV\2"[03L H65,,/6&%_WRM
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M6;__"XAF8Z@$KH;K  W)PL4+$!&9'T@2HAOG@Z,W<;DW2QO=!?25%ZG?TUU
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MN\_2C42%1'6\1+6;*GZ<11>5YQ"#-\5""X7$K!? J%.$\%1>RS7CS&9A-?-
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MI2)0G6VZ'E?+5@82103MO :1G &?(@,31-162<_C6JF\MVG^9A*FI^FW:?.
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MIVAL%SL:2+M[1;N867\7C-J[?5Y.B9^.XZWS^XL;MV6]8? JA73JTVS Z7#
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MEZ VJUJKT_#T&]Q4+BN:TJ+[D3-7-<X&WK5HG'Q:59+EO('7R9*?S"HX(>$
M)Z:V$O3,E.<XH:I>.047%E(,CDF<TLN  =CI?JB697->3J=J,IS 6^5\J8"W
M_P^?-;S!5=35\N2T6BY@67XP&<R0RNHDO7NX,AAH^V3@U3]5RRE([NZ]$X=$
MN<--F1X_J14Q,'@77SCJV[RL]:S_F\_@%2N<2;BQ7<TR;]2?2_@=G%ZMVL7"
MY-JCNNXT80.V[=#@4)&[RZ7 7LC3*;(,?%.EBV>!4SL7Y>(48Q .,)*3*98M
MGH!X@NF5B]618TG6*1N]<%10^R<+K'ZI!S)V& T(SQ:56-)&3I?TBP8W;3@S
MJ<YA_?-FDU) $0:I@3-RRC/8DP7FV0C0HM#WX<#N-?J=.2[O+(?/X<FSY711
MLNJL%+ SFAYHY['R$M8-NXF9 BA\T32< @=16*>I9NB.P(/3GEGX^9'SNX+9
MU0CJ#-<.CNE<S99@.];5F;.XJ&#5RUJHYI7SHGR),9[S<GU?<!WX4:/J\U*@
M5=HT%;P<SYIVZ 5_.;@MM$UF]7#@+W(<N*QJ/.1?^,KQO(DA[3=57<WX>5G#
M_K[5^PK?>)GSXLW'?[Q_R[SLI1GHQ=MN0E_QDY>:H[PH!]/.RVI^RF'M0BW)
MNV3.DJXESK5=!%&Z"5WU5XLBGM?B=-(=4O>1.6:Z*G0;UK<&S@'(<0KW0<\)
MVW@O%PW\0>?7#MFH!?T0!SFISE6--;1  N4,E*92+FGBLP7ZS<W$@;1K20X
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M!A:5MI>;4U#=C?V_7HP-RT:48R,V>KX%].L:453K<')#-OT95OYUV>S4,(^
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M6F@GU9$C'S'KK]W05=--@[TP[174+3F/G$_=Y6,[YDAZE;EM$^<<S[>=*%R
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M91)@B6$@CX!\Y&#]!6V1DQ$C0:SR1!%NC>D;O\^_3OO'[7927&4KK\2:^XN
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MQ:KN+RPD230!"8&DE+#_"H.5$6Q WELA7128JLZ1?4S,4Z(5T R+B!L.$L6
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M-I?>IBC;ISEH.TM%+"?YC3Z 0E,?CNR.FO3,QD,S'=5Q/A_'E:_F!G=$5B1
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M!#V,^U;QX?QI<-[N@5<^+&9 C[D5>%NE-7\>G+<OAW\&(;'5\-,$%:5D2#.
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M$2]V*Z;1YR!6XY!U5B$N?4(N.UP9_)T\%2ZY3E"L()X2'P0RSB6PIV6VIWU
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M;GU/8OR/T<V'P@R7"S/H56&&O#Z;Q/VLJP%\7,Q&X^GD!('<.0-8=//1^0R
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M#P\!/F$AD3',$4*YU$X= ,'8@&!#5.Z>F*7$F0_2X<6PRR 4MOJA8F,D 2E
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M\1-1V&CC#!+:8L0-,(B1W"'OE(LV2Z+8*6"EA(HI%W_Q0?+<$I8AHZ-&TJO
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M]33>8&#0J:_*\<..O6_5I(S]92KYP5U<WRH1D&,<\B%=?1U-Y;(N59,+E[,
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M&1(RE#E$O#;&>&)=Z+95N<.I9;$V_]:LQGM8C!^:M7AW*4%Z/\6.CJ^NW'P
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MV$<3L&/($0GR37N&C/(!*6$BTPGH$M/;4='[ M5%A.VK)+XX9CTDH!(-N[0
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MWCFZ',S7_"L:VPNPTF$)O\7PMEE.@O$Q_O/;]@:?XZ3.Z_BF!@K)M2[>KEX
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M5<PM:*\UUX.].*C)WIBEEQ/@^T*MQUME?D[MO2%N_YE(,3+& -FDSMT4:$Q
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M[(_1Y?5Z&7O")'R;,ODMA#FFEK\?LFN0,]1]Z&&[E'%2(GIE-OE-5N(?L4!
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MA-%)!MME/TW*)GTYB,6';,7=WKQ<BD_^$<'6I_[H7N#P4M %F6:^$Y#)/P_
M+?\1FU4&8WF!HC^!\"\S_5[._6)YO5@61'2[7ETNEO#CS<[0EM5B,FV:=9RL
MK\<XN%@)JY+W"K0E"!)1,TJT#(&HP'W-M*RL>!2DJ4)*F9+>7-IE;)YWV[4[
M.:')7]YO7#&G%(>#CVU >'F5,BHU\U&#;]^.B,2Q?Y-W=K8>Y_C2BE(18L4)
M$P:3SPAKEW1%=/2,LCI(*0?#T!Y(%J_M\M7R36:T?^"^O([+3"F[1B#\&4.^
MJGF5GF<-:G]!]*!ETUZ]2SG_3I]1>KS(Z01D@<,A,VD\^TR0A,"XME9@2C@;
M.!') TM'Q^ HN9*8LY%ZD)?Y%%-BZ^S^L4#C_8\\$^)D8KM8-<A.T9:9F,LX
MX+XI#I5835>S NZ_F,?).]3XFU,9'T[AGY>Q?PE<8FN^Y0&6VR\#!NDTQ#S4
MX#+.(TX<*#,.L"JKP'SG>V;Q;9YN:]_9Z2QC@N59EW!/F>.<D(> HS:3;W]>
MX/1GQ V=+J-?+9;-[DS0*<[\6"[+_(2M40B8WX#-:X=^S-NAY3ECAT_;+/A)
M$^,DFUZZM[P^_X[?W1+Z);H3SLM\.DJ02JWK&%P=0<2 MR)P8J&MJD1JFDS-
M>?*,#T+AGR)G?NFH9$O@W"TRL&\Z9!Q4,!\PL-K$^;_]^WPQ)LVP88?-T**>
M$T<'??\%1R:-R2=ZO8SM;)BS6_3MND5@)_$Z2D:4"R#;>&+$!!D(5_"Y]#8H
M,1B/_BGV;T]-G\<SDN/VBZY[7OJ*7"-J?-05BT0+C>-A;(VND2&5H2FQ)*@7
MCQ(3WR6-[] [&MTTWAY3_Y1@^6-C!Q.K2+UQ),D*)"5P!]%,)"*MT-18YGW]
M* #XAR3E2]0@]Y62 R/P6'5C)8)FCM#H)!$Z!&)H#4YU12NE0E4I-ICW]5CO
M]6J] M4Z#^!3?YZ7\U0F'75-8I U$:[6Q#%1D9"49,I2P8;#S(1U3M"((ZR\
MPY"0)#I5G&@GK9)*1F?IJ0]-6VIALR5)'+,HUL'>,Q#0%3?"6:] V W4]F.]
MUR,>VD&WY!,^&*.*1]3R;/F%R6(Y66PV[5L;P7IWEZ*DF":_3>=VCMCKD]?+
MQ=NEO6J^L1VY@W,QP4$F*_C_P].[3JGH6,U89:H ,E,[G!,OL"I"$*8%K:3R
MU->#?BP!LE2#+T%,A2.WJ*V(#MX3(Z(T5'"J@]SIQ_I]C1;'J_2;]<,*B,V'
M]Y EJ_>CBG&D\@[3[ [:U23.<P R%A9(/0OD(4OPW[<+_)>SS;29P.6'IJ$V
M"YP7.6W\,N+;7>1Q"79%X%H")/^OB+%&$$+XH"?/__Q;B:;A13N1X>OUTE_N
MC8U%?^2O4_!G9_,)6.#_FKQH!U3C=,Z+R5__^F+R9/O[ISM"#'8]?LBS*W=G
M><SB!Q)R(!66B[,/UE?SG^ %KF?VYD?\]J=K&U D;I5'3LN>MH6$Y8.6:;OM
MS;>2. \_N<4'/"<<X]#7I7RX8_$)XY\N11X&Z?[ B1KD=%3-V4X=35L @Z4S
MEWT)Z+5]&TMU)\D-E#_:V7M[T^ 4B6WBZ$X^EU,</O:'G.X7JOM_V'8>*$WJ
M*XUZAOJ&]>'+^>1W''&/OB>XF^QB)W*6>0RL)]"3BXF=-'8&#]V36;:3I""J
M0)>NIJMU$8T@Y)JUG>?D#"S?7^X\^LK>M%$YE)!-G,TN)FFYN)JL8.5Y%C;\
M[\66=3==-;M"]-*^0S$+.V;?PI+>EI!@*WROE],RT[K$_$87V5'425<S=-]\
M! U//;'1).)MI0PSTC'.!BX?5]&[D*<J(JYY#>XON%*DKFKCHO1*.7:P!JNX
M067P_6O8GT6)Z\#KY6\>;?0S'>=H]R=(=Z",)\5Y>GJQG3;$67\E:PEWANG6
MH/-R-1#Y;#9Q+6FU(]W!#.CSE1U!;Y,[TBJ\RKOI8MW,T-28M3=N,I<1'I<'
M<4V =*?-J@UAYS!WR5G.)[_!;D_>D.JB_&CFOKTD\P6F4.'G+_IU7MD0T7QI
MS9'," TN]BJN+A>A@1.%'\A)7(?,EW.@G/YTV(K)7[*?,"44(C!Z%@:3/]9@
M!H'W"D]?7*UG;W-H'LR4=N[\&YPP7PROYSYG7YFI\"VP.RT/D;QH)VTCJY;W
MRLLNE@KL3IN__?WYFU^>_^_)?\P6#J3+W_+2+M"7PPU?Y.'2\0-L'CX&=C _
MKGV!E#V^7;OK6W/[CDXOGN->@<!5.9C("P?\]?6+R:\]U?T"9_;TH]+^4XU4
M?.3K[M[GW;U/#RF$G4?!]?FTIJM5(<]^ 2.5X8X[H&L<,:&%(L)02ZSG->$6
MY+,14JI*[LMP95V,ON9$<@0$-*XF<'4@%)PT3U.MJU#O>&F] $??92#"7W3[
M]::-_'S3@AP$R1:]_F7/'NB)O/-=GSZ;_+V721LYORW\<[5+)_:[YP^)=Y=/
MD%#QW[DOXF+BUJO)?%'\Q84#[K?%_H'GHUF#_[M-YT68[U ^^)OMC5\'X=>U
M#I5(DO @:D2U5,2(%,!X82;5H>9,#HR7,^$_&N'WT8@=W39YL\9*M$-&PIZI
M,K09MEC"QR7&Q":S*>QOIN2F4"P:[ L/BOV0F7[G<,F[EAT_3SDB4\ESJA6A
M5>V(L#(0S;TF//&*)TDI'\X<-8)Y9[@D*9B(<3-!K,18FZ$F6"1TFG8(LQ,/
MO73 (<@'9R!O,@A?GG:JFL#YKR['5V)XG;DX$VCL W"'#91BB,]SH!*)NO4&
M]_W(0V*V1/7@._@!($*WAC\0'B&@WPE?H=F]GMGE1MA.QQ<'IK*R514KD)(X
MQ(H:070=.&%6>FFDI-(_G)[?@,AXE4IV:5OF@K3]Q=X<D*_#+!.]5:Z.LS"D
M*.\<'&YA,Y"<0" "(2VQ/3",M&8HBLBM!_$6(\?P05T3YP,E4<@ZZCI2J09H
MH??7P)^?,-A82X8NX"6N8TX6 @FT FK;I;Z+3N[48M:5*+YL6_^\I6\M//5#
M@?I"C3O*,J2ZEH(YAP7^"$21$B7@SROB*J9SVRZK!BCFCTQMV>A[)"N//3O>
MH'M"(P_+D?:54E& O8HJE-?7+>4@1VE 0-MOH-$Z\\YE288_L8Q8A[\5)FG#
M0W<AYBGHZX"3PF<W^" ?,W,,Z3O?=KW>#0D-?:IGDY>@AD/QO4H!_^[RFXN!
MHH?S7;1!HEUEO^TTE;A0D>=-CCEY'V?8] TKZA^>HTA-OP [.WS9Z4-&#[>*
M!:NM4]83QD(%5G'0Q-I("3=@%0ME$[#DPZV(K8*;5\N.>7$L38,])']%X?9+
M!$]@>HW[?1*;N$0#[/7U;.IS*GBYGFV(_W"P$6S%^6(2W\76.-@FR9*_ $(Z
M:(!^C/@G5PM@7S \YA-FGAGS0[>(3;[C5G[<JF?9X\TI+*F-;L0/T>=\S/'@
M1@F<_/H!/IZ_C1C1>WH!BY^AM?QD^G3GC1>N%$PTF]9NW,_EXIV=;>JLCW0C
MPE;&C"#4K67[-W$;GTS;G[/@)MJW<:-I+>SOUKD=]G+O=0#QO]8@3?!7<4TQ
M-)/_QI]QNA&N%T6H9N,07\O.45#N!.)76\U2]U_!^\4:LPCYC*ZN5ZU;O;\M
M&S^\?=K6-K04FZGXMEZR;SSD/8@D ]/F^%S1+/^UGF9^VVD*R%R;?<3#]#H(
MW*&S\-' W97]5]Q2,7;752V*J[DX%&[93CZA7IR59&HFNJ$>Q'!C7OU'TJ/W
MHD7LP\O5+Z!?"UW"8]>S%?+LSE-<G,<TQ60O9FG>S[,IT<NRL1FN-"29M*)$
M<RJP;4P20WT-2HTJ;:T/F@X*AN^M^?Y6['>P4[$F!<36J[35/?9\-EN\C^'/
M1;?K/]^\R&AJRVN[W"NZ LJ)O4U+^+91*VZQ:5&)C,BH_>$029[>EOHR+__<
MKT"W;-3$W<3++<H"3?GBDN;(UN2=74[CZ@:?FFQNDVTSNB%BJB-G:O<RU ?B
MMGT6]@(-9@S%H?$,$J=U#S9BJ0BA+LFZXP+ONKRPP&X))7R\OPS;=,9)MAS@
M45BYT2S@I<LN82,Q_@AZ-SLW8L,PT-2B(#CUB?IY]F,668MO8MOWV4Z\*J&6
MB'-??J?UBT#W#TM74/(V]Q"]>_W+2"8A[\$:DZOPT?8+;,R [$W=1;)C%"&\
M0U61KWV[7+Q?@4N()07Q;7D=W,JW(+J70)==QUS65-<+='(FKXY%8"^&!N_X
MNH,]M[43(*.=YH$("2+;1)J(KPV'KW@5AN,+'A0FW?)UGC<E%85D]=O>",Y/
MB(=I<<'5J,(3=Y1>Z$NWZ?O,82G&XEB\A/W VK#--G5U.)DJA^P5IB$;.!AB
M0#*$M333$+L>3ZPSZ"-R6[ ")7[K(DJ.90QK7TPR+ \K7V6+/P,Q+"?9N<DF
MR^B";49*Y9,6Q.,,*)$L):ZN Z$,?'9PU:43CU!5<)R"'S/2QL>93]T5:EV4
MK/42PL:/'1MI!(.-;RF15!DD#<X)?"(PI",ECT:(1T@';8AA0R3(8:_F+SIC
MP,Y^QB+Y!\JZFET(/D915^H%-X'!@>0JHZ<6;V..-.:BJ(]*N@LXD]FL:-79
M34]]>^*PF E''](IW]S5E%N6 YHGHY-?H'YEK7D",52C,@Z)F,II(BM=Z228
M9'S0%W=_9?RPXI![$.GX$E19 ^Y27UACF05X/A&-P/@![-JF)=,,P(/:N!EE
M:DDS$8.RDE25Q_Q2#1ZZ$8J IM/"4<U5-4ADWIM:?NFVYM>R,\_GX:^X+:#M
M'D0<C)N1$<<%:+&$D@:K=4LO9%\2[Q?-:IQ$4 6NM'.!) =&B^#"PX&"\6-9
M,MQP3RLY((*80FU\!$N_M-\*032KX#\*Z<G75 @Y0/=I]^15NR4O<$<>0@!J
MA 10#&K,#A;G/O8>KK.S["0VES'FR-Y?7F41,EM@$Q!X["UPUU^*)CI&09V]
M!#[U\BTJH;>8$EA-_K*E,J_M-! ,:Y;RX+\4B[V=;77<U=WQ,#Z>/"Q"/W]]
M$^URDLO*1X3@<%+@AM%QN.&Q%D9IHFSM"9BICH"@=L0% [Y-3";H 8<C[D&M
M R6:4@7W\(I8K(5*O$X55<(DLROFGP<,^^4137\N-L2(8P5?SMM"]<<7 7)D
M$B"#W1UC7;0=[\.W(T1&.?/5-G84FDDV1F *H\%\TAH<_RH1JD%S,A:4T .
M(*V41,Q5Y$5$&U&&&&H5<5+&4.N8=!BTD3TZV]12?$5\LXR(%?"]Y"_^/%*R
M4$HCN]#^,+^ 59286>TJPC$8/:@ 1W]EL2Y7XN9B- Z,<CM;@6,,#WP[?5=*
M@O=J=N>+%:8<#L2^^P4=M14.M!F]@Y_$D4:E<V,! @^#\5@-,'^+E0?34CT,
MVS1')^O2KIH%HIQ>3#:97+Q\.F__;BX7RY*4S<M?3BYC>)O_'"9)0*K.<!?>
M[@8^<66YURJ4I/7TRJV7L*J=Y6/,U):J *Q3@A_=*N[(;MX4;;O<:)A[]>!<
MYZ7]?Q.IN*W#I0O!7F/-%9[L5I546U>ULT+LM4-3\OVTR6^*7A8>R&ZR_/!:
M5DL+%_NV/R ;I#DPB]]U=1=;]3"[09'OA24/6[L#W;A[BDL[Q;J_G&7[ &(W
M5P>-3H7YVJ0J^428J+"465-B07D1:K1&5"3ODW@(ULD&1ZEX';^!T_&RI:N=
M3/TCQ;SILWI,6JUO@A[=P5?1.*I5(!K=>%$+3;1S8,!$)V(578AJ@/NN0,*%
MY /A"8<$44F)$^#U4U,%:6H1DZUVFW5N._7?X_%1=M_$P6<$$'B/L/:Y3SJ[
MU>^Q/1O^T<WVZSK@0;PV34[:9]R:S@KJ(XJ@$##B^C371;Y=+IKF(][\V B.
M<^T=4XS4M0 G-,9$') @<96NP)ET[@!BFZN R$P20)H@F$2EX!X%?BRETE42
MO%/JTQTQ%XK&.@RZ\"F J^ =7P@Y*IK;1H[/Q1-V4D;FH!K:J>G<U+"/,2!)
M4P7RI(Z@7T0BPDDX?V-KHB-+7*NJTF&@D^Y#*5DT_;/=F>=E8U[COGPJU&HK
ML.@V!?%;VR#J41'/)MZ'6!TM>-?-X<D57ZB0*\<^;K&R+FUH_<.,1M,7)'@+
MZ\E 8XN.U#=EQ%C2O&.6G>XE1\=\3G#$LJF(I[PFPFJ%U3R<5+6SEH+!%^V@
MVX@Y+ETM*&$>H1B4D,1X;PG(2&.X,XI5?C#V%IQ+, 7 39JN.LB /[J#_'FQ
M7"[>8Z2C/<;'JHC0S\94I]E9":-C^VQ_C!3^(!E5A50IHBMJB?"^)K;6EB3C
M*^EHK+P=E)NEE'1BW)/(JH >2R*:UX8 74INM*A8/0X"%?4H"72+3+!(L2.3
MBZ[];0?28V<43$Z";\ ,NE!"?M[L)M>9]CB1&:+H?6X+:";O$"PQ[MP[Z,!X
M\^N+MHD(?Z9TL)5+<]](:>F$GYLN.\W04G=SH.#U#.CX70(Z\NUC/P,ZG@$=
M'WN*S-K!UY,N=?.=1$Q?;0-;MBGY7<,=I]!F6+Y-2 3NG5R7[=K ^): ^<X>
M/AUC> -\3%M'%H@U5H(-+"W8S4R2H%U0VE&AA[G :'D=P9XA5(E(A$3WE45-
M!#.Z"I46RO!3A3?D!1U?<OTC71^'"&4#.;G!.QP;W20M*\H09*:.%*N*#='>
M!T(%4^"""96J057Q?>AFMV#SHT13_MEEI\+/-W_O.#,N'TQ0XD*.EIZZGM$^
MI[K>O/@.;B("E5]WB D;A,9-?JX\L%1P'2;&G;D(/9KIWH_L1(GM)DL8<N*W
MEZRL[B2K*RZ;BZOW.$MNOV_KGVC&VZO)SS,+MO#_9:^N?]K D?WUV5^?O7AV
M4:SBV<[+7Y0HXKY0_AJ"B)'C^%IA"9?2$!$E):;&NFA52R9C[84<!!$E=<(9
MS8DV&MS$VGGB3+3$U5I8YX/U0@_D\58OQPF"B&Q,)?R[K79M!U'8;; ;Q-Y&
M1SG""F]%+4A%$71'(]"SJH *M.3!RRB"&T3 =/"*5RD090*F43DCVIF: $7Y
M2AC*+3TP#^C+I$0K-4[$G3YCM2\H[Y8SN]A.F%U\/&.V5ROSO=0M'-)"[VV+
M]KRM<@ZAG6P@LO_8ALA^<P@B>PBWW1>8;*%1XQ%MT#7ZP\,';9P%DU4:*Y.,
M46PTU[",->BF]?7U[#8]N(P8 <):C?)2W6M_:R=^=__SS=KUL#^;@J/O9> 0
M^*'/P5J9=5C<'X'<;K8WJK>YNGZT_)",YGUD0Y]V\QBP81;KPM97V4^9OXM-
MQ@?8?\[+[IL=]V1U"0^<7&6ZSLH24=2'0[F+N-N%8-^9&+X+8731=_/W-5T=
ME,Y^&>$(76O#F56J9B0X9K 471-PM2VQ*E;)"E!T;&#*>>XU-6#^,8IC72N6
MB)',DJ"BXY'62O"[3FMX;->ZOI!47U1J5.G?>R!?9?Q6H.-W&<1@!DMII[RW
MHC8;@7>F8]^V_>X-$AD=$29TN6MLBZJ!C$1-$]$V&N*HK2L6O8UT@+K-:V>C
M!R/2P-?@>82*F)02B?!O73,:C3*GBN]<P*HON!8C),)]RP1?)/L-1V1OR?9T
M5;-MW]6DN"!;EDL&I&I]\TW)P-CHK.82I9,B2B.80(454DXFPK1357)>N6'Q
M"]5"AA# YX@XJ)C5CEC.):FM5*:B4DDY\#Z^$)WQ"ZW4!35\A'26(S&] '+M
M3)-/H+_W<%O<+\?O2\G1(#Z(.H;0=]<=QCOV!<[2L7$TV;: -5^WCX _>WRC
M##S?3<NYN]4]7TS 5N[JO6N*=?YM&>&>R30$"2DV/CSD/]?S.&FM[V_-QCZ>
MT=DEC]MMPXO]ZWK;;ROTN%VVMP<Y^V0+50JUK_>+9<A67#[P;2#"@0?4SA?Z
M&T@[A#G.'?K=6*$[:/NGHPSN5=(*&^J:>*8"$5%+HIW@) ;!9=3>\C@(T<10
M&5.%FDCMZH*E[&101'JA):NX<7RHC/%,<E3ORT3SU*B*/[; .(L(F#8;&)_<
M53-;- ,\LB/S818#3RSWTFQ;?7M4/_Y((7@41B<)3H82%=B$%JS#!.Z&U\FX
MFEM9#TN:4ZJUK (EU$2X!X.$IHJ><.?!C&0N>7_'YHG7Q01_W5G@CX7/#60X
M)BILPX7%;KM=UO;VGP<= 4]>HA4("VH0';)5MN_M<@D"O-..73]:CY6'V)!Y
M;FT+E-?WLGTG&N[V[/W=(R?;\RUO"YYTAM&6VPC+M&^W@))W'W<LAC+4:2\N
MIS&!'93QF-_EP"#(F&4^__+=;_T<S?:[^P5-QNZ_"JVBT* H*4V(\B$5,=PK
M4HO*!UG[)"L^[/?1U&D12*RL!_D6/-$54\19RKBE@6I_JB *QP*%<;5?/'8(
MY2Z<<U>OMZ!W=H@DLPSP<;U;J9F=Z)*<GK?!_TG8-#ZV<X/:H1RF=1>0]3-P
M9[:&!T+CV0F/XSN1U?O>R)WD[<6!2\\^R0,+#@PW)EI%*DU!6(:J(M@O07A5
M5US3.E1L$"!,X*@H"6:C$Y2!4 Z:&"4KHBC3@5=.RSCL;_O"/LFH*@QN]TFV
M:U5:4IW.#Z69OP4'A!M=<QHD"8DK(FCMB//<$U8K(TQ5B9H-@'TJ:SS5-<Z+
M!,]%).J(-94D'*Z/BOG*U0.E_JD.R-T12;@:&]+?W97PV>=XI$SM^BVL8%(=
MZO.[1ZJV/ 4?<5NN%L?&7-XA2W61+WW38F>,30A(3#X9,.5ES; :5&L"2E.3
MH U7051)63]0/,%[$X0G=1UK(A@+Q"#V0Y",2EU3S[C<J2#]/4^!?)5:WVC7
M@&\_O!=XXZA,]T7[5J6,:*N><XLTD%)^!A,X-M,/DUFTF&:_G%Y/5M%> >6U
MB*!MJ'>+!C<^ZC?E3])@&#4Q$D8CYC:!]%RE$0;4:!.TM3+0AU#=%_8G67T!
MEM<%*-0QT>6GNI2(I9VG4VS[D\>4UUT3IV=?[HMGEFY791^1-V<_[M,PD;VU
MRM"*>(]^G$E@4UMMB4;,H\"XJ/A@:E$5*V8=Q^(0HS"X9HE-V&E<>26"\T[H
MH6#[PGY</:H4_*/GEO9LQZ_?MQ/,)U\Q"1JUCI@H0J!(P0GH2N6%%JD2P\8@
M44>G*TN4<7"/\))8+2HBK?:UK+'3?=#G_D632WR<M>AM<NEV<?M9/;UM5.6V
M?@Y6>MFT>'-OXO6JA4*A!P'GNGZ+T9%RJ&U,.B92.QRJ(AGVJTD%_W0B:"J"
M48-T/?71!.HJXEB=B-"^(D;Y0)0TL=))5HD.>B._5$<%D\^J$5(QZN^^SR8'
M_,<Y,"IZB;FC&LX?YP+6*1&M0+*!YJU8X(RZH>OP*>3PA5P'<R&DN !?>TPD
M<61NU'YIVQ$QET>2;>0-5[>&9/*@)Y!35VTJ*("IB'5BZ$1WJGR$L9-**P\*
M,Q 7<'99$HS82D82*?<N.*J,&H#)2 SG*X]:-55$!.ST%L$37@DCJ(K.TL.Q
MD^W-[O?ZM\7RGV@ 8?IY]J+LU)^+G^,ON($Q[%#GP0=\C%A)$ST2['NPZ4%%
M_=N_+^9Q5%1Z,)"W7Z([.GVF(L,Y%S6IA*VPN4 0*YPC-&$53V0\AD'$3=6>
M>2$]H;8" 98<T%RTD:AH--AU+FH^2/5\,7W&GXW*.3BDSW)FNC=Q4+N-C2IP
M#EC4)I*J!D]0Z*C@A"4%!><Y#;%6@0X&O0OE4UT[1FB-JM"'"KL*@"JLB*;6
M F1*?2*UIBXDIQ>58F.BC"-J;;NG/GS4B![ "7YK^96[=P;^L_@IWTLK8.M<
M<<KTP;&JK=O6[$ [;-/;_%T$QPV[B6%9[:2"/O8*7_^?]7P/7+T?K+,9,W[H
M&9NI=MN(ZR&ZU=[LVK+0UG2;Q0*'UBU\9]UCDXTQ,,XX&/J,8G\\JT%C&H<S
MIA084-X'L.CW96-M*J_JQ(ATWH'&9 @S'A2QUM%*<\Q<#V3CBYEMFE>I)>U7
MRS\P=-W;7WU3Q L[FR' R:_67^Y>^_#N/E9=5-6HW,,-$;\!30%__<?'J+E@
M?F!W2ESZZ7; ;'1V&*T3N(5*$2,%:%P!?SGC:^(J5VMMK?%F$*I]-*KZM=V?
M',+MOVS:;QOV):*Z]-FXIA5O176W^IUL/QFJ#"+#+J9IFJ*NGLY*.6Z/S5LD
M7B?2$*Q@>G45P[0$:5N:S) .^5$[F=3XX7J:"?W!?F9/<" Z\*@Z"P]3GMK6
MX.HAVA)EGCBA.3'&2C#@?0QR4.(E):5*2 T>@O)$2*!1;5DB<(<2HM(VV4%O
M7D=+S^>A$-.K]:I9V5QZ^3>[0B%V@^/!=ZD#01%(-G;P:238&X+3*@CZ?:=
M=8QNN<8 *2]!>=W;&3M;>^(*GV4_!V:#=Q':E/NA_-6T'1 [P*E[^?K54S0$
M7OG5HJT7HA=M+UXK='L+H_5EKJ)MULM^4'8$X^BJ_>F$.$UYS.QDG6,G%K&;
M_+_(&W^YP%0<"F7\_&H1XBS/";-8SKN>K8ZM'!98UK-OO>PNRZXQKKT"\32;
MW71ZHJSQH(4T-IW@!6A@RL"C"E4-/&HD<5Q4X&?SJ+@4JAKB5_N:1X\Z06BX
M4:0 ]S@<::JX=2%6''3% RV-??7P\((%"G8&'U45S3'GK.!B#$81? 4&1N02
M; 7N"4\5)\(Q2C1("6(KDUQME&%I4%_Y:,0T!@-#/!.C(C%4\T5,S9I%&5[5
MRK)L9QR;I(@COV9[5-D)LQ)GG"PV*A:1\,8U=?&,3?U=8E-7V\=^QJ8^8U-_
MAJ[./(]QWDSAP$NU7U>D^AJT#\)3@$'\)TZG_NL"%MP-0I@\:2(6QX.UJG,9
M&&,_?0&!>??@YB_1K4['N4\/1ACW=O6?!^)V9>;&V,R@H&SM J7$2UH18:@C
M3C-.T#K2Z/C6U0#;6J7*."RCJRH9B @XIH.JBL#U,L4JP!/M^*)W&:%X9(TH
MAZN ]VK@]ON?7[9^:F<UGG*0T\MY;YIUP>O]Y;5EK!L#[I^]4XKS[O.8$1?A
MA>-.#"B7'HR.6P0%GA"<&(=%>!P8Q3(+C !>041\"'B1 ;=P[@3C@O :)ROZ
M&AR-*B0B)?=<B)K3:G=\V4%6V>S?OK/PZV;3;N&16QLWQLTA.S8^7)$G\<Y7
MLYM-5L9ULWMV CU_PGYY;/$HD !9W347'>82R.O9S6XV!BNE\^S&3F$>HE[0
MKK-I&3N3ZP&;HU>&12["OXIQ5>I?,P#WU.;'M_7\*[#S2AQUHW[%"1E[C(K_
M-XR<Y4KT$ZK_4TK;/R^WH=GW@BP=K>[+WYWRZ]&%81#*72KM2241 -1I1:PS
M8'^$6-,D*JZ&)?F^#MXZJ4L5M  G&L,PBE1*5S'4U"L^P'(_61A&W%J]3VLQ
MILZD8U7[L\5[(#T0J4^>/\T?,(J)B,D__OG\]9W:F!:E5WMG^/QV!@C(&$FX
MA:QN"PM_.2#'GQ>'!2Y^\O/306?XD2D&NTL984"2Q:3 WM;$>LUQ:C/:"19)
MVUG/:3*U''""YE9&H7",0>6!';"(UEM%N&.*VE0[R>R.;5$:Y;L^^9VA!A^I
M/OLN\ >*"3"0GEG2%AWM48:4[&8?K+QO"O/S93 MEZ:2/!+&:O#*3(62U-:$
MUE(+:8-7<=!4(I.E :B.*.D4>'))$LVU)$JSQ(P1*M+JF\Q@[D5+*C[*#.8!
M<LQ$E[.' 8LY1B?%;)"NYB# ?#(5>$@^$1!"FE#I*\LK6J<A%M5]J#!+L797
M>DJ\0FO]L=J81CJEL^G<_]UD<9E91'9RQN"+-.NKG.V8YWD9/F=Y8X&Z_3S2
MA\&!"<]K$FL.VLO@"'@!TJ>J))52!9.J0;4]3@*WL;:$^03G7E%.M*66\*2H
MJBA-*=U+^F L<U@C']9+E#0G$3.,CDZN3' S,BKQNP6V_,Y*-_GH0BW4VV1<
MQ G .'1/.D]L\HPXQ5U=>U&982>199XQ)B/AK 8BC#BJAVF<]*3!($W)@-]P
M+W56JCC0+7\YOU[OBICK]3'#A]TB8C0;58_9#T@,8?IN&B*8*3?3. MC) AG
MK0);-Q$P7A."<,'A&A.(\IHFA=56:E"A%8P HSJ 7%$UN(M)26(XW,U4K+0T
M,CDV  9^($'</=PVIC#;#^U0GN6T^1=)6%H_S2U@S6JR'"U*B71@UP(]&%DC
M4#1X3I)YV%^@"@T<#X[3@!ZTEU(X"BJ&6Q J2!E<!>*E5TI6+M$PZ-3Y# +B
M-L^H>E:/J>/PAU)C,;!%O[KRBF\[ _PW>S-A??OXT>3O;],E</7SOJ/SG.Z]
M1[IW,_HA)W[QCZVT[^&&C7$F?JD)JN;6$Z-KA:$C26RHL:(R,AM2JA,;I+(D
M%2*X2$FD6"1=13#'$*I?<493+95(B8XP\3OFI-:M4=,GAWBV$\%/6]R?8SF!
M\<;]E3<U%U$193U"51I/M L)PP9< &E60@^BG8]&?N.(^]=<CFE$T[&X_WW#
M_"V,]+VB_?OT_6M?L(^1Q!(*.\8#'XG0CB<X:Y2L15UI$H(41. <>1>H(<Y5
ML6;)6J8'XR0^A=R_B>#LQI"IJM'%3VXAQK''9Y5P@?,J$>LJ3* "(>I: HTY
MDW0=9*V8?@@A?O;X+!WE")/1QV<-=W#8X"/#*6-V43$P]T#?FNB8XXE930<"
M*"#P'<))JWSNAC&B@V9$FDHXBX5+U)WCL]]K?%8[#;($F[TQ'$<C)Q;S/K&2
MLJI4,M0,",HKF2A5GG@;%#;H@B")NL+@#06]:&L9!TA/)XC/*CTJ&?.5Q&<Y
M,[Y&.S[EB3*J"L1ZAEZE [W"P,ZI!QF@6ODH)=7$X[P:X;B#>VJ,^0>=1)6D
MLH..[7-\]NN(SPI>RQ1 <3B-55I8BJ"-3"1*RYBKC:-T0 ]>6,,K$P@%T@&Q
MX#PV8 =22R.LJ"JMV0!L]23Q63&F)'$;GSUJDY[CM*.*T_;OSF1Y]Q+CV50I
M_]Q7,:.KMA>!["(\X-VB[^N*@8"P?$O[?J_<>89E<N?X[BWUO"\S>L\\[B'\
M;+81=W8?CW73X+]S:<]SJRWX@6,GFV7Z,B(J=_N@=I0O,.L62L#VHS9C@W&B
MQ74;V\\(0Q=;$[MF-UC>OA4-R;..MQ[Y\8[:/P^_$P9:YHOWHP^V4.&34!SA
MV4R-&'Z<:%9'8H)55DC/%1O$%I.KJ+;2$!$48L<D2QQ58+V W2*X]<(;\4T&
M6_:DT2@C+J>MN#_ "9LHS^F6-L[X4E7;:+ M4&KP"(5D+A<PHQE7B<I:4ZL'
M\=YGCR^-JS;GJXDOA:AJ(PWB-UL!!QDX<4PKDI12PK'*@ \XL/8CMURK1#QV
M? A:483W8J2JN*>RXLRZ>^$GG>-+WU!\285$ZTKCR(T$0D%3$ J)@U,HM RF
MKIW3@T+B:%G4U"DBJ8(;:[C;Z @2B#G$=:8UT_=3XI\IOE2/"I/W*XDO,4$3
MYZPF(6/PQIH2:[@ :>'A>'T$83% ?U(J,46%(X'R''"DQ%#/B!4LJ&29M?I<
M__>5QI>B5%HR')!9(^ZHU0$,!H[S!KSTP/:5\(/Z/^9DJ"JCB6%8<0X*AA@5
M*%&5J9QG)JGA4-:3Q)?,F*"9?SBE[8^1K0,6^-&8UB"R=,+%[P#2[!L +>;/
M#L[3@\TP6:<J1<D(-19L,<,#P5FQ)$K.=1"N8G%@AE'EHI*.DN22P-%]AE@.
M)KN4-D41L;9Z$(3_([Z+\W5$]/H7\#"DT7].5Y<O\NB<N/P3GO[S+/<11F"
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MS=EU<USE665QF*FP1" 8K6$.5&>L?3#1:LH&]>A8=,Y]D@3T)P>'"%C;2J[
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M>ZY85'8XS'8<V8.A$V)J>E'147GRWV<ZX-<V*#O)KN;D=9?/^RX3 CG>TF8
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M(,\#"1[./,K4;1#[)&WI<M0W%\/)&'KR+?CG7:\(QCW\X^P&E[8QSMOPK T
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M\XPCF,JS]EEJ3Q_&<&EM7,X5ZS'&?MSA8F$]K@G' G.I%1&"7?:\&:3&HSP
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MH1PY0X614<;(_&.9QP7.]M,P+F'DR_']+< R&Z1#/7#363&#CT=VCE5O_/3
M W3WU$.<66F%1U2HM,OI(C+>!:05]IHQ+B6AZYC5UK??[J2$Y@+^-LGWIA30
MX;'IWFU#\^<"D$]P;@M [A] *LQ9;:)%M: "<0[VMI%8(<*B54J00,-2W.$^
MAOJ. 9(7@"PQ[,V:ZB]/S>!S2OFHOIC^]/"S2>>MS<"5I.E"D5LH<O=%MX'I
M+P7Q&$FL8Z(@<$AI,.FCE%+'@!FA[K%BZAUJO!V\"C$D#A>XZ$7;AG'[MQF(
MO)AAR#UT7PN3 U_?EO>XY7)U>TK 6UR) MD%LI\69 ?B1,#<(F)K@W@$3T1Q
M[Y .*H1(B2=J";*WM6^P4\C><F3G,"'[T?8A'D2>OD)!+#(>/4G^]-<W$5H5
MK;H[ME]]F&IU/;+?30W*IO7J?_R;HH0^XM*Y!=^WN7C*F<R"'04["G;L^*3C
MG!-[+V#AVKN_^[H["Q#X#J$C;+]*\=D/WY!O1B&[%(GC<G(V>.Z;]KQO+IZE
M7Y^?&Y\8A!=<@Z9[\=2([KZ8$B7/VI!O16'@8?E\2YU)=)WSE?3MCA!,Z,-I
MK-<CZ5EO^-^@W9$!IT*%"RM^2M_>+?/3N0-T;CZ'SK=!)L(X/3/]K^:B30R=
MB\MC-O=YX:^>^'7F]XG*TB53_ERDYIU=]-=X3R0NV/WH_ZVB=/?N7V/ZG0W(
M:N9@<NV]?WH)7;"CYD\GK1FTJ VC)EY&?Z[R3V/&,:^%0Y@$@N!O@8PC-4K4
MP31((]9,UEGFGUX*[:135(W)%,!-:+]+/7W@;/2)KCHY\QUE=9L)JL/9^7!D
M1A=3+NHP</"H\:D95Y]3"&#4M'#/,(>XF@BF1>(H'X[2HFEG!-=^.N*+\0*3
MASZ?">I?#GYE1HMDUM5/S0">,)S .O+MS\\6ENCAD$DS<BO/<X^K]?FD"5Z;
M3WH#[: ]21F^_.]^'-6%NG6;KN;!]J]02M_,0_DBPW1ADRYLTGLELH?>OT*-
M6]BDB\@4D2ELTD]*;\^*KA^,WEYC)V(62$DE^ZHNE/*L -1= .H ^EKZ][3[
M5];J0?2O9+\]MM9[EXA>S\/(C)O!YUR)M7)F-+J(P]%7,_+E&/_A'K#[]W)<
M]4[G[T,=;=J4PUX*Q(/&2-.(D8P\*"^UL?72\5(A,*ZY4,CPVB$NZAHI0R(R
MPM:<,V6B"=>W])8V\M[/Q/)7D,J7BT*Y7 CX067I:WI2)S_KP(Z7%CZK F@%
MT&X&-$.),M(*)&L3$"?*(<MKA9PGS%-34VSU=4#CQEJ. T-6.(LX3T47(J-(
M66%J48M@#=X#0,,GJ@#:1B)"Q9:^O[C=1 V;,T0*.^RQ"6#1.E?88:W3P5")
MHJ(8<>8#4I*P=+"=!BJ"MFRIA,)&S.@Y=^(5C;.21_'AFH>?$*Z+XBE05J;T
M\*',4#"1A.:(6*,15SH"E#F*;,VHXXYX);=C0#\*E+$3A>L"924>O1,;^FV"
MB=".J_#M/ S:4/6;LV:<L_:+OCD:N2OZ9E'?<%P+JD%M1*Q=TAT$&:D\\D0%
M'*(T/"Q5\]V$Z3R3Q45MLR$E(T[(MBF=#GVQ%_PZN"D]4/R*T7A!&$/410*N
M/^=(.Z:0-XQZ:;QURF[#7MXB?K$3S&3!KQ)HWDVIA5%*V1A?Y$!S^.>DR6'F
MHE^.1N2.5;]L@RWDT">]R/'!3>F3E^/5=B*I)<5.$D0]F'L<;$-D/8\H1*:$
M%-1(O>3G;B2N.M.GO_7-8/QBX%_/5.J&K$7*#H_$OP14GX:M^-*<-V-X\K^"
MKT:S! 4W;$LJPA&)7=$SBWJ&^AK7GM0(2^L0)]PC;7F-N"&D5MP2(M9*1<@%
M8Y:4S((@SG;L7B8QW%@& E6EF&-!L#*E1X!@"G,;HM"(499JTV*++#8.44$
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MO7KQM]?O.P<E#W'GM8!8A)$#%R 5$$Y7_*FM3L.Y&0_=!4C0Y]'P*]P:P3D
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MX4$A*VJPGUT=HA*,UQ[?56K>#>&I_YPT,*F?AO!ED:+-2-&G%:L8;',8YZP
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MBBO% +KJ"_.'S5S_\SY,P"P3%Y97:HD9C0RX ET*9^=HI"R1_=O_9(P&4GL
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M?DJ]R.39(@\'."]PJ'2+Z=JW;%G=K"$1HT]:B=S['G:X A^RIP3_,R.L7[[
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MRCMI:\X2 ,3FD&DLX79IOWY-CQ'+. G#T5(5K=-TT?8C8'KVV1/Y1H59@,+
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M]#Q%%8L5=C=A2WR"NO'$1CNXV:)X%U%W_MG^'B0?4,-5VE"_OA9EBK*&1I2
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MP"L>'U4KSUT9E-$K[9^<KB,27T^XP7ZJJ$Y#7)7RE&5GT32)R8;8"-KW9?2
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M3P#KDI9R&=V+,PYW9<"GKXNWH,H61YPC].%V8"/P,!<R!O/XC9[:M=TY?LR
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M,6F<,1N4UK,X\D4()/Y!IF'\UXJ54/F'#H>*\6CMDB/GOZ*='GX.1M=%J[=
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M^S9^!<N$A58O8_JL@%BW(;_<1(%WXV_]5+HL35253$2)&/*0^GS $Y2*(5$
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M#NVT\]@[APH0]*DT&%@B[)'><J]\Z7-2LK)*LM+]EN$V"1J%5X<R.P@4; ,
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M]6RB&G)#50618S$J.B)3[JE]+O'Z%N!#55$-%R[K( 4G1)];3J;&K#M&96=
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MVFY85INT^>Z2S 2FJ30=?)<IN5T@T:JH_W_-FT?%J^E<UB_H:C"UJNR39^Z
M:.;.2.<&;R>$_[GB6R)^A1]R_OJM'JBLY?%2?_<F0O@'& #<"7P$I,$A$+%!
M.*P(L4YPWJ0E@+Z)<$Z$=UD8=5C!<9(46'\'14A;F;(S5\F,NF^Z5F1FP.Q0
M@+ -&*)MK[0&I5'45NM?_E?.;QR^S%^Z7RJP*1J=B;:*.ZRK\2^#!LE>QQ?M
M:D[F%':&P![L=$[ S?#9X079?_=XS,P8+NQ._Q9AN%O+)4J! BGQ"V?%0I_
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MW1&V2/,)]_A05G(!Z6-F4-:#)];\ V$K&*+-"G=5DE$@N/8@=M+:VO=1L^Z
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MF_-U@*#><6O,5A9)KDW643JU_4!A-HH1:<VAWF_X/I,'\"76:""^AH7='GL
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M1_D%U<.UO.9*[2]=99^L$)0RG%>4FL3-3H=.W-Z__<M/7S__Y:]3R%)7,0J
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MV"88,6LMD>Q:D5Y?%-B'=E46<A+V08@E6MN85K6)PXKE&]I*^:5@"?^D[/\
M!Q4":NLC\+YPY4!3U_/0;%RW%3CGU-<1M20$,2IZ*#"$2[ENG%>G-.(AM3_
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MUF)EKWGY+I297<OD*0G"U7X>Y+!ZL$JM8T@O*8=05>PIB5_]E!!P^S ,NZ;
MDWT*!7/#X\-%(Z&@MM4T'N/Y$'<-R$/G0(&XHE9PLQJTU"IH,Q %BIV2+"*
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MDS*(7W%W:V!1[%29?%Y50C4;S;NP[G?$+C[O4598;LAX%#O7-!=;):\:AJ!
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MH?/B390D ;M)]<6,% -0,/IH46[EW^^3=$7"\P;8Z3^-@LQM(S1X5'P94:2
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M(?),'M5E-=1Y (3HF/?#CV\L7+P=]]#^'<6^Z#Q,<FVKI[-&,8M[F8?%U^S
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MX)!UZC46=8=8!NELV;67B3)O[YVP'HX!0>N+23_&'2I)O(8^6$])3L1+K,)
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MZG0KC3-]AKLK^I;$ZUR4%M3GJ$I!G9!<:[3M.X4STL^];$,?7/@?J-?S3B5
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M_I?DSRPN6(;&\9..+;I7$<+FTNQ*V!-1GIZOMS#V-$1B9U':+K[W',ZXYZD
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MNN.> HNBKH+D5]?5$%Y6%W"YTO4H+FX7]Q7DO#JD^AJ+Y84V3T+/B=VTPPM
M"^I?/5)'N:['V=63;,:%AF9KE<<12H*+O1C5AS7%O3#4(A=T'M7[HJ+S__E#
MA\QT[;_5 *2_EU@U:/X6)@')PL_?^\GV#Z(D_Q]R[S.)D^V>+^.03$N5P!VA
MSQZE'L3)[8 *LG^[);D71@<ZACE\LKV>WS48@X!M)"#![YRU'BD1>8[HEM:Q
M,?0]-8]SU^.L?""9^BY?9.-1:&%F/=Q=NQC5NCIGV7;3#@/Q(<7B?_LBQ ?A
M0\;8 -MF)#ZTNO'TMFC51CI#JUJ,ML-C&\K9<F>^7VR+B)5V(_1Y\7GT,?US
M1)CP 5FJ29J7=8.4I%?@.=KTS@CT2"4?LDFBX&&[2Q-NCI4W,+09@>^T/9'>
MKS(,<=?D)]GN"JKDVITS%;2[ACQ%&H<Y%02Y(@Y_TG.39H [H2A9Y1\>6Y+X
MXRUY)U&RXR5V,L,)L1_O#,6?R2;T(\/>M( <GHF8RLF%#U?H URB:\HD^J5K
MA^!02*VUB88GQUI>O_3B;/:"?2."Q" Y3Z+B4 ^)VXIV4ZH)V$.L;U=";SSG
MDV"TOM8%*VZ31!]-C]NTE]QX2L^HE13^QND;DS6L#!.?#CS46MUI$D4H3G+
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M8)/35VC-6Q?*AY9(FOP*MWFK OEPHZ?IKY":M]:&#ZD110,J&)>KUKG86>D
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MU59&5Z_AQZK"C[^$?@J\?P$G2 _T,&1"RP7&[XJ<.?"&'(>>P"F*45E+1AX
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M)U*\E%X@[TL<-Y?3:+<:1T=]BW(/P,OR^;$8?$+B\#1O,7GCZQ-@CJ<@.@/
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MYM4$'Y:\\5=1F"4O47GVF'M.:V[?=A<Z4Z0B!=Y=B&7 :KXA>1/+[8#RQ!.
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M=KL(*^Y5E..8C\^FIET4T^VO]3L,W$)A"X"*"A_K+DYH)%!1](,L,&ISH7X
MZ7V4))"N(=C'*,R1K95 : >RM(S AX#[+@HD]X,,O4>*?GF/30J%P5?8\C4
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MZVO,GE"/"Z&QY/ONY7OT<HBRQ F]E^\0K#,D7508]#YR0K(&CJ.77)"3.&T
M#'^JP84_?'M"=COL=+M_G71:9>$_XL3:?Y\>,0Q/:/_-S$U4=-TQIO<81U[F
M0FX2>J7;48(]O_2VLH]O<:=6'Z&<6&Q#;9SP%CV1P+W_C@(O4[BUJ&S-)DE
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MR%??VQUVJOJZB[[\R.X!>!D2!3'S2Z[.C9]PU68'#S-IRNV+1?D3B-YBYW2
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M)<)NKY][-$\DA5;([?4OP6X&J-_7]AD$<+BW3R $L1,@ ZAWA")?DJ*(S'=
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MJUN9-6D&_C61;C&I%SCV;M\0=B@7 ;[M6D)C^!(^ P<]9]"D[L)3EB*$J2>
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MW-V,7%#70#V$O76'4&1\+7V.L'K&7AM%<\!F$;B-XCS?"O*."K9!E* =CZ[
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MSC7MI&4.&Y9X/)J$LY6Y#N:5PFN"^+YY^./+MA&;G(;#6J0YS,HFQ_+KPWV
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MG05O[$L4IB]6"9Z7WIO_94Z\>X]LJL5UE2T!0F95&:YK;,IME,4V50&ZRI[
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MA,\" ]AYE[]X5F2*U9I.P8;<L)#M07.5=Z7";@(VA4GT[U2;-HAA2^?53YW
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M$UZ^^&R__@#*@F)=WC$<OI\_S]MT.D'^O.7;'S.5Y";P+E]U/EKV)]W%3IC
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M7"2>,"&2Z'8U=EX6[FPUJE\7#D)"+Z>(&,Q&^\PVEZHYUG5*H#_NS%A];L:
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M-C'<!7:.Y*2 &,IM>%@&(4HPS(%?(30-/3^U2CO294%DC1@PEENP*+"(WI6
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MLM@@_\YX2@T1\'S&%U7]YHDZ[J4TWJ.7DWMC_0102P,$%     @ :C%A6+)
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M211HDLH2'$6Y)%3.2"FM+AG82N$V@BH$$"4Y'&D.$$MI#*<T43E$;:N\W(J
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MNQ[9/.04=,1\1 EH"E /J9C0F7$QI7^ W_&=_=0_<%\ _A]02P,$%     @
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M& Z:0&9$P#YQ1DR)/V;CATRS:A+<0,Z-@ 0.$BHRY#:##9J"Q4Y!G!<\)5
MMCF 80F)QO-FV//AQ7PX>LM\8"3E$A"'X)TAK 9D '%XK.>><YF"8Z66PSQ<
MQJ),8$Y \1R<:L  KL68@/(&^8.\$F)&D J;9FEIT#3A.'$-)4H! L *!=!U
MRQFG3TQ-1E*AAF9"&<WZW%@-=0FA>-/K#5K6YI!O)LJL:+L'_XO!?_P&P/^P
M@)1?WH]:C>9%VU3XKK)'])XJ33E<'I@/#D>WA&KF$ L(Y)%@B"S"8.N1X";#
M$2B60_#  (+7L-U8*%/".%Q?*^&A6V@5LP1N&W( 2$T80-_#L3N*,RK[C%R!
MQ^Z5 B2:1S1HGAPPKT7S)/%7_I)CG2(]97!^@FY]CDD>V:C+S@NE"PNEL!#N
M<YE?((&Y5[B=,Q7,!4OM,JZ6:73Z8['HK-X\/FH=79Q=G+7.CR\NGD&H _KA
M^V<4)M1]Q)7+3+:#OH9)4TQ+L_L0S%XB1J8K^7Q(E1HF +\^X,9%"Y!BTLV#
MU=\LSLS'*LT$=8RH$J(9JFM5',.''&(.Z&*4X FU3M'(\(13S7$#W*=M+GI*
MG*DTF$HY'V)<WN5BBS(,%+(0RW!0 >^4QZ6@&!)A6TZ)64H&(WR"-Y^7PE\1
M0T%X83">)3M$J3WC7L*XZ,TQ;N<@L$*\W</'SOP#S@YX@K2B1DF*<9(:H"36
M,<@UJI,)[H&)G$9<<#O&%&[=LN@%'$4<^CV!%T3GZB 7CD?5AHI2%\ ^XU+.
M.%8Z<0JXBJC/)&22 D@(3UB![$81J/8\T< +\ (BXIYJKTRU^ U0C0VH*%T$
M0!RR-(5ZA0\ 069-W3'+)G<(:?YR?2WBJ 4#(1P97_%$JK2;5=@EZ-*I-,-R
M+MW>#B#1I%!TWJ(R!>C3QLGW['A==B1O@!T5[E;QB^VSJL)P3]:SY GQ!_,Y
M%<>E1IC.)4_KILV5L?  /\6!R4P,,_U9@E5A[H--8U)@',2&)?%*]Q@@YYI_
MV!=T[66OV0>O5T;---?$J.(8RA(7;IU)JE X)H(_,E%U I?D:R^WTHZTW'<Q
MOLR\DQ^ZB^$^,IGRMC;S\1ARYIDS<_<(_2<DF2N%U4P]"M655=I,$SMW ^;,
M<VXM8U\*J9&"W!$%$@X:NED.@& 0P0Q&2/B-1=[$+[ _2PX;<"Z@E+'K&W[8
MMROV[8I+[$!C&<.!&-C+PJY8S!G N$K*IFV#(:./F&7Y,L+E6:X <A_Z3+K1
M3R)'5>'[3N*:J$ 3&&C8-"AL)E)5-\$8( .4-S6?ZQE(]$R9 \S 1FXW54!>
MV[C?YW'[AH+G!*1KJ09G7 .$,A=# ./NX\2*##6?ZG Y4&+ ,-^1M%]]*JJK
ML,/R0J@Q@Z?#3/E 0Q>H!M3X.OE@?0-H7_-0T ;H;7LE6X_7;'@EO[QOGC;:
M2P=8K&NHK*$EGLMK5P?H4!<\3P?:HW@ X(+B$:8?L:0]!5X=H%<- (P)6A@6
M&M]EF5+2'9+S<[O#?:" GJR./1_OA,+)^$H(I))%G!^?_(QF.[3)!H'FEN?'
M]9/6-I&+^O'Y@@S\H9>UK@X?.E"L?7-#,$D0@7-^#-W/ &^LV=@ 4RPH%2IP
M ++6GB[\!H#<P6-LPMRO\.Y#\B^J(48U:Z35:!TOG$=<8_SOUPY/VOD*V][8
M9E_PTJ_'X3/V/3VLZU6LGQ2@"WY:,J\LNJ;7-LBSSVINLL>A.22]^^O;._+I
MJO=;MT=N[O]]VUUGHK^H@_E+$6N_V=?<[)MT$*NGCO?.8<^7_6;WS@&_OI)Q
MEI*/TY+UWO=?O^0AX#?6:=]K ?O<GL+: G:N!>*Z)+Z7RY7$(K+,Y6)C:?(%
MLEF6N?@=LB9<KFV^,)F\Z)MES[;Q!+-/,/#9U[+OK V232-.0?O,!Y2 IH#T
MD(HA'1L74CJ'^ V_RY\ZA^Z[@?\'4$L#!!0    ( &HQ85C...@_$04  -L=
M   /    8F1S>"UE>#,R7S$N:'1M[5EM;]LV$/[>7W%KL2(%+%FRG3?)"^ Z
M+AILBXM8 ;J/M$197"E*HZC8WJ_?D9)L)[&;+DV1%G60V)%X/#Y\^!S)(_N)
M2OG9"^@GE$3X#7W%%*=GHX]6MV.[_7;UB ;MVJ(_S:(E%&K)Z6\O4R)G3'A
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MW;O6'=99:\]Y]MEG[]_>9Y]GG^<9;J9N?@+NRTO+20/0[@  :*@_P,TTX"4
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M+;CT/*I[I,9.PW@/&7@7&/=O3?MMV?\]PS[]/[+L;\/^L0L!N(N.AG(>.A%
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M@A,RTR%8_[+D?]/^,%OYSBI$GAG-"K?3,KMJ5EP>8T#Z<!$S6NCKQOZT GW
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M2I'QQ?29*"_%%9A<B]HU\<C= /"?:J$NZSKT3?(A0_/ @R$W@-.6S.O.L1O
M[_&CR]ED$2,W@-:^<53/Q/0A;^"B>3%*@\KYA"*;2ZJ_A<N<\.?\I5B8O)$G
MS=,K]EG#:Y\_IQ'X8YJ)FM1M.Z7K]Q:WMCP>=A4_WT^]/N,]9_%?=IG?*X=#
MSX\KK_J!>^7'?U!.OS*MN=(LRA,T/-E[7MS)1;+DJ\]UZ_7M*+4C3?X6_E+[
M#^'54VFQ"Y5M))' 5WKCQWNK99L4+AO=XMO#VQM%'_OITU&FIQ7>  9A55NW
MPV1T_C1=Y#T/##S$[]"3^)X/=@.XI<+D)5<CAL&M(Q/@WU8#(:#N6[^@N%&[
M"<Y$U0W@Q8\F5J4S:=>F"ZS!<[7E3$ZK9+(K#E&;:Q^./]12 ZUS< 3M3-2T
M+<!LKC^67VLT_6S"-Q /^A:E4AK!L8AY[=AB-!*=(<W5\%&0W_T#^5B]8EYW
M^:;;,UV=LI5W;TZ.EN!6'@774OH*U]4"!S"VK_&V.RF+[D1MY+U<ZYB.UX_W
M<P+MK\3!#O?R\'L9V$FEG=ZP002BBR+*K=CX-:I&V8M%L#/T]%II95^;R3Y?
M+B&=*[2B](60RIB1KB+ $%[>/8-D(\Z,!P,I.JYK;'Z)1[H*U4]AD:L(%09.
M[D+A<8W5AOD$WFW/R; K3W"F]9K"*+_T?JX5HU$4ZB9Q ;7R!?<?U>CZY96:
M"4Y7O+TTKOS ^L,GM8/%"0NS_=':C*,>GQ<)BYK+:&FOJI,:?/#5?E=P4?$1
MS9/GU*U5$0E,4]YA\_*'W9G>GJ]*A&58DP)?^J7"W$' 0*7@*Y*2%CK8=2H;
M!L=P3$U+8?#3.YNGB3E3P.Z/'\^#Y7. OH+I45D8BQ=X>CO97C> 3W!/>--=
M7?T9<!%%Z/1ENWLAE.:L37FOHS_)[5T;W< ]][40+:7T#>7UVM>4[X%NC"WB
M<Z+]GCGM7^V4-/<Q'!$_%-GY-WQ[<C"AH(7,#-9&&47I)0*\ML5.."JH8YL2
M4(O.OQ0&'LPJ7K6)N0%\=M?90GYUA)XRHV@P*OR^V74A]VSJ?JAL.WG+YVB@
MO&^BBXHN!<.^X7_1DVRHV+DN1<7.%A2U-E'+2KP0/"2TA%H"#3&TK2<QPLE:
M5QP^#J@0$N>105&WP03FT2N^HK_H0J+_S@# *:$J)'J1.&K)E65,&4P4.Q>@
M=(/]H9OE/Z1--.4]V#\SO=V</R*\76O>0J+^.]:G0L5G(,3DU07H@WG<]<.B
M/\TL4KO$UNRZ\ML5JR,DF1R&,X?7QZK1,7\W5P7D;.>YD<$+;&:VP O66X:'
M&S;GB89GH-I;&=?FU2IS,:19MM(A:\/22ALR)3E3J0Y:-3-02.W@[^O0,U#B
M'U0-PX@KF7ZOD3/4HU_XDDH=A9U/%_*23ZPG[NT)/*SX^F%V^3^8Y]VNUS^L
MX<Q#=9,!3UNRKCO&Q==:;U'S9M7WW[%Q%TK;5]+Y ^);4$=1BW9D\I"O!VR,
MVIH6'&_W0L-M?53>X?P-6]:4 :)T_(_%C>+C;=JK@*>>'\%1^<9/ZC;SH60C
M$TNM%AH,#C8XEDJC>5+K>U[0KD;E2&'#BU=1*;?"]0]^(&JDKV<EBK+;:,*W
M>\!G)[VQ$E4KTWH#"'7A;\390^9P3;$!3[X[K&G+NVAV;X2R*XSW=&&B8D))
M$Z6PC=+E^FV */S^8GBY/IG#Z9_YK7D4)H,L(_G!2_-$ EXQ;0N4;2Y$9HFO
M\)Z0PO9IK<68;;"S8,6K5DH=!*@LR!&X:%.1VDQ+4^W4;ZJ>NEM#,O6!]LSM
MR> /&NBE*F6QE4QI7$F'2\3WJ2N%<7N'G9TYQ+1M)*8Q;G>_5XHSK9*C=NK>
M%TNC);,2#<MNLT=+&)HQ.\CLU'M;>2.,(@1=4=K]G4JS,E+D XGVF44>\*ZK
M4*4;@"%? M/%AOB\PQI([?X<LSGVHQD+OJ]/;[O$!^I,2@^.W<]C.:]WJI#.
MUW#-(GTI-L8Z=M5G!Q>?F1HD3CPOIWMOO>+.XQUL=0, 3LP?CX.3?= (+S[?
M %RT/B(DQ*=1P>OX]&+\&GW+X)SP(OJVGY\I;6?Y4O8PU&+Q84[.YBE_A.Z+
M[\1O'[RQAM[N-N+[6W;GB7W[M%&Y_8ML/^C*$R(RN]_F8)4-!*%BYX^]#9:!
MYS;6";.5CX(/I%X_M/]S+\M D;!;\@:04&1JF9AS=39XJZ!X*9_27WM4PN5[
MK811<&O_>-/:Q/PA[\K9U_RUKPK&8MDUCNF;X,,E<>2>E71PWMJUR._]C3JZ
M;7JQKKP(NNBS"_8TNB<:/Y%<W+Y%]MC>=C7DU.@3IF=[)1FJDMZ"F2LY4W1H
M8=\ BC"9I+]./10G(OBQ"W*'\/J\7IP[$9V?=8B^AI?<\\3F.RSY^0D7PPEG
M1_]AT)*HFJR93/3,-'J/K!,87;N7T.'S=EIB3M8K;T72J'2/3[WZ\ >(1FJ?
MLZ^_.*Q7:Q)MG"=#HN-XW1Y")!0D)*1(E-'^*TTN$=2V+P9#QF36A):*-+%Z
M0=44V>IPZ\@-V/>%'7R$.E^;!)FJ7> M@F$8D7),#$E16U*NG:PXK8IE-@HZ
MQ?:J<W/<!X(_\8X(@"UNL9#(N8^.S[<_K-\ * VQ-G MLCF60@:?#WCG7VBI
M:*M_;8C(-$FC?B9UQQ;"*W6D HF$L-&_2 ^SO#T R?Q3)S5 .H0%H&J2"))_
MZZD$,3^LEW'S9@%\T(!J\6D=NMKD[)J*#^1-VKK)",](+\C1V$RY6+U"\&7<
M $89@5D>2*^XSPS<'O934=TSXJ">LJ%\[Z\>_4(0MJ2I-U:6Z>'_KHYQ9?N(
M\+G07GP7^Q1;8PBTAN9X.([P3S.V'+30!'KE=GR?4IQ:%#%;/(=[Y['#&%A,
M*+IH3,6NQQU:Y]!\Y'D;QDYE;&<R7P88(3'-SIA>ZEOHJW"OSLUX1J)?&7QJ
MR%)G]04 W@%V]/F8MB<99!6^JF;%QIGE2.=9V5&_N&NF%77,YP0!K=A?)N(J
M_%FJJ:H.OR"GY0'NRUJ_O(Y/7.%5M&AYMQYKY>Y@:_^0<4ZQ4>[Y<8=K"C?&
MF8(*>G&D30?]/GMO=K!AR1,1V-<!'Z%),[SW>U4)@YIZ9<)(+<,]AEI%A"YC
M:LKP,^C]G[M=- 59>^3T+8GV7N?O)P<[WLS7.FZSK2NA?Q(!YJP5#6XI$2FJ
M^4=M*E(<]JK%GC684RF5U*-'Q_4R31T:R!F<[^-U&YSQG^(GT-UY=>%G@*U/
M+FB07$>Q2)KM>GUODG'$Q<[SD4]9/ 8$7!?&<S'Q4A\9>2!BK_PBPI[D^M#Q
MFF/V.N9>(-@A9UY8_]7!=#\1Y)7$=^R1BL*C.N\"%>J '2/CUTX]D#K",\TP
M%KEUR2CKKM(S)1T[FY<0'0K%=C"#OQ+!]>22[C=JK4%EJ2)++4)DLL<[P2<4
M6*/'I)[U*#_%?;_4]7KG"QRH7OEL-_?T93K?B*9%O4J*S: 8K<UDY->O'.9(
MT)+PHASYPZX//FQ#@:"5/&Q<IW*/[W+Z]](AK'B_SR7E0<QHD=WAG2/"F%(4
MQCYL'2(62\*A;CL['$E=.9WM;X''.6.76@[[ IK>A(2P"HY*A9RI=E?\N6K#
MP&N@HHW>H87B1&63\+V..KRM-$SR2SEJC=65I^:AA'A7(G'J$.'9UQ4/<Z*_
MO.L31;*-5B"Q7X\,:XX,,/>$8$W'7FV] 'P#/,/.$BK- ZEY?QW-(.?X%/M1
MRM261$4*@*KXE>]0GV1FY<Y99CR/5)?TYD%[43G6O@^$V-4+10316YF%FZGX
MB"HZQ@&)^5AP[X->DA\S1.E;!+T7S?$(>37H%=Y+AK?9O+^A$YL"&#)>7=V;
M$2B.)SO7W%M6F!/ID^QXXY:]':9S_<AF>=_Y@;?GV_&OXC1;987-@\3=Q*QU
M@-4ZWKW4 !,]G$5Q'6=UN .V91S_F\JGI W=*]2R7(E%7@X*Y#Z&9*1@*W!"
MA,4^ZR;ICUR=.S_?];:(^RLPM2=0FY-S3")/!(N<?(@-*HV+[[JC@4/*2JZX
MK9F/=J1-_++H!<ISK^$?!JB2;@"@]F+7\JRJ,W\WQD,S"(5=FW_XT[LUNVQ?
M]^VV3QL9:G@>LE!]?)#2MJ'K)?.YJ&@M9)-[&H1@P^(J(-B6>6&3L8_]^0AF
MK5ZMT%Z5_ (SXN,,-DP^FIY>1[5=*^,73S]X]:W2Q6933Z[<=:W2Z> AC(+,
M(LAM[7G2W8N)]ZE;J!KK_0U :%TF2D7G <?*F#41IYDZ->8]1XAAE0%X< :U
M#_W(/ZK85A()KHR;!-M58>V:)&@5I()./<J,),&U;,UVXDNHRJ^V^+ 8'(B\
M[8DCMB-T9K;+TX>F0]CB3_P[R#/3?<E(HE5>$$3RQN#5LK%LDIO7P&R:+S1S
M_=._Z"I=/25O'JPN2B51"TF<&LAB5M>,K/F)& AR3S.@LLG:.J7Q>GY2N'E*
M2+Q>N@42*8G&,L5,MU\H:*>0YZ%_UR-KM,M6&_/&Y?V<,/XV4W8?/'M32TAQ
M4Q\DJ_I*W(_PI<'DMRWEK40]=\=W74'$M8E[B9LB^(65"46%]^:K:\^IAF@[
ML^'"G>NC3SN$G)>CAE/:6:PP.1R!LK]#\;_02%?G!.H%*'NF_0Y:JZ^\)S,G
M(\[\@\\@9RDCX6P@^0,ZAY?<?DC+;T=%L<90L]'64*$IIMF#3G'6<KU?G_G4
M&T<T9Z&_=CHG:#,F:ED7(ZUE),?QI1YE93Y+AS #_F/[=I0. >P'_^P%.]:3
MBMG02A."BC?F^>8]MLP:X(5Y&%)SDH5]]4NDWQ$=-J+)VSOH]A_1.8$4WSM<
M6PUV^BC+>3SZO1P^C4^V*0>HBID_I\>&.3;2>&1/PM[R[Y/_"/NYY+AAD)F?
M#P  A-!T)N(DO]6&H;R+KOP?]2@6/LNFVJ[$/GO?=K[80 AW-G@^DJJQMYS.
M.,O+U">Q%=:4I<]DE?T]LE;PE_]'-VN,I0\+T&RVX8).$7P89T2Q?T)ERSN1
M2J8S)1.#/IQ'1-VB'0:/O4])^$LJ*J+A04;_VM71&8(8I<.D[@5^@G7S#9Q]
M51A=W!M(WS"[P]W<_DPBW%&?P^2V(K7[79'F^UG+)G#<<Y ?A1%^Y)TN+FT]
M8)9L__:=HH5O1C)"YD$F:P$M=YHT%AMV*Q?['&Z)__562\72'$QGGD $G^KD
MX(>8=B;]2H3WVXOQ,;OO%Q!<AF!$3.WL1ISF-C?M$V#6^]E[R8X<TPCI!(^I
M0).AMZ?%Z8P31B;+/]!=WWD@&LAF4N7W&KS5PJVU*DND']UQ.Y2_ 1!;I+;6
MOE,LR+@K"2)*L*V QM[GM.^:<SY5O_1A$UI3KJTW-D^(![N\:XK16H0<D=@Z
M.>.&N#!X.:M29)DA1@1I/X^YH$.,S1J>1R>ZJ;[DJ N7L;Z@:M,*N &T>?D,
MV_4SX,D5I]CRK.IY(1.V$(T4>LB,%K?>I'-VDZN"0"JJ@F1M]U\\I2@_#@C_
M?C83/C+\@E9GWU8<X;(TT!^:6F3]JU5#:7OV!;3>3.]:(VN?339*96^OVM]=
MSG+."#W/8+&Z.*!VT\IK%/%FX6T=.<:)XTB=R:^%[5IJ[O?5P>4(*Q9N;U7(
MHK#_OT($#;[6R+%75)ZWI>AJP^Q!#LC7Q13'.Q)ZGO\Y27\XU(L(1JM#"\Q=
M)[MX_25NDNC% '=:TJ%ZXP!XG1X;>6(SVOC8*M5V2+&GR+12.#"/-F8Y YL:
MNE?4X[2J93%@8EDH^D9[KF,059>-21)>;@^?.-\ ),C%?Y6_H7PO)7'IDWLR
M*W/RWO#P!F!S _#12)KP"4"BLO"0]"WS,O "9_H&,&^>C$PE0V)P@'_EBY<O
MHLH^_V+DD>6Y?ZI1$^IV.3<$>/HCI\/\H"^B"XPO_ PO#?JD0$\R7*Y"D3J#
M8B:0KA9XQZH)0?M83L>9M'I.J<E:U2W8;!A:D9N7\*9.Y!7),3' 1DSI> 3<
M"$[V"EWS??15TT>2*D?2L.^@9RT5YADZIN3@SJO&HJ7U5N)BQ%^VNUZ3UL6N
MOY2&)($V/02J J*V(D: NU %BZOAFL$-@.R/DF/PY+-/[73$-=S[<G+H_@T@
M#XH<UJM.":R+VJ&39TZO@=K^?4:,RLCW#Q/W%$V9)W[=\9GG76Q(;:>L]^*/
M$ATMN4M&Y#=;IQ4@7!')"SU-BA4/=35*/Q5YC<BT(S^FM/I._Y)5/I" "@NH
MHOCM2.QXQ"/O1[8/6K:>3\'KRE3!IY21/OO]NH7B.()@_*G2ZU4VI_H?]CZA
M+,X2J,3%0OE?>L[C^33(^-D9Y%"0*JGD0@NFA;[4>R=.V9!N1<\6[" _$E7Q
M)7%H*3<=LLG%/F4X8U5EXVR[HN\5UB>Z->P"?JB]*9_']H53.(.6<&@R?OCL
M.#>&CRZ#C1912&YZ_T- <N)^+I_"I40E?DV&RI2HOE\'J)TX,V!G!<]31H2R
M8]@'?TVFT!RRL-I8-\FAN!H*YM7"$?<VUSTF'1#XPA=M# ,+E3Q_E"+%J%AZ
MF#&Q7DQ_ _@<?'O><EO,C0/W(FR 1T2IUQ?Y)]R$EE"]]'KH]0,:D^M/M^>0
MZN#6EX7@(6F'R\VXTO"&=%$GR('XF:PK] ('5=OYJ-P <!^6H@(9]P;P*U\T
MQ ]!/\G\>X+ WQ/,_UM^QE2WZ'\4H'H#:)5"32 )OMR$FCR^?.4J?A^\U-KK
M!^4]/--BRHE")N3[$E[$+(,;5/2MJR:'O^P69<9(=-_U4N?25\2PC^CNB;S[
M'-C.9MF1.S7P9GMXKXF6L0RX ^R"''OMVW@'P9X02]#+L!Z9+9%Z_V$6\>75
M.!]+91<%@]<*Z;+A7OCF#> /_?XQ6R.U-,)@F+9.RA-XQ2#4A<1@0A6C>>(+
MC\=O .OTXLACF=)P[U=>.Z3+X+T(:]3X^_^,)[Z%S9L"NT*F2,5 !@70O;\!
M^E/ 8X&_!*S<"OA;@<Q;W+3^<@QM1R!*A"II]Z.??I-S]5$HZ8;_.*7@-C7<
M@F;<M4,D$/J>@B/DP!KTWFQ';S>2C[K3YP-JY>&=(0OI%#ATO9OK&=HB&[L0
M:=#VQ%I9ZGG9,Y&,@YQ-5E$EB<I]$4+/#%+X6+2Y[NL%TU/0K'6-N?G*.&V.
M1>Z/^79&>$V8AOBL=94A=W#HRS>U9@\&'=X%VG#*/AH_V@=_R0!PEKJ\V 9]
M;5%P^7[1HYNQ7LNV!CY3?"^',MD[=0#Z-XF*G[&<&;%RVJYA$JV!&\!>XEG4
M]:=3X&V H$C@ 5D-"N+<B^C+P F3J0LZR/G\-;'A _"0P=HMLO^0FVJ[0!VH
MR;KPUR\PCJSJY$]2E+%NHKY%Z*!]\[1"2ZT<Q>$G=H*+1B=YNI;T-7?J$5L=
M7CL[%;&GE$D'4H_:Z 4PU-D6.?1Y%W(XKEJ'..?9W,F/8(\_.XY'L4MZT8_4
M"R]^15*UQ1K:#9L)64L#:C_O+HU!?OV,G58M"[,\Z<7(IY"CZ.8[+#L+U(*^
MOA[0/9=*F6W4_*#GI5[Y@662]U*]$CZV%D:RH$[[*6B!\0F"Q":S<# ]P_\Q
MFHF4!HUO<?*51LZLU1QCD\*7!(&^$7J3 (Q]2-P_!N:#PIKRK8<*M4XC]1X)
MHEU2UHO1NJRXL<)-^-*21#^*-9N'")P"K\_Y&,@>3"NNMDX;%('MK8&'\]!3
M*3>;H34YBDO=2^CMHZ[77A/0D]6T&X#H#6!_6-W4+58F8D!G0(YF7>O.>"2W
MC/.[GU_J8Z&.U ]% <5J9Q)LR7B[#W*,^^0KGXO!5[BMR=2F.LP8LKZ%K! #
MW8JTS^*T1^W\&V*N2EX)(@*I)TCS>C*I5;($<^5X-O#^[7544/Z+KK[.$EN3
M^;_G4\C_-'B@>4K5U^7$ZSI$IM(R@(*[][TA^U!*#TZ?!QN_ME52.J;=U)V)
MCBXT":^>-#*@5E##(/)8D_W*LUA7KS!J3G1&GY:BT<QH Z36-I:]&Y(_0$H:
MUM0*)AIACNP"F1Q<%3A/7E_< "B/OMI,ZW;'*GA_69%>)GUKTUW$J\_3[J:4
M[^&C+I_!,Y62Z[U3]&'.:AOE6!V[9>S(0@G2I UI^RUIIUX:=N&5W")H&H]"
MXE[+8K*C-%:.XQE<^/H!S/WZD_.U:^KXLOB.EW["KF!FOP?XBA'T"XFQ=K4A
MOL Z"5YGNLTIX\M Q%$=STRYM$T;^.]N!50*T:Q#X2"(JH<,M<+!-B/;@^_2
MZ\7_DNP";M4H0J4#>?  M*!;'+[A9E&I=-?]F0AWT?*[EX362_42/Y-Y+A]*
MEU1RS;RJ44S6OKR81.4C7(-;J2PHJ;<ZB*\S\HO!'3.>-U"$ZK41:H!46&\
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M0%Z?YZN(3D8'59ZK35++KK$-3Q^=RV+9%+DL#RVM\7ARNQ#'J-[>YBZXU]/
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M:J4D:3%F8))7"W]ID'3.PUUYQ+^ (/+!Z!.Q@_W7^TVAAJ]'V'7EHWW2?SW
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MT\VV+=(&@58Z8TWG7):987L"_F%,/^[_.X(G\MQY&](.*;&V+;[#<_=$ 4Z
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MW;-WB]W >"$[2BLM@8,_*QS_+T3Y;R0-;:OR<"@2XE)V>\N( CR51C!#GJ(
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ML Z"D7YL;<=U:(]I,Y:?[S%7LI@2[R3\0KNA5ZB->Q"R:F#==@8S0P%\VU
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MRYV_CH^IKP@U1TH<M)4J"IW[LN2UB*VD$JB35&[U/%&Z,W-/O<M#/C[;"@E
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MZ_=5H>G 2&]@NT@<(K(KP6]=[K0:;LO/>_IAF4"[]FH]_7:=>\LPNO. &/S
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MW;&[)4J]S?T"X]DQ@ 2X3<LC@3QE>+=KU<-'7]*2E3\:_9,P8$6WZ5DZO1^
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M68VV:4P*66=$Q2$#_9MI[TQ4C$-7074<I=[.B0P(NT$W.#.0:7*$\Y(EY!1
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M)$CJ=X1O=3[VO=["]F>_\H6LJU8C =2;GS.JP?_\,?7:'K:;/NQ+=7RH!7G
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MZY>7IY\\(]ZSMH%6)3I2[>]UVF\4$U%OK,=+#]#O]_BR[L[&CG$(W%Y5Y3!
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M<;TX[V(<WF'&1.EJ/W <-'IIUT4"+T9O]Z$[20^XD*M)FN-(I==^U#'<QH:
M!<#"@)GK;"1 +V)_YPRYPVI4N1]QK?*:_@=N1?&V%O6^ S/\PQX)N6&9-L8=
M^^]O*2+>*5KQNUJ4"=;WG/PN,@@9?S1+D)]4E[M$5C!]\B)PJ7L!EC;\C02B
M^6T\!3WU_9R$04SR!$[S$M_RBZ^=7DT=V]MVRF??DQ'5\7E<:+5X_Q?__+?Z
M**SX-\(:'':X/JFLZ'['D!0Q9XHY-!+R.#?Q[P%)>ZW,D-XZBCLO[E.!&L+
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M_))XZ% 7B!VCD?O9LN^LUTRZ@9%E0V-^*8S^)]W&$]T7BHXG0>UB:#MIB]7
M#!>]37U#AWA]G'WFDVR2@5IPRIE++^1WW]IY\;.YDJBHLA,1_,PX.G'AO&3*
MP?O$S>$55T'8F[]'6, :DG@3YFXKT3;RSQ6+O-J:Y6J4K<'.Z4N.D(UR/9LY
M]QAVL=/8,EH)62E0$+M.-F\AEG9<6GD$PM_WV6$9'5.S"6>[Y0S&3(/4:< (
M98^*@.M@W,$._4IUNT[4;&\A?O4["XT4Y:N;2^@IZ0/+KC!X;,6-5UHV/ S(
M_W!:<O+T[%4<[9$"EMHU@F0<"90JV#IQ#OT,\'P"=7G/B-EN"AC;:R $WHN2
M1F8_43 T%8ZD7.>FA*6)6RV9AIOZU9,Y/?XAYO]:964(L+!.8ZP=LVL=X7\F
M^H$ =XUV*WJL882P4[!\E66"6:."LA=:ZTEXMF,8./7-S),[T>%#K 1O_46W
M"GZUX.B-JFP%2Q:>*B:'Y_B3G-WW6F$O^JCO/<OU2(>F]\<LOFDPXQ_KZE'Y
M7<M'9'!,F F[*C;MQXQBTH1^E=*B<Q3?*36A(<:+=9>I^UYU&I=RYW&9@7NE
MS*["H?#T%P/TVV.\K!.X]-Y>#VM]S-!-1,U/->(?#SUBW>_8NVK9&!5N9]50
MTE0GS,V.]]IA1_'2)/>,6/>QZ#T3W@B"5*F+#!P[^.0W5X'VNOM7F>M!%W9W
MO+ QQ7%^P8--!29FQR/[B30>AYWI7)W84=$CW=S(RT#3'*_.I3"5'SW%#T,7
M&:D/M*2'Q0D\1C$5#I\HB5KX0_AO\EDHN3*(W]PN^YCF>.;'J=?*&U_1'D%/
MB'/\;O 0CTN84^0K?'5N[(R93G6VF!#O8VDH&7 >\N!L0,5[H1L!DF2EAKGU
MC@>.\HGMC(=O2?S4O"O=IL[E;]3'</1!GPINVR9\!#Q$5=A?](EE*B6PQ43$
MQ<WS*YA@U(Y+KH0I=B>G28EW U(NY96+,FEON+9S.-Z^O2@CA*8)3WK1K8JR
M<JK9<=+/\,<,MKG7/7\4+-P.6C&*8;K_.*OV8P3EVRLZ-B[.C*:0;B<,)UF/
MG!!*4/LH=M22EWU#[&!N?-27!1YH(M-\1[HJ#Y_RM=F*N)S:-!)889T<DZ*N
M4B!1Y!F7AX1O/WOM[6!4C!U4S6'E-</OB;,^[,K9Z$^XH9?Z3Z3YOVN9;W"J
M1CJ_/::]]=WZECG11=\%#!?(+ON]L/1JCNN[7-I>XCK+/8%SEHEQ3ELON7<V
M=,WW\YXZ1* E( '<\5_G%7EZ7PXV#?I=A]AVAQ!DV9*4X),W2&""[PQR7/0<
MEAY28D1IH,,_C?W!BGS3OHS0>OOH*'.\9+TA]4<(F-@333>),V)L&-9RC004
M4WP.P%M?O8.G?#FW87H[\9ZZS0.A!#>YXH9M'?D3W)GC'W(:4U8>?A2MV,?4
M*W,KO]P*":L3U'/?F=U 16!(6C6:V<NIG#9WSO*W@E<ASV\L(GL]B/0%0E=I
MA,4*+D35PIOXFLVNXQJ3)JL;E ;DR\QN8UE-#@XD2?ZZ+*.);Z\8KO^KK'HG
M5#.1A]99EK:8\*,D.- XRU?8D/APJ6O.?$ZBS08O*37TM)QS0U5*/,?X4L<1
MI\C^>*YG2BOAY<0%/EOH<.^[A?2K/M3\,7%"$410Z$"0GV\HF%XR'R']*>!1
MPFT4.-2&T\NL9!L)-)RP!-OY&>$OIK5^4#F*RO*E;24_>4Q7NEIH*"Y3B04?
MTJL[_FRJF72I>W'_Z[K 0O(WE0*IT^C^(B30,3*J'Y(UP1QW&V[M]$J"^42B
MZK:%HO/(@@8R,)7AXBO^ @4VV^BNZDWCU1Q\KH4+10RW12(-Y^B%):E</5==
MC9]%ADO1ZBI\#RLJ[(W&A"[.0>M#.=>\CYNIXQM<8'G9$_SINVM(P-FFZ!\V
MD.(.H C8.H9F8":,QM?1*?VXZ)<UUW'O=618YR8\(\*3=A()L+DVK6V^18/A
M(8%(GKDN53;L>WP4QBM@1!$0?/"Z-IJ-=>C+0UO6^^+8$ILQ9;EN;^-!W,0/
M<WA8L(\+6P>H5)DX6?'K[Q.X=[//ORPBT\8%N:%G\*/=;V%S$%-G[;*DDD<P
M+OADGQ7$P[3(ES_+QHH?G%:]W:)<+6TIX6:(27A*"39:?JOA Z6<K<A1#J^V
MM9M PTL8HJUZ%.$5<8_V[C 1+FNMQH0$;'E!W .X-)G#S^3.\Q6L\#(#RER%
MG$8<(D!C.:?30\_6-CGJCE&1C8M>^-Z3;E&E*H51-.A%SJU:YY<BEP[FY762
M$2HXN^Y;75V=*@XN27,A(?'"R'</V L6,IX,<A!].^='HS$"QV]HNF)&1)S?
M1+%ZUD51!;!3Q?@7#).%[ISO:8B7O*9]&_E3ZB?T]5?_85K\?F/\^B/AOIYG
M$%P@M+Q=<)"4,E==M^I*!*(Q]-A0F4<F]*&P^I:#T/(:F<A<Q_>Y%/P9NE:[
M9@W," Y2A[QSHK))]BY:C_>^E-/JW@72GU6^*6 J.3KUR-$5"KCGU?XJMZ@;
M2:7E^K5L?H@>)3JQ]$Z*P=GB%5"OM>PWEI]!*%AQG<IOR3CQZ80QZD'7O *L
M$#5XH[6NH\4/BN=V:FW1>P43J>IX1JXDCXP"G7)WKH*?"VJ=@;0C2!1L<G:F
ME!OG>A;)$:<OT>#;Z-''A(&'3PUK]*\''1L/@@1O^PFU)!++3O^-BOGQQV"X
MYU[Z)64#PL90V7$1&P4EWDZ(3@KPD$UA*3O\0X@7*TII#O[("C.OA&)P/RTC
MYL=,C)9DO5=66"B3.RO0E<Y[6Q!07/>6([URO%F&;'#ZNN(Y!>73]^\7 FZS
MT</J\E_"-C,$/+\]1B&J_'?(VA8<";!O%Z!C(]C384$^]@C2OKP3SF9N_GPE
M^5'R]T^OT4_+@AH&\NR)=B&FH6VK^A]FZU&<SVD P9%(1P$:59:4<\F"7(FU
ME$M&=[6DB5SQVVEE^:*"S#>8JCS -J:YF_^ICJU9=0UX1]MV0P[1>VAYKV21
MA6@W68MXSA$<Q]R[70G:,7S(X"O5*_ "__$4':U5$_H+#1N/BD.?ALW":Q]W
MD[/SY'A.@<0.7@3KB#3"NP#=[J\'VD"Z8,X3H;;%5F$TZN,SS5;CP])7:V"U
M\07<V#%OBAX1Q<&IXX4N'^TP<\Q5NUTYS<=U'(F37DSO)F@T?W$;*TTDWYEE
M##I!6E,)IWP9(,%ZQ TVTN[OTE=JZ]^1,4E@CIN]?6=U6#%^H,&?GN>@V7T5
MS0EVY8K)-S9#Z'6"$](+3%GYW$Z1P+J^\O-7&G [A!EAN[DJUN^.G3F!]&17
M,9?+DRAL7 E?K7L"6Y%,1-VT\48@C3->&O/&2_IPK9)FH@<&I9L-GH+%GYJC
M14.FMVLFV0-5BP"U=O0:0)#2K"[P42 9HPQN43: II(5!I3RV%=W8)05S?92
M[K-3YG__#2A]>&\RS M]I0F_)P5]'&<-(]0#,LD&PTW'18G7O1H8(M)2<,6V
MXA?)B2O;OC-ZX5FDU=]!J!LK9-.=2;TQ1:UA! T[B[ZL+1,5!D/DCCB:X5&N
M9O#TX5BVW'B= %[HUPB7'[0I6S>:=\4I!U3#3F%68<^D6!OHA'8D2>,/C7G5
M>F\V'\G3::=$EZK8MPU_YX_ZJ6^)3>\[&5D,[1<2IE4%J-KW4-A<T_D@H/%%
MAN)#!BI***24?8'WM&>EOK^_<P8="4P5R_)ST18\%:%5993<Z "@A=V ZG-B
MRE^#/W$^@S^0J%"4V&L2WO?-,;L.&3$>*_V>S40<)K_L,)9:XQ"!ZK\DU8F1
M\O?8%\]YWV,0-M>#>T?'>VN#I(0LS+7F>Z28/EV6XO_IS0Y4T3*,AQ+#X+E:
M% K G[L;\YHZ_?9#:';LU?EPC-7<-H53OHOO[F7/=2W_3;56<&2XFY71X8N=
MD:^*G:BPID)J4!Z']=WLRTG#6U.Y+2TXQ_+>>&&DL1Z&/(V'[-;3H=VE%:/
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M!V"Q;L:5#9U:JHB-2NOQ[A12J6R27N%EJK5RO&5%#?=%6G1'>Q0O&G4,;YG
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M.<VG68_7+E@]:V3:5*;8#8Y)[*PQ;R2H+#*EZ*:*+XBT.+-BU;'8&17"0 1
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M.'P!G]W1MTY+T9*D^-?TP^'BDKXV#=O?;1C(]B@?_:G3;%9JDSJ=S#$HR1G
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M^CH*<]&6)257K]+0/A.&O[>0>#2_RK[\VG>T4&!;;V*]483<H*Y,LI)/E7X
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M7XW;CEF7$=V[+%Q\ZICBY[LU/S&KHQ]YL_+<75X$0($0EQY5 YQ)5I+?I/>
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MS]O0!FH[[]:K-*&FD>'M:N^#F=?D&N(X;00FX<NRZ0XLIL"166EC?!]H5LD
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M(L[VF9G09T[*AAI/W"=4&-T;9]FDOFTV2YD<-9\C!9DS;N\#&7F:2IO><+)
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M3U_%/DC26]OVK,DO27OXF,Y9/4=3E;.*+/SXEH+W9/6<*U. 7%)SX1KG/%1
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M^A=C(;KMB6(?B?[8UV<X^GK7M;\RR^\ZO0X%4/?#]2"'[H2XMKI14'_3.<O
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MYAK\T$WC8T,W$Y.6@$)%: ?^TE 1 ]%E9%ES:_#%XS.5%WLE4OZJH,N8'H\
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MUCP/L@RLO2=:U'<3WD(PY2<+4P]/+9IPNZ3C^3[0('?,@3R-6D&L6E5F>UE
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M8))>J^I;NNCL:$G!HU[JP]\F!^7'6[01--E)38.9F&G87]";$17F%!W&&-9
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MF]UBV*& PSN/-83A7Z3H-[_X]C)<JM3*7"%1P( Z"NCYX]S5(PP%R*Q<8:.
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MY>9^GO-;D1L)^:9CF79E2:M"LD1X*5*^7 ;9(7.N4$C':BZEN3QO@N6&Q7=
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M,RXC?JO(G>!"^XWJ,95\DU:SR*##T+>QJZD\$63N4FH"J"3>Z_!\4@O\]^X
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M.$!2T.DLI_Y7]^,%_O?O1/]K^?, TOX=ZJJ,7R6^GJ;/_+ZHX55N>B/?3^(
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M %@7K"L9PE+8YKW-V@-<M$X?.^7RADE5I I='+["7]JZJ7T@>78/SA_-XI4
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M _LPJGKM!$.R3)Z[\C"[Z$.W>R^S!SU6JUZ&E]6$P=D_O?=?4[J]/O2 I#'
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MT<:5LVKS=._=59R XHK;"YY.(.OJK#7!NS?/Z2)\,+.^;M;7T6_J&X8=W\&
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M>+NMD.*N^VIU@]C77;5%GN/)+"NKIM$^EUGJQ2S390702M(!?59B0 2)S/'
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M3 E4?O2@WP."&I8(X9OHE(_[ SUY9C-C,%7$G/>SZ!E_5]1=&1\+H>!QO2%
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MOG&QO_F47U;CEX;AZZU,K69@S/)NI/O&E#NB%+[/]B')5 ?D:'U#VK=9?O7
M)[!<BDSMGQKZIQBX>+@X/WL\UQ9:OE&C&!!13'O;65EPVTTDKDL+J:.#"N5:
MJ^.2G*\W("/<I.R@G]C#A_]OBR-R;TF96^OF(E-L3<TC_?O]6'_:W;'0("2-
M]=JHWOK/3FZ\+M?#,-!1Q,/(5S>@_9??:Y,NTM("MG\@O2<7KPS!YSQ8P!H.
M7T+*XMIFB")A><KB&W$F3NQU)AN*=E'3,\V]9>$8$F4BV B>/([Q7F(![=4I
MT0(-3.S3IQE_?S\'0Q&-5FB]?H5#SKNCK<MD1YMH@& Y"B_Z'UEUZAT99X"Q
MUB,B\%%1TRNBX?I-\%$3; <'#?H6,0B=!?8KG$ESG_=SF6#YGD.E5Q=QR@7\
MQOV'?0I! =P;"T QI>/$8R8^#KD'.&$!P2:>K;\N1#^'E'&[&M HAJ!GP#SO
M IDYA"-['*EH+9.=6GZ-BY5W9) *[>.9\_=?W BM]M69?I"YX9WP%Z&?W*<'
M'KM%AW,E^\C:,UE?Q;!&!!!7^HU?;\[4PQZA&,?.]N-V^6'6^D2^6?&ARN,E
M_B_I)[=^= ";V E)<E49VK.?::IN ;;E[7F-P_QDQLVQ  TLX"#9[87RN3)F
MN_#9"E?K6KH!#*&,3H+ QV!KC\QPYMHVCOZPM=+_Z<Y4P<X[V)MURZL@C-0-
M%H!<6OQ=52+<"3KA7<0"$/@8S50/*?$PI#(JC ^&:(3I;EAB ;$>!&A?8<PG
MG$Y9U&4+-HTLR]0FWWN1!!#9K#96Q )8#HB15P[H^R76AZ<"/KY1*9T9)YQS
ML(8,Y),IQ4.4OZ<V>A(+^,.!!7QQ@+,<S7<ZS;\^T'Q>PL"":J^L)I ]\.4Y
M^%U,(F?Y$N] +601MB9B;WCL@6P6P+127%-+X0CXN'B^BP%2A-GOEU$HZM@S
MQ03/Q)*TO6P[R_/*#NH9.)6-*?]3D6A,X*!+T7$9-)>HAC.M9^5PT!N*2FZ0
M7S_D8:P[SO]FDBP"B Q\]FLUY*PL.]N'*6>",V4*O 8=A2VYC?V'-W K9)G[
MTSAXS0-']&XR%L!:EE /%\#(^!EAZLM/=+>MT[>8@+]VP>2"4)!6_7ADWMJ)
M7GWD_.W@.=' N'1B.LZ6,@>U(XH0(9]KWG+7O-@-0X.I#Z1.YXPZA#<3)6XT
MK6\_-U[--<I6CMX73X9$F!WA(1'L);YJQQ*%#UC'=#IA(:/N&3=;L8LQP.U:
MV#T4I^.]$)H2-6_* C;0Y10D;M+_P7SWPVW17'78^*M/SV"'65]AC+H%MW5C
M-AL@VRZ+@C/GW9DJ:8,7YMI>XLX#'2!]ZO-'-"M&'YO 5A<& K(3F1$GG5)4
M5A*E[Y.$-DFWM=,I)N+=YA\.OE_M3TO3[/$KBQ"XSLCS5@X6S/A,SQEM3BU7
MVZR:6)UP8+"H^0IC@I$E6[?/UA8$+[MZNF!\JXUNSD'_Z)W+$TT$&TXHP0+\
M<[" E5TC#! 6U+I%C 7$"?RCF6WYD0<:IVY.+!TP/)5-#RXCHJ\,Z''\EL&M
MC4'+_+.1[\.<CHS3]6(L8+$0"[AJ0."8T&CI$(F'8_^!?_35+4'180&O8:BD
MO]KF9A\1>_;B'AE='KX^F80=3L#^>J1!3 0+D- M1R.C<<_ 85>:&"+<V0=C
MW@_^<Y,'K6V+9P0XF9#4>M7 "_BOA"!$5I7#R'6G8NZ(\E[$IZUI<SZ/_Y@/
MT+ICH9.^TEC^KPLBA%9A(0V^NF)X':("Z.8#3:(_:3]2]$3F.F]]%<E/Y6$;
ML+AR6:6;;.GW\U_<YSN[><_ &5U\!@X!4^^Z[</>(ZIFY<[Z>P^8Y[H^IO*G
M$E'22VXVFWHZ+,T]WJL[OMN3CO;OO\5(<#,X@:%$)F\UJ1?HVM2\>/Y!3\KA
M-L4M)I6<3+1G&>%XXD[E^@EJ=#[1:)>O]3RK?U0*>-PS^2\A"!&Z',>M+AU7
M#D>I%V'&<ERG2I+)VE^C@J=3_5VEG 2I3BQCQ<ZG.ZU."K<*!@Y]=G@T(3I:
MENY<G96DL7)]3W-O-'OBU[U.KCV[!S<ID1H::HKPP-PN+7/CW_(_1.[0DFC-
M:DU\>$&S^[&N6ZQ#8ZLX8AT4/*WVR:*!*#_^GUL[WWO)%!L6&ZZVHSW>L][O
M]:K@#9R1 6W[M*'.LRD_72L:8,<CNSJ3G5TTI.PN_TFKEV/%=B8"4NU0!C@[
M?:2>_<WJ&8JGXQLS;ZB^2^])O1==6K266:S-RLZ2U/K]=9)5&N%4LVU551D!
M@S>]'!"?QA0UQ::3KO1&RH@)037% M='3TO[%BX.Y#X-NPC(BHJXQ)P)]K$E
M?,#KXVR,BAB0 ]*1S>5>&N< ?[(F;'C](E5F"7#&JW^)VA&RE";,+<'[*ME&
M]DT-6NM^GZ4T/&,&^44QP[YN=AQM4OPI@2563EPN-[M8_5L+FY,T2=3O_[:5
M,D_<:@:Q3:VSI$?AM?.[=5HO?MK'CC(/#71]E8\<5=/^FKJ0CV,>SN$]?SH;
MZIH<H<Y+X=^GLF//(T< <GW=&@A54%LTT<_;#FY&-S<XMB,Q\E!(C#&J.';C
M'=J?^X/CA2P<NQ#"UJH645*@HRHQ'+=(1J,2<-SRI33Z2@WSUS&?U\9@>K"
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M6!3:+_MU[FF/=2\A08TD*,]Q\2@/A5/HX(9R-!JGT+\4ZS>_.QQ!_-^*.O>
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MP%_0T]L>+[TD>=>M'W!P2XQ8U^/COBR%AU7.XS"8.IHSJKHV86?C)>/=M"$
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M(*(LMW6*CC2F0E=Q;*NL=W9&-KUX=1WQ)<_C!C\T)2?:B%1<&]8D\4WG8 <
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MZ&>TD#WII49\O%.56W?!5=<NBU9@D&_65I_XQ2'Y-E*<Q!'IJFB5HB7^HEO
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M9502+Z]2Q!X"3\7(KS&0N@@/K&:F5;VA3E\W"D[Z@0-9PO691PY#O$['<VB
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MM?FE6XP?N!(0X.AV>]E0GZ(.$\OE9C\#W&&CH).O9O 2O24S2ZN6ZZKSD<A
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MHMG<0S8,I-P0.V3[YJSFB[L0JOG$U;/:Y5_Z81??$"6L*]/$<>Z3D.S@R,I
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M,9X^.QO8UD1IV93FU:ZJJ4G/]T/DQA9/7"G>-NDD].^GWE/&BN8!1P<X=""
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MRX# VL-@5+I<VC7)^8'NW#(EK7LSJ[R[D;UO5]MPAL:U.8&,_(\0O*)6]5<
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M!Z/V:HF5%M>#[X#63)/*F57F1U54K&@45V42"V;7I]MH)NMY[O%-=?9]ZU<
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M^]QQC7],1Z8Y,:T<2,QY:;6U1R-FK7_Z7,*XWGO'HXZHZ3;U+<:&2C &\@J
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M006\4U<0D3YZ+BZVUZL4Z.A1<Y!S5EUA77*,Q\XCL#9!XC9?$F]T2)%#AKE
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MIU$YLO@=SW)UV#29$D;?JY3'S >*VG3]]IGVQ.&;F$/TNTX= ^N,37-:>0K
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M=A;5/IF%Z]15V^3/H#&GR[ZX*T]VNJT:4O5Y]R(;"9!NCC$WO"S7OWN#*PO
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M!87)[7B2T:N V)ZJ9SQH^0IWKI+UA8E>?,P&]Q* KX+TLUBIVX2O4GY/\ ;
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M?@4MF.#NT^ 9BU\:H9+&(,##-F@;>F6MB[FR0FG_8H5*^F;1^GX+Y$V6S5*
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MUYEVTVW(5]*Z67D7+O'HSB_;A=*WK(0:2;M&:29'Q ,..FI$<CORS &E]%\
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M#!8ZA Q>7U,9C;+M#WB&H56W2YJ2;;:KT4W3GK9L,"(G,[Q2519IG:_QCH;
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M#90]%SM'AKOJ15BNP;1HN0TO)/!?!MMPST]&2/4<W2[H-EL.'IG6"GI/J?#
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MK=P\SFK]RB(O<A@Z"\);P'S7PPI"27F6'R9DKD5KMKRK+GXOA_0LI9XB8K3
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MANO$>2H\5RMK@ X/FFZ@ './0ST2S:/@VDMS[!<RU>.L%JDU52^^Q@R\7@(
MC@0'7"X9@<N6(<;)9EKOTC(D*FQE-*(^6UP+S<$#;$#/%'L?'AP_FBMT/%\(
M/&K$WR*9MC@8*/J0TI:;]SV924(C'/^^8)!X&GRY5:M\G*5@Q[*] O(@;-5>
ML>Y-TDT71%91I<SAGN_JIA#U,)Z7:55)P(='E?S@(!>'(B-S_25!-499I^1
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MR9T!M).(I0TWC#X=!N5KF7RB-8GBOL6U2-S[)KC>>B(? :KTM.M]Z.W#]F)
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M8K>1RS9B]"@EG53@M'GZ."EV.2\OSY,^>)W#>ONUO&;S@Q_UT74Q37'NB=!
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M6N\0)_ ;62XZ-BQ?FT9W-Q"D.,>?6 =<,Q\L1W>50(2_R>]D>>(DUZ$0<Q1
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MLGFE-TQO2YRBX\EEA%C??A%<U>-765<9%D[155KWTP7^IUIT)VR4)ZKX+UK
M2ZI.$*2S%KI%PJ[\E/<3!?V)<D&C\+=S*8R]4("6'!@0<8#N3AJ70^"J5XEH
MDEKC*4*]3E%AL@U8LNZ<A(^FSOJ#6@&N2D'W.VI8LM@7!;B"X:)A:>V4OZ*
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M!^[P!H$QNJG7^JB>-JQ-4U*L4&GR;9$E8.%- W__ESU,1SM%_*TB#5.]8I2
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M95^MKR)$-$">?:IKXFXP4&1\"3^>WN#;2A2X@OF8TI:!O4%JY+WY]9N7+ F
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M4XBZ.ZV'_!S=O#KJD3:*D-?97,(O4MNS!2CS(X(H&"A8).'SI;[/[P%:%?>
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M1_0;F:SDZ.DO]K"H[@'AOB]LUEJ''.PK;9+SXT;HWYGCALSYZ+TH&^+Y[,]
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MV);&6Y>DOW+K>\O&A%9F?$QI4&?D+9+5N()H'>H('CZL@LY>8XINATY?5W@
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MC/6GJH#&\.JAXZ_?AS\/M^Z_NOZK=8FR4F,0JS^:E"5&N__]WP!02P,$%
M  @ :C%A6/2](LD.2@  ,6P  !$   !I;6<S-3,W-S@R.%\T+FIP9^R\!U14
M2_(X/ B2$4&21$F"1,E9%!BB9$G# $J&8<@Y"P)*S@A*SAF$(0>5+'F 0;+D
MG'.:^?#M>V_?[OYVS^ZW>[[O'_9RZIQ+=76E6]U==;OOH+ZC?@#N*LHJR +0
M;@$ :#=_ -040!J C8F)A7D;&PL+"P<'&Q>?A  ?#P__/O$]0A(:2CI:&DIJ
MZ@=,7"P/&#@8J:E9A1YQ/.;AY^>G8Q&1$.85Y^+CY_W)! T'!P<?#Y^"@(""
MEYZ:GO=?OE"? 438: SH7]'1& "WB-#0B=!0[0"Z&SUOH_UR 7Z]T&ZA8]S&
MQ,+&P<6[(8#=!=Q"0T>_A8%^^S8&QDVKSTT[ (/H-C$]SS/,>^JOL!@<2'A?
MQV1B,TI5?B'5&-YCXC-V#,#!)2.GN$_)_)"%]1$;OX"@D+"(J+0,4%9.7D%1
M\X66MHZN'LC$U,S<PM+*VLG9Q=7-W<,S\$U0<,C;=Z&Q<?$)B4GODU.RLG-R
M\_(+"HL^557#:FKKZAN^MK5W='9U]WR#CXR.(<:_3TS.+RPN+:^LKJUO[!\<
M'AV?G)Z=7_RT"PV CO;;]3_:171CURT,#'0,K)]VH=UR^TE A'&;G@>3^)DZ
MUBN'>PR\K[%)I&(R*[_@,/)I[)$:.P[CDC'QSS/O_S3M%\O^.<,"_E]9]KMA
M?[9K$H"/CG;S\-") )* $U'6K&HFUJQ0P"_08;;YO)=:3#?J_9'PMAZM"0HP
M*(<"M$20D0Z4DQC7J_*@ *O9*,"<;-3O=V&W_]OTWZ;_U9NJL. 1^4/C'S><
MGG._Q\E!MUQ;*3P_O EO#[_=*A";FTZ]^&HA]$GP3Z+$WQODTB6O3I.0E_S7
M2>^=TG*K+R@%TZ4-]5<'40")Y9MQT4_KC0(<SAI=;@UO-;5]/.;,'QJ^(3J8
M>^)WOLM]?6)YN(H"I!W<Z& >9;9"_8\D>'$_7I50LCKBOR%IJAU,1WKUH@ ^
M*>+G-T8TM9Y.9$]XA(ALZ*MF9EL="2RW_"[W#[KT]HD,:DSZ$%"I9I9S_D'R
M;\J<&+X:\$P<6;.\H?&P^TVPQ^^J?#J\XS1:DRXM.[(&Z?7^7?#ONDC\UPG_
M=<*_X@1*MLAP)<L:X#NF=EZ%?L.2M* @$O6GMV\ !TBB=FL82 )0_Q.@)96B
M $6!UXM7Q90U+JW':GY-?@DFFC(56:&L@/\ H-O.*52*FNHDZ7#?]96HTCJF
M>02%QFY,OI*H<FBL*X:W<2!):^1-K*CLA=7C9M\9>Q'B\0NAV\36?@LIR/61
M#:4L2Z5YX]H7V;]2IK(S9CXBI1_Q&,P?7L6;*'-\JP2B)M"78LH^-D[WK=HT
M]AN-%, .PP[WW)BKB[\\@[HF_157IM-2_C<LKJXSH)5@0D[J\,/L=_'4<?#R
M2:F:AM+K GI*ESFB(I!K$BT*4&5H=<C?&&DV0$X'XK:'A8)D/]!F._&KTJ.1
MTR>U"G#FA3/7-06[FEEBRHHA$E.BGY4:=EGS4 (CZU=*)\! +PO.(8!J1==#
MB2II$_E5YQGV[8+#7M;@2<FFU6:0#^7 !KF/X&Z_\WW6F0TE?J%9REC$+?$E
M[X1!0R?90!,GB/.I#O:K=W<#6\-'[!P8\M)SVP1RDI+B*#*DP^_4YQFM#^DW
M$=K9,P<; U9C=+9LN<FHDG_4*H4)Q;P+.VM%4Q[C*%T,'3A@)6CL>4! E'41
M(H47<9>KE#2>EUITAV,F2.%)U$N39&@YG[BD!WCQ8:FU\=)9,.$GTGO8!T*T
MV$>%WF]&$<[-(U?OLNDV0Z1\(M@;[TQ^S"6AQ:&Q+&)J&Y-</&^=(54ILT[?
MOYK;"<TWX)FXVSOY@HR<W$R *LX.$^X69:2X;NO-EZ$WV>;P))\7^+C/1FYV
MH:[J5-D%R8("Q!C)H #.?FL"]UH23=Z1)H54YP\MCI:7Y[ZF"5VZ(QK-1B/7
MQ@,"ZTHT#Z=]VWD:\%3D?FG_8ZOM'[T4QTR<M@?;F^'$*CA%DT?PMK)UD+'^
M6YO,&$J&?/IS9,*C%B^/R-Y$I(Q0"^W>3KH]= >F9Q*/O\T(<VKP3;_.+I$S
MNT<<14^% DS0H !L.R[G-7,]%'M3L[&!Y "+VA&8Z1G7,"?P)-_U*\D;BD"A
MO;0C*=6$&F+0!(G+W)TI*R%!FZ0[""?!\6@4 (<&(B6)OT;\7<&'MO!13?C\
M'#5NHT1J8N:\_@<Q]MV:'MOG7]XN4:_2#50YMYZS-"1=KIZ'@@>3?$+,7%:D
M<\\<V[1'R^EK&F.V,Y^:Q-\I\8'0CBND+>H;/ [XY!%$?8$VBM0:=E?4KM@[
M*?9M]>"I??*U>J6Q$E85U[Y/>@ELQPU-BYJ[NM02$?XV-]:>,-QO[4L7W-7N
MVN#X;9ODTM=IU*+4J'D/!0CAX**<7=5.%(DW+:1M9CMI$I_Q:CLU.ARY+QE3
M3'E5UY+&,U_;9.R/%\TWM3Z9GZ)MQ#-A<!7I)KTW"AH+6NKA*ZD4T0TQ7PP?
MU4[!UU@C3SILBNFWHY=*K>MT.D>T!MDR5^XABD7Q%?!6L4;O)!06]$"<?EQ.
M;:H'-3QC))3]0>D8IWP5\$C,N^^#$?Z:4,VGZ6>%W_:_\C&BG;KW.X%*R,A.
M7_-OQCE@?G9+-U)<\^9$ 1@0,.0NLA?L?IF]KD5U*.#HV]^1%<HN)17*FG'K
MWP1"N6&_)2PS%  <9%@DRGWEO]6Z&5T\]NU44/]F5I3_28)Q,UNA6?Z6C]]
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MNOL-P2&0@NG<$04'.^?B"E7HPT[V-1\@TQ.ZD1\CMC9:3)8[5:O=!_>8DG=
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M(2RPYJJ#S,;DY4L^EPB%\V='$D@8? FN[L/!#G%B&&FK2:Q5!PMT+/>V(7/
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M^A,W>?<X4K6#]5(*!1@4D=P-30D%A R$1S]7D5][[OR7_/YG*?_K8I%+_T(
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M\LO)&ZO7EK2ZBCF?75B]QC8)0",:52D;$^\[\!I$&+'8$6&Z7(99E7/M%R]
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M%M4*D+AQ*KIJ>QW%AMJ'K!.^=5IPO^#5UF..>N=1/N.?2-I;T5BC[?W$G08
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MZW\OB2TNQR*?)<G,B9-4D#/VL^B>C92X$\2.YZ2\"O(2_IS^1^EAL ( EZN
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M6N*_'LR)HO.8[!EET!JE,U";59=>15*:47X7XP*UYCKOJ[/E1IWK@7TL[-!
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M4;LU8U$T.E<\1T=+CV>JR45RP">!EFBM8\,*66#35X!PR/[#<_S:H)]P<!M
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M2>906JU ">V$.;P8LK=7MJD87(:?<GA5*_?)?MZAI'BLWLU1(R7-NC__C0%
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MWT?)BKE"KI_YXY&WL\B[6DJ,LU3+RS?7?PX1<.+HQF6D*6# [2O6D#P9USQ
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MNM0X)?QC9L/("_,ZC>ECA':N;]+P3S][EAL%^XJ(&6P*75.+C+*TDIIN'W[
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M!8V"#O" )OL.R7)RUPN(HL'.6N _K_=.J7ME/#+_G%>Z[>H)>")4L$:3^Z.
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M,"U.FNXE_ KW5WG%@&(2V,ZRXL/O#+7Y?!LN3::CL[V???,*#E-N.JD.63C
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M-&[X,^; MJZ\IP.QO0*JG0FHB[LDVVM$0+=%8]_9C3!646&%\L.>3W1!<I5
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M6*TZV/M]Q#6C;#NU MY<&SCP&2S= _Q7 ,U)A3'X[]?%8SQPFQ1^TX'_U4C
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MQ\84Q<'$UMYY6Y/F;)DKS@-DEF)I>.4]ZQ?Y*M)BK$0"UD7J?PZ3Z+71%]@
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MI[<1N%16VI5'S.FTJP#"J/R@%8,J;#_\I):6*MRC2:FI G;:#RHJ<=&5*'_
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MW8V4M7)X#>TZ"\QIF@JREU/Z?"X86=#$_GA*/E5>19%%R<893UJ'<GDWP6?
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M,'Q]>S&!]-?I*C^O(B490XSF)\SO,WOF=GJL6'=F2T!+)9)80R> ,D[FZ[V
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MV'L<=QS/<646ITAW=#+-AN)C+54P"U&RF:_Z&(]!TXOP;"GX"A"*  TB//>
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M=@M%H'3!4G:6;UQ*6V9+7U/_I.E4&8^UI8W[#<,Y-J9KF]#[% :X&H$!*&"
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M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( &HQ85@+UI^9'A0  %+"   0
M          "  3[E!@!B9'-X+65X,3!?,S0N:'1M4$L! A0#%     @ :C%A
M6.B9' <!%0  /+P  !               ( !BOD& &)D<W@M97@Q,%\S-2YH
M=&U02P$"% ,4    " !J,6%8@F3+6+4"  !J"0  #P              @ &Y
M#@< 8F1S>"UE>#(S7S$N:'1M4$L! A0#%     @ :C%A6+) U@])"   "#@
M  \              ( !FQ$' &)D<W@M97@S,5\Q+FAT;5!+ 0(4 Q0    (
M &HQ85B;![[#8@@  "(X   /              "  1$:!P!B9'-X+65X,S%?
M,BYH=&U02P$"% ,4    " !J,6%8SCCH/Q$%  #;'0  #P
M@ &@(@< 8F1S>"UE>#,R7S$N:'1M4$L! A0#%     @ :C%A6,[VKFH:!0
MYQT   \              ( !WB<' &)D<W@M97@S,E\R+FAT;5!+ 0(4 Q0
M   ( &HQ85B;RO?J2A$  *%]   /              "  24M!P!B9'-X+65X
M.3=?,2YH=&U02P$"% ,4    " !J,6%8$_;*[!]>  #J:P  $0
M    @ &</@< :6UG,S4S-S<X,CA?,"YJ<&=02P$"% ,4    " !J,6%8Q]PH
M6UK8  #5!@$ $0              @ 'JG < :6UG,S4S-S<X,CA?,2YJ<&=0
M2P$"% ,4    " !J,6%8FNL0!:%[ 0#HS@$ $0              @ %S=0@
M:6UG,S4S-S<X,CA?,BYJ<&=02P$"% ,4    " !J,6%8U]F.]F+[  "G< $
M$0              @ %#\0D :6UG,S4S-S<X,CA?,RYJ<&=02P$"% ,4
M" !J,6%8]+TBR0Y*   Q;   $0              @ '4[ H :6UG,S4S-S<X
M,CA?-"YJ<&=02P$"% ,4    " !J,6%8BRDL:*CY  !U*@$ $0
M    @ $1-PL :6UG,S4S-S<X,CA?-2YJ<&=02P4&     !  $ #B P  Z# ,
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>bdsx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdsx="http://biodesix.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bdsx-20231231.xsd" xlink:type="simple"/>
    <context id="C_240c8f68-bf9d-46de-aa49-fa8df526c0a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_f5347cdc-ebae-4937-a95c-7a2fb92191f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20959b72-6f50-4526-8ce1-58ad102071d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d858a437-a837-4dd7-a056-993b112468b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_495df2dc-9e4b-4eba-91de-cd835b8ec284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:BiopharmaServicesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2b4b468c-46c8-4f63-a0d6-3132df34cab5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_6f68a71f-ae27-4a7e-8505-b345faef0785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b77a60af-bc6d-4b65-8356-5aad89c73994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="C_e6780030-af98-4868-9310-acae4f9730f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5c930115-3fec-4523-bf83-0ba7a2e9ab92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c2f00f89-3407-44e8-b573-6c7ef85347d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="C_e46eb83a-79be-44c5-a843-5a8c6569843c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-03</startDate>
            <endDate>2023-08-03</endDate>
        </period>
    </context>
    <context id="C_6c326e24-3804-4962-872f-a522021fc168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:AstrazenecaUkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_590d203a-30d9-4b19-b794-c99db48ab3b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_1f022e96-f9de-4099-becb-8ed34b6193c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3384de12-4804-4762-b479-c95f25937875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cc3d622b-07f0-4622-b168-11fadcf7c53f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_762beb25-d2a5-4129-9298-0e23686a893a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_355e90bf-4c9e-415d-b1b6-9150cd16a047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="C_c3fb17ed-8bf4-45c6-95cf-234368989352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_5cc23b54-53b8-41be-ba0d-255e20378a4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5662ec44-a16f-45a0-917c-97f0fd92ca72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2c13b6e2-c1b8-4e30-b455-351cad2472f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_b8740db4-2867-4e82-a5dd-07d9793a7524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f98ad46-d032-45e8-8dc6-864069fa3ada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_854423ce-c02a-4357-a5be-bd8070c81d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c75f007c-cad7-4f11-be83-4e80d54a65e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="C_9b9a9bf1-c88b-455d-836c-503d4aebec7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea1e80b7-5077-4687-98eb-b1b280706184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_6516a5f0-169d-455b-a52b-b1f028e503fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_cf25d082-7144-45c9-82a7-485c56547da3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_829c0cf6-e0e1-4b9b-b982-f1e2c2517ed1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="C_fb7558dc-7e0e-47e9-be24-11751dfeab98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_527ecbd0-9d14-456c-8b14-6369be5c77b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_941cb925-fd9e-40a4-a574-1909da8d340f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_e9449bbf-0db7-4011-804f-4ab3c76ffe06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_09d39f03-6b12-424b-8512-f460834da55b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7afe2c5e-ef01-4ae6-9496-8f640f10072d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c470b55e-4817-47fd-b1a2-60ddf9f1e696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_32ca7091-08cb-42b8-a3c3-0e36d7da15be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbf7a7b5-3d35-4435-8e39-b2016e8d14e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ba93e9bf-54a2-4a63-a29e-47cf3846d702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0845ddd1-8e8f-416b-a225-6a579305755e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ExistingShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_185c0faf-f292-4fd9-ace9-12ff64d5d8f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_6c99d259-788c-49d8-9e0a-022979f1851a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_62ca78ec-9f39-4920-83f6-28d44aeb971e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f01b403a-323f-485f-af41-68ca5c0839f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b7bda97d-3509-499d-a965-e2fdeb9c2460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_30e47baf-60a9-4e0a-aa84-25a0a6d4d64d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_757ef04f-cd64-48a3-98e8-6c7d33aefba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_7447f4c3-b576-4564-b8e9-f58111485a6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_820acf83-d376-4b0f-8f41-f85aedc1f651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_32deb686-8097-4424-ac3a-cb9f560483da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fdff4690-cd03-400e-9532-0ec16ccf2ac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_31b2a0f0-6bf1-4d74-ad13-990f695890b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dbece915-caf9-4b49-8367-e61f916c83c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ce211496-7721-4eba-82cd-0d0e044cc26e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c93f4cec-77cf-4fd9-a863-07647a7dfbe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef3c2187-563e-494f-893c-b00f9a7afdcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_a8c71793-b3d7-4472-9294-cc317e43c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_39f4972b-0662-4c51-a7b3-8e295b8cc3f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c2c8094a-10da-431f-951a-d7eb2e067421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_78dba0fb-71f8-42e4-a64b-0fd12fbe76a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c62ec6f1-4811-4fd5-bb74-172abde325bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e530c247-1fb1-40c9-a68a-591017a52ecf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f80b84d-e3ac-46dc-8317-ba012a0d08c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_25e96d73-e3b0-4a75-a22b-6a05aced6c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_103305fa-0498-4e12-8c27-50a1a8d26ffb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1b25b640-1c47-4745-9cca-376992b9713c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:AtTheMarketFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f8dffbb6-3dd7-4318-8445-46c6c30532bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_75eae973-2f26-420e-8dcd-287d48f37677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_9bb1d43b-581c-4729-85e9-b735fa97e35b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1ecadbe3-1544-4bda-a218-b85b4bdae48a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ecb41f0c-f59d-45ea-a050-526c1d52cf1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_458ca6db-5494-45ba-a80b-51438237e3b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04f15e86-b867-4b21-85db-2828b6000f59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c37573b7-4513-43c3-9695-25908f198e7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_d94f7ed2-8768-4f75-92ef-17e38595fb19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_c6dcab58-44c5-4023-bb77-3783ed60c728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_677ab76d-419b-473f-b103-ff9ac04bad1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_e430ec9b-f398-4f86-972f-96b4e020ff48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eca8f48e-2cf8-4fe3-bd45-8790ffacd616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_704abf95-1ce3-4ffb-aa7b-013f8330fca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa2e75a9-b401-42d8-9753-7018d23b85ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_7f39b903-335d-4dc6-a073-8be5fe3da6ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_a1c1115e-2162-4e21-818c-b98821ff9dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_72b4a1e8-4024-43cf-af5a-fe28f78fef95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_baaedbd4-6935-478d-9fd7-ed5496a4e509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_7d7940c5-ed73-407d-b4e5-5389b5b92763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_75b2228d-4f1c-40ab-9389-611290f07a73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7d5a6062-37b8-4fa8-a4da-c6e14c894954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b7739ff-0980-4012-9fc1-66675c283f56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_4ce221be-74ad-4978-8b6b-94c91f43b705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1c0d6b7f-113f-45cf-8621-8ade2e3145cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_ccfbd687-78ce-4465-b1b8-3bfc531b0880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_732dfeaf-3c70-43c0-9cb2-16621b310dc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20fb35f1-6660-4090-b128-abf211be9258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_ff19ba49-adcc-49c8-a36f-54b474d1fd4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1cccb8e-8913-45ca-a2a9-4d5492eb8d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c183917b-8a29-4963-b916-51ff5dc6f28a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d48cbf14-8cb6-4e55-8fec-7e43385ec4b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_e23c71c0-bc98-4ec5-ae85-cdfd84f091ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_39626716-1586-4d2d-8868-a094e33c5618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_de229b36-03e8-4ba3-9d97-4bb97a183372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a6b84852-36d5-4f3d-bb6a-b0b710f9dd00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6645f92e-5a21-48d7-be04-51e4d7d14345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_ce2a287f-cb92-4030-b3b1-332c05321abe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_82a5e47a-b63c-44b3-bca7-2b170af6b51a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_5009b344-d4d5-4e3f-897a-d9f8b21265c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_4270ff6e-22b1-452e-a4a6-a180a3e2a6f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_642aa182-ab63-4cc2-a2bb-672f223f0786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b343d002-35a7-4d20-972f-2d42c271e7a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d1ab286d-70e8-4911-8d81-5934ba62030b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="C_ba1bede0-706e-4693-ba5f-95a79f81fcbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:StockOptionExchangeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <context id="C_9312e759-444e-4716-9451-2b8b8320f87e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0a3cf0a-87dc-4d4e-85f5-ae4fff2592a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_26baecb2-9cae-47d3-9fff-e9ca8610e979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_67ce5508-c2c7-4b2b-ac66-a6d8f43f57a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="C_101bd2f5-f908-4988-9b9f-58f2c06e0547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3f300fdd-ce4b-4d8a-b6e0-51a7c1714a99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_286d0721-729c-4546-81b4-7c2234ec5f19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5636267d-0318-4aa5-a493-1e9d911a7cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ea26ef97-074e-45f4-81e8-41983d384792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_9caae3bf-4fbb-41ab-a4e1-b00953245f32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1e68ff14-2525-4276-b2c4-9d9450d9086c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_47a08558-9395-40a3-8dcc-94e5904208d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_96996321-13b7-427c-bd23-e8321fa8a247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_3a255c06-b8fd-42be-a476-41c0489c1cce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d34c69b7-5581-4027-8f30-edb22143832c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_42326201-3aba-4a78-8961-e432c28f468d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3e31ab29-a697-425a-af3d-43c74dbcb485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="C_6192e64b-6b5d-4c2e-807b-fa9c59db0323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">bdsx:CashCollateralizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_d33768d0-8007-4c23-a3e3-f26f30749f9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="C_fb308a59-4d7b-4ffa-b075-a3e642ac4c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_921ada3a-dad1-481f-91bb-6926ac721bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0f57e5e-3320-4697-9d41-f219f5580721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="C_ef8c27b1-4741-4250-99d6-cf03e3702f8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c69ea8bf-9f71-4ba2-a888-5910c8e5e8a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_e88dd606-cce8-4094-846e-9bb4b5f5df2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3a9c086d-ca5a-4f0b-a935-2933e71c3b61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_7ec35fb1-0374-47a3-b8d9-e1479123e997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4b0b71b-6cf2-47ef-afea-3440028e862e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_76c1c45c-0a3f-4fbd-beae-7e98904be82f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_693c76f1-5bcb-4f13-8dd7-aab03824f0b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_94dfe6a6-75a6-4855-8b8a-25382e1bcc1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_937cac9a-b5f5-41ce-8603-758663d5645c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4d399ad7-37d8-4601-9860-f4ed0a5dd125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e8071c03-dc27-49ba-8d1a-dda3eae00a0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fbe102ae-9f7e-4e28-816c-b752eedef674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e89c5ad9-ee99-495b-8bf2-d125fc70e5e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f5c7a2fb-eba1-497c-b9c5-a66efa1ceb59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c78507c9-28f4-4078-b9c2-60788d6de761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_77f1704b-d027-4f10-90c1-a41d7fa1aa89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_ab1111f8-759d-41b6-837c-e3d03f7a0ae9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:BiopharmaServicesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7feedfcd-2f75-4050-b434-093d5964efa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4348c38b-37a4-4aad-80bf-51c279e91cbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c641c015-2bd6-4a8d-8ea4-9455265a0578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_50b4b982-898d-46bc-b9ea-b684abcdac48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fff8f12c-e13d-40af-8269-13c52984316c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:LPCFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bced1c1d-85b9-42ae-8100-73aca910ab35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b34059f4-8b80-437f-b778-005b358d00cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:AtTheMarketFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ac9d67d1-000b-4fd0-b45a-e660f6627d18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_efd69ce4-92d9-4a44-8134-87ed7ac60445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_2c3c29e1-2f9b-4ce8-a3c1-35be4a21e942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_05eb759d-55fd-4a20-ad8a-062b720cf18a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_62d6cec9-2f4c-4985-b1ad-fb315c4d7129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_40f12cf5-75b2-497c-a527-a856346a9ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_da96c3b7-099a-40dd-9b01-f364329a97fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_0b1fa878-d68c-49bb-adba-1cf66b1bc52e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4dff87f-d0d5-422b-9f9a-13850ed49e16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_da03390b-83f8-418c-9f18-c9c25626feb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="C_85c18ff1-b0e9-4dde-b440-56dc6c7fe909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8dc723fd-79de-4621-8b96-50bc34902a0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_d8c554b0-2f2a-45d2-827d-c5c7753bf0df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_c4a9239d-0ac1-4ebc-99ad-6594a4338815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="C_d9e2f35d-f819-4cf0-98d0-27d991f1b000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheStateOfColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4fd25448-a781-4c46-af90-bee7da9ce5c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_234399c4-abaf-4cff-b6b4-cf1365245c8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_55007458-a47c-4577-8a1f-a5b74438afae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e27675e3-4b86-41b3-82b6-66aeb3068eb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fdcc9d4c-66e6-411d-9680-d5105860c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-03</startDate>
            <endDate>2023-08-03</endDate>
        </period>
    </context>
    <context id="C_35044628-f95d-4526-999c-ceb308c83552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_21cb25e9-02bb-4719-b5c1-a096cb7c970b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_118e49be-c761-4dd8-a46b-5ab677d5c06f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aae49741-9ea1-4f75-bfc7-d624530d36a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="C_d6b06b8a-9d90-4601-bafe-371bd4da5153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5fa0d7e8-75b7-4df5-8285-781f19947e03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_2a229531-ccdd-4632-a059-50b71306f89f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed3993d6-58b6-4ff5-b5d7-5c4851329b29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-08</instant>
        </period>
    </context>
    <context id="C_dd518e59-60e3-4745-ae35-197791782cc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d3bdd13a-c3cc-4e09-816e-ad5c1a5a1b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2753e6cc-4205-46f0-b9c5-73fa3a85b6e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_db52ea64-8d04-4f5f-808f-473c14c90cd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_18694c42-145b-4b80-97fa-d13aaaf257c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e811ab96-e279-4509-9656-8567a594d9e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2ff65011-fa8e-4a77-8fc2-78505357e43f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f95c0d4d-7ab7-4ea8-bed2-8c4d7965b3da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_47cf66b1-0604-4cd3-8aee-7a4e96842346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_980bcbe0-d568-4e08-a672-b071c73a3261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ff6853d0-09e3-4b96-93ec-2bc31e1bfcc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="C_c7c3261f-f9bd-43a8-901f-c9c1d238ad41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_87753004-7a65-4879-90a7-b55ed68ef8d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2bb7dca5-b8b4-43e7-8305-8b91be0a1148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b5d3398-91f7-41ab-97d0-7393bc19f7ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="C_e3ab2048-daf6-40f1-a535-fe1a3ed66ded">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_bc5a7859-ac48-440b-b875-07120eb3a782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_944a3fdd-0063-430b-812d-8df10d978153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dbc0f234-0a0a-4688-a7d0-ab581da9ada6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6410b666-1ca1-4444-9f01-8f35821f9a25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e4c92134-cf3d-4b48-a86a-aff01ba5002e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_722b4124-2675-4c60-83df-552c2446203f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_886c7268-fb43-44e3-b7bd-e66c3277e3a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_7d3ecb2f-0211-4617-a06a-2d4546f0e40f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_b6598444-e68b-421f-8188-c98635eea90e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-23</startDate>
            <endDate>2023-06-23</endDate>
        </period>
    </context>
    <context id="C_b8e10b10-ed99-44ce-9379-a3351b13b1d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:TrancheBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_63b83fa5-85b9-4152-a156-9afea82f699b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="C_35232c44-4da5-4420-b843-8dbdf84d2418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0f11691d-c0c2-4bb0-ab80-31641907e9da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d56ae6a-1cf7-4302-8a0a-2f707300fff3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_e9c98e4a-80fa-483a-9bc2-c5a38ceacbe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ccdfd811-c49b-4466-bf12-ded5e7a5e155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_532807c3-5af3-4d5a-94dc-2349407eba05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2023-09-27</startDate>
            <endDate>2023-09-27</endDate>
        </period>
    </context>
    <context id="C_01111575-2dc6-44fe-bdc7-2295733d2ca3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d3ff8863-2403-499a-a2df-4ae38da7415d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b293fb96-2665-4a34-bf96-3204f1af238a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_51c21cd5-9bbf-406e-95cd-7db5c3f7f76f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_acdf8992-5bd5-4c91-833c-0190220805bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_56c9ae72-9e34-4992-b029-01bdfc7ad040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="C_a4f1f778-0ed2-4f8c-a95b-459652dcae55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_81062d5c-36cb-4b6f-acd2-1864d8d3f30d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_SubscriptionAgreement">
        <measure>bdsx:SubscriptionAgreement</measure>
    </unit>
    <unit id="U_Facility">
        <measure>bdsx:Facility</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Officer">
        <measure>bdsx:Officer</measure>
    </unit>
    <unit id="U_Test">
        <measure>bdsx:Test</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>bdsx:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Installment">
        <measure>bdsx:Installment</measure>
    </unit>
    <unit id="U_RenewalOption">
        <measure>bdsx:RenewalOption</measure>
    </unit>
    <unit id="U_ShareHolder">
        <measure>bdsx:ShareHolder</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_d5282462-cbef-460a-bbd7-6dfd5e11ed79">0001439725</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_11f7e262-b3b3-43f8-aa23-9b8633f293d4">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_a5db4e91-6ac6-4602-956c-2ece0366f9fb">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      id="F_f09beae6-63bc-4fe9-8088-f12fc07a80bf"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      id="F_edf6892d-6c5b-4273-a943-cdd4ba7438d9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      id="F_e86b8b3b-a85c-44b9-8d6d-7549b1a94605"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      id="F_73a3f454-52cd-4af4-83d5-15d25b949308"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_19d8db26-ae6e-4ab2-b567-298bf67cb775"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      id="F_5b4950ae-8a2a-400a-848c-b12899bcf89d">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      id="F_9df9a806-ab12-4618-8e6a-94161b6cb0d5">http://fasb.org/us-gaap/2023#OtherAssetsCurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_9bb1d43b-581c-4729-85e9-b735fa97e35b"
      id="F_693c0deb-e916-4d0f-82f1-e7179ddec20e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d3bdd13a-c3cc-4e09-816e-ad5c1a5a1b08"
      id="F_9b208ef9-2e89-4c6b-beef-d077b508f0ac">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InvestmentTypeExtensibleEnumeration
      contextRef="C_1c0d6b7f-113f-45cf-8621-8ade2e3145cb"
      id="F_4a3ac985-50cc-430f-afc9-a367fa948051">http://biodesix.com/20231231#RepurchaseMember</us-gaap:InvestmentTypeExtensibleEnumeration>
    <bdsx:LeaseExpirationMonthYear
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_6810bc43-8b88-4896-94db-50fb78cff4b9">2023-01</bdsx:LeaseExpirationMonthYear>
    <bdsx:LeaseExpirationMonthYear
      contextRef="C_f4b0b71b-6cf2-47ef-afea-3440028e862e"
      id="F_d0f0a6d5-c980-4547-82e0-7fbd7882d4e9">2024-01</bdsx:LeaseExpirationMonthYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_9bb1d43b-581c-4729-85e9-b735fa97e35b"
      id="F_f032350b-436c-49d5-a43e-3d8d73323d62">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_d3bdd13a-c3cc-4e09-816e-ad5c1a5a1b08"
      id="F_d4ab91cf-5309-48b9-bf44-1a128879ae56">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_1e68ff14-2525-4276-b2c4-9d9450d9086c"
      id="F_d101e6ae-d1d1-4191-8ad1-1ab4d344cdcb">P7Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_2753e6cc-4205-46f0-b9c5-73fa3a85b6e5"
      id="F_afd70d36-dcbf-4fdb-b7a0-f4dc56cc9f89">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_ff19ba49-adcc-49c8-a36f-54b474d1fd4d"
      id="F_969e4251-ea3d-4fbe-a713-b5983a44c323">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b686a659-eddf-48d9-ac79-0fc138acfabc">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_5a7ece8e-7dad-45ee-a26b-81dbb662f18d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_3c2cf3b4-1b7d-4693-b155-5abdd162b9cd">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_93d2670d-2e98-49aa-87db-51d29a52572a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_8f482c86-652b-432b-bb16-4c2a6281d4e3">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_ce0a3684-a55d-4669-a10d-fae36047cbb9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0364b057-9f45-4722-96db-b0e10f7a7208">001-39659</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b311f35c-98de-4bc9-867e-e5cc29c9d301">Biodesix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_dc0b4ded-df24-459b-84fd-15a0857d5710">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_179dc34d-6721-488a-bf89-95ce1eccee6c">20-3986492</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_4cc11474-8401-4fd2-969d-6ce736865177">919 West Dillon Rd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_31e89ec4-47a6-4a1c-9dbb-8b0ada20d26b">Louisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_10808f2d-6e33-4e83-a472-c77495d69e01">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_96f59277-e87d-4245-9cac-9914865f277f">80027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_fd63bf97-c83d-47d8-8ad4-4424e4123e71">303</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_2fac7cd8-4cd0-449b-817b-2f0f734b7d4a">417-0500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_4df7b38d-9fc6-4fce-9cb1-9d25211e6110">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0f053ecb-40ff-4d0c-a3f7-55816743e433">BDSX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_66c83f99-4163-4ad2-9eda-f8aabde93fb0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_d379cb83-ef63-4c64-b026-51ba840fddda">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_c2f54cb2-6788-400c-b600-8462aa6201b8">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_454c3a86-54b3-454a-a229-e63193062f6a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_db0cd6f9-abb4-4c08-ac50-ba967a9734e3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_2bcd8156-7c20-4a76-af5b-59b6adcd1ac2">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e1ef7f33-94e2-4845-aef8-d5be6941d0ce">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_7f631311-715e-41ec-aa7d-b1e7204bb036">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_d09b8693-d7a9-41fc-a669-df15749543d3">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_60ae698e-b039-47ec-bc3a-928ae40657d1">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0cdc5e66-36fb-455e-a58a-3e099ae96b98">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_78ba50f8-a1c4-4025-a582-f1b16e777ce4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_6516a5f0-169d-455b-a52b-b1f028e503fa"
      decimals="-5"
      id="F_a2786e90-9340-47ba-8fb6-845d723215d5"
      unitRef="U_USD">36600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_e23c71c0-bc98-4ec5-ae85-cdfd84f091ab"
      decimals="INF"
      id="F_ff4f7e28-712d-4597-a2ee-1abf52293f2a"
      unitRef="U_shares">96942061</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_546db015-1ffd-4db1-b685-2ddf0b78a29a">&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the Company&#x2019;s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346"
      id="F_50cb6520-3ca3-4ffd-ab84-d70156078a00">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346"
      id="F_ee5f2666-65f2-4af2-9693-53aacef49c6b">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorName
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_cefc7cb1-ea5e-4cca-ba69-41a45656f75b">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_82e670ea-e9d9-48e7-b2a8-f19af0df8eb6">Denver, CO</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_a621f074-804a-452f-9e16-4ea5ddc14a76">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_e183e747-4142-4f33-b11d-aa34a347cf6b"
      unitRef="U_USD">26284000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_61fd9cfb-730d-4146-946d-23d85fe0283b"
      unitRef="U_USD">43088000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_cec62bbf-68e7-4ae6-9c3f-d2aa338bc613"
      unitRef="U_USD">65000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_a9f79195-2a94-485e-a40e-a783c57614c6"
      unitRef="U_USD">118000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c9447e57-3ea3-42dd-a3eb-581d58d036cd"
      unitRef="U_USD">7679000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_4166d85b-3856-4c76-ba1b-d3769af67f51"
      unitRef="U_USD">5065000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_9aabc236-f3e8-4e4a-8ef0-80a28a04a2ef"
      unitRef="U_USD">5720000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_11f9d6f2-3300-45de-b940-dd317f1851c7"
      unitRef="U_USD">5181000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_146c3d19-8a9a-43d7-b728-befe9771da40"
      unitRef="U_USD">39683000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b41362d7-447c-46eb-ae93-4403ede70d5a"
      unitRef="U_USD">53334000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c1b36cc5-6a1b-4e8a-9f8b-270a90eb1b40"
      unitRef="U_USD">27867000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_7a60b586-b548-4609-972c-41d2dd63cd55"
      unitRef="U_USD">5848000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_26cb3f8b-a3fc-4549-8907-eb02409dab15"
      unitRef="U_USD">7911000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_ffd3ae43-00f3-48ef-a17d-0c36c3fbe253"
      unitRef="U_USD">9797000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_691c1c36-d16e-4b70-920f-4c4a24269418"
      unitRef="U_USD">1745000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_6991f036-440e-4b0b-a109-07bdde3cf7c9"
      unitRef="U_USD">2973000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_e4d0b22a-7018-4f4d-b85c-888283893360"
      unitRef="U_USD">15031000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b367027c-d779-45a7-b3a0-a16e7279856f"
      unitRef="U_USD">15031000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_5c24f891-c11f-41ff-a5a9-f94a6c321a10"
      unitRef="U_USD">6859000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_bfdfb173-5cd3-4f9f-84fb-16483ed18400"
      unitRef="U_USD">5923000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_5300e302-5af5-41ad-bd27-718a459435ce"
      unitRef="U_USD">59413000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_6ba9c29b-4750-4cd1-a7da-06d21d2ad5d1"
      unitRef="U_USD">39572000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_14a0ff8c-71f8-49ed-bc96-0868625aef0a"
      unitRef="U_USD">99096000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_cd6dee58-328d-41c9-8a6a-8c4d610cfd81"
      unitRef="U_USD">92906000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_16c80c50-7e39-45ad-b983-74c3f34f44ed"
      unitRef="U_USD">2929000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_de9a547c-a251-4e75-8cde-e9ff59149245"
      unitRef="U_USD">1685000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_9bd162dc-729e-471f-9d8c-d5fa9ebaf659"
      unitRef="U_USD">7710000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_ab8a9f50-6604-4cb2-a463-721a9c338fe0"
      unitRef="U_USD">8218000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_fd395ae8-d9ba-407c-b8f8-a19559943afc"
      unitRef="U_USD">324000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_4eccce8e-2cbf-483d-bf1b-063e6010e6ba"
      unitRef="U_USD">962000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_15990cf7-a132-489e-b8ac-4107a52e283e"
      unitRef="U_USD">252000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_e545b842-ae93-4e6a-ba01-0c5d37c3cd17"
      unitRef="U_USD">1543000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_88e5dd56-fb16-4ac2-a5ac-6abc01b9b667"
      unitRef="U_USD">21857000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_a9d1e250-4963-4dc4-a187-419ce5bc953f"
      unitRef="U_USD">10341000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_d1421636-bf6a-4666-a678-77753003edbd"
      unitRef="U_USD">51000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_77bbf713-4512-475f-8053-199db6c1909c"
      unitRef="U_USD">49000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_12dd6122-a8a1-4663-ba35-7350b9861a8c"
      unitRef="U_USD">293000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_54e8c6e8-0014-4eea-a499-0f31ce8a0879"
      unitRef="U_USD">41000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c37190d1-68a7-4be9-941d-0256da0d6dab"
      unitRef="U_USD">33416000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b2c15498-9457-43d4-b3eb-0f609caf8bf2"
      unitRef="U_USD">22839000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_d1c052f2-7c6f-4962-9ec6-f0a8d07f76ae"
      unitRef="U_USD">35225000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_69743a28-2dac-48b4-af78-f427e5d606a1"
      unitRef="U_USD">25004000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_b8486855-1e47-4a20-93e5-edae7e92a05b"
      unitRef="U_USD">25163000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_8b81fbf9-836a-4208-be55-81bfcb1b97ad"
      unitRef="U_USD">5254000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_128272f3-09d6-4559-b2a0-a598f6a30bf6"
      unitRef="U_USD">18645000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_63697c30-59ee-470e-a967-92ba1053443d"
      unitRef="U_USD">712000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_a2843634-1b53-477e-aab7-5e2e28af46ad"
      unitRef="U_USD">558000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_628239ea-c8d4-467b-912f-8378a55309fe"
      unitRef="U_USD">61100000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_8aab09d8-29cc-4fce-a2e5-eff4b3bb0bda"
      unitRef="U_USD">49461000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_5168fe7f-80dc-4a0f-8262-5999da527135"
      unitRef="U_USD">94516000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_e2e2fd5e-4799-4093-bdcb-40c5de0f5a6f"
      unitRef="U_USD">72300000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_5d564c7c-c380-4295-9f1b-e0c0d32e9a62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_26b72a5b-0765-41d3-9f92-bafc43391b4e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_7a07dbfa-2621-440b-8a9a-d97171c75474"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_8318666e-9afa-4f81-8689-f8562bd5915a"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_8e29ed12-b977-49f3-81e3-2fe1450cbca9"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_e3c410f1-a8d2-410b-917b-8b9767b1b9c8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_9ff9bad9-f3c8-45fe-b089-95b5a623d35e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_73f16463-4231-4168-b441-58d7e88d1cfb"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_277f4a35-7098-49a4-bc39-fa01b9b6025e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_a4cf78c4-fa34-41cf-bd84-5c0278a390c2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_8618716b-aa14-4cf6-8fa7-f631da8d9529"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_375221e0-e3ef-4fb0-820a-3ac32cdf43b5"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_725199a2-c856-4c41-a17b-8c62cae43a41"
      unitRef="U_shares">96235883</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_5a3b40b6-9a22-4c19-bb4b-4f463a4e2fea"
      unitRef="U_shares">96235883</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_c72935bb-4731-4c31-9b86-22397aabe50b"
      unitRef="U_shares">77614358</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_5ae7cc13-1596-4d81-8740-f43fa9814f9f"
      unitRef="U_shares">77614358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_41dc0f28-8d6e-4949-b726-cab4fe03266e"
      unitRef="U_USD">96000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_e56429cd-a1af-40d7-a6e9-5a4827f25ea5"
      unitRef="U_USD">78000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_77922e51-1bcc-4fd5-9b9a-216f3b59baed"
      unitRef="U_USD">424050000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_bf60d0d7-9012-4fdf-979d-4a472fb6e61e"
      unitRef="U_USD">387948000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_11e5bad1-2dd2-4015-8c89-63a84bf0d4cf"
      unitRef="U_USD">-419566000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_ac8fc07f-ee3e-4f45-8032-23bb868cd6eb"
      unitRef="U_USD">-367420000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_2848e0b9-71c0-415f-90ab-7ca208f8184b"
      unitRef="U_USD">4580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_ef183434-82a4-4c08-9438-be9761a0897e"
      unitRef="U_USD">20606000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_7a68827b-2dc8-41fa-90f4-f4411a96a1df"
      unitRef="U_USD">99096000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_5ea7d625-d3c3-4a24-a4da-f951c0d1ee80"
      unitRef="U_USD">92906000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_3524be26-f357-4e42-aa03-25678be8206f"
      unitRef="U_USD">49087000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_6a922670-b997-4c75-ad24-4a734200be61"
      unitRef="U_USD">38212000</us-gaap:Revenues>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_831fd023-e235-4b1b-8840-d3160d7d65d4"
      unitRef="U_USD">13010000</bdsx:DirectCostsAndExpenses>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_de719140-494b-4001-8dfe-064b89bdb88c"
      unitRef="U_USD">14154000</bdsx:DirectCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_2ec58785-b0b3-42b0-9739-20a21cf15329"
      unitRef="U_USD">9988000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_fee37dc8-711a-4364-9044-e96f45a3915f"
      unitRef="U_USD">13102000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_3f99e1ee-297f-435f-a4af-d797443fa428"
      unitRef="U_USD">67387000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_944b6b5a-3d36-4e32-a18c-106f82c64903"
      unitRef="U_USD">61462000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_14b47f46-dcd5-4de1-8e32-04a9dc84968a"
      unitRef="U_USD">44000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_1d7b37d8-e1fc-4128-988c-52c18aaeb96e"
      unitRef="U_USD">81000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OperatingExpenses
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_399dbb66-915c-450d-bbbd-ae5d35a85a7e"
      unitRef="U_USD">90429000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_b7d09d8f-2654-499a-bfc6-f0738b5b4989"
      unitRef="U_USD">88799000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_2aa6aef4-d84e-42b8-a197-39c2191b756b"
      unitRef="U_USD">-41342000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_70ae9509-2bb7-4ece-af7e-9874be72e913"
      unitRef="U_USD">-50587000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_0df4b841-7033-467f-9f7f-91df9481adbd"
      unitRef="U_USD">9536000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_dbdbd059-06f4-47e7-b4d4-f075702687df"
      unitRef="U_USD">8072000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_c514d31b-4c8b-48c4-8c6d-49573eeea41a"
      unitRef="U_USD">-6981000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_07659e0c-0d8d-4f5b-9d8f-d8714c769e39"
      unitRef="U_USD">1274000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_e667ae5b-3285-4acb-bbc6-288ed3b7b288"
      unitRef="U_USD">-84000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_da9e42fb-deb1-40be-805f-f5c6dd64b4f3"
      unitRef="U_USD">6000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_b3674c21-1bb2-4bf2-8fb6-f9a0b921b062"
      unitRef="U_USD">109000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_042db79e-0688-4e6c-aead-d2ca818e655f"
      unitRef="U_USD">-10804000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_a26ee879-423b-432f-9716-e12e61a93eed"
      unitRef="U_USD">-14860000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_f2b20f22-f0c8-46c1-887a-b16e3f2bec20"
      unitRef="U_USD">-52146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_21f735bd-6a4b-479c-9531-d5bff1614e98"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_e0bf7609-688c-48b9-9b6b-5e30380105b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_2478c1f0-9a77-4ffd-b104-7c0a211dccc6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_c25fee03-361e-434c-9545-e143131c2066"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_f2036274-085b-4f94-98a5-ce8f553dae4f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_95d3b2b4-4c3f-4c43-86e7-ac10dec15e4c"
      unitRef="U_shares">82113000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_4b192312-c93c-4d21-a6e8-35365bc1cf2d"
      unitRef="U_shares">82113000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_88c84438-3b34-4dd0-a740-6a2f428dfca6"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_48569190-bda6-4550-8ea8-aa03bdf4fcbf"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_31b2a0f0-6bf1-4d74-ad13-990f695890b4"
      decimals="-3"
      id="F_1991e22c-fc8d-41a7-9541-895b537a6721"
      unitRef="U_shares">30790000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_31b2a0f0-6bf1-4d74-ad13-990f695890b4"
      decimals="-3"
      id="F_86012fbe-42f1-49fd-ac7d-37611d37c91a"
      unitRef="U_USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5c930115-3fec-4523-bf83-0ba7a2e9ab92"
      decimals="-3"
      id="F_390b8f2a-8c44-4361-bb76-78f8279e765e"
      unitRef="U_USD">321669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_39f4972b-0662-4c51-a7b3-8e295b8cc3f4"
      decimals="-3"
      id="F_32dad6b3-dcb8-42c3-b9b4-21a6003e9b45"
      unitRef="U_USD">-301973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_762beb25-d2a5-4129-9298-0e23686a893a"
      decimals="-3"
      id="F_640125d7-b18c-4b0b-8281-cea297142fbc"
      unitRef="U_USD">19727000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_a96012f6-a180-4a4f-8287-9f80b5ecaf14"
      unitRef="U_shares">45705000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_68a445c6-ab47-42e6-9d9e-63fb2078dd71"
      unitRef="U_USD">46000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418"
      decimals="-3"
      id="F_b01b87fd-3e82-4518-a9ab-ac0713232e1b"
      unitRef="U_USD">56189000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_fb661296-d603-47c3-bfef-3b5e5f570d03"
      unitRef="U_USD">56235000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_bc55b989-9564-4def-a282-3cc724d5124e"
      unitRef="U_shares">194000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418"
      decimals="-3"
      id="F_660f173a-b4ee-4817-b190-80cb9d40cd9b"
      unitRef="U_USD">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_905951b1-fe49-472e-93a8-55294aee8806"
      unitRef="U_USD">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <bdsx:StockIssuedDuringPeriodSharesForDeferredOfferingCosts
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_1f6c3aaa-c4ed-4ef5-9c9c-0872c5d4d501"
      unitRef="U_shares">184000</bdsx:StockIssuedDuringPeriodSharesForDeferredOfferingCosts>
    <bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts
      contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418"
      decimals="-3"
      id="F_e6b1d66f-f027-4dd7-8852-17bff88db1f1"
      unitRef="U_USD">600000</bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts>
    <bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_ec6ba6db-9123-40dd-b0d8-00bf998110f7"
      unitRef="U_USD">600000</bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_24b02182-aa92-44bc-95fb-99e815b98ed0"
      unitRef="U_shares">384000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_17466085-6c84-4969-888c-a4db775e8125"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418"
      decimals="-3"
      id="F_97befe96-0894-4209-bdeb-f411bad71c98"
      unitRef="U_USD">268000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_59748931-921c-4553-a3c8-0834c0271280"
      unitRef="U_USD">269000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_79f285e9-9f9e-45b3-8778-a00c68cd39aa"
      decimals="-3"
      id="F_a4608a6b-93d8-4f5f-b75d-7bfb7e76eb68"
      unitRef="U_shares">357000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418"
      decimals="-3"
      id="F_02fe91be-78ed-468d-a475-5c35cefb7318"
      unitRef="U_USD">2906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_bcd749b3-28bd-406b-94c6-6cb4cf700eca"
      unitRef="U_USD">2906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_35232c44-4da5-4420-b843-8dbdf84d2418"
      decimals="-3"
      id="F_cc62af4b-0cc0-499b-affd-3417bd9894e4"
      unitRef="U_USD">5961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_f0f9881f-a3f5-4242-be46-bc109f6d75ac"
      unitRef="U_USD">5961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_f95c0d4d-7ab7-4ea8-bed2-8c4d7965b3da"
      decimals="-3"
      id="F_bcdffdc1-5a25-4da3-8568-271214c17f9e"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_5dcc90fd-b0c5-4599-9f9f-347dad39d663"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_854423ce-c02a-4357-a5be-bd8070c81d4a"
      decimals="-3"
      id="F_7fb7d11a-6578-4439-97d3-ff8f75f2b2d7"
      unitRef="U_shares">77614000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_854423ce-c02a-4357-a5be-bd8070c81d4a"
      decimals="-3"
      id="F_5b3168db-a6ab-4e78-8f85-8fe9e31df17b"
      unitRef="U_USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ecadbe3-1544-4bda-a218-b85b4bdae48a"
      decimals="-3"
      id="F_671aa13f-dd71-4fb0-a2f8-c5d4ebd7087c"
      unitRef="U_USD">387948000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1cccb8e-8913-45ca-a2a9-4d5492eb8d7b"
      decimals="-3"
      id="F_7718f478-0174-4c63-9986-f5df1f7a6937"
      unitRef="U_USD">-367420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_8c9333d9-a22f-4763-85d5-b9f2dcb825a0"
      unitRef="U_USD">20606000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"
      decimals="-3"
      id="F_c8512daa-9912-4c93-beef-c6abb3d31b49"
      unitRef="U_shares">17352000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"
      decimals="-3"
      id="F_d9c4ddf1-d01c-4a3b-b83d-7c433ee668c8"
      unitRef="U_USD">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9"
      decimals="-3"
      id="F_02dfad55-ef74-4c48-9844-2391589c8d00"
      unitRef="U_USD">27986000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_449bf27f-d48c-4825-a3fa-ce9a36ffb13a"
      unitRef="U_USD">28003000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"
      decimals="-3"
      id="F_1c6d7944-1cf7-4ab4-9bf2-be24820925af"
      unitRef="U_shares">437000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9"
      decimals="-3"
      id="F_0e5c39d5-aba4-4091-8090-e088d14f7268"
      unitRef="U_USD">643000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_ec80822a-3ffa-4450-a1a1-4bebb3248c13"
      unitRef="U_USD">643000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"
      decimals="-3"
      id="F_7f5e2ab3-62db-4103-9cba-f37b67e61f0d"
      unitRef="U_shares">123000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9"
      decimals="-3"
      id="F_5ee7cc42-78cc-4179-9d3c-7298a8f02563"
      unitRef="U_USD">91000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_0c66bc0b-3e13-4fd3-bff5-3df06cd1df71"
      unitRef="U_USD">91000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"
      decimals="-3"
      id="F_ec1b6ea0-f19f-44a5-a1b2-4762391d6858"
      unitRef="U_shares">710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount
      contextRef="C_e78f81b5-f674-44fa-9e66-9368bc8ffa76"
      decimals="-3"
      id="F_b99a49e7-7f54-4846-b1cf-aecbd632ef04"
      unitRef="U_USD">1000</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_74944cba-ad45-4378-8428-58f442361fbf"
      unitRef="U_USD">1000</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount>
    <bdsx:AdjustmentsToFirstAmendmentWarrants
      contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9"
      decimals="-3"
      id="F_e55d0f57-44ab-4145-bfe1-439b69ebcefa"
      unitRef="U_USD">674000</bdsx:AdjustmentsToFirstAmendmentWarrants>
    <bdsx:AdjustmentsToFirstAmendmentWarrants
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_01bd8c31-d465-4915-b250-c226d9a6e5b3"
      unitRef="U_USD">674000</bdsx:AdjustmentsToFirstAmendmentWarrants>
    <bdsx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant
      contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9"
      decimals="-3"
      id="F_b45512c4-40a4-4e92-9b3e-ce6e2287bb5d"
      unitRef="U_USD">1335000</bdsx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant>
    <bdsx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_08286b39-8c7d-415d-afaa-fcdf0b32ed78"
      unitRef="U_USD">1335000</bdsx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_dd518e59-60e3-4745-ae35-197791782cc9"
      decimals="-3"
      id="F_50159b81-2530-407d-aa1c-f4bd082a472a"
      unitRef="U_USD">5373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_11fcd2fc-8d69-4ebe-8061-ebafbb62d5f7"
      unitRef="U_USD">5373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_e6780030-af98-4868-9310-acae4f9730f3"
      decimals="-3"
      id="F_b8e45864-da26-442f-ba81-a41ecaeeff86"
      unitRef="U_USD">-52146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_f24359bd-bdf0-4c12-bc3b-70f892e3ed89"
      unitRef="U_USD">-52146000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_acdf8992-5bd5-4c91-833c-0190220805bf"
      decimals="-3"
      id="F_c091efc6-db37-4730-bc9d-f479ffefedb7"
      unitRef="U_shares">96236000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_acdf8992-5bd5-4c91-833c-0190220805bf"
      decimals="-3"
      id="F_ceec43ef-bf7e-462b-898b-faacf9036125"
      unitRef="U_USD">96000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e430ec9b-f398-4f86-972f-96b4e020ff48"
      decimals="-3"
      id="F_c1397405-ae74-4a46-9283-ddf8165ac6e7"
      unitRef="U_USD">424050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b293fb96-2665-4a34-bf96-3204f1af238a"
      decimals="-3"
      id="F_54a189b5-e69c-4cb2-99df-6c4e48e97714"
      unitRef="U_USD">-419566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_359337ab-9e01-4807-b7a7-debdcb031ccc"
      unitRef="U_USD">4580000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_47e2f920-22f8-4238-98f5-2612e7b1257e"
      unitRef="U_USD">-52146000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_59597b1d-362b-4463-a165-ec7401aa3531"
      unitRef="U_USD">-65447000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_c9f030c4-5f81-4e17-a092-95c92eab92dd"
      unitRef="U_USD">3328000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_9fe45614-9ee3-4cec-814f-29e147ebe37d"
      unitRef="U_USD">3597000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_9f3e3ce3-3f95-4a43-b5f1-ce7eee593620"
      unitRef="U_USD">2179000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_3eec480c-f969-4f9d-aed0-3b4b2f70e88b"
      unitRef="U_USD">2247000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_6b6242f6-70d3-4fcc-b1b5-7fd318fbf272"
      unitRef="U_USD">-6981000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_9ee0c7bf-58c2-4957-9fd7-f2def995b466"
      unitRef="U_USD">5373000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_87a3e39d-d645-4a38-bab8-a963e050c1c3"
      unitRef="U_USD">5961000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_01d595de-4579-4ff7-8c33-a01ed77269c6"
      unitRef="U_USD">1274000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_a624465a-1d35-4fd0-925a-c77a6b8e2718"
      unitRef="U_USD">-84000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_a9efd17a-a1e3-4222-9cd5-3656cb670793"
      unitRef="U_USD">497000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_836a072f-1ab8-4c33-82f4-221e3e0d5a86"
      unitRef="U_USD">93000</us-gaap:ProvisionForDoubtfulAccounts>
    <bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_61f55b14-c003-4b73-a1e2-d53a33ad8621"
      unitRef="U_USD">5111000</bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther>
    <bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_852c4c20-8952-442d-b6b5-088110580c06"
      unitRef="U_USD">5037000</bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther>
    <us-gaap:InventoryWriteDown
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_d57f82d6-3221-4eb9-99e4-0070f6752a04"
      unitRef="U_USD">166000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_9f5133c4-0672-4d40-9acb-0380de14b842"
      unitRef="U_USD">906000</us-gaap:InventoryWriteDown>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_370722fc-cdb3-4059-b04c-5cd6a79b09fe"
      unitRef="U_USD">44000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_4b248cb3-5367-40d5-ab05-c833c0c43db7"
      unitRef="U_USD">81000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_10144a2f-58b0-406f-99c0-08063d4f5adf"
      unitRef="U_USD">4718000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_a5f44a16-9fd9-41de-a671-be657dd16bd6"
      unitRef="U_USD">1501000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_eab4ccde-a04c-4e3c-a4b7-63610c4eecfb"
      unitRef="U_USD">-905000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_041864c7-aa3e-44bc-902e-9e0090b19a07"
      unitRef="U_USD">-1113000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_9b29bcf9-3010-43f9-8397-75ff7e3dc3a9"
      unitRef="U_USD">-33000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_b2f74f7b-96a0-4620-8a69-473145945991"
      unitRef="U_USD">3504000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_c11af3b0-a3d6-4991-8bed-712317e7ffd1"
      unitRef="U_USD">513000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_8c726a9b-5507-4372-b6b7-476472570080"
      unitRef="U_USD">-773000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_e6e2f479-379b-4d50-a5c8-069ccd06ac8e"
      unitRef="U_USD">-755000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_9d668301-ec45-47d6-bb12-db086be1d210"
      unitRef="U_USD">-1213000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <bdsx:IncreaseDecreaseInContingentConsideration
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_3e74a041-abf5-4cc2-aa95-3dfa0b4a1f6c"
      unitRef="U_USD">-2494000</bdsx:IncreaseDecreaseInContingentConsideration>
    <bdsx:TenantImprovementAllowancesReceived
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_239fbc15-8708-4d01-93b3-012ca1f5811d"
      unitRef="U_USD">18323000</bdsx:TenantImprovementAllowancesReceived>
    <bdsx:TenantImprovementAllowancesReceived
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_eaf74361-7ae2-43de-9728-d3c08d78446a"
      unitRef="U_USD">2471000</bdsx:TenantImprovementAllowancesReceived>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_d96e7aa9-3aad-43c5-83a3-908068e99368"
      unitRef="U_USD">-503000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_eeba07a1-ceaf-4c8b-aa54-77d4e12e7588"
      unitRef="U_USD">-937000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_a3d9877b-27c4-4168-9128-39319d48907c"
      unitRef="U_USD">-22870000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_fcc13ea8-1e61-4fd5-9698-382f5b7b11ec"
      unitRef="U_USD">-44972000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_51426140-c90e-4fab-858b-f6f21cd9f12a"
      unitRef="U_USD">22919000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_bb02a6d7-f6f8-4721-908b-6526e8f66f03"
      unitRef="U_USD">3298000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_53072b9f-453e-4822-b288-cf95756e7e0e"
      unitRef="U_USD">143000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_85757cde-61e2-4070-a410-21ca895207cc"
      unitRef="U_USD">236000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_de734fe8-ac48-4f1e-820d-cea5d9be480b"
      unitRef="U_USD">-23062000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_398da69e-da94-425f-9c05-509ad4a223aa"
      unitRef="U_USD">-3534000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_0550ecff-2c5b-4ade-a767-4fcf3632ee53"
      unitRef="U_USD">28126000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_2b5796dc-a845-47b3-85ab-6d00a4393a78"
      unitRef="U_USD">59538000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_5c3b09d6-2aa5-41a0-88e4-61bd09a1c7f9"
      unitRef="U_USD">643000</bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_5b010ddf-9443-4e3b-b069-b40a49b0aa67"
      unitRef="U_USD">355000</bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_812b9ad2-293f-4039-b156-ecc4b726fc86"
      unitRef="U_USD">91000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_6e9f4de9-a8db-4951-aa05-9f4f9e486049"
      unitRef="U_USD">269000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_51605d81-8d76-4e44-a850-f1c644f84552"
      unitRef="U_USD">8581000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_25ac86c8-8849-4227-bc64-c4092413320b"
      unitRef="U_USD">10822000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_32f8a71d-90f7-4226-8638-459426b25d4c"
      unitRef="U_USD">10000000</bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable>
    <bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_8be6034d-0a53-45b4-88de-5268a887b411"
      unitRef="U_USD">45102000</bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_a13f6bc4-c2a7-4248-9eb8-8673081ad88e"
      unitRef="U_USD">49000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_4d24f1a3-1421-413f-8921-c07ef64b78f5"
      unitRef="U_USD">28604000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_cb88e442-d1b3-445e-a453-b2c2a57aac47"
      unitRef="U_USD">833000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_f5e21b17-c6bc-4c5c-a208-3abd56c35b2f"
      unitRef="U_USD">3725000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <bdsx:PaymentOfDeferredOfferingCosts
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_b7d50074-d958-4362-80e9-e07749c0aeeb"
      unitRef="U_USD">129000</bdsx:PaymentOfDeferredOfferingCosts>
    <bdsx:PaymentOfEquityFinancingCosts
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_7ddd767c-d538-4a87-98be-977eafee1180"
      unitRef="U_USD">80000</bdsx:PaymentOfEquityFinancingCosts>
    <bdsx:PaymentOfEquityFinancingCosts
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_8320cc41-2adb-40b6-8fc6-ce6e7a48a35a"
      unitRef="U_USD">3069000</bdsx:PaymentOfEquityFinancingCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_39e4d1fc-2410-42ee-9cd5-c5aa308c8c44"
      unitRef="U_USD">-188000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_35f2f6a9-07e5-4687-b92f-1f987f67097e"
      unitRef="U_USD">-33000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_5812018c-ddd4-4ac9-b491-ed959b792b35"
      unitRef="U_USD">29129000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_2ad61eca-5310-4b6b-bffc-23196b4278bb"
      unitRef="U_USD">58882000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_77676be8-8dc4-4f4c-b5e9-89f1cfc6ebf8"
      unitRef="U_USD">-16803000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_77c9bd13-18ed-4773-9c62-aa5fc8b70117"
      unitRef="U_USD">10376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_0554232f-aecd-4fe2-92dd-5ccbc7c3a12e"
      unitRef="U_USD">43174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_762beb25-d2a5-4129-9298-0e23686a893a"
      decimals="-3"
      id="F_7d1be953-a394-46ce-8bc4-c341d33be8d3"
      unitRef="U_USD">32798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_e31781a7-720f-4ee4-a0fd-571988bd4896"
      unitRef="U_USD">26371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_cdbda019-30ad-41f8-8bbb-91ec099e4150"
      unitRef="U_USD">43174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bdsx:CommonStockIssuedForDeferredOfferingCosts
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_bdec6021-3d3d-4d3a-b365-324ad8cb20ab"
      unitRef="U_USD">600000</bdsx:CommonStockIssuedForDeferredOfferingCosts>
    <bdsx:DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_0223a41c-6e2a-438b-980e-6f5bc13c7760"
      unitRef="U_USD">75000</bdsx:DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital>
    <bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_b8743599-2ea2-4b95-bb35-e3cbccca49e8"
      unitRef="U_USD">18000</bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_a19a0653-fc8e-46e7-9ae6-cc5f4365fe15"
      unitRef="U_USD">631000</bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_d19d9cd6-9fbd-4393-80c4-9f9376b3d964"
      unitRef="U_USD">43000</bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_689297c0-8490-4008-944e-55eec7d7c014"
      unitRef="U_USD">160000</bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:IssuanceOfPerceptiveWarrants
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_edaddda6-7ad3-4051-b347-15c8d70be5b2"
      unitRef="U_USD">674000</bdsx:IssuanceOfPerceptiveWarrants>
    <bdsx:IssuanceOfPerceptiveWarrants
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_070e932a-fe3e-4c3f-9617-877fd65c4bdd"
      unitRef="U_USD">3051000</bdsx:IssuanceOfPerceptiveWarrants>
    <bdsx:OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_4f99a153-f470-4234-99b5-bf57ca3e08e8"
      unitRef="U_USD">1269000</bdsx:OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_fb034cb1-eb7d-4075-ab7f-0111ba0a1816"
      unitRef="U_USD">797000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_b5a96e77-d88e-4bef-a006-b17fa25e3358"
      unitRef="U_USD">3936000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_b3da3424-66ae-4947-82a7-f871d1f81694"
      unitRef="U_USD">773000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_7d5aa2be-a146-4f65-9b10-fa5bcdd54095"
      unitRef="U_USD">123000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_ac2b7ca9-a570-4d02-873e-05f7e69e603f"
      unitRef="U_USD">3994000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_5fbd2fd0-d929-447e-bada-757da4cc45b9"
      unitRef="U_USD">1009000</us-gaap:InterestPaidNet>
    <bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_a8f614d8-9e71-48ff-9fc1-7b32ad1fca2e"
      unitRef="U_USD">1335000</bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital>
    <bdsx:PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_42b1fd01-cdd8-4cb0-aa7a-4037a4d21842"
      unitRef="U_USD">793000</bdsx:PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_934946fb-898b-4867-9cfa-2a23702e3cf5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 1 &#x2013; Organization and Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Biodesix, Inc. (the &#x201c;Company&#x201d;, &#x201c;Biodesix&#x201d;, &#x201c;we&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#x2019;s headquarters are in Colorado and the Company performs its blood-based diagnostic tests in its laboratory facilities which are located in Louisville, Colorado and De Soto Kansas. Throughout 2023, the Company leased its headquarters and laboratory facilities in Boulder, Colorado, under a lease agreement that expired in January 2024 and the Company subsequently relocated its corporate headquarters and laboratory facilities to Louisville, Colorado. The Company conducts all of its operations within a single legal entity. Biodesix is a leading diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the use of artificial intelligence enabled informatics. We derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) prior to May 11, 2023, Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other). Biodesix offers five Medicare-covered tests for patients with lung diseases which includes our blood-based Nodify Lung&#xae; Nodule Risk Assessment testing, consisting of the Nodify XL2&#xae; and the Nodify CDT&#xae; tests. These tests evaluate the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Additionally, our blood-based IQLung&#x99; testing strategy for lung cancer patients integrates the GeneStrat&#xae; ddPCR test, the GeneStrat NGS&#xae; test and the VeriStrat&#xae; test to support treatment decisions across all stages of lung cancer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also offered &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; SARS-CoV-2 tests. The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;&#x99;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test were granted Emergency Use Authorization (EUA) by the Federal Drug Administration (FDA). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. In connection with the expiration of the Public Health Emergency declaration under Section 319, the Company no longer provides commercial COVID-19 diagnostic testing services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Blood-Based Lung Tests&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company offers &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; blood-based lung cancer tests across the lung cancer continuum of care:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Diagnosis&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nodify CDT&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nodify&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;XL2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; tests, marketed as Nodify Lung Nodule Risk Assessment testing, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. The Nodify CDT and XL2 tests have an established average turnaround time of one and five business days, respectively, from receipt of the blood sample, providing physicians with timely results to guide diagnostic planning. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We believe we are the only company to offer &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Treatment &amp;amp; Monitoring&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GeneStrat&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ddPCR, GeneStrat NGS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;VeriStrat&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to help guide treatment decisions. The GeneStrat ddPCR tumor genomic profiling test and the VeriStrat immune profiling test have established an average turnaround time of two business days from receipt of the blood sample, and the GeneStrat NGS test has an established average turnaround time of three business days from receipt of the blood sample, providing physicians with timely results to facilitate treatment decisions. The GeneStrat ddPCR test evaluates the presence of actionable mutations in lung cancer. The test is covered independent of stage and can be used multiple times per patient to monitor changes in mutation status. The GeneStrat NGS test is a broad 52 gene panel, including guideline recommended mutations that help identify advanced stage patients eligible for targeted therapy or clinical trial enrollment. The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#x2019;s immune response to their lung cancer.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In developing the Company's products, the Company has built or gained access to regulatory approvals, product development know-how, unique biorepositories, proprietary and patented technologies, specimen collection kit manufacturing capabilities, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#x2019;s testing services are made available through its clinical laboratories.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bdsx:NumberOfSARSCoV2Test
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_53a28f17-5338-42cf-b5ae-93fe84b07d4d"
      unitRef="U_Test">3</bdsx:NumberOfSARSCoV2Test>
    <bdsx:NumberOfCancerTest
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_2e8ebfbc-0bf8-4776-92ea-2d2b56ff92d3"
      unitRef="U_Test">5</bdsx:NumberOfCancerTest>
    <bdsx:NumberOfCommercialBloodBasedTest
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="0"
      id="F_f9159cc9-2840-4a7e-9d74-2f3725fdff0f"
      unitRef="U_Test">2</bdsx:NumberOfCommercialBloodBasedTest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_6fa687f1-e9cf-47f2-a460-c495ab93b55b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets pursuant to the Company's annual impairment analysis; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; fair value of warrant liabilities; leases, including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the estimated incremental borrowing rates&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we maintained cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and we have &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in outstanding aggregate principal amount on our Perceptive Term Loan Facility (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technologies. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our Perceptive Term Loan Facility (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) or to obtain waivers or amendments that impact the related covenants. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default (as defined in the Perceptive Term Loan Facility), causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. The Perceptive Term Loan Facility requires the Company to recognize revenue in amounts agreed to between the Company and Perceptive as of the last day of each fiscal quarter, which commenced with the fiscal quarter ending March 31, 2023. On May 10, 2023 (the First Amendment Effective Date), the Company entered into the First Amendment to the Credit Agreement (the First Amendment), whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold through the twelve month period ended March 31, 2024. On August 4, 2023, the Company entered into a second amendment to the Perceptive Term Loan Facility, whereby subject to the terms and conditions of the second amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the twelve month period ended December 31, 2025 (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and raised approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net proceeds through a private placement equity offering (see Note 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). Subsequent to December 31, 2023, the Company entered into a third amendment to the Perceptive Term Loan Facility, whereby, subject to the terms and conditions of the third amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the fiscal quarter ended December 31, 2025 (see Note 16 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_19d8db26-ae6e-4ab2-b567-298bf67cb775;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#x2019;s revenue and all long-lived assets were derived or located in the United States for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company generates revenues from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other revenue).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diagnostic test revenues consist of blood-based lung tests and are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price and amount to accrue related to its blood-based lung diagnostic test contracts using a portfolio approach by considering:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the nature of the payer and payer coverage;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payment history;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;test type;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the historical amount of time until payment by a payer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;historical price concessions granted to groups of customers;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;whether there is a reimbursement contract between the payer and the Company;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payment as a percentage of agreed upon rate (if applicable);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount paid per test; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;any current developments or changes that could impact reimbursement.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Biopharma Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Customers for these services are typically large biopharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements, and considering factors including, but not limited to: enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from contracts with customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company recognizes revenue for these patients when contracts are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 11 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Direct Costs and Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development &lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For a discussion of credit risk concentration of accounts receivable as of December 31, 2023 and 2022, see Note 11 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card. As of December 31, 2023 and 2022, the Company had&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million restricted cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, which was included in &#x2018;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5b4950ae-8a2a-400a-848c-b12899bcf89d;"&gt;&lt;span style="-sec-ix-hidden:F_9df9a806-ab12-4618-8e6a-94161b6cb0d5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019; in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#x2018;Direct c&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;osts and expenses&#x2019;. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for both years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The Company recorded a reserve for excess inventory of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for both years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, to the statement of operations for excess and obsolete inventory.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_693c0deb-e916-4d0f-82f1-e7179ddec20e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_9b208ef9-2e89-4c6b-beef-d077b508f0ac;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments for th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were immaterial impairments during the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2023, there&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company acts as a lessee under all its lease agreements and holds various real estate leases for its headquarters and laboratory facilities in Colorado and Kansas and other various copier leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company elected the following practical expedients as part of the adoption of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Package of practical expedients which allows the Company to carry forward the historical lease classification;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of right-of-use (ROU) assets;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the fair value of the underlying asset.&#x201d;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional information and disclosures required by this standard are contained in Note 9 &#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million cash refundable deposit to secure the performance of the Company&#x2019;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million refundable deposit is reported within 'Other long-term assets' in the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The three levels of the hierarchy and the related inputs are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:86.1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 4 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recorded as &#x2018;Interest expense&#x2019; in the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of warrant liabilities is assessed at each balance sheet date and changes, if any, to the fair value are recorded as 'Change in fair value of warrant liability, net' in the statement of operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options, if granted, vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 12 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information related to share-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 14 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information related to income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e9a24d59-7f0c-4f1a-a1cd-ad108d76ad60">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets pursuant to the Company's annual impairment analysis; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; fair value of warrant liabilities; leases, including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the estimated incremental borrowing rates&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we maintained cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and we have &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in outstanding aggregate principal amount on our Perceptive Term Loan Facility (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and, prior to May 11, 2023, COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services and licensing our technologies. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our Perceptive Term Loan Facility (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) or to obtain waivers or amendments that impact the related covenants. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on our current operating plan, unless we continue to raise additional capital (debt or equity), we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default (as defined in the Perceptive Term Loan Facility), causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. The Perceptive Term Loan Facility requires the Company to recognize revenue in amounts agreed to between the Company and Perceptive as of the last day of each fiscal quarter, which commenced with the fiscal quarter ending March 31, 2023. On May 10, 2023 (the First Amendment Effective Date), the Company entered into the First Amendment to the Credit Agreement (the First Amendment), whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold through the twelve month period ended March 31, 2024. On August 4, 2023, the Company entered into a second amendment to the Perceptive Term Loan Facility, whereby subject to the terms and conditions of the second amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the twelve month period ended December 31, 2025 (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and raised approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net proceeds through a private placement equity offering (see Note 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). Subsequent to December 31, 2023, the Company entered into a third amendment to the Perceptive Term Loan Facility, whereby, subject to the terms and conditions of the third amendment, the Minimum Net Revenue Covenant was amended to reduce the relevant threshold through the fiscal quarter ended December 31, 2025 (see Note 16 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;</bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d34c69b7-5581-4027-8f30-edb22143832c"
      decimals="-5"
      id="F_00054e17-0b03-49a1-aa99-4c20d5591168"
      unitRef="U_USD">26300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="C_d34c69b7-5581-4027-8f30-edb22143832c"
      decimals="-5"
      id="F_a3f2b90b-db66-4ae6-8726-ce30b449c545"
      unitRef="U_USD">40000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_e0f57e5e-3320-4697-9d41-f219f5580721"
      decimals="-5"
      id="F_61841e5e-88bc-47d4-82cf-694747bc0510"
      unitRef="U_USD">27500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_ce8e68fc-e5d9-46a3-9b48-ce34b24d1aac">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_19d8db26-ae6e-4ab2-b567-298bf67cb775;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#x2019;s revenue and all long-lived assets were derived or located in the United States for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_3b86beba-1ad1-4f47-a2eb-2ec3020b928b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company generates revenues from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other revenue).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diagnostic test revenues consist of blood-based lung tests and are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price and amount to accrue related to its blood-based lung diagnostic test contracts using a portfolio approach by considering:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the nature of the payer and payer coverage;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payment history;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;test type;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the historical amount of time until payment by a payer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;historical price concessions granted to groups of customers;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;whether there is a reimbursement contract between the payer and the Company;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payment as a percentage of agreed upon rate (if applicable);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount paid per test; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;any current developments or changes that could impact reimbursement.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Biopharma Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Customers for these services are typically large biopharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements, and considering factors including, but not limited to: enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from contracts with customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company recognizes revenue for these patients when contracts are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 11 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <bdsx:DirectCostsAndExpensesPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_dbf39877-757a-4332-806c-0d8ab9a90793">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Direct Costs and Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/p&gt;</bdsx:DirectCostsAndExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b9fbaedd-1639-4891-bbf6-e42eebbe76c1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development &lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_5781c26e-4bf3-447a-a6cc-ff7a76cff26b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_44b3b7dd-fcf5-4075-8f1a-b3793e9c7068">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For a discussion of credit risk concentration of accounts receivable as of December 31, 2023 and 2022, see Note 11 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_3ea50ae9-9928-46b7-b62e-dffcfc8db46c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_f65363c0-78d4-43bf-8f66-b032d99ea029">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card. As of December 31, 2023 and 2022, the Company had&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million restricted cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, which was included in &#x2018;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5b4950ae-8a2a-400a-848c-b12899bcf89d;"&gt;&lt;span style="-sec-ix-hidden:F_9df9a806-ab12-4618-8e6a-94161b6cb0d5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019; in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-5"
      id="F_38170f71-283a-4bef-9b1d-9244c5255363"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-5"
      id="F_e650ba05-3e8b-4a5f-ae36-5ad505a2263d"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_4640bf6a-3a03-4d40-8543-e23295b56782">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventorySuppliesPolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_ee11c39a-955c-4449-9e9f-a192e12c4c77">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#x2018;Direct c&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;osts and expenses&#x2019;. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for both years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The Company recorded a reserve for excess inventory of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for both years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, to the statement of operations for excess and obsolete inventory.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventorySuppliesPolicy>
    <us-gaap:OtherInventorySupplies
      contextRef="C_5cc23b54-53b8-41be-ba0d-255e20378a4f"
      decimals="-5"
      id="F_380b1375-6394-4e37-8a18-b126d3debb04"
      unitRef="U_USD">1400000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="C_2c3c29e1-2f9b-4ce8-a3c1-35be4a21e942"
      decimals="-5"
      id="F_06886c5c-4fea-463b-9fd2-84d54592beb9"
      unitRef="U_USD">1400000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryValuationReserves
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-5"
      id="F_7fe510c1-6ccc-47b8-b159-62313ca21979"
      unitRef="U_USD">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-5"
      id="F_c1da150a-e500-48e4-aa6c-04f8156a4cc4"
      unitRef="U_USD">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryWriteDown
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-5"
      id="F_50d95b90-6956-4107-9dee-62318671ac74"
      unitRef="U_USD">200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-5"
      id="F_6770e7b8-5725-48dc-bae5-05a5c8ac7018"
      unitRef="U_USD">900000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_eb922b72-a621-4b88-bb99-ab24d515fc36">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_693c0deb-e916-4d0f-82f1-e7179ddec20e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_9b208ef9-2e89-4c6b-beef-d077b508f0ac;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments for th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="INF"
      id="F_7e50146c-469b-40c1-ae9b-072ddb09861b"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_d1717e6d-77e2-43eb-a4ea-acd84a214394"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_97ae6637-f5de-4108-a416-0e6dcdc44eae">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were immaterial impairments during the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_642aa182-ab63-4cc2-a2bb-672f223f0786"
      id="F_d32b26f3-4763-475b-b891-d05c3bf44a60">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e0254a35-510e-4497-b718-1df6929381e1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2023, there&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_f18d3f95-1107-40cb-897e-0107147a39d4"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_324fee01-49c4-4c6e-8f15-36ea4a714139">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company acts as a lessee under all its lease agreements and holds various real estate leases for its headquarters and laboratory facilities in Colorado and Kansas and other various copier leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company elected the following practical expedients as part of the adoption of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Package of practical expedients which allows the Company to carry forward the historical lease classification;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of right-of-use (ROU) assets;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the fair value of the underlying asset.&#x201d;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional information and disclosures required by this standard are contained in Note 9 &#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_7ea34298-beb1-468b-9648-47213b8647c6"> For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.</us-gaap:LesseeOperatingLeaseDescription>
    <bdsx:OtherAssetsPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_ddf71a23-bfc1-4f3f-ba1a-5b6604bb5751">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million cash refundable deposit to secure the performance of the Company&#x2019;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million refundable deposit is reported within 'Other long-term assets' in the balance sheet.&lt;/span&gt;&lt;/p&gt;</bdsx:OtherAssetsPolicyTextBlock>
    <us-gaap:CustomerFunds
      contextRef="C_234399c4-abaf-4cff-b6b4-cf1365245c8a"
      decimals="-5"
      id="F_1519dc09-c555-481c-a1ed-b460c0610bf1"
      unitRef="U_USD">5000000</us-gaap:CustomerFunds>
    <us-gaap:CustomerFunds
      contextRef="C_234399c4-abaf-4cff-b6b4-cf1365245c8a"
      decimals="-5"
      id="F_47d4a73c-1680-41ba-a310-7f12dfc33838"
      unitRef="U_USD">5000000</us-gaap:CustomerFunds>
    <us-gaap:CustomerFunds
      contextRef="C_7ec35fb1-0374-47a3-b8d9-e1479123e997"
      decimals="-5"
      id="F_471af43f-3e87-4621-8b79-43a20c2053c6"
      unitRef="U_USD">5000000</us-gaap:CustomerFunds>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_3b85c163-268e-4431-9853-0d52bb8967cb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The three levels of the hierarchy and the related inputs are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:86.1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 4 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bdsx:ContingentConsiderationPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_c7bde607-595d-4d29-a4cc-da70d35bdbbe">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recorded as &#x2018;Interest expense&#x2019; in the statements of operations.&lt;/span&gt;&lt;/p&gt;</bdsx:ContingentConsiderationPolicyTextBlock>
    <bdsx:WarrantLiabilityPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_56c1c404-2040-453a-984b-7e34bd6c45ea">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of warrant liabilities is assessed at each balance sheet date and changes, if any, to the fair value are recorded as 'Change in fair value of warrant liability, net' in the statement of operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</bdsx:WarrantLiabilityPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_5daffc79-3399-456c-b869-4fe25e48096f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options, if granted, vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 12 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information related to share-based compensation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_7fba7876-731f-44d5-8fb1-9dfb8cc86246">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 14 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information related to income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0a4330dd-71d0-40a3-a63c-a2ab01b1a925">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_67aaf853-a65a-41ed-8455-cc5cfb9fb22b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_3506de10-2560-4880-a13a-e37e65a434a0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 3 &#x2013; Recent Issued Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for the Company beginning January 1, 2023. The Company evaluated the guidance and determined the overall impact of the adoption had an immaterial impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Standards being evaluated&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting: Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC Topic 280). This ASU requires all public entities to provide additional disclosures about the entity's reportable segments and more detailed information about a reportable segment's expenses. This guidance will become effective for the Company beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. This ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid by jurisdiction. This guidance will become effective for the Company beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_ea680e74-88e0-44ca-9266-009d2a88efcf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for the Company beginning January 1, 2023. The Company evaluated the guidance and determined the overall impact of the adoption had an immaterial impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Standards being evaluated&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting: Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC Topic 280). This ASU requires all public entities to provide additional disclosures about the entity's reportable segments and more detailed information about a reportable segment's expenses. This guidance will become effective for the Company beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. This ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid by jurisdiction. This guidance will become effective for the Company beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_1c18c8a3-447e-409c-97c1-7d4b5a9e261e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 4 - Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair value of borrowings as of December 31, 2023 and 2022 is primarily associated with the Perceptive Term Loan Facility entered into with Perceptive Credit Holdings IV, LP, in November 2022 and was determined using a discounted cash flow analysis, excluding the fair value of the Perceptive Warrant (as defined below) issued in conjunction with the transaction. The carrying value of outstanding borrowings approximates the fair value as of December 31, 2023. The difference between the carrying value and fair value of outstanding borrowings as of December 31, 2022 is due to the debt issuance costs and the fair value of the Perceptive Warrant netted against the Perceptive Term Loan Facility. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.739%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.885%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.404%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.204%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi and the warrant liabilities granted as consideration for the Perceptive Term Loan Facility (see Note 8 - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;), which were accounted for as liabilities and remeasured through our statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below presents the reported fair values of contingent consideration and warrant liabilities,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.412%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.924%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#160;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the changes in contingent consideration &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and warrant liabilities for the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.687%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.537%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.977%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss on extinguishment of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reclassification of Tranche B Warrants to additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance - December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; gross margin target of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period after the acquisition date, which was achieved during the three months ended June 30, 2021. Under the terms of the original agreement, when the gross margin target was achieved the Company was required to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,520,108&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;eight&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; equal quarterly installments. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; equal and consecutive quarterly cash installments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; mi&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4a3ac985-50cc-430f-afc9-a367fa948051;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ll&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ion.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2021, the Company entered into an amendment to the original agreement in which all parties agreed to forgo the issuance of common stock and agreed that the Company would, in lieu thereof, make &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; quarterly installments of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million each beginning in January 2022 and a final payment of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in July 2023 for a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA, in which the parties agreed to restructure the Milestone Payments. The Company made &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; quarterly installments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million each beginning in April 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; quarterly installments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which began in July 2023, will make &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; installment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in April 2024, and will make &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; installment of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in July 2024. In addition, the Company agreed to an exit fee of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, with such interest to be payable quarterly on the following installment payment date. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan Facility. We obtained consent from Perceptive and subsequently paid the contractual Milestone Payment due January 1, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. As a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate could result in a significantly higher or lower fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the years ended December 31, 2023 and 2022, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, r&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;espectively, in interest expense due to the passage of time and fixed payment schedule.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with ASC 230, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Statement of Cash Flows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) should be reflected as a cash outflow for financing activities while the remaining portion of the amount paid should be reflected as a cash outflow from operating activities in the statement of cash flows. A portion of the October 2023 and all 2024 Milestone Payments are classified as cash outflows from operating activities in the Company's statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;), the Company issued Perceptive a warrant to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the Company's common stock (the Perceptive Warrant), including Initial Warrants and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants (as defined in Note 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; below). The Initial Warrants and First Amendment Warrants are equity classified (see Note 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) while the Tranche B and C Warrants were initially classified as liabilities within 'Other short-term liabilities' and recognized at fair value. The fair value of the Tranche B and C Warrants is determined using a Black-Scholes model and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the fair value of the Company's common stock, risk-free rate, the volatility of common stock, and the probability of the expected borrowing. Significant increases or decreases in the unobservable inputs could result in a significantly higher or lower fair value measurement. During the year ended December 31, 2023, the Company recorded a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; loss as a change in fair value through the statement of operations due to changes in unobservable inputs. This is a result of changes in the probability of our ability to draw on Tranche B and C loans. During the year ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as a change in fair value through the statement of operations due to changes in unobservable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital (see Note 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_16fde6e0-4ddf-4e69-b5ed-6c477b46ee9b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.739%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.885%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.404%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.204%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_c78507c9-28f4-4078-b9c2-60788d6de761"
      decimals="-3"
      id="F_8c9c7e7f-16f5-4fc5-9004-e415da65d261"
      unitRef="U_USD">35276000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_56c9ae72-9e34-4992-b029-01bdfc7ad040"
      decimals="-3"
      id="F_263fa273-e34d-413b-8e4d-419f0d6c59fa"
      unitRef="U_USD">35506000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_9caae3bf-4fbb-41ab-a4e1-b00953245f32"
      decimals="-3"
      id="F_c88fcc2e-772e-4b79-b16e-781ddb116801"
      unitRef="U_USD">25053000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_944a3fdd-0063-430b-812d-8df10d978153"
      decimals="-3"
      id="F_83cd0e95-afee-486c-a2ca-179934a06b5b"
      unitRef="U_USD">26785000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b8d6416c-8a70-46f0-91d1-b17648bb0814">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below presents the reported fair values of contingent consideration and warrant liabilities,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.412%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.924%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#160;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_32deb686-8097-4424-ac3a-cb9f560483da"
      decimals="-3"
      id="F_f6502c32-0b59-42fb-a9e6-ae4822623fa5"
      unitRef="U_USD">21857000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_e530c247-1fb1-40c9-a68a-591017a52ecf"
      decimals="-3"
      id="F_753a3291-50ff-49c6-a03d-0b18a89260a8"
      unitRef="U_USD">10341000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_fb7558dc-7e0e-47e9-be24-11751dfeab98"
      decimals="-3"
      id="F_49b4d682-0e44-4c7e-87f2-ab04ecd5011d"
      unitRef="U_USD">18645000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_f5c7a2fb-eba1-497c-b9c5-a66efa1ceb59"
      decimals="-3"
      id="F_84594212-6cbc-4787-b4ed-4cb96eb3e3eb"
      unitRef="U_USD">21857000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_35044628-f95d-4526-999c-ceb308c83552"
      decimals="-3"
      id="F_79807f5c-bf13-4e11-8606-f7c5168a4c42"
      unitRef="U_USD">28986000</us-gaap:LiabilitiesFairValueDisclosure>
    <bdsx:WarrantLiabilitiesFairValueDisclosure
      contextRef="C_35044628-f95d-4526-999c-ceb308c83552"
      decimals="-3"
      id="F_d1c2e5df-6c5f-4f50-ae23-175e9a1e180e"
      unitRef="U_USD">61000</bdsx:WarrantLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0a2cbe07-8db4-4a6b-bda0-4afe1014f7a2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the changes in contingent consideration &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and warrant liabilities for the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.687%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.537%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.977%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss on extinguishment of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reclassification of Tranche B Warrants to additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance - December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a8c71793-b3d7-4472-9294-cc317e43c263"
      decimals="-3"
      id="F_74482ff4-ad58-4e1d-a98d-260685c44321"
      unitRef="U_USD">33792000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_f5347cdc-ebae-4937-a95c-7a2fb92191f3"
      decimals="-3"
      id="F_45549ac0-ca56-4dca-b3e2-94031e8911ba"
      unitRef="U_USD">145000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_f5347cdc-ebae-4937-a95c-7a2fb92191f3"
      decimals="-3"
      id="F_27e0c921-d1c5-45db-b52d-bdf119096115"
      unitRef="U_USD">-84000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense
      contextRef="C_75b2228d-4f1c-40ab-9389-611290f07a73"
      decimals="-3"
      id="F_6bc4ca10-d3c8-46d5-926d-a852ba3e7f02"
      unitRef="U_USD">3082000</bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_75b2228d-4f1c-40ab-9389-611290f07a73"
      decimals="-3"
      id="F_2503d335-d695-4fa4-ac0a-45d99f7195e4"
      unitRef="U_USD">-2934000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration
      contextRef="C_75b2228d-4f1c-40ab-9389-611290f07a73"
      decimals="-3"
      id="F_e689fce5-a6c5-477b-892c-c845dd89f771"
      unitRef="U_USD">10822000</bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_fb7558dc-7e0e-47e9-be24-11751dfeab98"
      decimals="-3"
      id="F_a56d07e2-b9ac-45c2-9fc6-6f034e986b8b"
      unitRef="U_USD">28986000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_cf25d082-7144-45c9-82a7-485c56547da3"
      decimals="-3"
      id="F_3723ce93-4e28-4a82-bb47-7472f0755885"
      unitRef="U_USD">61000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_e4c92134-cf3d-4b48-a86a-aff01ba5002e"
      decimals="-3"
      id="F_8e6c823f-14c9-45a2-b876-171b6dbfda5d"
      unitRef="U_USD">1274000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense
      contextRef="C_94dfe6a6-75a6-4855-8b8a-25382e1bcc1d"
      decimals="-3"
      id="F_ff3c9b1d-4a5f-4f0e-8aa1-b2326c22cbe3"
      unitRef="U_USD">3946000</bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense>
    <bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration
      contextRef="C_94dfe6a6-75a6-4855-8b8a-25382e1bcc1d"
      decimals="-3"
      id="F_8efcdf93-5750-496b-ab1a-6dd63d677044"
      unitRef="U_USD">11075000</bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="C_b8e10b10-ed99-44ce-9379-a3351b13b1d3"
      decimals="-3"
      id="F_f3a3edd7-9ef1-4034-89f6-0fc526497f41"
      unitRef="U_USD">-1335000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_7d7940c5-ed73-407d-b4e5-5389b5b92763"
      decimals="-3"
      id="F_d5063d56-217d-4cdf-841c-b847cf705d25"
      unitRef="U_USD">21857000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_e811ab96-e279-4509-9656-8567a594d9e7"
      id="F_a07cfc94-0ccc-4c7f-885b-b160bb5df6e0">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_d48cbf14-8cb6-4e55-8fec-7e43385ec4b8"
      decimals="-5"
      id="F_a26c2d42-dacb-423f-8dc6-d36a6867444f"
      unitRef="U_USD">2000000</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_d48cbf14-8cb6-4e55-8fec-7e43385ec4b8"
      id="F_2de32df4-d361-4ba9-8539-af9f1184678f">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:BusinessCombinationContingentConsiderationShares
      contextRef="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5"
      decimals="0"
      id="F_d3e194ca-0f16-45e7-ad8d-457fc3546f64"
      unitRef="U_shares">2520108</bdsx:BusinessCombinationContingentConsiderationShares>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5"
      decimals="-5"
      id="F_c00809c5-a3fd-4f9d-b5f2-bcab65c880ec"
      unitRef="U_USD">37000000</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_1c0d6b7f-113f-45cf-8621-8ade2e3145cb"
      decimals="INF"
      id="F_06ece330-cf19-4cf3-a184-fb5240f51804"
      unitRef="U_Installment">8</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_42326201-3aba-4a78-8961-e432c28f468d"
      id="F_20dcdfd6-cf94-430b-99ce-d3610fd1c08f">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_3f300fdd-ce4b-4d8a-b6e0-51a7c1714a99"
      decimals="INF"
      id="F_98b1b48d-7ba8-4e4d-8be1-7ecdd696f3ab"
      unitRef="U_Installment">2</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_2c4d07e7-9000-4f06-b7e8-24c8e90121a5"
      decimals="-5"
      id="F_1f4ead9b-8744-4632-8247-75de225acc73"
      unitRef="U_USD">37000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_62ca78ec-9f39-4920-83f6-28d44aeb971e"
      decimals="INF"
      id="F_2837cdd6-044d-4ebd-8e0a-df77db1b8d12"
      unitRef="U_Installment">6</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_25e96d73-e3b0-4a75-a22b-6a05aced6c60"
      decimals="-5"
      id="F_52cd1025-9b9f-4e01-9e24-28914f4d4386"
      unitRef="U_USD">4600000</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_c37573b7-4513-43c3-9695-25908f198e7a"
      decimals="-5"
      id="F_59795ede-bd7f-4d84-b52d-c65f29e2c7de"
      unitRef="U_USD">9300000</us-gaap:RepaymentsOfDebt>
    <bdsx:BusinessCombinationContingentConsiderationFinalPayment
      contextRef="C_c37573b7-4513-43c3-9695-25908f198e7a"
      decimals="-5"
      id="F_d6b94559-ab9a-4f7e-bb5d-a150d266c897"
      unitRef="U_USD">37000000</bdsx:BusinessCombinationContingentConsiderationFinalPayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_c3fb17ed-8bf4-45c6-95cf-234368989352"
      decimals="INF"
      id="F_d7e32268-e7bb-409c-bf33-97f26167a512"
      unitRef="U_Installment">5</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_7d3ecb2f-0211-4617-a06a-2d4546f0e40f"
      decimals="-5"
      id="F_ee07eb25-32a1-4b99-8f14-549f4d60f6a7"
      unitRef="U_USD">2000000</bdsx:MilestonePayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_da96c3b7-099a-40dd-9b01-f364329a97fd"
      decimals="INF"
      id="F_8774fd1c-8a59-411c-a2f6-2993340e4a59"
      unitRef="U_Installment">3</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_f0a3cf0a-87dc-4d4e-85f5-ae4fff2592a5"
      decimals="-5"
      id="F_6fd5f731-0e3c-44df-8fa9-edf966e8885e"
      unitRef="U_USD">3000000</bdsx:MilestonePayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_b77a60af-bc6d-4b65-8356-5aad89c73994"
      decimals="INF"
      id="F_1bb6f28a-b0da-4b66-999b-d73ae68ebe6e"
      unitRef="U_Installment">1</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_a4f1f778-0ed2-4f8c-a95b-459652dcae55"
      decimals="-5"
      id="F_20101343-56a4-465f-a7ac-224c1f11bad0"
      unitRef="U_USD">5000000</bdsx:MilestonePayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_ef3c2187-563e-494f-893c-b00f9a7afdcc"
      decimals="INF"
      id="F_f6181fd5-6664-470c-bdad-cca56be5027b"
      unitRef="U_Installment">1</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_da03390b-83f8-418c-9f18-c9c25626feb4"
      decimals="-5"
      id="F_afccc2cc-c34f-4ef0-a19b-2a297c9603fa"
      unitRef="U_USD">8400000</bdsx:MilestonePayment>
    <bdsx:ExitFeePayment
      contextRef="C_5009b344-d4d5-4e3f-897a-d9f8b21265c3"
      decimals="-5"
      id="F_7905576d-5689-4fb1-baa8-a9efd428afd0"
      unitRef="U_USD">6100000</bdsx:ExitFeePayment>
    <bdsx:PercentageOfInterestOnContingentConsideration
      contextRef="C_240c8f68-bf9d-46de-aa49-fa8df526c0a5"
      decimals="2"
      id="F_d21dae54-c0ae-4f3d-84a9-79b7dd2ba7ab"
      unitRef="U_pure">0.10</bdsx:PercentageOfInterestOnContingentConsideration>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_ccdfd811-c49b-4466-bf12-ded5e7a5e155"
      decimals="2"
      id="F_3d739cfe-f5a7-432e-9c78-16ed468ffaa6"
      unitRef="U_pure">0.11</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_980bcbe0-d568-4e08-a672-b071c73a3261"
      decimals="2"
      id="F_34fd0fc3-a0a3-4429-be5a-b3cf31feb2b3"
      unitRef="U_pure">0.16</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
      contextRef="C_4270ff6e-22b1-452e-a4a6-a180a3e2a6f8"
      decimals="-5"
      id="F_3ed81067-3bfb-4bc2-87b5-6463dcac4943"
      unitRef="U_USD">3900000</bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule>
    <bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
      contextRef="C_bc5a7859-ac48-440b-b875-07120eb3a782"
      decimals="-5"
      id="F_ac2d3921-81b1-41ad-8b1c-6f5be6cc32c8"
      unitRef="U_USD">3100000</bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_75eae973-2f26-420e-8dcd-287d48f37677"
      decimals="INF"
      id="F_47ceafdd-3201-42a7-b982-4cabda038885"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_c7c3261f-f9bd-43a8-901f-c9c1d238ad41"
      decimals="-5"
      id="F_be45a9fc-f343-4b71-a0b3-90cf473b08f4"
      unitRef="U_USD">-1300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_4d399ad7-37d8-4601-9860-f4ed0a5dd125"
      decimals="-5"
      id="F_c635f6ea-1a64-460e-9c68-252882d1db64"
      unitRef="U_USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e61d44f9-77d2-417c-99a3-2652645aa47f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 5 &#x2013; Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense related to pr&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;operty and equipment was:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_a58affdb-6a9a-430e-8e7e-b07188411254">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ef8c27b1-4741-4250-99d6-cf03e3702f8f"
      decimals="-3"
      id="F_318dea6d-3288-402d-957a-3184f3166b88"
      unitRef="U_USD">6089000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d5a6062-37b8-4fa8-a4da-c6e14c894954"
      decimals="-3"
      id="F_f1892a8d-8e3b-4a7c-a114-4c8fd4d7db72"
      unitRef="U_USD">6035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9312e759-444e-4716-9451-2b8b8320f87e"
      decimals="-3"
      id="F_f820c3f7-0a8b-4d6f-9332-1a53882af850"
      unitRef="U_USD">24713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e27675e3-4b86-41b3-82b6-66aeb3068eb6"
      decimals="-3"
      id="F_f4835e64-9223-40ec-8356-ced315613d00"
      unitRef="U_USD">2365000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ecb41f0c-f59d-45ea-a050-526c1d52cf1c"
      decimals="-3"
      id="F_c3112677-90cb-4e3c-9937-79dcd9d1fa34"
      unitRef="U_USD">1221000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b8740db4-2867-4e82-a5dd-07d9793a7524"
      decimals="-3"
      id="F_77403a46-2d28-4ea5-bd92-6aecef12d891"
      unitRef="U_USD">749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_101bd2f5-f908-4988-9b9f-58f2c06e0547"
      decimals="-3"
      id="F_29d7e663-83dd-4e2a-8735-1de4165b16b7"
      unitRef="U_USD">1034000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_baaedbd4-6935-478d-9fd7-ed5496a4e509"
      decimals="-3"
      id="F_a8b2e0ba-4f2a-4de0-ac3e-826762334193"
      unitRef="U_USD">349000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_286d0721-729c-4546-81b4-7c2234ec5f19"
      decimals="-3"
      id="F_1030de9b-9fab-481b-a383-1798895673ac"
      unitRef="U_USD">325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a6b84852-36d5-4f3d-bb6a-b0b710f9dd00"
      decimals="-3"
      id="F_b8315e10-e891-41a6-bc27-e8a89819eead"
      unitRef="U_USD">324000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fdff4690-cd03-400e-9532-0ec16ccf2ac4"
      decimals="-3"
      id="F_558f66fd-9fc1-4017-8fd7-2893cc78088e"
      unitRef="U_USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_30e47baf-60a9-4e0a-aa84-25a0a6d4d64d"
      decimals="-3"
      id="F_2aee2fdf-cea1-4121-90c1-f8756d89b8ff"
      unitRef="U_USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_51c21cd5-9bbf-406e-95cd-7db5c3f7f76f"
      decimals="-3"
      id="F_ec3a759b-aba7-46cf-b891-3abafc25bfb1"
      unitRef="U_USD">2947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_55c13f7c-fcb7-421f-b3e0-b39b39b24c1e"
      unitRef="U_USD">33479000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_fedfa77d-ea40-4df5-9206-6b387f50270c"
      unitRef="U_USD">12866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_6a5cf9ea-da91-4c5a-9d0d-05229cc19e53"
      unitRef="U_USD">5612000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_77527404-b556-42b2-b726-f7bc8ff82e26"
      unitRef="U_USD">7018000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_a941af18-61e7-4931-92df-27bfc9a21efe"
      unitRef="U_USD">27867000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_acfbd072-d474-4638-9c5d-1d0fb0f8bc87"
      unitRef="U_USD">5848000</us-gaap:PropertyPlantAndEquipmentNet>
    <bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_9f365155-7527-4353-a1d0-30901bcaf2a0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense related to pr&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;operty and equipment was:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock>
    <us-gaap:Depreciation
      contextRef="C_c470b55e-4817-47fd-b1a2-60ddf9f1e696"
      decimals="-3"
      id="F_f0da5be5-5c2d-4402-92b5-b71d451cd773"
      unitRef="U_USD">460000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_de229b36-03e8-4ba3-9d97-4bb97a183372"
      decimals="-3"
      id="F_526bbd8a-e97b-416a-8112-f4e4a72987b4"
      unitRef="U_USD">591000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_e8071c03-dc27-49ba-8d1a-dda3eae00a0a"
      decimals="-3"
      id="F_ec7ec489-18e3-48cb-af2b-c68311581cc3"
      unitRef="U_USD">885000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_937cac9a-b5f5-41ce-8603-758663d5645c"
      decimals="-3"
      id="F_a378406d-deea-4756-bd59-50c488e010d1"
      unitRef="U_USD">1031000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_4348c38b-37a4-4aad-80bf-51c279e91cbe"
      decimals="-3"
      id="F_d9fac1b0-384f-4600-9ad9-f663ff120a09"
      unitRef="U_USD">1345000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_32ca7091-08cb-42b8-a3c3-0e36d7da15be"
      decimals="-3"
      id="F_e133004d-2937-4d63-be78-c5dc2c9cd766"
      unitRef="U_USD">1622000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_8b396b91-5a3f-4a68-b6cd-dbf5a51e3f62">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 6 &#x2013; Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets, excluding goodwill, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.195%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.824%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets subject to amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchased technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets not subject to&lt;br/&gt;&#160;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trademarks&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.613%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.723%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.023%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future estimated amortization expense of intangible &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;assets is (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.784%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.476%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_3eba6ae4-63f1-47ee-9693-a95370106c32">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets, excluding goodwill, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.195%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.824%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets subject to amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchased technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets not subject to&lt;br/&gt;&#160;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trademarks&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d"
      decimals="-3"
      id="F_903cdff0-f390-4ef1-b4f5-6b6d6ef19331"
      unitRef="U_USD">1975000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d"
      decimals="-3"
      id="F_31dbf65c-2cac-4f29-a3c9-2ed3d80fd160"
      unitRef="U_USD">752000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_ae33ae01-4e5a-4b40-bd86-324ce7a2286d"
      decimals="-3"
      id="F_8f593437-ee6a-4068-a735-de62b7c8e5ce"
      unitRef="U_USD">1223000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_1f022e96-f9de-4099-becb-8ed34b6193c3"
      decimals="-3"
      id="F_ba7d8107-b3fe-426a-b9c1-d09ef0e55da9"
      unitRef="U_USD">1880000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_1f022e96-f9de-4099-becb-8ed34b6193c3"
      decimals="-3"
      id="F_e36ced89-134c-44da-bcea-6df1db28c4b2"
      unitRef="U_USD">647000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_1f022e96-f9de-4099-becb-8ed34b6193c3"
      decimals="-3"
      id="F_b10eb91a-7445-4acd-a4a6-41a8f3f1249e"
      unitRef="U_USD">1233000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20959b72-6f50-4526-8ce1-58ad102071d0"
      decimals="-3"
      id="F_fcde596e-fb5a-4b73-bfbd-5c95a1f92278"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20959b72-6f50-4526-8ce1-58ad102071d0"
      decimals="-3"
      id="F_fa28b917-b260-4618-b8f6-eb09de524b30"
      unitRef="U_USD">10328000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_20959b72-6f50-4526-8ce1-58ad102071d0"
      decimals="-3"
      id="F_4e2d9b54-3714-41fa-937c-0724342a63b8"
      unitRef="U_USD">6572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_01111575-2dc6-44fe-bdc7-2295733d2ca3"
      decimals="-3"
      id="F_8f501e89-51b6-4d52-ae7d-213e3d035649"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_01111575-2dc6-44fe-bdc7-2295733d2ca3"
      decimals="-3"
      id="F_dbfe89be-20a7-4bee-a17e-a67dc6b09647"
      unitRef="U_USD">8450000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_01111575-2dc6-44fe-bdc7-2295733d2ca3"
      decimals="-3"
      id="F_20d8feab-9dcc-41b2-af15-af012bc0ad69"
      unitRef="U_USD">8450000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_118e49be-c761-4dd8-a46b-5ab677d5c06f"
      decimals="-3"
      id="F_db184ade-e487-419f-8bd8-f1f0772b2bbb"
      unitRef="U_USD">116000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_118e49be-c761-4dd8-a46b-5ab677d5c06f"
      decimals="-3"
      id="F_4803f4e5-12d2-4631-b098-e7f1ecacb949"
      unitRef="U_USD">116000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_820acf83-d376-4b0f-8f41-f85aedc1f651"
      decimals="-3"
      id="F_d7011a18-4026-41a6-8109-05102fa086f9"
      unitRef="U_USD">114000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_820acf83-d376-4b0f-8f41-f85aedc1f651"
      decimals="-3"
      id="F_f29be6f4-130d-4bed-acbb-03b5717f452d"
      unitRef="U_USD">114000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_93e115ac-2e01-4fab-9faa-c32109b30635"
      unitRef="U_USD">18991000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_2c2b92ee-cfe1-4ef5-83c3-d8223fd1a80a"
      unitRef="U_USD">11080000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_fc9c963f-9a1c-4da0-a567-b846fadfd7bd"
      unitRef="U_USD">7911000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_aac16d4b-0b26-470b-b89b-3d65d56c6f33"
      unitRef="U_USD">18894000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_af930c4f-4140-4bb6-a097-aef0355c2dbb"
      unitRef="U_USD">9097000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_0af753f0-bac9-41dc-954e-b2de417d6bed"
      unitRef="U_USD">9797000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_81bcb83f-586e-4bb0-a8e2-edb5a289e164">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.613%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.723%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.023%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_3a255c06-b8fd-42be-a476-41c0489c1cce"
      decimals="-3"
      id="F_3f62a854-f3d0-4cf5-b38b-8fa903a74b86"
      unitRef="U_USD">2000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_dbc0f234-0a0a-4688-a7d0-ab581da9ada6"
      decimals="-3"
      id="F_684043a2-14ff-4879-bc05-48d62b4743c1"
      unitRef="U_USD">2000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_bced1c1d-85b9-42ae-8100-73aca910ab35"
      decimals="-3"
      id="F_566a44ce-6460-4923-a603-1f6193b2e4c3"
      unitRef="U_USD">1981000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_78dba0fb-71f8-42e4-a64b-0fd12fbe76a6"
      decimals="-3"
      id="F_6a1aab1b-d251-4c17-8455-149fe53afdaa"
      unitRef="U_USD">1973000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_3fba15ab-9f38-4cef-a61a-465290dc4435"
      unitRef="U_USD">1983000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_17339b98-b697-4ba4-887f-112186c22bac"
      unitRef="U_USD">1975000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_1ee70be9-083a-4ec2-ab94-70dca2999c3c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future estimated amortization expense of intangible &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;assets is (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.784%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.476%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_987dbab1-4a23-4319-8334-d61e6a1f4fba"
      unitRef="U_USD">1978000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_5abb2d66-2d72-4f2e-8f46-d50741cbf732"
      unitRef="U_USD">1972000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_71270a33-98e9-4bdf-89e0-86a6331fcfbe"
      unitRef="U_USD">1959000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_13fadfce-2d56-4afb-97e8-1f95210fbb9d"
      unitRef="U_USD">1007000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_4cbf82d0-1471-4b93-8df1-6d64e171dceb"
      unitRef="U_USD">59000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_1fd8c05a-6876-4a1a-881b-ad3e935769fe"
      unitRef="U_USD">820000</bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_89657b96-12bc-4d31-8c66-0713ff6c00a1"
      unitRef="U_USD">7795000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_c3eb5183-13e4-4518-8696-5493877960b5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 7 &#x2013; Accrued Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.713%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical trial expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0d798553-bbb5-4f1d-a749-0ca9ba8a2fde">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.713%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical trial expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_1532389c-4f5a-4b80-a692-8a90b628a398"
      unitRef="U_USD">3855000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_28499113-732d-4cb3-b3f0-2610d801bd44"
      unitRef="U_USD">4671000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_d81bb4de-59c1-402b-a795-3b51414194b9"
      unitRef="U_USD">983000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_618a4588-b6d3-476b-ab99-4c114eef5a94"
      unitRef="U_USD">1232000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_b488e144-80ed-4dbf-991f-b40edad5670a"
      unitRef="U_USD">2872000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_ddf7d7f2-6bc7-4172-9c0f-c6cef0de129e"
      unitRef="U_USD">2315000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_e3a1fe5c-48af-4a8b-9419-13c7292edf52"
      unitRef="U_USD">7710000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_11e1f4e4-ef19-40fa-beed-d40c2e35abf7"
      unitRef="U_USD">8218000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_7eca4939-c476-49dc-a951-9ed2ccfcf854">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 8 &#x2013; Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our long-term debt primarily consists of notes payable associated with our Perceptive Term Loan Facility which is described in further detail below. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-term notes payable were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.360000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Perceptive Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Perceptive Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the Perceptive Term Loan Facility). The Tranche A Loan, in an aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the Tranche A Loan), was funded under the Perceptive Term Loan Facility on November 21, 2022 (the Funding Date). The Company's net proceeds from the Tranche A Loan were approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;debt issuance costs and expenses. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and an additional Tranche C Loan, in an aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which are accessible by the Company so long as the Company satisfies certain customary conditions precedent, including revenue milestones. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 15, 2023, the Company exercised its ability to draw the Tranche B loan for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Tranche C loan has a loan commitment date through September 30, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Perceptive Term Loan Facility has a maturity date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the Maturity Date) and provides for an interest-only period during the term of the loan with principal due at the Maturity Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum, plus an applicable margin of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the stated interest rate was approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Amortization and Prepayment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On the Maturity Date, the Company is required to pay the Lender the aggregate outstanding principal amount underlying the Perceptive Term Loan Facility and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Security Instruments and Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to a Security Agreement, dated as of the Funding Date (the Security Agreement), between the Company and the Lender, substantially all of the Company&#x2019;s obligations under the Credit Agreement are secured by a first lien perfected security interest on all of the Company&#x2019;s assets, subject to customary exceptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As consideration for the Credit Agreement, the Company has issued, on the Funding Date, the Perceptive Warrant of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, including the Initial Warrants which are equity classified at a per share exercise price equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0648&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which is equal to the 10-day volume weighted average price (VWAP) of the Company&#x2019;s common stock, on the business day immediately prior to the Closing Date of the Tranche A Loan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with the Tranche B borrowing, additional warrants became exercisable into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with a per share exercise price equal t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;o $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0648&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which is equal to the Initial Warrant exercise price (the Tranche B Warrants) and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 15, 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the Initial and Tranche B Warrants, additional warrants will become exercisable into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock concurrently with the borrowing date of the Tranche C Loan (the Tranche C Warrants). The per share exercise price for the Tranche C Warrants will be equal to the lower of (A) the Initial Warrant exercise price or (B) the 10-day VWAP ending on the business day immediately preceding the funding date of the Tranche C loan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Each warrant will be exercisable, in whole or in part, until the 10th anniversary of the date of issuance. If the Tranche C loan is not drawn by the loan commitment date, the associated Tranche C Warrants expire and will not become exercisable. The Company accounts for the Tranche C Warrants as liabilities as the Tranche C Warrants do not meet the criteria for equity treatment (see Note 4 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Representations, Warranties, Covenants, and Events of Default&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting and notice requirements, maintain insurance and maintain in full force and effect all Regulatory Approvals, Material Agreements, Material Intellectual Property (each as defined in the Credit Agreement) and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the Company&#x2019;s business. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s business activities; make certain Investments or Restricted Payments (each as defined in the Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that has the impact of restricting the Company&#x2019;s ability to make loan repayments under the Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million; and (ii) as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2023, recognize revenue in amounts agreed to between the Company and Perceptive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 10, 2023, the Company entered into the First Amendment with the Lender, whereby subject to the terms and conditions of the First Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold of each fiscal quarter commencing on the fiscal quarter ending June 30, 2023 through and including the fiscal quarter ending March 31, 2024. As consideration for the First Amendment, the Company agreed to issue to Perceptive a warrant to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (the First Amendment Warrants) which are equity classified at a per share exercise price equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6254&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (see Note 10 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 4, 2023 (the Second Amendment Effective Date), the Company entered into the Second Amendment to the Credit Agreement and Guaranty (the Second Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby subject to the terms and conditions of the Second Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending June 30, 2024 through and including the fiscal quarter ending December 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Second Amendment, the conditions precedent for drawing on the Tranche B Loan were amended to (i) reduce the trailing-twelve month revenue milestone and (ii) add the receipt of aggregate cash proceeds of at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from an equity offering of the Company's common stock. During the three months ended September 30, 2023, the Company met the amended trailing-twelve month revenue milestone associated with the Tranche B Loan. On August 3, 2023, the Company entered into subscription agreements for the issuance and sale by the Company of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,975,298&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the Company&#x2019;s common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. During the three months ended September 30, 2023, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in proceeds and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,454,927&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock pursuant to the Subscription Agreements. On September 27, 2023, the Company entered into an amendment to delay final closing on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; subscription agreement. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in proceeds were received and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,520,371&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued during the three months ended December 31, 2023 (see Note 10 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Credit Agreement also contains certain customary Events of Default which include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross- defaults to material contracts, certain regulatory-related events and events constituting a change of control. As of December 31, 2023, the Company was in compliance with all restrictive covenants associated with its borrowing and entered into a limited waiver on February 14, 2024 to the Perceptive Term Loan Facility (the Limited Waiver). Subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit. The occurrence of an Event of Default could result in, among other things, the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility are immediately due and payable in whole or in part.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Initial Warrants and Additional Warrants were valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, using the Black-Scholes option-pricing model, estimated settlement probabilities and estimated exercise prices. As a result of the fees paid to Perceptive and the value of the Perceptive Warrant, the Company recognized a discount on the Perceptive Term Loan in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The First Amendment Warrants were valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using the Black-Scholes option-pricing model which the recognized as a discount on the Perceptive Term Loan Facility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company recorded the debt discount as a reduction to the principal amount of the debt and is amortized as interest expense over the life of the debt.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b3d144f7-dd8d-4305-93b8-815438dff722">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-term notes payable were as follows (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.360000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Perceptive Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_103305fa-0498-4e12-8c27-50a1a8d26ffb"
      decimals="-3"
      id="F_234e0b7f-69f9-4ab2-90f1-a7a42cf0f06d"
      unitRef="U_USD">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_d858a437-a837-4dd7-a056-993b112468b7"
      decimals="-3"
      id="F_27c74a46-60a4-4de1-ace2-2edf1d10c401"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_9b9a9bf1-c88b-455d-836c-503d4aebec7d"
      decimals="-3"
      id="F_409961e2-1f15-47cb-a313-cb14c2dfc9b9"
      unitRef="U_USD">78000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_e9449bbf-0db7-4011-804f-4ab3c76ffe06"
      decimals="-3"
      id="F_4c3e3655-166d-4a60-8cb6-5e22a334c94f"
      unitRef="U_USD">127000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_93f83049-782b-4d37-b713-b078d4dbeb63"
      unitRef="U_USD">4802000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_d74900c6-787d-4a23-9fb6-5bd2e3706c76"
      unitRef="U_USD">5074000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_d74a34ed-6b9e-4374-8218-8ac3826d6ccb"
      unitRef="U_USD">35276000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_890af284-71a3-475d-8897-d4ec0341a0b3"
      unitRef="U_USD">25053000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_6415d91f-6914-4456-9002-89bc7979e957"
      unitRef="U_USD">51000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b2cdb763-b13c-49a9-bbb2-eee05686595d"
      unitRef="U_USD">49000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_e39e92ba-76a4-4b84-8d5b-7801b67f0d24"
      unitRef="U_USD">35225000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_759cd0d8-033b-439c-8bdb-a507874a25be"
      unitRef="U_USD">25004000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_7447f4c3-b576-4564-b8e9-f58111485a6f"
      decimals="-5"
      id="F_8a5d90b5-4d28-4cc7-9730-004a70b73bae"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_c69ea8bf-9f71-4ba2-a888-5910c8e5e8a9"
      decimals="-5"
      id="F_6430da9f-d4f2-4c46-8b28-d9499250cb07"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_ac9d67d1-000b-4fd0-b45a-e660f6627d18"
      decimals="-5"
      id="F_b4e8ccf7-ec7a-4d57-a1d7-77b5949810e7"
      unitRef="U_USD">27900000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_2c13b6e2-c1b8-4e30-b455-351cad2472f7"
      decimals="-5"
      id="F_25825fbc-f554-4ecf-a122-dc871c31c5e3"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6645f92e-5a21-48d7-be04-51e4d7d14345"
      decimals="-5"
      id="F_ae5d4f95-a8d4-4009-9373-a01714f92cda"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="C_c641c015-2bd6-4a8d-8ea4-9455265a0578"
      decimals="-5"
      id="F_2fb7e414-387f-4b4d-bb89-a424c125b790"
      unitRef="U_USD">10000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_757ef04f-cd64-48a3-98e8-6c7d33aefba1"
      id="F_170989b9-58a0-494d-964b-cb7bea5d4fe9">2027-11-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"
      decimals="3"
      id="F_28f18727-19ee-4f74-8973-250d70a112ed"
      unitRef="U_pure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_757ef04f-cd64-48a3-98e8-6c7d33aefba1"
      decimals="3"
      id="F_4fb98d23-7b3c-4cd2-8c8d-48bd4e91b8a5"
      unitRef="U_pure">0.09</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_d34c69b7-5581-4027-8f30-edb22143832c"
      decimals="3"
      id="F_020e2087-f260-49b8-8816-b9fe93f8b629"
      unitRef="U_pure">0.144</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount
      contextRef="C_4fd25448-a781-4c46-af90-bee7da9ce5c2"
      decimals="2"
      id="F_1e20df0f-9a68-4b0e-9e0f-b3af32f145dd"
      unitRef="U_pure">0.02</bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount>
    <bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount
      contextRef="C_20fb35f1-6660-4090-b128-abf211be9258"
      decimals="2"
      id="F_9ed707c3-222b-4047-9904-f737b41d59e7"
      unitRef="U_pure">0.10</bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_7447f4c3-b576-4564-b8e9-f58111485a6f"
      decimals="INF"
      id="F_094141b7-0047-479f-9eeb-301383948a33"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"
      decimals="4"
      id="F_82b0c374-f232-4917-ab83-18d66334ecad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.0648</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0"
      decimals="INF"
      id="F_b38c2dba-233c-49db-9e4b-22e39243188c"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0"
      decimals="4"
      id="F_c5b615f9-6068-4393-80bc-75a7b0654c43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.0648</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0"
      id="F_7314e2ef-c364-467d-9e03-fcf28de18a2e">2033-12-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_590d203a-30d9-4b19-b794-c99db48ab3b0"
      decimals="INF"
      id="F_ca3cc2d3-456a-41b4-8477-5ca3f01979c6"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_886c7268-fb43-44e3-b7bd-e66c3277e3a8"
      decimals="INF"
      id="F_f57d7591-15f8-4125-a4c8-0c32401608b4"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <bdsx:MinimumCashBalanceAtMaturityDate
      contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"
      decimals="-5"
      id="F_79dd84d3-8e51-4cdf-923b-1c8999c1abd7"
      unitRef="U_USD">2500000</bdsx:MinimumCashBalanceAtMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      decimals="INF"
      id="F_9ec93eb5-3b07-4388-96f4-c5bcca4596a3"
      unitRef="U_shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      decimals="4"
      id="F_bfb60323-5d09-4c9d-b054-60a986454906"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6254</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_63b83fa5-85b9-4152-a156-9afea82f699b"
      decimals="-5"
      id="F_a5b53a81-e89f-46da-8212-4e4f4278a7c2"
      unitRef="U_USD">27500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fdcc9d4c-66e6-411d-9680-d5105860c125"
      decimals="0"
      id="F_26dfb21f-401b-4859-aa7e-a885cdb2f2d2"
      unitRef="U_shares">16975298</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_3e31ab29-a697-425a-af3d-43c74dbcb485"
      decimals="2"
      id="F_8a8af026-a672-4421-8508-14caae0750fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.62</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_e46eb83a-79be-44c5-a843-5a8c6569843c"
      decimals="-5"
      id="F_a53f86f2-5ae4-43de-a8df-5a7733cd6f52"
      unitRef="U_USD">27500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02"
      decimals="-5"
      id="F_85095038-522e-4e6c-bf00-cbc4485acc49"
      unitRef="U_USD">15300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02"
      decimals="INF"
      id="F_5eaca825-f061-470e-8b54-979213d8529b"
      unitRef="U_shares">9454927</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed
      contextRef="C_532807c3-5af3-4d5a-94dc-2349407eba05"
      decimals="INF"
      id="F_a3f9baa3-a071-4a78-bf62-64bd731bd3c3"
      unitRef="U_SubscriptionAgreement">1</bdsx:NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_76c1c45c-0a3f-4fbd-beae-7e98904be82f"
      decimals="-5"
      id="F_08c342e9-8f17-4bc8-8ecc-a29b731de168"
      unitRef="U_USD">12200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346"
      decimals="INF"
      id="F_ca19a70e-fc37-4053-80de-b3beabeb48d4"
      unitRef="U_shares">7520371</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:InitialWarrantsAmount
      contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"
      decimals="-5"
      id="F_e91b324c-33d0-4d46-a228-7449f5564f28"
      unitRef="U_USD">2900000</bdsx:InitialWarrantsAmount>
    <bdsx:AdditionalWarrantsAmount
      contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"
      decimals="-5"
      id="F_7158cb47-644b-49b5-92f0-f4327a470e85"
      unitRef="U_USD">100000</bdsx:AdditionalWarrantsAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_5e2420bd-e9c1-412c-a7af-4f5be0bb78b3"
      decimals="-5"
      id="F_acc7dc83-547d-4a38-a1c9-fa5e4b1b1f51"
      unitRef="U_USD">5200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <bdsx:InitialWarrantsAmount
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      decimals="-5"
      id="F_a001e053-90fa-4529-946f-00269653aeec"
      unitRef="U_USD">700000</bdsx:InitialWarrantsAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_def22ed6-b3f4-4142-a754-d6aff1cc2ad3">
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_004ef27b-6261-4a7d-803c-3d1e3f9e512b"
      unitRef="U_USD">50000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_e016ae86-b4d1-4fab-93c2-fce20d4bbd30"
      unitRef="U_USD">21000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_1901937c-9dc4-4b10-9386-aa7efb6c362e"
      unitRef="U_USD">7000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <bdsx:LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_4dfac190-e175-438a-ae46-422d7aaab38c"
      unitRef="U_USD">40000000</bdsx:LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter>
    <us-gaap:LongTermDebt
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_9eebb9fd-bc06-4870-96f8-edf46bed1924"
      unitRef="U_USD">40078000</us-gaap:LongTermDebt>
    <bdsx:LesseeOperatingAndFinanceLeasesTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_c7a713ee-04c4-4d15-a74c-8af42999959c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 9 &#x2013; Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company acts as a lessee under all its lease agreements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Throughout 2023, the Company leased its headquarters and laboratory facilities in Boulder, Colorado, under a lease agreement that expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6810bc43-8b88-4896-94db-50fb78cff4b9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d0f0a6d5-c980-4547-82e0-7fbd7882d4e9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the Company subsequently relocated its corporate headquarters and laboratory facilities to Louisville, Colorado. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,066&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet that was set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In April 2023, the Company amended the agreement to extend the lease agreement through October 2026. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also holds various copier leases under non-cancelable lease agreements that expire in the next &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f032350b-436c-49d5-a43e-3d8d73323d62;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to three&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d4ab91cf-5309-48b9-bf44-1a128879ae56;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Centennial Valley Properties I, LLC Lease Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space in Louisville, Colorado (the Leased Premises). The Leased Premises replaced the Company&#x2019;s headquarters and laboratory facilities in Boulder, Colorado in January 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The initial term of the Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; renewal options to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the term of the Lease for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d101e6ae-d1d1-4191-8ad1-1ab4d344cdcb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;- or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten-year &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in ROU assets and lease liabilities being recorded&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, however, the Lease commenced for legal purposes on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the Commencement Date)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Lease, the Company will lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,980&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per month and escalating, based on fixed escalation provisions, to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;326,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,980&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability at lease commencement because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease commencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximat&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ely $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; mil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;lion by November 2024 after receiving $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in lessor reimbursements. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Company has &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;utilized the total $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the years ended December 31, 2023, and 2022, respectively) in tenant improvement allowances for capital expenditures for leasehold improvements related to the Leased Premises and have been reimbursed from the Landlord.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. During the three months ended September 30, 2022, a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million cash collateralized letter of credit under the operating lease agreement was released and the funds were subsequently transferred to the Landlord as a refundable deposit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#x2019;s obligations. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million refundable deposit is included within '&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_afd70d36-dcbf-4fdb-b7a0-f4dc56cc9f89;"&gt;&lt;span style="-sec-ix-hidden:F_969e4251-ea3d-4fbe-a713-b5983a44c323;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;' in the balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease expense for all operating leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2023 and 2022, respectively. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the weighted-average remaining lease term and discount rate associated with our operating leases were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ctively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments associated with our operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.996%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.964%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</bdsx:LesseeOperatingAndFinanceLeasesTextBlock>
    <bdsx:AreaOfOfficeSpaceLeased
      contextRef="C_62d6cec9-2f4c-4985-b1ad-fb315c4d7129"
      decimals="INF"
      id="F_17438265-7ddc-49e2-9b9c-d5c482a8ff6c"
      unitRef="U_sqft">9066</bdsx:AreaOfOfficeSpaceLeased>
    <bdsx:LeaseExpirationMonthYear
      contextRef="C_ba93e9bf-54a2-4a63-a29e-47cf3846d702"
      id="F_07b006c7-361d-4ea5-83e3-7a4c003eb2c1">2023-10</bdsx:LeaseExpirationMonthYear>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription
      contextRef="C_05eb759d-55fd-4a20-ad8a-062b720cf18a"
      id="F_3e857092-10b4-47d9-8a2b-2bc34fbfcf61">The initial term of the Lease is twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023. The Company has two renewal options to extend the term of the Lease for an additional seven- or ten-year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $2.0 million in ROU assets and lease liabilities being recorded, however, the Lease commenced for legal purposes on April 1, 2023 (the Commencement Date).</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="C_db52ea64-8d04-4f5f-808f-473c14c90cd0"
      id="F_96808220-dfb2-4a09-a9ae-1ab110483d9b">P12Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <bdsx:LeaseCommencementDate
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      id="F_c3a4a5da-9552-4909-ad2e-8d3da7345269">2023-04-01</bdsx:LeaseCommencementDate>
    <bdsx:LeaseAgreementNumberOfOptionsToExtend
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      decimals="INF"
      id="F_eee3338f-68f3-42ef-95ec-8c85b3993eba"
      unitRef="U_RenewalOption">2</bdsx:LeaseAgreementNumberOfOptionsToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      id="F_d9819f44-9ee0-4168-8cea-d0561631774b">true</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_2b4b468c-46c8-4f63-a0d6-3132df34cab5"
      id="F_5db12d08-8fa1-4dce-9d59-a35cc4cc982e">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f8dffbb6-3dd7-4318-8445-46c6c30532bd"
      decimals="-5"
      id="F_52e1fcc6-dcef-4905-8c91-335dd36ece05"
      unitRef="U_USD">2000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_f8dffbb6-3dd7-4318-8445-46c6c30532bd"
      decimals="-5"
      id="F_ab053d16-dbcb-4302-b42c-58b397652d34"
      unitRef="U_USD">2000000</us-gaap:OperatingLeaseLiability>
    <bdsx:LeaseCommencementDate
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      id="F_3fc31582-f9ea-4074-874d-3450c49d0e31">2023-04-01</bdsx:LeaseCommencementDate>
    <bdsx:LeasedPropertyBuildingCapacity
      contextRef="C_db52ea64-8d04-4f5f-808f-473c14c90cd0"
      decimals="INF"
      id="F_9a3a34a1-f9c6-4bca-a678-c96dac42f9b5"
      unitRef="U_sqft">79980</bdsx:LeasedPropertyBuildingCapacity>
    <bdsx:BaseRentPerMonthFromCommencementDate
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      decimals="0"
      id="F_ac175da7-f560-44ca-83ca-765a8ab59438"
      unitRef="U_USD">227000</bdsx:BaseRentPerMonthFromCommencementDate>
    <bdsx:RentAfterFixedEscalationProvisions
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      decimals="0"
      id="F_b0f86a41-79e6-40a6-a30c-54c947835e27"
      unitRef="U_USD">326000</bdsx:RentAfterFixedEscalationProvisions>
    <bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent
      contextRef="C_db52ea64-8d04-4f5f-808f-473c14c90cd0"
      decimals="INF"
      id="F_ded8896b-a92d-4eec-844b-d684c68ffebe"
      unitRef="U_sqft">19980</bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent>
    <bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      decimals="-5"
      id="F_a0bf5463-fc3c-49bf-beab-dda1b19a2211"
      unitRef="U_USD">18800000</bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements>
    <bdsx:AdditionalTenantImprovementAllowanceAmount
      contextRef="C_05eb759d-55fd-4a20-ad8a-062b720cf18a"
      decimals="-5"
      id="F_5549db94-3c99-4668-8804-330e233e6e55"
      unitRef="U_USD">2000000</bdsx:AdditionalTenantImprovementAllowanceAmount>
    <bdsx:InterestRateOnExtraAllowanceAmount
      contextRef="C_95aec402-735c-45bd-a94f-c4ad24f1d7d3"
      decimals="2"
      id="F_08cf1060-a088-4995-8ac4-d541144ac5c7"
      unitRef="U_pure">0.06</bdsx:InterestRateOnExtraAllowanceAmount>
    <bdsx:AccretionOfLeaseLiability
      contextRef="C_e3ab2048-daf6-40f1-a535-fe1a3ed66ded"
      decimals="-5"
      id="F_4b7d603f-0dd1-45d8-9894-0a7d937caade"
      unitRef="U_USD">25500000</bdsx:AccretionOfLeaseLiability>
    <bdsx:LessorReimbursementsReceived
      contextRef="C_e9c98e4a-80fa-483a-9bc2-c5a38ceacbe3"
      decimals="-5"
      id="F_3d5d0fde-43a6-465d-8ae4-46b65181465c"
      unitRef="U_USD">20800000</bdsx:LessorReimbursementsReceived>
    <us-gaap:TenantImprovements
      contextRef="C_2753e6cc-4205-46f0-b9c5-73fa3a85b6e5"
      decimals="-5"
      id="F_d7f6b987-a7c7-4b7f-ba96-cf2f7adcc756"
      unitRef="U_USD">20800000</us-gaap:TenantImprovements>
    <bdsx:TenantImprovementsIncurredDuringThePeriod
      contextRef="C_05eb759d-55fd-4a20-ad8a-062b720cf18a"
      decimals="-5"
      id="F_daa35327-726c-4939-9477-b6e687210265"
      unitRef="U_USD">18300000</bdsx:TenantImprovementsIncurredDuringThePeriod>
    <bdsx:TenantImprovementsIncurredDuringThePeriod
      contextRef="C_2ff65011-fa8e-4a77-8fc2-78505357e43f"
      decimals="-5"
      id="F_7cd7ea37-9572-4cf1-88b6-0781d55ab62f"
      unitRef="U_USD">2500000</bdsx:TenantImprovementsIncurredDuringThePeriod>
    <us-gaap:LineOfCredit
      contextRef="C_6192e64b-6b5d-4c2e-807b-fa9c59db0323"
      decimals="-5"
      id="F_b14c1b97-451e-487f-9e25-3afad93ed364"
      unitRef="U_USD">5000000</us-gaap:LineOfCredit>
    <us-gaap:CustomerFunds
      contextRef="C_d3ff8863-2403-499a-a2df-4ae38da7415d"
      decimals="-5"
      id="F_8cb83b46-7309-4014-8152-9e83b069d148"
      unitRef="U_USD">5000000</us-gaap:CustomerFunds>
    <us-gaap:CustomerFunds
      contextRef="C_b4dff87f-d0d5-422b-9f9a-13850ed49e16"
      decimals="-5"
      id="F_9bad851a-2135-42e3-9e70-fc1e672128b8"
      unitRef="U_USD">5000000</us-gaap:CustomerFunds>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-5"
      id="F_19745e2d-2895-4492-bdaf-73401940b696"
      unitRef="U_USD">4300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-5"
      id="F_2ba5fb26-8de5-47d4-8850-9d1c1f992703"
      unitRef="U_USD">2600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      id="F_483110f5-f1cc-4f18-95bd-e194ecdaa2bd">P10Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="4"
      id="F_1dfb828f-9c6c-4004-a3c6-235186647f22"
      unitRef="U_pure">0.114</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_f9d515b3-abe3-4206-975f-095760061b9b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments associated with our operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.996%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.964%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_1de6c824-4541-4577-b612-11f829bc7eb0"
      unitRef="U_USD">2406000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_5b6fb366-8821-4ebd-a707-68423b709773"
      unitRef="U_USD">4032000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_7b8beae5-0b1d-449e-9304-d1706930e520"
      unitRef="U_USD">4144000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_9d0f215f-a80e-47f1-8b22-c85771101aaa"
      unitRef="U_USD">4063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_7983e762-aca8-4769-9e9c-578794059bff"
      unitRef="U_USD">4151000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <bdsx:LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_cd1344ff-17cd-44c2-a3f8-bee77e567a86"
      unitRef="U_USD">28113000</bdsx:LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_35867c81-86f2-4b80-8c9f-77df0d35c1f9"
      unitRef="U_USD">46909000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_ec473b05-a8f5-4320-9828-0e3fdd3b754c"
      unitRef="U_USD">21494000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_322029c5-a975-4aa5-b2ab-8ba314b6e373"
      unitRef="U_USD">25415000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_8ab9d499-89d9-4d2a-958c-1e061400080b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 10 &#x2013; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The holder of each share of common stock is entitled to one vote per share.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Financing Programs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; facilities that enable equity financing on an ongoing basis at the Company&#x2019;s sole discretion, our at-the-market offering (ATM) and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the ATM Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3, and sales of common stock, if any, will be made at market prices by methods deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on the NASDAQ Global Market, or any other existing trading market for our common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 7, 2022 (the LPC Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (the Purchase Agreement), pursuant to which Lincoln Park has committed to purchase up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company's common stock (the LPC Facility). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#x2019;s sole discretion, over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period commencing on the LPC Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, but that amount may be increased up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, depending upon the market price of the Company&#x2019;s common stock at the time of sale and subject to a maximum limit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#x2019;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under applicable rules of the NASDAQ Global Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the LPC Effective Date, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;184,275&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, the Company will be required to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and, together with due diligence expenses and legal fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, reflect deferred offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;729,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which are included on the balance sheet in 'Other long-term assets'. The deferred offering costs will be charged against 'Additional paid-in capital' upon future proceeds from the sale of common stock under the Purchase Agreement. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of deferred offering costs were charged against 'Additional paid-in capital'. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;654,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of deferred offering costs remain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;376,456&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common shares at a weighted average price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; under the ATM facility. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had remaining available capacity for share issuances of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; under the ATM facility and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 21, 2022, the Company closed an underwritten public offering (the Public Offering) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,075,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock (the Public Offering Shares), including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,575,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares purchased by the underwriter pursuant to an option to purchase additional shares. The Public Offering Shares were issued and sold pursuant to an underwriting agreement, dated November 16, 2022, by and between the Company and William Blair &amp;amp; Company, L.L.C., as sole underwriter, at a public offering price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Public Offering after deducting underwriting discounts, commissions, and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Public Offering was made pursuant to the Company&#x2019;s effective Registration Statement on Form S-3 previously filed with the Securities and Exchange Commission on November 29, 2021 and a prospectus supplement, dated November 16, 2022, relating to the Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Subscription Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April 2022 Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,508,376&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock in a private placement offering. The three members of our Board of Directors acquired an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,631,284&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,877,092&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the April 2022 Subscription Agreements, the April 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The April 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management (the November 2022 Investors), including the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235,056&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock in a private placement offering. The November 2022 Subscription Agreement did not include any registration rights and included lock up restrictions that were in effect during the period ending 90 days subsequent to November 21, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the November 2022 Subscription Agreements, the November 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which is equal to the public offer price in the Public Offering, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;270,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The November 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 3, 2023, the Company entered into subscription agreements (the August 2023 Subscription Agreements) with all the members of our Board of Directors, all Section &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; officers, and additional members of the Biodesix leadership team (together, the August 2023 Investors) for the issuance and sale by the Company of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,975,298&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock in a private equity offering. The Subscription Agreements did not include any registration rights.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the August 2023 Subscription Agreements, the August 2023 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which is equal to the closing price of the Company's common stock on August 3, 2023, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The August 2023 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement. During the three months ended September 30, 2023, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in proceeds and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,454,927&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock pursuant to the Subscription Agreements. On September 27, 2023, the Company entered into an amendment to delay final closing on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; subscription agreement. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in proceeds were received and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,520,371&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued during the three months ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;613,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series G convertible preferred stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 23, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Through the effective date of the Company&#x2019;s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company&#x2019;s IPO, the preferred stock warrants were automatically converted to warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,326&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and were also transferred to additional paid-in capital. All common stock warrants remain outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;), the Company issued the Perceptive Warrant to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, including the Initial Warrants. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the Initial Warrants, the Additional Warrants will each become exercisable into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The per share exercise price for the Initial Warrants is equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0648&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which is equal to the lower of (A) the 10-day VWAP of the Company&#x2019;s common stock on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of common stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Initial Warrants are equity classified and were immediately exercisable upon issuance and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 21, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Initial Warrants were valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using the Black-Scholes option-pricing model assuming an expected term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, a volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. All Initial Warrants remain outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 10, 2023, as consideration for the First Amendment (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;), the Company agreed to issue to Perceptive a warrant to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (the First Amendment Warrants) at a per share exercise price equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6254&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which is equal to the 10-day VWAP of the Company&#x2019;s common stock ending on the business day immediately prior to the First Amendment Effective Date. The First Amendment Warrants are equity classified and immediately exercisable upon issuance and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 10, 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The First Amendment Warrants were valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using the Black-Scholes option-pricing model assuming an expected term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, a volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. All First Amendment Warrants remain outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 15, 2023 (the Tranche B Borrowing Date), the Company exercised its ability to draw the Tranche B loan (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). In connection with the Tranche B draw, the Company remeasured the Tranche B Warrants through the Tranche B Borrowing Date and recorded the change in fair value through the statement of operations and, subsequently, reclassified the fair value to additional paid-in capital. The Tranche B Warrants are now equity classified and immediately exercisable upon issuance and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 15, 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Tranche B Warrants were value&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;d at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using the Black-Scholes option-pricing model assuming an expected term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, a volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. All Tranche B Warrants remain outstanding as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_74a7fcc7-deb0-4610-85dd-7d2c61853a42"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_3004de32-149d-4418-9f83-8ec1016d555e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_2c6a6799-bad2-4fc0-8eb1-142755867589">The holder of each share of common stock is entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_886edb6e-4f2a-4fde-a33f-60f9622fc12c"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_55826e51-7bda-42f1-9d5d-278265cad747"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_09ce831e-848f-4fa6-9f89-390ff1f40c43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_9e3e0c9b-f53a-409c-814f-5a4809a1cc6d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_3534d81b-0eb5-48dd-9069-b30377d33718"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_c05f8e86-ed56-4b68-b143-df7517a041b8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_8a0aa5b5-f2d9-4abf-a1a6-3294bac70017"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <bdsx:NumberOfFacility
      contextRef="C_47a08558-9395-40a3-8dcc-94e5904208d5"
      decimals="INF"
      id="F_1611393d-ed8b-46f4-a974-1840357c0c66"
      unitRef="U_Facility">2</bdsx:NumberOfFacility>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_527ecbd0-9d14-456c-8b14-6369be5c77b1"
      decimals="-5"
      id="F_70b5b618-a4ce-460c-ae9f-ca379195b121"
      unitRef="U_USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6"
      decimals="-5"
      id="F_b2b19324-4847-490a-ac26-2ad149455735"
      unitRef="U_USD">50000000</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6"
      decimals="-5"
      id="F_668d34f5-2d46-47f7-94fd-ca19f6d62151"
      unitRef="U_USD">50000000</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:PurchaseAgreementTerm
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      id="F_17fc2087-036b-4a5d-82c8-2f232f50029b">P36M</bdsx:PurchaseAgreementTerm>
    <bdsx:SaleOfStockStockIssuablePerDayShares
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      decimals="0"
      id="F_053a33e3-0e41-4094-86d2-1a5c595505cb"
      unitRef="U_shares">50000</bdsx:SaleOfStockStockIssuablePerDayShares>
    <bdsx:SaleOfStockStockIssuablePerDayShares
      contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6"
      decimals="0"
      id="F_e4e2ac5d-ee2e-4666-bcd0-e456e86e057f"
      unitRef="U_shares">100000</bdsx:SaleOfStockStockIssuablePerDayShares>
    <bdsx:SaleOfStockStockIssuablePerDayValue
      contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6"
      decimals="-5"
      id="F_66541bb2-4ff5-4ff0-9337-b3183220213a"
      unitRef="U_USD">1500000</bdsx:SaleOfStockStockIssuablePerDayValue>
    <bdsx:SharesIssuedOrIssuableThresholdLimitDescription
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      id="F_416ab7ac-11d3-4ad8-aae0-2923247afe59">Under applicable rules of the NASDAQ Global Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.</bdsx:SharesIssuedOrIssuableThresholdLimitDescription>
    <bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      decimals="4"
      id="F_0df5f870-8204-4fd5-90c6-fd078aacd80d"
      unitRef="U_pure">0.0999</bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty>
    <bdsx:SaleOfStockSharesIssuedAsCommitmentFee
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      decimals="0"
      id="F_c2a6b474-b82d-45a4-9e0f-c6922a623d86"
      unitRef="U_shares">184275</bdsx:SaleOfStockSharesIssuedAsCommitmentFee>
    <bdsx:SharesIssuedAsCommitmentFeeValue
      contextRef="C_7abeec62-520e-49b6-ad1d-0e59c0f683d6"
      decimals="-5"
      id="F_9557cf84-c769-4fa0-b66d-01ae0fe55b45"
      unitRef="U_USD">20000000</bdsx:SharesIssuedAsCommitmentFeeValue>
    <bdsx:CommitmentSharesIssuableOnConditionalBasis
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      decimals="0"
      id="F_d9f53aff-f399-4f22-9f54-4ad552e944cb"
      unitRef="U_shares">61425</bdsx:CommitmentSharesIssuableOnConditionalBasis>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      decimals="0"
      id="F_45a5682f-496d-45df-93b8-53838f415127"
      unitRef="U_USD">600000</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:DiligenceExpenseAndLegalFees
      contextRef="C_941cb925-fd9e-40a4-a574-1909da8d340f"
      decimals="0"
      id="F_814ed7a5-33c2-4f65-9947-0fe84b08273f"
      unitRef="U_USD">129000</bdsx:DiligenceExpenseAndLegalFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_efd69ce4-92d9-4a44-8134-87ed7ac60445"
      decimals="0"
      id="F_3d278bbd-fb1d-424c-a569-a1f9292c035f"
      unitRef="U_USD">729000</us-gaap:DeferredOfferingCosts>
    <bdsx:AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts
      contextRef="C_d33768d0-8007-4c23-a3e3-f26f30749f9f"
      decimals="0"
      id="F_92e64978-7a6c-4cbb-a8db-bd966def9d8f"
      unitRef="U_USD">75000</bdsx:AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_87753004-7a65-4879-90a7-b55ed68ef8d1"
      decimals="0"
      id="F_5fe84aee-f298-4f88-ad3f-08f9211d7483"
      unitRef="U_USD">654000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_47a08558-9395-40a3-8dcc-94e5904208d5"
      decimals="-5"
      id="F_c69f3fcf-143e-4680-af92-09885a75ccf4"
      unitRef="U_USD">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bdsx:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_7feedfcd-2f75-4050-b434-093d5964efa3"
      decimals="-5"
      id="F_3e9b087d-8ce4-4648-8bb8-aeb4e3ebde7e"
      unitRef="U_USD">600000</bdsx:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b34059f4-8b80-437f-b778-005b358d00cf"
      decimals="INF"
      id="F_228cb171-664c-4eef-b9b0-b3839f9bb017"
      unitRef="U_shares">376456</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:WeightedAveragePricePerShare
      contextRef="C_b34059f4-8b80-437f-b778-005b358d00cf"
      decimals="2"
      id="F_0f33d56e-934f-4b54-89a6-8e1f287338d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.66</bdsx:WeightedAveragePricePerShare>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_1b25b640-1c47-4745-9cca-376992b9713c"
      decimals="-5"
      id="F_b425c773-c026-4a87-9e02-36baa0395eaa"
      unitRef="U_USD">28900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_fff8f12c-e13d-40af-8269-13c52984316c"
      decimals="-5"
      id="F_f973df37-830a-4cc6-a68a-f9c35b0e3ca6"
      unitRef="U_USD">46900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ea26ef97-074e-45f4-81e8-41983d384792"
      decimals="INF"
      id="F_58da6e1d-a9a5-475a-9e15-d8bd78b04883"
      unitRef="U_shares">35075000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter
      contextRef="C_ea26ef97-074e-45f4-81e8-41983d384792"
      decimals="INF"
      id="F_f85301e3-06e0-4f29-8ccd-0417c0247f3b"
      unitRef="U_shares">4575000</bdsx:StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_50b4b982-898d-46bc-b9ea-b684abcdac48"
      decimals="2"
      id="F_e210164a-2559-4e50-962f-476515e6c454"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8dc723fd-79de-4621-8b96-50bc34902a0e"
      decimals="-5"
      id="F_4a4ca464-30b2-486c-873a-b852dc5e4dba"
      unitRef="U_USD">37500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c2c8094a-10da-431f-951a-d7eb2e067421"
      decimals="INF"
      id="F_921a7761-db19-4c28-a6ea-a7e3fa4dec14"
      unitRef="U_shares">6508376</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_26baecb2-9cae-47d3-9fff-e9ca8610e979"
      decimals="INF"
      id="F_f26ef669-a61a-460f-8ae9-b0a631ecae01"
      unitRef="U_shares">3631284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0845ddd1-8e8f-416b-a225-6a579305755e"
      decimals="INF"
      id="F_62506747-780e-43b0-bb5f-18b73fbc7bd4"
      unitRef="U_shares">2877092</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_ed3993d6-58b6-4ff5-b5d7-5c4851329b29"
      decimals="2"
      id="F_35a4ad66-c17d-4e85-8b42-ed425e8ca2ea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.79</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_ff6853d0-09e3-4b96-93ec-2bc31e1bfcc5"
      decimals="-5"
      id="F_95198f5a-1743-46a9-afda-c8f9b62a5617"
      unitRef="U_USD">11700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7f80b84d-e3ac-46dc-8317-ba012a0d08c1"
      decimals="INF"
      id="F_487e4885-00fd-4257-92c7-643cd56cf532"
      unitRef="U_shares">235056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_fa2e75a9-b401-42d8-9753-7018d23b85ef"
      decimals="2"
      id="F_e9299ea7-380c-4d33-a039-23632806d311"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_3a9c086d-ca5a-4f0b-a935-2933e71c3b61"
      decimals="0"
      id="F_298620d5-df27-406b-bc2c-16794933461f"
      unitRef="U_USD">270000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <bdsx:NumberOfOfficers
      contextRef="C_fdcc9d4c-66e6-411d-9680-d5105860c125"
      decimals="0"
      id="F_5ecae9c7-561e-4588-8218-d8927d43f7ac"
      unitRef="U_Officer">16</bdsx:NumberOfOfficers>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fdcc9d4c-66e6-411d-9680-d5105860c125"
      decimals="INF"
      id="F_0d9109ee-10ee-471e-b384-19989d8aa5d0"
      unitRef="U_shares">16975298</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_3e31ab29-a697-425a-af3d-43c74dbcb485"
      decimals="2"
      id="F_8caa7903-cc0c-49fb-ba8a-80855d12432d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.62</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_e46eb83a-79be-44c5-a843-5a8c6569843c"
      decimals="-5"
      id="F_41cfc315-196e-4b99-9042-5107c484f34b"
      unitRef="U_USD">27500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02"
      decimals="-5"
      id="F_d6aef8ef-6b69-4514-8157-6bb4d804d97a"
      unitRef="U_USD">15300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0ce9d0b3-b16f-48c3-97cd-759e38f53f02"
      decimals="INF"
      id="F_ec50d086-6b04-46ff-8742-8ca31d210bd0"
      unitRef="U_shares">9454927</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed
      contextRef="C_532807c3-5af3-4d5a-94dc-2349407eba05"
      decimals="INF"
      id="F_387cb83d-bd2d-4f41-a35e-e02cbdb07976"
      unitRef="U_SubscriptionAgreement">1</bdsx:NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_76c1c45c-0a3f-4fbd-beae-7e98904be82f"
      decimals="-5"
      id="F_7e17ed76-34a3-4314-a4bb-0f2bc3e12edc"
      unitRef="U_USD">12200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_47cf66b1-0604-4cd3-8aee-7a4e96842346"
      decimals="INF"
      id="F_4ad5e89e-3629-48e7-be50-46c20de67d09"
      unitRef="U_shares">7520371</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_693c76f1-5bcb-4f13-8dd7-aab03824f0b6"
      decimals="INF"
      id="F_ed1212ff-10de-4164-a9b9-a174d5ccd48c"
      unitRef="U_shares">613333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_693c76f1-5bcb-4f13-8dd7-aab03824f0b6"
      decimals="2"
      id="F_06fce977-9549-4477-b9c6-b3b688aa9c9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      id="F_491098a6-23e8-401c-b482-99a5be8ced51">2028-02-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_c62ec6f1-4811-4fd5-bb74-172abde325bc"
      decimals="INF"
      id="F_c4613011-0d36-4095-b243-7e2e725473aa"
      unitRef="U_shares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c62ec6f1-4811-4fd5-bb74-172abde325bc"
      decimals="2"
      id="F_e2576f2c-2f32-4b10-8fec-a39fb69791ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_7f39b903-335d-4dc6-a073-8be5fe3da6ba"
      decimals="INF"
      id="F_d7a6bd00-c503-490b-b812-25768be8c633"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_722b4124-2675-4c60-83df-552c2446203f"
      decimals="0"
      id="F_d40be842-9bbe-4212-a1a3-3c6feafdabec"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c6dcab58-44c5-4023-bb77-3783ed60c728"
      decimals="4"
      id="F_2101578c-3519-4b87-ab92-2de60f43272d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.0648</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bdsx:PublicOfferingPricePerShareOfCommonStock
      contextRef="C_82a5e47a-b63c-44b3-bca7-2b170af6b51a"
      decimals="2"
      id="F_1ef7e8c8-ac82-4640-83a3-bbbac20f965d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</bdsx:PublicOfferingPricePerShareOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_5fa0d7e8-75b7-4df5-8285-781f19947e03"
      id="F_a259352e-116d-4937-aba6-065845adc7eb">2032-11-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bdsx:InitialWarrantsAmount
      contextRef="C_5fa0d7e8-75b7-4df5-8285-781f19947e03"
      decimals="-5"
      id="F_ad5b6282-cf93-42cf-b518-05c3a2306f32"
      unitRef="U_USD">2900000</bdsx:InitialWarrantsAmount>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_3d56ae6a-1cf7-4302-8a0a-2f707300fff3"
      id="F_12854c26-e622-49ef-b4a6-3350557d9f36">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_a1c1115e-2162-4e21-818c-b98821ff9dca"
      decimals="1"
      id="F_0caf9be6-a6a5-45bc-afc1-b72b66c439d0"
      unitRef="U_pure">81.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_d94f7ed2-8768-4f75-92ef-17e38595fb19"
      decimals="0"
      id="F_baa7e47f-ffef-4d31-899d-7c80f738af71"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_d8c554b0-2f2a-45d2-827d-c5c7753bf0df"
      decimals="2"
      id="F_0d5b45af-f956-4e88-a51c-de99d8988bbb"
      unitRef="U_pure">3.67</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      decimals="INF"
      id="F_09d762ac-9867-44b5-ad65-b2e1adff6f1c"
      unitRef="U_shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      decimals="4"
      id="F_7c9624e7-7aca-4f9c-8bdf-cf9249d7348d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6254</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      id="F_97564638-dd54-49a5-bd09-bb3e61faa187">2033-05-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bdsx:InitialWarrantsAmount
      contextRef="C_5044dbe0-e0e8-43e1-bd66-7210f6574ff0"
      decimals="-5"
      id="F_74bd223f-ab38-44a5-8650-eb9f86d56718"
      unitRef="U_USD">700000</bdsx:InitialWarrantsAmount>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_d1ab286d-70e8-4911-8d81-5934ba62030b"
      id="F_92b44a88-f862-4671-addf-9eb1b2f1a807">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_c75f007c-cad7-4f11-be83-4e80d54a65e2"
      decimals="1"
      id="F_08b84bd4-a9ef-40e2-a282-e355337f9097"
      unitRef="U_pure">78.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_67ce5508-c2c7-4b2b-ac66-a6d8f43f57a6"
      decimals="0"
      id="F_219c6f9c-f3ac-473d-ac15-adb6d513e666"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_c4a9239d-0ac1-4ebc-99ad-6594a4338815"
      decimals="2"
      id="F_4265fde8-b8c5-4ba6-895f-e5a11b69b006"
      unitRef="U_pure">3.49</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_fb308a59-4d7b-4ffa-b075-a3e642ac4c94"
      id="F_04cf4720-4696-4312-816e-9da7a45c271d">2033-12-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bdsx:InitialWarrantsAmount
      contextRef="C_fb308a59-4d7b-4ffa-b075-a3e642ac4c94"
      decimals="-5"
      id="F_36ae935d-58e2-451b-bbba-99a343aa967d"
      unitRef="U_USD">1300000</bdsx:InitialWarrantsAmount>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_ce2a287f-cb92-4030-b3b1-332c05321abe"
      id="F_de76959f-48a4-4dd2-b187-f7774b1396d5">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_ea1e80b7-5077-4687-98eb-b1b280706184"
      decimals="1"
      id="F_7df06387-42fb-480a-bf21-4485d966bb82"
      unitRef="U_pure">76.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_77f1704b-d027-4f10-90c1-a41d7fa1aa89"
      decimals="0"
      id="F_140f2216-d629-4e60-a924-33c1b2ceabea"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_1b5d3398-91f7-41ab-97d0-7393bc19f7ef"
      decimals="2"
      id="F_e57851d5-d6de-4a8d-a32f-87c5c98e34cb"
      unitRef="U_pure">3.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_56f3fe51-09af-492d-9334-e5228d4b31e5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 11 &#x2013; Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diagnostic test revenues consist of blood-based lung tests and, prior to May 11, 2023, COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer, test type, and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). In addition, other revenue includes amounts derived from licensing our digital sequencing technologies to our international laboratory partners. We are compensated through royalty-based payments for the licensed technology, and depending on the nature of the technology licensing arrangements and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these revenues are recognized in the period when royalty-bearing sales occur.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.713%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Diagnostic Tests&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Biopharma Services and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in 'Revenues' in the statements of operations. The Company had &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in &#x2018;Deferred revenue&#x2019; recorded in the balance sheet as of December 31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was added throughout 2023 to &#x2018;Deferred revenue&#x2019; for up-front cash payments received while $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recognized in 'Revenues' during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The &#x2018;Deferred revenue&#x2019; of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million re&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;corded in the balance sheet as of December 31, 2023 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2023 and 2022, the Company had &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in non-cu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;rrent deferred revenue, respectively, recorded within &#x2018;Other long-term liabilities&#x2019; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;United Healthcare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;The State of Colorado&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company&#x2019;s total revenue for the years ended December 31, 2023 and 2022, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Medicare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;AstraZeneca UK&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <bdsx:PrimarySourcesOfRevenueDescription
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_8f8b03e2-594c-43ad-9391-57aa17de7a78">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).</bdsx:PrimarySourcesOfRevenueDescription>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_bc29a516-97e2-4080-b51b-e7b52acccd4f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.713%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Diagnostic Tests&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Biopharma Services and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_cc3d622b-07f0-4622-b168-11fadcf7c53f"
      decimals="-3"
      id="F_075c2bf0-56c2-408a-828f-fdd211ee4bf6"
      unitRef="U_USD">45192000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_7afe2c5e-ef01-4ae6-9496-8f640f10072d"
      decimals="-3"
      id="F_14e43d91-17b4-4da2-b311-cdafa3766a76"
      unitRef="U_USD">34538000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_495df2dc-9e4b-4eba-91de-cd835b8ec284"
      decimals="-3"
      id="F_c400f5d5-49c2-4801-9cda-ddf1e40e0377"
      unitRef="U_USD">3895000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_ab1111f8-759d-41b6-837c-e3d03f7a0ae9"
      decimals="-3"
      id="F_9de0b07b-f372-4ac6-ad9a-b3f0eaec749c"
      unitRef="U_USD">3674000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_7feb0b7d-ea9f-49a2-9605-32c5b2b7b50e"
      unitRef="U_USD">49087000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_288e25df-8d39-4b0e-a132-a1d0242554ee"
      unitRef="U_USD">38212000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-5"
      id="F_51cd4b72-acb6-46ad-a303-4906424bc567"
      unitRef="U_USD">1000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_c93f4cec-77cf-4fd9-a863-07647a7dfbe6"
      decimals="-5"
      id="F_f79d7566-d92b-4630-8e85-8a77ddf91c69"
      unitRef="U_USD">600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-5"
      id="F_f0d056ed-efa3-4433-8e54-b86078419dba"
      unitRef="U_USD">1300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-5"
      id="F_92747a70-c705-412f-b677-cf2489247149"
      unitRef="U_USD">300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_40f12cf5-75b2-497c-a527-a856346a9ab1"
      decimals="-5"
      id="F_5b3c13a1-8d4a-4391-91b4-be6cd9ea8016"
      unitRef="U_USD">300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_eca8f48e-2cf8-4fe3-bd45-8790ffacd616"
      decimals="-5"
      id="F_fca4e3c0-7345-4e05-a871-d1da6e6b5a35"
      unitRef="U_USD">400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_84bc106f-1dcd-4ea8-ac5a-f00a44f7d259">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;United Healthcare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;The State of Colorado&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Medicare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;AstraZeneca UK&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6c99d259-788c-49d8-9e0a-022979f1851a"
      decimals="2"
      id="F_c70317aa-ffbd-4167-9624-92da7feb67c9"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d9e2f35d-f819-4cf0-98d0-27d991f1b000"
      decimals="2"
      id="F_e71f4e4c-ad89-4a25-99db-efdcc7703ce0"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e89c5ad9-ee99-495b-8bf2-d125fc70e5e0"
      decimals="2"
      id="F_1a910f3f-06a6-4fed-a394-255443397010"
      unitRef="U_pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5636267d-0318-4aa5-a493-1e9d911a7cf4"
      decimals="2"
      id="F_c6305b6a-c0a2-4148-be85-ad9b52a9861f"
      unitRef="U_pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_81062d5c-36cb-4b6f-acd2-1864d8d3f30d"
      decimals="2"
      id="F_346ae618-dd5b-416b-a71f-39bebf017876"
      unitRef="U_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c183917b-8a29-4963-b916-51ff5dc6f28a"
      decimals="2"
      id="F_a4cfac70-b3a5-4287-910d-84295d30b0a3"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6c326e24-3804-4962-872f-a522021fc168"
      decimals="2"
      id="F_1a8b39f5-b64d-4bca-8497-b96d9a5a5139"
      unitRef="U_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_6e886473-31ed-47f2-90a8-093d108b8dea">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 12 &#x2013; Share Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Predecessor 2016 and 2006 Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional awards may be granted under the 2006 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultants. Awards granted under the 2016 Plan or the 2006 Plan that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#x2019;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional awards may be granted under the 2016 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective upon the closing of our IPO, the Company&#x2019;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The number of shares originally reserved for issuance under the 2020 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,893,395&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The 2020 Plan includes an annual increase on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#x2019;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a prior plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all plans as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;960,305&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective with our IPO in October 2020, the Company&#x2019;s Board of Directors and its stockholders approved the Company&#x2019;s Employee Stock Purchase Plan (the ESPP). The number of shares originally reserved for issuance under the ESPP was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;338,106&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value of the Company&#x2019;s common stock on the first or last day of the offering period, whichever is lower. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 437,135 shares were issued under the ESPP leaving 309,012 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares remaining for future issuance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Awards Granted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Non-statutory stock options, which may be issued to employees, non-employees and directors, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Performance-based options vest in three equal annual installments beginning one year after the grant date&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#x2019;s common stock on the grant date. There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; performance-based stock options outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU holders have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Exchange Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 23, 2023, the Company commenced a voluntary offer to exchange certain eligible options held by eligible employees of the Company for new options (the Exchange Offer). The Exchange Offer expired on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;July 24, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Pursuant to the Exchange Offer, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;757,595&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total shares of common stock underlying the eligible options. On July 24, 2023, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156,868&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, pursuant to the terms of the Exchange Offer and the Company&#x2019;s 2020 Equity Incentive Plan. The exercise price of the new options granted pursuant to the Exchange Offer was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;share, which was the closing price of the common stock on the NASDAQ Global Market on the grant date of the new options. Each new option granted in exchange for the vested shares underlying an eligible option will fully vest on the first day of the month following the first anniversary of the month in which the Exchange Offer is completed. Each new option granted in exchange for the unvested shares underlying an eligible option will vest under an extended vesting schedule, with vesting commencing on the first day of the month following the first anniversary of the month in which the Exchange Offer is completed, and occurring in a series of equal monthly installments over the number of months that were&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;remaining &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in the surrendered eligible option&#x2019;s vesting schedule immediately prior to the Exchange Offer. Each new option has a maximum term of ten years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The exchange of stock options was treated as a modification for accounting purposes. The incremental expense was immaterial for the new options and was calculated using the Black-Scholes option pricing model. The incremental expense and the unamortized expense remaining on the exchanged options as of the modification date will be recognized over the new vesting schedule.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Bonus-To-Options Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also has a Bonus-to-Options Program (the Bonus Option Program) which is separate from previously described plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011, 2015, and 2022. For fiscal year 2023, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the closing market price of the Company's common stock on the grant date, as disclosed below under &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201d;. Bonus Options issued must be exercised within a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded the following activity related to the Bonus Option Program during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands, excepted weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company record&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million du&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ring the years ended December 31, 2023 and 2022, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in the first quarter of 2024 and 2023, respectively, by the Compensation Committee of the Board of Directors. In determining the amount of share-based compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The unrecognized remaining share-based compensation expense for optio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ns and RSUs was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and is expected to be amortized to expense over the next &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding - January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the Company&#x2019;s common stock is determined based on its closing market price on the date of grant. The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.080000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.080000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.39&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk&#x2011;free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock unit activity during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 was (in thousands, except weighted average grant date fair value per share):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cceeff;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_6f98ad46-d032-45e8-8dc6-864069fa3ada"
      decimals="INF"
      id="F_667925d7-5134-4ebf-a879-5b2cda2b2c76"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b7bda97d-3509-499d-a965-e2fdeb9c2460"
      decimals="INF"
      id="F_efc811a1-567b-488d-a655-163afdeb1f99"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_04f15e86-b867-4b21-85db-2828b6000f59"
      decimals="0"
      id="F_5baa9764-f84e-42d2-b3d4-5de40343381f"
      unitRef="U_shares">1893395</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0f11691d-c0c2-4bb0-ab80-31641907e9da"
      decimals="2"
      id="F_ccee5167-0e78-4454-9751-d5739decd757"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b343d002-35a7-4d20-972f-2d42c271e7a6"
      decimals="INF"
      id="F_db558560-5b26-4389-9511-e29c676f8466"
      unitRef="U_shares">960305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3b7739ff-0980-4012-9fc1-66675c283f56"
      decimals="0"
      id="F_17123169-1d47-4400-a742-648ec0f35a63"
      unitRef="U_shares">338106</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542"
      decimals="INF"
      id="F_2beb5f2a-9b52-4387-8dd4-06e2f1968a9d"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_72b4a1e8-4024-43cf-af5a-fe28f78fef95"
      decimals="INF"
      id="F_1143fb8b-a248-48bf-b226-a4fce40f3ff5"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542"
      decimals="INF"
      id="F_d16c5ec0-7652-4268-b564-9b399412167e"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod
      contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542"
      id="F_f124ebf4-4541-4810-ab7a-ca569c372536">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.</bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod>
    <bdsx:DescriptionOfOfferingPeriodUnderPlan
      contextRef="C_e1e8c78c-0de9-49b2-87a6-2aecc4f5e542"
      id="F_e560ed78-cf73-4698-969a-4c99f8dca0f5">The ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. During the year ended December 31, 2023, 437,135 shares were issued under the ESPP leaving 309,012 shares remaining for future issuance.</bdsx:DescriptionOfOfferingPeriodUnderPlan>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_4ce221be-74ad-4978-8b6b-94c91f43b705"
      id="F_0f9d1495-7e45-4c22-964c-f8408912c075">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_2a229531-ccdd-4632-a059-50b71306f89f"
      id="F_3ffcfece-fe07-42ac-b730-b491438c07ee">Performance-based options vest in three equal annual installments beginning one year after the grant date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0b1fa878-d68c-49bb-adba-1cf66b1bc52e"
      decimals="INF"
      id="F_212fbb92-095a-4bb7-8905-f1dc330a9e10"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="C_b6598444-e68b-421f-8188-c98635eea90e"
      id="F_ffc7bbf0-4f6c-4b02-b47d-7551d9291a8d">2023-07-24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="C_b6598444-e68b-421f-8188-c98635eea90e"
      decimals="INF"
      id="F_8e9965b1-1331-4c0d-840f-7deac3708bbb"
      unitRef="U_ShareHolder">83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_b6598444-e68b-421f-8188-c98635eea90e"
      decimals="INF"
      id="F_91497b9b-9f40-409e-94d4-71230bdfd472"
      unitRef="U_shares">757595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_b6598444-e68b-421f-8188-c98635eea90e"
      decimals="2"
      id="F_66bc91ca-d36d-4e67-b58c-eb6143a35f5e"
      unitRef="U_pure">0.99</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_ba1bede0-706e-4693-ba5f-95a79f81fcbf"
      decimals="INF"
      id="F_e0d80fe5-2481-4876-8db7-669e90a202d1"
      unitRef="U_shares">156868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ba1bede0-706e-4693-ba5f-95a79f81fcbf"
      decimals="2"
      id="F_7193119f-9e19-40e5-abbb-3fb1f0287ade"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_185c0faf-f292-4fd9-ace9-12ff64d5d8f1"
      id="F_d33792b8-c45a-491d-830e-4f5a6b5a5a93">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      id="F_26c148df-2043-4b10-b2e9-5ffecb26b2df">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded the following activity related to the Bonus Option Program during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands, excepted weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_921ada3a-dad1-481f-91bb-6926ac721bcf"
      decimals="-3"
      id="F_380fc413-1610-4861-a29e-64c64638fb97"
      unitRef="U_shares">526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_921ada3a-dad1-481f-91bb-6926ac721bcf"
      decimals="2"
      id="F_93c229fc-0e43-43d8-a53a-9ef0113382fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_dbece915-caf9-4b49-8367-e61f916c83c7"
      id="F_7ea51dcc-5da7-44bc-9d76-af27d0e7e804">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_921ada3a-dad1-481f-91bb-6926ac721bcf"
      decimals="-3"
      id="F_d435bdb7-92c6-4256-a098-12be9584faf4"
      unitRef="U_USD">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="-3"
      id="F_bf449979-464b-4a80-9013-6673134bf36b"
      unitRef="U_shares">876000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="2"
      id="F_59266bfa-0686-4f5e-9424-19217b48d946"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="-3"
      id="F_9a166088-1431-4370-8e6d-566163b7769b"
      unitRef="U_shares">217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="2"
      id="F_04fa2307-32aa-43ca-a691-c5c15d39162a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <bdsx:StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="-3"
      id="F_d2d1b873-cddc-45c1-8d04-5ddbf1c0c63b"
      unitRef="U_shares">169000</bdsx:StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange>
    <bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="2"
      id="F_b6b40d45-337d-4ac1-a468-496c6ce1f747"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.67</bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice>
    <bdsx:StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="-3"
      id="F_bdce4a68-92a5-4d1b-9dd4-38b8ac3ad341"
      unitRef="U_shares">34000</bdsx:StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange>
    <bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="2"
      id="F_4779a37f-bf2d-4565-ba05-26db53edbadd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.2</bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b"
      decimals="-3"
      id="F_c35e9a5f-a4b8-466d-9d5b-ee9923ffd8e4"
      unitRef="U_shares">1050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b"
      decimals="2"
      id="F_b914e343-0714-4507-834b-775834ec0720"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      id="F_91c2dff8-2a03-4ce1-af92-e65f4a53411f">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b"
      decimals="-3"
      id="F_ea95cfc3-8a89-447b-9e84-45f2e6ec2fcb"
      unitRef="U_USD">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b"
      decimals="-3"
      id="F_3947deaf-f754-45a8-a9be-f2a6203dfd7d"
      unitRef="U_shares">1016000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_a8b0d10b-f80f-4a10-a661-abc02234ba9b"
      decimals="2"
      id="F_9ac05ab3-6a16-487a-a8ff-3df88f609d2f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      id="F_da174018-7413-45f3-b0b3-a8b5d80297d7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bc9f7a62-a78b-40a9-8fd1-9b6361e9ccc3"
      decimals="-5"
      id="F_3d8c1e22-4b37-4b82-ad24-0c5ed2e3abe4"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dbece915-caf9-4b49-8367-e61f916c83c7"
      decimals="-5"
      id="F_af02ddaf-bc58-46a7-adda-e11cf0374ae1"
      unitRef="U_USD">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_49893e9a-39de-4c42-baab-603eded76e3a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3a255c06-b8fd-42be-a476-41c0489c1cce"
      decimals="-3"
      id="F_ad448474-04cd-4774-a5a9-cc2f7cb0b81c"
      unitRef="U_USD">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dbc0f234-0a0a-4688-a7d0-ab581da9ada6"
      decimals="-3"
      id="F_425a3cee-4905-4bc9-b13b-b57f04c17d7b"
      unitRef="U_USD">65000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ccfbd687-78ce-4465-b1b8-3bfc531b0880"
      decimals="-3"
      id="F_52d0e4b1-763e-4a3e-86f5-1a91e34c02e7"
      unitRef="U_USD">331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f01b403a-323f-485f-af41-68ca5c0839f6"
      decimals="-3"
      id="F_a87c0461-2d79-451f-aa20-034a6bae2513"
      unitRef="U_USD">427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bced1c1d-85b9-42ae-8100-73aca910ab35"
      decimals="-3"
      id="F_303046ef-049f-4603-95b6-5a863d2382b2"
      unitRef="U_USD">4989000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_78dba0fb-71f8-42e4-a64b-0fd12fbe76a6"
      decimals="-3"
      id="F_8dee59cf-3b57-46ef-8351-ee33243673af"
      unitRef="U_USD">5469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_55b979c7-72c9-409a-83d6-31bd9eabf0c4"
      unitRef="U_USD">5373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_bd5cb710-dad8-4c17-a210-8c57c1bb6f15"
      unitRef="U_USD">5961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_5662ec44-a16f-45a0-917c-97f0fd92ca72"
      decimals="-5"
      id="F_ecce7236-2209-4b70-9e24-9fb66707ded7"
      unitRef="U_USD">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ce211496-7721-4eba-82cd-0d0e044cc26e"
      id="F_b5f64baf-8eb6-4018-a9bc-4bfa356c5cf2">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_a9960eed-3f80-471b-bdfc-db5827176ccb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding - January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted under the Option Exchange&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_d1294232-c29b-42cb-a033-dd2e81529655"
      unitRef="U_shares">2541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="2"
      id="F_2d764bce-b811-426f-9e69-2a9e8f7f4926"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      id="F_26223a05-3bea-4c10-8437-475b5ac874f8">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_e716a33e-7ea4-4912-b1ba-bf01ccaceac6"
      unitRef="U_USD">1489000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_92ba33ac-b462-4c68-91cc-5a4622e5141b"
      unitRef="U_shares">454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_04ec116f-08bf-4d21-bde7-a2bdb993b7bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_6d556fe0-444a-495c-aaa5-c3d36936af5d"
      unitRef="U_shares">365000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_e73668e9-2976-4272-8259-305c496c99a9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_7c27bd20-646d-4664-a6d1-a352196f5773"
      unitRef="U_shares">123000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_6a926e6f-4934-46b3-90de-36528a770c52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bdsx:StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_bafcd3e2-56ad-428b-82d8-5df7a20a4f7b"
      unitRef="U_shares">-589000</bdsx:StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange>
    <bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_f82f4403-533e-4988-a142-56ca6093a7b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.43</bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice>
    <bdsx:StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_55cbef81-0232-4584-92e7-8efd7529fb76"
      unitRef="U_shares">123000</bdsx:StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange>
    <bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_3009b578-8e37-4135-9824-34480415c012"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.2</bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_9953972b-af40-4cca-aef7-9879728c4fd4"
      unitRef="U_shares">2041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="2"
      id="F_583d9f9a-1b61-4be9-b260-1c8c1da8823d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_5e57bab7-8e83-441e-919d-178ed8c1fbd8">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c2e539db-0a54-4905-9578-cc01340b63f0"
      unitRef="U_USD">964000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c03853e0-eaba-427b-bdc9-76796e97f9bc"
      unitRef="U_shares">1298000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="2"
      id="F_2e16359d-0392-4bf7-8cd9-777ffb6fe5a8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_79b5d3eb-cb76-4982-822d-f2e295d448c4">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c9fdc184-611f-44e4-90b5-64a1a42cdda4"
      unitRef="U_USD">748000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:DividendsCommonStock
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="INF"
      id="F_5ae80642-f7ad-4d8b-a3fb-538c6ae8e810"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_9b7c7ae7-862d-4e81-bd02-a1392617eb86"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_4f0d9f50-1ef2-4f5f-8a4f-4c1cb778be51">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.080000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.080000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.39&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk&#x2011;free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e54a6219-cdb5-44ec-a853-ffb6559a45b1">P5Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      id="F_4c0e9efb-6e87-45d5-9add-cf23896e1771">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="3"
      id="F_1d9295d8-a683-48d7-9367-3426ca5f3ef5"
      unitRef="U_pure">0.801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="3"
      id="F_e09869a6-4a3f-4f0b-963a-8da81d182a57"
      unitRef="U_pure">0.726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="4"
      id="F_6caffce7-71b0-46c1-9f9e-6bf79e6efa80"
      unitRef="U_pure">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="4"
      id="F_c9c7ddf4-c15d-4de2-bf79-6b3fec4488ab"
      unitRef="U_pure">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_1991822e-01df-4d79-9a4f-55529e380694">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock unit activity during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 was (in thousands, except weighted average grant date fair value per share):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cceeff;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df"
      decimals="-3"
      id="F_b62655dd-57b0-4434-98ba-ffba986c7893"
      unitRef="U_shares">1211000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3622c6dd-b0a5-4c7b-8381-11eb4fef75df"
      decimals="2"
      id="F_716aa073-86e3-4789-a2e1-4073a43f0fb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"
      decimals="-3"
      id="F_e175f1c3-a147-489d-8146-b34b4e63ff77"
      unitRef="U_shares">2474000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"
      decimals="2"
      id="F_259b7219-c32c-41d2-8a1f-6ad99f7962f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"
      decimals="-3"
      id="F_e29be295-8ee2-4176-8b34-e69dfc5c1bfe"
      unitRef="U_shares">246000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"
      decimals="2"
      id="F_4698bc95-dbba-4987-a799-199b6d8a1762"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"
      decimals="-3"
      id="F_3f47a044-3c5d-4510-ad54-bbbbc8f80a8d"
      unitRef="U_shares">710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8ff6833a-ac78-44ae-9687-bfa5a27559c4"
      decimals="2"
      id="F_027e1381-616b-43f6-8643-aa23a6042c87"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_458ca6db-5494-45ba-a80b-51438237e3b3"
      decimals="-3"
      id="F_29d425b2-d4d8-41bd-81dd-1da569bb508f"
      unitRef="U_shares">2729000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_458ca6db-5494-45ba-a80b-51438237e3b3"
      decimals="2"
      id="F_2538eb7e-f4d5-4d0f-b1ab-c68d3fb5aaf6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_088b90c0-17e0-49b4-a134-a570f622a6fe">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 13 &#x2013; Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted loss per share as of the dates indicated were (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.647%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares outstanding used&lt;br/&gt;&#160;&#160;&#160;in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The potentially dilutive securities as of December 31, 2023 and 2022 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our ESPP, the terms of which are described in further detail in Note 12 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The potentially dilutive securities would be subject to the treasury stock method when dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_9c544bf5-0756-4e08-9526-adc6d90ee286">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted loss per share as of the dates indicated were (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.647%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares outstanding used&lt;br/&gt;&#160;&#160;&#160;in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_8a29a0e1-c02c-4338-9ddb-cfb9364d07f4"
      unitRef="U_USD">-52146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_36aa9de4-8d61-4022-9589-95d10c8db282"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_c473d4d8-f4a0-4e94-8284-2fcfc9135b17"
      unitRef="U_shares">82113000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_6beaa39d-2f78-4328-970c-f28e18daaaf8"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_1abdafa9-b5e0-4172-b9ca-1421b0528b3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_0a0fd1bf-46c8-4e66-b50c-360a65262521"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b7e33aca-9429-4802-9a2b-bde694f5b3b7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_21cb25e9-02bb-4719-b5c1-a096cb7c970b"
      decimals="-3"
      id="F_a7e45569-9277-41eb-8f33-b1e54978875b"
      unitRef="U_shares">3091000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_85c18ff1-b0e9-4dde-b440-56dc6c7fe909"
      decimals="-3"
      id="F_58d67fac-01ea-4df3-86cf-15322aa295b4"
      unitRef="U_shares">3067000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2bb7dca5-b8b4-43e7-8305-8b91be0a1148"
      decimals="-3"
      id="F_6bee2fb9-d2b9-4fff-925f-4f914ce30a38"
      unitRef="U_shares">59000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_18694c42-145b-4b80-97fa-d13aaaf257c8"
      decimals="-3"
      id="F_0965edd6-e0ff-4cc6-b4b1-65a5e4369bb7"
      unitRef="U_shares">80000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_704abf95-1ce3-4ffb-aa7b-013f8330fca8"
      decimals="-3"
      id="F_b60a83ba-af31-4062-bc32-50b1aeb8a3b1"
      unitRef="U_shares">5603000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d6b06b8a-9d90-4601-bafe-371bd4da5153"
      decimals="-3"
      id="F_bb67d9ee-7997-4ee2-bb42-7ff0fa647c0e"
      unitRef="U_shares">5103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e88dd606-cce8-4094-846e-9bb4b5f5df2d"
      decimals="-3"
      id="F_e665d72c-1363-40ac-90c0-9f538d728a25"
      unitRef="U_shares">2729000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_39626716-1586-4d2d-8868-a094e33c5618"
      decimals="-3"
      id="F_9cf64b33-b170-46c7-8d87-a5e5a59323f9"
      unitRef="U_shares">1211000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_20063d2e-416c-49fb-a226-3ed709540abe"
      unitRef="U_shares">11482000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_695ba3c1-e07e-49da-84af-22c9ec02596e"
      unitRef="U_shares">9461000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_9e984d7f-7b4f-43b1-8d2e-b48941c851fb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 14 - Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since inception, the Company has incurred net taxable losses, and accordingly, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; current provision for income taxes has been recorded. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.233%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and developments credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.103%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.623000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-Use Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023, the Company ha&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;expire beginning in 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of net deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The valuation allowance increased&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During 2023, the Company determined that it has uncertain tax positions related to its U.S. research and development credits. As of December 31, 2023 and 2022, there w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrued interest related &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions related to settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions related to a lapse of statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. As of December 31, 2023, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_eac0993e-4f9b-49fe-b6e0-66a41a32cb83"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_a8e3b60f-7f43-4528-a962-4b287da2f884">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.233%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and developments credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_ce7f6e7a-022a-4b0e-815d-7f1ff66eba44"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_dcc3f915-8ca1-4df0-82c4-f5d3af014983"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_b0d9bcb0-da1a-43b9-a4ca-354e626f1bb7"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_bd962c4e-00d2-410e-85ba-c62ddabaec65"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_d054acd6-68f0-4fe0-9977-d236755eb338"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_77014037-9f8e-4720-b124-ca25a6f6ff3d"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_743b6b5d-2581-4dcf-adce-980d93346612"
      unitRef="U_pure">0.03</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_80437afb-7525-447b-a608-13fb8851e2e8"
      unitRef="U_pure">0.04</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="2"
      id="F_3b6651d0-609f-4b2c-89f4-f6669fe0312c"
      unitRef="U_pure">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="2"
      id="F_e1c5e04b-1b7a-4f08-84dc-9e8eef21d18c"
      unitRef="U_pure">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0340475c-01e1-4045-ac17-287d2e6a5612">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.103%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.623000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-Use Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_7e7fb119-0d65-4e90-92f0-6f4e8d69ab78"
      unitRef="U_USD">72722000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_a218a6b5-67ae-418c-b478-cd13d2a720b9"
      unitRef="U_USD">70822000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_dbc9ea26-f820-43de-8613-6092e25e9b37"
      unitRef="U_USD">4149000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_a2eff594-1ba9-489f-86c2-b732c4c1d869"
      unitRef="U_USD">3807000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_407529cb-f09c-4411-a68d-d18e0ef6a4e4"
      unitRef="U_USD">5120000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_ffad5133-2cf1-4344-9c38-da32d6adbc8b"
      unitRef="U_USD">3036000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_17620c61-2d15-42d6-bd4f-ef385652a694"
      unitRef="U_USD">234000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <bdsx:DeferredTaxAssetsCapitalizedResearchCosts
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_2d707d17-06bc-414d-9b47-4a11784b1157"
      unitRef="U_USD">4281000</bdsx:DeferredTaxAssetsCapitalizedResearchCosts>
    <bdsx:DeferredTaxAssetsCapitalizedResearchCosts
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_804bef59-323e-470b-b0ac-251a1fc23742"
      unitRef="U_USD">2874000</bdsx:DeferredTaxAssetsCapitalizedResearchCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_ec5e8202-f40f-4f7b-ad75-48fe5901121d"
      unitRef="U_USD">1685000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_d63fff8e-8322-4556-9c6a-8524a1b550bf"
      unitRef="U_USD">1619000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <bdsx:DeferredTaxAssetsLeaseLiability
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_70425032-836b-4881-ab13-ae038cf172d7"
      unitRef="U_USD">6398000</bdsx:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c3be4d58-2a32-4f4e-b04e-42c68312ac84"
      unitRef="U_USD">667000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_caeabb58-434b-4ae2-ae92-dae1047056c9"
      unitRef="U_USD">1932000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_c4f10cf0-7fa5-481f-b138-5c1d684a77a9"
      unitRef="U_USD">95022000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b043e63e-762c-4ed3-a4e3-242a77d36c03"
      unitRef="U_USD">84324000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_3fb787e9-f534-4883-ab2f-2b95361b3d76"
      unitRef="U_USD">93023000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b61e54b4-fa72-4893-bd38-9c36c8e68674"
      unitRef="U_USD">82552000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_6a1e8808-bd5e-465b-bc4e-45db72633eed"
      unitRef="U_USD">1999000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_e57077be-66a1-47f2-9821-c0a27077a15d"
      unitRef="U_USD">1772000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_94bd1ff5-00a9-44f8-8556-401804ed5fd3"
      unitRef="U_USD">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <bdsx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_1a573709-4aba-443e-9bd2-37422182e726"
      unitRef="U_USD">-692000</bdsx:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_5490404b-2268-4b85-b967-668ef6c46fe6"
      unitRef="U_USD">1303000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_80c1b722-91ee-4163-9d70-408d0ad9a00b"
      unitRef="U_USD">1772000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_6bbb9c02-2f10-4060-b466-fbb48de02bfc"
      unitRef="U_USD">1999000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_a5d46df6-26fd-4639-8c8d-7ca7a8d44eda"
      unitRef="U_USD">1772000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-5"
      id="F_6c301da8-83d2-44f1-b3c6-d799071bb87a"
      unitRef="U_USD">310400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-5"
      id="F_cf331762-8824-4f0b-8b08-3286892e3bc0"
      unitRef="U_USD">5200000</bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e6f7a977-8869-47ee-8157-7d5880625afd">expire beginning in 2026</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_e2c92d30-4808-4b4e-ac0e-b4f048bb9347">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
    <bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="INF"
      id="F_45c0183e-89c8-4c33-bdc4-f2a3c4fb9467"
      unitRef="U_pure">1</bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-5"
      id="F_758207b8-c305-4764-ba0a-c6f64ff8356d"
      unitRef="U_USD">10500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-5"
      id="F_5531eccd-dce3-47ca-9df8-36de3e3175b8"
      unitRef="U_USD">15100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="INF"
      id="F_d37280bb-a5c4-4e2d-bf91-d215172618ae"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="INF"
      id="F_3ff16bba-577b-4e6f-b5f5-1e429a4535da"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_0a19c07b-1570-4736-8b83-f904964b9da5">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions related to settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions related to a lapse of statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_b106a880-2a0c-45b4-be4f-ba91973088f9"
      unitRef="U_USD">952000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_762beb25-d2a5-4129-9298-0e23686a893a"
      decimals="-3"
      id="F_e44aa981-9772-4538-a98b-921f223b8b58"
      unitRef="U_USD">843000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_1614d221-a384-45f5-8547-164ef50129bd"
      unitRef="U_USD">57000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_ed8fa078-03db-41e9-8b7b-34ec5d7e3e63"
      decimals="-3"
      id="F_9b02fdf2-8b2c-4b19-bb16-319d4b166423"
      unitRef="U_USD">109000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      decimals="-3"
      id="F_686eea42-a4ea-482a-8576-8262dee2c541"
      unitRef="U_USD">28000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_55007458-a47c-4577-8a1f-a5b74438afae"
      decimals="-3"
      id="F_38d7adba-6bbb-4c14-98f3-8053bcce3d64"
      unitRef="U_USD">1037000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4abb40e3-b5cb-4415-8f32-8b5a7575eba0"
      decimals="-3"
      id="F_84c7dcd1-d96e-489c-9a7a-0ebf77b2f93f"
      unitRef="U_USD">952000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_b56383d2-2ec0-4ace-80e1-7dfbc17d35c2">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_c1d751d0-deaa-4630-912a-969dd8d4a789">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 15 &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Co&#x2011;Development Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#x2019;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2020, the Company exercised its opt-out right with AVEO for the payment of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the AVEO Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; remaining obligations related to the AVEO agreement as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Following the AVEO Effective Date, the Company is entitled to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty of net sales of ficlatuzumab and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of license income generated from the licensing of ficlatuzumab from AVEO.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; royalties received or expenses related to this agreement for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#x99; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company no longer paid a royalty of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Either party may terminate for the other&#x2019;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There wer&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; expenses &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;related to this agreement for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 13, 2021 (the CellCarta Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly &#x201c;Caprion Biosciences, Inc.&#x201d;) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% fee on net sales made from the first commercial sale of the Nodify XL2 test to the CellCarta Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.675&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on future Nodify XL2 test net sales worldwide for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the first commercial sale, ending in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Royalty expense under the CellCarta License for each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 wa&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 31, 2019, we completed an acquisition of Freenome's United States operations (formerly "Oncimmune USA" or "Oncimmune") including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule malignancy test, then marketed in the United States as the EarlyCDT Lung&#xae; test. We renamed and relaunched the test on February 28, 2020 as the Nodify CDT test. As part of the acquisition of the assets of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to the Nodify CDT test of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of recognized revenue for non-screening tests up to an annual minimum volume and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% thereafter, with an escalating minimum&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through the first four years of sales&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Royalty expenses we&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;re $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Litigation, Claims and Assessments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCosts
      contextRef="C_aae49741-9ea1-4f75-bfc7-d624530d36a2"
      decimals="2"
      id="F_345543ca-cbb5-4cca-bd9e-dff2f1e12052"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCosts>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
      contextRef="C_677ab76d-419b-473f-b103-ff9ac04bad1d"
      decimals="2"
      id="F_41ebba61-6547-4d0b-b4c4-571ef79d793b"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight>
    <bdsx:RemainingEstimatedObligation
      contextRef="C_dbf7a7b5-3d35-4435-8e39-b2016e8d14e5"
      decimals="-5"
      id="F_5ab53077-f5cb-456f-9dd7-f40ebad469bc"
      unitRef="U_USD">100000</bdsx:RemainingEstimatedObligation>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_829c0cf6-e0e1-4b9b-b982-f1e2c2517ed1"
      decimals="2"
      id="F_d38f111d-3e06-4a5f-ae6e-29499e98b65c"
      unitRef="U_pure">0.10</bdsx:PercentageOfRoyaltyPaymentsOnNetSales>
    <bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing
      contextRef="C_829c0cf6-e0e1-4b9b-b982-f1e2c2517ed1"
      decimals="2"
      id="F_b9ab6c0b-69c4-4b38-a600-ed7928a0ff8b"
      unitRef="U_pure">0.25</bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dbf7a7b5-3d35-4435-8e39-b2016e8d14e5"
      decimals="INF"
      id="F_b0d9bf39-376a-4d71-9439-12e49113f731"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_09d39f03-6b12-424b-8512-f460834da55b"
      decimals="INF"
      id="F_b7faa5fa-aff4-4181-8c94-abf54187cb93"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_96996321-13b7-427c-bd23-e8321fa8a247"
      decimals="3"
      id="F_66745948-7e0e-4c15-acd9-cf3aae8ce338"
      unitRef="U_pure">0.025</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue
      contextRef="C_c2f00f89-3407-44e8-b573-6c7ef85347d0"
      decimals="3"
      id="F_8764ae5c-aef5-47c9-9da5-ee9b5915da36"
      unitRef="U_pure">0.025</bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue>
    <bdsx:LicenseAgreementExpiryDate
      contextRef="C_6f68a71f-ae27-4a7e-8505-b345faef0785"
      id="F_5586ab72-6c7b-4d1a-ba67-5a4446360a6b">2024-08</bdsx:LicenseAgreementExpiryDate>
    <us-gaap:RoyaltyExpense
      contextRef="C_6f68a71f-ae27-4a7e-8505-b345faef0785"
      decimals="INF"
      id="F_ab55f8fb-b800-4f2e-b1ae-21db7dd01173"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_fbe102ae-9f7e-4e28-816c-b752eedef674"
      decimals="INF"
      id="F_4c7ab6f8-b573-4819-8411-3797b0b54fe4"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfFeePaymentsOnNetSales
      contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047"
      decimals="2"
      id="F_332e17de-9480-4263-990f-0ede8e33b479"
      unitRef="U_pure">0.01</bdsx:PercentageOfFeePaymentsOnNetSales>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047"
      decimals="5"
      id="F_d720f663-c8e6-4d2c-b2f5-6a670451fe21"
      unitRef="U_pure">0.00675</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale
      contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047"
      id="F_0b318718-b1d9-4bc5-a659-9f46cbaf6965">P15Y</bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale>
    <bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale
      contextRef="C_355e90bf-4c9e-415d-b1b6-9150cd16a047"
      id="F_dc1c875f-1547-462d-8a20-8d3efb12fa6d">2034</bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale>
    <us-gaap:RoyaltyExpense
      contextRef="C_732dfeaf-3c70-43c0-9cb2-16621b310dc5"
      decimals="-5"
      id="F_efa292f2-d606-48c6-90ef-8d53b0dd712d"
      unitRef="U_USD">200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_3384de12-4804-4762-b479-c95f25937875"
      decimals="-5"
      id="F_dac6a051-70a2-4538-8ced-b972f779c30e"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests
      contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed"
      decimals="2"
      id="F_5317c85c-0f3e-41ef-86b2-7a480cd728fc"
      unitRef="U_pure">0.08</bdsx:PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests>
    <bdsx:MinimumAnnualVolumePercentageThereafter
      contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed"
      decimals="INF"
      id="F_25b141b6-6679-430f-8d05-a0c0b39bdda8"
      unitRef="U_pure">0.05</bdsx:MinimumAnnualVolumePercentageThereafter>
    <bdsx:PeriodOfEscalationsOfSales
      contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed"
      id="F_89c1e279-f1bf-4b93-9319-fbae5baa230e"> through the first four years of sales</bdsx:PeriodOfEscalationsOfSales>
    <us-gaap:RoyaltyExpense
      contextRef="C_1adb3675-1ce1-4d1d-809a-95ce3176e1ed"
      decimals="-5"
      id="F_5fc07990-0ec9-41f7-b7ef-e1b5d1b66a67"
      unitRef="U_USD">1000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_6410b666-1ca1-4444-9f01-8f35821f9a25"
      decimals="-5"
      id="F_357ae5d3-d1a0-4f17-b837-25861af7054a"
      unitRef="U_USD">900000</us-gaap:RoyaltyExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_07be75b0-fbf4-4119-a2ba-55afe4ef7386"
      id="F_7a9b45d2-d0f5-43e7-802c-b3de39fb0c40">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 16 &#x2013; Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Perceptive Term Loan Facility Limited Waiver and Amendment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 14, 2024 a limited waiver to the Perceptive Term Loan Facility was executed (the Limited Waiver), whereby, subject to the terms and conditions of the Limited Waiver, Perceptive agreed to (i) waive compliance with the December 31, 2023 Minimum Net Revenue covenant and (ii) waive the requirement that the Annual Report on Form 10-K for the year-ended December 31, 2023 and auditor's opinion on the financial statements herein shall not be subject to any going concern or like qualification or exception audit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 29, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024 (the Third Amendment Effective Date), the Company entered into the Third Amendment to the Credit Agreement and Guaranty (the Third Amendment) with Perceptive as lender and administrative agent and the Company, as borrower, whereby subject to the terms and conditions of the Third Amendment, the Minimum Net Revenue Covenant (as defined in the Credit Agreement) was amended to reduce the relevant threshold as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2024 through and including the fiscal quarter ending December 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
